Clustering O 0 0.0001567022263770923
of O 0 7.529351364610193e-07
missense O 0 6.116153235780075e-05
mutations O 0 2.828334118021303e-06
in O 0 1.2965389259989024e-06
the O 0 0.00016961553774308413
ataxia B-Disease 1 0.9999579191207886
- I-Disease 1 0.9998630285263062
telangiectasia I-Disease 1 0.9998965263366699
gene O 0 1.198946961267211e-06
in O 0 3.8406579250249706e-08
a O 0 1.0937301908597874e-07
sporadic B-Disease 0 6.40295329503715e-05
T I-Disease 1 0.9894385933876038
- I-Disease 1 0.5570342540740967
cell I-Disease 0 0.444009006023407
leukaemia I-Disease 1 0.6914929747581482
. O 0 3.1442363251699135e-05

Ataxia B-Disease 1 0.9985560774803162
- I-Disease 1 0.9988712668418884
telangiectasia I-Disease 1 0.9995749592781067
( O 0 0.0003489196242298931
A B-Disease 0 0.4246988594532013
- I-Disease 1 0.9998373985290527
T I-Disease 1 0.9999679327011108
) O 0 6.922492048033746e-06
is O 0 4.835583666817911e-08
a O 0 9.662338840144002e-08
recessive B-Disease 0 0.00018234626622870564
multi I-Disease 0 0.22653280198574066
- I-Disease 1 0.9987241625785828
system I-Disease 1 0.9427986145019531
disorder I-Disease 1 0.9589411616325378
caused O 0 0.00021965954510960728
by O 0 3.8605546137659985e-07
mutations O 0 2.219231731714899e-07
in O 0 1.4872525433418105e-08
the O 0 1.6485886433770247e-08
ATM O 0 6.776888767490163e-05
gene O 0 7.475226482256403e-08
at O 0 1.219917749040178e-06
11q22 O 0 3.027075217687525e-05
- O 0 0.0011306519154459238
q23 O 0 5.187632268643938e-05
( O 0 2.8829738596414245e-08
ref O 0 4.295981489121914e-05
. O 0 6.77460363363025e-08
3 O 0 2.416518611880747e-07
) O 0 1.735600818619787e-07
. O 0 1.101521888813295e-06

The O 0 2.8824691980844364e-05
risk O 0 0.0014268773375079036
of O 0 2.0086681615794078e-05
cancer B-Disease 0 0.1270296573638916
, O 0 3.7451839034474688e-06
especially O 0 8.623662210993643e-07
lymphoid B-Disease 0 0.0025625303387641907
neoplasias I-Disease 0 0.04402075335383415
, O 0 1.589632802279084e-06
is O 0 5.629300048326513e-08
substantially O 0 1.621017759134702e-06
elevated O 0 3.5880743780580815e-06
in O 0 1.833084070312907e-06
A B-Disease 1 0.5618346333503723
- I-Disease 1 0.9999773502349854
T I-Disease 1 0.9999947547912598
patients O 0 2.72209490503883e-05
and O 0 3.1323640996561153e-06
has O 0 7.725802788627334e-06
long O 0 3.243485480197705e-05
been O 0 1.6460741107948706e-06
associated O 0 4.306769824324874e-06
with O 0 4.5545733883045614e-05
chromosomal O 1 0.9998052716255188
instability O 1 0.996619701385498
. O 0 9.295931522501633e-05

By O 0 2.9893790269852616e-06
analysing O 0 0.0016438710736110806
tumour B-Disease 1 0.9996452331542969
DNA O 0 0.01866060122847557
from O 0 3.2780528727016645e-06
patients O 0 1.6745399022966012e-07
with O 0 1.3914909402501507e-07
sporadic B-Disease 0 2.2542821170645766e-05
T I-Disease 1 0.9692297577857971
- I-Disease 0 0.23319193720817566
cell I-Disease 0 0.24022860825061798
prolymphocytic I-Disease 1 0.9150978922843933
leukaemia I-Disease 1 0.8890210390090942
( O 0 1.7426376643925323e-06
T B-Disease 0 0.4336209297180176
- I-Disease 0 0.01929420419037342
PLL I-Disease 0 0.01948603428900242
) O 0 2.963820691093133e-07
, O 0 2.2877825855971423e-08
a O 0 3.7400862851200145e-08
rare O 0 9.605483910490875e-07
clonal B-Disease 0 5.087740646558814e-05
malignancy I-Disease 0 0.034722112119197845
with O 0 3.5432793765721726e-07
similarities O 0 6.446838369811303e-07
to O 0 7.486281816682094e-09
a O 0 1.0471499223285718e-07
mature B-Disease 0 5.791664989374112e-06
T I-Disease 1 0.6494617462158203
- I-Disease 0 0.0954827293753624
cell I-Disease 0 0.20080305635929108
leukaemia I-Disease 0 0.22706803679466248
seen O 0 3.840380031761015e-06
in O 0 3.490675624107098e-07
A B-Disease 0 0.03384603559970856
- I-Disease 1 0.99930739402771
T I-Disease 1 0.9999734163284302
, O 0 1.2282059742574347e-06
we O 0 5.98903104886972e-09
demonstrate O 0 8.398609807613866e-09
a O 0 1.567678098446379e-09
high O 0 2.355223926997496e-08
frequency O 0 2.374405783100997e-09
of O 0 9.295416658616773e-10
ATM O 0 7.126654963940382e-05
mutations O 0 1.3969889778309152e-07
in O 0 3.892978668318392e-07
T B-Disease 1 0.5675613880157471
- I-Disease 0 0.06098902225494385
PLL I-Disease 0 0.01701570302248001
. O 0 5.816201792185893e-06

In O 0 4.856083705817582e-06
marked O 0 1.7523134374641813e-05
contrast O 0 8.749997846280166e-07
to O 0 7.167944904296064e-09
the O 0 1.204926203257628e-08
ATM O 0 5.050036634202115e-05
mutation O 0 6.332378887918821e-08
pattern O 0 5.547426098928554e-06
in O 0 1.7391957953805104e-06
A B-Disease 0 0.07906021177768707
- I-Disease 1 0.9996614456176758
T I-Disease 1 0.9999808073043823
, O 0 4.6230346129050304e-07
the O 0 3.0598485967203715e-09
most O 0 2.2317936387850068e-10
frequent O 0 8.340148571761574e-10
nucleotide O 0 1.0224338709008407e-08
changes O 0 3.665366898886191e-09
in O 0 4.039194934080115e-08
this O 0 1.5241988648995175e-07
leukaemia B-Disease 0 0.018574409186840057
were O 0 4.625005658454029e-07
missense O 0 8.165909093804657e-06
mutations O 0 2.3993929971766192e-06
. O 0 4.460629497771151e-06

These O 0 5.618679779217928e-07
clustered O 0 1.5808800526428968e-05
in O 0 1.7708454436160537e-07
the O 0 4.722414459479296e-08
region O 0 1.4623699939875223e-07
corresponding O 0 4.192812319558925e-09
to O 0 1.3060121872854324e-09
the O 0 5.947378589610253e-09
kinase O 0 1.0675430530682206e-06
domain O 0 4.075645065881872e-08
, O 0 1.1171777458685028e-07
which O 0 2.4757643046768862e-08
is O 0 8.679878482631409e-10
highly O 0 4.37074015868788e-10
conserved O 0 2.280701627555004e-09
in O 0 6.680672903769391e-09
ATM O 0 0.00012181989586679265
- O 0 0.0002641263126861304
related O 0 3.180734040597599e-07
proteins O 0 6.133594521173791e-09
in O 0 1.0461413957330024e-08
mouse O 0 3.689394725370221e-05
, O 0 1.9300466647109715e-07
yeast O 0 9.02226020116359e-07
and O 0 3.428629042900866e-07
Drosophila O 0 2.143774509022478e-06
. O 0 2.7336457151250215e-06

The O 0 3.8104943200778507e-07
resulting O 0 4.820647063752403e-07
amino O 0 3.385446945003423e-08
- O 0 1.3157113244233187e-05
acid O 0 3.870470521860625e-08
substitutions O 0 1.7357855597310845e-08
are O 0 3.25634119668905e-09
predicted O 0 9.471943940297933e-07
to O 0 1.3565001344417738e-09
interfere O 0 3.66411754271212e-08
with O 0 5.478347375742487e-08
ATP O 0 9.057028364622965e-05
binding O 0 2.3281981498257664e-07
or O 0 1.5664406305404555e-07
substrate O 0 2.677675638551591e-06
recognition O 0 3.403329742468486e-07
. O 0 2.4052442313404754e-06

Two O 0 2.0737206796184182e-07
of O 0 5.243963130396878e-08
seventeen O 0 1.044205532707565e-06
mutated O 0 6.26048567937687e-05
T B-Disease 0 0.26576024293899536
- I-Disease 0 0.00550997955724597
PLL I-Disease 0 0.0005563449230976403
samples O 0 2.2106662811438582e-07
had O 0 1.106843910747557e-06
a O 0 1.7379494465785683e-07
previously O 0 2.144003883586265e-05
reported O 0 0.0005106866010464728
A B-Disease 0 0.000799976522102952
- I-Disease 1 0.9715623259544373
T I-Disease 1 0.9995121955871582
allele O 0 3.429906064411625e-05
. O 0 5.7006072893273085e-06

In O 0 8.33209833217552e-06
contrast O 0 3.772405398194678e-05
, O 0 9.159971341432538e-07
no O 0 1.1455592385800628e-07
mutations O 0 6.374404648568088e-08
were O 0 5.964933080804258e-08
detected O 0 4.609501900176838e-07
in O 0 8.108507643100893e-09
the O 0 8.992073752267515e-09
p53 O 0 5.8915841094631105e-08
gene O 0 4.626933858276061e-08
, O 0 2.2329673754484247e-07
suggesting O 0 1.4168966799843474e-06
that O 0 2.834599399648141e-07
this O 0 9.106299785344163e-07
tumour B-Disease 1 0.9997840523719788
suppressor O 0 0.00021993576956447214
is O 0 3.76056590312146e-08
not O 0 6.754473425019114e-09
frequently O 0 6.636516758362632e-08
altered O 0 2.399196318947361e-06
in O 0 2.2230190666050476e-07
this O 0 2.6358404738857644e-06
leukaemia B-Disease 1 0.6859846115112305
. O 0 3.341619230923243e-05

Occasional O 0 7.455564627889544e-06
missense O 0 3.201934669050388e-05
mutations O 0 1.6300587049045134e-06
in O 0 1.812594092598374e-07
ATM O 0 0.0003539870376698673
were O 0 2.2293636448011966e-06
also O 0 1.7013770730045508e-06
found O 0 4.355097189545631e-06
in O 0 1.4102120076131541e-05
tumour B-Disease 1 0.9999030828475952
DNA O 0 0.008533068001270294
from O 0 2.38668144447729e-06
patients O 0 1.689401187832118e-07
with O 0 2.4481633431605587e-07
B B-Disease 0 3.497769284876995e-05
- I-Disease 0 0.001620195689611137
cell I-Disease 0 0.0009316812502220273
non I-Disease 0 9.484901966061443e-06
- I-Disease 1 0.9808875322341919
Hodgkins I-Disease 1 0.9995285272598267
lymphomas I-Disease 1 0.8531315326690674
( O 0 2.084851047357006e-07
B B-Disease 0 3.6830892895522993e-06
- I-Disease 0 1.3941588804300409e-05
NHL I-Disease 0 7.313157084354316e-07
) O 0 2.7143952863184495e-08
and O 0 1.2622580314314291e-08
a O 0 1.5425326793661043e-08
B B-Disease 0 3.1615106763638323e-06
- I-Disease 0 1.184293614642229e-05
NHL I-Disease 0 8.258710408881598e-07
cell O 0 2.1811460101162083e-05
line O 0 9.577946002536919e-06
. O 0 5.829718247696292e-06

The O 0 1.897382048809959e-06
evidence O 0 2.1815912987221964e-06
of O 0 2.540273236206758e-08
a O 0 8.680698471152937e-08
significant O 0 5.6474640075521165e-08
proportion O 0 1.2525370607363584e-07
of O 0 1.6251431134151062e-07
loss O 0 0.0028420083690434694
- O 0 0.00022885137877892703
of O 0 8.880709145842047e-08
- O 0 0.0004133271286264062
function O 0 2.128230036646528e-08
mutations O 0 1.4969172568157774e-08
and O 0 3.161716932709169e-08
a O 0 7.615018660089845e-08
complete O 0 1.4342811027745483e-06
absence O 0 9.787709842612458e-08
of O 0 2.1061481447759434e-09
the O 0 8.19497003590186e-09
normal O 0 1.5612632964234763e-08
copy O 0 7.488855402471017e-08
of O 0 3.5179972268650772e-09
ATM O 0 0.00023333175340667367
in O 0 3.811562265809698e-08
the O 0 3.035065532230874e-08
majority O 0 7.393734335892077e-08
of O 0 1.1651783182742292e-07
mutated O 0 0.001259870594367385
tumours B-Disease 1 0.9978813529014587
establishes O 0 6.455109996750252e-06
somatic O 0 2.2229266960493987e-06
inactivation O 0 0.0004465045058168471
of O 0 2.190508396893165e-08
this O 0 1.2903199397840126e-08
gene O 0 6.320758672018201e-08
in O 0 2.4615117055759583e-08
the O 0 7.732857199016507e-08
pathogenesis O 0 1.7919424863066524e-05
of O 0 2.0308217330011757e-08
sporadic B-Disease 0 2.4370629034820013e-05
T I-Disease 1 0.8755749464035034
- I-Disease 0 0.01705009676516056
PLL I-Disease 0 0.007429670542478561
and O 0 3.344248113990034e-07
suggests O 0 1.064094732328158e-07
that O 0 1.3100397211474046e-08
ATM O 0 8.403400715906173e-05
acts O 0 4.9208850327886466e-08
as O 0 2.1924227766589865e-08
a O 0 1.7891783272716566e-06
tumour B-Disease 1 0.9996201992034912
suppressor O 0 0.0013743395684286952
. O 0 5.5478967624367215e-06

As O 0 2.1450718179494288e-07
constitutional O 0 5.370613394006796e-07
DNA O 0 4.7146433644229546e-05
was O 0 7.021305918897269e-06
not O 0 2.026665768539715e-08
available O 0 1.3761738415496438e-08
, O 0 3.964818873214426e-08
a O 0 5.818016290959349e-08
putative O 0 0.0003594151057768613
hereditary O 0 0.012264324352145195
predisposition O 0 0.0007016579620540142
to O 0 4.358168098406168e-06
T B-Disease 1 0.8661200404167175
- I-Disease 0 0.03690800815820694
PLL I-Disease 0 0.0023717223666608334
will O 0 7.790426970188946e-09
require O 0 6.334016089404315e-10
further O 0 1.5471992576010507e-09
investigation O 0 4.912126883027668e-07
. O 0 3.3731689086380356e-07
. O 0 2.8117890451540006e-06

Myotonic B-Disease 1 0.9992017149925232
dystrophy I-Disease 1 0.9995511174201965
protein O 0 0.0006207567057572305
kinase O 0 0.0011381555814296007
is O 0 2.665120746314642e-07
involved O 0 3.564767325769935e-08
in O 0 2.6561011168269033e-09
the O 0 1.3765589779168863e-09
modulation O 0 6.739882252304596e-08
of O 0 6.846510580693632e-10
the O 0 2.0664293387540056e-08
Ca2 O 0 2.5905870643327944e-05
+ O 0 3.751089025172405e-05
homeostasis O 0 0.00044326577335596085
in O 0 7.294266879398492e-07
skeletal O 0 0.1445763111114502
muscle O 0 0.006271432153880596
cells O 0 1.9256196537753567e-05
. O 0 8.569573765271343e-06

Myotonic B-Disease 1 0.9990265369415283
dystrophy I-Disease 1 0.9997045397758484
( O 0 0.009595616720616817
DM B-Disease 1 0.9998130202293396
) O 0 7.619855023222044e-05
, O 0 5.803419185212988e-07
the O 0 6.331425339567431e-08
most O 0 2.5280428417318035e-07
prevalent O 0 0.001683412934653461
muscular B-Disease 1 0.9996436834335327
disorder I-Disease 1 0.9636795520782471
in O 0 0.00013544588000513613
adults O 0 0.0009762643021531403
, O 0 0.0001445851376047358
is O 0 5.368921847548336e-06
caused O 0 5.713324571843259e-05
by O 0 1.5779362172452238e-07
( O 0 3.380420565690656e-08
CTG O 0 5.079038965050131e-05
) O 0 3.94040782225602e-08
n O 0 1.7199832882397459e-06
- O 0 1.3674467481905594e-05
repeat O 0 7.322383339669614e-07
expansion O 0 4.9008313851572893e-08
in O 0 1.4017133009858185e-09
a O 0 8.06223865446043e-10
gene O 0 7.401346202584591e-10
encoding O 0 1.8666630463570755e-09
a O 0 2.291153755606956e-08
protein O 0 5.814820838168089e-07
kinase O 0 1.1194594662811141e-05
( O 0 5.18043812292035e-08
DM B-Disease 1 0.9041538238525391
protein O 0 1.746826114867872e-07
kinase O 0 2.0514103198365774e-06
; O 0 1.5349817772403185e-07
DMPK O 0 0.00040145963430404663
) O 0 1.4675078041648248e-08
and O 0 3.82345799465611e-09
involves O 0 4.988194302057991e-09
changes O 0 5.960847815345005e-09
in O 0 3.7696718635515936e-08
cytoarchitecture O 0 0.0001375958527205512
and O 0 1.3337592008610955e-06
ion O 0 0.0003219815553165972
homeostasis O 0 0.021731503307819366
. O 0 1.3774121725873556e-05

To O 0 1.9487082170144276e-07
obtain O 0 7.397049017754398e-08
clues O 0 1.3465783013089094e-06
to O 0 5.9089462212114086e-09
the O 0 3.6678775572340783e-09
normal O 0 1.743606325987912e-08
biological O 0 3.321534620681632e-07
role O 0 5.471274988622099e-09
of O 0 6.853255740679742e-09
DMPK O 0 0.00030137680005282164
in O 0 2.1527215565697588e-08
cellular O 0 1.7261572793358937e-05
ion O 0 0.00015293901378754526
homeostasis O 0 0.011902016587555408
, O 0 2.9139832236069196e-07
we O 0 1.7400914487097907e-08
have O 0 9.124467403864855e-09
compared O 0 1.6851434736508963e-07
the O 0 1.1836982949375852e-08
resting O 0 6.172729626996443e-06
[ O 0 6.365122118268118e-08
Ca2 O 0 2.139044681825908e-06
+ O 0 8.534063454135321e-06
] O 0 6.296368724179047e-07
i O 0 2.870453030823228e-08
, O 0 1.7461648793570816e-09
the O 0 5.903299515885863e-10
amplitude O 0 9.211040818968286e-09
and O 0 1.8696891146419148e-08
shape O 0 3.405589268368203e-07
of O 0 8.197690526401402e-09
depolarization O 0 1.1892938346136361e-05
- O 0 0.00018355374049860984
induced O 0 1.086272550310241e-05
Ca2 O 0 1.5229506971081719e-06
+ O 0 2.2193701170181157e-06
transients O 0 4.222486950311577e-06
, O 0 1.8111109056917485e-08
and O 0 2.0182324700357412e-09
the O 0 2.2335268357043248e-10
content O 0 2.7659236012667066e-10
of O 0 3.9407194174501115e-10
ATP O 0 5.974559826427139e-06
- O 0 6.157618827273836e-06
driven O 0 1.8377701849203731e-07
ion O 0 2.1409577755093778e-07
pumps O 0 6.636731200160284e-07
in O 0 1.3879808413719275e-08
cultured O 0 6.747214683855418e-06
skeletal O 0 0.009374408982694149
muscle O 0 0.000182703384780325
cells O 0 4.419567289914994e-07
of O 0 1.8464445972199428e-08
wild O 0 1.8774062482407317e-06
- O 0 0.0022157994098961353
type O 0 1.9319538751005894e-06
and O 0 1.1337964451740845e-06
DMPK O 0 0.0018172536510974169
[ O 0 2.1530341598463565e-07
- O 0 6.45686814095825e-05
/ O 0 7.626829756191e-06
- O 0 0.0004285935137886554
] O 0 1.4420919796975795e-05
knockout O 0 0.0014051286270841956
mice O 0 0.0003227711422368884
. O 0 3.826673946605297e-06

In O 0 1.6668153648424777e-06
vitro O 0 4.256807005731389e-05
- O 0 0.0008461971883662045
differentiated O 0 1.2768415217578877e-05
DMPK O 0 0.002065162407234311
[ O 0 1.3197562793720863e-06
- O 0 0.0004933462478220463
/ O 0 2.785837568808347e-05
- O 0 0.00072300317697227
] O 0 3.3025623906723922e-06
myotubes O 0 1.9768558559007943e-05
exhibit O 0 2.8512348038134405e-08
a O 0 5.26465493422279e-09
higher O 0 5.939514835517912e-08
resting O 0 3.2715911402192432e-06
[ O 0 7.134639190553571e-08
Ca2 O 0 2.0246470739948563e-06
+ O 0 2.995672048200504e-06
] O 0 3.1094060659597744e-07
i O 0 1.2613290856222648e-08
than O 0 3.604714027272138e-10
do O 0 5.829184912542473e-10
wild O 0 9.905200215598597e-08
- O 0 0.0008401504601351917
type O 0 5.356575456971768e-06
myotubes O 0 0.0017972770147025585
because O 0 4.5615642818575e-08
of O 0 1.4315204577286522e-09
an O 0 8.584832400515552e-09
altered O 0 8.169175202965562e-07
open O 0 2.467411377438111e-07
probability O 0 1.0340796663399487e-08
of O 0 1.32207267355966e-09
voltage O 0 6.928746643097838e-07
- O 0 0.0001806916407076642
dependent O 0 4.659342778268183e-07
l O 0 0.00034917815355584025
- O 0 3.535789574016235e-06
type O 0 4.954119603439722e-08
Ca2 O 0 6.887104291308788e-07
+ O 0 4.5789374780724756e-07
and O 0 4.0512620813615285e-08
Na O 0 2.58902787209081e-06
+ O 0 5.868615176041203e-07
channels O 0 1.794905557517268e-07
. O 0 7.210344961094961e-07

The O 0 6.94416655733221e-07
mutant O 0 2.4896376999095082e-05
myotubes O 0 0.0004472691216506064
exhibit O 0 2.218343752247165e-06
smaller O 0 1.5818807241885224e-07
and O 0 3.0339890599861974e-08
slower O 0 1.979497028514743e-06
Ca2 O 0 2.895765192079125e-06
+ O 0 6.486208121714299e-07
responses O 0 3.200516296431033e-09
upon O 0 4.688621046966546e-09
triggering O 0 1.1656367178147775e-06
by O 0 8.346139424020294e-08
acetylcholine O 0 0.00023201799194794148
or O 0 1.5732420877156983e-07
high O 0 1.1901342986675445e-06
external O 0 5.055116616858868e-06
K O 0 2.3239057554746978e-05
+ O 0 1.30922262542299e-05
. O 0 1.0334644002796267e-06

In O 0 1.8202365481556626e-06
addition O 0 3.860024264668027e-07
, O 0 2.842579931439104e-07
we O 0 9.770434239442238e-09
observed O 0 1.1271771072074444e-08
that O 0 8.497962888931454e-10
these O 0 1.1773344521515128e-09
Ca2 O 0 2.7401267743698554e-06
+ O 0 4.7274566895794123e-05
transients O 0 3.1916792067931965e-05
partially O 0 6.343419499899028e-06
result O 0 5.774799660684948e-08
from O 0 1.751976341779482e-09
an O 0 1.5724065383082575e-09
influx O 0 2.7166107141596285e-09
of O 0 1.5171773559696788e-10
extracellular O 0 2.932823406354146e-08
Ca2 O 0 4.0336678353014577e-07
+ O 0 1.0300996677869989e-07
through O 0 5.175089801134902e-10
the O 0 3.058846687054029e-08
l O 0 0.0026187344919890165
- O 0 2.299198786204215e-05
type O 0 1.6832224503104953e-07
Ca2 O 0 1.2504323194661993e-06
+ O 0 1.0386398798800656e-06
channel O 0 1.708684521872783e-06
. O 0 1.1089759937021881e-06

Neither O 0 8.745894774619956e-06
the O 0 9.798132794003322e-08
content O 0 5.275403225368791e-08
nor O 0 5.8028330585102594e-08
the O 0 9.067212536351121e-10
activity O 0 7.057018081013666e-09
of O 0 5.534311675603476e-09
Na O 0 1.958832763193641e-05
+ O 0 1.8394725884718355e-06
/ O 0 2.6250509677083755e-07
K O 0 3.126420153876097e-07
+ O 0 2.3321626940742135e-07
ATPase O 0 1.7393401776644168e-06
and O 0 1.4178096918726624e-08
sarcoplasmic O 0 5.625013272947399e-06
reticulum O 0 3.4500646961532766e-06
Ca2 O 0 1.258217025679187e-06
+ O 0 2.1949033452983713e-06
- O 0 3.357577952556312e-05
ATPase O 0 8.160658762790263e-05
are O 0 2.7502065069739956e-09
affected O 0 1.5630899241614316e-08
by O 0 7.86908813665832e-08
DMPK O 0 0.0011290276888757944
absence O 0 3.7517438613576815e-06
. O 0 2.694325758056948e-06

In O 0 1.8890946194005664e-06
conclusion O 0 8.357989713658753e-07
, O 0 2.5564889938323176e-07
our O 0 1.5753823134900813e-08
data O 0 3.691722270104947e-07
suggest O 0 2.3260520265466766e-07
that O 0 3.4459699804756383e-07
DMPK O 0 0.04159203916788101
is O 0 2.8396746287739916e-08
involved O 0 1.3256690856167097e-08
in O 0 1.2139341087902267e-08
modulating O 0 1.0724584171839524e-06
the O 0 8.48117487350919e-09
initial O 0 2.6762656091250392e-08
events O 0 5.736450869875398e-09
of O 0 2.103530682973087e-09
excitation O 0 3.484249759821978e-07
- O 0 0.0008613975369371474
contraction O 0 8.522588359483052e-06
coupling O 0 3.9188698792713694e-06
in O 0 2.077375711451168e-06
skeletal O 1 0.6485535502433777
muscle O 0 0.0033992910757660866
. O 0 2.5322560759377666e-06
. O 0 5.624584446195513e-06

Constitutional O 0 0.000120746080938261
RB1 O 1 0.5886358022689819
- O 0 0.159694641828537
gene O 0 5.739263360737823e-05
mutations O 0 1.8314680346520618e-05
in O 0 5.24782262800727e-06
patients O 0 2.520414454920683e-06
with O 0 5.839667210238986e-06
isolated O 0 0.0018440164858475327
unilateral B-Disease 0 0.0008294208091683686
retinoblastoma I-Disease 0 0.015298666432499886
. O 0 2.7814390705316328e-05

In O 0 1.3379659321799409e-05
most O 0 1.3895511301598162e-06
patients O 0 3.7633035390172154e-06
with O 0 1.3749441905019921e-06
isolated O 0 7.290784560609609e-05
unilateral B-Disease 0 0.00022833504772279412
retinoblastoma I-Disease 1 0.5355163216590881
, O 0 0.0006303191184997559
tumor B-Disease 0 0.013787224888801575
development O 0 3.0136908435451915e-07
is O 0 8.413040042398734e-09
initiated O 0 4.005950415830739e-08
by O 0 6.7071272980001595e-09
somatic O 0 4.1374835291208e-07
inactivation O 0 7.579900557175279e-05
of O 0 6.459686119342223e-09
both O 0 1.2056571740970412e-08
alleles O 0 2.474121529871809e-08
of O 0 6.926135220908236e-09
the O 0 1.7314442857241374e-06
RB1 O 0 0.03446587547659874
gene O 0 3.614901970649953e-06
. O 0 3.44400291396596e-06

However O 0 1.0293635568814352e-05
, O 0 6.100927976149251e-07
some O 0 2.1556254559129684e-09
of O 0 1.849059572123224e-08
these O 0 2.0553882507101662e-07
patients O 0 9.449352091905894e-07
can O 0 7.726753636916328e-08
transmit O 0 3.13549317070283e-05
retinoblastoma B-Disease 0 0.0019111208384856582
predisposition O 0 1.4427989299292676e-05
to O 0 2.0157019164912526e-08
their O 0 1.9784430094205163e-07
offspring O 0 1.2716914170596283e-05
. O 0 6.6923084887093864e-06

To O 0 1.6058115193118283e-07
determine O 0 1.5947985332331882e-07
the O 0 1.1692853796319014e-08
frequency O 0 1.1018165224641052e-07
and O 0 1.2228396428781707e-07
nature O 0 2.1698827623595207e-08
of O 0 3.7348377723844806e-09
constitutional O 0 9.69379016169114e-07
RB1 O 0 0.13513995707035065
- O 0 0.0038772528059780598
gene O 0 8.376734967896482e-07
mutations O 0 2.980594899781863e-07
in O 0 6.575571092071186e-07
patients O 0 2.770526066342427e-07
with O 0 8.255213970187469e-07
isolated O 0 0.0005843641120009124
unilateral B-Disease 0 0.0001399702887283638
retinoblastoma I-Disease 0 0.002376820659264922
, O 0 1.5530207519987016e-07
we O 0 3.7527039253859584e-09
analyzed O 0 1.1705287050745028e-07
DNA O 0 8.187447747332044e-06
from O 0 2.319395662198076e-07
peripheral O 0 0.0008745442610234022
blood O 0 7.150910823838785e-05
and O 0 4.5061692617309745e-06
from O 0 1.3630669855047017e-05
tumor B-Disease 0 0.3392927050590515
tissue O 0 0.008370750583708286
. O 0 3.8963979022810236e-05

The O 0 4.156744068950502e-07
analysis O 0 1.6549265637877397e-06
of O 0 5.7457673392491415e-06
tumors B-Disease 1 0.9996175765991211
from O 0 1.0364807394580566e-06
54 O 0 1.4105872651271056e-05
( O 0 1.316465016998336e-07
71 O 0 6.790854058635887e-06
% O 0 5.279046888517769e-08
) O 0 2.4544979382312704e-08
of O 0 2.0137228773364768e-08
76 O 0 1.9281296772533096e-05
informative O 0 4.694986728281947e-06
patients O 0 4.572955276671564e-06
showed O 0 0.00470640417188406
loss O 0 0.0009795700898393989
of O 0 6.880921432639298e-08
constitutional O 0 2.130600478267297e-05
heterozygosity O 0 0.3474721312522888
( O 0 1.863426950876601e-05
LOH O 1 0.7592349052429199
) O 0 4.0330215256290103e-07
at O 0 2.0888678591290955e-06
intragenic O 0 0.0003352734202053398
loci O 0 1.7138170278485632e-06
. O 0 4.0294562495546415e-06

Three O 0 4.811424787476426e-07
of O 0 5.030264560446085e-07
13 O 0 3.5077104257652536e-05
uninformative O 0 0.0992327630519867
patients O 0 2.6215979232802056e-05
had O 0 8.081064152065665e-06
constitutional O 0 3.4366207728453446e-06
deletions O 0 0.0001228736073244363
. O 0 4.654447911889292e-05

For O 0 1.6079231102139602e-07
39 O 0 3.5904866990676965e-07
randomly O 0 2.2794246490320802e-07
selected O 0 2.4798155209282413e-06
tumors B-Disease 1 0.999239444732666
, O 0 5.3260423555911984e-06
SSCP O 0 0.002052775351330638
, O 0 8.0387349044031e-07
hetero O 0 3.4324089938309044e-05
- O 0 0.0002682862977962941
duplex O 0 0.0027919874992221594
analysis O 0 3.78680127255393e-08
, O 0 5.863398655492347e-09
sequencing O 0 2.4304739554281696e-07
, O 0 1.0400061967175134e-07
and O 0 2.592387460254031e-08
Southern O 0 4.0397956979632e-08
blot O 0 1.605813486094121e-05
analysis O 0 6.689282372462912e-08
were O 0 2.2076465100440146e-08
used O 0 1.642844438265456e-08
to O 0 1.1701621893678293e-08
identify O 0 6.166712296362675e-07
mutations O 0 1.3640868701259024e-06
. O 0 6.647786904068198e-06

Mutations O 0 9.666090591053944e-06
were O 0 4.008190330750949e-07
detected O 0 7.197620107035618e-06
in O 0 2.3328300358116394e-07
21 O 0 2.2933324999030447e-06
( O 0 1.1047288950294387e-07
91 O 0 6.31793545835535e-06
% O 0 4.05929085900425e-08
) O 0 3.105564871930255e-08
of O 0 7.765492426869969e-08
23 O 0 0.010629338212311268
tumors B-Disease 1 0.9998113512992859
with O 0 0.00024471088545396924
LOH O 1 0.9909576177597046
. O 0 3.0377981602214277e-05

In O 0 4.7293328861997e-06
6 O 0 9.5708055596333e-06
( O 0 2.96297855584271e-07
38 O 0 1.4250016420191969e-06
% O 0 5.751660481223553e-08
) O 0 3.1627784835563943e-08
of O 0 2.4810351106907547e-08
16 O 0 0.00036416956572793424
tumors B-Disease 1 0.999921441078186
without O 0 1.4774389455851633e-05
LOH O 1 0.9428678154945374
, O 0 4.3209527689214156e-07
one O 0 1.0221142154875906e-08
mutation O 0 3.5060754299820474e-08
was O 0 4.4366211113811005e-06
detected O 0 1.6563318467888166e-06
, O 0 9.421693647482243e-08
and O 0 7.557127190693791e-08
in O 0 5.161195915093231e-08
9 O 0 1.7856174281405401e-06
( O 0 2.5230201927683993e-08
56 O 0 1.0068466735901893e-06
% O 0 1.0762309265999193e-08
) O 0 1.5551973930882923e-08
of O 0 1.7091254633783137e-08
the O 0 0.00013511793804354966
tumors B-Disease 1 0.9999499320983887
without O 0 5.22735399499652e-06
LOH O 1 0.8855381608009338
, O 0 1.6784184708740213e-07
both O 0 8.805765006059119e-09
mutations O 0 1.3100589058012702e-07
were O 0 3.0529309924531844e-07
found O 0 6.066018158890074e-06
. O 0 8.627227543911431e-06

Thus O 0 6.0216934798518196e-06
, O 0 4.882670054939808e-07
a O 0 8.590269828800956e-09
total O 0 3.820235683349438e-09
of O 0 2.5520194846251343e-09
45 O 0 3.174615414991422e-07
mutations O 0 3.039294824702665e-07
were O 0 1.071491766424515e-07
identified O 0 2.7535836579772877e-06
in O 0 2.0435727492440492e-05
tumors B-Disease 1 0.999062716960907
of O 0 5.385543886404776e-07
36 O 0 0.00015354335482697934
patients O 0 1.1201364941371139e-05
. O 0 1.3980760741105769e-05

Thirty O 0 3.751278427444049e-06
- O 0 6.8618894147221e-05
nine O 0 2.7919679723709123e-07
of O 0 1.0268605521446261e-08
the O 0 1.5981839851519908e-08
mutations O 0 8.24269150712098e-08
- O 0 9.769813914317638e-06
including O 0 9.266848621791723e-09
34 O 0 1.2408250427142775e-07
small O 0 2.691582245972768e-08
mutations O 0 2.8587495037868393e-08
, O 0 2.950013389124706e-08
2 O 0 1.9593694844388665e-07
large O 0 2.0810767864531954e-07
structural O 0 3.18904421874322e-05
alterations O 0 3.8144678455864778e-06
, O 0 1.0913171166748725e-07
and O 0 1.9439249854258378e-07
hypermethylation O 0 0.0001458738261135295
in O 0 4.1547150431142654e-07
3 O 0 0.001155378995463252
tumors O 1 0.9997132420539856
- O 0 0.006014005746692419
were O 0 3.127765069166344e-07
not O 0 1.6251176404580292e-08
detected O 0 1.924769321703934e-07
in O 0 4.1889753887858205e-09
the O 0 9.202699047250462e-09
corresponding O 0 5.23596739299137e-08
peripheral O 0 0.0002074194053420797
blood O 0 9.008740016724914e-05
DNA O 0 0.00023613963276147842
. O 0 2.9542099582613446e-05

In O 0 3.5427526654530084e-06
6 O 0 1.5667510524508543e-05
( O 0 2.6405703579257533e-07
17 O 0 1.1560528037080076e-06
% O 0 3.2570319774549716e-08
) O 0 6.996559775984679e-09
of O 0 1.4584827789931865e-09
the O 0 1.8768965048820974e-07
36 O 0 1.9333407180965878e-05
patients O 0 5.233870865595236e-07
, O 0 1.4883342203120264e-07
a O 0 4.168931155845712e-08
mutation O 0 1.310017552214049e-07
was O 0 4.936744062433718e-06
detected O 0 4.052793087794271e-07
in O 0 9.678658763334624e-09
constitutional O 0 5.565902938542422e-08
DNA O 0 6.263000250328332e-05
, O 0 7.063766815917916e-07
and O 0 1.0923061921630506e-07
1 O 0 1.2476855992815672e-08
of O 0 2.1691080043240163e-09
these O 0 8.530950168506024e-09
mutations O 0 1.4024875838458684e-07
is O 0 1.6199988905896134e-08
known O 0 3.7401719055196736e-08
to O 0 2.0675962275618076e-08
be O 0 1.9202694545583654e-08
associated O 0 1.70208167560304e-07
with O 0 5.095523647469236e-07
reduced O 0 6.239752110559493e-06
expressivity O 0 0.0024985955096781254
. O 0 1.872326356533449e-05

The O 0 5.198164672037819e-07
presence O 0 1.290413962351522e-07
of O 0 1.706936281209437e-08
a O 0 8.0065881036262e-08
constitutional O 0 3.344946719607833e-07
mutation O 0 7.749688393232645e-07
was O 0 4.76579116366338e-05
not O 0 3.009603517512005e-07
associated O 0 2.790892494886066e-07
with O 0 3.276597126955494e-08
an O 0 6.88902375145517e-08
early O 0 2.6296088435628917e-06
age O 0 6.89833223077585e-06
at O 0 2.554857564973645e-05
treatment O 0 1.3987987586006057e-05
. O 0 1.3010007023694925e-05

In O 0 8.774449270276818e-06
1 O 0 4.7971479943953454e-06
patient O 0 2.9111299681972014e-06
, O 0 6.355696768878261e-07
somatic O 0 5.234657237451756e-06
mosaicism O 0 0.0028516214806586504
was O 0 1.4980251762608532e-05
demonstrated O 0 1.5858200868024142e-06
by O 0 3.485026667249258e-08
molecular O 0 1.2971423757335288e-06
analysis O 0 3.548770877159768e-08
of O 0 5.528456359371603e-09
DNA O 0 7.894463124102913e-06
and O 0 5.00305191053485e-07
RNA O 0 1.556297434035514e-06
from O 0 2.236633065422211e-07
peripheral O 0 0.000361822807462886
blood O 0 0.00020432312157936394
. O 0 1.9293491277494468e-05

In O 0 3.0424200303968973e-05
2 O 0 0.00018957347492687404
patients O 0 2.0866420982201817e-06
without O 0 2.5264201397590114e-08
a O 0 3.871201670335722e-08
detectable O 0 3.330330287099059e-07
mutation O 0 6.014893472183758e-08
in O 0 1.6262050905879732e-07
peripheral O 0 0.001734676887281239
blood O 0 0.0004100155201740563
, O 0 5.755249276262475e-06
mosaicism O 0 0.0035922382958233356
was O 0 3.147920870105736e-05
suggested O 0 2.4375940483878367e-06
because O 0 5.001716019137348e-08
1 O 0 2.134567900213824e-08
of O 0 1.1431338542422509e-08
the O 0 3.0646069717477076e-06
patients O 0 1.5318160876631737e-05
showed O 0 0.07228317856788635
multifocal O 1 0.9997193217277527
tumors B-Disease 1 0.9999749660491943
and O 0 4.703608738054754e-07
the O 0 1.9154628105866323e-08
other O 0 1.918120595689743e-08
later O 0 1.7165306189781404e-06
developed O 0 3.076143912039697e-06
bilateral B-Disease 0 2.985351784445811e-05
retinoblastoma I-Disease 0 0.00665638642385602
. O 0 2.7094691176898777e-05

In O 0 4.018795152660459e-06
conclusion O 0 1.098837969948363e-06
, O 0 2.4272750920317776e-07
our O 0 1.3637231788266035e-08
results O 0 4.685101373524958e-08
emphasize O 0 2.5904697054102144e-08
that O 0 6.940284791312479e-09
the O 0 1.420532669271779e-08
manifestation O 0 7.068443892421783e-07
and O 0 3.7334513081077603e-07
transmissibility O 0 6.450917135225609e-05
of O 0 3.941234538729077e-08
retinoblastoma B-Disease 0 8.463184349238873e-05
depend O 0 1.2334978372052774e-08
on O 0 5.315034812269914e-08
the O 0 3.326710995565918e-08
nature O 0 2.5031186012824946e-08
of O 0 1.7095387327970002e-09
the O 0 1.5150186882806338e-08
first O 0 1.7544451225148805e-08
mutation O 0 2.043858771116902e-08
, O 0 6.784170114570998e-09
its O 0 6.935864771406841e-09
time O 0 1.774915858732129e-08
in O 0 3.8299923232898436e-08
development O 0 1.1254245890768289e-07
, O 0 9.258690880642462e-08
and O 0 2.6418742749001467e-08
the O 0 1.3136821630510553e-09
number O 0 3.920776758814526e-10
and O 0 2.386279440713679e-08
types O 0 1.7085811876427215e-08
of O 0 3.159691175369517e-08
cells O 0 4.4223852455616e-06
that O 0 1.0272605521777223e-07
are O 0 7.281407032877496e-09
affected O 0 7.053346706697994e-08
. O 0 2.1389945459304727e-07
. O 0 2.9443917810567655e-06

Hereditary B-Disease 1 0.9975009560585022
deficiency I-Disease 1 0.9959704875946045
of I-Disease 0 1.0244546899684792e-07
the I-Disease 0 1.1992541715244442e-07
fifth I-Disease 0 1.3691111462321714e-06
component I-Disease 0 1.3800882925352198e-07
of I-Disease 0 3.1252196386333253e-09
complement I-Disease 0 1.340388280368643e-07
in O 0 4.685061298914661e-07
man O 0 7.796882709953934e-05
. O 0 9.481284905632492e-06

I O 0 0.0009160147747024894
. O 0 0.00013743351155426353

Clinical O 0 0.0006204391247592866
, O 0 8.895945939002559e-05
immunochemical O 0 0.03870917111635208
, O 0 7.969829312060028e-06
and O 0 5.82971233598073e-06
family O 0 0.00011629953951342031
studies O 0 1.0348767318646424e-06
. O 0 3.844751972792437e-06

The O 0 1.0024308494394063e-06
first O 0 7.670454351682565e-07
recognized O 0 7.346823167608818e-07
human O 0 4.926124802295817e-06
kindred O 0 0.012034746818244457
with O 0 0.0023275301791727543
hereditary B-Disease 1 0.9990411400794983
deficiency I-Disease 1 0.8887258768081665
of I-Disease 0 1.092018386827931e-08
the I-Disease 0 8.493304193279982e-08
fifth I-Disease 0 2.0714389847853454e-06
component I-Disease 0 2.541580386150599e-07
of I-Disease 0 1.211036426695955e-08
complement I-Disease 0 7.25927748135291e-07
( O 0 2.2210737427030836e-07
C5 O 0 0.00316499057225883
) O 0 3.5056581282333354e-07
is O 0 8.661000805432195e-08
described O 0 2.3678056095377542e-05
. O 0 1.0975604709528852e-05

The O 0 7.651293344679289e-06
proband O 0 0.008784853853285313
, O 0 7.688573191444448e-07
a O 0 3.0434129882905836e-08
20 O 0 6.618503078925642e-08
- O 0 0.00010087317059515044
year O 0 9.384233976561518e-07
- O 0 0.00014144992746878415
old O 0 5.8111545513384044e-05
black O 0 0.00014364712114911526
female O 0 3.104881034232676e-05
with O 0 0.24171598255634308
systemic B-Disease 1 0.9999760389328003
lupus I-Disease 1 0.9999785423278809
erythematosus I-Disease 1 0.9999696016311646
since O 0 0.0037608447019010782
age O 0 1.1827913112938404e-05
11 O 0 1.0824937817233149e-05
, O 0 4.193745098746149e-06
lacked O 0 0.000140153118991293
serum O 0 0.003975714556872845
hemolytic O 0 0.05978008359670639
complement O 0 2.078533256621995e-08
activity O 0 1.0941620587345824e-07
, O 0 8.189629596699888e-08
even O 0 6.212411562955822e-08
during O 0 9.73112832980405e-07
remission O 0 4.062047810293734e-05
. O 0 5.859091743332101e-06

C5 O 0 0.19349636137485504
was O 0 0.0002477505477145314
undetectable O 0 9.738359221955761e-05
in O 0 6.127423830548651e-07
her O 0 2.304379449924454e-05
serum O 0 1.2418789992807433e-05
by O 0 2.019823774901397e-08
both O 0 1.224396442012221e-07
immunodiffusion O 0 0.028282081708312035
and O 0 9.02922693057917e-05
hemolytic O 1 0.841788649559021
assays O 0 2.374268115090672e-05
. O 0 1.0657399798219558e-05

Other O 0 7.487598452371458e-08
complement O 0 1.2584855824115948e-07
components O 0 5.046678666076332e-07
were O 0 2.851647984414285e-08
normal O 0 3.973593365458328e-08
during O 0 3.4189835673714697e-07
remission O 0 2.9411280593194533e-06
of O 0 1.3460338550430606e-06
lupus O 1 0.9401707649230957
, O 0 1.4344834653456928e-06
but O 0 3.8257181245171523e-07
C1 O 0 0.00026722560869529843
, O 0 1.0720764009874983e-07
C4 O 0 0.008107957430183887
, O 0 1.5314651591324946e-06
C2 O 0 0.0019055866869166493
, O 0 1.4270536041749438e-07
and O 0 3.691271786010475e-07
C3 O 0 0.006444984115660191
levels O 0 4.901294232695363e-07
fell O 0 0.0034048883244395256
during O 0 6.775715974072227e-06
exacerbations O 0 0.0046408106572926044
. O 0 7.746933079033624e-06

A O 0 4.680940037360415e-06
younger O 0 1.076196349458769e-05
half O 0 3.164002009725664e-06
- O 0 0.01012232806533575
sister O 0 0.004796819295734167
, O 0 6.208163085830165e-06
who O 0 1.1498665116960183e-05
had O 0 0.00023257661086972803
no O 0 2.9064252885291353e-05
underlying O 1 0.7256481051445007
disease O 0 0.033713921904563904
, O 0 9.799085091799498e-06
was O 0 0.00031644085538573563
also O 0 1.4302446516012424e-06
found O 0 6.235203500182251e-07
to O 0 3.4680184057833685e-08
lack O 0 9.491637911196449e-07
immunochemically O 0 0.003386514727026224
detectable O 0 1.2718382095044944e-05
C5 O 0 0.0017844202229753137
. O 0 5.082806183054345e-06

By O 0 0.0001582698168931529
hemolytic O 1 0.990954577922821
assay O 0 0.0009242912638001144
, O 0 1.7562082575750537e-05
she O 0 4.435876689967699e-06
exhibited O 0 2.792343423152488e-07
1 O 0 2.6376248740689334e-08
- O 0 3.700078377733007e-05
2 O 0 7.99549127350474e-07
% O 0 1.4819678817445947e-09
of O 0 1.5138214293219932e-10
the O 0 2.3846311592023994e-09
normal O 0 3.8613787722852067e-08
serum O 0 3.88101170756272e-06
C5 O 0 4.8109428462339565e-05
level O 0 6.702383092971331e-09
and O 0 1.8207746421694537e-08
normal O 0 6.12293460378055e-09
concentrations O 0 9.339530926411044e-09
of O 0 2.3740243104697356e-10
other O 0 1.3507787111066705e-09
complement O 0 4.708617495907674e-08
components O 0 2.072798679364496e-06
. O 0 1.2351549685263308e-06

C5 O 0 0.05209670960903168
levels O 0 6.324259175016778e-06
of O 0 5.845200590215427e-08
other O 0 1.1288212675708564e-07
family O 0 2.6489592528378125e-06
members O 0 4.541698572779751e-09
were O 0 8.883110247381865e-09
either O 0 4.547245691099988e-09
normal O 0 1.0413316431368003e-08
or O 0 2.5829113070585663e-08
approximately O 0 7.568923265921512e-09
half O 0 7.882998431796295e-08
- O 0 0.00044993110350333154
normal O 0 3.3298286439276126e-07
, O 0 6.528233598146471e-07
consistent O 0 3.793521443640202e-07
with O 0 3.884066245518625e-05
autosomal O 0 0.2551277279853821
codominant O 0 0.2015313357114792
inheritance O 0 7.689007361477707e-06
of O 0 7.628170983764448e-09
the O 0 3.253263969327236e-07
gene O 0 1.9559320207918063e-05
determining O 0 0.0011459984816610813
C5 B-Disease 1 0.9999017715454102
deficiency I-Disease 1 0.9997041821479797
. O 0 4.8946294555207714e-05

Normal O 0 0.0011207264615222812
hemolytic O 1 0.9940516352653503
titers O 0 0.0014978679828345776
were O 0 6.895779733895324e-07
restored O 0 1.4838020661045448e-06
to O 0 8.937954376619928e-09
both O 0 2.081198857695199e-08
homozygous O 0 2.3371474526356906e-05
C5 B-Disease 1 0.9997861981391907
- I-Disease 1 0.9992973804473877
deficient I-Disease 1 0.9999152421951294
( O 0 1.3767148629995063e-05
C5D B-Disease 1 0.999743640422821
) O 0 3.680287591123488e-06
sera O 0 9.352434972242918e-06
by O 0 3.0400928441309816e-09
addition O 0 1.341315503111673e-09
of O 0 1.9927606231817663e-09
highly O 0 9.56729024892411e-08
purified O 0 8.112360205814184e-07
human O 0 1.2932687241118401e-06
C5 O 0 0.006117545533925295
. O 0 5.6509775276936125e-06

In O 0 4.462521303594258e-07
specific O 0 1.0703622166374771e-07
C5 O 0 0.005355733912438154
titrations O 0 0.003946216311305761
, O 0 6.657792255282402e-06
however O 0 3.7457766666193493e-07
, O 0 1.9343418955486413e-07
it O 0 5.101474798152594e-08
was O 0 3.3266971968259895e-06
noted O 0 1.893566548005765e-07
that O 0 2.006572508150839e-08
when O 0 4.070797032795781e-08
limited O 0 2.194471493410788e-09
amounts O 0 1.2522529679870331e-09
of O 0 1.924822967680484e-09
C5 O 0 0.0004918338963761926
were O 0 3.582523433465212e-08
assayed O 0 7.743490755274252e-07
in O 0 1.8047444649837985e-09
the O 0 1.615696465506744e-09
presence O 0 3.7853551404509744e-09
of O 0 2.832775791716813e-09
low O 0 2.2126003784705972e-07
dilutions O 0 3.1698432394478004e-06
of O 0 1.0598426136709804e-08
either O 0 9.304591799264017e-07
C5D B-Disease 1 0.9993451237678528
serum O 0 0.00013617247168440372
, O 0 6.458062529191011e-08
curving O 0 6.906171847731457e-07
rather O 0 2.7167714744535942e-09
than O 0 7.093464149399153e-10
linear O 0 5.80488084267472e-08
dose O 0 5.522336365970659e-08
- O 0 1.418039119016612e-05
response O 0 3.647981117183008e-08
plots O 0 8.287761374958791e-07
were O 0 1.2578723840306338e-07
consistently O 0 1.3325069403435919e-06
obtained O 0 2.5652076374171884e-07
, O 0 1.8272251622875046e-07
suggesting O 0 3.907753125531599e-07
some O 0 1.2252200365381327e-09
inhibitory O 0 1.2567397789098322e-06
effect O 0 4.941021529702994e-07
. O 0 1.6764106476330198e-06

Further O 0 1.6095137880256516e-06
studies O 0 6.398017262654321e-07
suggested O 0 9.33401054226124e-07
that O 0 4.222943417175884e-08
low O 0 6.978609121688351e-07
dilutions O 0 4.192156848148443e-05
of O 0 1.1164848956468632e-06
C5D B-Disease 1 0.9997891783714294
serum O 0 0.00014642346650362015
contain O 0 9.588664084958509e-08
a O 0 9.839578041237473e-08
factor O 0 1.6493709154019598e-06
( O 0 5.2075428413900227e-08
or O 0 3.163976600717433e-07
factors O 0 1.3407411358912213e-07
) O 0 5.072512365700277e-08
interfering O 0 2.595668604499224e-07
at O 0 5.5519183916885595e-08
some O 0 8.806864265631376e-11
step O 0 1.8084184816302695e-08
in O 0 3.205619236723578e-08
the O 0 1.883715640360606e-06
hemolytic O 0 0.4739157259464264
assay O 0 2.198156607846613e-06
of O 0 5.528554325451296e-08
C5 O 0 0.016801612451672554
, O 0 1.6744903064136452e-07
rather O 0 3.4400966519854137e-09
than O 0 9.354894636715017e-10
a O 0 1.7981825806145935e-08
true O 0 2.3373556814476615e-06
C5 O 0 0.008337418548762798
inhibitor O 0 1.759413135005161e-05
or O 0 2.051359388133278e-06
inactivator O 0 0.0015207653632387519
. O 0 7.160115728765959e-06

Of O 0 2.026627043960616e-06
clinical O 0 2.4082459276542068e-05
interest O 0 1.4445187161982176e-06
are O 0 2.8659941975206493e-08
( O 0 2.0138189782414884e-08
a O 0 3.7376548078782434e-08
) O 0 3.747062393699707e-08
the O 0 1.476697786273462e-08
documentation O 0 8.650382596897543e-07
of O 0 3.123313717878773e-06
membranous O 1 0.9991563558578491
glomerulonephritis B-Disease 1 0.9999703168869019
, O 0 0.06101410090923309
vasculitis B-Disease 1 0.9999386072158813
, O 0 0.06527667492628098
and O 1 0.9132100939750671
arthritis B-Disease 1 0.9999924898147583
in O 0 1.2677297718255431e-06
an O 0 1.1103691832659024e-07
individual O 0 1.612748405932507e-07
lacking O 0 1.946039446920622e-05
C5 O 0 0.4394610822200775
( O 0 9.310044646326787e-08
and O 0 2.623290917824761e-08
its O 0 2.907048823885816e-08
biologic O 0 0.0001809509558370337
functions O 0 7.392151779583855e-09
) O 0 6.008404085378061e-08
, O 0 1.929428208313766e-07
and O 0 4.889682827524666e-07
( O 0 1.4082787913594075e-07
b O 0 2.124188540619798e-06
) O 0 1.3535674803222264e-08
a O 0 1.2400840354587217e-08
remarkable O 0 2.2789452032156987e-06
propensity O 0 0.0004722600569948554
to O 0 5.32616104464978e-05
bacterial B-Disease 1 0.9995530247688293
infections I-Disease 1 0.8793159127235413
in O 0 5.8723326645804264e-08
the O 0 3.6261437230677984e-07
proband O 0 0.05484139919281006
, O 0 3.9991184053178586e-07
even O 0 2.3063284615432167e-08
during O 0 9.159411007431117e-09
periods O 0 4.362879835184685e-09
of O 0 3.683884086669309e-09
low O 0 6.597511514883081e-07
- O 0 1.9244374925619923e-05
dose O 0 2.7042977635005627e-08
or O 0 2.4612707427706937e-09
alternate O 0 6.101355420895516e-09
- O 0 0.00016036865417845547
day O 0 3.5299642604513792e-06
corticosteroid O 0 5.323068762663752e-05
therapy O 0 6.785434834455373e-06
. O 0 2.556889512561611e-06

Other O 0 4.7467744934692746e-07
observations O 0 1.2413428294166806e-06
indicate O 0 1.2190943152745604e-06
that O 0 8.345470803305943e-08
the O 0 1.0468498885529698e-06
C5D B-Disease 1 0.9979268312454224
state O 0 1.2049586928242206e-07
is O 0 5.937562885804937e-09
compatible O 0 5.20010416948935e-07
with O 0 1.0843496056622826e-07
normal O 0 2.7668190227814193e-07
coagulation O 0 2.117702752002515e-05
function O 0 8.728809675062621e-09
and O 0 1.43580072275995e-08
the O 0 7.28382332226829e-09
capacity O 0 3.4132426662836224e-08
to O 0 1.1584103454254091e-08
mount O 0 2.8483323148975614e-06
a O 0 2.6285655962965393e-07
neutrophilic O 0 0.053090739995241165
leukocytosis O 0 0.24010814726352692
during O 0 6.449261854868382e-05
pyogenic B-Disease 1 0.659877359867096
infection I-Disease 0 0.0003691453894134611
. O 0 1.2252437500137603e-06
. O 0 7.140960406104568e-06

Susceptibility O 0 0.021679166704416275
to O 0 0.008436606265604496
ankylosing B-Disease 1 0.9998644590377808
spondylitis I-Disease 1 0.9999600648880005
in O 0 0.0033935713581740856
twins O 0 0.06623727828264236
: O 0 4.1528494421072537e-07
the O 0 7.359892251201927e-09
role O 0 9.881514273502034e-09
of O 0 4.021956989674891e-09
genes O 0 9.552100976861766e-08
, O 0 1.7082265912904404e-06
HLA O 0 0.0002789690624922514
, O 0 1.3968796963581553e-07
and O 0 5.758982268844193e-08
the O 0 1.68590872817731e-07
environment O 0 1.5211539903248195e-05
. O 0 6.1326891227508895e-06

OBJECTIVE O 0 1.549867874928168e-06
To O 0 3.437291340446791e-08
determine O 0 8.460288114520154e-08
the O 0 9.450958771139994e-08
relative O 0 1.0688340807973873e-05
effects O 0 1.107172238334897e-06
of O 0 4.157805832960548e-08
genetic O 0 5.3481635404750705e-05
and O 0 1.2434835298336111e-05
environmental O 0 4.989375611330615e-06
factors O 0 2.8295676202105824e-07
in O 0 6.803408609812323e-07
susceptibility O 0 0.0016881113406270742
to O 0 0.032560307532548904
ankylosing B-Disease 1 0.9999868869781494
spondylitis I-Disease 1 0.9999932050704956
( O 0 9.627401595935225e-05
AS B-Disease 0 0.0017727643717080355
) O 0 6.749531621608185e-06
. O 0 1.0453580216562841e-05

METHODS O 0 4.914254532195628e-05
Twins O 0 0.0007975613698363304
with O 0 5.354323093342828e-06
AS B-Disease 0 0.00025819000438787043
were O 0 6.636978469032329e-07
identified O 0 8.567837426198821e-07
from O 0 2.176477487125794e-08
the O 0 1.5873392555931787e-07
Royal O 0 8.300312765641138e-05
National O 0 5.095261803944595e-05
Hospital O 0 0.0056451489217579365
for O 0 0.00013025519729126245
Rheumatic B-Disease 1 0.999871015548706
Diseases I-Disease 0 0.3486796021461487
database O 0 9.408916957909241e-05
. O 0 7.601637480547652e-05

Clinical O 0 7.507582631660625e-05
and O 0 1.2774492461176123e-05
radiographic O 0 0.0030229450203478336
examinations O 0 2.245045379822841e-06
were O 0 1.302456098528637e-07
performed O 0 6.74383002774448e-08
to O 0 3.0974543818729217e-08
establish O 0 1.8914741986009176e-06
diagnoses O 0 0.019946379587054253
, O 0 0.000839596672449261
and O 0 0.07446033507585526
disease O 0 0.2964506149291992
severity O 0 0.0017755867447704077
was O 0 3.270819433964789e-05
assessed O 0 4.943830731463095e-07
using O 0 7.523154543775945e-09
a O 0 4.038332335198902e-08
combination O 0 2.3378900948500814e-07
of O 0 7.270803514813906e-09
validated O 0 6.56205202176352e-07
scoring O 0 4.812539486920286e-07
systems O 0 0.00029376833117567003
. O 0 9.261140803573653e-06

HLA O 0 0.0011672242544591427
typing O 0 3.0096953196334653e-05
for O 0 1.554336392928235e-07
HLA O 0 0.00017945368017535657
- O 0 0.00026954803615808487
B27 O 0 3.334749271743931e-05
, O 0 3.7723549439760973e-07
HLA O 0 1.2693602911895141e-05
- O 0 4.6768363972660154e-05
B60 O 0 8.536619134247303e-06
, O 0 6.056902179807366e-08
and O 0 1.988422582144267e-07
HLA O 0 0.00021741502860095352
- O 0 0.0058707683347165585
DR1 O 0 0.05062374100089073
was O 0 2.0596828562702285e-06
performed O 0 1.4023611605296082e-08
by O 0 6.225005844129328e-09
polymerase O 0 5.880676781089278e-06
chain O 0 4.781992174685001e-06
reaction O 0 3.0380640225757816e-09
with O 0 5.416448400907825e-10
sequence O 0 3.1992772875355513e-09
- O 0 1.5972262872310239e-06
specific O 0 8.999928580166738e-10
primers O 0 2.4982996364997234e-06
, O 0 3.33326624968322e-07
and O 0 8.849434038893378e-07
zygosity O 0 0.0007944725221022964
was O 0 2.346385144846863e-06
assessed O 0 3.4932665471387736e-07
using O 0 1.800819120489905e-07
microsatellite O 0 0.0075447517447173595
markers O 0 0.0002407192951068282
. O 0 1.4752284187125042e-05

Genetic O 0 0.0002901022380683571
and O 0 4.537519998848438e-06
environmental O 0 5.0986540145459e-07
variance O 0 3.5233306050486135e-08
components O 0 5.102660452394048e-06
were O 0 1.044644335479461e-07
assessed O 0 1.7448846278966812e-07
with O 0 1.6982170336632407e-08
the O 0 4.886885562882526e-08
program O 0 6.506839440589829e-07
Mx O 0 0.00017925257270690054
, O 0 1.885191025507993e-08
using O 0 2.3083253086753075e-09
data O 0 8.093461190128437e-08
from O 0 5.694611004969374e-09
this O 0 3.323817221456693e-09
and O 0 6.929123941290527e-08
previous O 0 7.983071554917842e-07
studies O 0 4.3975447283628455e-08
of O 0 3.4416668626136016e-08
twins O 0 9.398623660672456e-05
with O 0 2.1691605525120394e-06
AS B-Disease 0 0.0021378512028604746
. O 0 3.2565709261689335e-05

RESULTS O 0 1.794351737771649e-05
Six O 0 3.592192285850615e-07
of O 0 8.586539479438215e-08
8 O 0 9.07029698282713e-06
monozygotic O 0 0.0011272658593952656
( O 0 1.1820737881862442e-06
MZ O 1 0.9697149991989136
) O 0 3.967091743106721e-06
twin O 0 0.021156037226319313
pairs O 0 0.00023373433214146644
were O 0 0.00023809201957192272
disease O 0 0.0011271799448877573
concordant O 0 0.0003714353370014578
, O 0 1.5712463437012048e-06
compared O 0 1.7034323036568821e-06
with O 0 3.012532445723082e-08
4 O 0 2.164988757158426e-07
of O 0 1.05217274892766e-08
15 O 0 4.6408192133640114e-07
B27 O 0 2.216740176663734e-05
- O 0 0.00012490525841712952
positive O 0 4.12137595162676e-08
dizygotic O 0 3.893222310580313e-05
( O 0 1.0291766727732465e-07
DZ O 0 0.02259046398103237
) O 0 3.6783328027922835e-07
twin O 0 0.0006646753172390163
pairs O 0 2.708717147470452e-06
( O 0 2.0989268989524135e-08
27 O 0 5.911530251978547e-07
% O 0 6.292668608409713e-09
) O 0 8.134484197341862e-09
and O 0 8.442101240291322e-09
4 O 0 2.508280338986424e-08
of O 0 6.584064404790979e-09
32 O 0 2.536536612751661e-06
DZ O 1 0.6510766744613647
twin O 0 0.0459752194583416
pairs O 0 7.67820074543124e-06
overall O 0 1.922397132148035e-06
( O 0 2.3286727213189806e-08
12 O 0 4.001131870268182e-08
. O 0 2.488983597004335e-08
5 O 0 1.6365714827770717e-07
% O 0 5.01523302887108e-08
) O 0 3.308935276891134e-07
. O 0 2.14744341064943e-06

Nonsignificant O 0 0.06653089821338654
increases O 0 1.956312553375028e-05
in O 0 1.5544817699719715e-07
similarity O 0 3.6562920513460995e-07
with O 0 1.1480769757099551e-07
regard O 0 1.2233623181145958e-07
to O 0 4.3647051484185795e-07
age O 0 7.408746751025319e-05
at O 0 0.06689448654651642
disease O 0 0.049696821719408035
onset O 0 0.0008577878470532596
and O 0 3.341834542425204e-07
all O 0 3.2895766111096236e-09
of O 0 1.1314855896671361e-07
the O 0 0.0004367873480077833
disease O 0 0.08169873058795929
severity O 0 0.00022956711472943425
scores O 0 4.57098849437898e-06
assessed O 0 4.998243639420252e-06
were O 0 9.84520625024743e-07
noted O 0 5.902674274693709e-06
in O 0 5.5508557124994695e-05
disease O 0 0.01097057107836008
- O 0 0.11804468184709549
concordant O 0 0.10411044955253601
MZ O 1 0.9986739158630371
twins O 0 0.0021789269521832466
compared O 0 1.0104691682499833e-05
with O 0 3.481317889963975e-06
concordant O 0 0.032050713896751404
DZ O 1 0.9913013577461243
twins O 0 0.008131851442158222
. O 0 2.4011233108467422e-05

HLA O 0 0.007854851894080639
- O 0 0.003174523124471307
B27 O 0 0.00050154491327703
and O 0 6.411573394871084e-06
B60 O 0 0.00015198563050944358
were O 0 1.2101033917133464e-06
associated O 0 8.648699463265075e-07
with O 0 2.7964927085122326e-07
the O 0 2.1954683688818477e-05
disease O 0 0.0014920079847797751
in O 0 8.302633887069533e-07
probands O 0 0.13677291572093964
, O 0 1.510799279458297e-06
and O 0 2.3093686252195766e-07
the O 0 2.164703829521386e-07
rate O 0 4.164848633081419e-06
of O 0 3.338706733302388e-07
disease O 0 5.3461957577383146e-05
concordance O 0 3.3694759622449055e-06
was O 0 9.548450179863721e-06
significantly O 0 5.41244617124903e-07
increased O 0 4.163043243465836e-08
among O 0 6.597480961545443e-08
DZ O 1 0.67038893699646
twin O 0 0.11693166196346283
pairs O 0 3.2864663808140904e-06
in O 0 7.246246269687617e-08
which O 0 1.2209682154207258e-07
the O 0 6.243968755370588e-07
co O 0 0.006501043681055307
- O 0 0.015566064976155758
twin O 0 0.031587377190589905
was O 0 1.3768664075541892e-06
positive O 0 7.536018475917672e-10
for O 0 1.097723023590902e-09
both O 0 3.033045814504476e-08
B27 O 0 2.9881144655519165e-05
and O 0 2.0441668766579824e-06
DR1 O 0 0.05185643583536148
. O 0 8.540837370674126e-06

Additive O 0 3.908463258994743e-05
genetic O 0 0.0003630909195635468
effects O 0 2.5070901756407693e-05
were O 0 1.2650800726987654e-06
estimated O 0 6.327103392322897e-07
to O 0 5.927515367432079e-09
contribute O 0 1.803444504844265e-08
97 O 0 2.8767621529368625e-07
% O 0 3.21406012915304e-09
of O 0 7.658315093195256e-10
the O 0 2.3136202287332708e-08
population O 0 2.2192651272234798e-08
variance O 0 1.3647422747453675e-07
. O 0 4.259323304722784e-06

CONCLUSION O 0 4.401671321829781e-05
Susceptibility O 0 0.00010734464012784883
to O 0 4.7135779368545627e-07
AS B-Disease 0 3.9053182263160124e-05
is O 0 1.6669919489231688e-07
largely O 0 1.9895114178325457e-07
genetically O 0 1.7876450328913052e-06
determined O 0 2.9878344776079757e-06
, O 0 5.013272925680212e-07
and O 0 3.034411975022522e-07
the O 0 3.1646948173147393e-07
environmental O 0 7.280073532456299e-06
trigger O 0 1.538399374112487e-05
for O 0 1.4973147699492984e-07
the O 0 3.5202971048420295e-05
disease O 0 0.005009504966437817
is O 0 3.202118250555941e-07
probably O 0 5.540648089663591e-06
ubiquitous O 0 7.764309702906758e-05
. O 0 1.6488378605572507e-05

HLA O 0 0.010121984407305717
- O 0 0.006354787386953831
B27 O 0 0.00020618189591914415
accounts O 0 2.487167023446091e-07
for O 0 7.502977794615617e-09
a O 0 3.1637558350894324e-08
minority O 0 1.2402335869410308e-07
of O 0 3.5797214081867423e-09
the O 0 2.1339904776596086e-07
overall O 0 9.625303391658235e-06
genetic O 0 1.9289425836177543e-05
susceptibility O 0 3.5247914638603106e-05
to O 0 4.987383590560057e-07
AS B-Disease 0 0.0003886110498569906
. O 0 1.6209782188525423e-05

Cell O 0 0.001592719811014831
cycle O 0 0.00024143735936377198
- O 0 0.0010620508110150695
dependent O 0 3.890064363076817e-06
colocalization O 0 9.397987014381215e-05
of O 0 3.516804625292025e-08
BARD1 O 0 0.0020018978975713253
and O 0 4.811075768884621e-07
BRCA1 O 0 2.459405550325755e-06
proteins O 0 1.3716638491700905e-08
in O 0 6.041013467239509e-09
discrete O 0 2.188188091167831e-06
nuclear O 0 0.0009725078125484288
domains O 0 2.1435434973682277e-06
. O 0 3.970945272158133e-06

Germ O 0 0.0988273099064827
- O 0 0.006219011265784502
line O 0 5.5507392971776426e-05
mutations O 0 4.131024979869835e-07
of O 0 7.518664801864361e-09
the O 0 2.404986787496455e-07
BRCA1 O 0 7.404375355690718e-05
gene O 0 8.062228289418272e-07
predispose O 0 5.772217264166102e-06
women O 0 5.119868973224584e-08
to O 0 1.2956122397156378e-08
early O 0 1.95874508790439e-06
- O 1 0.968390166759491
onset O 1 0.9245613217353821
breast B-Disease 1 0.9965104460716248
and I-Disease 1 0.9980461597442627
ovarian I-Disease 1 0.9999966621398926
cancer I-Disease 1 0.9997586607933044
by O 0 2.2047929633117747e-06
compromising O 0 9.727296855999157e-05
the O 0 2.570457979800267e-07
genes O 0 3.043676770175807e-06
presumptive O 0 0.12922795116901398
function O 0 5.6413597349092015e-08
as O 0 1.7855096956509442e-08
a O 0 5.808291803077736e-07
tumor B-Disease 0 0.003802419872954488
suppressor O 0 0.00020424557442311198
. O 0 8.88769773155218e-06

Although O 0 1.7230813682544976e-06
the O 0 3.359531319802045e-07
biochemical O 0 4.570332748699002e-05
properties O 0 2.0900954496028135e-06
of O 0 4.577391621296556e-08
BRCA1 O 0 4.3254392949165776e-05
polypeptides O 0 5.5968616834434215e-06
are O 0 1.1070339311913813e-08
not O 0 2.1876273237353416e-08
understood O 0 1.6122962165354693e-07
, O 0 2.2193836102246678e-08
their O 0 1.5747897430529179e-09
expression O 0 3.410032700656984e-09
pattern O 0 1.56099304149393e-06
and O 0 1.4168614370646537e-07
subcellular O 0 1.6197722061406239e-06
localization O 0 2.812003685903619e-06
suggest O 0 3.517945401654288e-08
a O 0 2.4135089482513195e-09
role O 0 2.1392104088135966e-08
in O 0 6.731275448146334e-08
cell O 0 0.0001135189231717959
- O 0 0.003726076800376177
cycle O 0 1.798941957531497e-05
regulation O 0 1.6830954336910509e-06
. O 0 1.809842274269613e-06

When O 0 1.63823915499961e-05
resting O 0 0.00031810568179935217
cells O 0 1.8677645130082965e-05
are O 0 2.6190662083536154e-08
induced O 0 6.489762199635152e-06
to O 0 3.4440770235733e-08
proliferate O 0 1.8793816707329825e-05
, O 0 3.459271624706162e-08
the O 0 1.2229651957795795e-08
steady O 0 2.3819288799131755e-06
- O 0 1.0174838280363474e-05
state O 0 7.831262749391499e-09
levels O 0 3.1334268513205643e-09
of O 0 1.24256227529429e-09
BRCA1 O 0 8.775878654887492e-07
increase O 0 8.233056014717022e-09
in O 0 7.824513481580198e-09
late O 0 1.634710315556731e-06
G1 O 0 0.08922955393791199
and O 0 5.997080876340988e-08
reach O 0 1.2216596623204623e-08
a O 0 1.0634667590991853e-09
maximum O 0 9.578460691272994e-09
during O 0 3.2140255257218087e-07
S O 0 0.0034093603026121855
phase O 0 3.204291942893178e-06
. O 0 2.3743900783301797e-06

Moreover O 0 4.8967209295369685e-05
, O 0 1.944074710991117e-06
in O 0 1.9168265907865134e-07
S O 0 0.0008302455535158515
phase O 0 1.4816598650213564e-06
cells O 0 1.4389501075129374e-06
, O 0 1.2531715753993922e-07
BRCA1 O 0 2.206839553764439e-06
polypeptides O 0 6.249765078791825e-07
are O 0 8.00701194236808e-09
hyperphosphorylated O 0 5.6855620641727e-05
and O 0 2.0429475000582897e-07
accumulate O 0 5.866689889444388e-07
into O 0 8.713339383348284e-09
discrete O 0 1.4457025372394128e-06
subnuclear O 0 0.0012890631332993507
foci O 0 5.254768984741531e-05
termed O 0 8.316253115481231e-06
" O 0 7.55110306727147e-07
BRCA1 O 0 1.6508454791619442e-05
nuclear O 0 0.00010457966709509492
dots O 0 3.708846270455979e-05
. O 0 9.23611059988616e-06

" O 0 0.0001262814039364457
BRCA1 O 0 0.00940017495304346
associates O 1 0.854110062122345
in O 0 2.200107019234565e-06
vivo O 0 0.00017702106561046094
with O 0 4.0364076880905486e-07
a O 0 4.790381922248343e-07
structurally O 0 0.002365413587540388
related O 0 1.7806940377340652e-05
protein O 0 1.1273876907580416e-06
termed O 0 5.8989026001654565e-05
BARD1 O 0 0.0174383744597435
. O 0 6.661292445642175e-06

Here O 0 4.309678388381144e-06
we O 0 9.349906804345665e-08
show O 0 6.24227212142614e-08
that O 0 2.1803572280987282e-09
the O 0 2.703073986864979e-09
steady O 0 7.639108048351773e-07
- O 0 3.6204681236995384e-05
state O 0 1.3540865317906992e-08
levels O 0 2.371111085253119e-09
of O 0 4.868387915024641e-09
BARD1 O 0 0.008128698915243149
, O 0 1.517425687325158e-07
unlike O 0 2.91081043712893e-08
those O 0 2.4548805210855562e-09
of O 0 1.672673377584033e-08
BRCA1 O 0 6.070845847716555e-05
, O 0 6.76513195685402e-07
remain O 0 5.257212620790597e-08
relatively O 0 1.6302463379247456e-08
constant O 0 1.7428050114176585e-08
during O 0 3.9085509229153104e-07
cell O 0 0.0003088375960942358
cycle O 0 4.244435694999993e-05
progression O 0 6.330950418487191e-05
. O 0 7.071301752148429e-06

However O 0 2.5868319426081143e-05
, O 0 1.8672924852580763e-05
immunostaining O 0 0.020288443192839622
revealed O 0 0.00030605250503867865
that O 0 1.3299919601195143e-06
BARD1 O 0 0.012271372601389885
resides O 0 2.5982938041124726e-06
within O 0 4.692038313436342e-09
BRCA1 O 0 6.651941021118546e-06
nuclear O 0 8.776783215580508e-05
dots O 0 3.19729565489979e-06
during O 0 6.248215527193679e-07
S O 0 0.0012447364861145616
phase O 0 7.930110257348133e-08
of O 0 1.2724316045265027e-09
the O 0 3.904750300876003e-08
cell O 0 9.010072244564071e-05
cycle O 0 5.5011182666930836e-06
, O 0 5.9477674341223974e-08
but O 0 5.718120199560417e-09
not O 0 4.2146028333966967e-10
during O 0 5.188088181284911e-09
the O 0 4.933958308583897e-08
G1 O 0 0.03226565569639206
phase O 0 7.869109140301589e-06
. O 0 2.8354343157843687e-06

Nevertheless O 0 0.00015076249837875366
, O 0 4.929485385218868e-06
BARD1 O 0 0.0017143877921625972
polypeptides O 0 3.7860793327126885e-06
are O 0 3.5238463258480124e-09
found O 0 1.6172110761658587e-08
exclusively O 0 2.504779494927334e-09
in O 0 4.6807491216327435e-09
the O 0 4.0485490515607125e-09
nuclear O 0 9.626318160371738e-07
fractions O 0 7.53506979034313e-10
of O 0 1.5494074079303033e-10
both O 0 5.213045550789275e-09
G1 O 0 0.0033023676369339228
- O 0 6.029604628565721e-05
and O 0 4.345483262113703e-07
S O 0 0.0006493347464129329
- O 0 1.8494090909371153e-05
phase O 0 1.55973111759522e-06
cells O 0 1.8156368923882837e-06
. O 0 1.0584839174043736e-06

Therefore O 0 3.924996235582512e-06
, O 0 7.154930017350125e-07
progression O 0 6.720647434121929e-06
to O 0 2.789019504234602e-07
S O 0 0.02849241904914379
phase O 0 6.032419605617179e-06
is O 0 4.316101254175919e-08
accompanied O 0 7.114933708862736e-08
by O 0 3.4880109911483714e-09
the O 0 2.518000252749175e-09
aggregation O 0 4.8807471841882943e-08
of O 0 1.558894879849504e-08
nuclear O 0 0.00016867076919879764
BARD1 O 0 2.9020300644333474e-05
polypeptides O 0 5.446019457622242e-08
into O 0 4.457434243931857e-08
BRCA1 O 0 1.7970369299291633e-05
nuclear O 0 0.00013748029596172273
dots O 0 3.5294135159347206e-05
. O 0 4.232937044434948e-06

This O 0 5.533764806386898e-07
cell O 0 9.361127740703523e-05
cycle O 0 2.8866172215202823e-05
- O 0 0.00026504529523663223
dependent O 0 8.152838404384966e-07
colocalization O 0 3.903256219928153e-05
of O 0 4.48864305724328e-08
BARD1 O 0 0.004032504744827747
and O 0 2.140730430255644e-06
BRCA1 O 0 4.241506030666642e-05
indicates O 0 2.98841058565813e-07
a O 0 5.865602226151623e-09
role O 0 3.040198848225373e-08
for O 0 4.512661533340179e-08
BARD1 O 0 0.0019159846706315875
in O 0 2.6567593636173115e-07
BRCA1 O 0 0.00010812324762810022
- O 0 0.009824305772781372
mediated O 0 0.005135107785463333
tumor B-Disease 0 0.056090231984853745
suppression O 0 9.98933392111212e-05
. O 0 1.0730910616985057e-05

Ethnic O 0 3.4318063626415096e-06
differences O 0 7.371396804956021e-06
in O 0 1.6441555317214807e-07
the O 0 1.0331633149007757e-07
HFE O 0 0.0001613790518604219
codon O 0 2.7095234145235736e-07
282 O 0 6.0798316553700715e-05
( O 0 8.86928035015444e-07
Cys O 0 0.004952986724674702
/ O 0 0.00012127689842600375
Tyr O 0 0.000488949241116643
) O 0 5.415844270828529e-07
polymorphism O 0 3.275137260061456e-06
. O 0 1.8346266870139516e-06

Recent O 0 2.0655781554523855e-05
studies O 0 1.5816212908248417e-06
have O 0 6.417810709535843e-07
shown O 0 1.094555227609817e-05
that O 0 0.0003250234585721046
hereditary B-Disease 1 0.9999624490737915
hemochromatosis I-Disease 1 0.9999959468841553
( O 0 0.0009096910362131894
HH B-Disease 1 0.9996305704116821
) O 0 8.050848009588663e-06
is O 0 1.9334528644776583e-07
likely O 0 3.455559749454551e-07
to O 0 3.596373332470648e-08
be O 0 6.990559597852553e-08
caused O 0 2.1413713966467185e-06
by O 0 7.181824202007192e-08
homozygosity O 0 0.0002701665216591209
for O 0 4.2096077734754545e-09
a O 0 1.3708431367831508e-07
Cys282Tyr O 0 0.000631730305030942
mutation O 0 6.70391955281957e-08
in O 0 1.2776683711024361e-08
the O 0 8.956935459991655e-08
HFE O 0 0.00021799707610625774
gene O 0 1.8178047866967972e-07
located O 0 1.7214800607234793e-07
4 O 0 3.645272954599932e-06
. O 0 5.8033360801346134e-06

5 O 0 1.692175464995671e-05
Mb O 0 0.0021661370992660522
telomeric O 0 0.004097677301615477
to O 0 1.5551074739050819e-06
HLA O 0 0.0006753892521373928
- O 0 0.0005087975296191871
A O 0 4.01219313062029e-06
. O 0 9.579626748745795e-06

Population O 0 2.7967300866293954e-06
studies O 0 2.8316438260844734e-07
of O 0 9.47394873662688e-09
this O 0 1.2062391085976287e-08
polymorphism O 0 7.704766176175326e-07
are O 0 1.896528933897912e-09
facilitated O 0 1.5253358753852808e-07
by O 0 1.9270867568366157e-08
the O 0 5.224694632488536e-08
fact O 0 8.626626168961593e-08
that O 0 1.9709547771640246e-08
the O 0 2.1558696516876807e-07
Cys282Tyr O 0 0.001254718634299934
mutation O 0 6.621117165650503e-08
creates O 0 1.8955032032863528e-07
a O 0 2.41146778989787e-07
Rsal O 0 0.0008382113883271813
restriction O 0 5.282482220536622e-07
site O 0 2.066179149551317e-06
. O 0 1.96512155525852e-06

We O 0 5.033882644056575e-07
have O 0 1.7757827208697563e-08
studied O 0 8.185659261528144e-09
the O 0 1.5219111526576512e-09
codon O 0 2.193250914217515e-08
282 O 0 7.718615051999222e-06
( O 0 7.347790642597829e-08
Cys O 0 0.0005420663510449231
/ O 0 8.26046471047448e-06
Tyr O 0 3.085970820393413e-05
) O 0 2.0388284838190884e-08
polymorphism O 0 5.6223363742446963e-08
in O 0 1.5151163657023403e-09
different O 0 3.0528574113120044e-10
ethnic O 0 2.09275867746328e-08
groups O 0 1.1883837913728712e-07
. O 0 4.861041816184297e-06

In O 0 3.4477818644518266e-06
agreement O 0 9.117110266743111e-07
with O 0 3.606760046181989e-08
previous O 0 1.3108250129789667e-07
observations O 0 4.318867752317601e-08
the O 0 5.5480118277273505e-08
Tyr O 0 0.000176386529346928
allele O 0 1.8610116967465729e-06
appeared O 0 1.0765799061118742e-06
to O 0 1.3130740050826262e-08
be O 0 2.0076253548495515e-08
rare O 0 2.2000912736075406e-07
or O 0 9.084946839266195e-08
absent O 0 4.4731993398272607e-07
in O 0 2.035733928096306e-07
Asiatic O 0 0.0015657554613426328
( O 0 5.231455446619293e-08
Indian O 0 1.2604614596511965e-07
, O 0 1.0013265949737615e-07
Chinese O 0 4.757256633070028e-08
) O 0 2.093513842282846e-07
populations O 0 3.073775474149443e-07
. O 0 1.0936410035355948e-06

The O 0 3.4389901770737197e-07
highest O 0 4.916569764645828e-07
allele O 0 4.926388328385656e-07
frequency O 0 2.410662887086801e-07
( O 0 2.620115502338649e-08
7 O 0 1.4437375739362324e-07
. O 0 4.149035959244429e-08
5 O 0 3.7607813396789425e-07
% O 0 4.8628219673219064e-08
) O 0 1.7576880395608896e-07
was O 0 2.15109594137175e-06
found O 0 3.4359482015133835e-07
in O 0 3.0265221084846416e-07
Swedes O 0 0.0002146205079043284
. O 0 8.598003660154063e-06

Saamis O 0 0.020077301189303398
( O 0 2.313347977178637e-06
2 O 0 1.9280630567664048e-06
% O 0 8.594354738988841e-08
) O 0 5.073228237506555e-08
and O 0 3.931512253529945e-07
Mordvinians O 0 0.00018168226233683527
( O 0 4.1917331827789894e-09
1 O 0 4.7880859277427135e-09
. O 0 6.550394893167777e-09
8 O 0 1.8349453512200853e-07
% O 0 1.4008294080269934e-08
) O 0 2.7814802905368197e-08
had O 0 3.1121234655984154e-07
significantly O 0 1.1332328142543702e-07
lower O 0 6.730707546864778e-09
frequencies O 0 1.7176181588141048e-09
of O 0 1.7201000623856544e-09
the O 0 1.0231483571487843e-07
Tyr O 0 0.00024217696045525372
allele O 0 4.160795469942968e-06
. O 0 1.8165063693231787e-06

Comparisons O 0 1.2749366078423918e-06
with O 0 1.2692876794062613e-07
allele O 0 1.909779712150339e-07
frequencies O 0 9.376248755188499e-08
based O 0 1.135341562985559e-06
on O 0 5.635430170514155e-06
prevalence O 0 0.0004945141263306141
estimates O 0 1.8062048184219748e-05
of O 0 6.024274625815451e-07
HH B-Disease 1 0.9855521321296692
showed O 0 1.855406299000606e-05
some O 0 8.214840474529694e-10
disagreements O 0 3.6992852869843773e-07
with O 0 1.2493525325396604e-08
the O 0 4.0040180948608395e-08
RFLP O 0 4.3227424612268806e-05
data O 0 2.4769178708083928e-06
, O 0 3.2619814760437293e-07
particularly O 0 9.568877601395798e-08
in O 0 1.1497468932475385e-07
Finns O 0 2.6245574190397747e-05
. O 0 6.506897079816554e-06

The O 0 1.980259867195855e-06
newly O 0 4.4979951780987903e-05
described O 0 0.00028167080017738044
HFE O 0 0.0030393232591450214
marker O 0 4.953353254677495e-06
provides O 0 8.840853382707792e-09
a O 0 5.498915545132377e-09
new O 0 1.7598207335822735e-08
approach O 0 2.0579884463245435e-08
to O 0 1.4714647278424309e-09
the O 0 3.29977556390304e-09
screening O 0 3.528414893594345e-08
of O 0 2.987293257206147e-08
HH B-Disease 0 0.33582210540771484
as O 0 1.0482805734568501e-08
well O 0 1.0694598095994934e-08
as O 0 7.024399284460969e-09
studies O 0 8.616197533228842e-09
of O 0 1.3121546071914736e-09
the O 0 1.8822412073404848e-08
relationship O 0 8.931106094678398e-07
between O 0 1.1857120796321396e-07
the O 0 4.591802564846148e-07
HFE O 0 0.010646692477166653
Tyr O 0 0.000539833796210587
allele O 0 3.165668204019312e-06
and O 0 1.4733378748132964e-06
different O 0 7.24804294804926e-07
disorders O 1 0.9304995536804199
including O 0 0.000603684049565345
cancer B-Disease 1 0.7981459498405457

Autosomal B-Disease 1 0.9822371602058411
dominant I-Disease 1 0.9854059219360352
neurohypophyseal I-Disease 1 0.9995449185371399
diabetes I-Disease 1 0.9997926354408264
insipidus I-Disease 1 0.9991238713264465
associated O 0 0.0001585072313901037
with O 0 5.87999807066808e-07
a O 0 9.86033725780544e-08
missense O 0 5.723763933929149e-07
mutation O 0 1.6231412658385125e-08
encoding O 0 1.0390009919092336e-07
Gly23 O 0 7.763755274936557e-05
- O 0 0.00032752746483311057
- O 0 0.002071948489174247
> O 0 4.243729563313536e-06
Val O 0 5.992236765450798e-05
in O 0 6.421864213734807e-07
neurophysin O 0 0.009596508927643299
II O 0 0.13258813321590424
. O 0 7.401532457151916e-06

Autosomal B-Disease 1 0.9826048016548157
dominant I-Disease 1 0.9923750758171082
neurohypophyseal I-Disease 1 0.9995566010475159
diabetes I-Disease 1 0.9997989535331726
insipidus I-Disease 1 0.9989782571792603
( O 0 0.00015196882304735482
ADNDI B-Disease 1 0.9719290733337402
) O 0 4.968235225533135e-05
is O 0 3.5491579183144495e-05
an O 1 0.5572629570960999
inherited B-Disease 1 0.9999972581863403
disease I-Disease 1 0.9999878406524658
caused O 0 0.11756258457899094
by O 0 7.254098454723135e-05
progressive O 0 0.03261633962392807
degeneration O 0 0.4884536862373352
of O 0 3.249362734436545e-08
the O 0 2.602229187687044e-07
magnocellular O 0 0.00021277816267684102
neurons O 0 1.1270070672253496e-06
of O 0 3.2201841193568725e-09
the O 0 4.2474034955830575e-08
hypothalamus O 0 9.005024708130804e-07
leading O 0 3.868851194965828e-07
to O 0 1.1390316956294555e-07
decreased O 0 1.1182047501279158e-06
ability O 0 1.0777860381949722e-08
to O 0 2.1355972545933355e-09
produce O 0 6.581339917488549e-09
the O 0 2.5105968859406858e-08
hormone O 0 1.3465343329244206e-07
arginine O 0 1.5906912267382722e-06
vasopressin O 0 2.45665341935819e-06
( O 0 9.656369570620882e-08
AVP O 0 0.0002518995606806129
) O 0 3.6317536000751716e-07
. O 0 8.312837849189236e-07

Affected O 0 0.00010579927038634196
individuals O 0 4.712813677087979e-07
are O 0 3.7377400730065347e-08
not O 0 1.5179972479018033e-07
symptomatic O 0 1.912578045448754e-05
at O 0 5.2351821068441495e-05
birth O 0 1.43804472827469e-05
, O 0 3.253628619859228e-06
but O 0 3.959536115871742e-06
usually O 0 2.2515894215757726e-06
develop O 0 0.0015018985141068697
diabetes B-Disease 1 0.9083605408668518
insipidus I-Disease 0 0.06777002662420273
at O 0 2.1959524474368664e-06
1 O 0 2.2530878140969435e-07
- O 0 0.001739696366712451
6 O 0 4.4264561438467354e-05
yr O 0 0.015080232173204422
of O 0 2.313073679260924e-07
age O 0 7.741955414530821e-06
. O 0 4.281237124814652e-06

The O 0 3.048019152629422e-06
genetic O 0 8.110525959637016e-05
locus O 0 8.816265471978113e-05
of O 0 1.4710382174598635e-06
the O 0 0.0002566420880611986
disease O 0 0.03304442763328552
is O 0 5.6396388004031905e-08
the O 0 3.372712171767489e-07
AVP O 0 0.1576240360736847
- O 0 0.2785423994064331
neurophysin O 1 0.513988733291626
II O 1 0.6354920268058777
( O 0 2.9874274787289323e-07
NPII O 0 0.0016170148737728596
) O 0 1.0437899078397095e-07
gene O 0 7.713030925060593e-08
, O 0 2.2755064321700047e-07
and O 0 5.046996420787764e-07
mutations O 0 3.5054139857493283e-07
that O 0 4.1167959352605976e-07
cause O 0 1.1818046914413571e-05
ADNDI B-Disease 0 0.025575097650289536
have O 0 1.2068655053099064e-07
been O 0 2.533606107135711e-07
found O 0 5.135233891451207e-07
in O 0 6.986584644153027e-09
both O 0 1.4796630587454729e-09
the O 0 2.2503974239640456e-09
signal O 0 1.3828628198098158e-07
peptide O 0 4.226609817692406e-08
of O 0 1.738945765161759e-09
the O 0 1.353511152046849e-07
prepro O 0 0.0037829645443707705
- O 0 0.0011336273746564984
AVP O 0 0.0012356609804555774
- O 0 0.00041702741873450577
NPII O 0 0.0003750111209228635
precursor O 0 2.169002044638546e-07
and O 0 4.6270571374407155e-08
within O 0 1.7585524147989418e-08
NPII O 0 0.0018542802426964045
itself O 0 8.990738933789544e-06
. O 0 4.7716421249788254e-06

An O 0 8.039754902711138e-06
affected O 0 3.7697944208048284e-05
girl O 0 0.0021150007378309965
who O 0 5.81102904106956e-06
presented O 0 9.889406555885216e-07
at O 0 2.9537122827605344e-06
9 O 0 5.666903234669007e-06
months O 0 2.2396434360416606e-06
of O 0 5.039425943209608e-08
age O 0 1.296209916290536e-06
and O 0 4.7310155082413985e-07
her O 0 7.2712609835434705e-06
similarly O 0 1.1509559044498019e-05
affected O 0 4.532216451025306e-07
younger O 0 4.551822712528519e-06
brother O 0 7.692103099543601e-05
and O 0 8.281976988655515e-07
father O 0 9.957582733477466e-06
were O 0 6.224058068937666e-08
all O 0 4.127257646757698e-09
found O 0 1.1609212435814698e-07
to O 0 4.7670183356274265e-09
have O 0 1.395567661433006e-08
a O 0 3.29589013858822e-08
novel O 0 4.549521293029102e-07
missense O 0 8.335097732015129e-07
mutation O 0 3.3814909983220787e-08
( O 0 7.4408559314065315e-09
G1758 O 0 2.1744085643149447e-06
- O 0 0.00022643069678451866
- O 0 0.003938157577067614
> O 0 1.9581175365601666e-06
T O 0 7.659354741917923e-05
) O 0 2.3412297101010893e-10
encoding O 0 1.1429081292479992e-10
the O 0 1.2276053784621155e-10
amino O 0 1.4109613477586436e-10
acid O 0 1.8644559507396963e-10
substitution O 0 3.650030555579775e-10
Gly23 O 0 3.0097180570010096e-06
- O 0 1.5861704014241695e-05
- O 0 0.00045185282942838967
> O 0 1.6623436067675357e-06
Val O 0 1.1198577340110205e-05
within O 0 2.0763696539916054e-08
NPII O 0 0.0007464250084012747
. O 0 2.911565843533026e-06

The O 0 3.6751457628270146e-06
mutation O 0 1.6957777916104533e-05
was O 0 4.4743967009708285e-05
confirmed O 0 8.462267032882664e-06
by O 0 2.9490101383089495e-07
restriction O 0 1.012672782962909e-06
endonuclease O 0 5.828059511259198e-05
analysis O 0 2.8973065582249546e-06
. O 0 6.868031505291583e-06

A O 0 5.875352144357748e-06
T1 O 0 0.024358078837394714
- O 0 0.00011618270946200937
weighted O 0 1.119359126278141e-06
magnetic O 0 8.718711228539178e-07
resonance O 0 5.920354055888311e-07
imaging O 0 1.120972228818573e-05
of O 0 1.2819743488989843e-08
the O 0 5.852049866916786e-07
fathers O 0 0.00012656614126171917
pituitary O 0 0.0025947478134185076
gland O 0 5.080768823972903e-05
demonstrates O 0 8.085389140433108e-07
an O 0 1.2878984989583842e-07
attenuated O 0 0.00035515494528226554
posterior O 0 0.0007428500684909523
pituitary O 0 0.00035032365121878684
bright O 0 1.4702370208397042e-05
spot O 0 2.8576199838425964e-05
. O 0 9.754833627084736e-06

This O 0 1.5073351278260816e-06
mutation O 0 8.686262845003512e-06
may O 0 1.0078670129587408e-06
be O 0 1.7560043419351246e-09
valuable O 0 1.7364268911634895e-09
for O 0 8.39506630878617e-10
developing O 0 9.176883963846194e-08
models O 0 5.504857654159423e-07
of O 0 1.0748137668770141e-07
dominantly B-Disease 0 0.3550426661968231
inherited I-Disease 1 0.9996786117553711
neurodegeneration I-Disease 1 0.999981164932251
, O 0 2.263650458189659e-06
as O 0 3.960984873430107e-09
the O 0 1.0641409531331192e-08
early O 0 5.186191742723167e-07
age O 0 1.6856560023370548e-06
of O 0 4.422459483066632e-07
onset O 0 0.012348143383860588
of O 0 1.4265395293477923e-05
symptoms O 0 0.0002068837347906083
suggests O 0 1.792040507098136e-06
that O 0 9.517220433963303e-08
this O 0 3.097147427411073e-08
mutation O 0 3.8526471257682715e-07
may O 0 9.95250388768909e-07
be O 0 1.4007305537688808e-08
particularly O 0 4.535874609246093e-08
deleterious O 0 1.616277387483933e-07
to O 0 1.1238088681864156e-08
the O 0 1.178099324761206e-07
magnocellular O 0 0.00013343173486646265
neuron O 0 0.00017057503282558173
. O 0 6.904367637616815e-07
. O 0 4.303558853280265e-06

Frequent O 0 1.949235775100533e-05
inactivation O 0 0.0007574321934953332
of O 0 1.1180030696777976e-06
PTEN O 0 0.04831146448850632
/ O 0 0.0013846904039382935
MMAC1 O 0 0.21373195946216583
in O 0 9.029614739120007e-05
primary O 0 0.07487224042415619
prostate B-Disease 1 0.9998480081558228
cancer I-Disease 1 0.9994648098945618
. O 0 0.0006389444461092353

Sporadic B-Disease 0 0.4227356016635895
prostate I-Disease 1 0.9996899366378784
carcinoma I-Disease 1 0.9999263286590576
is O 0 1.3211856639827602e-05
the O 0 6.981497904234857e-07
most O 0 2.58136054753777e-07
common O 0 9.091617357626092e-06
male B-Disease 0 0.0014342872891575098
cancer I-Disease 0 0.005327677354216576
in O 0 7.271736279790275e-08
the O 0 9.737322415048766e-08
Western O 0 1.5429644690811983e-06
world O 0 2.980083809234202e-05
, O 0 2.885719823098043e-07
yet O 0 2.2048354253456637e-08
many O 0 2.197863419040047e-10
of O 0 1.4582713925292978e-09
the O 0 5.35088027220354e-08
major O 0 1.2632750667762593e-07
genetic O 0 1.3069931128484313e-06
events O 0 2.6804275421454804e-07
involved O 0 8.276168017573582e-08
in O 0 3.862903596996148e-08
the O 0 1.3191117886890424e-07
progression O 0 3.1590207072440535e-05
of O 0 1.4774280998608447e-07
this O 0 1.5404031046273303e-06
often O 0 0.00035431928699836135
fatal O 1 0.9912681579589844
cancer B-Disease 0 0.08995971828699112
remain O 0 1.3028354715061141e-06
to O 0 1.013313521980308e-07
be O 0 1.5944547726576275e-07
elucidated O 0 0.00012614998559001833
. O 0 4.37298967881361e-06

Numerous O 0 4.343388809502358e-06
cytogenetic O 0 0.0026490436866879463
and O 0 3.3911666832864285e-05
allelotype O 0 0.032085731625556946
studies O 0 2.3637915091967443e-06
have O 0 1.1827999060187722e-06
reported O 0 0.0003802178252954036
frequent O 0 8.260033723672677e-07
loss O 0 0.00019535909814294428
of O 0 5.513390277656072e-08
heterozygosity O 0 0.00026356932357884943
on O 0 7.99597182776779e-06
chromosomal O 0 0.062417320907115936
arm O 1 0.5084779262542725
10q O 0 0.0006042891182005405
in O 0 1.188722308143042e-05
sporadic B-Disease 0 0.11707259714603424
prostate I-Disease 1 0.9999436140060425
cancer I-Disease 1 0.9996708631515503
. O 0 0.0009927161736413836

Deletion O 0 0.00031700305407866836
mapping O 0 6.702625250909477e-05
studies O 0 3.680371719383402e-06
have O 0 5.68106315768091e-07
unambiguously O 0 6.787580787204206e-05
identified O 0 4.786267595591198e-07
a O 0 7.241438737537464e-08
region O 0 2.5137336479019723e-07
of O 0 3.683387106434566e-08
chromosome O 0 0.0006679284269921482
10q23 O 0 3.149987242068164e-05
to O 0 1.6419578585669115e-08
be O 0 2.8182838285317757e-09
the O 0 1.065379784392917e-08
minimal O 0 9.401767897543323e-08
area O 0 1.1402153177186847e-07
of O 0 7.590177233396389e-07
loss O 0 0.10066219419240952
. O 0 2.8632393878069706e-05

A O 0 7.521057341364212e-06
new O 0 2.293629768246319e-05
tumor B-Disease 0 0.0037767677567899227
suppressor O 0 4.4137854274595156e-05
gene O 0 1.106843910747557e-06
, O 0 3.0361277367774164e-06
PTEN O 0 0.0009915521368384361
/ O 0 7.110830483725294e-05
MMAC1 O 0 0.03167036175727844
, O 0 1.819941530811775e-06
was O 0 6.396744538506027e-06
isolated O 0 1.2296673048695084e-05
recently O 0 9.377915375807788e-06
at O 0 1.5853302102186717e-06
this O 0 5.782533563092329e-09
region O 0 5.45250529171426e-08
of O 0 1.5818407916867727e-08
chromosome O 0 0.00034797005355358124
10q23 O 0 0.00010014113649958745
and O 0 5.793311288471159e-07
found O 0 9.327339256515188e-08
to O 0 3.1494968855128036e-09
be O 0 1.3409010568565805e-09
inactivated O 0 6.7430455885642e-08
by O 0 6.537376862070232e-09
mutation O 0 7.486541164780647e-08
in O 0 3.751460724288336e-07
three O 0 0.011994391679763794
prostate B-Disease 1 0.9999865293502808
cancer I-Disease 1 0.9994456171989441
cell O 0 0.01997157745063305
lines O 0 0.00020906460122205317
. O 0 4.460261334315874e-05

We O 0 3.733248377102427e-06
screened O 0 5.461552063934505e-05
80 O 0 0.0008947678143158555
prostate B-Disease 1 0.9990717172622681
tumors I-Disease 1 0.9997698664665222
by O 0 1.5133948636503192e-06
microsatellite O 0 0.004287377465516329
analysis O 0 1.2871657872892683e-06
and O 0 2.6337650069763185e-06
found O 0 1.1020683814422227e-05
chromosome O 0 0.00012096342834411189
10q23 O 0 7.7632339525735e-06
to O 0 7.692268155778947e-09
be O 0 3.088238553772271e-09
deleted O 0 9.646998933021678e-08
in O 0 5.82150185834962e-08
23 O 0 3.4108199997717747e-06
cases O 0 1.2865804137618397e-06
. O 0 6.199749805091415e-06

We O 0 3.605130700634618e-07
then O 0 1.0050290200069867e-07
proceeded O 0 1.0694724039694847e-07
with O 0 3.410104421064375e-09
sequence O 0 4.0583678639904974e-09
analysis O 0 5.209606079858986e-09
of O 0 5.581482498406842e-10
the O 0 3.93435470869008e-08
entire O 0 8.430003504145134e-07
PTEN O 0 0.00029499988886527717
/ O 0 1.1393698514439166e-05
MMAC1 O 0 0.00102597801014781
coding O 0 0.00017225755436811596
region O 0 5.751879257331893e-07
and O 0 2.316261316082091e-07
tested O 0 2.2834325363874086e-07
for O 0 2.3799329174067907e-09
homozygous O 0 1.0745801404254962e-07
deletion O 0 3.2030590091380873e-07
with O 0 3.542109894283385e-08
new O 0 1.7637677274251473e-06
intragenic O 0 0.13845840096473694
markers O 0 1.7565163943800144e-05
in O 0 3.680437288267058e-08
these O 0 4.070686454582528e-09
23 O 0 9.002200158647611e-07
cases O 0 8.137126883411838e-08
with O 0 1.681510411799536e-06
10q23 O 0 0.004913894925266504
loss O 0 0.0004711885703727603
of O 0 1.0512318340261118e-06
heterozygosity O 0 0.007552943658083677
. O 0 1.0385753739683423e-05

The O 0 2.0908481701553683e-07
identification O 0 1.4896862410296308e-07
of O 0 9.611109241802751e-09
the O 0 2.1266963301513897e-08
second O 0 3.8774092558924167e-07
mutational O 0 2.074223812087439e-05
event O 0 2.9375819394772407e-06
in O 0 9.726890937145072e-08
10 O 0 2.8942503149664844e-07
( O 0 4.730338432068493e-08
43 O 0 1.7601751096663065e-06
% O 0 4.028946705147973e-07
) O 0 4.1740466258488595e-05
tumors B-Disease 1 0.9963802695274353
establishes O 0 0.00011195801198482513
PTEN O 0 0.004958959762006998
/ O 0 1.3834139281243552e-05
MMAC1 O 0 0.00012739117664750665
as O 0 1.3044737512402094e-09
a O 0 3.462504505336028e-09
main O 0 9.59009014422918e-08
inactivation O 0 1.2953997611475643e-05
target O 0 1.4912211554474197e-07
of O 0 1.6544918324257196e-08
10q O 0 0.0002676667645573616
loss O 0 0.0025967329274863005
in O 0 3.878610186802689e-06
sporadic B-Disease 0 0.09012240916490555
prostate I-Disease 1 0.9999748468399048
cancer I-Disease 1 0.9997255206108093
. O 0 3.971843034378253e-05
. O 0 3.028900573553983e-05

Risk O 0 0.00048210215754806995
reversals O 0 0.0003584848309401423
in O 0 6.112301207394921e-07
predictive O 0 2.9390244890237227e-05
testing O 0 0.00011777143663493916
for O 0 0.0005993121885694563
Huntington B-Disease 1 0.9998819828033447
disease I-Disease 1 0.9986444115638733
. O 0 0.00035916693741455674

The O 0 1.8193343009897944e-07
first O 0 1.3058489400918916e-07
predictive O 0 8.384770808333997e-06
testing O 0 0.00010398184531368315
for O 0 0.0017579608829692006
Huntington B-Disease 1 0.9999812841415405
disease I-Disease 1 0.9991229176521301
( O 0 6.480310048573301e-07
HD B-Disease 0 0.008032090030610561
) O 0 3.6462739672060707e-07
was O 0 4.6920456497900886e-07
based O 0 3.3176370095588936e-08
on O 0 5.782933598652562e-08
analysis O 0 2.1925984583504032e-08
of O 0 8.131863182825327e-09
linked O 0 1.1182601156178862e-05
polymorphic O 0 1.3264173048810335e-06
DNA O 0 8.063547284109518e-05
markers O 0 9.114571184909437e-06
to O 0 7.525812861786108e-08
estimate O 0 2.22859853238333e-06
the O 0 2.644364727188986e-08
likelihood O 0 1.648209035920445e-07
of O 0 2.3748690125557914e-08
inheriting O 0 5.106221215100959e-05
the O 0 4.6381376961335263e-08
mutation O 0 2.8430076071117583e-08
for O 0 3.67490997632558e-08
HD B-Disease 0 0.0008024846320040524
. O 0 6.000827397656394e-06

Limits O 0 4.4474899141278e-07
to O 0 1.5722216417657364e-08
accuracy O 0 2.40593209355211e-07
included O 0 5.036434824745584e-09
recombination O 0 6.990105703152949e-07
between O 0 2.9494113817918333e-08
the O 0 7.277382962911361e-08
DNA O 0 0.00024207652313634753
markers O 0 4.116608761250973e-05
and O 0 1.401010223389676e-07
the O 0 5.720708529111107e-08
mutation O 0 3.3239840036003443e-07
, O 0 8.234219990299607e-07
pedigree O 0 8.80043298820965e-05
structure O 0 2.079601472360082e-06
, O 0 2.351552694790371e-07
and O 0 5.5772950702248636e-08
whether O 0 1.8267611423539165e-08
DNA O 0 1.7553372799739009e-06
samples O 0 7.217280284521621e-08
were O 0 2.844059743267735e-08
available O 0 6.307472322220065e-09
from O 0 2.5947519688429566e-08
family O 0 7.485993592126761e-06
members O 0 1.5745359860375174e-07
. O 0 3.7587051338050514e-06

With O 0 3.4746469168567273e-07
direct O 0 3.468574405474101e-08
tests O 0 8.926407701892458e-08
for O 0 6.192766854873355e-10
the O 0 6.93175161714521e-09
HD B-Disease 0 0.00011367577826604247
mutation O 0 3.94887926802312e-08
, O 0 7.435821913759355e-08
we O 0 6.484239367665623e-09
have O 0 3.747403720666398e-09
assessed O 0 2.4661547470827827e-08
the O 0 3.5770253425937426e-09
accuracy O 0 5.886484473194287e-07
of O 0 1.6410217185125475e-08
results O 0 4.906648882752052e-07
obtained O 0 2.4487510685844427e-08
by O 0 9.663643218971174e-09
linkage O 0 9.126522968472273e-07
approaches O 0 5.7629488736665735e-08
when O 0 1.6566809790674597e-07
requested O 0 4.265329067720813e-08
to O 0 9.964887581759285e-09
do O 0 1.3271256316116364e-09
so O 0 9.41292044309705e-10
by O 0 9.731744299301681e-10
the O 0 3.434676543179194e-08
test O 0 1.9269159565737937e-06
individuals O 0 1.431472611557183e-07
. O 0 1.428787300028489e-06

For O 0 8.34171316910215e-07
six O 0 1.2875169659309904e-06
such O 0 3.6537958436611007e-08
individuals O 0 1.1999966886833136e-07
, O 0 2.576367990059225e-07
there O 0 1.5478198278628952e-08
was O 0 5.449507170851575e-06
significant O 0 9.618851493087277e-08
disparity O 0 3.5888135698769474e-06
between O 0 7.739142660057041e-08
the O 0 4.971797693542612e-07
tests O 0 6.0871930145367514e-06
. O 0 5.208444235904608e-06

Three O 0 1.8394549670119886e-06
went O 0 5.486772806762019e-06
from O 0 9.47738598711112e-08
a O 0 4.857427029492101e-07
decreased O 0 0.0001532332826172933
risk O 0 1.7446863012082758e-06
to O 0 4.45604619869755e-09
an O 0 2.2851573078241927e-08
increased O 0 2.3204363515105797e-06
risk O 0 4.6112568270473275e-06
, O 0 1.3522441122404416e-07
while O 0 1.3893082950744429e-07
in O 0 1.3868481474332839e-08
another O 0 2.6745205161660124e-08
three O 0 1.0597541688639467e-07
the O 0 2.5366744011989795e-06
risk O 0 3.5400851629674435e-05
was O 0 1.3202033187553752e-05
decreased O 0 1.5123362572921906e-05
. O 0 3.519050324030104e-06

Knowledge O 0 3.3565882517905266e-07
of O 0 7.609558849708264e-08
the O 0 2.0889984853056376e-07
potential O 0 6.143127961877326e-07
reasons O 0 1.4547412163778972e-08
for O 0 8.03558719564279e-10
these O 0 1.217281497822853e-09
changes O 0 5.635280686533406e-09
in O 0 5.2794092653130065e-08
results O 0 1.7942242038770928e-06
and O 0 5.705528565158602e-07
impact O 0 1.224770187491231e-07
of O 0 5.733989283385199e-09
these O 0 7.05443667925465e-08
risk O 0 2.6776092454383615e-06
reversals O 0 0.00013508291158359498
on O 0 7.1168660724652e-06
both O 0 2.5141439436993096e-06
patients O 0 3.8264298041212896e-07
and O 0 6.334058610946158e-08
the O 0 2.1875065314702624e-08
counseling O 0 5.115047088111169e-07
team O 0 3.456581509908574e-07
can O 0 2.252351194442781e-09
assist O 0 8.291047848274502e-09
in O 0 6.006144026571292e-09
the O 0 8.589942979142506e-09
development O 0 2.481641026008674e-08
of O 0 4.346889959094824e-09
strategies O 0 4.473386638892407e-07
for O 0 3.7108018879905558e-09
the O 0 1.2170575303116493e-07
prevention O 0 5.825550033478066e-06
and O 0 2.6512338990869466e-07
, O 0 1.074241993137548e-07
where O 0 3.611372179079808e-08
necessary O 0 2.8846294242157455e-08
, O 0 1.833862484090787e-07
management O 0 5.114003442940884e-07
of O 0 1.162746876559595e-08
a O 0 1.4222320032786229e-06
risk O 0 3.718656444107182e-05
reversal O 0 2.1347945221350528e-05
in O 0 6.759873993900101e-09
any O 0 1.0866032518208613e-09
predictive O 0 2.48771243605006e-07
testing O 0 1.4026493033725274e-07
program O 0 6.264062903937884e-07
. O 0 1.9332611600475502e-07
. O 0 1.5524417449341854e-06

A O 0 1.687390795268584e-05
novel O 0 4.837612777919276e-06
common O 0 4.29432049031675e-07
missense O 0 2.8866936645499663e-06
mutation O 0 3.473805065823399e-07
G301C O 0 9.047023013408761e-06
in O 0 3.056677044810385e-08
the O 0 1.2404251492625917e-07
N O 0 6.676177144981921e-05
- O 0 0.00040455322596244514
acetylgalactosamine O 0 0.00024815936922095716
- O 0 6.999514880590141e-05
6 O 0 1.7380153849444469e-06
- O 0 0.0008812042069621384
sulfate O 0 4.8657660954631865e-05
sulfatase O 0 7.659442053409293e-05
gene O 0 1.4739534037744306e-07
in O 0 3.7243438555378816e-07
mucopolysaccharidosis B-Disease 0 0.011094857938587666
IVA I-Disease 0 0.48830270767211914
. O 0 1.2984769455215428e-05

Mucopolysaccharidosis B-Disease 1 0.9120482802391052
IVA I-Disease 1 0.9947633743286133
( O 0 0.0002362468367209658
MPS B-Disease 1 0.983665406703949
IVA I-Disease 1 0.9999001026153564
) O 0 0.00038053790922276676
is O 0 3.44670388585655e-06
an O 0 2.0179419152555056e-05
autosomal B-Disease 1 0.9694539904594421
recessive I-Disease 1 0.9882248640060425
lysosomal I-Disease 1 0.9998984336853027
storage I-Disease 1 0.999929666519165
disorder I-Disease 1 0.9995642304420471
caused O 0 0.0030482090078294277
by O 0 2.0449683688639197e-06
a O 0 6.077170473872684e-05
genetic B-Disease 1 0.9937396049499512
defect I-Disease 1 0.9967856407165527
in O 0 1.579165996190568e-06
N O 0 0.0005940449191257358
- O 0 0.0028673179913312197
acetylgalactosamine O 0 0.002471919870004058
- O 0 0.0005194306140765548
6 O 0 6.480590400315123e-06
- O 0 0.059217169880867004
sulfate O 0 0.010453851893544197
sulfatase O 0 0.007025912869721651
( O 0 4.0332216144634003e-07
GALNS O 0 0.0013841644395142794
) O 0 6.229973337212869e-07
. O 0 6.060867008272908e-07

In O 0 3.761007292268914e-06
previous O 0 1.1722791896318085e-05
studies O 0 1.028149995363492e-06
, O 0 3.530812193730526e-07
we O 0 2.004288823798106e-08
have O 0 6.003624708483812e-09
found O 0 4.3414235761929376e-08
two O 0 2.57035441819653e-08
common O 0 5.970373706531973e-08
mutations O 0 1.1796755217119426e-07
in O 0 7.599043527761751e-08
Caucasians O 0 1.0040084816864692e-06
and O 0 1.9138201423629653e-07
Japanese O 0 6.609258889511693e-06
, O 0 7.702488460381574e-07
respectively O 0 2.6109421469300287e-06
. O 0 1.781399305400555e-06

To O 0 3.6725771224155324e-07
characterize O 0 2.5765721147763543e-06
the O 0 5.270525704759166e-08
mutational O 0 1.7645283151068725e-05
spectrum O 0 4.227142369472858e-07
in O 0 4.9094732723631296e-09
various O 0 1.6750405229526422e-10
ethnic O 0 7.189263850904126e-09
groups O 0 1.374615443694438e-08
, O 0 1.4934300907043507e-07
mutations O 0 3.1731715921523573e-08
in O 0 7.433067938933391e-09
the O 0 4.147509002905281e-08
GALNS O 0 0.0001973448961507529
gene O 0 1.9623684011094156e-08
in O 0 5.993867091547145e-08
Colombian O 0 3.136602754238993e-05
MPS B-Disease 1 0.9870330095291138
IVA I-Disease 1 0.9999799728393555
patients O 0 7.457761512341676e-06
were O 0 6.667117986580706e-07
investigated O 0 0.00014185514010023326
, O 0 2.620051418489311e-06
and O 0 6.284238907028339e-07
genetic O 0 1.874036115623312e-06
backgrounds O 0 5.423700599749282e-07
were O 0 7.808088753336051e-08
extensively O 0 1.6424911564172362e-07
analyzed O 0 3.6614355281017197e-07
to O 0 9.074759610427918e-09
identify O 0 1.2722374265194958e-07
racial O 0 2.9527558353947825e-07
origin O 0 2.59720366102556e-07
, O 0 3.1375014941659174e-07
based O 0 1.9956416963395895e-07
on O 0 1.2293144209252205e-06
mitochondrial O 0 8.497422822983935e-05
DNA O 0 6.046562339179218e-05
( O 0 7.41682697480428e-08
mtDNA O 0 5.713587256650499e-07
) O 0 2.333675581667194e-07
lineages O 0 2.0801492155442247e-06
. O 0 3.0752726161153987e-06

Three O 0 4.547314802039182e-06
novel O 0 1.0251060302834958e-05
missense O 0 1.7287800801568665e-05
mutations O 0 4.0996615098265465e-06
never O 0 5.263726961857174e-06
identified O 0 5.144802344148047e-07
previously O 0 3.784993225508515e-07
in O 0 3.638787404725008e-08
other O 0 4.043326384817192e-08
populations O 0 1.8913898713890376e-07
and O 0 1.4557508620782755e-07
found O 0 3.1044339721120195e-07
in O 0 1.4647254076294303e-08
16 O 0 5.1587058180757595e-08
out O 0 8.28080626291694e-09
of O 0 4.8469481761515e-09
19 O 0 1.5854919865887496e-06
Colombian O 0 3.7615132896462455e-05
MPS B-Disease 1 0.8062419295310974
IVA I-Disease 1 0.9998669624328613
unrelated O 0 0.00036528342752717435
alleles O 0 2.2107316510755481e-07
account O 0 1.1764646501433162e-07
for O 0 8.83529480688594e-08
84 O 0 2.6396355679025874e-05
. O 0 6.377812951541273e-06

2 O 0 1.762587453413289e-05
% O 0 1.4174248974541115e-07
of O 0 6.412852471271435e-09
the O 0 9.012235580030392e-08
alleles O 0 4.240543489686388e-07
in O 0 7.456586104126472e-08
this O 0 2.960429945630949e-08
study O 0 3.39096033030728e-07
. O 0 3.8527018659806345e-06

The O 0 2.2845135845273035e-06
G301C O 0 0.00024241420032922179
and O 0 3.7660608995793154e-06
S162F O 0 0.0001292032393394038
mutations O 0 5.528906399376865e-07
account O 0 9.29093957324767e-08
for O 0 9.623585839335647e-08
68 O 0 6.458161806222051e-05
. O 0 6.431623660319019e-06

4 O 0 4.144583363085985e-05
% O 0 6.104087901803723e-07
and O 0 6.230793019312841e-07
10 O 0 9.215628438141721e-07
. O 0 4.978106517228298e-06

5 O 0 1.7860595107777044e-05
% O 0 2.0702250935755728e-07
of O 0 3.057761688296523e-08
mutations O 0 1.0465065543030505e-06
, O 0 9.439219752493955e-07
respectively O 0 1.1507706858537858e-06
, O 0 8.280209584654585e-08
whereas O 0 1.674805716334049e-08
the O 0 9.03965613474611e-09
remaining O 0 1.0533674412727123e-06
F69V O 0 0.013998840004205704
is O 0 1.014655293118949e-08
limited O 0 1.307632335745268e-09
to O 0 6.000266949968136e-10
a O 0 5.6857221153450155e-09
single O 0 4.797980324156015e-08
allele O 0 3.9366250348393805e-06
. O 0 4.835528216062812e-06

The O 0 3.5217292406741763e-06
skewed O 0 0.00010654329526005313
prevalence O 0 0.00015555489517282695
of O 0 1.5046924772832426e-07
G301C O 0 8.330127457156777e-05
in O 0 1.106662779193357e-07
only O 0 1.1384644338363614e-08
Colombian O 0 7.907356120995246e-06
patients O 0 1.30719377011701e-06
and O 0 1.241413770003419e-06
haplotype O 0 0.0001239107659785077
analysis O 0 9.40946378591434e-08
by O 0 1.3212061666934005e-08
restriction O 0 4.1176043907853455e-08
fragment O 0 6.666380727438082e-07
length O 0 3.732909874543111e-07
polymorphisms O 0 6.214509085111786e-07
in O 0 5.682960235731116e-08
the O 0 3.05556682178576e-07
GALNS O 0 0.023054318502545357
gene O 0 2.0689974178367265e-07
suggest O 0 7.90128780181476e-08
that O 0 7.829250137092458e-08
G301C O 0 2.5923143766704015e-05
originated O 0 4.737354117878567e-07
from O 0 1.0256410831743779e-08
a O 0 4.76111416958247e-08
common O 0 6.319058911685715e-07
ancestor O 0 1.840337790781632e-05
. O 0 2.269794640596956e-05

Investigation O 0 2.520382622606121e-05
of O 0 2.7888066256309685e-07
the O 0 4.298856310924748e-07
genetic O 0 3.700061824929435e-06
background O 0 1.5680399201301043e-07
by O 0 3.102592671666571e-08
means O 0 1.3153651501340846e-08
of O 0 3.722938846095758e-09
mtDNA O 0 9.164043603959726e-07
lineages O 0 1.292771798944159e-06
indicate O 0 1.6727537399674475e-07
that O 0 2.1475338840559743e-08
all O 0 7.625741815786569e-09
our O 0 3.5620902849586855e-07
patients O 0 1.0988257770350174e-07
are O 0 2.7070417019103843e-09
probably O 0 1.544296708289039e-07
of O 0 8.30746227364898e-09
native O 0 1.3335965149963158e-06
American O 0 5.13192244397942e-05
descent O 0 0.004822196438908577

Low O 0 2.8062170258635888e-06
frequency O 0 4.857478188569075e-07
of O 0 8.160393605294303e-08
BRCA1 O 0 6.720410601701587e-05
germline O 0 6.783219578210264e-05
mutations O 0 7.87358942488936e-07
in O 0 3.634937968399754e-07
45 O 0 1.1485184586490504e-05
German O 1 0.8089542388916016
breast B-Disease 1 0.9997596144676208
/ I-Disease 1 0.9998170733451843
ovarian I-Disease 1 0.9999699592590332
cancer I-Disease 1 0.9997995495796204
families O 0 0.0005355071043595672
. O 0 0.00011285730579402298

In O 0 2.405308578090626e-06
this O 0 2.533349352518144e-08
study O 0 2.8717451527882076e-08
we O 0 1.8648064425974553e-08
investigated O 0 2.387728500252706e-06
45 O 0 3.933964308089344e-06
German O 1 0.5134453773498535
breast B-Disease 1 0.9997785687446594
/ I-Disease 1 0.9999125003814697
ovarian I-Disease 1 0.9999945163726807
cancer I-Disease 1 0.9997509121894836
families O 0 6.681524610030465e-06
for O 0 1.864451206756712e-07
germline O 0 5.239817255642265e-05
mutations O 0 2.7582515826907184e-07
in O 0 3.816668936451606e-08
the O 0 4.3328040533197054e-07
BRCA1 O 0 0.00011965447629336268
gene O 0 2.486014864189201e-06
. O 0 5.946053988736821e-06

We O 0 6.553996740876755e-07
identified O 0 1.342831183137605e-06
four O 0 1.7631376181270753e-07
germline O 0 2.163668796129059e-05
mutations O 0 2.6571419198262447e-07
in O 0 2.603994175842672e-07
three O 0 0.0005421844543889165
breast B-Disease 1 0.9976166486740112
cancer I-Disease 0 0.4754742681980133
families O 0 5.750064701715019e-06
and O 0 9.124921120928775e-07
in O 0 7.909096666480764e-07
one O 0 0.0002811550803016871
breast B-Disease 1 0.9997640252113342
- I-Disease 1 0.9999959468841553
ovarian I-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999802112579346
family O 0 0.04392978921532631
. O 0 8.468019245810865e-07
among O 0 1.7039793576145712e-08
these O 0 3.926990288505294e-09
were O 0 3.9907284588025504e-08
one O 0 4.717688284472388e-08
frameshift O 0 1.1775677194236778e-05
mutation O 0 8.545774221602187e-08
, O 0 1.776381566287455e-07
one O 0 2.0097401076668575e-08
nonsense O 0 5.2360105655679945e-06
mutation O 0 4.8536669794430054e-08
, O 0 2.559274214775087e-08
one O 0 4.747654713810334e-09
novel O 0 1.253822006219707e-07
splice O 0 2.2258871467784047e-05
site O 0 3.413676950003719e-06
mutation O 0 1.202807169420339e-07
, O 0 1.1598633165021965e-07
and O 0 1.3799409259718232e-07
one O 0 1.0137387818076604e-07
missense O 0 5.782972039014567e-06
mutation O 0 9.111964232033642e-07
. O 0 5.608290848613251e-06

The O 0 1.939393541761092e-06
missense O 0 3.326548539916985e-05
mutation O 0 5.3424996622197796e-06
was O 0 2.0824492821702734e-05
also O 0 1.0672589496607543e-06
found O 0 7.446984113812505e-07
in O 0 2.196684363298118e-07
2 O 0 6.136082447483204e-06
. O 0 7.5361567724030465e-06

8 O 0 2.7867119570146315e-05
% O 0 3.250069937621447e-07
of O 0 1.3447205127192774e-08
the O 0 3.923084790358189e-08
general O 0 4.6802959730030125e-08
population O 0 4.7470230413182435e-08
, O 0 4.6132660713738005e-07
suggesting O 0 4.607687060342869e-06
that O 0 2.1406148675851e-07
it O 0 4.6400310793615063e-07
is O 0 5.765135711044422e-07
not O 0 6.284601568040671e-06
disease O 0 0.004126591142266989
associated O 0 6.053038305253722e-06
. O 0 1.176369005406741e-05

The O 0 2.9692091629840434e-06
average O 0 0.00016946648247539997
age O 0 6.677826604573056e-05
of O 0 4.5305834646569565e-05
disease O 1 0.5716695189476013
onset O 0 0.006094109266996384
in O 0 1.421745196239499e-06
those O 0 1.53955136283912e-06
families O 0 7.505591929657385e-05
harbouring O 0 0.39015018939971924
causative O 0 9.57923384703463e-06
mutations O 0 6.431707788578933e-07
was O 0 3.5833893434755737e-06
between O 0 1.201066424982855e-06
32 O 0 1.9290289856144227e-05
. O 0 1.1960043593717273e-05

3 O 0 3.261723759351298e-05
and O 0 4.783073563885409e-06
37 O 0 2.9228749554022215e-05
. O 0 8.501296179019846e-06

4 O 0 4.108278881176375e-05
years O 0 1.8372795238974504e-05
, O 0 1.3032032484261435e-06
whereas O 0 3.351831594500254e-07
the O 0 1.51783524415805e-07
family O 0 0.00013475226296577603
harbouring O 0 0.018618296831846237
the O 0 3.151484975205676e-07
missense O 0 5.233978299656883e-06
mutation O 0 1.884393299178555e-07
had O 0 2.369888306930079e-06
an O 0 9.194317129868068e-08
average O 0 4.426182385941502e-06
age O 0 5.715407382922422e-07
of O 0 1.7339429803087114e-07
onset O 0 0.00012247974518686533
of O 0 3.2103434932651e-07
51 O 0 9.5655421318952e-05
. O 0 1.8187794921686873e-05

2 O 0 0.00011884710693266243
years O 0 6.651508738286793e-05
. O 0 3.018608913407661e-05

These O 0 7.731470645921945e-07
findings O 0 4.069822352903429e-06
show O 0 2.947566372313304e-06
that O 0 8.738655878914869e-07
BRCA1 O 0 4.7857123718131334e-05
is O 0 2.8331348289611924e-07
implicated O 0 1.10817154563847e-05
in O 0 3.6621962351546244e-08
a O 0 3.3064239346458635e-08
small O 0 1.8023085601726052e-07
fraction O 0 5.787424584013934e-07
of O 0 1.100818371924106e-05
breast B-Disease 1 0.9994175434112549
/ I-Disease 1 0.9999233484268188
ovarian I-Disease 1 0.9999960660934448
cancer I-Disease 1 0.9999531507492065
families O 0 0.00010605815623421222
suggesting O 0 2.7672418582369573e-05
the O 0 8.056588995941638e-08
involvement O 0 1.198770974042418e-06
of O 0 4.241347895117542e-08
another O 0 2.185035327784135e-06
susceptibility O 0 5.756364407716319e-05
gene O 0 5.290717581374338e-06
( O 0 1.5838355693631456e-06
s O 0 0.006077839061617851
) O 0 1.4899753296049312e-05

Paternal O 0 0.008111201226711273
transmission O 1 0.8097054362297058
of O 1 0.5176119208335876
congenital B-Disease 1 0.9998607635498047
myotonic I-Disease 1 0.9997835755348206
dystrophy I-Disease 1 0.9996566772460938
. O 0 0.019649257883429527

We O 0 1.2441169019439258e-05
report O 0 1.0951932381431106e-05
a O 0 2.9035862780801835e-07
rare O 0 4.099246780242538e-06
case O 0 9.943359145836439e-06
of O 0 1.669920857239049e-05
paternally O 1 0.9988223910331726
transmitted O 1 0.9990837574005127
congenital B-Disease 1 0.9999574422836304
myotonic I-Disease 1 0.9999783039093018
dystrophy I-Disease 1 0.9999624490737915
( O 0 0.048918575048446655
DM B-Disease 1 0.9998434782028198
) O 0 5.744387817685492e-05
. O 0 1.050811533787055e-05

The O 0 5.778837930847658e-06
proband O 0 0.007523281034082174
is O 0 7.77411770513936e-08
a O 0 5.8015828585666895e-08
23 O 0 1.8668723669179599e-06
year O 0 7.484342177122016e-07
old O 0 0.00029238019487820566
, O 0 0.0018441937863826752
mentally B-Disease 1 0.9999285936355591
retarded I-Disease 1 0.9999090433120728
male O 0 0.03331391140818596
who O 1 0.7661503553390503
suffers O 1 0.9998025298118591
severe O 1 0.9755166172981262
muscular B-Disease 1 0.9992928504943848
weakness I-Disease 1 0.9923456311225891
. O 0 0.0003061984316445887

He O 0 0.00021937362907920033
presented O 0 0.00015964821795932949
with O 0 0.0006429952336475253
respiratory O 1 0.5683785676956177
and O 0 4.6643559471704066e-05
feeding O 0 0.00040407339110970497
difficulties O 0 0.001920606242492795
at O 0 8.405677363043651e-05
birth O 0 2.6771527700475417e-05
. O 0 1.8917857232736424e-05

His O 0 3.9228434616234154e-05
two O 0 0.00014747832028660923
sibs O 1 0.9948375821113586
suffer O 0 0.0959339290857315
from O 0 1.1379930583643727e-05
childhood O 0 0.027915604412555695
onset O 1 0.6433714032173157
DM B-Disease 1 0.999440610408783
. O 0 0.000505461182910949

Their O 0 1.4680924778076587e-06
late O 0 8.173329115379602e-05
father O 0 7.574959454359487e-05
had O 0 1.009091306514165e-06
the O 0 1.4495396882807654e-08
adult O 0 8.64817479850899e-08
type O 0 4.7582958018210775e-07
of O 0 7.523163958467194e-07
DM B-Disease 1 0.9999508857727051
, O 0 2.4887094696168788e-06
with O 0 6.84297788211552e-07
onset O 0 5.056403097114526e-05
around O 0 9.7152458522487e-08
30 O 0 2.667190415195364e-07
years O 0 2.3117138425732264e-06
. O 0 3.7406505271064816e-06

Only O 0 1.7546349795338756e-07
six O 0 7.635087513335748e-07
other O 0 6.132123075985874e-08
cases O 0 3.3642177044157506e-08
of O 0 2.2714946368296296e-08
paternal O 0 0.0001149842282757163
transmission O 0 0.18424928188323975
of O 0 0.0074425796046853065
congenital B-Disease 1 0.9999849796295166
DM I-Disease 1 0.9999768733978271
have O 0 7.0710593718104064e-06
been O 0 4.775229626829969e-06
reported O 0 0.00022191157040651888
recently O 0 0.00019752318621613085
. O 0 1.6420366591773927e-05

We O 0 3.8212004938031896e-07
review O 0 1.2188682774194604e-07
the O 0 1.0366156999452869e-07
sex O 0 1.9704564238054445e-06
related O 0 8.35659920994658e-06
effects O 0 4.857890303355816e-07
on O 0 1.8534221908339532e-06
transmission O 0 0.008788698352873325
of O 0 0.00035120852407999337
congenital B-Disease 1 0.9998379945755005
DM I-Disease 1 0.9997240900993347
. O 0 0.00042923749424517155

Decreased O 0 0.0009334823116660118
fertility O 0 0.00011335775343468413
of O 0 1.002303022801243e-07
males O 0 6.352490800054511e-07
with O 0 5.958071369605022e-07
adult O 0 5.515660814126022e-05
onset O 0 0.2750433385372162
DM B-Disease 1 0.9999464750289917
and O 0 5.008346488466486e-05
contraction O 0 1.3937534276919905e-05
of O 0 5.518963508421848e-09
the O 0 5.209887632418031e-08
repeat O 0 3.1777735784999095e-06
upon O 0 1.8077908947589094e-08
male O 0 3.9609494706382975e-07
transmission O 0 1.2442687875591218e-05
contribute O 0 8.93291041137445e-09
to O 0 2.343598648479883e-09
the O 0 1.1736178251453566e-08
almost O 0 4.391953822846517e-08
absent O 0 3.185117236625956e-07
occurrence O 0 8.208035495727017e-08
of O 0 2.781772145965533e-08
paternal O 0 0.00011945382721023634
transmission O 0 0.028671739622950554
of O 0 0.00158958591055125
congenital B-Disease 1 0.9998961687088013
DM I-Disease 1 0.999823272228241
. O 0 0.0003855957475025207

Also O 0 3.773661092054681e-06
the O 0 3.217607797978417e-07
fathers O 0 4.836243192585243e-07
of O 0 1.5439601597222463e-08
the O 0 1.4278310800364125e-06
reported O 0 0.005953969433903694
congenitally O 0 0.08195984363555908
affected O 0 2.5560896119714016e-06
children O 0 1.19974538392853e-06
showed O 0 6.304153794189915e-05
, O 0 1.0151280349646186e-07
on O 0 5.171404993120632e-08
average O 0 4.0624286157253664e-07
, O 0 1.6756581544541405e-07
shorter O 0 1.3773917544313008e-06
CTG O 0 5.8355559303890914e-05
repeat O 0 1.951331796590239e-06
lengths O 0 0.00011994211672572419
and O 0 9.9582666734932e-07
hence O 0 1.2605519259523135e-06
less O 0 7.383047432085732e-06
severe O 0 0.006326361559331417
clinical O 0 0.0001686382747720927
symptoms O 0 1.016308397083776e-05
than O 0 3.485099853151041e-08
the O 0 8.789037337919581e-07
mothers O 0 4.4796379370382056e-06
of O 0 4.0512784948987246e-07
children O 0 6.186202517710626e-05
with O 0 0.06922802329063416
congenital B-Disease 1 0.999876856803894
DM I-Disease 1 0.9998012185096741
. O 0 0.000707472674548626

We O 0 1.4464128526014974e-06
conclude O 0 1.5692032320657745e-05
that O 0 4.336143888394872e-07
paternal O 0 5.674604108207859e-05
transmission O 0 0.048985034227371216
of O 0 0.004747616592794657
congenital B-Disease 1 0.9999840259552002
DM I-Disease 1 0.9999871253967285
is O 0 2.3822198272682726e-05
rare O 0 4.362076651887037e-06
and O 0 5.491386900757789e-07
preferentially O 0 2.947589109680848e-06
occurs O 0 6.112213668529876e-08
with O 0 6.33800993909972e-07
onset O 0 0.0002730580454226583
of O 0 6.75898604640679e-07
DM B-Disease 1 0.9996168613433838
past O 0 5.061085062152415e-07
30 O 0 2.395092053575354e-07
years O 0 2.0142766743447282e-07
in O 0 2.210752114706338e-08
the O 0 7.722790229536258e-08
father O 0 7.447656389558688e-05
. O 0 1.0311626965631149e-06
. O 0 7.1876738729770295e-06

The O 0 5.530770522454986e-06
RB1 O 0 0.00772540969774127
gene O 0 2.254412720503751e-06
mutation O 0 1.4045583611732582e-06
in O 0 2.6879865799855907e-07
a O 0 2.1437538180180127e-06
child O 0 0.0004328038776293397
with O 0 0.00012044204777339473
ectopic B-Disease 1 0.998783528804779
intracranial I-Disease 1 0.9984532594680786
retinoblastoma I-Disease 0 0.15127229690551758
. O 0 5.558685370488092e-05

The O 0 1.4949783690099139e-05
RB1 O 0 0.04418233409523964
gene O 0 3.4630525078682695e-06
mutation O 0 6.6788425101549365e-06
was O 0 4.754057590616867e-05
investigated O 0 4.82350260426756e-05
in O 0 5.788070325252193e-07
a O 0 1.5619864370819414e-06
child O 0 6.829744233982638e-05
with O 0 2.2998259737505578e-05
ectopic B-Disease 1 0.8677167892456055
intracranial I-Disease 1 0.841093897819519
retinoblastoma I-Disease 0 0.00017313587886746973
using O 0 7.795647860575627e-08
DNA O 0 2.0354291336843744e-05
obtained O 0 1.8161169634822727e-07
from O 0 7.706820959185734e-09
both O 0 7.609483709813958e-09
the O 0 1.5253475282861473e-07
pineal B-Disease 0 0.0011733282590284944
and I-Disease 0 0.00026214407989755273
retinal I-Disease 1 0.9779337048530579
tumours I-Disease 1 0.9998045563697815
of O 0 3.0060468247938843e-07
the O 0 4.769012775796e-06
patient O 0 3.687720891321078e-05
. O 0 3.091815597144887e-05

A O 0 6.787952770537231e-06
nonsense O 0 3.362688948982395e-05
mutation O 0 7.433977771142963e-07
in O 0 4.6839576839374786e-07
exon O 0 6.499853770947084e-05
17 O 0 4.648624781111721e-06
( O 0 6.039573285931965e-09
codon O 0 5.695088400869963e-09
556 O 0 7.287244443432428e-07
) O 0 1.0022758623051686e-08
of O 0 8.348392532830928e-10
the O 0 1.4768858136449126e-07
RB1 O 0 0.002189693972468376
gene O 0 1.8717591387940047e-07
was O 0 1.2104208508390002e-05
found O 0 3.9857729916548124e-07
to O 0 5.412981174401921e-09
be O 0 8.076002089296708e-09
present O 0 3.838973583469851e-08
homozygously O 0 0.00038393394788727164
in O 0 2.4777058627023507e-08
both O 0 1.8607311247365033e-08
the O 0 4.0731470107857604e-07
retinal B-Disease 0 0.0007432494894601405
and I-Disease 0 1.2501199080361403e-06
the I-Disease 0 6.07389029028127e-06
pineal I-Disease 0 0.3949942886829376
tumours I-Disease 1 0.9989597797393799
. O 0 6.136097363196313e-05

The O 0 4.1218166302314785e-07
same O 0 1.948665442341735e-07
mutation O 0 4.5416922489494027e-07
was O 0 5.551384674618021e-06
present O 0 8.259294759227487e-08
heterozygously O 0 0.00035374268190935254
in O 0 3.3431984292064953e-08
the O 0 4.4864087556106824e-08
DNA O 0 1.0618370652082376e-05
from O 0 1.1288057599756485e-08
the O 0 5.810161685104731e-09
constitutional O 0 7.239187738150576e-08
cells O 0 4.10378191872951e-07
of O 0 1.187540377145524e-08
the O 0 3.3060715054489265e-07
patient O 0 4.432949936017394e-06
, O 0 4.173500656179385e-06
proving O 0 0.00023966218577697873
it O 0 1.628257528807353e-08
to O 0 4.148298149431184e-09
be O 0 2.4983952684465294e-09
of O 0 1.6649956080527772e-08
germline O 0 3.468333670753054e-05
origin O 0 5.203576733947557e-07
. O 0 3.3212318157893606e-06

The O 0 6.699720529468323e-07
initial O 0 3.4931572372443043e-06
mutation O 0 2.5059284780581947e-06
was O 0 3.96492123400094e-06
shown O 0 1.1962067958393163e-07
to O 0 9.606289097519038e-09
have O 0 1.4701217132540023e-08
occurred O 0 1.1790276488454765e-07
in O 0 1.0230055025317597e-08
the O 0 1.2430730578216753e-07
paternally O 0 0.00043777923565357924
derived O 0 3.466842031230044e-07
RB1 O 0 0.002050819806754589
allele O 0 4.435546543390956e-06
. O 0 3.917509729944868e-06

The O 0 2.68849407802918e-06
mutation O 0 8.916493243305013e-06
is O 0 2.3030277418456535e-07
in O 0 5.091724730732494e-08
an O 0 3.0780078930092714e-08
area O 0 1.19983070590024e-07
of O 0 1.0922662774248693e-08
the O 0 3.081714439190364e-08
gene O 0 4.050582091963406e-08
that O 0 3.926840630441575e-09
encodes O 0 8.957155017697005e-09
the O 0 6.452950174207217e-09
protein O 0 5.292375249155157e-08
- O 0 7.497939805034548e-06
binding O 0 9.672683631833934e-08
region O 0 4.576885359597327e-08
known O 0 4.111676776830109e-09
as O 0 2.850276237253979e-09
the O 0 9.935379807757272e-08
pocket O 0 0.3391200304031372
region O 0 1.6116732695081737e-06
and O 0 3.46759918556927e-07
has O 0 1.6341539321729215e-07
been O 0 7.869493146017703e-08
detected O 0 9.037261747835146e-07
in O 0 1.4276984039440777e-08
other O 0 2.3479575617102455e-08
cases O 0 1.3089636752283695e-07
of O 0 3.3190931958415604e-07
retinoblastoma B-Disease 0 0.002762667601928115
. O 0 1.459181476093363e-06
. O 0 9.358697752759326e-06

Low O 0 1.9284056179458275e-05
levels O 0 2.261957803284531e-07
of O 0 1.2527839210463299e-08
beta O 0 5.469320853990212e-07
hexosaminidase O 0 0.00017968655447475612
A O 0 5.677304102391645e-07
in O 0 1.052100401466305e-06
healthy O 0 3.73620468963054e-06
individuals O 0 1.7717407274631114e-07
with O 0 0.00010566085984464735
apparent O 1 0.9476975202560425
deficiency O 0 0.17826315760612488
of O 0 6.790163986636344e-09
this O 0 6.0972979554208e-08
enzyme O 0 2.625529077704414e-06
. O 0 6.888050847919658e-06

Appreciable O 0 2.417648101982195e-05
beta O 0 2.555042738094926e-05
hexosaminidase O 0 0.0015879119746387005
A O 0 1.3063313417660538e-06
( O 0 9.460229222213457e-08
hex O 0 7.158108473959146e-06
A O 0 1.0677990047724961e-07
) O 0 4.873992764942159e-08
activity O 0 3.0329996292266515e-08
has O 0 6.406950348036844e-08
been O 0 2.4312708291063245e-08
detected O 0 3.026568151653919e-07
in O 0 5.878989739471763e-08
cultured O 0 0.00012836522364523262
skin O 0 0.0062068160623312
fibroblasts O 0 0.0016607666620984674
and O 0 0.02541697956621647
melanoma B-Disease 1 0.9998483657836914
tissue O 0 0.007898139767348766
from O 0 3.8130640405142913e-06
healthy O 0 1.0443955034133978e-05
individuals O 0 1.3291318623487314e-07
previously O 0 1.6984078683890402e-05
reported O 0 0.020623883232474327
as O 0 8.007005817489699e-06
having O 0 0.002418546238914132
deficiency B-Disease 0 0.0758698582649231
of I-Disease 0 1.1427524704288317e-08
hex I-Disease 0 3.487756475806236e-05
A I-Disease 0 4.8864102097923023e-08
activity O 0 1.46818322832587e-07
indistinguishable O 0 1.0454311905050417e-06
from O 0 2.5072806053572094e-08
that O 0 4.031759814893121e-08
of O 0 6.245451800168667e-08
patients O 0 3.6763235584658105e-06
with O 0 0.019522514194250107
Tay B-Disease 1 0.9999867677688599
- I-Disease 1 0.9999878406524658
Sachs I-Disease 1 0.9999901056289673
disease I-Disease 0 0.2920718491077423
( O 0 2.6530144623393426e-06
TSD B-Disease 0 0.04424376040697098
) O 0 4.686532520281617e-06
. O 0 2.835209897966706e-06

Identification O 0 2.646131406436325e-06
and O 0 1.4746213992111734e-06
quantitation O 0 6.149224645923823e-05
of O 0 6.37335872966105e-08
hex O 0 9.209648851538077e-05
A O 0 9.493014658801258e-07
, O 0 6.787407755837194e-07
amounting O 0 5.336835329217138e-07
to O 0 2.243053565109676e-08
3 O 0 1.3062007155895117e-06
. O 0 1.8072172451866209e-06

5 O 0 3.246276901336387e-05
% O 0 2.36670825870533e-06
- O 0 0.000999457435682416
6 O 0 5.990340287098661e-05
. O 0 9.09288337425096e-06

9 O 0 9.587742533767596e-05
% O 0 2.0393929389683763e-07
of O 0 4.05246591839159e-09
total O 0 3.535636494689243e-08
beta O 0 1.7326438239706476e-07
hexosaminidase O 0 3.1534127629129216e-05
activity O 0 1.1360852880670791e-07
, O 0 6.089766202421742e-08
has O 0 3.523586045162119e-08
been O 0 1.4205354226248801e-08
obtained O 0 8.593416644941954e-09
by O 0 1.7094809123818777e-08
cellulose O 0 9.363331628264859e-05
acetate O 0 1.186377903650282e-05
gel O 0 0.00012154524301877245
electrophoresis O 0 0.00048785575199872255
, O 0 1.950680967865992e-07
DEAE O 0 8.5509913333226e-05
- O 0 2.060450970020611e-05
cellulose O 0 9.6656576715759e-06
ion O 0 1.7230320281669265e-06
- O 0 2.126423169102054e-05
exchange O 0 4.568094311707682e-07
chromatography O 0 0.0001601742405910045
, O 0 1.3512837426787883e-07
radial O 0 3.624520468292758e-05
immunodiffusion O 0 0.0012356090592220426
, O 0 5.33815352810052e-07
and O 0 9.520940125185007e-07
radioimmunoassay O 0 0.0017786386888474226
. O 0 5.925160166952992e-06

Previous O 0 0.0006052285898476839
family O 0 0.0014531216584146023
studies O 0 5.846789008501219e-06
suggested O 0 8.204720870708115e-06
that O 0 1.548328327771742e-07
these O 0 3.26929949778787e-08
individuals O 0 1.0472277978124112e-07
may O 0 2.574535642452247e-07
be O 0 9.964165492704069e-09
compound O 0 3.141350589430658e-06
heterozygotes O 0 1.0227205393675831e-06
for O 0 1.0887546419979799e-09
the O 0 2.2350887363131733e-08
common O 0 1.2348070299594838e-07
mutant O 0 0.00012064228212693706
TSD B-Disease 0 0.007113355211913586
gene O 0 6.102231395743729e-07
and O 0 4.571371619022102e-07
a O 0 6.617303824896226e-07
rare O 0 3.140302396786865e-06
( O 0 6.577904088089781e-08
allelic O 0 7.59117165216594e-06
) O 0 3.396896488538914e-07
mutant O 0 9.537211553833913e-06
gene O 0 2.7334215246810345e-06
. O 0 7.266894044732908e-06

Thus O 0 9.748481716087554e-06
, O 0 4.452888333617011e-07
the O 0 2.0170441317191035e-08
postulated O 0 8.167858140950557e-07
rate O 0 2.0753410012730455e-07
mutant O 0 1.327334757661447e-06
gene O 0 1.6016956294606643e-07
appears O 0 7.492440659007116e-07
to O 0 1.5640762018875876e-09
code O 0 3.2999645238618314e-09
for O 0 8.851225863359957e-10
the O 0 3.545595816945024e-09
expression O 0 7.868090068363642e-10
of O 0 3.061331410592061e-09
low O 0 4.185443458482041e-07
amounts O 0 7.1250623179253125e-09
of O 0 4.795050578820792e-09
hex O 0 9.27535438677296e-05
A O 0 1.9622320905909874e-06
. O 0 1.024109405989293e-05

Heterozygotes O 0 0.00038204764132387936
for O 0 2.0561802216434444e-07
the O 0 2.2256962495248445e-07
rare O 0 4.699493729276583e-06
mutant O 0 0.00014392159937415272
may O 0 1.6872803598744213e-06
be O 0 1.311199504527849e-08
indistinguishable O 0 1.2922897667522193e-06
from O 0 3.979797824626985e-08
heterozygotes O 0 1.7150678104371764e-06
for O 0 5.655211410271477e-09
the O 0 8.465324441431221e-08
common O 0 1.3854464668838773e-06
TSD B-Disease 0 0.01853117160499096
mutant O 0 0.0001866753736976534
. O 0 1.3784818293061107e-05

However O 0 1.6925213230933878e-06
, O 0 1.307481483081574e-07
direct O 0 4.23352242151509e-09
visualization O 0 2.885851245082449e-06
and O 0 1.7372170191265468e-07
quantitation O 0 1.2706112102023326e-05
of O 0 1.7773110982943763e-08
hex O 0 2.777648660412524e-05
A O 0 3.4483100819215906e-08
by O 0 6.054879264638657e-09
the O 0 8.931938744183299e-09
methods O 0 3.033361508641974e-07
described O 0 0.0003794135118369013
may O 0 1.5047771739773452e-06
prevent O 0 1.093071659852285e-06
false O 0 6.278395630943123e-06
- O 0 0.001664392533712089
positive O 0 7.724440109768693e-08
prenatal O 0 1.7621806591705536e-06
diagnosis O 0 3.388633786016726e-06
of O 0 1.0252053073145362e-07
TSD B-Disease 0 0.12175026535987854
in O 0 1.969396862477879e-06
fetuses O 0 8.920010441215709e-05
having O 0 2.952125157662522e-07
the O 0 7.272956992210311e-08
incomplete O 0 1.6834081179695204e-05
hex B-Disease 0 0.09807503968477249
A I-Disease 0 0.006876966916024685
deficiency I-Disease 1 0.502785325050354
of O 0 1.0551832296812336e-08
the O 0 4.5370862267191114e-07
type O 0 6.763449164282065e-06
described O 0 1.8367436496191658e-05
in O 0 7.132733514936263e-08
the O 0 1.9939029982651846e-07
four O 0 1.224082734552212e-05
healthy O 0 6.28785855951719e-05
individuals O 0 4.509367499849759e-06

The O 0 1.1324326806061435e-05
tumor B-Disease 0 0.007466535549610853
suppressor O 0 0.00027950710500590503
gene O 0 1.03877937362995e-05
Smad4 O 0 0.005881653632968664
/ O 0 6.711386959068477e-05
Dpc4 O 0 0.000547939445823431
is O 0 1.2704461482826446e-08
required O 0 5.315840545527806e-10
for O 0 2.9104425536274903e-09
gastrulation O 0 6.190345447976142e-05
and O 0 6.569221113750245e-07
later O 0 9.996546168622444e-07
for O 0 5.691019566711475e-08
anterior O 0 5.575216709985398e-05
development O 0 2.0103350095723727e-07
of O 0 8.26412893673023e-09
the O 0 2.8840582899647416e-07
mouse O 0 0.0006068869261071086
embryo O 0 0.00018019646813627332
. O 0 2.685020081116818e-05

Mutations O 0 2.453987326589413e-05
in O 0 8.443923320555768e-07
the O 0 1.8540762312113657e-06
SMAD4 O 1 0.6647242903709412
/ O 0 0.008284089155495167
DPC4 O 1 0.729194700717926
tumor B-Disease 0 0.002697243355214596
suppressor O 0 2.195035085605923e-05
gene O 0 3.7182255141487985e-07
, O 0 4.859095170672845e-08
a O 0 2.5886159882304582e-09
key O 0 5.008140036011355e-08
signal O 0 1.4481226173757022e-07
transducer O 0 2.376655629632296e-06
in O 0 2.850288538525092e-08
most O 0 8.964948783329874e-09
TGFbeta O 0 0.0004996395437046885
- O 0 0.0033646179363131523
related O 0 3.925071268895408e-06
pathways O 0 5.624244749924401e-07
, O 0 6.599242396987393e-08
are O 0 2.439708990387146e-10
involved O 0 3.4984448671337987e-09
in O 0 1.0596687971542451e-08
50 O 0 1.7310121336322482e-07
% O 0 8.590667022190246e-08
of O 0 8.820551556709688e-06
pancreatic B-Disease 1 0.9996949434280396
cancers I-Disease 1 0.751650869846344
. O 0 2.8294942239881493e-05

Homozygous O 0 0.00015934828843455762
Smad4 O 0 0.010904471389949322
mutant O 0 0.0050476957112550735
mice O 0 0.03807041049003601
die O 0 0.0005550628411583602
before O 0 5.883151175112289e-07
day O 0 1.0796026117532165e-06
7 O 0 4.616686510416912e-06
. O 0 3.552906491677277e-06

5 O 0 7.041966910037445e-06
of O 0 7.703641813350259e-07
embryogenesis O 0 0.0008634917321614921
. O 0 7.163673581089824e-05

Mutant O 0 0.00010566105629550293
embryos O 0 1.97013341676211e-05
have O 0 6.763899591533118e-07
reduced O 0 2.6730983790912433e-06
size O 0 9.124706411967054e-05
, O 0 2.3649438389838906e-06
fail O 0 2.3442132714990294e-06
to O 0 6.416610887072238e-08
gastrulate O 0 0.0007708379998803139
or O 0 1.6423345527982747e-07
express O 0 9.698675995650774e-08
a O 0 4.3283680639660815e-08
mesodermal O 0 0.0001994448248296976
marker O 0 0.00010796797869261354
, O 0 7.866594842198538e-07
and O 0 2.6880837822318426e-07
show O 0 1.49793891068839e-06
abnormal O 0 8.01030546426773e-06
visceral O 0 4.818358320335392e-06
endoderm O 0 0.00014791276771575212
development O 0 5.36359902980621e-06
. O 0 6.264280727918958e-06

Growth B-Disease 1 0.9985734224319458
retardation I-Disease 1 0.9990984201431274
of O 0 2.522780562230764e-07
the O 0 2.6851014354178915e-06
Smad4 O 0 0.11329906433820724
- O 1 0.6885877251625061
deficient O 0 0.033272452652454376
embryos O 0 2.268482830913854e-06
results O 0 6.750753982487367e-07
from O 0 2.0624641550170963e-08
reduced O 0 1.9133054252051807e-07
cell O 0 0.0002717107709031552
proliferation O 0 0.00013174378545954823
rather O 0 3.988215535599693e-09
than O 0 1.5219517868203525e-09
increased O 0 5.08795814369023e-08
apoptosis O 0 3.928992555302102e-06
. O 0 2.287068582518259e-06

Aggregation O 0 3.837656095129205e-06
of O 0 1.7341911018320388e-07
mutant O 0 5.3099636716069654e-05
Smad4 O 0 0.0023293299600481987
ES O 0 9.847514593275264e-05
cells O 0 2.778040197881637e-07
with O 0 6.903611193820325e-08
wild O 0 1.5822110981389415e-06
- O 0 0.001183614949695766
type O 0 3.082877810811624e-06
tetraploid O 0 4.346742935013026e-05
morulae O 0 0.002074071206152439
rescues O 0 0.0003471811069175601
the O 0 3.0504736514558317e-06
gastrulation B-Disease 0 0.04891528561711311
defect I-Disease 0 0.008964511565864086
. O 0 1.2186945241410285e-05

These O 0 1.2505789754868601e-06
results O 0 9.847433830145746e-06
indicate O 0 2.055918685073266e-06
that O 0 5.192031267142738e-07
Smad4 O 0 0.0015434942906722426
is O 0 1.230154822451368e-07
initially O 0 2.2528342924488243e-07
required O 0 6.871524460549949e-10
for O 0 3.2278382744443945e-10
the O 0 2.7082502906949912e-09
differentiation O 0 2.613801441953001e-08
of O 0 5.117032353396667e-10
the O 0 1.4425617145263914e-08
visceral O 0 3.559930519259069e-07
endoderm O 0 2.8832910174969584e-05
and O 0 1.0270607475604265e-07
that O 0 4.174493284381242e-08
the O 0 4.6147889065650816e-07
gastrulation B-Disease 0 0.026804309338331223
defect I-Disease 0 0.0004563018155749887
in O 0 5.08045197022966e-08
the O 0 7.499889420614636e-07
epiblast O 0 0.12538795173168182
is O 0 4.797229991027052e-08
secondary O 0 8.691992903209211e-09
and O 0 6.07864905077804e-08
non O 0 1.5579263390463893e-07
- O 0 0.0002040272083831951
cell O 0 8.958231774158776e-05
autonomous O 0 1.9694043658091687e-06
. O 0 2.9590380563604413e-06

Rescued O 0 0.0074328710325062275
embryos O 0 0.0006370446062646806
show O 0 0.0037554351147264242
severe O 0 0.05193312466144562
anterior O 0 0.005055177956819534
truncations O 0 0.0006998038734309375
, O 0 1.354736650682753e-05
indicating O 0 2.5294659735664027e-06
a O 0 3.304425533201538e-08
second O 0 1.4947822535305022e-07
important O 0 3.101780388092834e-09
role O 0 2.4361540340578358e-08
for O 0 2.681073318910876e-08
Smad4 O 0 0.00021049434144515544
in O 0 3.960450953854888e-07
anterior O 0 0.00019327709742356092
patterning O 0 0.0021870764903724194
during O 0 1.5986641301424243e-05
embryogenesis O 0 0.0009658110211603343
. O 0 1.66068766702665e-05

Prevalence O 0 0.00024771070457063615
of O 0 3.3676627708700835e-07
p16 O 0 8.460594835923985e-05
and O 0 9.232895536115393e-06
CDK4 O 0 0.006774179637432098
germline O 0 2.9681546948268078e-05
mutations O 0 5.354249879019335e-07
in O 0 5.7537550901543e-07
48 O 0 0.0003055055858567357
melanoma B-Disease 1 0.9965822100639343
- O 1 0.9379069805145264
prone O 1 0.630285918712616
families O 0 6.735436727467459e-06
in O 0 7.222801627904119e-07
France O 0 4.7066565457498655e-05
. O 0 1.5693125533289276e-05

The O 0 1.4020413800608367e-05
French O 0 0.0017615233082324266
Familial B-Disease 1 0.8746899366378784
Melanoma I-Disease 1 0.9976638555526733
Study O 0 6.008855962136295e-06
Group O 0 6.41591614112258e-05
. O 0 1.4113932593318168e-05

Germline O 0 0.0009472972596995533
mutations O 0 1.079953017324442e-05
in O 0 2.3955374217621284e-07
the O 0 1.7011630859542493e-07
p16 O 0 2.90011284960201e-05
and O 0 3.4518088796176016e-06
CDK4 O 0 0.003257570555433631
genes O 0 1.0551333673447516e-07
have O 0 3.9897543047118234e-08
been O 0 3.3818980682553956e-07
reported O 0 1.4619067769672256e-05
in O 0 8.855908006921709e-09
a O 0 9.526152311423175e-09
subset O 0 1.6846067296683032e-07
of O 0 3.0744690775463823e-06
melanoma B-Disease 1 0.9949666857719421
pedigrees O 0 0.0004525791446212679
, O 0 6.96940446687222e-07
but O 0 6.635023197532064e-08
their O 0 2.9200199946899374e-07
prevalence O 0 0.00011341268691467121
is O 0 7.706736226964495e-08
not O 0 7.592260153899133e-09
well O 0 2.8803356144635472e-08
known O 0 5.625875587611517e-07
. O 0 3.4789645724231377e-06

We O 0 4.364887900010217e-07
searched O 0 3.4580689316499047e-06
for O 0 9.223664498847484e-09
such O 0 3.632759426608345e-09
germline O 0 2.6661632546165492e-06
mutations O 0 5.735370223192149e-08
in O 0 2.6516834950029988e-08
48 O 0 3.04214177049289e-06
French O 0 0.016639117151498795
melanoma B-Disease 1 0.9994962215423584
- O 1 0.8304638266563416
prone O 0 0.11797965317964554
families O 0 2.99372771905837e-07
selected O 0 4.458341695823265e-09
according O 0 1.267565874485399e-08
to O 0 6.22102946934433e-09
two O 0 4.4820808398071676e-08
major O 0 4.640288011614757e-07
criteria O 0 3.6644743772740185e-07
families O 0 4.4103299501330184e-07
with O 0 7.31331155634507e-08
at O 0 1.069448444468435e-06
least O 0 2.4082991156859634e-09
three O 0 6.144978925703981e-08
affected O 0 7.316673844570687e-08
members O 0 1.05702433472743e-08
( O 0 1.9346437341027922e-08
n O 0 1.3558274076785892e-05
= O 0 4.739740234072087e-06
20 O 0 6.588212642100189e-08
) O 0 3.38561498836043e-08
or O 0 5.232872268834399e-08
families O 0 4.87646616420534e-08
with O 0 4.014249199713049e-08
two O 0 2.3722121511582372e-07
affected O 0 8.86373570097021e-08
members O 0 3.2390830018158567e-09
, O 0 5.399465763389344e-08
one O 0 2.4291419986610663e-09
of O 0 9.145859625192543e-10
them O 0 1.1541164468553688e-08
affected O 0 2.9105775567472847e-08
before O 0 3.3479015115744915e-08
the O 0 2.9643061338902044e-08
age O 0 4.9082210296091944e-08
of O 0 2.5621251786844823e-09
50 O 0 4.039179657411296e-08
( O 0 1.3689482436518574e-08
n O 0 6.277832653722726e-06
= O 0 6.720230885548517e-06
28 O 0 3.31833376776558e-07
) O 0 2.9918208355184106e-08
, O 0 3.521637381709297e-08
and O 0 1.313883224440815e-08
one O 0 1.8233661247535338e-09
additional O 0 4.401847331081399e-09
minor O 0 7.300474749172281e-07
criterion O 0 1.899026938190218e-05
. O 0 4.168647592450725e-06

Sixteen O 0 9.4156007435231e-07
different O 0 9.088239494303707e-08
p16 O 0 3.558138996595517e-05
germline O 0 9.674309694673866e-05
mutations O 0 1.1198866332051693e-06
were O 0 2.425231855340826e-07
found O 0 8.02756574103114e-07
in O 0 2.3662832404625078e-07
21 O 0 3.460810603428399e-06
families O 0 5.635132538373e-07
, O 0 1.0459702082243894e-07
while O 0 6.760507886838241e-08
one O 0 3.0376021697975375e-08
germline O 0 7.78774938225979e-06
mutation O 0 8.068337820077431e-08
, O 0 6.163702437333995e-07
Arg24His O 0 0.0014132774667814374
, O 0 6.410886044250219e-07
was O 0 2.8237575406819815e-06
detected O 0 4.871706664744124e-07
in O 0 2.4178000046504167e-08
the O 0 4.758862814924214e-07
CDK4 O 0 0.010789277963340282
gene O 0 4.989090029994259e-06
. O 0 5.721870820707409e-06

The O 0 1.1069772654082044e-07
frequency O 0 6.309893478828599e-07
of O 0 5.876040987118358e-08
p16 O 0 1.353916377411224e-05
gene O 0 2.5515737434034236e-07
mutation O 0 4.6469128989201636e-08
in O 0 5.642368350322613e-09
our O 0 6.631781790389368e-09
sample O 0 1.166549790099225e-08
( O 0 1.1432473634442886e-08
44 O 0 5.110824758958188e-07
% O 0 7.933619627920052e-08
) O 0 6.123170237515296e-08
is O 0 2.616413530276418e-09
among O 0 1.2121126324871057e-09
the O 0 5.6356814326363747e-08
highest O 0 2.89385184260027e-06
rates O 0 2.4031280645431252e-06
yet O 0 2.368746550018841e-07
reported O 0 1.1855163393192925e-05
and O 0 1.2418290395999065e-07
the O 0 2.432055339340877e-07
CDK4 O 0 0.009863431565463543
mutation O 0 6.261685570052578e-08
is O 0 3.4036842233575726e-09
the O 0 4.816674170626811e-09
second O 0 3.0785017202106246e-07
mutation O 0 9.919966004190428e-08
detected O 0 5.304502224134922e-07
in O 0 1.0347563694779183e-08
this O 0 6.556557519132866e-09
gene O 0 3.4354238209743926e-07
worldwide O 0 1.7621050574234687e-06
. O 0 4.78027823191951e-06

In O 0 5.691339993063593e-06
summary O 0 8.566906763007864e-05
, O 0 1.977321517188102e-06
our O 0 1.2738752275254228e-07
results O 0 3.0635823122793227e-07
show O 0 2.650829458161752e-07
frequent O 0 5.316231366236934e-08
involvement O 0 3.5849984669766854e-07
of O 0 2.808710597435038e-09
the O 0 2.207650773300429e-08
p16 O 0 6.10187407801277e-06
gene O 0 4.367020096651686e-07
in O 0 2.2974215880822157e-06
familial B-Disease 1 0.526113748550415
melanoma I-Disease 1 0.9979022741317749
and O 0 4.091264599992428e-06
confirm O 0 4.076648565387586e-07
the O 0 1.0264825434092018e-08
role O 0 1.0695210050926107e-08
of O 0 5.682653902994161e-09
the O 0 8.980234156297229e-08
CDK4 O 0 0.0016958798514679074
gene O 0 6.019002540824658e-08
as O 0 4.3312503805736924e-08
a O 0 1.3762804883299395e-05
melanoma B-Disease 1 0.9779579043388367
- O 0 0.05252722650766373
predisposing O 0 0.00010405047214590013
gene O 0 5.860237024535309e-07
. O 0 5.207572826293472e-07
. O 0 2.7078544917458203e-06

Progression O 0 3.486326750135049e-05
of O 0 1.0830329699729191e-07
somatic O 0 4.427221483638277e-06
CTG O 0 0.0011268585221841931
repeat O 0 1.5583467757096514e-05
length O 0 1.9349447484273696e-06
heterogeneity O 0 2.9875379823351977e-06
in O 0 1.3084269312457764e-07
the O 0 3.343141656841908e-07
blood O 0 0.0004091074224561453
cells O 0 0.00028357014525681734
of O 0 0.004644840490072966
myotonic B-Disease 1 0.999954342842102
dystrophy I-Disease 1 0.9999376535415649
patients O 0 0.002407385967671871
. O 0 0.00019585520203690976

The O 0 1.6217861684708623e-06
genetic O 0 1.3260671039461158e-05
basis O 0 3.683046998048667e-06
of O 0 0.01876785419881344
myotonic B-Disease 1 0.9999780654907227
dystrophy I-Disease 1 0.9999819993972778
( O 0 0.006042883265763521
DM B-Disease 1 0.9999722242355347
) O 0 8.95613084139768e-06
is O 0 1.2611944377738382e-08
the O 0 6.521510886869919e-09
expansion O 0 2.2579899905394996e-07
of O 0 8.229853243335583e-09
an O 0 2.5749139354047657e-07
unstable O 0 0.07066808640956879
CTG O 0 0.0011751730926334858
repeat O 0 1.1882017361131147e-06
in O 0 5.707812444910587e-09
the O 0 5.0811084228996606e-09
34 O 0 1.5168207312399318e-07
UTR O 0 2.8834197109972592e-06
of O 0 2.386483233252079e-09
the O 0 4.5045354113426583e-07
DM B-Disease 1 0.9973783493041992
protein O 0 7.12025567395358e-08
kinase O 0 2.2478424455130153e-07
gene O 0 7.661416390192244e-09
on O 0 3.088234450387972e-07
chromosome O 0 8.4030965808779e-05
19 O 0 9.53341896092752e-06
. O 0 8.078159225988202e-06

One O 0 2.1803360539252026e-07
of O 0 2.1310450293299255e-08
the O 0 2.7287327952763007e-08
principal O 0 6.964554444266469e-08
features O 0 4.5098307310809105e-08
of O 0 1.4968657424674348e-08
the O 0 1.91889853340399e-06
DM B-Disease 1 0.999914288520813
mutation O 0 3.9338075907835446e-07
is O 0 1.2509167035545943e-08
an O 0 1.7001097418756217e-08
extraordinarily O 0 1.1247609108977485e-05
high O 0 8.527372870048566e-07
level O 0 5.5110955798909345e-09
of O 0 3.698485739889179e-09
somatic O 0 2.3014083581074374e-06
mosaicism O 0 0.013033537194132805
, O 0 3.171663593093399e-06
due O 0 2.1437200814489188e-07
to O 0 5.948603831740229e-09
an O 0 1.4061994235703423e-08
extremely O 0 1.2060571634719963e-06
high O 0 1.8187495243182639e-06
degree O 0 5.446819528742708e-08
of O 0 5.83175641111211e-09
somatic O 0 2.3480483832827304e-06
instability O 0 1.0651120646798518e-05
both O 0 4.6721240209990356e-09
within O 0 2.680949240385644e-09
and O 0 8.543525353843506e-08
between O 0 3.997966402380371e-08
different O 0 1.5316002688336994e-08
tissues O 0 5.081345443613827e-05
. O 0 1.0622067748045083e-05

This O 0 8.063680979830679e-06
instability O 0 0.0014450129820033908
appears O 0 5.726423751184484e-06
to O 0 7.567855675461033e-09
be O 0 1.0761113111712461e-09
biased O 0 6.476380320918906e-08
towards O 0 4.370975581480252e-09
further O 0 1.804265958860185e-09
expansion O 0 3.337012444148968e-08
and O 0 2.0238024589502857e-09
continuous O 0 2.035847046499839e-09
throughout O 0 2.0095090036420515e-09
the O 0 1.4215681076734654e-08
life O 0 3.928018799115307e-08
of O 0 2.4630508743683777e-09
an O 0 1.5572810596609088e-08
individual O 0 5.03485217961952e-08
, O 0 4.1916433701771894e-07
features O 0 4.400355919642607e-07
that O 0 5.402905571827432e-07
could O 0 1.2107312841180828e-06
be O 0 3.743662091437727e-08
associated O 0 9.651287768974726e-08
with O 0 6.359516646625707e-08
the O 0 3.989047172581195e-07
progressive O 0 2.042475898633711e-05
nature O 0 6.261697080844897e-07
of O 0 1.4139753545805434e-07
the O 0 0.00015521944442298263
disease O 0 0.016825582832098007
. O 0 1.8679835193324834e-05

Although O 0 1.3132215599398478e-06
increasing O 0 1.657480623862284e-07
measured O 0 1.3253096540211118e-06
allele O 0 3.203185769962147e-06
size O 0 0.0002359679201617837
between O 0 7.899818228906952e-06
patients O 0 1.392549165757373e-06
clearly O 0 3.5677683172252728e-06
correlates O 0 7.020528755674604e-06
with O 0 1.399393170231633e-07
an O 0 1.412412018453324e-07
increased O 0 7.797641046636272e-06
severity O 0 0.0009602027712389827
of O 0 1.7984419855565648e-06
symptoms O 0 2.8628845029743388e-05
and O 0 2.4985592972370796e-07
an O 0 1.1949457245918893e-07
earlier O 0 0.0010952971642836928
age O 0 1.950809064510395e-06
of O 0 1.8792786704580067e-07
onset O 0 0.002261023735627532
, O 0 3.5719008906198724e-07
this O 0 3.2472855515663923e-09
correlation O 0 7.503095389438386e-08
is O 0 7.504752375098178e-09
not O 0 6.089970194800287e-10
precise O 0 1.21605685521331e-08
and O 0 1.0155289231761344e-07
measured O 0 3.249635938118445e-07
allele O 0 5.582253947977733e-07
length O 0 2.6381264888186706e-06
cannot O 0 1.0797658234196206e-07
be O 0 1.4065286713105252e-09
used O 0 5.765980137795168e-09
as O 0 2.166792301139253e-09
an O 0 8.527257122636911e-09
accurate O 0 8.67099913648417e-07
predictor O 0 4.7464527597185224e-06
of O 0 4.043680945642336e-08
age O 0 1.2156173170296825e-06
of O 0 5.1911649734393e-07
onset O 0 0.002502738032490015
. O 0 2.6518042432144284e-05

In O 0 3.1724896416562842e-06
order O 0 2.293408130071839e-07
to O 0 1.1342292438598633e-08
further O 0 6.400925567362492e-09
characterize O 0 3.443952607540268e-07
the O 0 6.413209518996155e-08
dynamics O 0 0.0004569272277876735
of O 0 7.349668180722801e-07
DM B-Disease 1 0.9998192191123962
CTG O 0 0.00456572137773037
repeat O 0 3.5099876640742877e-06
somatic O 0 1.0285364169249078e-06
instability O 0 4.344203262007795e-05
, O 0 2.0175335180283582e-07
we O 0 8.669078788159368e-09
have O 0 2.5278212856250093e-09
studied O 0 1.7010794550742503e-08
repeat O 0 6.679566695311223e-07
length O 0 7.45706927318679e-08
changes O 0 1.4103029855050409e-09
over O 0 2.7101068056367694e-08
time O 0 1.6864393614923756e-07
in O 0 1.215635802509496e-05
111 O 1 0.9977301955223083
myotonic B-Disease 1 0.9999936819076538
dystrophy I-Disease 1 0.9999947547912598
patients O 0 9.434972162125632e-05
with O 0 2.4434916667814832e-06
varying O 0 1.991969384107506e-06
clinical O 0 7.227622518257704e-06
severity O 0 0.00020690623205155134
and O 0 3.83623273592093e-06
CTG O 0 0.001637966139242053
repeat O 0 4.203106072964147e-06
size O 0 1.5006585272203665e-06
over O 0 2.6673221853457107e-08
time O 0 1.8041318439188103e-09
intervals O 0 1.061533416724103e-09
of O 0 7.092612053227754e-10
1 O 0 4.6043787449434603e-08
- O 0 8.454820635961369e-05
7 O 0 5.553121354751056e-06
years O 0 3.7699344375141663e-06
. O 0 2.644012738528545e-06

We O 0 4.9760656111175194e-06
have O 0 5.268370273370238e-07
found O 0 2.1342468414786708e-07
a O 0 5.820632864583786e-09
direct O 0 1.8889980690772745e-09
progression O 0 3.916909463441698e-07
of O 0 1.0303228270558407e-09
the O 0 1.4600561648592247e-08
size O 0 8.466327017231379e-06
heterogeneity O 0 2.5720080429891823e-06
over O 0 3.207289580586803e-07
time O 0 1.545684682469073e-07
related O 0 1.8336595530854538e-07
to O 0 4.918227158867694e-09
initial O 0 1.3904005413678533e-07
CTG O 0 7.274874224094674e-05
repeat O 0 1.5777479802636662e-06
size O 0 1.830205405894958e-06
and O 0 1.2932494186657095e-08
the O 0 2.769424911619467e-09
time O 0 7.506785415500872e-09
interval O 0 5.761860677466757e-08
and O 0 2.973071211442857e-08
always O 0 6.0382601141384384e-09
biased O 0 6.442093791747538e-08
towards O 0 7.87743381636119e-09
further O 0 1.105059332928704e-08
expansion O 0 1.5099205938895466e-06
. O 0 2.306932628926006e-06

Attempts O 0 5.785691882920219e-06
to O 0 2.3616031796791503e-07
mathematically O 0 2.420618329779245e-06
model O 0 4.755931968247751e-07
the O 0 7.692506187595427e-08
dynamics O 0 0.001356158871203661
have O 0 3.703012794176175e-07
proved O 0 2.729911830101628e-05
only O 0 7.71402763888318e-09
partially O 0 4.816097771254135e-06
successful O 0 1.0521966942178551e-06
suggesting O 0 1.5840585547266528e-05
that O 0 1.366277757597345e-07
individual O 0 4.403863052004908e-09
specific O 0 2.5357844712914357e-09
genetic O 0 3.661865093818051e-06
and O 0 1.4203224054654129e-05
/ O 0 0.000369622721336782
or O 0 4.9818490879260935e-06
environmental O 0 8.194610018108506e-06
factors O 0 1.229476964681453e-07
also O 0 1.9147504914940328e-08
play O 0 2.236208995753941e-09
a O 0 8.244401605850271e-09
role O 0 4.025789124284529e-08
in O 0 1.2955682393567258e-07
somatic O 0 5.3526737247011624e-06
mosaicism O 0 0.0011093101929873228
. O 0 1.2429514981704415e-06
. O 0 4.5358328861766495e-06

Aspartylglucosaminuria B-Disease 1 0.8612567186355591
among O 0 3.4699949083005777e-06
Palestinian O 0 2.8808723072870634e-05
Arabs O 0 7.584362174384296e-05
. O 0 1.70838538906537e-05

Aspartylglucosaminuria B-Disease 1 0.9975437521934509
( O 0 0.013978629373013973
AGU B-Disease 1 0.9992554783821106
) O 0 6.707752618240193e-05
is O 0 7.414026299557008e-07
a O 0 5.94926996200229e-06
rare O 0 0.0019138477509841323
disorder B-Disease 0 0.14417728781700134
of I-Disease 0 1.997505023609847e-06
glycoprotein I-Disease 0 0.4274331331253052
metabolism I-Disease 0 0.016146548092365265
caused O 0 6.621524516958743e-05
by O 0 2.2738327061233576e-06
the O 0 0.0005025771679356694
deficiency B-Disease 0 0.32445546984672546
of I-Disease 0 3.0757835389749744e-08
the I-Disease 0 2.9404043289105175e-06
lysosomal I-Disease 0 0.0967985987663269
enzyme I-Disease 0 1.7823198504629545e-05
aspartylglucosaminidase I-Disease 0 0.001779743004590273
( O 0 2.1088411017444741e-07
AGA O 0 0.0008918967796489596
) O 0 5.281907533571939e-07
. O 0 1.7791480786399916e-06

AGU B-Disease 1 0.9990422129631042
is O 0 0.009946630336344242
inherited O 1 0.9229175448417664
as O 0 1.187025281979004e-05
an O 0 0.00010351153468945995
autosomal O 1 0.9732260704040527
recessive O 1 0.9024131298065186
trait O 0 0.03145527094602585
and O 0 8.195768168661743e-05
occurs O 0 5.491287424774782e-07
with O 0 3.8643257482817717e-08
a O 0 7.314817906944882e-08
high O 0 1.687985331955133e-06
frequency O 0 1.0876368605750031e-07
in O 0 2.4021352373893023e-07
Finland O 0 1.5693858586018905e-05
because O 0 2.6953685505759495e-08
of O 0 1.987829456595591e-09
a O 0 1.8327995121580898e-07
founder O 0 0.0002321715874131769
effect O 0 1.476601369176933e-06
. O 0 2.758401251412579e-06

While O 0 1.035161767504178e-05
very O 0 9.12187658741459e-07
few O 0 1.2159048310422804e-06
patients O 0 5.430591954791453e-06
with O 0 0.00010410764662083238
AGU B-Disease 1 0.9999290704727173
have O 0 1.9772405721596442e-06
been O 0 1.7315315972155076e-06
reported O 0 2.7664977096719667e-05
from O 0 1.7107366190316498e-08
non O 0 4.9316721373315886e-08
- O 0 0.00015512475511059165
Finnish O 0 1.3434610082185827e-05
origin O 0 6.038999913471343e-07
, O 0 1.0126223969564307e-05
we O 0 1.877166323538404e-05
diagnosed O 0 0.03235616907477379
the O 0 2.28055414481787e-05
disorder O 0 0.15180158615112305
in O 0 1.3883404790249187e-06
8 O 0 9.623410733183846e-05
patients O 0 1.145324858953245e-06
originating O 0 5.7918416729307864e-08
from O 0 3.145764537748619e-08
3 O 0 1.1963634278799873e-06
unrelated O 0 0.00022163245012052357
families O 0 1.3301834087542375e-06
, O 0 2.9675192081413115e-08
all O 0 5.372770561784534e-10
Palestinian O 0 8.733207437217061e-07
Arabs O 0 8.513251259500976e-07
from O 0 9.455426663862454e-09
the O 0 2.361917772475408e-08
region O 0 2.8890792691527167e-07
of O 0 3.5077807325478716e-08
Jerusalem O 0 3.385983654879965e-05
. O 0 8.851233360473998e-06

The O 0 1.0691460374800954e-05
clinical O 0 0.0002128573105437681
diagnosis O 0 0.009493687190115452
of O 0 0.00019424869969952852
AGU B-Disease 1 0.9999544620513916
is O 0 6.064351964596426e-06
often O 0 8.02191777893313e-07
difficult O 0 8.06884236226324e-06
, O 0 2.904821485572029e-07
in O 0 2.0516077725574178e-08
particular O 0 2.320491354623755e-09
early O 0 6.964076249005302e-08
in O 0 3.002848814048775e-08
the O 0 6.624212289807474e-08
course O 0 6.727656455041142e-06
of O 0 1.5914559980956255e-07
the O 0 0.00044877181062474847
disease O 0 0.008871866390109062
, O 0 5.168427037460788e-07
and O 0 2.036213544442944e-07
most O 0 3.873725340497458e-09
of O 0 3.462083597582932e-08
the O 0 1.0351578566769604e-05
patients O 0 1.403338865202386e-05
are O 0 8.237275324063376e-07
diagnosed O 0 0.0052582030184566975
after O 0 2.804654650390148e-05
the O 0 5.185173108657182e-07
age O 0 2.841213984083879e-07
of O 0 1.8503826026972092e-08
5 O 0 1.8920443380920915e-06
years O 0 4.59913098893594e-06
. O 0 4.368545887700748e-06

However O 0 3.833293521893211e-05
, O 0 5.137098014529329e-06
since O 0 1.0841527000593487e-06
these O 0 2.6123609941919312e-08
patients O 0 1.2338206545337016e-07
excrete O 0 2.537608168040606e-07
early O 0 2.3134791860002224e-08
large O 0 4.3720703502003744e-08
amounts O 0 7.303940119385288e-09
of O 0 2.0865289940275034e-08
aspartylglucosamine O 0 0.0013609169982373714
in O 0 1.6714683681584575e-07
urine O 0 1.541143660688249e-06
, O 0 2.208125238212233e-07
biochemical O 0 1.553201514070679e-06
screening O 0 7.126573109417222e-08
is O 0 5.5292157519204466e-09
easy O 0 2.2854534265093207e-08
by O 0 5.5297249446084606e-08
urine O 0 1.8561285060059163e-06
chromatography O 0 0.00414328183978796
. O 0 8.523438168595021e-07
. O 0 3.940749593311921e-06

Detection O 0 2.7873285944224335e-05
of O 0 2.279989956832651e-07
heterozygous O 0 3.050997065656702e-06
carriers O 0 7.050991825963138e-06
of O 0 3.031617836768419e-07
the O 0 0.0007707535405643284
ataxia B-Disease 1 0.9999669790267944
- I-Disease 1 0.9999376535415649
telangiectasia I-Disease 1 0.9999498128890991
( O 0 1.261408101527195e-06
ATM O 0 0.0006334039499051869
) O 0 1.01296762977654e-07
gene O 0 8.385132588273336e-09
by O 0 6.707155364438222e-08
G2 O 0 0.08018425852060318
phase O 0 2.2428592274081893e-05
chromosomal O 0 0.003168526105582714
radiosensitivity O 0 0.0015041985316202044
of O 0 1.9968791775681893e-07
peripheral O 0 0.0024308280553668737
blood O 0 0.0007454725564457476
lymphocytes O 0 0.007071508094668388
. O 0 1.869478728622198e-05

In O 0 0.002666127635166049
ataxia B-Disease 1 0.9993699193000793
- I-Disease 1 0.999602735042572
telangiectasia I-Disease 1 0.9998303651809692
( O 0 9.086554200621322e-05
A B-Disease 0 0.4744633138179779
- I-Disease 1 0.9999295473098755
T I-Disease 1 0.9999891519546509
) O 0 0.00011116078530903906
patients O 0 1.298611664424243e-06
, O 0 3.4799529657902895e-07
mutations O 0 6.856343759409356e-08
in O 0 1.0735329958322382e-08
a O 0 8.570745890779108e-09
single O 0 1.9589950994713945e-08
gene O 0 2.954367062102392e-07
, O 0 6.548280566676112e-07
ATM O 0 0.00574816670268774
, O 0 1.216746932186652e-05
result O 0 2.015499194385484e-05
in O 0 5.627875361824408e-05
an O 1 0.5864158272743225
autosomal B-Disease 1 0.9999957084655762
recessive I-Disease 1 0.9999910593032837
syndrome I-Disease 1 0.9999974966049194
that O 0 2.4541419406887144e-05
embraces O 0 2.4086111807264388e-05
a O 0 2.9738777129750815e-07
variety O 0 5.4894030654395465e-08
of O 0 6.058450452428588e-08
clinical O 0 1.1597421689657494e-06
features O 0 1.6226107391048572e-06
and O 0 7.786479727656115e-06
manifests O 0 3.0155964850564487e-05
extreme O 0 8.482709745294414e-06
radiosensitivity O 0 0.0032021014485508204
and O 0 1.874971502502376e-07
a O 0 3.745404697497179e-08
strong O 0 4.6399296138588397e-07
pre O 0 0.0001327547652181238
- O 0 0.0034321043640375137
disposition O 0 4.3131480197189376e-05
to O 0 4.637855909095379e-06
malignancy B-Disease 0 0.11485357582569122
. O 0 1.327551308349939e-05

Heterozygotes O 0 0.00023252250684890896
for O 0 1.2712527563962794e-07
the O 0 1.957232882432436e-07
ATM O 0 0.0011018714867532253
gene O 0 2.565207751104026e-06
have O 0 3.0581529131268326e-07
no O 0 7.819444647338969e-08
clinical O 0 1.6014894299587468e-07
expression O 0 5.9317226686061986e-09
of O 0 1.0566035513193128e-07
A B-Disease 0 0.3521815538406372
- I-Disease 1 0.9999703168869019
T I-Disease 1 0.9999923706054688
but O 0 0.00034939043689519167
may O 0 5.193442848394625e-05
be O 0 1.1310231457173359e-05
cancer B-Disease 0 0.17636685073375702
prone O 0 0.014382016845047474
with O 0 6.354993615786952e-07
a O 0 1.3900123576604528e-06
moderate O 0 3.52344723069109e-05
increase O 0 1.5546640952379676e-07
in O 0 5.1615405283200744e-08
in O 0 4.399210240535467e-07
vitro O 0 0.000512072176206857
radiosensitivity O 0 0.02073955163359642
. O 0 7.1564431891602e-06

We O 0 4.269343662599567e-06
performed O 0 8.916222213883884e-07
a O 0 2.599389006263664e-07
blind O 0 2.1122572434251197e-05
chromosomal O 0 5.755409074481577e-05
analysis O 0 1.5811326647963142e-07
on O 0 8.016739911909099e-07
G2 O 0 0.23355349898338318
- O 0 0.0003111416008323431
phase O 0 1.831282702369208e-06
lymphocytes O 0 1.1896590876858681e-05
from O 0 1.1893515505789765e-08
7 O 0 1.1086588074249448e-06
unrelated O 0 0.00043617075425572693
A B-Disease 0 0.28657904267311096
- I-Disease 1 0.9999192953109741
T I-Disease 1 0.9999897480010986
patients O 0 4.0927006921265274e-06
, O 0 1.248721730462421e-07
13 O 0 3.0275958806669223e-07
obligate O 0 8.527795785084891e-07
A B-Disease 0 0.004926747176796198
- I-Disease 1 0.9995319843292236
T I-Disease 1 0.999980092048645
heterozygotes O 0 0.000800769601482898
( O 0 4.035852541051099e-08
parents O 0 1.5957807519839662e-08
of O 0 1.2778778923916434e-08
the O 0 2.788104438877781e-06
patients O 0 2.6215959678665968e-06
) O 0 1.4595528341487807e-07
, O 0 5.6222823729967786e-08
and O 0 5.514105794190982e-08
14 O 0 2.2241890107466133e-08
normal O 0 3.0471929424180644e-09
controls O 0 8.971776566113476e-08
following O 0 3.24702078557948e-08
X O 0 8.700991020305082e-05
- O 0 5.3597027545038145e-06
irradiation O 0 4.077277893088649e-08
with O 0 7.202288543339819e-09
1 O 0 1.5511536943790816e-08
Gy O 0 1.3566893812821945e-06
in O 0 1.223501189251408e-09
order O 0 1.8787826849830935e-09
to O 0 1.0163109243066515e-09
evaluate O 0 1.7679750996535404e-09
this O 0 3.4342009791465955e-10
cytogenetic O 0 4.103022774870624e-07
method O 0 5.5210800375959934e-09
as O 0 2.38529529461573e-09
a O 0 6.3488969637148784e-09
tool O 0 6.480395882135781e-07
for O 0 1.8739261253841732e-09
detection O 0 2.591577299426717e-07
of O 0 1.0658554039366663e-08
ATM O 0 0.0006721228128299117
carriers O 0 1.446262285753619e-05
. O 0 3.867640771204606e-06

Both O 0 7.732039193797391e-06
A B-Disease 0 0.005352940410375595
- I-Disease 1 0.9899441003799438
T I-Disease 1 0.9997949004173279
homozygotes O 0 0.0006417419645003974
and O 0 1.464255660721392e-06
heterozygotes O 0 2.0348545149317943e-05
showed O 0 5.948997568339109e-06
significantly O 0 2.1528535398829263e-07
increased O 0 1.0563955044062823e-08
levels O 0 1.8643608878932127e-09
of O 0 5.473122843824285e-09
radiation O 0 0.00012720450467895716
- O 0 0.05587159842252731
induced O 0 0.0344134159386158
chromatid O 1 0.7551601529121399
damage O 0 0.010581625625491142
relative O 0 8.9080032239508e-07
to O 0 1.1557090395797331e-08
that O 0 1.5862127611399046e-08
of O 0 5.576749728675168e-09
normal O 0 1.1613553141387456e-07
controls O 0 9.437299013370648e-06
. O 0 6.950885563128395e-06

These O 0 3.076417556258093e-07
results O 0 1.3373013416639878e-06
show O 0 2.8130313012297847e-07
that O 0 1.1241048092358596e-08
the O 0 6.18611437630534e-08
G2 O 0 0.03964962437748909
- O 0 0.0003757246595341712
phase O 0 2.600817424536217e-06
chromosomal O 0 0.0006619203486479819
radiosensitivity O 0 0.0006162845529615879
assay O 0 7.254927822941681e-06
can O 0 3.092222922163046e-09
be O 0 4.297769640171367e-10
used O 0 7.127831658237938e-10
for O 0 2.2745706707016922e-10
the O 0 5.210917919384883e-09
detection O 0 1.7032731420840719e-06
of O 0 1.5609916204084584e-07
A B-Disease 0 0.03846268355846405
- I-Disease 1 0.999346911907196
T I-Disease 1 0.9997826218605042
heterozygotes O 0 0.0002469609898980707
. O 0 3.0193257316568634e-06

In O 0 1.432576254956075e-06
combination O 0 2.538937451390666e-06
with O 0 9.661248441261705e-07
molecular O 0 0.00018784345593303442
genetic O 0 2.913357639044989e-05
analyses O 0 1.333845648332499e-05
, O 0 8.713574288776726e-07
this O 0 3.3601779136915866e-08
test O 0 3.2218190426647197e-06
may O 0 2.1360591517805005e-07
be O 0 9.050987181957737e-10
of O 0 2.46886422416992e-09
value O 0 4.68168899203647e-08
in O 0 3.233794387824673e-08
studies O 0 2.7980606276400977e-08
of O 0 2.2006299005283836e-08
familial B-Disease 0 8.478062954964116e-05
and I-Disease 0 4.252342023391975e-06
sporadic I-Disease 0 5.510503615369089e-05
cancers I-Disease 0 0.013013309799134731
aimed O 0 6.253724859561771e-05
at O 0 8.43065936351195e-06
determination O 0 8.00838790837588e-07
of O 0 1.7770152016538532e-09
the O 0 2.9109548549399733e-08
potential O 0 3.2026284202402167e-07
involvement O 0 1.653662877743045e-07
of O 0 1.2811970151460628e-08
ATM O 0 0.006070719566196203
mutations O 0 6.188361112435814e-06
in O 0 2.755239802354481e-05
tumor B-Disease 1 0.5481649041175842
risk O 0 1.8144000932807103e-05
or O 0 1.7592174117453396e-07
development O 0 3.5204362802687683e-07
. O 0 9.95510504253616e-07
. O 0 7.089066457410809e-06

Ataxia B-Disease 1 0.9989311099052429
- I-Disease 1 0.9988603591918945
telangiectasia I-Disease 1 0.9995293617248535
: O 0 3.068455725951935e-06
identification O 0 1.1950163525398239e-07
and O 0 1.5279566412118584e-07
detection O 0 1.261518718820298e-06
of O 0 5.983723383451434e-08
founder O 0 0.0006740845274180174
- O 0 0.0015091439709067345
effect O 0 2.161712444603836e-07
mutations O 0 1.6517109457936385e-08
in O 0 3.7409333408788825e-09
the O 0 1.3797192721654028e-08
ATM O 0 8.647037611808628e-05
gene O 0 7.657109790670802e-08
in O 0 2.6870836222769867e-08
ethnic O 0 4.0117660660143883e-07
populations O 0 2.9870880098314956e-06
. O 0 6.5619792621873785e-06

To O 0 1.259836466260822e-07
facilitate O 0 3.77375819482495e-08
the O 0 7.52358442213108e-09
evaluation O 0 6.719086620421422e-09
of O 0 3.089740907569194e-09
ATM O 0 0.0008186103659681976
heterozygotes O 0 9.941737516783178e-06
for O 0 2.5469926612231575e-08
susceptibility O 0 4.858427473664051e-06
to O 0 1.4905870671100274e-07
other O 0 2.177841224693111e-06
diseases O 0 0.00253081857226789
, O 0 5.74637965655711e-07
such O 0 9.48581373449997e-08
as O 0 4.278327833162621e-05
breast B-Disease 1 0.9550767540931702
cancer I-Disease 0 0.14479243755340576
, O 0 1.4087706858845195e-06
we O 0 3.490921329785124e-08
have O 0 5.914821077368515e-09
attempted O 0 1.473287397857348e-06
to O 0 7.4795734050781e-09
define O 0 4.194006208990686e-08
the O 0 1.3821371602773525e-08
most O 0 5.31669508418986e-09
common O 0 3.8854114592368205e-08
mutations O 0 2.2546991829131002e-08
and O 0 2.1643924430492234e-09
their O 0 1.3414025445968036e-09
frequencies O 0 3.3430333701289783e-07
in O 0 3.728521187440492e-05
ataxia B-Disease 1 0.9999574422836304
- I-Disease 1 0.9998856782913208
telangiectasia I-Disease 1 0.9999659061431885
( O 0 3.1591598599334247e-06
A B-Disease 0 0.059307344257831573
- I-Disease 1 0.9994951486587524
T I-Disease 1 0.999953031539917
) O 0 1.1019085377483862e-06
homozygotes O 0 3.4537119972810615e-06
from O 0 4.797904740172498e-09
10 O 0 2.2332095284127718e-08
ethnic O 0 1.1635104613105796e-07
populations O 0 6.985840173001634e-07
. O 0 3.989925062342081e-06

Both O 0 1.008181357065041e-06
genomic O 0 7.016348536126316e-05
mutations O 0 4.2781107367773075e-06
and O 0 1.9679687568441295e-07
their O 0 4.980838141932509e-08
effects O 0 2.823709905896976e-07
on O 0 6.5106256386116e-08
cDNA O 0 8.3568147601909e-06
were O 0 7.136202953006432e-07
characterized O 0 6.650112482020631e-05
. O 0 8.888926458894275e-06

Protein O 0 1.4354687664308585e-05
- O 0 0.00013826739450450987
truncation O 0 1.0648561328707729e-05
testing O 0 2.4879213356143737e-07
of O 0 1.0476743916854048e-09
the O 0 2.7893949372526095e-09
entire O 0 1.1194382310009132e-08
ATM O 0 8.371858712052926e-06
cDNA O 0 1.6345356925739907e-06
detected O 0 1.133973910327768e-06
92 O 0 1.9594419882196235e-06
( O 0 5.020114102194384e-08
66 O 0 4.073231139045674e-06
% O 0 4.1628048563779885e-08
) O 0 5.0930744066590705e-08
truncating O 0 1.820800775931275e-06
mutations O 0 2.1924353887925463e-08
in O 0 3.063708842176993e-09
140 O 0 9.180753579585144e-08
mutant O 0 2.547341182435048e-06
alleles O 0 1.7742075897331233e-07
screened O 0 2.233061877632281e-06
. O 0 5.181038886803435e-06

The O 0 1.6741718354751356e-05
haplotyping O 0 0.06986355781555176
of O 0 4.041012743982719e-06
patients O 0 7.129582627385389e-06
with O 0 1.8067208884531283e-06
identical O 0 0.001210457063280046
mutations O 0 4.731029093818506e-06
indicates O 0 2.2645099306828342e-06
that O 0 4.7452580531626154e-08
almost O 0 8.301729081949816e-09
all O 0 6.152666709446919e-10
of O 0 2.557828171489973e-09
these O 0 8.876065216156803e-09
represent O 0 2.1110075465458067e-08
common O 0 4.461764149255032e-07
ancestry O 0 4.137627456657356e-06
and O 0 1.4606405329686822e-06
that O 0 1.5850761769797828e-07
very O 0 2.861558812128351e-08
few O 0 5.3387083198686014e-08
spontaneously O 0 1.780094976311375e-06
recurring O 0 2.354879143240396e-06
ATM O 0 0.0025841149035841227
mutations O 0 1.8148683693652856e-06
exist O 0 2.133225365241742e-07
. O 0 3.263791086283163e-06

Assays O 0 3.6238117900211364e-05
requiring O 0 6.589168037862692e-07
minimal O 0 3.3761330087145325e-07
amounts O 0 1.6338571384721945e-08
of O 0 2.9725195638263813e-09
genomic O 0 1.3902960063205683e-06
DNA O 0 1.8504219042370096e-05
were O 0 6.559311600540241e-07
designed O 0 3.2520340482733445e-06
to O 0 2.7676454461555977e-09
allow O 0 1.2838922147651033e-09
rapid O 0 2.228010487215215e-08
screening O 0 1.119391335180353e-08
for O 0 3.0645155302266858e-09
common O 0 2.562532053218547e-08
ethnic O 0 3.1762931484990986e-07
mutations O 0 3.8003286135790404e-06
. O 0 1.3311136171978433e-05

These O 0 1.1430383750621331e-07
rapid O 0 8.523388714820612e-07
assays O 0 2.9670577532669995e-06
detected O 0 3.2001141789805843e-06
mutations O 0 2.0656851518197072e-07
in O 0 6.064752255952044e-08
76 O 0 1.6548710846109316e-05
% O 0 1.920492920248762e-08
of O 0 3.1592090721233035e-08
Costa O 0 2.417805080767721e-05
Rican O 0 8.024214366741944e-06
patients O 0 1.497439029662928e-06
( O 0 2.1920298465261112e-08
3 O 0 2.496544198038464e-07
) O 0 3.385201452488218e-08
, O 0 2.0705403613874296e-08
50 O 0 1.4480254328930187e-08
% O 0 3.6157126181990407e-09
of O 0 2.8597201051638876e-08
Norwegian O 0 0.003217782359570265
patients O 0 1.7617840057937428e-06
( O 0 1.3020631683957617e-08
1 O 0 2.9049978422790446e-08
) O 0 2.4741781956549858e-08
, O 0 3.383323132766236e-08
25 O 0 1.1168624070023725e-07
% O 0 5.900668398339803e-09
of O 0 1.2725342557473596e-08
Polish O 0 0.0005391421727836132
patients O 0 2.336847501283046e-06
( O 0 3.127654224499565e-08
4 O 0 3.0179731425050704e-07
) O 0 6.491654147566805e-08
, O 0 3.5953856780679416e-08
and O 0 3.965272554751209e-08
14 O 0 1.3523241193524882e-07
% O 0 1.0797962524122795e-08
of O 0 2.6585199819351146e-08
Italian O 0 0.0004980853409506381
patients O 0 2.282930154251517e-06
( O 0 2.087528194749666e-08
1 O 0 5.256299928646513e-08
) O 0 3.722940888906123e-08
, O 0 4.6593559233087944e-08
as O 0 3.5765341799276484e-09
well O 0 1.483826839177027e-08
as O 0 2.189489123338717e-08
in O 0 2.1107102554651647e-07
patients O 0 3.008633342460598e-08
of O 0 9.827100910797526e-09
Amish O 0 0.0004474502056837082
/ O 0 2.680461147974711e-05
Mennonite O 0 0.00014282613119576126
and O 0 1.093195805879077e-06
Irish O 0 1.6251754004770191e-06
English O 0 6.408600228269279e-08
backgrounds O 0 4.7100638767005876e-06
. O 0 7.5602570177579764e-06

Additional O 0 4.7224415311575285e-07
mutations O 0 1.6719496898076613e-06
were O 0 1.4501681278034084e-07
observed O 0 1.9995050593024644e-07
in O 0 3.181977348276632e-08
Japanese O 0 2.4118182864185655e-06
, O 0 2.577306474904617e-07
Utah O 0 2.0372481230879202e-06
Mormon O 0 4.152286976477626e-07
, O 0 1.9308805576656596e-07
and O 0 3.517073707826057e-07
African O 0 2.22222956836049e-06
American O 0 1.3327965461940039e-05
patients O 0 5.0971061682503205e-06
. O 0 6.341750122373924e-06

These O 0 6.854631351416174e-08
assays O 0 5.717113822356623e-07
should O 0 5.9638498584035915e-09
facilitate O 0 1.744184130458848e-09
screening O 0 1.5765756700147904e-08
for O 0 1.8573130589061293e-08
A B-Disease 0 0.001431194832548499
- I-Disease 1 0.9984569549560547
T I-Disease 1 0.9999629259109497
heterozygotes O 0 3.4003183827735484e-05
in O 0 3.381729740681294e-08
the O 0 3.633197565022783e-08
populations O 0 9.586578642029053e-08
studied O 0 1.3767387940788467e-07
. O 0 5.107608558319043e-07
. O 0 5.954310381639516e-06

The O 0 6.879475404275581e-05
von B-Disease 1 0.9875175356864929
Hippel I-Disease 1 0.9835277795791626
- I-Disease 1 0.9883137941360474
Lindau I-Disease 1 0.9838539361953735
tumor I-Disease 0 0.33257442712783813
suppressor O 0 0.00012572246487252414
gene O 0 3.700781689985888e-07
is O 0 1.4017835781032773e-08
required O 0 1.3793448605525782e-09
for O 0 1.0622955848305082e-08
cell O 0 0.00011956037633353844
cycle O 0 2.6891607376455795e-06
exit O 0 5.415033115241386e-07
upon O 0 1.4572579232208227e-07
serum O 0 3.536657095537521e-05
withdrawal O 0 5.655274435412139e-06
. O 0 3.7064719435875304e-06

The O 0 1.5699102959843003e-06
inactivation O 0 0.0001994588819798082
of O 0 1.3435212053991563e-07
the O 0 5.350367246137466e-06
von B-Disease 1 0.9795446991920471
Hippel I-Disease 1 0.9854711294174194
- I-Disease 1 0.9773855805397034
Lindau I-Disease 1 0.7916415929794312
( I-Disease 0 1.945287749549607e-06
VHL I-Disease 0 0.028675377368927002
) I-Disease 0 4.494452696235385e-06
tumor I-Disease 0 0.0004945949767716229
suppressor O 0 2.657804543559905e-05
gene O 0 4.223445557727246e-06
predisposes O 0 0.0008883349946700037
affected O 0 7.820129326319147e-07
individuals O 0 7.992364103870386e-09
to O 0 5.554152693321157e-08
the O 0 6.545997166540474e-06
human O 0 0.11600087583065033
VHL B-Disease 1 0.9999713897705078
cancer I-Disease 1 0.9999845027923584
syndrome I-Disease 1 0.9999523162841797
and O 0 0.00013319667777977884
is O 0 2.3387960936815944e-06
associated O 0 2.8662511795118917e-06
with O 0 3.818005552602699e-06
sporadic B-Disease 0 0.06388647854328156
renal I-Disease 1 0.9999357461929321
cell I-Disease 1 0.9991231560707092
carcinomas I-Disease 1 0.9999724626541138
( O 0 1.2573112144309562e-05
RCC B-Disease 1 0.7247739434242249
) O 0 3.655779664768488e-06
and O 0 7.514791377616348e-06
brain B-Disease 0 0.00962219387292862
hemangioblastomas I-Disease 0 0.03809738904237747
. O 0 1.6294667148031294e-05

VHL O 0 0.055875007063150406
- O 0 0.0004194995271973312
negative O 0 1.620550960979017e-06
786 O 0 6.671620212728158e-05
- O 0 0.001438030623830855
0 O 0 4.845517651119735e-06
RCC B-Disease 0 0.0030579317826777697
cells O 0 9.210884286403598e-07
are O 0 7.73739827764075e-09
tumorigenic O 0 0.00012702340609394014
in O 0 2.795906084429589e-07
nude O 0 0.002377779921516776
mice O 0 0.0011079974938184023
which O 0 4.790537104781833e-07
is O 0 2.514401842290681e-08
suppressed O 0 7.886276875979092e-08
by O 0 2.5124160529799155e-09
the O 0 9.684013591026996e-09
reintroduction O 0 2.077159706459497e-06
of O 0 2.874974143196596e-07
VHL B-Disease 0 0.02684089168906212
. O 0 7.12489963916596e-06

Remarkably O 0 0.0022615166381001472
, O 0 1.852003697422333e-05
this O 0 9.682023005552765e-08
occurs O 0 8.579745269798877e-08
without O 0 8.758378022832858e-09
affecting O 0 8.283621610871705e-08
the O 0 9.87373738325914e-08
growth O 0 4.277600510249613e-06
rate O 0 1.6293469684569573e-07
and O 0 7.40830188306063e-08
cell O 0 2.596025115053635e-05
cycle O 0 1.2087515415259986e-06
profile O 0 1.1537096611391462e-07
of O 0 1.7231965854236364e-09
these O 0 5.212687614886136e-09
cells O 0 3.927221428057237e-07
in O 0 4.938581099622752e-08
culture O 0 2.1744792775280075e-06
. O 0 8.146495019900613e-06

The O 0 9.357147519040154e-07
786 O 0 0.0001394278515363112
- O 0 0.0005672036786563694
0 O 0 1.4045182297195424e-06
cell O 0 2.884718560380861e-05
line O 0 1.24557600429398e-05
, O 0 5.029391445532383e-07
like O 0 1.2964235907020338e-07
many O 0 1.0932921412631913e-07
cancer B-Disease 0 0.0019286134047433734
cells O 0 8.06258867669385e-06
, O 0 1.4532279237755574e-06
fails O 0 7.217235634016106e-06
to O 0 2.8459357093169046e-09
exit O 0 1.4303073214705364e-07
the O 0 1.7661829332382695e-08
cell O 0 1.789100861060433e-05
cycle O 0 1.196080575027736e-06
upon O 0 1.0474995093545658e-07
serum O 0 8.446037099929526e-06
withdrawal O 0 6.006449893902754e-06
. O 0 5.0773119255609345e-06

Here O 0 2.2416466890717857e-05
, O 0 1.3970571899335482e-06
it O 0 6.220498249831508e-08
is O 0 1.283080042213669e-08
shown O 0 1.856466447236471e-08
that O 0 7.66989671774354e-09
reintroduction O 0 1.1929803633847769e-07
of O 0 8.145954466520777e-10
the O 0 2.7101428656806092e-08
wild O 0 2.0424033664312446e-06
- O 0 0.012644966132938862
type O 0 2.5780198029679013e-06
VHL B-Disease 0 1.8517741409596056e-05
gene O 0 1.4782393087386936e-08
restores O 0 1.3292209359860863e-06
the O 0 2.256544995304921e-08
ability O 0 6.462128965267766e-08
of O 0 9.396533329208978e-08
VHL O 0 0.08140785992145538
- O 0 0.3237811028957367
negative O 0 4.5485488954000175e-05
RCC B-Disease 1 0.9833145141601562
cancer I-Disease 0 0.0007867834065109491
cells O 0 3.0090757263678825e-07
to O 0 6.398020335751653e-09
exit O 0 1.2571504726111016e-07
the O 0 2.1417660533984417e-08
cell O 0 3.5322620533406734e-05
cycle O 0 1.098628445106442e-06
and O 0 4.5318966357399404e-08
enter O 0 4.8990742129717546e-08
G0 O 0 0.0002322439686395228
/ O 0 3.6732324133481598e-06
quiescence O 0 7.828581874491647e-05
in O 0 2.047328138132798e-07
low O 0 2.674284769454971e-05
serum O 0 9.636017784941941e-05
. O 0 3.64824995813251e-06

Both O 0 4.596236522047548e-06
VHL O 0 0.007708788849413395
- O 0 0.0003628601261880249
positive O 0 1.2674661320488667e-07
and O 0 2.1488958736881614e-06
VHL O 0 0.005957148037850857
- O 0 0.0016430034302175045
negative O 0 1.322037633144646e-06
RCC B-Disease 0 0.0061761499382555485
cells O 0 3.110666568773013e-07
exit O 0 4.3752655187745404e-07
the O 0 5.9015267339646016e-08
cell O 0 0.0002868855372071266
cycle O 0 3.370703780092299e-06
by O 0 4.2527616983534244e-08
contact O 0 9.735425692269928e-07
inhibition O 0 2.0719448912132066e-06
. O 0 2.546993982832646e-06

The O 0 1.6237314639511169e-06
cyclin O 0 0.0010206986917182803
- O 0 0.0002209749654866755
dependent O 0 4.074374828633154e-07
kinase O 0 3.0361277367774164e-06
inhibitor O 0 6.714694791298825e-07
, O 0 2.3845869279170984e-08
p27 O 0 4.6752731464039243e-07
, O 0 1.5063287506222878e-08
accumulates O 0 1.1396424071108413e-07
upon O 0 2.1285387674652156e-08
serum O 0 8.181014891306404e-06
withdrawal O 0 1.2835545248890412e-06
, O 0 8.857719535626529e-08
only O 0 2.686322553291376e-10
in O 0 1.3435328405364544e-09
the O 0 3.1225861896189144e-09
presence O 0 1.0756173729475904e-08
of O 0 8.7766267142797e-08
VHL B-Disease 0 0.03094872087240219
, O 0 4.998940426048648e-07
as O 0 6.1939160467261445e-09
a O 0 5.808746195157255e-08
result O 0 5.504794842181582e-08
of O 0 2.6160893451532274e-09
the O 0 3.4050557928821945e-08
stabilization O 0 3.1645586773265677e-07
of O 0 2.1227155588832147e-09
the O 0 9.358345920418287e-08
protein O 0 1.4373550811797031e-06
. O 0 2.860958829842275e-06

We O 0 1.9065182641497813e-06
propose O 0 2.657146751516848e-06
that O 0 9.909054909940096e-08
the O 0 1.574961032702049e-07
loss O 0 6.863250018795952e-05
of O 0 1.5272245690312047e-08
wild O 0 3.268522277721786e-06
- O 0 0.028013328090310097
type O 0 7.098733476595953e-06
VHL B-Disease 0 0.0005138266715221107
gene O 0 2.102304819118217e-07
results O 0 4.21726895183383e-07
in O 0 6.3133223093814195e-09
a O 0 7.1932824141640594e-09
specific O 0 2.7229617671764572e-08
cellular O 0 0.023425376042723656
defect O 0 0.0012907043565064669
in O 0 8.0285457215723e-07
serum O 0 0.0002029321767622605
- O 0 0.001717392005957663
dependent O 0 1.0035729474111577e-06
growth O 0 6.16530144270655e-07
control O 0 5.721144020753854e-07
, O 0 3.099245304838405e-07
which O 0 2.533082010813814e-07
may O 0 4.6246927354332e-07
initiate O 0 1.8088035176333506e-06
tumor B-Disease 0 0.0005151090444996953
formation O 0 6.111303264333401e-06
. O 0 9.901090379571542e-06

This O 0 2.902383812397602e-06
is O 0 7.617516075697495e-07
corrected O 0 1.0532235137361567e-05
by O 0 5.340314412904945e-09
the O 0 3.2225619950310147e-09
reintroduction O 0 3.196010425199347e-07
of O 0 8.891841041247517e-09
wild O 0 1.9985986909887288e-06
- O 0 0.05166823789477348
type O 0 2.4917328119045123e-05
VHL B-Disease 0 0.005665653385221958
, O 0 7.762479071971029e-06
implicating O 0 0.010082573629915714
VHL B-Disease 0 0.0010730435606092215
as O 0 1.0227772406778968e-08
the O 0 3.585722652132972e-08
first O 0 3.4208883903374954e-07
tumor B-Disease 0 0.000690519402269274
suppressor O 0 1.5241394066833891e-05
involved O 0 5.558222326840223e-08
in O 0 1.8805724977255522e-08
the O 0 8.147092778187925e-09
regulation O 0 5.876298914131439e-08
of O 0 1.0265922334440347e-08
cell O 0 0.0002584619214758277
cycle O 0 2.0387589756865054e-05
exit O 0 1.4574621673091315e-05
, O 0 1.7472738136348198e-06
which O 0 2.706649127048877e-07
is O 0 1.003033212043647e-08
consistent O 0 1.3321376002295438e-08
with O 0 2.1949290385236964e-08
its O 0 4.479722193195812e-08
gatekeeper O 0 1.2525981219368987e-05
function O 0 5.513264156320474e-08
in O 0 3.113738671345345e-07
the O 0 2.2913625798537396e-05
kidney O 0 0.2667388617992401
. O 0 2.086944505208521e-06
. O 0 1.4429256225412246e-05

Piebaldism B-Disease 1 0.9970073103904724
with O 0 0.05364324152469635
deafness B-Disease 1 0.999782383441925
: O 0 3.307742372271605e-05
molecular O 0 8.942067506723106e-05
evidence O 0 2.9884129162383033e-06
for O 0 1.2076068856003985e-07
an O 0 6.632513304793974e-06
expanded O 0 0.013197039254009724
syndrome O 1 0.997559666633606
. O 0 5.152067024027929e-05

In O 0 8.676863672008039e-07
a O 0 4.191247455764824e-07
South O 0 7.181725777627435e-06
African O 0 7.374761139544717e-07
girl O 0 4.039984105475014e-06
of O 0 1.0000745476190787e-07
Xhosa O 0 0.061371032148599625
stock O 0 0.000290193798718974
with O 0 3.080837268498726e-05
severe O 0 0.09961407631635666
piebaldism B-Disease 1 0.962936520576477
and O 0 0.012828373350203037
profound O 1 0.7201827764511108
congenital O 1 0.999984860420227
sensorineural B-Disease 1 0.9999791383743286
deafness I-Disease 1 0.9999936819076538
we O 0 1.733149474603124e-05
identified O 0 7.77866944190464e-07
a O 0 6.583552902839074e-08
novel O 0 1.5489885640818102e-07
missense O 0 1.3412552846148174e-07
substitution O 0 7.660729828273816e-09
at O 0 2.589808332231769e-07
a O 0 3.0061708677919796e-09
highly O 0 8.517926808337961e-09
conserved O 0 9.376227794177794e-09
residue O 0 6.516626172015094e-08
in O 0 8.815002616735512e-10
the O 0 6.431234989001666e-10
intracellular O 0 3.263057379854217e-08
kinase O 0 6.657385398511906e-08
domain O 0 5.133866665119058e-10
of O 0 2.357567474575717e-10
the O 0 1.8125970058235907e-08
KIT O 0 0.0005569375935010612
proto O 0 0.00029322493355721235
- O 0 0.0015843360451981425
oncogene O 0 7.464351074304432e-05
, O 0 4.99990335356415e-07
R796G O 0 1.8885051758843474e-05
. O 0 1.8498303688829765e-06

Though O 0 6.963988562347367e-05
auditory B-Disease 0 0.001367853838019073
anomalies I-Disease 0 0.028526702895760536
have O 0 2.2776863772833167e-07
been O 0 1.0249550541630015e-07
observed O 0 3.657788170130516e-07
in O 0 2.8673400720435893e-07
mice O 0 3.450749136391096e-05
with O 0 6.092195121709665e-07
dominant O 0 0.0001654882653383538
white O 0 0.10986398160457611
spotting O 0 0.4838733971118927
( O 0 2.123197009495925e-05
W O 1 0.9710444211959839
) O 0 2.2291332868462632e-07
due O 0 2.9783723931586792e-08
to O 0 5.186152307601333e-08
KIT O 0 0.07144922018051147
mutations O 0 2.2650783648714423e-05
, O 0 0.0010609960881993175
deafness B-Disease 1 0.9999572038650513
is O 0 8.526884585080552e-07
not O 0 9.502528541815991e-08
typical O 0 5.446283353194303e-07
in O 0 5.844531756338256e-07
human O 0 1.5736843124614097e-05
piebaldism B-Disease 0 0.05419078469276428
. O 0 1.3343927093956154e-05

Thus O 0 1.136745595431421e-05
, O 0 8.961316098066163e-07
the O 0 1.1778521979977086e-07
occurrence O 0 4.877824721916113e-06
of O 0 1.3294174095790368e-05
sensorineural B-Disease 1 0.9999293088912964
deafness I-Disease 1 0.9999910593032837
in O 0 1.557278483232949e-05
this O 0 3.0123260330583435e-07
patient O 0 7.196550768640009e-07
extends O 0 2.491287887096405e-07
considerably O 0 1.8581143024221092e-07
the O 0 4.182013846332211e-09
phenotypic O 0 4.156891719730993e-09
range O 0 1.4381637924998358e-07
of O 0 5.5449014269015606e-08
piebaldism B-Disease 0 0.013540208339691162
due O 0 2.004274080036339e-07
to O 0 4.570307510221028e-08
KIT O 0 0.0006528099183924496
gene O 0 6.129363328000181e-08
mutation O 0 2.1495171864671647e-08
in O 0 6.596071244757695e-08
humans O 0 1.9533467821020167e-07
and O 0 5.335451191967877e-07
tightens O 0 0.005747245624661446
the O 0 1.3473294302457361e-07
clinical O 0 1.8504042031963763e-07
similarity O 0 2.4795573949631944e-07
between O 0 1.2023477893308154e-06
piebaldism B-Disease 0 0.01307584811002016
and O 0 1.268698497369769e-07
the O 0 6.496928328658669e-09
various O 0 3.4844203078421288e-09
forms O 0 3.142089042285079e-07
of O 0 0.0010368407238274813
Waardenburg B-Disease 1 0.999942421913147
syndrome I-Disease 1 0.9995228052139282
. O 0 5.225454970059218e-06
. O 0 1.1672992513922509e-05

Cycloheximide O 0 0.0013122956734150648
facilitates O 0 7.206163900264073e-06
the O 0 1.2452338182811218e-07
identification O 0 3.775083143864322e-07
of O 0 3.8059248197441775e-08
aberrant O 0 3.0061844881856814e-05
transcripts O 0 8.070589501585346e-06
resulting O 0 4.0857875660549325e-07
from O 0 8.85264839212141e-09
a O 0 1.0756440183001814e-08
novel O 0 1.4553552318830043e-07
splice O 0 3.886178456014022e-05
- O 0 0.0013544460525736213
site O 0 3.300579010101501e-06
mutation O 0 5.701395267010412e-08
in O 0 2.2650662856449344e-07
COL17A1 O 0 0.0669800192117691
in O 0 2.3218234446176211e-07
a O 0 4.768794497067574e-07
patient O 0 4.0917911974247545e-06
with O 0 2.0862977180513553e-05
generalized O 0 0.0011737423483282328
atrophic B-Disease 1 0.9957183003425598
benign I-Disease 1 0.9805676341056824
epidermolysis I-Disease 1 0.993023157119751
bullosa I-Disease 1 0.9421627521514893
. O 0 0.00014103228750173002

Patients O 0 0.0009461548761464655
with O 0 9.843064617598429e-05
generalized O 0 0.008769959211349487
atrophic B-Disease 1 0.9978132247924805
benign I-Disease 1 0.9658817648887634
epidermolysis I-Disease 1 0.9927512407302856
bullosa I-Disease 1 0.9622159004211426
often O 0 1.213972154801013e-05
show O 0 2.8231384021637496e-06
decreased O 0 1.027211169457587e-06
expression O 0 4.333801317812913e-09
of O 0 6.049086209714005e-08
type O 0 0.00017100822879001498
XVII O 1 0.9052610397338867
collagen O 0 0.0006460751756094396
, O 0 1.9206400736493379e-07
a O 0 8.323056732706391e-08
transmembrane O 0 1.2730096159430104e-06
hemidesmosomal O 0 3.682990063680336e-05
protein O 0 1.0284678886307574e-08
encoded O 0 2.348320471412535e-08
by O 0 4.670968110076501e-07
COL17A1 O 0 0.008648420684039593
. O 0 9.091218998946715e-06

This O 0 1.189419435831951e-06
report O 0 4.213926331431139e-06
documents O 0 5.83966198064445e-07
a O 0 3.695956252158794e-08
novel O 0 2.0205295925279643e-07
splice O 0 2.1840351109858602e-05
- O 0 0.0005748121766373515
site O 0 1.7771944840205833e-06
mutation O 0 1.259444957213418e-07
in O 0 3.4791631264852185e-07
COL17A1 O 0 0.07637111097574234
in O 0 6.369725724653108e-07
a O 0 5.319426463756827e-07
patient O 0 1.8047112462227233e-06
with O 0 7.477189683413599e-06
generalized O 0 0.0009097322472371161
atrophic B-Disease 1 0.9946519136428833
benign I-Disease 1 0.9042850136756897
epidermolysis I-Disease 1 0.9877662658691406
bullosa I-Disease 1 0.9324672818183899
, O 0 4.703205831901869e-06
and O 0 1.508805098637822e-07
applies O 0 1.2735394960827762e-08
a O 0 2.2953254852353666e-09
new O 0 1.2647355163153406e-08
methodology O 0 2.7349133802090364e-07
to O 0 2.3192402665017653e-08
define O 0 7.148423719627317e-08
and O 0 7.0673927154985e-08
characterize O 0 3.6701402450489695e-07
the O 0 2.1942538896979613e-09
resulting O 0 1.892020584648435e-08
mRNA O 0 1.1726870141615109e-08
splice O 0 5.092014816909796e-06
variants O 0 1.949179932125844e-06
. O 0 2.7197338567930274e-06

Mutational O 0 0.000715496251359582
analysis O 0 4.3685627133527305e-06
of O 0 6.968646744098805e-07
COL17A1 O 0 0.04339803382754326
identified O 0 4.334492132329615e-06
a O 0 1.9658994006022112e-06
maternally O 0 0.07064281404018402
inherited O 0 0.13723349571228027
G O 0 0.0175461545586586
- O 0 0.0003142060013487935
to O 0 2.336530542379478e-07
- O 0 0.013774232007563114
T O 0 0.23234397172927856
transversion O 0 7.103104871930555e-05
at O 0 1.1174186198559255e-07
the O 0 4.4099990326174066e-09
- O 0 8.897331099433359e-06
1 O 0 6.751665893034442e-09
position O 0 3.111486401863317e-09
of O 0 3.369411416542789e-09
exon O 0 1.1162899681949057e-05
32 O 0 3.486653895379277e-06
. O 0 2.7221055916015757e-06

This O 0 4.4243911645480694e-08
acceptor O 0 4.786851377502899e-07
splice O 0 2.6135550797334872e-05
- O 0 0.000593810633290559
site O 0 3.53725681634387e-06
mutation O 0 9.447714433008514e-08
led O 0 2.455608409945853e-07
to O 0 4.004886200448254e-09
the O 0 3.567146134031418e-09
formation O 0 8.331761591762188e-08
of O 0 4.409276055383771e-09
aberrant O 0 5.702716862288071e-06
transcripts O 0 5.887247880309587e-07
present O 0 3.3344164762638684e-08
at O 0 1.2114890068914974e-06
extremely O 0 1.2840786212109379e-06
low O 0 2.2432220703194616e-06
levels O 0 5.081896574665734e-07
. O 0 1.3336116353457328e-06

Based O 0 5.668800440616906e-06
on O 0 4.5914438828731363e-07
our O 0 3.9931570938733785e-08
recent O 0 1.1489992601809718e-07
finding O 0 1.1821024514802048e-07
that O 0 1.2349389066912408e-07
cycloheximide O 0 0.00014494404604192823
stabilized O 0 5.9958612837363034e-05
mutant O 0 2.313021695954376e-06
COL17A1 O 0 3.182336513418704e-05
transcripts O 0 3.432424193761108e-07
in O 0 3.663893721750355e-08
keratinocytes O 0 4.8596230044495314e-06
homozygous O 0 9.827591895827936e-08
for O 0 4.790114083164099e-09
a O 0 1.287424424845085e-07
frameshift O 0 5.8505502238404006e-05
mutation O 0 2.2640924157713016e-07
, O 0 2.1843132458343462e-07
the O 0 4.9815316316426106e-08
effects O 0 1.5643267659015692e-07
of O 0 6.402766095092716e-10
the O 0 1.2475451782734126e-08
splice O 0 5.704483191948384e-05
- O 0 0.0001233317598234862
site O 0 2.545225754602143e-07
mutation O 0 8.708899712495111e-10
on O 0 4.848973222948416e-09
splicing O 0 5.1638352260852116e-08
of O 0 1.0394881400088707e-08
COL17A1 O 0 0.00027019024128094316
transcripts O 0 2.2374608477093716e-07
were O 0 1.4084568178418522e-08
determined O 0 1.4264244896367018e-08
using O 0 7.789833667004586e-09
reverse O 0 1.2159036486991681e-05
transcriptase O 0 4.7019508201628923e-05
polymerase O 0 1.925135074998252e-05
chain O 0 5.701482223230414e-06
reaction O 0 1.161618534695208e-08
of O 0 1.1496690266454834e-09
total O 0 5.685255821674673e-09
RNA O 0 7.208626584542799e-08
from O 0 5.06405095634932e-09
keratinocytes O 0 8.826365842651285e-07
incubated O 0 4.939306563755963e-07
for O 0 1.0140594142171722e-08
2 O 0 1.9071130736847408e-06
. O 0 2.844171149263275e-06

5 O 0 5.913688073633239e-05
h O 0 0.0011658219154924154
in O 0 2.16418769127813e-07
the O 0 5.548477943762009e-08
presence O 0 1.4801811687448208e-07
or O 0 8.62524416334054e-08
absence O 0 3.810704285456268e-08
of O 0 9.699023806319929e-09
10 O 0 6.252996627154062e-07
microg O 0 0.0009481979068368673
cycloheximide O 0 0.00011860641825478524
per O 0 1.1230336838252697e-07
ml O 0 2.554993989178911e-05
. O 0 1.3379507208810537e-06

Using O 0 5.362174988476909e-07
this O 0 6.490873971642941e-08
approach O 0 5.835169076817692e-07
, O 0 1.8970983717281342e-07
an O 0 1.5032547651117056e-08
abnormally O 0 1.8803533748723567e-05
spliced O 0 0.0002860432432498783
transcript O 0 0.0006806875462643802
was O 0 4.446823368198238e-05
identified O 0 5.166480718798994e-07
that O 0 5.7098374917075034e-09
contains O 0 1.8546066071767342e-10
an O 0 1.0926589494308914e-10
extra O 0 3.231053480323709e-10
264 O 0 7.159285075886146e-08
bases O 0 1.616051648056782e-08
upstream O 0 2.7269324576195686e-08
from O 0 2.531237219827176e-09
exon O 0 1.0052607422039728e-06
32 O 0 3.8522796330653364e-07
, O 0 2.6828851673599274e-07
resulting O 0 2.505252041373751e-07
in O 0 7.449819605653829e-08
a O 0 4.6835734224259795e-07
premature O 0 2.011528158618603e-05
termination O 0 1.6577382666582707e-07
codon O 0 6.711836864070619e-09
27 O 0 4.357983414138289e-07
bp O 0 8.859018635121174e-06
downstream O 0 1.2672956017922843e-07
from O 0 8.769606707481614e-10
the O 0 7.154040471135659e-09
cryptic O 0 3.4218026030430337e-06
splice O 0 3.96976392949e-05
site O 0 2.313409095222596e-05
. O 0 1.0519325769564603e-05

Three O 0 7.116779698890241e-08
other O 0 9.400652700719547e-09
splice O 0 7.5311418186174706e-06
variants O 0 2.7079629489890067e-06
, O 0 3.9603074242222647e-07
including O 0 1.9202255785444322e-08
one O 0 7.527058087930527e-09
derived O 0 2.0724753024836673e-09
from O 0 9.044757720566565e-10
the O 0 1.1810162847680772e-09
skipping O 0 9.97207791897381e-08
of O 0 1.943615712818314e-09
exon O 0 3.6851761251455173e-06
32 O 0 1.4055203791940585e-06
, O 0 4.456584292711341e-07
were O 0 8.256743200263372e-08
also O 0 1.9815283280877338e-07
identified O 0 1.3621162224808359e-06
. O 0 3.4071006211888744e-06

These O 0 5.949412411609956e-07
results O 0 2.662986616996932e-06
indicate O 0 2.2665312826575246e-07
the O 0 2.084886219222426e-08
usefulness O 0 8.886026989785023e-07
of O 0 1.0886538603926965e-07
cycloheximide O 0 0.017056314274668694
treatment O 0 8.02034151092812e-07
in O 0 2.558180867140436e-08
evaluating O 0 7.280881675342243e-08
the O 0 2.3338172283615677e-08
abnormal O 0 6.750554462087166e-07
processing O 0 2.7901201349322946e-08
of O 0 2.562984269260937e-10
mRNA O 0 3.0895581648593406e-09
due O 0 1.5672334541250166e-08
to O 0 2.581905134135809e-09
splice O 0 9.597401003702544e-06
- O 0 0.004953155759721994
site O 0 1.3900645171815995e-05
mutations O 0 7.09774667484453e-07
, O 0 7.562994710497151e-07
because O 0 7.190431006165454e-07
( O 0 1.56333737066916e-08
i O 0 1.6656792922731256e-07
) O 0 1.631020829506724e-08
aberrant O 0 1.4737159403921396e-07
splicing O 0 3.3822907141711767e-08
often O 0 2.8073676716644513e-08
generates O 0 2.2837715718537765e-08
a O 0 5.077177789303278e-08
premature O 0 8.820375114737544e-06
termination O 0 2.4252690877801797e-07
codon O 0 3.980306573225789e-08
, O 0 4.4117473407823127e-07
( O 0 4.689491106546484e-08
ii O 0 0.0015172911807894707
) O 0 4.20786818722263e-08
transcripts O 0 3.941362933801429e-07
with O 0 4.1159714214700216e-07
premature O 0 2.989551103382837e-05
termination O 0 8.853274948705803e-07
codons O 0 7.386123002106615e-08
can O 0 2.4810005161413073e-09
occur O 0 4.507257234109829e-09
at O 0 5.412467203314009e-07
low O 0 2.4227131234511035e-06
or O 0 5.645890723826597e-07
undetectable O 0 1.8141165128326975e-05
levels O 0 4.1026620323236784e-08
due O 0 2.496672202312311e-08
to O 0 2.8343591917945332e-09
nonsense O 0 4.065098835326353e-07
- O 0 1.854652737165452e-06
mediated O 0 3.0805807682554587e-07
mRNA O 0 8.203930867978215e-09
decay O 0 4.888759121968178e-07
, O 0 6.642975591830691e-08
and O 0 1.8988758654359117e-07
( O 0 8.800681428056123e-08
iii O 0 0.019458938390016556
) O 0 6.757414183766741e-08
the O 0 6.123354712173068e-09
levels O 0 4.26340696080274e-09
of O 0 3.318861852008581e-10
these O 0 7.996690531975048e-10
transcripts O 0 4.2640925812520436e-07
can O 0 4.583277313230383e-09
be O 0 8.557460851044141e-10
increased O 0 1.2864420639857599e-08
by O 0 1.75284043280044e-07
cycloheximide O 0 0.0008624544716440141
. O 0 5.612067980109714e-06

A O 0 9.308886546932627e-06
deletion O 0 7.635274960193783e-05
mutation O 0 4.661881121137412e-06
in O 0 2.1442610886879265e-06
COL17A1 O 0 0.045722294598817825
in O 0 4.229303556257946e-07
five O 0 6.963650776015129e-07
Austrian O 0 0.000395391572965309
families O 0 1.2119039638491813e-05
with O 0 7.770404408802278e-06
generalized O 0 0.0007078264025039971
atrophic B-Disease 1 0.9974130988121033
benign I-Disease 1 0.9020999073982239
epidermolysis I-Disease 1 0.962186872959137
bullosa I-Disease 1 0.7719605565071106
represents O 0 1.4049039691599319e-06
propagation O 0 6.413589517251239e-07
of O 0 2.7126150214940026e-08
an O 0 2.007845978369005e-07
ancestral O 0 0.00023562686692457646
allele O 0 3.330370600451715e-05
. O 0 6.471505912486464e-06

Patients O 0 0.0003383238799870014
with O 0 5.568596316152252e-05
generalized O 0 0.00407989090308547
atrophic B-Disease 1 0.9961532950401306
benign I-Disease 1 0.9874070882797241
epidermolysis I-Disease 1 0.9966848492622375
bullosa I-Disease 1 0.9926177859306335
, O 0 6.395805030479096e-06
a O 0 8.478721014171242e-08
usually O 0 1.8224005415845568e-08
nonlethal O 0 7.540525075455662e-07
form O 0 1.4242659496233046e-08
of O 0 1.6625212140297663e-07
junctional B-Disease 1 0.7542887330055237
epidermolysis I-Disease 1 0.8807705044746399
bullosa I-Disease 1 0.8567606806755066
, O 0 3.602247943490511e-06
have O 0 1.0404387040807705e-07
generalized O 0 8.599123475505621e-07
blistering B-Disease 0 0.00611027842387557
, O 0 0.0009940103627741337
nail B-Disease 1 0.9999364614486694
dystrophy I-Disease 1 0.9996410608291626
, O 0 0.00175024988129735
patchy B-Disease 1 0.9392796754837036
alopecia I-Disease 1 0.9999096393585205
, O 0 0.00010841014591278508
and O 0 0.0003809367772191763
dental B-Disease 0 0.1551753431558609
abnormalities I-Disease 1 0.8764302134513855
. O 0 6.45951004116796e-05

Skin B-Disease 1 0.9876691699028015
fragility I-Disease 1 0.987236499786377
in O 0 2.0499535821727477e-05
most O 0 1.0478686363057932e-06
cases O 0 2.6938375867757713e-06
is O 0 2.500156313089974e-07
due O 0 4.746797230836819e-07
to O 0 5.743197561969282e-08
mutations O 0 4.827640154303481e-08
in O 0 4.5175938545582994e-09
the O 0 5.01621588711032e-09
gene O 0 1.9312189181164285e-08
encoding O 0 1.1367853858246235e-07
type O 0 1.1022659236914478e-05
XVII O 1 0.6439576148986816
collagen O 0 0.004219735041260719
( O 0 5.452067739497579e-07
COL17A1 O 0 0.004031925927847624
) O 0 7.510038813052233e-07
. O 0 1.4302461295301327e-06

Recently O 0 0.00042625804780982435
, O 0 1.1644728147075512e-05
we O 0 5.177222988095309e-07
reported O 0 5.041068561695283e-06
five O 0 9.401230016692352e-08
Austrian O 0 2.3800488634151407e-05
families O 0 5.218676960794255e-06
with O 0 1.0509878848097287e-05
generalized O 0 0.0014053910272195935
atrophic B-Disease 1 0.9965458512306213
benign I-Disease 1 0.9216721057891846
epidermolysis I-Disease 1 0.9898820519447327
bullosa I-Disease 1 0.8725555539131165
who O 0 3.6228636872692732e-06
share O 0 6.848540579085238e-07
the O 0 1.0722666132778613e-07
same O 0 6.990446195231925e-07
COL17A1 O 0 0.01380509790033102
mutation O 0 1.579452259647951e-06
. O 0 5.112533926876495e-06

Affected O 0 0.00014772926806472242
individuals O 0 4.212047883811465e-07
in O 0 1.217152600929694e-07
three O 0 9.792602639890902e-08
families O 0 6.234965894691413e-07
are O 0 3.2011817641119933e-09
homozygous O 0 7.238607935278196e-08
for O 0 3.5295322220463277e-08
4003delTC O 0 0.0006781048141419888
, O 0 5.869140977665666e-07
whereas O 0 1.1427267310182287e-07
those O 0 1.0832432728591357e-08
in O 0 1.1057951887494255e-08
two O 0 6.928450346777026e-08
others O 0 2.6244777018291643e-07
are O 0 1.0693863572441842e-08
compound O 0 1.5958550648065284e-05
heterozygotes O 0 3.36501507263165e-05
. O 0 4.005823484476423e-06

To O 0 1.1263173291808926e-06
determine O 0 1.6758079937062575e-06
if O 0 4.5357879230323306e-08
the O 0 7.957241976441765e-09
occurrence O 0 1.0187007859485675e-07
of O 0 2.949338373525734e-08
4003delTC O 0 0.000395314913475886
in O 0 4.634989636542741e-08
these O 0 2.503037599410618e-08
unrelated O 0 0.00010670923802535981
families O 0 2.401036454102723e-06
signifies O 0 1.1655645266728243e-06
propagation O 0 1.2002016092083068e-07
of O 0 2.301840273943867e-09
an O 0 4.1654260485302075e-08
ancestral O 0 5.2085604693274945e-05
allele O 0 8.653055942886567e-07
or O 0 3.619820176936628e-08
a O 0 1.718425046703942e-08
mutational O 0 2.580041382316267e-06
hot O 0 9.686065141067957e-07
spot O 0 2.5332681161671644e-06
, O 0 4.925082635054423e-07
haplotypes O 0 7.4178556133119855e-06
were O 0 6.237547012233335e-08
determined O 0 1.2517166680936498e-07
for O 0 8.254787076111825e-09
polymorphisms O 0 3.0639270676147135e-07
both O 0 4.097115979817545e-09
within O 0 2.850102376328323e-09
and O 0 1.011192352962098e-06
flanking O 0 0.0011619991855695844
COL17A1 O 0 0.06889292597770691
. O 0 8.599816283094697e-06

Five O 0 1.9838891603285447e-05
intragenic O 0 0.002825132803991437
polymorphisms O 0 2.4452272555208765e-05
were O 0 8.555640818030952e-08
chosen O 0 7.212419994573338e-09
based O 0 3.060848285940665e-08
on O 0 1.3610912219519378e-07
their O 0 5.744357736148231e-07
informativeness O 0 0.003371357684955001
. O 0 5.525804226635955e-06

One O 0 1.984111293040769e-07
of O 0 4.478594206602793e-08
these O 0 1.8600319506845153e-08
, O 0 2.3748198429984768e-07
not O 0 4.51169768211912e-08
previously O 0 8.885205602382484e-07
reported O 0 4.07755323976744e-05
, O 0 3.056053685668303e-07
was O 0 2.578083694970701e-06
2988 O 0 1.926850382005796e-05
A O 0 6.766339311070624e-08
or O 0 4.816497494175564e-07
C O 0 3.449657015153207e-05
that O 0 1.0550262885544726e-08
introduces O 0 8.618008706662295e-08
a O 0 4.570130940351191e-09
new O 0 1.5231286454309156e-08
restriction O 0 3.9615457581021474e-08
site O 0 9.546764090373472e-08
for O 0 1.789396364415552e-08
Eco0109 O 0 4.232475475873798e-05
I O 0 8.408056601183489e-06
. O 0 2.4074106477200985e-06

All O 0 4.847468559887602e-08
the O 0 1.8466828066721064e-07
4003delTC O 0 9.297731594415382e-05
alleles O 0 1.0733608633017866e-06
showed O 0 3.5737443795369472e-06
the O 0 1.2483568845311765e-08
same O 0 3.58307019610038e-08
haplotype O 0 0.0001272321678698063
for O 0 3.895085587402036e-09
these O 0 8.567275777693339e-10
five O 0 3.1192485039355233e-08
polymorphic O 0 4.264395556674572e-06
markers O 0 5.0442184146959335e-05
. O 0 1.5392519344459288e-05

Fourteen O 0 2.2046937374398112e-05
microsatellite O 0 0.0047013661824166775
polymorphisms O 0 5.328106999513693e-05
were O 0 2.1016955997765763e-07
selected O 0 4.668916808725498e-09
based O 0 6.561489129808251e-08
on O 0 9.587017757439753e-08
their O 0 1.2805305971141934e-07
high O 0 1.199554571940098e-05
heterozygosity O 0 5.688838064088486e-05
and O 0 3.026013573048658e-08
their O 0 1.712635921968797e-09
location O 0 1.6820791870486573e-08
within O 0 4.97717911329687e-09
10q23 O 0 2.461605254211463e-05
- O 0 0.0007949458668008447
q25 O 0 8.140854333760217e-05
near O 0 1.7719139577820897e-05
COL17A1 O 0 0.008946736343204975
. O 0 5.831875569128897e-06

Three O 0 5.906091701035621e-06
families O 0 2.4594884962425567e-05
shared O 0 9.415167369297706e-06
microsatellite O 0 0.015655938535928726
polymorphisms O 0 3.803405707003549e-05
covering O 0 6.865307568659773e-06
at O 0 7.408962119370699e-06
most O 0 5.101017563902133e-08
19 O 0 5.988656084809918e-06
cM O 0 0.002357868477702141
, O 0 6.561251097991772e-07
whereas O 0 4.6843236845006686e-08
the O 0 1.0660913041249387e-08
others O 0 3.267809489670981e-08
shared O 0 8.922595640115105e-08
smaller O 0 1.2143808589826222e-06
regions O 0 2.069884885713691e-08
consistent O 0 5.398775826392921e-08
with O 0 1.6570285765737935e-07
cross O 0 1.3047763331996975e-06
- O 0 0.00010317587293684483
over O 0 3.039857290332293e-07
events O 0 9.009485779643e-08
during O 0 9.671023804003198e-08
passage O 0 6.14462720704978e-08
of O 0 3.842451246072187e-09
this O 0 1.994917120384798e-09
mutation O 0 1.8268786483588428e-09
through O 0 1.683098993510157e-09
several O 0 1.5133263531197372e-08
generations O 0 2.7788425995822763e-06
. O 0 2.8999215828662273e-06

These O 0 1.564622266414517e-06
results O 0 9.55214818532113e-06
indicate O 0 1.5554323908872902e-06
that O 0 4.229545709222293e-07
4003delTC O 0 0.00011370396532583982
occurs O 0 3.292145578370764e-08
on O 0 1.814322914128752e-08
a O 0 1.794502679786092e-08
single O 0 9.143391821453406e-08
ancestral O 0 3.277495125075802e-05
allele O 0 4.4195226109877694e-06
. O 0 3.4339140597694495e-07
. O 0 1.5557246797470725e-06

The O 0 4.565421477309428e-06
haptoglobin O 0 0.00306173088029027
- O 0 0.000968446780461818
gene O 0 5.734140358981676e-06
deletion O 0 1.1880933016072959e-05
responsible O 0 5.573519388235582e-07
for O 0 2.599294930405449e-07
anhaptoglobinemia B-Disease 0 0.005218738690018654
. O 0 2.064955697278492e-05

We O 0 3.782903604587773e-06
have O 0 1.8686272085233213e-07
found O 0 6.19293842873958e-08
an O 0 3.451697150325117e-09
allelic O 0 5.124019480717834e-06
deletion O 0 2.1156245111342287e-06
of O 0 1.752959910561458e-08
the O 0 5.483719860421843e-07
haptoglobin O 0 0.0013696110108867288
( O 0 1.6548776216041006e-07
Hp O 0 0.0001483041123719886
) O 0 1.0287566709621387e-07
gene O 0 2.6940423225596533e-08
from O 0 1.4336881015708514e-08
an O 0 7.629888720828149e-09
individual O 0 2.5235017631075607e-08
with O 0 3.1509159725828795e-06
anhaptoglobinemia B-Disease 0 0.10522641241550446
. O 0 2.5330089556518942e-05

The O 0 1.8277843309988384e-06
Hp O 0 8.959189290180802e-05
gene O 0 9.654866062192013e-07
cluster O 0 4.802329385711346e-06
consists O 0 2.8745947844299735e-08
of O 0 1.51254155866809e-08
coding O 0 0.00016065177624113858
regions O 0 1.0978952857954027e-08
of O 0 3.9459693845778077e-10
the O 0 7.044994809746186e-09
alpha O 0 2.4592080194452137e-07
chain O 0 7.470973741874332e-06
and O 0 6.12259825061301e-08
beta O 0 6.54926068932582e-08
chain O 0 1.517628220426559e-06
of O 0 8.141621266055665e-10
the O 0 3.7720237600069595e-08
haptoglobin O 0 2.866154318326153e-05
gene O 0 1.8700961845752317e-07
( O 0 1.553332751313974e-08
Hp O 0 9.607401807443239e-06
) O 0 1.7165808330332766e-08
and O 0 3.3891796036300548e-09
of O 0 2.3524696080023944e-10
the O 0 3.502718115555581e-09
alpha O 0 5.4052872400234264e-08
chain O 0 3.353581632836722e-06
and O 0 4.870452485761234e-08
beta O 0 3.3394130127817334e-08
chain O 0 4.6722865931769775e-07
of O 0 6.588772305526902e-10
the O 0 4.586673085782422e-08
haptoglobin O 0 0.0013441868359223008
- O 0 0.0073563032783567905
related O 0 8.973221156338695e-06
gene O 0 4.450960773283441e-07
( O 0 6.65327206661459e-08
Hpr O 0 4.351521420176141e-05
) O 0 1.0349680223953328e-07
, O 0 7.113807498626556e-08
in O 0 4.389240615410017e-08
tandem O 0 0.00011204044858459383
from O 0 2.3127599391159492e-08
the O 0 2.9573936188853622e-08
5 O 0 7.466661600119551e-07
side O 0 4.452932444110047e-06
. O 0 4.817328772332985e-06

Southern O 0 1.739075014484115e-05
blot O 0 0.0003058850415982306
and O 0 8.46094792450458e-07
PCR O 0 6.696044147247449e-05
analyses O 0 1.9311182768433355e-05
have O 0 1.7329379886632523e-07
indicated O 0 1.3802373359794728e-06
that O 0 1.3454465985773822e-08
the O 0 5.537902136865114e-09
individual O 0 1.4389343050424941e-08
with O 0 1.0168173503188882e-06
anhaptoglobinemia B-Disease 0 0.021382536739110947
was O 0 7.934291716082953e-06
homozygous O 0 8.943312934661662e-08
for O 0 1.2768004431507052e-09
the O 0 2.4678016075085907e-08
gene O 0 2.852293334854039e-07
deletion O 0 3.987369382230099e-06
and O 0 1.7896563520025666e-07
that O 0 1.194541798810178e-08
the O 0 1.1400201671563082e-08
gene O 0 1.9386078520255978e-07
deletion O 0 3.467560418357607e-06
was O 0 9.441695283385343e-07
included O 0 1.6653642020969528e-08
at O 0 8.094555710158602e-07
least O 0 3.123312941610834e-09
from O 0 3.6596037311653618e-09
the O 0 6.29010044050915e-09
promoter O 0 2.891973281293758e-06
region O 0 4.607119663546655e-08
of O 0 2.6851560974705535e-09
Hp O 0 8.225577403209172e-06
to O 0 2.2475074246131044e-08
Hpr O 0 2.8717263376165647e-06
alpha O 0 2.5512715495779048e-08
but O 0 4.793669461378158e-09
not O 0 1.0440278641610234e-09
to O 0 1.9401127815399377e-08
Hpr O 0 1.4444814041780774e-05
beta O 0 2.2830666068784922e-07
( O 0 6.463595525474375e-08
Hpdel O 0 0.00013798342843074352
) O 0 2.6143155196223233e-07
. O 0 8.720731443645491e-07

In O 0 1.4515118209601496e-06
addition O 0 7.478013799300243e-07
, O 0 9.173662078865163e-07
we O 0 6.639087501980612e-08
found O 0 1.0733183586353334e-07
seven O 0 2.950632449483237e-08
individuals O 0 4.873702330598917e-09
with O 0 1.4909227274984005e-07
hypohaptoglobinemia B-Disease 0 0.0012743395054712892
in O 0 3.500535683542694e-08
three O 0 2.1907386837938247e-07
families O 0 2.727544369918178e-06
, O 0 2.4928755237851874e-07
and O 0 9.43401161634938e-08
the O 0 4.470418346613769e-08
genotypes O 0 8.149845029947755e-07
of O 0 1.5979545464617217e-09
six O 0 4.9769443677405434e-08
of O 0 5.360776267337997e-09
the O 0 8.678810559104022e-08
seven O 0 6.578010243174504e-07
individuals O 0 2.087098316394531e-08
were O 0 6.794454776581915e-08
found O 0 3.732016295998619e-07
to O 0 2.6322272361767318e-08
be O 0 9.93384503544803e-08
Hp2 O 0 0.0010262408759444952
/ O 0 9.961634350474924e-05
Hpdel O 0 0.001188896014355123
. O 0 3.940674105251674e-06

The O 0 3.620204324761289e-06
phenotypes O 0 0.0002477588423062116
and O 0 4.124555289308773e-06
genotypes O 0 9.638677511247806e-06
in O 0 7.782351474361349e-08
one O 0 6.410223019059913e-09
of O 0 2.4624824401797696e-09
these O 0 2.8600404267109525e-09
three O 0 1.9280872720628395e-07
families O 0 1.3489069715433288e-05
showed O 0 4.855012957705185e-05
the O 0 7.923154754507777e-08
father O 0 4.9546570153324865e-06
to O 0 2.709243673848505e-08
be O 0 8.951914765020774e-08
hypohaptoglobinemic B-Disease 0 0.0040434603579342365
( O 0 1.6352156251286942e-07
Hp2 O 0 0.00031866785138845444
) O 0 5.101221844938664e-08
and O 0 1.817579260432467e-07
Hp2 O 0 0.00026210484793409705
/ O 0 1.0829522580024786e-05
Hpdel O 0 0.00016764616884756833
, O 0 9.417220070417898e-08
the O 0 1.7410542341167456e-08
mother O 0 1.295594529437949e-06
to O 0 2.9141919988262543e-09
be O 0 3.8524019529972975e-09
Hp2 O 0 1.3661042430612724e-05
- O 0 1.7974449292523786e-05
1 O 0 1.6463326701909864e-08
and O 0 9.018683755357415e-08
Hp1 O 0 0.00027343217516317964
/ O 0 4.164241090620635e-06
Hp2 O 0 0.0001776290882844478
, O 0 1.6444433370566003e-08
one O 0 2.765311868380138e-10
of O 0 5.109220824195404e-10
the O 0 1.1913222408566071e-08
two O 0 1.4526359848332504e-07
children O 0 2.5482373189333885e-07
to O 0 4.169336875747831e-08
be O 0 2.624993271638232e-07
hypohaptoglobinemic B-Disease 0 0.0035107089206576347
( O 0 4.347555560002547e-08
Hp2 O 0 4.090062066097744e-05
) O 0 2.6010251730212985e-08
and O 0 1.629824311066841e-07
Hp2 O 0 0.00033879445982165635
/ O 0 9.64305490924744e-06
Hpdel O 0 0.0002951056230813265
, O 0 6.007429931287334e-08
and O 0 1.6867698349187776e-08
the O 0 8.196360923307111e-09
other O 0 1.2167459928491553e-08
child O 0 4.2149127921220497e-07
to O 0 1.4990286345550885e-08
be O 0 2.6910020878290197e-08
Hp1 O 0 5.042351767770015e-05
and O 0 9.523599828753504e-07
Hp1 O 0 0.0019662226550281048
/ O 0 1.8727476344793104e-05
Hpdel O 0 0.00040182354860007763
, O 0 1.3641815144183056e-07
showing O 0 3.12947776137662e-07
an O 0 1.470794863678293e-08
anomalous O 0 2.206789076808491e-06
inheritance O 0 1.983870333788218e-06
of O 0 9.32858412738824e-08
Hp O 0 0.005082153715193272
phenotypes O 0 2.691898771445267e-05
in O 0 1.2463387122352287e-07
the O 0 3.1275055789592443e-07
child O 0 3.617755646700971e-05
with O 0 1.177003014163347e-05
Hp1 O 0 0.07235896587371826
. O 0 1.962699752766639e-05

The O 0 2.1397107047960162e-05
Hp2 O 0 0.11676337569952011
/ O 0 0.0026215354446321726
Hpdel O 0 0.05386006832122803
individuals O 0 6.150478952804406e-07
had O 0 7.2743222290228e-07
an O 0 2.344431315748352e-08
extremely O 0 5.929395001658122e-07
low O 0 3.102436494373251e-07
level O 0 6.985438449902404e-09
of O 0 1.2745868360752866e-08
Hp O 0 8.557712862966582e-05
( O 0 1.3084564542964472e-08
mean O 0 1.75238472621686e-08
+ O 0 5.867238428436394e-07
/ O 0 7.81276625616556e-08
- O 0 2.223020146630006e-06
SD O 0 1.8701155568123795e-05
= O 0 1.4420630805034307e-06
0 O 0 4.805707831678774e-09
. O 0 1.6256624935095942e-09
049 O 0 2.5456631647102768e-06
+ O 0 4.632214256616862e-07
/ O 0 8.535869966408427e-08
- O 0 1.1147994882776402e-06
0 O 0 5.146104431474896e-09
. O 0 9.71464575449943e-10
043 O 0 4.660062700168055e-07
mg O 0 1.6927635897445725e-06
/ O 0 4.562033950605837e-07
ml O 0 2.2633482785749948e-06
; O 0 1.8653185662742544e-08
n O 0 9.772838893695734e-07
= O 0 9.192560810333816e-07
6 O 0 8.001092055565096e-08
) O 0 2.4787647490143172e-08
, O 0 5.813091163986428e-08
compared O 0 2.3342632005096675e-07
with O 0 7.979934935065103e-09
the O 0 6.456803980370296e-09
level O 0 8.013077312796213e-09
( O 0 9.913015963647354e-10
1 O 0 1.5810407427707673e-09
. O 0 3.5096463513184517e-09
64 O 0 4.1833806108115823e-07
+ O 0 7.782423949720396e-07
/ O 0 6.217437942268589e-08
- O 0 6.558091740771488e-07
1 O 0 3.1202227468440924e-09
. O 0 2.3415209771115997e-09
07 O 0 1.2778528457602079e-07
mg O 0 1.5242845847751596e-06
/ O 0 8.691514494785224e-07
ml O 0 3.3752905892470153e-06
) O 0 4.709576284511741e-09
obtained O 0 1.6999857077593106e-09
from O 0 2.9993270089789803e-09
52 O 0 1.392967305946513e-07
healthy O 0 2.431702128546931e-08
volunteers O 0 1.027444351819895e-08
having O 0 2.1808247652188584e-07
phenotype O 0 1.1880264537467156e-05
Hp2 O 0 0.0006445726612582803
, O 0 1.6656586865337886e-07
whereas O 0 1.252564096887454e-08
the O 0 1.1917085984691766e-08
serum O 0 4.759752300742548e-06
Hp O 0 7.3718188104976434e-06
level O 0 7.735037499401187e-09
of O 0 1.0696836749701788e-09
an O 0 4.882718229737293e-09
individual O 0 7.072041618982894e-09
with O 0 9.750115168571938e-07
Hp1 O 0 0.03210412710905075
/ O 0 9.52587288338691e-05
Hpdel O 0 0.000895822246093303
was O 0 9.54340703174239e-06
0 O 0 8.66484867856343e-07
. O 0 1.1244627557971398e-06

50 O 0 1.3210748875280842e-05
mg O 0 0.0006075322744436562
/ O 0 0.00015058377175591886
ml O 0 0.0006558435270562768
, O 0 1.2568451666084002e-06
which O 0 1.104303350984992e-07
was O 0 1.6118811174692382e-07
approximately O 0 1.3287466682498916e-09
half O 0 2.2376382968758435e-09
the O 0 1.178709685412116e-09
level O 0 2.032444434973968e-09
of O 0 3.490819633356068e-09
Hp O 0 5.279304969008081e-05
in O 0 1.0076779233259003e-07
control O 0 3.2792531783343293e-06
sera O 0 3.0307495762826875e-05
from O 0 6.597024704291243e-09
the O 0 2.6271965936075503e-08
Hp1 O 0 0.000506408279761672
phenotype O 0 1.7156664853246184e-06
( O 0 2.5941369052873142e-09
1 O 0 3.9841174803711965e-09
. O 0 8.755538516425077e-09
26 O 0 1.8897472386925074e-07
+ O 0 1.7877372329166974e-06
/ O 0 1.0145686246687546e-07
- O 0 1.4415653595278854e-06
0 O 0 4.373293727155669e-09
. O 0 8.771798287732224e-10
33 O 0 2.9268216295008642e-08
mg O 0 1.6225612853304483e-06
/ O 0 4.836893481297011e-07
ml O 0 1.5433087128258194e-06
; O 0 2.7594927232144073e-08
n O 0 1.8156368923882837e-06
= O 0 3.6448557239054935e-06
9 O 0 2.3317534214584157e-07
) O 0 2.5516900592492675e-08
, O 0 1.4583334539963744e-08
showing O 0 1.7223767656560085e-07
a O 0 1.592615284096155e-08
gene O 0 1.6569590854942362e-07
- O 0 0.00020035283523611724
dosage O 0 3.849297627311898e-06
effect O 0 4.352517635197728e-07
. O 0 8.267393809546775e-07

The O 0 5.995983087814238e-07
other O 0 3.04594550470938e-07
allele O 0 9.248184142052196e-06
( O 0 4.846530146096484e-07
Hp2 O 0 0.0006859585992060602
) O 0 1.1208766181880492e-07
of O 0 5.599495533914478e-09
individuals O 0 1.2022034923120373e-08
with O 0 6.888746497679676e-07
Hp2 O 0 0.014119080267846584
/ O 0 0.00013428600504994392
Hpdel O 0 0.0026899506337940693
was O 0 1.362539296678733e-05
found O 0 4.5494172695725865e-07
to O 0 2.717005820329632e-08
have O 0 2.2900440654893828e-08
, O 0 2.6555047938359166e-08
in O 0 1.4712430163044132e-09
all O 0 4.723454405386462e-10
exons O 0 1.4249174000724452e-06
, O 0 3.8623960563199944e-07
no O 0 2.080345851140919e-08
mutation O 0 1.8834622750318886e-08
, O 0 1.0294157526402614e-08
by O 0 7.892744235959981e-09
DNA O 0 2.076110149573651e-06
sequencing O 0 9.600606063031591e-06
. O 0 5.1701308620977215e-06

On O 0 8.299981004711299e-07
the O 0 3.371161483300966e-08
basis O 0 9.177038684526906e-09
of O 0 8.000997198109872e-09
the O 0 7.85933806923822e-08
present O 0 6.053126355709537e-08
study O 0 2.2424119450192848e-08
, O 0 2.102849805396545e-08
the O 0 4.183545954106194e-09
mechanism O 0 1.3315029434579628e-07
of O 0 3.8062154317231034e-08
anhaptoglobinemia B-Disease 0 0.001717046950943768
and O 0 1.1473698435793267e-07
the O 0 1.0800043526160152e-08
mechanism O 0 5.0161322207031844e-08
of O 0 5.611737297073205e-09
anomalous O 0 3.6925709991919575e-06
inheritance O 0 5.821145805384731e-06
of O 0 1.130812421479277e-07
Hp O 0 0.0016229067696258426
phenotypes O 0 8.881672329152934e-06
were O 0 8.790766514721327e-08
well O 0 6.597429802468469e-08
explained O 0 4.107574568479322e-06
. O 0 3.226726448701811e-06

However O 0 1.7195590771734715e-05
, O 0 6.182252150210843e-07
the O 0 2.6556767451779706e-08
mechanism O 0 4.585960198255634e-07
of O 0 6.438095851990511e-07
hypohaptoglobinemia B-Disease 0 0.028669077903032303
remains O 0 8.637575228931382e-05
unknown O 0 3.1370935175800696e-05

ATM O 0 0.007332243025302887
mutations O 0 6.714306800859049e-05
and O 0 2.926818524429109e-05
phenotypes O 0 0.001224443200044334
in O 0 0.0013271612115204334
ataxia B-Disease 1 0.9999425411224365
- I-Disease 1 0.9999163150787354
telangiectasia I-Disease 1 0.9999665021896362
families O 0 7.524670218117535e-05
in O 0 1.0474715850250504e-07
the O 0 1.741250912346004e-07
British O 0 2.757610855042003e-05
Isles O 0 7.708609336987138e-05
: O 0 1.2828035522716164e-08
expression O 0 1.7790423301189406e-10
of O 0 3.648325253013951e-10
mutant O 0 1.0879891760851024e-06
ATM O 0 8.550845814170316e-05
and O 0 3.172312403876276e-07
the O 0 8.664270012559427e-07
risk O 0 1.2626992429431994e-05
of O 0 1.2152394447184633e-05
leukemia B-Disease 1 0.9999289512634277
, O 0 0.4571262001991272
lymphoma B-Disease 1 0.999993085861206
, O 0 0.003584912046790123
and O 0 0.03243764862418175
breast B-Disease 1 0.9752968549728394
cancer I-Disease 0 0.35814231634140015
. O 0 0.00011876464122906327

We O 0 2.8689914870483335e-06
report O 0 5.552986976908869e-07
the O 0 7.535504664701875e-09
spectrum O 0 1.0064293576306227e-07
of O 0 1.1341254158026004e-08
59 O 0 4.244793672114611e-06
ATM O 0 0.0002522377180866897
mutations O 0 6.242664767341921e-07
observed O 0 1.5018166550362366e-06
in O 0 0.00010205393482465297
ataxia B-Disease 1 0.9999699592590332
- I-Disease 1 0.9999572038650513
telangiectasia I-Disease 1 0.9999707937240601
( O 0 8.606741175753996e-06
A B-Disease 0 0.13218198716640472
- I-Disease 1 0.9999271631240845
T I-Disease 1 0.9999912977218628
) O 0 9.802141903492156e-06
patients O 0 8.459272038408017e-08
in O 0 9.537223455424737e-09
the O 0 8.067569012837339e-08
British O 0 3.9917704270919785e-05
Isles O 0 0.00017757166642695665
. O 0 9.934960871760268e-06

Of O 0 1.4047176364329061e-06
51 O 0 2.289296389790252e-05
ATM O 0 0.0010382828768342733
mutations O 0 6.05985997026437e-06
identified O 0 1.5618373936376884e-06
in O 0 3.139261366413848e-07
families O 0 3.017869175891974e-06
native O 0 6.750921244247365e-08
to O 0 3.4911791235714418e-09
the O 0 1.7995514411950353e-08
British O 0 2.9514314974221634e-06
Isles O 0 2.8098989787395112e-05
, O 0 1.8495786946459702e-07
11 O 0 6.711596256536723e-07
were O 0 1.494213677233347e-07
founder O 0 3.69918197975494e-05
mutations O 0 8.651127814118809e-08
, O 0 4.255845453826623e-08
and O 0 6.007647357364476e-08
2 O 0 4.3176488162544047e-08
of O 0 1.1159947410632753e-09
these O 0 4.16000922598414e-09
11 O 0 1.0471484301888268e-06
conferred O 0 6.711903210998571e-07
a O 0 2.611843399336067e-07
milder O 0 1.3078349184070248e-05
clinical O 0 3.6780697882932145e-06
phenotype O 0 9.321501238446217e-06
with O 0 7.912116473107744e-08
respect O 0 1.5305692713241115e-08
to O 0 1.4895114475166338e-07
both O 0 3.6956571420887485e-06
cerebellar B-Disease 1 0.8908485770225525
degeneration I-Disease 0 0.31109941005706787
and O 0 2.550070803408744e-06
cellular O 0 0.0002638574515003711
features O 0 1.4614634892495815e-05
. O 0 2.02884002646897e-05

We O 0 4.18552235714742e-06
report O 0 9.525167115498334e-06
, O 0 1.1252786435989037e-07
in O 0 9.978581516634222e-09
two O 0 1.8060060824609536e-07
A B-Disease 0 0.03344446420669556
- I-Disease 1 0.9998544454574585
T I-Disease 1 0.9999872446060181
families O 0 1.1159462701471057e-05
, O 0 1.3395244025105058e-07
an O 0 1.1079697159743773e-08
ATM O 0 0.0001460480852983892
mutation O 0 1.3170728152545053e-07
( O 0 1.1854131010125002e-08
7271T O 0 2.091988108077203e-06
- O 0 0.0009678906644694507
- O 0 0.006369323004037142
> O 0 4.803941919817589e-06
G O 0 0.012849319726228714
) O 0 2.5016683480316715e-07
that O 0 4.4169212287670234e-07
may O 0 7.98328471773857e-07
be O 0 1.604414734401871e-08
associated O 0 6.570832056240761e-08
with O 0 1.6386822565550574e-08
an O 0 7.642242394467758e-08
increased O 0 6.8587369241868146e-06
risk O 0 1.627320671104826e-05
of O 0 1.2805804544768762e-05
breast B-Disease 1 0.96869295835495
cancer I-Disease 0 0.01129869930446148
in O 0 2.0381526155688334e-07
both O 0 4.888274816039484e-07
homozygotes O 0 6.271558231674135e-05
and O 0 3.5552723147702636e-06
heterozygotes O 0 7.978286885190755e-05
( O 0 7.621542863489594e-08
relative O 0 2.319940904271789e-06
risk O 0 6.708345381412073e-07
12 O 0 9.320651628286214e-08
. O 0 6.644141592460073e-08
7 O 0 2.2162673758430174e-06
; O 0 1.393771412949718e-06
P O 0 0.006746015511453152
= O 0 9.998386303777806e-06
. O 0 3.1416867329880915e-08
0025 O 0 9.954882989404723e-05
) O 0 6.909657201958908e-08
, O 0 6.272754404790248e-08
although O 0 2.2564933033208945e-08
there O 0 3.0846061260803026e-09
is O 0 9.246492460590616e-09
a O 0 9.093476194266259e-08
less O 0 1.2780359384123585e-06
severe O 0 0.000987301697023213
A B-Disease 0 0.29318299889564514
- I-Disease 1 0.999915361404419
T I-Disease 1 0.9999852180480957
phenotype O 0 9.635310561861843e-05
in O 0 1.605985211483585e-08
terms O 0 3.5219178684542385e-09
of O 0 1.950523298432927e-09
the O 0 1.1251777465304258e-07
degree O 0 2.8989372822252335e-06
of O 0 5.421820787887555e-06
cerebellar B-Disease 1 0.9884874820709229
degeneration I-Disease 1 0.9902392625808716
. O 0 0.000298037426546216

This O 0 6.650239470218366e-07
mutation O 0 1.4821573586232262e-06
( O 0 9.345912843627957e-08
7271T O 0 9.07973026187392e-06
- O 0 0.001059901900589466
- O 0 0.030225951224565506
> O 0 1.1678894225042313e-05
G O 0 0.00023008599237073213
) O 0 2.028816226129493e-08
also O 0 8.725309919022095e-10
allows O 0 2.20688661789481e-10
expression O 0 9.880769813452872e-11
of O 0 1.655904580122325e-10
full O 0 5.6513944635128155e-09
- O 0 2.0180148567305878e-05
length O 0 1.5465649028101325e-07
ATM O 0 1.3658241186931264e-05
protein O 0 1.4815586979466389e-08
at O 0 3.218577049324267e-08
a O 0 2.2227630847027058e-09
level O 0 1.447876218918509e-08
comparable O 0 2.578944133801997e-07
with O 0 6.87640806518175e-08
that O 0 4.1879553691615e-07
in O 0 1.9519759462127695e-06
unaffected O 0 0.00011107242607977241
individuals O 0 2.7031330773752416e-07
. O 0 3.1855443012318574e-06

In O 0 9.452001563658996e-07
addition O 0 2.863699819499743e-07
, O 0 1.3672148213572655e-07
we O 0 9.239987441844733e-09
have O 0 2.2119235332240805e-09
studied O 0 3.091433953272826e-08
18 O 0 9.430805789634178e-07
A B-Disease 0 0.07647302001714706
- I-Disease 1 0.9999594688415527
T I-Disease 1 0.9999943971633911
patients O 0 3.6805120089411503e-06
, O 0 1.1748119277399383e-07
in O 0 1.9974804033040527e-08
15 O 0 4.948179821440135e-07
families O 0 2.808883664329187e-06
, O 0 2.9754394290648634e-06
who O 0 6.168225081637502e-05
developed O 0 0.10437022894620895
leukemia B-Disease 1 0.9999336004257202
, O 0 0.3504485785961151
lymphoma B-Disease 1 0.9999936819076538
, O 0 0.0002608510840218514
preleukemic O 1 0.5763365626335144
T O 1 0.809941828250885
- O 0 0.022835321724414825
cell O 0 0.015181481838226318
proliferation O 0 0.0295480377972126
, O 0 2.6998792236554436e-05
or O 0 0.0028226757422089577
Hodgkin B-Disease 1 0.9999762773513794
lymphoma I-Disease 1 0.9999934434890747
, O 0 1.7174055756186135e-05
mostly O 0 2.8012439656777133e-07
in O 0 3.355347416800214e-06
childhood O 0 0.0004446372913662344
. O 0 2.55608101724647e-05

A O 0 3.2739601465436863e-06
wide O 0 1.0316289262846112e-06
variety O 0 3.046630681069473e-08
of O 0 3.045532537271356e-08
ATM O 0 0.003965103533118963
mutation O 0 7.375014661192836e-07
types O 0 4.830646957998397e-07
, O 0 3.0514465265696344e-07
including O 0 6.422512655035462e-08
missense O 0 2.375690201006364e-06
mutations O 0 2.0354097785002523e-07
and O 0 2.829937386650272e-07
in O 0 1.5844746314996883e-07
- O 0 0.001052909530699253
frame O 0 0.0023772437125444412
deletions O 0 4.676923708757386e-06
, O 0 3.745819583400589e-07
were O 0 7.248181788099828e-08
seen O 0 3.1037413350532006e-07
in O 0 6.808399888313943e-08
these O 0 8.260192885245488e-08
patients O 0 1.510804963800183e-06
. O 0 5.9884673646593e-06

We O 0 1.455785763937456e-06
also O 0 2.5782753709790995e-07
show O 0 1.9420052410623612e-07
that O 0 2.7380387734865508e-08
25 O 0 7.935602752695559e-08
% O 0 1.5710844847305339e-09
of O 0 6.622967729796869e-10
all O 0 1.2984324726517116e-08
A B-Disease 0 0.0926872193813324
- I-Disease 1 0.99994957447052
T I-Disease 1 0.9999918937683105
patients O 0 9.500595297140535e-07
carried O 0 3.7272965869306063e-07
in O 0 1.2241126512435585e-07
- O 0 0.003226699074730277
frame O 0 0.004100883845239878
deletions O 0 5.0261396609130315e-06
or O 0 1.9594030220559944e-07
missense O 0 9.327567909167556e-07
mutations O 0 1.822736521717161e-07
, O 0 7.620874242775244e-08
many O 0 5.981481421279966e-10
of O 0 9.39617095241374e-09
which O 0 6.353878347908903e-07
were O 0 7.885973900556564e-07
also O 0 7.391674330392561e-07
associated O 0 4.418513199766494e-08
with O 0 2.5058404240496657e-09
expression O 0 7.526767542564983e-10
of O 0 3.507237167355015e-09
mutant O 0 4.148319021624047e-06
ATM O 0 0.00012901118316221982
protein O 0 9.272507668356411e-07
. O 0 1.2431388540790067e-06

The O 0 5.479294941324042e-06
DMPK O 0 0.004864722490310669
gene O 0 1.068479468813166e-05
of O 0 3.1382456654682755e-05
severely O 1 0.9992478489875793
affected O 1 0.9461325407028198
myotonic B-Disease 1 0.9999736547470093
dystrophy I-Disease 1 0.9999840259552002
patients O 0 0.005146269220858812
is O 0 9.180180313705932e-06
hypermethylated O 0 0.08764111250638962
proximal O 0 0.00013134503387846053
to O 0 2.2468173099809974e-08
the O 0 3.088010203100566e-08
largely O 0 3.137402870834194e-07
expanded O 0 1.2291199027458788e-06
CTG O 0 0.0014435496414080262
repeat O 0 4.044603701913729e-05
. O 0 3.5592586300481344e-06

Using O 0 5.580093329626834e-07
methylation O 0 6.5074304984591436e-06
- O 0 0.00010979549551848322
sensitive O 0 1.570853783050552e-06
restriction O 0 3.225340492463147e-07
enzymes O 0 1.638693873928787e-07
, O 0 1.990722182654281e-07
we O 0 1.3126808973140669e-08
characterized O 0 2.3430304452176642e-07
the O 0 4.290310329224667e-09
methylation O 0 2.2291034440513613e-07
pattern O 0 8.381816769542638e-07
on O 0 6.689295162232156e-08
the O 0 2.7972122396136e-08
5 O 0 2.699101457892539e-07
side O 0 4.975558809405811e-08
of O 0 1.1847931524755495e-09
the O 0 1.0738876454752244e-07
CTG O 0 0.0035983999259769917
repeat O 0 2.154230742235086e-06
in O 0 8.792238048727086e-09
the O 0 3.954320959564939e-08
DMPK O 0 0.0007943522068671882
gene O 0 3.064382525508336e-08
of O 0 4.335769521190969e-09
normal O 0 9.669695799630063e-08
individuals O 0 1.1456134707543697e-08
and O 0 1.7854493705726782e-07
of O 0 4.990413913219527e-07
patients O 0 1.547331703477539e-05
affected O 0 8.888671800377779e-06
with O 0 0.0629977136850357
myotonic B-Disease 1 0.9999946355819702
dystrophy I-Disease 1 0.9999933242797852
, O 0 0.00015492843522224575
showing O 0 2.053373827948235e-05
expansions O 0 1.8465434550307691e-06
of O 0 5.269497727056205e-09
the O 0 6.165947752378997e-08
repetitive O 0 9.100725947064348e-06
sequence O 0 5.787236432297505e-07
. O 0 6.689819201710634e-06

The O 0 6.150291369522165e-07
gene O 0 1.0583507901174016e-06
segment O 0 3.4352315196883865e-06
analyzed O 0 4.423615678206261e-07
corresponds O 0 4.1053393573520225e-08
to O 0 1.7548725805838217e-09
the O 0 4.5475583299037226e-09
genomic O 0 1.8466332676325692e-06
SacI O 0 9.903631871566176e-05
- O 0 0.00020666528143920004
HindIII O 0 2.530874371586833e-05
fragment O 0 1.1229823115854742e-07
carrying O 0 2.0724367999491733e-08
exons O 0 9.288902447224245e-08
11 O 0 6.860005896669463e-07
- O 0 0.00028113205917179585
15 O 0 1.957163476618007e-06
. O 0 1.7787136812330573e-06

There O 0 6.694355079162051e-07
is O 0 4.7489066901107435e-08
constitutive O 0 4.2139402012253413e-07
methylation O 0 2.861892767214158e-07
in O 0 5.2233296798931406e-08
intron O 0 4.724631071439944e-05
12 O 0 1.9389945293823985e-07
at O 0 3.147868312680657e-07
restriction O 0 1.1649311737471635e-08
sites O 0 1.3877684557073167e-09
of O 0 3.0604205836226583e-09
SacII O 0 0.00013344291073735803
and O 0 6.344662324409001e-07
HhaI O 0 7.002874190220609e-05
, O 0 2.520432751396129e-08
localized O 0 1.9835923126265698e-08
1 O 0 7.286061087796725e-09
, O 0 1.0863593580268116e-08
159 O 0 8.593336247031402e-07
- O 0 4.235782762407325e-05
1 O 0 4.164313693877375e-08
, O 0 2.330738979594571e-08
232 O 0 1.446049822106943e-07
bp O 0 1.1585913171074935e-06
upstream O 0 3.3487874695481423e-09
of O 0 8.674214124759771e-11
the O 0 8.229413595017832e-09
CTG O 0 0.0001328725484199822
repeat O 0 2.4387450139329303e-06
, O 0 5.423732574172391e-08
whereas O 0 2.763954221052245e-08
most O 0 2.0217036933445343e-09
, O 0 9.630673503124854e-08
if O 0 1.3681495047990211e-08
not O 0 2.79479883680267e-10
all O 0 1.3827475275896006e-10
, O 0 6.1579297216951545e-09
of O 0 2.4058002812132884e-10
the O 0 1.2908287772006588e-09
other O 0 6.469719759927273e-10
sites O 0 8.106218807313326e-09
of O 0 2.575792201753302e-08
SacII O 0 0.0008838724461384118
, O 0 4.877359742749832e-07
HhaI O 0 0.0002774195745587349
, O 0 2.1729110244450567e-07
and O 0 3.2412356176791945e-07
HpaII O 0 6.481878517661244e-05
in O 0 1.6307563299733374e-08
this O 0 3.2641203073779934e-09
region O 0 5.2841240716361426e-08
are O 0 2.92586022077046e-09
unmethylated O 0 1.9884348148480058e-05
, O 0 4.261312085418467e-07
in O 0 3.001354542675472e-08
normal O 0 1.1502688579412279e-07
individuals O 0 9.572250547762451e-09
and O 0 7.531370016522487e-08
most O 0 2.5116542179404178e-09
of O 0 5.773620870286322e-08
the O 0 1.0119870239577722e-05
patients O 0 1.2784998943971004e-05
. O 0 7.226312845887151e-06

In O 0 3.991102062173013e-07
a O 0 3.1876570716349306e-08
number O 0 6.3747180867324005e-09
of O 0 8.523115013758797e-08
young O 0 1.0172121619689278e-05
and O 0 0.0003310465544927865
severely O 1 0.7085759043693542
affected O 0 3.2890642614802346e-05
patients O 0 1.4652334812126355e-06
, O 0 1.1656311471597292e-06
however O 0 1.7136244423454627e-07
, O 0 3.6248085422130316e-08
complete O 0 2.3390983372451046e-08
methylation O 0 1.951060539795435e-07
of O 0 1.1451344317237044e-09
these O 0 1.7427010945425536e-09
restriction O 0 2.41067628081737e-08
sites O 0 9.466709371963589e-08
was O 0 8.52684024721384e-06
found O 0 5.055701421952108e-07
in O 0 1.5564051381034005e-08
the O 0 2.035207380401971e-08
mutated O 0 2.4458065581711708e-06
allele O 0 3.7131019325897796e-06
. O 0 3.262916379753733e-06

In O 0 2.7225676149100764e-06
most O 0 3.4518176761366703e-08
of O 0 3.793705261045943e-08
these O 0 2.175822260142013e-07
patients O 0 6.54802420285705e-07
, O 0 4.960057253811101e-07
the O 0 1.01324656043289e-06
onset O 0 0.001347638200968504
of O 0 2.4325245249201544e-06
the O 0 0.017056720331311226
disease O 1 0.800507128238678
was O 1 0.6445608735084534
congenital O 1 0.9997627139091492
. O 0 0.0016702240100130439

Preliminary O 0 1.088352655642666e-05
in O 0 3.0007875011506258e-06
vivo O 0 0.0003070895036216825
footprinting O 0 0.010992264375090599
data O 0 1.945113353940542e-06
gave O 0 5.515214525075862e-07
evidence O 0 6.79525840041606e-08
for O 0 2.8999809220664474e-09
protein O 0 5.3052005455356266e-08
- O 0 5.621030868496746e-05
DNA O 0 3.3506855743326014e-06
contact O 0 1.2785170611095964e-07
in O 0 1.4384569091419053e-08
normal O 0 3.0737190570562234e-08
genes O 0 3.2412664552339265e-08
at O 0 1.819363660615636e-06
an O 0 1.962290383517029e-07
Sp1 O 0 0.00013219618995208293
consensus O 0 9.147608892590142e-09
binding O 0 1.1303569635856547e-08
site O 0 1.065587085236075e-08
upstream O 0 9.205648687782286e-09
of O 0 1.0341520972900753e-09
the O 0 5.6808794113294425e-08
CTG O 0 0.00045169732766225934
repeat O 0 1.5511128594880574e-06
and O 0 3.5567193634733485e-08
for O 0 2.80443890332549e-09
a O 0 1.7394841123063998e-08
significant O 0 9.815899204568268e-09
reduction O 0 6.195336510472771e-08
of O 0 5.401262770377002e-10
this O 0 3.367077450189271e-10
interaction O 0 1.1414404976761716e-09
in O 0 7.151557568363387e-09
cells O 0 1.1384453557639063e-07
with O 0 7.922354683387312e-08
a O 0 9.583504834154155e-07
hypermethylated O 0 0.08149876445531845
DMPK O 0 0.005961989518254995
gene O 0 2.4711368951102486e-07
. O 0 4.846201591135468e-07
. O 0 3.2343825751013355e-06

The O 0 0.00018701975932344794
hemochromatosis B-Disease 1 0.9988055229187012
gene O 0 1.0937361366814002e-05
product O 0 7.091040970408358e-06
complexes O 0 2.0391551061038626e-06
with O 0 3.179362906280403e-08
the O 0 3.000919335249819e-08
transferrin O 0 4.899280611425638e-05
receptor O 0 4.0276859181176405e-08
and O 0 7.135972168725857e-08
lowers O 0 3.431043751334073e-06
its O 0 3.732466336003881e-09
affinity O 0 3.389077818383157e-08
for O 0 2.298313095394633e-09
ligand O 0 2.254005408985904e-07
binding O 0 4.6584318624809384e-07
. O 0 1.417679300175223e-06

We O 0 1.0176294381381012e-05
recently O 0 3.745088179130107e-05
reported O 0 2.938674697361421e-06
the O 0 5.789453361160213e-09
positional O 0 3.73050085045179e-07
cloning O 0 4.583132522384403e-06
of O 0 6.735459301410174e-09
a O 0 5.7850407131354586e-08
candidate O 0 3.80771155050752e-07
gene O 0 3.4434742701705545e-06
for O 0 0.0001387971278745681
hereditary B-Disease 1 0.9999226331710815
hemochromatosis I-Disease 1 0.9999716281890869
called O 0 0.0117984339594841
HFE O 0 0.4607425034046173
. O 0 4.935275137540884e-05

The O 0 8.189760478671815e-07
gene O 0 3.2476330034114653e-06
product O 0 1.2956555110577028e-05
, O 0 3.8005245528438536e-07
a O 0 1.2075559219226761e-08
member O 0 5.434021677075407e-09
of O 0 1.0744214407054642e-09
the O 0 2.10737880479428e-08
major O 0 2.3801527504474507e-07
histocompatibility O 0 0.0011892913607880473
complex O 0 2.7974181193712866e-06
class O 0 6.801228664699011e-07
I O 0 2.67025734501658e-06
- O 0 0.0017758377362042665
like O 0 1.3082376426609699e-06
family O 0 0.0002154477988369763
, O 0 2.9799348340020515e-06
was O 0 3.9268161344807595e-06
found O 0 3.529250136580231e-07
to O 0 6.769770521941609e-09
have O 0 3.088662658967678e-09
a O 0 1.4857383767719057e-08
mutation O 0 3.2397089455571404e-08
, O 0 4.7198302155493366e-08
Cys O 0 1.3191209291107953e-05
- O 0 9.311958820035215e-06
282 O 0 2.424176045678905e-06
- O 0 0.00048284075455740094
- O 0 0.0010664763394743204
> O 0 1.5277714737749193e-06
Tyr O 0 2.1941852537565865e-05
( O 0 1.2616852451685645e-08
C282Y O 0 1.2575140999615542e-06
) O 0 2.048268754606397e-08
, O 0 1.5199566050227986e-08
in O 0 1.911236857665699e-08
85 O 0 3.9690945641268627e-07
% O 0 1.7910560146106036e-08
of O 0 3.002860538003915e-08
patient O 0 3.0884339139447547e-06
chromosomes O 0 0.00019617030920926481
. O 0 3.2249732612399384e-05

This O 0 5.151337063580286e-07
mutation O 0 1.5338081311710994e-06
eliminates O 0 8.59174906508997e-06
the O 0 9.134257084042474e-08
ability O 0 1.6101128608170256e-07
of O 0 2.1103515379650162e-08
HFE O 0 0.00023368129041045904
to O 0 1.9104568593775184e-08
associate O 0 9.949412316245798e-08
with O 0 4.881589461547264e-07
beta2 O 0 0.038716405630111694
- O 0 0.15859098732471466
microglobulin O 0 0.11446740478277206
( O 0 1.675902581155242e-07
beta2m O 0 0.00018606230150908232
) O 0 2.3981014507512555e-08
and O 0 6.835660570914115e-08
prevents O 0 6.451192575696041e-07
cell O 0 8.001441165106371e-05
- O 0 0.00015272478049155325
surface O 0 7.67065466789063e-06
expression O 0 1.7121574558132124e-07
. O 0 2.5643712433520705e-06

A O 0 6.366547040670412e-06
second O 0 3.4617053188412683e-06
mutation O 0 1.8490861748432508e-06
that O 0 6.031494876879151e-07
has O 0 1.1236095360800391e-06
no O 0 2.1609450229220784e-08
effect O 0 5.029755811847281e-08
on O 0 2.192035481130006e-06
beta2m O 0 0.05216246843338013
association O 0 4.550649634893489e-07
, O 0 3.9850357325121877e-07
H63D O 0 0.018919505178928375
, O 0 1.2424371789165889e-06
was O 0 2.8348529212962603e-06
found O 0 1.5074387249569554e-07
in O 0 7.0870029844627425e-09
eight O 0 5.023849780627643e-08
out O 0 2.600573800748407e-08
of O 0 3.230958611766255e-08
nine O 0 7.930024366942234e-06
patients O 0 2.931876394995925e-07
heterozygous O 0 2.13501181178799e-08
for O 0 3.772589796113834e-09
the O 0 6.74726550187188e-08
C282Y O 0 5.251086622592993e-05
mutant O 0 2.6954181521432474e-05
. O 0 6.227754965948407e-06

In O 0 6.095290700613987e-06
this O 0 3.9624228520551696e-07
report O 0 1.5282100775948493e-06
, O 0 6.65318324877262e-08
we O 0 2.0507264775204703e-09
demonstrate O 0 4.15891410199265e-09
in O 0 1.301886265459018e-09
cultured O 0 7.150175065362419e-07
293 O 0 2.627730964377406e-06
cells O 0 7.150898113650328e-07
overexpressing O 0 1.3402824151853565e-05
wild O 0 2.579785416401137e-07
- O 0 0.00015019631246104836
type O 0 5.150084234628594e-07
or O 0 1.0038527165079358e-07
mutant O 0 1.1248187547607813e-05
HFE O 0 0.00015246638213284314
proteins O 0 4.791999330677754e-08
that O 0 6.219403658747069e-09
both O 0 7.495693510328749e-10
the O 0 1.5166003564104358e-08
wild O 0 1.8025010604105773e-06
- O 0 0.0008288847748190165
type O 0 9.8757402611227e-07
and O 0 9.369934446112893e-07
H63D O 0 0.015941884368658066
HFE O 0 0.0001717733684927225
proteins O 0 3.03383274058433e-08
form O 0 7.987152272903586e-09
stable O 0 1.6463911833852762e-06
complexes O 0 1.7075180949177593e-06
with O 0 7.173582616815111e-08
the O 0 4.842385692427342e-07
transferrin O 0 0.001332419808022678
receptor O 0 1.010896312436671e-06
( O 0 1.6233741462201579e-07
TfR O 0 2.295653939654585e-05
) O 0 3.9833827258917154e-07
. O 0 1.4133163404039806e-06

The O 0 3.9855899558460806e-06
C282Y O 0 0.00027687475085258484
mutation O 0 2.4538296656828607e-06
nearly O 0 1.7869494968181243e-06
completely O 0 1.871248059615027e-05
prevents O 0 2.431341954434174e-06
the O 0 1.883615396991445e-07
association O 0 3.606767151609347e-08
of O 0 8.536919504642526e-10
the O 0 5.980277961725733e-08
mutant O 0 2.577336817921605e-05
HFE O 0 0.00019331119256094098
protein O 0 4.362016525760737e-08
with O 0 7.538785951055615e-08
the O 0 1.846284590101277e-06
TfR O 0 0.000729509221855551
. O 0 6.161789769976167e-06

Studies O 0 1.5527763252976001e-06
on O 0 1.6881656392797595e-06
cell O 0 0.0005686986842192709
- O 0 0.018052546307444572
associated O 0 1.0105693945661187e-05
transferrin O 0 5.014085036236793e-05
at O 0 2.4169312951016764e-07
37 O 0 1.164578407042427e-07
degrees O 0 2.928838682692003e-07
C O 0 6.0188565839780495e-05
suggest O 0 3.7376690187329586e-08
that O 0 4.6968375855271915e-09
the O 0 1.9791292160675766e-08
overexpressed O 0 6.128842414909741e-06
wild O 0 1.2111539717807318e-06
- O 0 0.0019763309974223375
type O 0 3.8566427065234166e-06
HFE O 0 7.50549224903807e-05
protein O 0 4.050775359587533e-08
decreases O 0 2.338937754586823e-08
the O 0 1.6123931079192744e-09
affinity O 0 5.666724334218998e-08
of O 0 5.686665804915947e-09
the O 0 1.0868156863352851e-07
TfR O 0 3.155139711452648e-05
for O 0 2.2500795182622824e-07
transferrin O 0 0.001210937392897904
. O 0 3.972547801822657e-06

The O 0 2.865578835553606e-06
overexpressed O 0 0.00043163931695744395
H63D O 0 0.025039196014404297
protein O 0 3.1453557767235907e-06
does O 0 1.4733758746388048e-07
not O 0 1.2814488137280478e-08
have O 0 6.3828213825445346e-09
this O 0 9.142789858529454e-10
effect O 0 1.5769366257245565e-08
, O 0 1.3175270652254767e-08
providing O 0 3.5914207718867885e-10
the O 0 1.6409019698571115e-09
first O 0 2.1593453691792774e-09
direct O 0 1.1903609209440447e-09
evidence O 0 1.0002175798717872e-07
for O 0 4.301101252934814e-09
a O 0 6.97373963021164e-08
functional O 0 1.673535621193878e-07
consequence O 0 1.2627377543594775e-07
of O 0 8.076633584153114e-09
the O 0 1.8036084838968236e-06
H63D O 0 0.03548680618405342
mutation O 0 1.5402591770907748e-06
. O 0 3.156826323902351e-06

Addition O 0 1.177769490823266e-06
of O 0 2.0469182970828115e-07
soluble O 0 3.5857583498000167e-06
wild O 0 2.5079295937757706e-06
- O 0 0.002205386757850647
type O 0 1.6138257706188597e-05
HFE O 0 0.005265368614345789
/ O 0 3.167714748997241e-05
beta2m O 0 6.243905227165669e-05
heterodimers O 0 1.0751599575087312e-06
to O 0 8.591958255976806e-09
cultured O 0 2.920938186434796e-06
cells O 0 1.449682940801722e-06
also O 0 1.910712512653845e-07
decreased O 0 3.551479892394127e-07
the O 0 2.8273630547914763e-08
apparent O 0 2.033629925790592e-06
affinity O 0 7.575773253165607e-08
of O 0 3.9712957367044055e-09
the O 0 1.0179491027884069e-07
TfR O 0 6.213399046828272e-06
for O 0 5.358309906888792e-10
its O 0 3.5021971989124268e-09
ligand O 0 3.8214185593687944e-08
under O 0 2.546798327784927e-08
steady O 0 7.259371614054544e-06
- O 0 0.0004974009352736175
state O 0 1.8177735228164238e-07
conditions O 0 1.8552560732132406e-06
, O 0 2.8711536259606874e-08
both O 0 1.951375283582024e-09
in O 0 1.113239989081194e-08
293 O 0 2.9511472803278593e-06
cells O 0 3.6979804463044275e-07
and O 0 1.440500057015015e-07
in O 0 1.5047240253807104e-07
HeLa O 0 0.0024696961045265198
cells O 0 8.511355190421455e-06
. O 0 2.247504653496435e-06

Furthermore O 0 2.7507292543305084e-05
, O 0 1.6270766991510754e-06
at O 0 1.0748073009381187e-06
4 O 0 2.0324731053733558e-07
degrees O 0 2.957422964300349e-07
C O 0 5.114773739478551e-05
, O 0 4.792245889007063e-08
the O 0 1.6536843006065283e-08
added O 0 2.553779552272317e-07
soluble O 0 6.518217787743197e-08
complex O 0 1.0557855745219058e-07
of O 0 3.820106897478581e-08
HFE O 0 0.0019217911176383495
/ O 0 2.4494096578564495e-05
beta2m O 0 5.474264617078006e-05
inhibited O 0 1.3024884992773877e-07
binding O 0 2.492322126457225e-09
of O 0 2.1157833263174552e-09
transferrin O 0 1.0086669135489501e-05
to O 0 1.0420091456353475e-08
HeLa O 0 7.731498044449836e-05
cell O 0 5.683057679561898e-05
TfR O 0 5.853104994457681e-06
in O 0 7.0617174330323e-09
a O 0 7.928688461333877e-08
concentration O 0 5.860410510649672e-06
- O 0 0.0005137073458172381
dependent O 0 1.3178686231185566e-06
manner O 0 1.3707494872505777e-06
. O 0 3.7987670111760963e-06

Scatchard O 0 0.0006323459674604237
plots O 0 1.9109809727524407e-05
of O 0 7.923321021507945e-08
these O 0 3.44165371757299e-08
data O 0 1.120927322517673e-06
indicate O 0 2.1058164634268906e-07
that O 0 1.461003407143835e-08
the O 0 2.6879755310460496e-08
added O 0 5.1874974360544e-07
heterodimer O 0 5.064632205176167e-06
substantially O 0 1.5498811762881815e-06
reduced O 0 6.908877026035043e-09
the O 0 1.869934429521436e-09
affinity O 0 1.8132874401999288e-07
of O 0 5.7929909758058784e-08
TfR O 0 3.9232210838235915e-05
for O 0 1.6132590019424242e-07
transferrin O 0 0.0018035973189398646
. O 0 3.279346856288612e-06

These O 0 4.676378750900767e-07
results O 0 6.493808655250177e-07
establish O 0 3.4120514413871206e-08
a O 0 5.629923194305775e-08
molecular O 0 1.3186757314542774e-05
link O 0 1.8187069144914858e-05
between O 0 2.9241127776913345e-06
HFE O 0 0.003968681674450636
and O 0 2.3673712234995037e-07
a O 0 2.511727181797596e-08
key O 0 4.0298613157574437e-07
protein O 0 3.846016838338073e-08
involved O 0 2.9572920112741485e-08
in O 0 1.1621885676049715e-07
iron O 0 0.003005894599482417
transport O 0 3.254391913287691e-06
, O 0 1.0441802089644625e-07
the O 0 2.890842409897232e-08
TfR O 0 4.207641177345067e-05
, O 0 1.6604707298029098e-07
and O 0 3.803740256103083e-08
raise O 0 1.5704381794989786e-08
the O 0 6.345531211593425e-09
possibility O 0 1.8482984387446777e-07
that O 0 5.2087546720258615e-08
alterations O 0 7.760671110190742e-07
in O 0 3.4113877944719206e-08
this O 0 4.954608279206241e-09
regulatory O 0 1.340418066320126e-06
mechanism O 0 7.78370065290801e-07
may O 0 1.2779076996594085e-07
play O 0 2.3324233655586113e-09
a O 0 6.330372226415193e-09
role O 0 3.907685552917428e-08
in O 0 7.736825580195728e-08
the O 0 7.502464995923219e-07
pathogenesis O 0 0.11333100497722626
of O 0 0.00043588478001765907
hereditary B-Disease 1 0.9999512434005737
hemochromatosis I-Disease 1 0.9999735355377197
. O 0 0.0001374723215121776
. O 0 5.18091837875545e-05

Genomic O 0 0.00010920294153038412
organization O 0 1.5783891740284162e-06
of O 0 8.126517769824204e-08
the O 0 1.0798992207128322e-06
UBE3A O 0 0.0025909224059432745
/ O 0 5.653609332512133e-05
E6 O 0 0.00315472180955112
- O 0 0.022163528949022293
AP O 0 9.346231672680005e-05
gene O 0 1.3512837426787883e-07
and O 0 7.069994012454117e-07
related O 0 1.7263317204196937e-05
pseudogenes O 0 3.542523700161837e-05
. O 0 9.702220268081874e-06

The O 0 1.2877920880782767e-06
UBE3A O 0 0.00011835357145173475
gene O 0 2.837959129919909e-07
encodes O 0 2.0756179708314448e-07
the O 0 1.0570529695996811e-07
E6 O 0 0.002977064112201333
- O 0 0.027924006804823875
AP O 0 0.00013321304868441075
ubiquitin O 0 8.417363460466731e-06
- O 0 9.112137377087492e-06
protein O 0 6.101997485075117e-08
ligase O 0 1.689412215455377e-06
and O 0 4.8583906675503385e-08
has O 0 4.988919855009044e-08
recently O 0 5.815974191136775e-07
been O 0 1.965784868218634e-08
shown O 0 1.2444010266676742e-08
to O 0 2.502969387307985e-09
be O 0 1.332737866732714e-07
mutated O 0 0.0020978234242647886
in O 1 0.8236598372459412
Angelman B-Disease 1 0.9999971389770508
syndrome I-Disease 1 0.9999970197677612
patients O 0 0.00010301947622792795
who O 0 3.865199687425047e-06
lack O 0 9.127697921940126e-07
15q11 O 0 8.324997907038778e-05
- O 0 0.000634314666967839
q13 O 0 7.260334677994251e-05
deletions O 0 4.564820756058907e-06
or O 0 1.2452176179067465e-06
chromosome O 0 5.660427996190265e-05
15 O 0 2.4568034859839827e-06
paternal O 0 0.00044395122677087784
uniparental B-Disease 0 0.24749648571014404
disomy I-Disease 0 0.03346168249845505
. O 0 2.5827399440458976e-05

Previous O 0 6.748655778210377e-06
UBE3A O 0 0.00015640906349290162
cDNA O 0 9.051476808963344e-06
analysis O 0 1.6737379837650224e-06
has O 0 2.898761124470184e-07
shown O 0 4.1771610170826534e-08
a O 0 2.246157571050844e-08
coding O 0 6.626766116824001e-05
region O 0 1.0467624633747619e-07
of O 0 3.5415337329425256e-09
approximately O 0 5.189397711546917e-08
2 O 0 3.6200665363139706e-06
. O 0 6.2936110225564335e-06

6 O 0 4.055936369695701e-05
kb O 0 0.010552660562098026
and O 0 4.812379188479099e-07
a O 0 8.435956289076785e-08
3 O 0 1.176017576653976e-06
- O 0 0.0029600944835692644
untranslated O 0 0.0004966140841133893
region O 0 1.7899481008498697e-06
( O 0 4.672660836035902e-08
UTR O 0 7.096472472767346e-06
) O 0 4.986938417772535e-09
of O 0 1.1848361181066025e-09
< O 0 4.2554398760330514e-07
50 O 0 1.2217341804898751e-08
bp O 0 9.813178621698171e-06
, O 0 3.3350207928606324e-08
whereas O 0 7.59066764999261e-09
Northern O 0 4.195724212507912e-09
analysis O 0 1.8441285831727328e-08
has O 0 1.2269277149812297e-08
indicated O 0 7.988569805661427e-09
mRNA O 0 3.8196221185948787e-10
sizes O 0 4.1655528804085407e-08
of O 0 1.159050633248171e-09
5 O 0 1.1303541924689853e-07
- O 0 0.00023764501383993775
8 O 0 6.9730208451801445e-06
kb O 0 0.00692439591512084
. O 0 5.158871772437124e-06

We O 0 1.2708711665254668e-06
have O 0 1.0484865420323786e-08
analyzed O 0 1.2481045530421397e-08
additional O 0 7.841886584536439e-10
cDNA O 0 1.4290340004663449e-06
clones O 0 1.8857390386983752e-05
and O 0 6.926058659928458e-08
provide O 0 4.905186479220447e-09
evidence O 0 6.610290625985726e-08
for O 0 3.013254978867508e-09
an O 0 5.964043037209876e-09
additional O 0 2.949895261394886e-08
0 O 0 5.944988288320019e-07
. O 0 1.8748012280411785e-06

5 O 0 6.850187673990149e-06
kb O 0 0.0006645214161835611
of O 0 6.160657051168528e-08
5 O 0 7.733740972071246e-07
- O 0 0.00020757866150233895
UTR O 0 2.4836002921801992e-05
and O 0 3.4938189230615535e-08
> O 0 4.1527968619448075e-08
2 O 0 2.988484126831281e-08
kb O 0 3.403231312404387e-05
of O 0 8.9351939180915e-09
3 O 0 7.098572609720577e-07
- O 0 0.001932255458086729
UTR O 0 0.00038078284705989063
. O 0 1.3102367120154668e-06

We O 0 1.334030116595386e-06
have O 0 5.7875791270589616e-08
established O 0 7.601722806782618e-09
the O 0 9.092189223736113e-09
genomic O 0 5.517681529454421e-07
organization O 0 1.497122781302096e-08
of O 0 1.7503303695320938e-08
UBE3A O 0 9.895758557831869e-05
and O 0 2.09221990843389e-08
the O 0 4.6552026122803625e-10
sequence O 0 1.5696348665272808e-09
of O 0 1.1257290211119653e-08
intron O 0 0.0009297985816374421
- O 0 0.0013459809124469757
exon O 0 0.00012901781883556396
borders O 0 6.881104127387516e-06
. O 0 2.710600938371499e-06

We O 0 1.2271661944396328e-06
have O 0 1.1429860791167812e-07
also O 0 1.6405303782107694e-08
mapped O 0 8.659217343165437e-08
two O 0 2.8149371722463457e-09
highly O 0 4.922328322720659e-09
homologous O 0 5.4905132884641716e-08
processed O 0 5.337771469271502e-08
pseudogenes O 0 1.1109937076980714e-06
, O 0 5.650200591844623e-07
UBE3AP1 O 0 0.0030348070431500673
and O 0 1.3002362493352848e-06
UBE3AP2 O 0 0.0006348513416014612
, O 0 1.2529798532057157e-08
to O 0 8.070531465342867e-10
chromosomes O 0 2.1476367351169756e-07
2 O 0 7.024387826959355e-08
and O 0 9.26376060306211e-08
21 O 0 1.0598233757264097e-06
, O 0 3.9882445435068803e-07
respectively O 0 8.828941417959868e-07
, O 0 7.353538933330128e-08
and O 0 5.7959638866122987e-08
determined O 0 7.822711722837994e-08
their O 0 1.9064165357463025e-08
genomic O 0 2.215375616287929e-06
organization O 0 1.3605608728539664e-06
. O 0 4.8857014007808175e-06

These O 0 1.1631881307039293e-06
results O 0 8.477703886455856e-06
will O 0 6.375438488248619e-08
form O 0 9.820800839221988e-10
the O 0 1.8174703964035643e-09
basis O 0 4.657763064130904e-09
for O 0 8.234374959670276e-09
studies O 0 1.3332382309272361e-08
of O 0 1.3291014955285618e-09
mutation O 0 2.407818122662775e-08
and O 0 2.8248899752725265e-07
imprinting O 0 5.862099351361394e-05
of O 0 9.389918886881787e-07
UBE3A O 0 0.007557945791631937
. O 0 1.2843497643189039e-05

Mutation O 0 5.68707537240698e-06
spectrum O 0 9.11627557798056e-06
and O 0 3.138865167784388e-06
genotype O 0 0.00017654875409789383
- O 0 0.06208832189440727
phenotype O 0 0.00024648464750498533
analyses O 0 2.6444551622262225e-05
in O 0 0.00012512448302004486
Cowden B-Disease 1 0.9995934367179871
disease I-Disease 0 0.0075678094290196896
and O 0 6.691857561236247e-05
Bannayan B-Disease 1 0.959145724773407
- I-Disease 1 0.9999021291732788
Zonana I-Disease 1 0.9999041557312012
syndrome I-Disease 1 0.9996687173843384
, O 0 7.751382327114698e-06
two O 0 5.719276668969542e-05
hamartoma B-Disease 1 0.9983059167861938
syndromes I-Disease 1 0.6880552768707275
with O 0 1.9338311176397838e-05
germline O 0 0.005038913805037737
PTEN O 0 0.004805565811693668
mutation O 0 5.459817657538224e-06
. O 0 1.1812953744083643e-05

The O 0 0.00012220838107168674
tumour B-Disease 1 0.9979655742645264
suppressor O 0 0.0013877023011446
gene O 0 1.834768772823736e-05
PTEN O 0 0.004152539186179638
, O 0 8.589681215198652e-07
which O 0 4.573979239808068e-08
maps O 0 1.5761735028263502e-07
to O 0 1.7423272424821334e-07
10q23 O 0 0.00013166980352252722
. O 0 5.19059312864556e-06

3 O 0 1.1462621841928922e-05
and O 0 1.924081090010077e-07
encodes O 0 1.1748030459557413e-07
a O 0 5.502703182003188e-09
403 O 0 6.307462996346658e-08
amino O 0 3.044863028378586e-09
acid O 0 3.552615757129729e-09
dual O 0 8.516400029634497e-09
specificity O 0 1.630797470397738e-07
phosphatase O 0 0.00024690519785508513
( O 0 1.0275619466426633e-08
protein O 0 1.201288934993272e-08
tyrosine O 0 1.093974262289521e-07
phosphatase O 0 5.5241729569388554e-05
; O 0 1.725740759184191e-07
PTPase O 0 6.678317004116252e-05
) O 0 7.706104554472404e-08
, O 0 8.718431132592741e-08
was O 0 1.4316694887384074e-06
shown O 0 1.6182205797576898e-07
recently O 0 6.066371724955388e-07
to O 0 1.1487988338387822e-09
play O 0 3.4194769238382605e-09
a O 0 3.635422629599816e-08
broad O 0 5.777932869932556e-07
role O 0 3.0982437237980776e-07
in O 0 4.792986487700546e-07
human O 0 2.509843216103036e-05
malignancy B-Disease 0 0.24357980489730835
. O 0 2.9958699087728746e-05

Somatic O 0 0.00012441823491826653
PTEN O 0 0.005319128278642893
deletions O 0 0.000127968261949718
and O 0 9.669133760326076e-06
mutations O 0 1.5476124417546089e-06
were O 0 8.28602395586131e-08
observed O 0 1.8259152056998573e-07
in O 0 1.3189583114581183e-07
sporadic B-Disease 0 3.4592630981933326e-05
breast I-Disease 0 0.251139372587204
, I-Disease 0 0.00082939158892259
brain I-Disease 0 0.49429622292518616
, I-Disease 0 0.01772143505513668
prostate I-Disease 1 0.9988197684288025
and I-Disease 1 0.9519367218017578
kidney I-Disease 1 0.999875545501709
cancer I-Disease 0 0.12814410030841827
cell O 0 0.009557539597153664
lines O 0 3.322686461615376e-05
and O 0 6.077269745219382e-07
in O 0 4.1121808180832886e-08
several O 0 2.0578673343152332e-07
primary O 0 0.00014278104936238378
tumours B-Disease 1 0.9995691180229187
such O 0 1.0836776453970742e-07
as O 0 1.2995125871384516e-05
endometrial B-Disease 1 0.9884010553359985
carcinomas I-Disease 1 0.9999843835830688
, O 1 0.9996022582054138
malignant B-Disease 1 0.999993085861206
melanoma I-Disease 1 0.9999867677688599
and O 1 0.9717730283737183
thyroid B-Disease 1 0.999796450138092
tumours I-Disease 1 0.999826967716217
. O 0 0.001485660090111196

In O 0 1.8317595049666124e-06
addition O 0 1.327903191850055e-06
, O 0 9.104910532187205e-06
PTEN O 0 0.0024636362213641405
was O 0 8.694724783708807e-06
identified O 0 3.140878561680438e-07
as O 0 4.424262733948581e-09
the O 0 2.9216010943855508e-08
susceptibility O 0 1.3641337091030437e-06
gene O 0 8.012775509769199e-08
for O 0 1.2234252722009842e-07
two O 0 0.006164558697491884
hamartoma B-Disease 1 0.9998403787612915
syndromes I-Disease 1 0.999925971031189
Cowden B-Disease 1 0.9999366998672485
disease I-Disease 0 0.24514977633953094
( O 0 1.9634096304343984e-07
CD B-Disease 0 3.449353971518576e-05
; O 0 3.2387870305683464e-06
MIM O 0 0.0034208663273602724
158350 O 0 3.1518618925474584e-05
) O 0 4.540081022241793e-08
and O 0 2.3698491702361935e-07
Bannayan B-Disease 0 0.0004128494474571198
- I-Disease 0 0.03523559868335724
Zonana I-Disease 0 0.23928815126419067
( I-Disease 0 1.0607470102286243e-07
BZS I-Disease 0 1.9221301045035943e-05
) I-Disease 0 1.1671263067114523e-08
or I-Disease 0 2.8969527221534008e-08
Ruvalcaba I-Disease 0 0.0002890877949539572
- I-Disease 0 0.02185087464749813
Riley I-Disease 0 0.015210174955427647
- I-Disease 1 0.9914873838424683
Smith I-Disease 1 0.9959598183631897
syndrome I-Disease 1 0.9978126287460327
( O 0 1.0971479014187935e-06
MIM O 0 0.028115542605519295
153480 O 0 0.00042192687396891415
) O 0 7.203403242783679e-07
. O 0 1.0455747769810841e-06

Constitutive O 0 2.9980932595208287e-05
DNA O 0 5.0205300794914365e-05
from O 0 3.408747772937204e-07
37 O 0 1.167310870187066e-06
CD B-Disease 0 7.931280379125383e-06
families O 0 1.1118055454062414e-06
and O 0 4.3096602553305274e-07
seven O 0 2.4996652427944355e-06
BZS B-Disease 0 0.0024817995727062225
families O 0 6.591354804186267e-07
was O 0 1.5018825934021152e-06
screened O 0 1.850234809808171e-07
for O 0 1.168969134823783e-07
germline O 0 0.00022629926388617605
PTEN O 0 0.0010191935580223799
mutations O 0 2.4141379526554374e-06
. O 0 5.4355555221263785e-06

PTEN O 0 0.012710105627775192
mutations O 0 3.7188550777500495e-05
were O 0 1.165946855508082e-06
identified O 0 1.1016016969733755e-06
in O 0 5.749038933799966e-08
30 O 0 3.000375414785594e-08
of O 0 2.193066883648953e-08
37 O 0 5.6123144531738944e-06
( O 0 9.090216224194592e-08
81 O 0 8.466695362585597e-07
% O 0 9.047971261111343e-09
) O 0 2.8570433130425954e-08
CD B-Disease 0 3.083422143390635e-06
families O 0 5.390008368522103e-07
, O 0 7.632337428731262e-08
including O 0 1.2017656203511251e-08
missense O 0 3.695766395139799e-07
and O 0 1.6909550026866782e-07
nonsense O 0 3.2910643312789034e-06
point O 0 4.378546520911186e-07
mutations O 0 4.5766757494902777e-08
, O 0 4.0174050752739277e-08
deletions O 0 5.384295604926592e-07
, O 0 2.1170968977912707e-07
insertions O 0 4.12446115660714e-06
, O 0 2.7247287448517454e-07
a O 0 9.066631889709242e-08
deletion O 0 4.3388431549828965e-06
/ O 0 1.7089157609007088e-06
insertion O 0 2.2138287647521793e-07
and O 0 7.276106828157936e-08
splice O 0 1.2649771633732598e-05
site O 0 3.964716597693041e-06
mutations O 0 1.4809830872763996e-06
. O 0 3.856318926409585e-06

These O 0 6.44477324840409e-07
mutations O 0 1.1621679050222156e-06
were O 0 6.143525865809352e-08
scattered O 0 3.0128086336844717e-07
over O 0 6.438727950808243e-08
the O 0 8.852749644461255e-09
entire O 0 7.057155215761668e-08
length O 0 7.317077574953146e-07
of O 0 7.468912599506439e-08
PTEN O 0 0.0020610333885997534
, O 0 7.887239661386047e-08
with O 0 2.4927228281512726e-08
the O 0 2.787630570821875e-08
exception O 0 4.749683313320929e-09
of O 0 3.452202135267868e-10
the O 0 1.0105222436607164e-08
first O 0 4.867369085559403e-08
, O 0 1.3550997834954615e-07
fourth O 0 2.0218626559653785e-06
and O 0 4.3942540628449933e-07
last O 0 5.189702278585173e-06
exons O 0 1.9668819732032716e-05
. O 0 7.210618605313357e-06

A O 0 2.366640501350048e-06
hot O 0 6.050926003808854e-06
spot O 0 1.8661212379811332e-06
for O 0 3.536311155016847e-08
PTEN O 0 4.3238556827418506e-05
mutation O 0 2.8893099468518813e-08
in O 0 2.391364439802146e-08
CD B-Disease 0 6.204836608958431e-06
was O 0 2.71539011009736e-06
identified O 0 1.5118210683340294e-07
in O 0 1.935533333607964e-08
exon O 0 2.744973244261928e-06
5 O 0 1.1774871921943486e-07
that O 0 8.28995716517511e-09
contains O 0 4.9920179101548e-10
the O 0 7.835386561794166e-09
PTPase O 0 3.171762728015892e-05
core O 0 9.962589047063375e-07
motif O 0 3.676754261050519e-07
, O 0 1.0708661513092466e-08
with O 0 9.172558712577938e-09
13 O 0 5.59756507811926e-08
of O 0 4.536659492515582e-09
30 O 0 3.771060050894448e-07
( O 0 1.2624290057772214e-08
43 O 0 6.510725256703154e-07
% O 0 1.5115148244149168e-08
) O 0 2.0817866541733565e-08
CD B-Disease 0 1.4275070725489059e-06
mutations O 0 4.720388346868276e-08
identified O 0 1.218374450218107e-07
in O 0 4.090223271191462e-08
this O 0 4.2441481440391726e-08
exon O 0 7.949268911033869e-05
. O 0 5.5337936828436796e-06

Seven O 0 1.1332386975482223e-06
of O 0 9.856783833583904e-08
30 O 0 1.0017847671406344e-06
( O 0 6.268496122174838e-08
23 O 0 3.911414694357518e-07
% O 0 1.4435883599617227e-08
) O 0 1.5673291997586603e-08
were O 0 2.1795796278922808e-09
within O 0 1.037065155973238e-10
the O 0 2.375823759948048e-09
core O 0 2.072217512250063e-06
motif O 0 1.7138937664640252e-06
, O 0 9.564297442921088e-08
the O 0 2.4731354741902578e-08
majority O 0 1.8873645046824095e-07
( O 0 3.5248615137817296e-09
five O 0 4.926282493045164e-09
of O 0 2.8190634271396675e-09
seven O 0 2.2188592652128136e-07
) O 0 2.6612241299517336e-08
of O 0 5.076700837491899e-09
which O 0 1.0981678855159771e-07
were O 0 6.379805483902601e-08
missense O 0 1.1223606861676672e-06
mutations O 0 2.847376947556768e-07
, O 0 1.0026544714492047e-06
possibly O 0 6.623225772273145e-07
pointing O 0 4.06271783504053e-06
to O 0 5.743763686893999e-09
the O 0 4.54069359889786e-09
functional O 0 2.552663502797259e-08
significance O 0 2.191757886293999e-08
of O 0 5.756145782243038e-09
this O 0 3.653705249462291e-08
region O 0 1.6096150829980616e-06
. O 0 4.47323827756918e-06

Germline O 0 0.013271558098495007
PTEN O 0 0.03152483329176903
mutations O 0 2.246774783998262e-05
were O 0 7.841038609512907e-07
identified O 0 9.06909349396301e-07
in O 0 5.294232607866434e-08
four O 0 6.023825704914998e-08
of O 0 3.853168450973499e-08
seven O 0 2.1275741346471477e-06
( O 0 1.3387428055011696e-07
57 O 0 8.663892003824003e-06
% O 0 2.1722230769682938e-07
) O 0 4.240159228174889e-07
BZS B-Disease 0 9.25218264455907e-05
families O 0 5.393906690187578e-07
studied O 0 5.137447942615836e-07
. O 0 3.6551139146467904e-06

Interestingly O 0 0.00036931788781657815
, O 0 6.78337119097705e-06
none O 0 2.270271721727113e-07
of O 0 8.472945012272248e-09
these O 0 2.463446691081117e-08
mutations O 0 2.3127648773879628e-07
was O 0 1.4309282505564624e-06
observed O 0 9.379807863751921e-08
in O 0 1.5386010687734597e-08
the O 0 1.586579543300104e-07
PTPase O 0 0.0003555577131919563
core O 0 9.65703384281369e-06
motif O 0 9.310901987191755e-06
. O 0 2.8000631573377177e-06

It O 0 7.585837920487393e-06
is O 0 4.042008470150904e-07
also O 0 8.9021277460688e-08
worthy O 0 9.017049507065167e-08
of O 0 1.1494350360408134e-08
note O 0 3.9262516793314717e-07
that O 0 9.232939746084412e-09
a O 0 4.8473549618677225e-09
single O 0 1.5299272959623522e-08
nonsense O 0 2.627007006594795e-06
point O 0 1.97282830072254e-07
mutation O 0 1.359619528074063e-08
, O 0 1.888421365947579e-07
R233X O 0 1.7245791241293773e-05
, O 0 3.755312434350344e-07
was O 0 1.5469086065422744e-06
observed O 0 3.7342484660030095e-08
in O 0 5.671251912531261e-09
the O 0 1.1408816114055753e-08
germline O 0 2.7416504053690005e-06
DNA O 0 3.199595312253223e-06
from O 0 1.179510888960067e-08
two O 0 4.1307249176725236e-08
unrelated O 0 2.6867388442042284e-05
CD B-Disease 0 5.025166683481075e-05
families O 0 1.7757831756171072e-06
and O 0 3.1687565638094384e-07
one O 0 4.5771341206091165e-07
BZS B-Disease 0 0.002220227150246501
family O 0 0.00018845355953089893
. O 0 8.836170309223235e-06

Genotype O 0 0.0021870939526706934
- O 0 0.04488030821084976
phenotype O 0 0.0012447158806025982
studies O 0 3.822796657004801e-07
were O 0 1.4754526489468844e-07
not O 0 6.704812260949211e-09
performed O 0 1.4063254560880978e-08
on O 0 4.200009939836491e-08
this O 0 3.378878066229163e-09
small O 0 4.9785583655648225e-08
group O 0 1.5454841104656225e-06
of O 0 1.9043453391986986e-07
BZS B-Disease 0 0.002387777203693986
families O 0 2.679315684872563e-06
. O 0 6.146676696516806e-06

However O 0 1.5039312529552262e-05
, O 0 2.438438059471082e-06
genotype O 0 1.796668402676005e-05
- O 0 0.0003845726605504751
phenotype O 0 3.7744350720458897e-06
analysis O 0 4.0059962458371956e-08
inthe O 0 4.981463916919893e-06
group O 0 3.647790549621277e-07
of O 0 1.3274883414737815e-08
CD B-Disease 0 5.1341055950615555e-05
families O 0 2.0165537080174545e-06
revealed O 0 9.670766303315759e-06
two O 0 1.7081543290942136e-08
possible O 0 3.301099127384077e-08
associations O 0 1.56763035885632e-09
worthy O 0 5.9099267701867575e-09
of O 0 1.5044614443127102e-09
follow O 0 1.8466311146880798e-08
- O 0 4.4762055040337145e-05
up O 0 5.046611022407888e-07
in O 0 3.97678547869873e-08
independent O 0 3.620476363153102e-08
analyses O 0 5.625046014756663e-06
. O 0 2.049220256594708e-06

The O 0 9.243547651749395e-07
first O 0 1.1839556464110501e-06
was O 0 2.4679065973032266e-05
an O 0 1.0526222240514471e-06
association O 0 4.101686954527395e-06
noted O 0 4.5777147761327797e-07
in O 0 1.0480945888957649e-08
the O 0 1.8883758556853536e-08
group O 0 8.086091725090228e-07
of O 0 1.3795877329414452e-08
CD B-Disease 0 6.362130807247013e-05
families O 0 3.592507346183993e-05
with O 0 0.00232302350923419
breast B-Disease 1 0.9909255504608154
disease I-Disease 0 0.04160582646727562
. O 0 4.593885023496114e-05

A O 0 5.66193375561852e-06
correlation O 0 2.110398781951517e-05
was O 0 2.0907153157168068e-05
observed O 0 5.603087060990219e-07
between O 0 9.44286853155063e-08
the O 0 6.407499597571586e-08
presence O 0 3.874182823437877e-07
/ O 0 6.28409861747059e-06
absence O 0 4.781746199000736e-08
of O 0 2.3542390259478907e-09
a O 0 2.8565264642566035e-07
PTEN O 0 0.002775078173726797
mutation O 0 6.818042663780943e-08
and O 0 2.0735882344524725e-07
the O 0 1.4438228390645236e-07
type O 0 1.5588998394377995e-06
of O 0 1.553251763652952e-06
breast O 0 0.08521990478038788
involvement O 0 0.0006710065645165741
( O 0 1.082993208001426e-06
unaffected O 0 0.00028465877403505147
versus O 0 0.028118163347244263
benign O 1 0.5628669857978821
versus O 1 0.9482954144477844
malignant O 1 0.9989032745361328
) O 0 1.6733274605940096e-05
. O 0 9.220391802955419e-06

Specifically O 0 5.740563665312948e-06
and O 0 6.536606633744668e-07
more O 0 1.3075633020775967e-08
directly O 0 1.2072776200966473e-07
, O 0 2.5055936703211046e-07
an O 0 6.73345823543059e-08
association O 0 2.0777124518644996e-06
was O 0 6.648142516496591e-06
also O 0 2.0799616606836935e-07
observed O 0 1.1063925597909474e-07
between O 0 1.9799522021912708e-08
the O 0 6.52823084479337e-09
presence O 0 1.3041510094069508e-08
of O 0 6.4459264592642285e-09
a O 0 9.363628237224475e-07
PTEN O 0 0.04085616022348404
mutation O 0 9.782549568626564e-06
and O 0 0.0554494708776474
malignant B-Disease 1 0.9999396800994873
breast I-Disease 1 0.9987118244171143
disease I-Disease 0 0.16664351522922516
. O 0 6.450455111917108e-05

Secondly O 0 0.0026035355404019356
, O 0 1.7892101823235862e-05
there O 0 1.0798132166200958e-07
appeared O 0 1.3153121471987106e-06
to O 0 3.0550975083087906e-08
be O 0 2.3648253133501385e-08
an O 0 1.1555838597132606e-07
interdependent O 0 0.15733957290649414
association O 0 2.019733074121177e-06
between O 0 2.712799584969616e-07
mutations O 0 2.367307985196021e-07
upstream O 0 3.758831041977828e-07
and O 0 2.426258483012589e-08
within O 0 6.887243553244105e-10
the O 0 1.2449565822691966e-08
PTPase O 0 3.2361571356887e-05
core O 0 1.6152894204424229e-06
motif O 0 7.70017436479975e-07
, O 0 1.0351531187779983e-08
the O 0 1.2351238920516039e-09
core O 0 6.868961577310984e-07
motif O 0 6.925787374711945e-07
containing O 0 3.6241516454538214e-08
the O 0 1.401804983203192e-08
majority O 0 5.1145985224820834e-08
of O 0 9.756188745768668e-09
missense O 0 1.7600980299903313e-06
mutations O 0 2.801858727252693e-07
, O 0 1.060465848468084e-07
and O 0 5.2811920170370286e-08
the O 0 1.168623153802173e-08
involvement O 0 9.199120540870354e-07
of O 0 1.3132267717708146e-08
all O 0 1.8746455054952094e-08
major O 0 1.117236820391554e-06
organ O 0 0.001103783491998911
systems O 0 0.002391102956607938
( O 0 1.5812140929938323e-07
central O 0 4.746642900954612e-07
nervous O 0 0.00015839241677895188
system O 0 0.00010334327089367434
, O 0 0.005822967272251844
thyroid O 1 0.9800776243209839
, O 0 0.0028074979782104492
breast O 1 0.7580472230911255
, O 0 0.010506009683012962
skin O 1 0.9080729484558105
and O 0 0.3406835198402405
gastrointestinal O 1 0.9930301308631897
tract O 0 0.4340996742248535
) O 0 1.3524905625672545e-05
. O 0 1.714335667202249e-05

However O 0 1.5009109120001085e-05
, O 0 3.468548186447151e-07
these O 0 2.0834778347023075e-09
observations O 0 4.132080277940986e-08
would O 0 1.4107691015396995e-08
need O 0 1.9859498490149008e-09
to O 0 4.32960467477983e-09
be O 0 8.662500050604649e-09
confirmed O 0 7.476709384945934e-08
by O 0 1.6871745112112535e-09
studying O 0 3.715178387153628e-09
a O 0 5.507312383912222e-09
larger O 0 2.958217315551792e-08
number O 0 5.572887151750194e-10
of O 0 1.0002648487272836e-08
CD B-Disease 0 5.078743561170995e-05
families O 0 8.745752893446479e-06
. O 0 5.542751296161441e-06

Molecular O 1 0.8648291826248169
defects O 1 0.9954181909561157
leading O 0 1.8357086446485482e-05
to O 0 5.663871860406289e-08
human O 0 2.1522458837353042e-07
complement B-Disease 0 8.331446224474348e-06
component I-Disease 0 0.09828563034534454
C6 I-Disease 1 0.9999822378158569
deficiency I-Disease 1 0.9999468326568604
in O 0 2.473716449458152e-07
an O 0 2.2615608941123355e-07
African O 0 6.380477316270117e-06
- O 0 0.0026230483781546354
American O 0 1.9110684661427513e-05
family O 0 0.0002704876533243805
. O 0 1.057318331731949e-05

Complement B-Disease 0 0.0001967607531696558
component I-Disease 0 0.4389282464981079
C6 I-Disease 1 0.9998749494552612
deficiency I-Disease 1 0.9999295473098755
( O 0 1.7454820408602245e-05
C6D B-Disease 1 0.8350933790206909
) O 0 2.024726927629672e-05
was O 0 0.0014825444668531418
diagnosed O 0 0.0027767240535467863
in O 0 5.020784143994206e-08
a O 0 5.035649408569043e-08
16 O 0 1.6491318319822312e-06
- O 0 0.0024291255977004766
year O 0 1.399087750542094e-06
- O 0 0.0003081870381720364
old O 0 1.5393563444376923e-05
African O 0 8.760367791182944e-07
- O 0 0.00015800836263224483
American O 0 1.3274449202071992e-06
male O 0 2.6642567263479577e-06
with O 0 0.00036218552850186825
meningococcal B-Disease 1 0.9994029998779297
meningitis I-Disease 1 0.9943086504936218
. O 0 6.923476757947356e-05

The O 0 3.108839155174792e-05
patients O 0 8.718815661268309e-05
father O 0 6.640607898589224e-05
and O 0 1.4025653172211605e-06
two O 0 1.541493588774756e-06
brothers O 0 0.015737751498818398
also O 0 1.490523118263809e-06
had O 0 1.9508761397446506e-05
C6D B-Disease 0 0.047326963394880295
, O 0 6.943636776668427e-07
but O 0 1.3723682457111863e-07
gave O 0 1.4065700781884516e-07
no O 0 4.128519393020724e-08
history O 0 9.117110266743111e-07
of O 0 5.691709247912513e-06
meningitis B-Disease 1 0.9949856996536255
or O 0 2.566103376011597e-06
other O 0 2.4404666874033865e-06
neisserial B-Disease 1 0.7832585573196411
infection I-Disease 0 0.0007140371599234641
. O 0 1.0458346878294833e-05

By O 0 2.3797667836333858e-07
using O 0 1.5033656097784842e-07
exon O 0 6.767927061446244e-06
- O 0 2.179696639359463e-05
specific O 0 1.172879393607218e-08
polymerase O 0 3.6529712815536186e-05
chain O 0 6.409311754396185e-05
reaction O 0 6.601307234177511e-08
( O 0 4.885336135629359e-09
PCR O 0 1.7015911453199806e-06
) O 0 2.3930663672899755e-08
/ O 0 5.598269936513134e-08
single O 0 1.7640542360197742e-09
- O 0 2.877096449083183e-06
strand O 0 5.849572062288644e-07
conformation O 0 1.2802107107745542e-07
polymorphism O 0 1.0312595577488537e-07
as O 0 5.936665603556435e-10
a O 0 1.2364272938825138e-09
screening O 0 1.8313336402897562e-09
step O 0 2.026274481536916e-09
and O 0 3.656922542560892e-10
nucleotide O 0 2.5510790702121255e-10
sequencing O 0 2.7143423064757144e-09
of O 0 4.2625430962672795e-10
target O 0 8.788469330056614e-08
exons O 0 2.4549621002734057e-07
, O 0 7.387743039544148e-08
we O 0 3.844350171533506e-09
determined O 0 2.1035800656932224e-08
that O 0 6.259079921022703e-09
the O 0 3.0079220891821024e-08
proband O 0 0.0008400416118092835
was O 0 6.165331001284358e-07
a O 0 1.934001936376717e-08
compound O 0 8.966393920672999e-07
heterozygote O 0 6.829743597336346e-07
for O 0 2.7840478811214098e-09
two O 0 2.0663847521973366e-07
C6 O 0 0.013647562824189663
gene O 0 1.0922350384134916e-06
mutations O 0 1.509236767560651e-06
. O 0 4.2789474719029386e-06

The O 0 2.553107094627194e-07
first O 0 1.4225722111405048e-07
, O 0 2.2604785954172257e-07
1195delC O 0 1.0521452168177348e-05
located O 0 3.270166359925497e-08
in O 0 1.8569657811440266e-08
exon O 0 8.664520464662928e-06
7 O 0 8.905904905986972e-06
, O 0 4.808103994946578e-07
is O 0 1.7391323936521985e-08
a O 0 2.1594988908191226e-08
novel O 0 2.3145123861922912e-07
mutation O 0 2.7921750245241128e-08
, O 0 7.370951493612665e-08
while O 0 1.9246696680852438e-08
the O 0 2.796303855134852e-09
second O 0 4.1105341352931646e-08
, O 0 6.743739788817038e-08
1936delG O 0 2.653161345733679e-06
in O 0 1.5058173374882244e-08
exon O 0 5.426512871054001e-06
12 O 0 1.7930524336406961e-06
, O 0 1.9049717820962542e-06
has O 0 5.531443889594811e-07
been O 0 1.612579154652849e-07
described O 0 3.488729589662398e-06
before O 0 4.867165444011334e-07
to O 0 3.667057910661242e-07
cause O 0 3.4962133668159368e-06
C6D B-Disease 0 0.0014970609918236732
in O 0 4.193390168438782e-08
an O 0 5.0839222609511125e-08
unrelated O 0 0.00017334766744170338
African O 0 3.7404186059575295e-06
- O 0 0.00042391015449538827
American O 0 1.4245696320358547e-06
individual O 0 1.7354170722683193e-07
. O 0 4.958992121828487e-06

Both O 0 4.361215815151809e-06
mutations O 0 2.2993830498307943e-05
result O 0 4.4119760786998086e-06
in O 0 1.190136572404299e-06
premature O 0 6.700037192786112e-05
termination O 0 1.021607317852613e-06
codons O 0 1.1097085916844662e-07
and O 0 6.766041451555793e-07
C6 O 0 0.012405387125909328
null O 0 8.603714377386495e-05
alleles O 0 1.076522380571987e-06
. O 0 4.898349743598374e-06

Allele O 0 2.538977423682809e-05
- O 0 2.1585887225228362e-05
specific O 0 3.6024975003101645e-08
PCR O 0 4.352757605374791e-05
indicated O 0 3.6797748634853633e-06
that O 0 1.2943450755642516e-08
the O 0 1.9074530399620926e-08
probands O 0 0.00024608359672129154
two O 0 1.059345436260628e-06
brothers O 0 0.11457689851522446
also O 0 1.2469818102545105e-05
inherited O 0 0.0002156457194359973
the O 0 2.5706047068752014e-08
1195delC O 0 0.00012246410187799484
mutation O 0 4.356628480195468e-08
from O 0 3.0666436057202873e-09
their O 0 2.3003096316642768e-08
heterozygous O 0 4.796118560079776e-07
mother O 0 1.0793578439916018e-05
and O 0 1.7935280993697233e-07
the O 0 1.27431746932416e-07
1936delG O 0 7.514014578191563e-05
mutation O 0 1.3518335784112878e-08
from O 0 1.929185700078051e-09
their O 0 7.717265049222988e-09
homozygous O 0 5.545641670323675e-07
father O 0 1.1390210602257866e-05
. O 0 4.0432269088341855e-07
. O 0 5.821739705424989e-06

PAX6 O 0 0.019599057734012604
mutations O 0 0.0004936277982778847
reviewed O 0 0.00027339954976923764
. O 0 9.562942432239652e-05

Mutations O 0 5.163979949429631e-05
in O 0 3.6431110856938176e-06
PAX6 O 0 0.0007573632756248116
are O 0 2.998939763187991e-08
responsible O 0 2.2088222806360136e-07
for O 0 6.22427194230113e-08
human O 0 8.444957529718522e-06
aniridia B-Disease 1 0.9993042945861816
and O 0 3.896866928698728e-06
have O 0 1.1191846027713837e-07
also O 0 2.615120990867581e-07
been O 0 3.205625773716747e-07
found O 0 3.6298429222370032e-06
in O 0 1.2062158702974557e-06
patients O 0 1.6083922673715279e-06
with O 0 0.0005609187646768987
Peters B-Disease 1 0.9999769926071167
anomaly I-Disease 1 0.9999805688858032
, O 0 0.09641863405704498
with O 1 0.9465389847755432
congenital B-Disease 1 0.9999954700469971
cataracts I-Disease 1 0.9999347925186157
, O 0 0.0004725994076579809
with O 0 0.00025330172502435744
autosomal B-Disease 0 0.1945892572402954
dominant I-Disease 0 0.015640022233128548
keratitis I-Disease 1 0.9353951811790466
, O 0 1.2197188880236354e-05
and O 0 5.294715265335981e-06
with O 0 7.146158895920962e-05
isolated B-Disease 1 0.7098467350006104
foveal I-Disease 1 0.9998050332069397
hypoplasia I-Disease 1 0.9996102452278137
. O 0 0.000288501352770254

No O 0 1.1497526202219888e-06
locus O 0 5.614498604700202e-06
other O 0 2.919645858412423e-08
than O 0 9.379020582400699e-08
chromosome O 0 0.00038972642505541444
11p13 O 0 0.00023701389727648348
has O 0 5.454439246932452e-07
been O 0 1.878366617802385e-07
implicated O 0 4.121428355574608e-05
in O 0 4.981787242286373e-06
aniridia B-Disease 1 0.99977046251297
, O 0 6.247808869375149e-06
and O 0 2.3302113731915597e-06
PAX6 O 0 0.00028808414936065674
is O 0 3.9700100984418896e-08
clearly O 0 3.430159551953693e-07
the O 0 4.527050023739321e-08
major O 0 2.3283159578113555e-07
, O 0 7.881492933847767e-07
if O 0 7.402962864944129e-08
not O 0 5.688054027785938e-09
only O 0 1.2106824431867835e-09
, O 0 7.366256937757498e-08
gene O 0 1.384625960554331e-07
responsible O 0 1.365500452266133e-06
. O 0 3.7795823573105736e-06

Twenty O 0 3.08247831526387e-06
- O 0 0.00023218021669890732
eight O 0 6.130104793555802e-06
percent O 0 3.04393470287323e-05
of O 0 2.8316966549368772e-08
identified O 0 1.1016816188202938e-06
PAX6 O 0 3.122313501080498e-05
mutations O 0 8.238164639351453e-08
are O 0 1.0038026410086331e-08
C O 0 0.00010518966155359522
- O 0 0.005544440820813179
T O 0 0.011933774687349796
changes O 0 7.457080286599194e-09
at O 0 6.372283678501844e-07
CpG O 0 6.680087244603783e-05
dinucleotides O 0 0.0001019636620185338
, O 0 1.5091870864125667e-08
20 O 0 6.061164903314875e-09
% O 0 4.917221074762779e-10
are O 0 5.06507023823044e-11
splicing O 0 1.350676797073902e-07
errors O 0 5.980466085020453e-06
, O 0 1.2100670687686943e-07
and O 0 1.884349742908853e-08
more O 0 7.072065710822528e-10
than O 0 4.343616577529019e-09
30 O 0 7.601392582046174e-08
% O 0 7.3822321589034345e-09
are O 0 2.5956117255532263e-09
deletion O 0 4.979394816473359e-07
or O 0 3.496618816711816e-08
insertion O 0 4.6001304099263507e-07
events O 0 7.719107770753908e-07
. O 0 4.672340764955152e-06

There O 0 9.301575687459263e-07
is O 0 7.080872421738604e-08
a O 0 3.989731567344279e-08
noticeably O 0 1.3279438462632243e-05
elevated O 0 2.432807605146081e-06
level O 0 2.580685354303114e-08
of O 0 2.5595070507478113e-09
mutation O 0 1.0728880894816939e-08
in O 0 7.697507520276758e-09
the O 0 3.8629845988680245e-08
paired O 0 6.888668394822162e-06
domain O 0 5.67558288366854e-07
compared O 0 2.6972818432113854e-06
with O 0 6.975003685738557e-08
the O 0 5.3822020618099486e-08
rest O 0 5.522525725609739e-08
of O 0 3.322866426458404e-09
the O 0 1.6038417527397542e-07
gene O 0 2.9113268738001352e-06
. O 0 6.228836355148815e-06

Increased O 0 1.1555409400898498e-05
mutation O 0 4.19524894823553e-06
in O 0 3.1879920925348415e-07
the O 0 2.534403620302328e-07
homeodomain O 0 0.0004271333455108106
is O 0 1.401131868306038e-07
accounted O 0 6.169441917336371e-07
for O 0 1.1556555712388672e-09
by O 0 9.612263873748361e-09
the O 0 6.003558183920177e-08
hypermutable O 0 0.0009263163083232939
CpG O 0 0.00020081413094885647
dinucleotide O 0 2.6738001906778663e-05
in O 0 6.421701836956117e-09
codon O 0 2.344019911504347e-08
240 O 0 4.426679254265764e-07
. O 0 7.307391456379264e-07

Very O 0 1.552792696202232e-06
nearly O 0 1.1263259693805594e-06
all O 0 4.960492461236754e-08
mutations O 0 1.3431757679427392e-06
appear O 0 1.4506869092656416e-06
to O 0 1.22971562177554e-06
cause O 0 2.77463022939628e-05
loss O 0 0.0002391303569311276
of O 0 1.0726589394494113e-08
function O 0 4.153444255194927e-09
of O 0 4.450616541973318e-10
the O 0 1.1220461892946787e-08
mutant O 0 4.805435764865251e-06
allele O 0 1.0757065638244967e-06
, O 0 7.134910617878631e-08
and O 0 6.275193698002113e-09
more O 0 2.3684476602170434e-10
than O 0 1.7728579715381443e-09
80 O 0 2.5153802596378227e-08
% O 0 1.9523282990263624e-09
of O 0 4.056873947888562e-09
exonic O 0 0.00017266502254642546
substitutions O 0 1.5820889132101001e-07
result O 0 2.0448187854071875e-07
in O 0 3.852396801562463e-08
nonsense O 0 4.5147808123147115e-06
codons O 0 8.722420261619845e-07
. O 0 1.9368519588169875e-06

In O 0 1.57888746343815e-06
a O 0 1.928731023781438e-07
gene O 0 3.967459747400426e-07
with O 0 1.326914258470424e-07
such O 0 2.0456528915246963e-08
extraordinarily O 0 7.369710601778934e-06
high O 0 4.2165288505202625e-07
sequence O 0 7.751252972809652e-09
conservation O 0 5.2953410545342194e-09
throughout O 0 3.90806165206925e-10
evolution O 0 1.688424333678995e-08
, O 0 8.69315783802449e-08
there O 0 7.192555440127535e-09
are O 0 1.0932062366464379e-08
presumed O 0 9.819317347137257e-05
undiscovered O 0 7.95393279986456e-05
missense O 0 1.5763193914608564e-06
mutations O 0 1.9838616083234228e-07
, O 0 3.7875018676913896e-08
these O 0 8.539720597333655e-10
are O 0 6.617487668947319e-10
hypothesized O 0 6.869341717674615e-08
to O 0 9.295243685869536e-09
exist O 0 7.2080323931800194e-09
in O 0 1.660796300484435e-08
as O 0 3.969919148971712e-08
- O 0 0.0005528081092052162
yet O 0 1.1212705430807546e-06
unidentified O 0 0.00027597733424045146
phenotypes O 0 1.0212400411546696e-05
. O 0 3.8691425174874894e-07
. O 0 1.4820767546552815e-06

Genetic O 0 0.0001169601600850001
heterogeneity O 0 0.0001953155006049201
and O 0 9.770223186933435e-06
penetrance O 0 0.00016294569650199264
analysis O 0 2.455177536830888e-07
of O 0 1.4782139068358902e-08
the O 0 2.596406147858943e-07
BRCA1 O 0 6.93087640684098e-05
and O 0 5.42763064004248e-06
BRCA2 O 0 4.672173236031085e-05
genes O 0 2.4313185349456035e-06
in O 0 0.0008430933230556548
breast B-Disease 1 0.9990527033805847
cancer I-Disease 1 0.7626171112060547
families O 0 7.801634637871757e-05
. O 0 3.640944487415254e-05

The O 0 0.0246222373098135
Breast B-Disease 1 0.9985364675521851
Cancer I-Disease 1 0.9973942041397095
Linkage O 0 0.014836825430393219
Consortium O 0 0.003403118345886469
. O 0 6.704287807224318e-05

The O 0 3.34901955056921e-07
contribution O 0 2.2036337554709462e-07
of O 0 1.0870977007471083e-07
BRCA1 O 0 0.00020565022714436054
and O 0 3.481947715044953e-05
BRCA2 O 0 0.04224051907658577
to O 0 0.050127673894166946
inherited B-Disease 1 0.9999921321868896
breast I-Disease 1 0.9999721050262451
cancer I-Disease 1 0.9999762773513794
was O 0 0.01162194088101387
assessed O 0 1.5661864381399937e-05
by O 0 1.4369176426498598e-07
linkage O 0 2.0185614630463533e-05
and O 0 2.1574943787072698e-07
mutation O 0 1.750380462794965e-08
analysis O 0 4.542619436165296e-08
in O 0 4.397620401164204e-08
237 O 0 4.8102225264301524e-05
families O 0 4.663419531425461e-06
, O 0 1.0409448236714525e-07
each O 0 8.865452261197504e-10
with O 0 4.8130306851135174e-08
at O 0 9.216243483933795e-07
least O 0 2.532884124661905e-09
four O 0 1.2326232479153987e-07
cases O 0 2.6184327452938305e-06
of O 0 0.00014461106911767274
breast B-Disease 1 0.9983071088790894
cancer I-Disease 0 0.43221795558929443
, O 0 1.484890731262567e-06
collected O 0 1.606724424618733e-07
by O 0 2.269071273985901e-06
the O 0 0.0011968610342592
Breast B-Disease 1 0.9999079704284668
Cancer I-Disease 1 0.9960875511169434
Linkage O 0 0.0015828030882403255
Consortium O 0 0.0003256918862462044
. O 0 2.6458275897311978e-05

Families O 0 5.7384531828574836e-05
were O 0 5.475056354953267e-07
included O 0 8.945666962745236e-08
without O 0 2.724665826292494e-08
regard O 0 3.681067450855835e-09
to O 0 5.96491966931012e-09
the O 0 5.174285888642771e-08
occurrence O 0 1.711526920189499e-06
of O 0 3.6142641874903347e-06
ovarian B-Disease 1 0.9854745864868164
or I-Disease 0 6.507014859380433e-06
other I-Disease 0 4.0488862396159675e-06
cancers I-Disease 0 0.04161322861909866
. O 0 2.8483260393841192e-05

Overall O 0 0.006535551510751247
, O 0 0.047070130705833435
disease O 0 0.10439004749059677
was O 0 7.507582631660625e-05
linked O 0 0.0001369215315207839
to O 0 2.6280216047780414e-07
BRCA1 O 0 2.2792017261963338e-05
in O 0 5.697938476600939e-08
an O 0 4.9191115181201894e-08
estimated O 0 1.853542357821425e-06
52 O 0 2.1606829250231385e-06
% O 0 8.692357944539708e-09
of O 0 2.2558348078405288e-08
families O 0 1.6196147498703795e-06
, O 0 7.91385161846847e-08
to O 0 9.151273516749825e-09
BRCA2 O 0 1.028607016451133e-06
in O 0 1.599300070154186e-08
32 O 0 4.195294422970619e-07
% O 0 3.239713164404634e-09
of O 0 8.211101132360454e-09
families O 0 1.5835772728678421e-06
, O 0 7.474213248315209e-07
and O 0 1.199325083689473e-07
to O 0 1.1918131370691754e-08
neither O 0 5.795742907821477e-08
gene O 0 4.987242618881282e-09
in O 0 1.8034789661669492e-08
16 O 0 4.292621156309906e-07
% O 0 2.982465474588025e-08
( O 0 6.846748501487809e-09
95 O 0 8.82459971762728e-08
% O 0 7.545874147751874e-09
confidence O 0 1.8651145694548177e-07
interval O 0 1.547686281355709e-07
[ O 0 5.5957716682542014e-08
CI O 0 0.00017056592332664877
] O 0 2.2321283665860392e-07
6 O 0 8.873580981116902e-08
% O 0 1.137672089868147e-08
- O 0 0.00010759387077996507
28 O 0 3.2719842693040846e-06
% O 0 7.27885449691712e-08
) O 0 7.157837700333403e-08
, O 0 1.0136227501789108e-07
suggesting O 0 1.0568186326054274e-06
other O 0 1.0314995790849935e-07
predisposition O 0 2.7334339392837137e-05
genes O 0 1.1229967640247196e-06
. O 0 8.66951268108096e-06

The O 0 7.774629921186715e-06
majority O 0 1.0296012078470085e-05
( O 0 3.4705470852713916e-07
81 O 0 4.064260338054737e-06
% O 0 3.8966106785665033e-08
) O 0 1.411848504773161e-08
of O 0 1.0220966295548806e-08
the O 0 9.464484173804522e-05
breast B-Disease 1 0.9995777010917664
- I-Disease 1 0.9999942779541016
ovarian I-Disease 1 0.9999984502792358
cancer I-Disease 1 0.999880313873291
families O 0 1.126950064644916e-05
were O 0 1.0446368605698808e-06
due O 0 1.2736678627334186e-06
to O 0 3.4643764479369565e-07
BRCA1 O 0 5.9172645705984905e-05
, O 0 5.906503588448686e-07
with O 0 2.0448655391192005e-07
most O 0 3.2607676558882304e-08
others O 0 6.363252964547428e-07
( O 0 4.736079972644802e-08
14 O 0 1.2846885510953143e-06
% O 0 1.5899207994607423e-07
) O 0 2.770874800717138e-07
due O 0 1.2575857510910282e-07
to O 0 1.688772925945159e-07
BRCA2 O 0 6.271994789130986e-05
. O 0 6.170339929667534e-06

Conversely O 0 0.00018630018166732043
, O 0 1.233103603226482e-06
the O 0 1.3558857858697593e-07
majority O 0 9.343452944676756e-08
of O 0 2.6166794953041972e-08
families O 0 7.066623197715671e-07
with O 0 2.618891983274807e-07
male B-Disease 0 4.181771600997308e-06
and I-Disease 0 5.343830707715824e-05
female I-Disease 0 0.004867671523243189
breast I-Disease 1 0.9700834155082703
cancer I-Disease 0 0.02947692573070526
were O 0 1.440825940335344e-06
due O 0 1.692710270617681e-06
to O 0 7.622457474099065e-07
BRCA2 O 0 0.00018120960157830268
( O 0 3.193000281953573e-07
76 O 0 1.824415085138753e-05
% O 0 2.1616999390516867e-07
) O 0 1.0052702918983414e-06
. O 0 1.6919533436521306e-06

The O 0 2.600148036435712e-06
largest O 0 2.967582804558333e-05
proportion O 0 2.657445975273731e-06
( O 0 1.0266612093801086e-07
67 O 0 3.7427166716952343e-06
% O 0 3.767968337342609e-08
) O 0 5.050511120430201e-08
of O 0 2.0988027316093394e-08
families O 0 2.57389979196887e-06
due O 0 9.544616119683269e-08
to O 0 2.1786776827070753e-09
other O 0 3.815480820179573e-09
genes O 0 1.548669530393454e-07
was O 0 3.550444307620637e-05
found O 0 3.571056595319533e-06
in O 0 1.9312341237309738e-07
families O 0 2.3021539163892157e-07
with O 0 3.9361712111940506e-08
four O 0 2.76755798722661e-07
or O 0 3.2126652627084695e-07
five O 0 2.514627794880653e-07
cases O 0 2.072840743494453e-07
of O 0 7.518623874602781e-07
female O 0 0.028698105365037918
breast B-Disease 1 0.9956133365631104
cancer I-Disease 0 0.05364561453461647
only O 0 2.869164745789021e-07
. O 0 9.533746379020158e-06

These O 0 6.48552145321446e-07
estimates O 0 1.7888451111502945e-05
were O 0 2.8722993761221005e-07
not O 0 8.035380005821935e-08
substantially O 0 4.162597633694531e-06
affected O 0 2.4226469719224042e-08
either O 0 2.2413075839722296e-09
by O 0 6.178518141553013e-09
changing O 0 8.160300524195918e-08
the O 0 3.736571230206209e-08
assumed O 0 6.65317031689483e-07
penetrance O 0 6.4565874708932824e-06
model O 0 8.331823551088746e-07
for O 0 5.0506169912978294e-08
BRCA1 O 0 4.886402530246414e-05
or O 0 1.679006089716495e-07
by O 0 6.166970933918492e-08
including O 0 4.621765015144774e-08
or O 0 4.184593649370072e-07
excluding O 0 6.745541668351507e-06
BRCA1 O 0 8.980173333839048e-06
mutation O 0 8.81136372754554e-08
data O 0 2.3815723579900805e-06
. O 0 5.264113497105427e-06

Among O 0 9.895255971059669e-06
those O 0 6.22870584265911e-06
families O 0 0.00017128924082498997
with O 0 0.002308120019733906
disease O 0 0.2813597321510315
due O 0 4.208898189972388e-06
to O 0 3.220450537355646e-07
BRCA1 O 0 2.2044834622647613e-05
that O 0 4.465969993816543e-07
were O 0 3.578064706744044e-07
tested O 0 6.573476412086166e-07
by O 0 7.461420814536268e-09
one O 0 3.2139313432821837e-09
of O 0 1.0007357165164876e-09
the O 0 8.410408369741162e-09
standard O 0 6.530225959977543e-08
screening O 0 1.8998571604811332e-08
methods O 0 2.1713441711312953e-08
, O 0 4.0884838625743214e-08
mutations O 0 2.5881533360916364e-08
were O 0 3.627581790510703e-08
detected O 0 1.4728756525528297e-07
in O 0 1.3922170083446872e-09
the O 0 1.286490580731936e-09
coding O 0 7.51052596115187e-07
sequence O 0 6.431030374898228e-09
or O 0 6.446946532179254e-09
splice O 0 9.832886007643538e-07
sites O 0 5.555763493703125e-08
in O 0 1.513323510948794e-08
an O 0 3.7143301767628145e-08
estimated O 0 3.60056492354488e-06
63 O 0 1.8504938452679198e-06
% O 0 1.801863014350147e-08
( O 0 6.8579497636278575e-09
95 O 0 2.1299362629179086e-07
% O 0 8.111418736689302e-08
CI O 0 0.0016346906777471304
51 O 0 3.5927923818235286e-06
% O 0 6.32692263025092e-08
- O 0 8.1445905379951e-05
77 O 0 4.172052285866812e-06
% O 0 6.871871249813921e-08
) O 0 2.985889580031653e-07
. O 0 1.008615072350949e-06

The O 0 7.32117996449233e-06
estimated O 0 2.9372597055044025e-05
sensitivity O 0 1.9144456473441096e-06
was O 0 1.7226673207915155e-06
identical O 0 5.206251785239147e-07
for O 0 9.284926716368602e-10
direct O 0 6.812161390534754e-10
sequencing O 0 2.359345359081999e-07
and O 0 4.794147301367957e-08
other O 0 1.1490842055650319e-08
techniques O 0 1.8074067611451028e-06
. O 0 4.2574711187626235e-06

The O 0 2.2063600226829294e-06
penetrance O 0 0.0003988661919720471
of O 0 9.544485237711342e-07
BRCA2 O 0 0.0003340479452162981
was O 0 2.1475689209182747e-05
estimated O 0 3.9585023614563397e-07
by O 0 4.060280112128112e-09
maximizing O 0 7.58454916649498e-08
the O 0 1.633713786475255e-08
LOD O 0 2.943091567431111e-05
score O 0 2.0881254059190724e-08
in O 0 8.141271479189527e-08
BRCA2 O 0 1.6266567399725318e-05
- O 0 0.0022432543337345123
mutation O 0 5.639594746753573e-07
families O 0 3.273842992257414e-07
, O 0 8.827360886698443e-08
over O 0 2.9311010507626634e-08
all O 0 2.2743289473936557e-09
possible O 0 6.287380216463134e-08
penetrance O 0 7.049015493976185e-06
functions O 0 5.50526770837223e-08
. O 0 2.4308619686053135e-06

The O 0 8.422839528066106e-06
estimated O 0 0.00016717879043426365
cumulative O 0 7.32190819690004e-05
risk O 0 6.366149318637326e-05
of O 0 1.605003490112722e-05
breast B-Disease 1 0.9658335447311401
cancer I-Disease 0 0.04310588166117668
reached O 0 1.664992669248022e-05
28 O 0 8.191594133677427e-06
% O 0 7.145956004706022e-08
( O 0 8.463577394479671e-09
95 O 0 1.0649860371358955e-07
% O 0 3.143035343100564e-08
CI O 0 0.000664563151076436
9 O 0 2.0532852431642823e-06
% O 0 3.23944924218722e-08
- O 0 0.00015159338363446295
44 O 0 3.2714942790335044e-06
% O 0 1.99047498483651e-08
) O 0 6.750403791500048e-09
by O 0 2.415834865487909e-09
age O 0 5.6802075931727813e-08
50 O 0 1.496728785355117e-08
years O 0 6.903400162627804e-08
and O 0 1.1823674128663697e-07
84 O 0 1.6127619346661959e-06
% O 0 1.5835675881703537e-08
( O 0 3.162631934117144e-09
95 O 0 6.843605149242649e-08
% O 0 1.5698871536073966e-08
CI O 0 0.000214518207940273
43 O 0 2.677062695966015e-07
% O 0 5.670440561544865e-09
- O 0 3.5514469345798716e-05
95 O 0 1.0606454452499747e-06
% O 0 4.846267032121432e-08
) O 0 2.9705999438078834e-08
by O 0 1.663408433216773e-08
age O 0 1.6715385697807505e-07
70 O 0 2.2894114692917356e-07
years O 0 2.8660053885687375e-06
. O 0 1.95149391402083e-06

The O 0 0.00033244257792830467
corresponding O 0 0.4677535593509674
ovarian B-Disease 1 0.9999250173568726
cancer I-Disease 1 0.9998161196708679
risks O 0 0.003030320629477501
were O 0 3.814911906374618e-06
0 O 0 7.08945208316436e-06
. O 0 4.418675416673068e-06

4 O 0 3.082153125433251e-05
% O 0 4.7405993086613307e-07
( O 0 3.614473342850033e-08
95 O 0 3.02398888152311e-07
% O 0 4.203528547463975e-08
CI O 0 0.00013177155051380396
0 O 0 4.5363158562850003e-08
% O 0 6.617882686299481e-09
- O 0 1.2007208169961814e-05
1 O 0 1.3486869931966794e-07
% O 0 1.603227772761784e-08
) O 0 9.34626598336763e-09
by O 0 5.620778509296542e-09
age O 0 2.2904721674876782e-08
50 O 0 6.4649618991552416e-09
years O 0 9.995309824262222e-08
and O 0 1.5660359053981665e-07
27 O 0 1.8947130229207687e-06
% O 0 8.920123306666028e-09
( O 0 3.272011550592424e-09
95 O 0 5.457312113321677e-08
% O 0 1.567380003564267e-08
CI O 0 0.0002697037998586893
0 O 0 5.3302226632467864e-08
% O 0 9.250638477453776e-09
- O 0 2.6827523470274173e-05
47 O 0 4.420036475494271e-06
% O 0 4.322197355577373e-08
) O 0 2.332219750655895e-08
by O 0 2.0354789853627153e-08
age O 0 2.4800800701996195e-07
70 O 0 1.3912600138610287e-07
years O 0 2.1205210032348987e-06
. O 0 2.8240699521120405e-06

The O 0 1.5094487935130019e-05
lifetime O 0 0.00031241620308719575
risk O 0 0.00014256664144340903
of O 0 7.094690226949751e-05
breast B-Disease 1 0.9988822340965271
cancer I-Disease 0 0.4547964632511139
appears O 0 7.199047558970051e-06
similar O 0 9.825642877103746e-08
to O 0 9.554524638133444e-08
the O 0 8.939099416238605e-07
risk O 0 7.772998287691735e-06
in O 0 4.96622021728399e-07
BRCA1 O 0 0.00011067446030210704
carriers O 0 2.1769108570879325e-05
, O 0 9.267061500395357e-07
but O 0 1.1775376407285876e-07
there O 0 4.673549991451864e-09
was O 0 3.0292187602753984e-07
some O 0 2.1894284996104574e-10
suggestion O 0 6.86267611627045e-08
of O 0 4.44162084889399e-09
a O 0 3.0180481758179667e-07
lower O 0 8.908729796530679e-05
risk O 0 4.285350769350771e-06
in O 0 9.371117215550839e-08
BRCA2 O 0 1.1763801921915729e-05
carriers O 0 2.0754055185534526e-06
< O 0 1.2351043778835447e-06
50 O 0 3.9805190255037814e-08
years O 0 1.1004282640669771e-07
of O 0 7.07987268810939e-08
age O 0 4.079124664713163e-06
. O 0 7.193626515800133e-06

Eye B-Disease 0 0.017807476222515106
movement I-Disease 0 0.000525922398082912
abnormalities I-Disease 0 0.0696645975112915
correlate O 0 1.061863440554589e-05
with O 0 1.2752777365676593e-05
genotype O 0 0.006829415448009968
in O 0 0.00015931972302496433
autosomal O 1 0.8290834426879883
dominant O 1 0.6885459423065186
cerebellar B-Disease 1 0.9993040561676025
ataxia I-Disease 1 0.9991030693054199
type I-Disease 0 0.001208090572617948
I I-Disease 0 0.0009266448323614895
. O 0 3.720536551554687e-05

We O 0 2.710319222387625e-06
compared O 0 1.0254051630909089e-05
horizontal O 0 3.9826525608077645e-05
eye O 0 0.00013133387255948037
movements O 0 2.3016978047962766e-06
( O 0 6.487198334070854e-08
visually O 0 1.556894062559877e-06
guided O 0 4.756503130920464e-06
saccades O 0 0.0002236145519418642
, O 0 1.0451699381519575e-06
antisaccades O 0 0.0007083993405103683
, O 0 1.1926071863399557e-07
and O 0 3.9508382343456105e-08
smooth O 0 2.0584614048857475e-06
pursuit O 0 0.0001100308945751749
) O 0 8.677321261529869e-08
in O 0 9.071766449153529e-09
control O 0 2.6073885805999453e-07
subjects O 0 5.427664717672087e-08
( O 0 2.0298264402640598e-08
n O 0 1.5006789908511564e-05
= O 0 1.9875929865520447e-05
14 O 0 2.9912192189840425e-07
) O 0 1.2784099112650438e-07
and O 0 1.2186526419100119e-06
patients O 0 7.094228493542687e-08
with O 0 3.9632308102000025e-08
three O 0 1.396151247945454e-07
forms O 0 1.0005610562302536e-07
of O 0 1.2872714023615117e-06
autosomal O 0 0.02822740748524666
dominant O 0 0.004019434098154306
cerebellar B-Disease 1 0.8975180983543396
ataxias I-Disease 1 0.5311175584793091
type I-Disease 0 1.5684896425227635e-05
I I-Disease 0 0.00012955533748026937
spinocerebellar B-Disease 0 0.09824991226196289
ataxias I-Disease 0 0.00051602948224172
1 I-Disease 0 6.146573383603027e-08
and I-Disease 0 1.5358266125531372e-07
2 I-Disease 0 6.725320531586476e-07
( O 0 4.21414085849392e-08
SCA1 B-Disease 0 0.0004035704187117517
, O 0 3.2950643458207196e-07
n O 0 5.359099759516539e-06
= O 0 2.503640189388534e-06
11 O 0 1.72825068034399e-07
; O 0 1.1546541145435185e-07
SCA2 B-Disease 0 0.00041610930929891765
, O 0 2.706930501972238e-07
n O 0 3.6535284380079247e-06
= O 0 2.9539883144025225e-06
10 O 0 2.0345900964002794e-08
) O 0 2.766411988375239e-08
and O 0 5.929247777203273e-07
SCA3 B-Disease 1 0.9973970651626587
/ O 0 0.00018637051107361913
Machado B-Disease 0 0.0014121419517323375
- I-Disease 1 0.5297297835350037
Joseph I-Disease 0 0.09623022377490997
disease I-Disease 0 0.016264593228697777
( O 0 1.2120483461330878e-06
MJD B-Disease 1 0.9983887672424316
) O 0 1.1630438621068606e-06
( O 0 4.677172782407979e-08
n O 0 6.5017793531296775e-06
= O 0 1.693148624326568e-05
16 O 0 4.748082744754356e-07
) O 0 3.5135639109284966e-07
. O 0 6.941849051145255e-07

In O 0 1.0397724508948158e-05
SCA1 B-Disease 0 0.006703564897179604
, O 0 9.187950240630016e-07
saccade O 0 6.155352821224369e-06
amplitude O 0 6.798576350774965e-07
was O 0 2.4706448584765894e-06
significantly O 0 1.4747394061487284e-06
increased O 0 9.672683631833934e-08
, O 0 1.1466588745179251e-07
resulting O 0 3.7625537174790225e-07
in O 0 8.519358516423381e-07
hypermetria B-Disease 0 0.008580677211284637
. O 0 9.286576641898137e-06

The O 0 8.852380233292934e-07
smooth O 0 2.2456864826381207e-05
pursuit O 0 0.0002568971540313214
gain O 0 2.1267638658173382e-05
was O 0 4.1889685235219076e-05
decreased O 0 5.013219561078586e-05
. O 0 5.074784894532058e-06

In O 0 9.352229426440317e-06
SCA2 B-Disease 0 0.003038947470486164
, O 0 9.156670444099291e-07
saccade O 0 8.053443707467522e-06
velocity O 0 1.9271108158136485e-06
was O 0 2.7207377115701092e-06
markedly O 0 2.2031174012226984e-05
decreased O 0 1.0167524123971816e-05
. O 0 3.531287120495108e-06

The O 0 1.8025593817583285e-06
percentage O 0 1.5733075997559354e-05
of O 0 6.1593411260219e-08
errors O 0 1.47200471474207e-05
in O 0 1.1846987035823986e-06
antisaccades O 0 0.00507253548130393
was O 0 1.565411548654083e-05
greatly O 0 8.332951892953133e-07
increased O 0 3.302346129885336e-08
and O 0 1.623895826696753e-07
was O 0 3.504749656713102e-06
significantly O 0 4.5454706310010806e-07
correlated O 0 6.237154366317554e-07
with O 0 2.1675143671018304e-06
age O 0 0.00015779606474097818
at O 0 0.03972989693284035
disease O 0 0.2688436806201935
onset O 0 0.015698270872235298
. O 0 9.18209771043621e-05

In O 0 4.795931090484373e-06
addition O 0 5.520976742445782e-07
, O 0 1.4696905736855115e-07
a O 0 3.623113142836587e-09
correlation O 0 6.322555634596938e-08
between O 0 4.5558426364777915e-08
smooth O 0 2.6300251647626283e-06
pursuit O 0 0.00015361409168690443
gain O 0 3.5064679195784265e-06
and O 0 3.274285731436066e-08
the O 0 3.0617284263456668e-09
number O 0 1.0627589919209868e-09
of O 0 3.4161800499532546e-08
trinucleotide O 0 0.0016456859884783626
repeats O 0 1.2827033060602844e-05
was O 0 1.1742596143449191e-05
found O 0 5.193019205762539e-06
. O 0 3.924506472685607e-06

In O 0 0.00013623233826365322
SCA3 B-Disease 1 0.9977752566337585
, O 0 1.4328387806017417e-05
gaze B-Disease 0 6.903402390889823e-05
- I-Disease 0 0.015913624316453934
evoked I-Disease 0 0.0007523609674535692
nystagmus I-Disease 0 0.00065155781339854
was O 0 1.4758236829948146e-05
often O 0 7.260399570441223e-08
present O 0 4.743336834422962e-09
as O 0 3.997407738154379e-09
was O 0 8.046358743740711e-07
saccade O 0 1.2213205081934575e-05
hypometria O 0 9.005391621030867e-05
and O 0 6.95688058272026e-08
smooth O 0 1.2475128414735082e-06
pursuit O 0 3.981672489317134e-05
gain O 0 4.749078925669892e-06
was O 0 1.4402969100046903e-05
markedly O 0 6.478381692431867e-05
decreased O 0 2.051072078756988e-05
. O 0 3.786509068959276e-06

Three O 0 1.3923897768108873e-06
major O 0 6.487965151791286e-07
criteria O 0 1.7112841987909633e-07
, O 0 8.038170307145265e-08
saccade O 0 6.081583592276729e-07
amplitude O 0 4.720433111060629e-08
, O 0 1.23412373653764e-08
saccade O 0 4.0642731846673996e-07
velocity O 0 8.944385285758472e-07
, O 0 2.7592610862825495e-08
and O 0 4.033365197386729e-09
presence O 0 1.336305399668447e-09
of O 0 1.6522205825708625e-09
gaze B-Disease 0 9.098816917685326e-06
- I-Disease 0 0.0038629232440143824
evoked I-Disease 0 5.716038140235469e-05
nystagmus I-Disease 0 1.547119245515205e-05
, O 0 2.7128114865604402e-08
permitted O 0 1.1876553074330332e-09
the O 0 4.942092957094246e-09
correct O 0 1.7837508892171172e-07
assignment O 0 8.63788418570266e-09
of O 0 1.1355750784147745e-09
90 O 0 2.341455207499621e-08
% O 0 1.1770605601313378e-09
of O 0 9.041186688207858e-10
the O 0 8.028104048207751e-08
SCA1 B-Disease 0 0.008263908326625824
, O 0 6.773389316094836e-08
90 O 0 1.2866482101969723e-08
% O 0 4.054149238541527e-10
of O 0 5.314320095095582e-10
the O 0 8.520920147248034e-08
SCA2 B-Disease 0 0.026349658146500587
, O 0 2.4938600517998566e-07
and O 0 1.1317359138729444e-07
93 O 0 1.328584744442196e-06
% O 0 2.8537197049871565e-09
of O 0 3.4912059909686377e-09
the O 0 5.535142690860084e-07
patients O 0 7.618881454618531e-07
with O 0 7.21086644261959e-06
SCA3 B-Disease 1 0.9992755055427551
to O 0 4.3354408063578376e-08
their O 0 9.605503947796024e-08
genetically O 0 1.776451972546056e-05
confirmed O 0 2.6758256353787147e-05
patient O 0 5.010634254176694e-07
group O 0 3.1950032735039713e-06
and O 0 8.970525300355803e-07
, O 0 4.4573877744369383e-07
therefore O 0 4.669845310445453e-08
, O 0 8.148283541231649e-07
may O 0 3.8751693409722066e-07
help O 0 2.2267663268848992e-07
orient O 0 0.0003755287907551974
diagnoses O 0 3.3467827051936183e-06
of O 0 2.763479933776125e-08
SCA1 B-Disease 0 0.020241834223270416
, O 0 2.038731054199161e-06
SCA2 B-Disease 0 0.0038164984434843063
, O 0 1.1494018963276176e-06
and O 0 7.515035576943774e-06
SCA3 B-Disease 1 0.9984692931175232
at O 0 9.715164196677506e-06
early O 0 2.0456458571516123e-07
clinical O 0 1.90026710811253e-07
stages O 0 6.820253020123346e-07
of O 0 7.873651952650107e-08
the O 0 2.062896965071559e-05
diseases O 0 0.030415421351790428
. O 0 2.3910258732939838e-06
. O 0 1.4856335837976076e-05

Genetic O 0 1.3186153410060797e-05
basis O 0 2.450160252465139e-07
and O 0 2.0323116132203722e-06
molecular O 0 0.00015334933414123952
mechanism O 0 0.00045096248504705727
for O 0 0.012271049432456493
idiopathic B-Disease 1 0.9999183416366577
ventricular I-Disease 1 0.9990043044090271
fibrillation I-Disease 1 0.9992130994796753
. O 0 0.0012140918988734484

Ventricular B-Disease 1 0.9647823572158813
fibrillation I-Disease 1 0.6773771643638611
causes O 0 1.0696050594560802e-05
more O 0 1.4595717523491203e-08
than O 0 1.6691229731691237e-08
300 O 0 3.201080005510448e-07
, O 0 3.543161142260942e-07
000 O 0 1.0837680974873365e-06
sudden O 0 5.194899131311104e-05
deaths O 0 2.6151335532631492e-06
each O 0 4.349187232577378e-09
year O 0 1.815820951378555e-07
in O 0 8.007993557157533e-08
the O 0 1.3933939726484823e-06
USA O 0 0.0009946271311491728
alone O 0 3.772167838178575e-05
. O 0 2.2318270112009486e-06

In O 0 3.8885480080352863e-07
approximately O 0 1.9392551564578753e-07
5 O 0 6.093014235375449e-07
- O 0 0.00014686562644783407
12 O 0 1.2175872825537226e-06
% O 0 7.774707100338674e-09
of O 0 2.5612603149482993e-09
these O 0 2.2738268157240782e-08
cases O 0 5.045292823524505e-07
, O 0 6.988345830905018e-07
there O 0 1.3064539672313913e-08
are O 0 7.509205701694555e-09
no O 0 2.202860400757345e-07
demonstrable O 0 0.00028777855914086103
cardiac O 0 0.03141379356384277
or O 0 2.550606041040737e-06
non O 0 9.265840162697714e-06
- O 1 0.9564213156700134
cardiac O 1 0.924263060092926
causes O 0 3.888899755111197e-06
to O 0 1.826116502456898e-08
account O 0 3.028271322591536e-08
for O 0 1.2798432313942953e-09
the O 0 1.6755247855826383e-08
episode O 0 1.6526773833902553e-06
, O 0 5.391946729105257e-07
which O 0 2.4885903826543654e-07
is O 0 8.593141842538898e-08
therefore O 0 4.5834551087864384e-07
classified O 0 0.0005470357136800885
as O 0 0.014808159321546555
idiopathic B-Disease 1 0.9999854564666748
ventricular I-Disease 1 0.9998075366020203
fibrillation I-Disease 1 0.9999295473098755
( O 0 0.0009609409025870264
IVF B-Disease 1 0.9992179870605469
) O 0 3.3084932510973886e-05
. O 0 6.769683295715367e-06

A O 0 2.461587882862659e-06
distinct O 0 6.193795343278907e-07
group O 0 3.820884376182221e-05
of O 0 1.6090065400931053e-05
IVF B-Disease 1 0.9998843669891357
patients O 0 4.267114127287641e-05
has O 0 3.269950411777245e-06
been O 0 2.520063617339474e-06
found O 0 8.622404266134254e-07
to O 0 1.820364836646604e-08
present O 0 1.2586855113738693e-08
with O 0 4.525918839703991e-08
a O 0 3.287079550773342e-07
characteristic O 0 5.993026206851937e-06
electrocardiographic O 0 0.008288026787340641
pattern O 0 0.0003792234929278493
. O 0 2.7984669941361062e-05

Because O 0 8.202860612982477e-07
of O 0 2.7829980098204032e-08
the O 0 5.0320011268922826e-08
small O 0 9.494791441966299e-08
size O 0 2.512696028134087e-06
of O 0 4.987918078569464e-09
most O 0 9.463708039447738e-09
pedigrees O 0 2.5618792278692126e-05
and O 0 3.044580694222532e-07
the O 0 2.1195128852014022e-07
high O 0 0.00017008553550112993
incidence O 0 0.0001944392133736983
of O 0 2.572998880623345e-07
sudden B-Disease 0 0.0053837173618376255
death I-Disease 0 4.252765575074591e-05
, O 0 1.0354048072258593e-06
however O 0 1.1468513605450426e-07
, O 0 5.070935671369625e-08
molecular O 0 1.6627573131700046e-06
genetic O 0 1.887013240775559e-06
studies O 0 1.2438675867088023e-07
of O 0 5.764223374171706e-07
IVF B-Disease 1 0.9995083808898926
have O 0 4.1238808989874087e-07
not O 0 1.4957585392494366e-08
yet O 0 5.041483319701001e-08
been O 0 1.4406016646262287e-07
done O 0 6.077780199120753e-07
. O 0 1.8691847571972176e-06

Because O 0 0.0022749288473278284
IVF B-Disease 1 0.9986525177955627
causes O 0 0.004313501995056868
cardiac O 0 0.17495837807655334
rhythm O 0 0.004464411176741123
disturbance O 0 0.003956429194658995
, O 0 4.233453637425555e-06
we O 0 7.404968016544444e-08
investigated O 0 1.5013140455266694e-06
whether O 0 2.687427809178189e-07
malfunction O 0 0.003165656700730324
of O 0 1.4602337117253228e-09
ion O 0 5.864491868123878e-06
channels O 0 2.7547418994799955e-06
could O 0 6.238145942916162e-06
cause O 0 3.3776477721403353e-06
the O 0 5.564147159020649e-06
disorder O 0 0.011584535241127014
by O 0 7.464085172159685e-08
studying O 0 2.0263881594928534e-07
mutations O 0 1.9616092572505295e-07
in O 0 2.2804719890245906e-08
the O 0 9.162088332459462e-08
cardiac O 0 0.00011681825708365068
sodium O 0 1.2853560349412874e-07
channel O 0 2.8722274691972416e-06
gene O 0 2.21190066440613e-06
SCN5A O 0 0.00294696819037199
. O 0 4.540749159787083e-06

We O 0 2.4385542474192334e-06
have O 0 3.5853881286129763e-07
now O 0 2.0743199513617583e-07
identified O 0 1.3711726865039964e-07
a O 0 1.9082825986060925e-08
missense O 0 7.692959798077936e-07
mutation O 0 6.97416524531036e-08
, O 0 4.450841473158107e-08
a O 0 2.1839335673234928e-08
splice O 0 8.39991625980474e-05
- O 0 0.06669130176305771
donor O 0 2.184472577937413e-05
mutation O 0 1.8635054743754154e-07
, O 0 1.0898110502921554e-07
and O 0 1.3639682094890304e-07
a O 0 7.633079235347395e-08
frameshift O 0 8.046505172387697e-06
mutation O 0 1.1799744292773084e-08
in O 0 3.520601588036243e-09
the O 0 2.2413942701859924e-08
coding O 0 5.156637053005397e-05
region O 0 2.20112170268294e-07
of O 0 4.128535024960911e-08
SCN5A O 0 0.03601962700486183
in O 0 3.237293810798292e-07
three O 0 5.3885210036241915e-06
IVF B-Disease 1 0.995907187461853
families O 0 0.00010604744602460414
. O 0 2.5972831281251274e-05

We O 0 4.995147264708066e-07
show O 0 7.587689054844304e-08
that O 0 1.7182275602323216e-09
sodium O 0 2.366385087881895e-09
channels O 0 3.3356808426532325e-09
with O 0 6.730117352304887e-09
the O 0 2.0136230460821025e-08
missense O 0 9.31750378185825e-07
mutation O 0 3.8339726415870246e-07
recover O 0 3.840201679849997e-05
from O 0 1.8341310692449042e-08
inactivation O 0 3.944416675949469e-05
more O 0 5.803716174312967e-09
rapidly O 0 4.5176051344242296e-07
than O 0 3.616733357247881e-09
normal O 0 2.8295371379272183e-08
and O 0 5.517598111737243e-08
that O 0 2.0690913871135308e-08
the O 0 8.858057043426015e-08
frameshift O 0 7.364847988355905e-05
mutation O 0 7.091144027526752e-08
causes O 0 1.1650711506661082e-08
the O 0 1.4696948102965735e-09
sodium O 0 1.5639635364550486e-08
channel O 0 2.3917982616694644e-07
to O 0 9.322160821056968e-09
be O 0 2.967902590356175e-09
non O 0 5.458790042212058e-08
- O 0 5.484919165610336e-05
functional O 0 8.717231025912042e-07
. O 0 3.4884035358118126e-06

Our O 0 2.880088686652016e-06
results O 0 9.30485657590907e-06
indicate O 0 9.483078997618577e-07
that O 0 7.248043232266355e-08
mutations O 0 1.4546627369327325e-07
in O 0 1.90139829214786e-07
cardiac O 0 0.0002805954427458346
ion O 0 1.1087265193054918e-05
- O 0 6.221640069270507e-05
channel O 0 1.1884126251970883e-06
genes O 0 1.7554190989699237e-08
contribute O 0 8.359550385250714e-09
to O 0 5.287650317598036e-09
the O 0 7.56569420445885e-08
risk O 0 2.8339994173620653e-07
of O 0 3.5965587841246816e-08
developing O 0 2.9562701456598006e-05
IVF B-Disease 1 0.9418736100196838
. O 0 1.5024398862806265e-06
. O 0 4.768539838551078e-06

Molecular O 0 0.0001806955988286063
heterogeneity O 0 0.0001925389951793477
in O 0 6.998629942245316e-06
mucopolysaccharidosis B-Disease 0 0.05998571589589119
IVA I-Disease 1 0.6525179743766785
in O 0 7.344602295233926e-07
Australia O 0 2.834431995779596e-07
and O 0 9.411312618112788e-08
Northern O 0 8.869114509479914e-08
Ireland O 0 2.8333022328297375e-07
: O 0 1.6640527178424236e-08
nine O 0 1.8659877198956565e-08
novel O 0 1.064856078869525e-07
mutations O 0 5.7196828606720374e-08
including O 0 3.3565651591516144e-08
T312S O 0 8.251477993326262e-05
, O 0 1.5370852679552627e-07
a O 0 2.607139570898198e-08
common O 0 8.594403766437608e-08
allele O 0 2.089475628963555e-06
that O 0 2.49685825792767e-07
confers O 0 2.5214289962605108e-06
a O 0 1.3699352621188154e-06
mild O 0 0.0002571991353761405
phenotype O 0 0.0001740890584187582
. O 0 1.7821432265918702e-05

Mucopolysaccharidosis B-Disease 1 0.8602996468544006
IVA I-Disease 1 0.994085431098938
( O 0 0.0004609245515894145
MPS B-Disease 1 0.9953365921974182
IVA I-Disease 1 0.9999181032180786
) O 0 0.0012799338437616825
is O 0 8.1188381955144e-06
an O 0 3.1904921343084425e-05
autosomal B-Disease 1 0.9875710010528564
recessive I-Disease 1 0.9972903728485107
lysosomal I-Disease 1 0.999927282333374
storage I-Disease 1 0.9999456405639648
disorder I-Disease 1 0.9994514584541321
caused O 0 0.0012902200687676668
by O 0 2.4017945179366507e-06
a O 0 9.43922859732993e-05
genetic B-Disease 1 0.9984140396118164
defect I-Disease 1 0.9979123473167419
in O 0 1.2455632258934202e-06
N O 0 0.0006531730177812278
- O 0 0.006899693515151739
acetylgalactosamine O 0 0.0048219901509583
- O 0 0.0007981706876307726
6 O 0 1.4870892300677951e-05
- O 0 0.06173144280910492
sulfate O 0 0.005125212483108044
sulfatase O 0 0.006869634613394737
( O 0 2.1737109534569754e-07
GALNS O 0 0.0003657348279375583
) O 0 5.562029059547058e-07
. O 0 1.3554335964727215e-06

Previous O 0 5.38534986844752e-05
studies O 0 6.734897851856658e-06
of O 0 3.572084779079887e-07
patients O 0 1.4384480664375587e-06
from O 0 2.5009187609725814e-08
a O 0 9.962457880874354e-08
British O 0 2.5285897208959796e-05
- O 0 0.019720470532774925
Irish O 0 7.890225788287353e-06
population O 0 7.073919761069192e-08
showed O 0 4.780191375175491e-06
that O 0 2.150517808274799e-08
the O 0 3.150940486307263e-08
I113F O 0 1.806995533115696e-05
mutation O 0 5.324176655108204e-08
is O 0 7.621713926653229e-09
the O 0 5.371472155957235e-09
most O 0 2.2755786144301737e-09
common O 0 1.8388004008329517e-08
single O 0 7.703650339863088e-08
mutation O 0 2.934962139988784e-07
among O 0 6.646221208939096e-06
MPS B-Disease 1 0.9995439648628235
IVA I-Disease 1 0.9999902248382568
patients O 0 4.483793964027427e-05
and O 0 2.541970843594754e-06
produces O 0 8.466730832878966e-06
a O 0 1.5118214832909871e-05
severe O 0 0.009187320247292519
clinical O 0 0.00011267601075815037
phenotype O 0 0.0004962629172950983
. O 0 4.175535650574602e-05

We O 0 7.88885472502443e-07
studied O 0 9.742818747326965e-07
mutations O 0 6.527884579554666e-07
in O 0 5.1959442970428427e-08
the O 0 7.087925268933759e-08
GALNS O 0 0.0014710291288793087
gene O 0 6.115023865049807e-08
from O 0 9.451316174136082e-09
23 O 0 3.085679338710179e-07
additional O 0 1.8584970007395896e-07
MPS B-Disease 1 0.9584991335868835
IVA I-Disease 1 0.9999825954437256
patients O 0 1.6490706912009045e-05
( O 0 2.1331802102508846e-08
15 O 0 5.580604423016666e-08
from O 0 3.4634570766911565e-08
Australia O 0 8.474468415897718e-08
, O 0 2.2629153662023782e-08
8 O 0 6.329626245360487e-08
from O 0 5.679944514724866e-09
Northern O 0 7.22350463888688e-08
Ireland O 0 5.689445288226125e-07
) O 0 1.0101584280164388e-07
, O 0 1.987284647952947e-08
with O 0 1.2323079445764051e-08
various O 0 1.4499544676027654e-08
clinical O 0 1.509343655925477e-05
phenotypes O 0 0.005108542274683714
( O 0 1.3026120541326236e-05
severe O 0 0.0005079487455077469
, O 0 1.010339246931835e-06
16 O 0 2.0027887330797967e-06
cases O 0 2.89708623313345e-07
; O 0 1.1080483375280892e-07
intermediate O 0 3.211378327705461e-07
, O 0 4.3213361777816317e-07
4 O 0 2.1357911919039907e-06
cases O 0 1.4918144870534888e-06
; O 0 6.152564765216084e-06
mild O 0 9.207123184751254e-06
, O 0 8.704919878255168e-07
3 O 0 1.931047791003948e-06
cases O 0 7.832362030057993e-07
) O 0 6.533390433105524e-07
. O 0 3.10401878778066e-06

We O 0 2.199685241066618e-06
found O 0 1.5468525589312776e-06
two O 0 1.4488340127627453e-07
common O 0 3.9916614014146035e-07
mutations O 0 4.557981299058156e-07
that O 0 1.052618685548623e-07
together O 0 1.1337510841258336e-06
accounted O 0 6.533390433105524e-07
for O 0 1.972303875774628e-09
32 O 0 1.7698981480407383e-07
% O 0 2.259554321426549e-09
of O 0 8.478178714632634e-10
the O 0 3.940031945148803e-08
44 O 0 9.737766504258616e-07
unrelated O 0 2.3086155124474317e-05
alleles O 0 2.7852954076479364e-07
in O 0 1.559389062322225e-07
these O 0 2.0393073896229907e-07
patients O 0 3.2705709145375295e-06
. O 0 9.956376743502915e-06

One O 0 4.644653586183267e-07
is O 0 1.0857176135914415e-07
the O 0 1.0343522660605231e-07
T312S O 0 8.837275527184829e-05
mutation O 0 5.914620828662009e-07
, O 0 1.6010358194762375e-07
a O 0 3.486249866568869e-08
novel O 0 4.13384697139918e-07
mutation O 0 9.412982393541824e-08
found O 0 1.6710588113255653e-07
exclusively O 0 9.432734060510484e-08
in O 0 1.1233202030780376e-06
milder O 0 0.0001446469104848802
patients O 0 1.25001333799446e-05
. O 0 1.3986094018036965e-05

The O 0 1.8175495597461122e-06
other O 0 2.7508329480951943e-07
is O 0 1.0922562410087266e-07
the O 0 7.853674333091476e-08
previously O 0 1.3864059837942477e-06
described O 0 1.0525416655582376e-05
I113F O 0 3.9872546039987355e-05
that O 0 2.2615222405875102e-07
produces O 0 3.638791440607747e-06
a O 0 9.23682364373235e-06
severe O 0 0.0026591515634208918
phenotype O 0 0.0003460979787632823
. O 0 4.01173674617894e-05

The O 0 1.40246754654072e-06
I113F O 0 0.00014847557758912444
and O 0 1.4088417401580955e-06
T312S O 0 3.618224582169205e-05
mutations O 0 4.752486404413503e-07
accounted O 0 1.1018159966624808e-06
for O 0 8.912641291658474e-09
8 O 0 5.593546461568621e-07
( O 0 2.893694528438573e-08
18 O 0 3.181052647960314e-07
% O 0 1.832410845281629e-08
) O 0 2.7045969019923177e-08
and O 0 1.4400714576368046e-07
6 O 0 1.6045851225499064e-06
( O 0 1.0142605866292342e-08
14 O 0 1.7585348643933685e-07
% O 0 1.602277066581337e-08
) O 0 5.108327094660581e-09
of O 0 2.2808364086301935e-09
44 O 0 7.347060773099656e-07
unrelated O 0 9.926996426656842e-06
alleles O 0 2.3755764289035142e-07
, O 0 1.0017656677518971e-06
respectively O 0 3.3332578368572285e-06
. O 0 6.258429948502453e-06

The O 0 1.7827758256316883e-06
relatively O 0 3.546995458236779e-06
high O 0 1.1972985703323502e-05
residual O 0 1.528485881863162e-05
GALNS O 0 0.0008948913891799748
activity O 0 2.1315334208793502e-07
seen O 0 5.508575995349929e-08
when O 0 5.6652083024744115e-09
the O 0 1.392740256456193e-09
T312S O 0 4.0695519487599086e-07
mutant O 0 1.0531006466862891e-07
cDNA O 0 2.9250006150505214e-07
is O 0 3.921870828094143e-09
overexpressed O 0 2.3745026567212335e-07
in O 0 1.1651377640475857e-08
mutant O 0 2.2701642592437565e-06
cells O 0 8.203637236192662e-08
provides O 0 8.280707786134656e-10
an O 0 5.687923465558242e-09
explanation O 0 2.6920803364305357e-08
for O 0 1.029769247651302e-08
the O 0 1.7637880773690995e-06
mild O 0 0.0008635221747681499
phenotype O 0 0.0012791453627869487
in O 0 5.016389877710026e-06
patients O 0 6.269022492233489e-07
with O 0 1.9649868931992387e-07
this O 0 2.464034878357779e-07
mutation O 0 1.7050967926479643e-06
. O 0 5.4502870625583455e-06

The O 0 4.074160813161143e-07
distribution O 0 3.5103451523355034e-07
and O 0 2.7387649481624976e-08
relative O 0 6.884266046114362e-09
frequencies O 0 3.0933495764884356e-09
of O 0 6.256236084745126e-10
the O 0 1.822713358023975e-08
I113F O 0 5.090373633720446e-06
and O 0 1.8027745340987167e-07
T312S O 0 3.7841844005015446e-06
mutations O 0 4.377034557023762e-08
in O 0 1.650740877323642e-08
Australia O 0 2.1993082910398698e-08
corresponded O 0 9.772913145411621e-09
to O 0 2.1296908681023297e-09
those O 0 2.488963479763129e-09
observed O 0 2.132610532612489e-08
in O 0 6.545674224867071e-09
Northern O 0 9.252300259277035e-08
Ireland O 0 3.6758919463864004e-07
and O 0 6.432823340674076e-08
are O 0 2.2913786146272486e-10
unique O 0 5.292076776797217e-10
to O 0 9.269885414830981e-10
these O 0 3.706824291960231e-10
two O 0 1.1519677656224303e-08
populations O 0 1.9828553377010394e-07
, O 0 2.203259725774842e-07
suggesting O 0 8.635052495264972e-07
that O 0 3.554535865646358e-08
both O 0 7.0846923883038926e-09
mutations O 0 2.8009333519207757e-08
were O 0 4.361933392260653e-08
probably O 0 1.6763884502779547e-07
introduced O 0 3.665648407036315e-08
to O 0 7.600084117598271e-09
Australia O 0 4.77753410166315e-08
by O 0 9.87874404501099e-09
Irish O 0 2.22057394694275e-07
migrants O 0 9.110038234894091e-08
during O 0 1.3835746770496371e-08
the O 0 9.731414785107972e-09
19th O 0 5.246524210633652e-07
century O 0 1.6189381994990981e-06
. O 0 4.312687906349311e-06

Haplotype O 0 0.00036452230415306985
analysis O 0 4.4285710032454517e-07
using O 0 1.277271621802356e-07
6 O 0 3.8924545151530765e-06
RFLPs O 0 7.963753159856424e-05
provides O 0 3.2772142777304225e-09
additional O 0 1.6753991527451717e-09
data O 0 7.4166862873426e-08
that O 0 9.732565864339904e-09
the O 0 5.470985797728645e-08
I113F O 0 2.7729904104489833e-05
mutation O 0 6.743765368355525e-08
originated O 0 1.4416009719298017e-07
from O 0 1.0906278546940484e-08
a O 0 1.0032650266111887e-07
common O 0 3.816793423538911e-07
ancestor O 0 1.3181614122004248e-05
. O 0 1.96849196072435e-05

The O 0 7.157536288104893e-07
other O 0 2.5396224145879387e-07
9 O 0 8.638317012810148e-06
novel O 0 2.1256535092106787e-06
mutations O 0 3.605770189096802e-07
identified O 0 4.782457381224958e-07
in O 0 3.1907411823794973e-08
these O 0 5.0549346042316756e-08
23 O 0 1.2818058166885749e-05
patients O 0 8.823590036399764e-08
were O 0 7.901044263292079e-09
each O 0 1.0016715235039442e-09
limited O 0 9.665376055068009e-09
to O 0 5.89380677595841e-09
a O 0 4.092650129905451e-08
single O 0 7.226501566037768e-07
family O 0 0.0006775117944926023
. O 0 1.5162356248765718e-05

These O 0 1.1208467043388737e-07
data O 0 5.24013387348532e-07
provide O 0 1.2417124217733999e-08
further O 0 8.609084112265464e-09
evidence O 0 4.7172473927048486e-08
for O 0 9.76320135848141e-10
extensive O 0 1.3640769402911701e-08
allelic O 0 4.022905613965122e-06
heterogeneity O 0 3.5003453376702964e-05
in O 0 2.643649622768862e-06
MPS B-Disease 1 0.6769384145736694
IVA I-Disease 1 0.9998006224632263
in O 0 5.048670118412701e-06
British O 0 0.0009123002528212965
- O 0 0.31748244166374207
Irish O 0 0.00026469348813407123
patients O 0 3.7165560229368566e-07
and O 0 7.936525747709311e-08
provide O 0 5.264424007833668e-09
evidence O 0 3.761685007930282e-08
for O 0 4.423889032878492e-10
their O 0 5.962382587654247e-09
transmission O 0 3.7220079320832156e-06
to O 0 5.519858348179696e-09
Australia O 0 3.261657255393402e-08
by O 0 1.261357951420905e-08
British O 0 2.9151442504371516e-06
- O 0 0.00045368706923909485
Irish O 0 1.0301620250174892e-06
migrants O 0 5.137183620718133e-07
. O 0 1.4241224732813862e-07
. O 0 2.1611219835904194e-06

Identification O 0 1.822753688429657e-06
of O 0 2.562400993610936e-07
constitutional O 0 1.6705691450624727e-05
WT1 O 0 0.26596179604530334
mutations O 0 1.6022386262193322e-05
, O 0 6.055302037566435e-06
in O 0 1.5187690678430954e-06
patients O 0 1.028607016451133e-06
with O 0 3.2562857086304575e-06
isolated O 0 0.07599098980426788
diffuse B-Disease 1 0.9704123139381409
mesangial I-Disease 1 0.9999812841415405
sclerosis I-Disease 1 0.9999843835830688
, O 0 8.507818711223081e-05
and O 0 1.2340447028691415e-06
analysis O 0 2.0104498332784715e-07
of O 0 2.2003305844009446e-07
genotype O 0 0.0007456952589564025
/ O 0 0.00024507069610990584
phenotype O 0 1.0444772669870872e-05
correlations O 0 1.2290917084101238e-06
by O 0 7.048905903417335e-09
use O 0 8.015014207884974e-10
of O 0 2.526495679333607e-09
a O 0 8.917371729921797e-08
computerized O 0 5.92849864915479e-05
mutation O 0 6.700519179503317e-07
database O 0 3.670119212983991e-06
. O 0 8.401997547480278e-06

Constitutional O 0 7.3972282734757755e-06
mutations O 0 2.7780558866652427e-06
of O 0 1.99276168899587e-08
the O 0 1.7643353089624725e-07
WT1 O 0 0.00034559451160021126
gene O 0 9.537554745975285e-08
, O 0 1.6232835520213484e-08
encoding O 0 1.5926699958868085e-08
a O 0 4.079985842508904e-07
zinc O 0 0.0010406381916254759
- O 0 0.0006223621894605458
finger O 0 4.577511936076917e-05
transcription O 0 1.2456898446089326e-07
factor O 0 7.352080189093613e-08
involved O 0 9.769319575525515e-08
in O 0 6.222477622941369e-06
renal O 1 0.944617509841919
and O 0 9.848035006143618e-06
gonadal O 0 0.35363858938217163
development O 0 1.4320189620775636e-06
, O 0 1.6132067059970723e-07
are O 0 4.137330478215517e-09
found O 0 2.558120684170717e-07
in O 0 3.912338897293921e-08
most O 0 3.870773213066059e-08
patients O 0 3.562110464372381e-07
with O 0 1.7481972463428974e-05
Denys B-Disease 1 0.999574601650238
- I-Disease 1 0.9999457597732544
Drash I-Disease 1 0.9999635219573975
syndrome I-Disease 1 0.9999394416809082
( O 0 8.165341569110751e-06
DDS B-Disease 1 0.9996623992919922
) O 0 2.539760771469446e-06
, O 0 1.0081582786369836e-06
or O 0 2.7445035811979324e-05
diffuse B-Disease 1 0.8996719717979431
mesangial I-Disease 1 0.999983549118042
sclerosis I-Disease 1 0.9999874830245972
( O 0 0.0003859889111481607
DMS B-Disease 1 0.9665563106536865
) O 0 3.753532837436069e-06
associated O 0 6.200762641128676e-07
with O 0 1.7799592342271353e-06
pseudohermaphroditism B-Disease 1 0.9995684027671814
and O 0 3.674731851788238e-05
/ O 0 0.0008052977500483394
or O 0 0.00019332263036631048
Wilms B-Disease 1 0.995411217212677
tumor I-Disease 0 0.3699994385242462
( O 0 8.253849955508485e-06
WT B-Disease 1 0.9981721639633179
) O 0 3.2209156870521838e-06
. O 0 3.007442728630849e-06

Most O 0 2.8222284527146257e-06
mutations O 0 5.7713368732947856e-05
in O 0 0.00019198423251509666
DDS B-Disease 1 0.9998502731323242
patients O 0 9.339255484519526e-05
lie O 0 6.383559230016544e-05
in O 0 1.5680264198181249e-07
exon O 0 4.341413387010107e-06
8 O 0 5.148070840732544e-07
or O 0 5.8574435968239413e-08
exon O 0 2.1849518816452473e-06
9 O 0 3.7583433254440024e-07
, O 0 2.2101703578414345e-08
encoding O 0 1.1709999370168589e-07
zinc O 0 0.0001984462869586423
finger O 0 3.6265017115511e-05
2 O 0 2.7115706302538456e-07
or O 0 3.14137594159547e-07
zinc O 0 7.227694004541263e-05
finger O 0 3.552679845597595e-05
3 O 0 6.064278181838745e-07
, O 0 3.052511772239086e-07
respectively O 0 4.3186622633584193e-07
, O 0 2.210005867198106e-08
with O 0 3.007828430767745e-09
a O 0 1.4823219096626872e-08
hot O 0 1.239625021298707e-06
spot O 0 3.5689286050910596e-06
( O 0 3.5210199200719217e-08
R394W O 0 5.288901320454897e-06
) O 0 3.317675023595257e-08
in O 0 1.2568910356947072e-08
exon O 0 8.217994945880491e-06
9 O 0 9.155953193840105e-06
. O 0 2.7177552510693204e-06

We O 0 4.6608224124611297e-07
analyzed O 0 4.023348765258561e-07
a O 0 1.4794719227495534e-08
series O 0 3.342108811921207e-07
of O 0 1.2051701503423828e-07
24 O 0 2.2360847651725635e-05
patients O 0 6.493647788374801e-07
, O 0 2.1185552157021448e-07
10 O 0 1.8186680961207458e-07
with O 0 2.6006289317592746e-06
isolated B-Disease 0 0.019374044612050056
DMS I-Disease 1 0.9649457335472107
( O 0 4.994794835511129e-07
IDMS B-Disease 0 0.009002935141324997
) O 0 1.258592305930506e-07
, O 0 7.20099961881715e-08
10 O 0 5.0033758469680834e-08
with O 0 3.394063924133661e-06
DDS B-Disease 1 0.9999325275421143
, O 0 1.708130412225728e-06
and O 0 3.3644238328633946e-07
4 O 0 2.372149538132362e-06
with O 0 1.074305509973783e-05
urogenital B-Disease 1 0.9759010076522827
abnormalities I-Disease 1 0.7306929230690002
and O 0 4.161280958214775e-05
/ O 0 0.0009196294122375548
or O 0 6.740416574757546e-05
WT B-Disease 1 0.9963228702545166
. O 0 8.56372389534954e-06

We O 0 5.082451934868004e-06
report O 0 1.430701831850456e-05
WT1 O 0 0.0005942998104728758
heterozygous O 0 7.938022577036463e-07
mutations O 0 3.398523062969616e-07
in O 0 2.0855608795500302e-07
16 O 0 1.709491880319547e-05
patients O 0 3.1130634852161165e-06
, O 0 5.562527576330467e-07
4 O 0 1.0320560477339313e-06
of O 0 1.2378561109471775e-07
whom O 0 8.41097607917618e-06
presented O 0 7.648900464118924e-06
with O 0 2.6386062017991208e-05
IDMS B-Disease 0 0.4212060570716858
. O 0 2.2530184651259333e-05

One O 0 8.274619176518172e-07
male O 0 1.7027177818818018e-06
and O 0 9.023869438351539e-07
two O 0 7.342493972828379e-07
female O 0 5.5283195251831785e-05
IDMS B-Disease 1 0.9403168559074402
patients O 0 6.512049367302097e-06
with O 0 3.7806853470101487e-06
WT1 O 0 0.08051716536283493
mutations O 0 6.532913175760768e-06
underwent O 0 2.926751403720118e-05
normal O 0 1.973811549760285e-06
puberty O 0 0.00023663816682528704
. O 0 1.9039120161323808e-05

Two O 0 1.129837164626224e-05
mutations O 0 6.597836181754246e-05
associated O 0 1.2192535905342083e-05
with O 0 4.290568540454842e-06
IDMS B-Disease 0 0.15608273446559906
are O 0 4.0078744767413355e-09
different O 0 1.0930659710695068e-09
from O 0 6.613885261685937e-08
those O 0 2.586347989108617e-07
described O 0 0.0014094588113948703
in O 0 0.0004238964756950736
DDS B-Disease 1 0.999823272228241
patients O 0 0.00016682113346178085
. O 0 2.867775401682593e-05

No O 0 2.0846151528530754e-05
WT1 O 0 0.006604302674531937
mutations O 0 3.2671605367795564e-06
were O 0 5.59283648726705e-07
detected O 0 3.293343752375222e-06
in O 0 2.96540871858042e-08
the O 0 4.1321197130628207e-08
six O 0 2.7749895252782153e-06
other O 0 1.5225195966195315e-05
IDMS B-Disease 1 0.972198486328125
patients O 0 1.0145507985725999e-05
, O 0 1.87986779565108e-06
suggesting O 0 1.296769278269494e-05
genetic O 0 3.634602308011381e-06
heterogeneity O 0 4.3480820750119165e-05
of O 0 9.855784810497425e-07
this O 0 2.025873982347548e-05
disease O 0 0.0032652278896421194
. O 0 2.6547697416390292e-05

We O 0 2.8648194074776256e-06
analyzed O 0 1.1146656106575392e-05
genotype O 0 0.00012572917330544442
/ O 0 9.526590292807668e-05
phenotype O 0 4.493741653277539e-05
correlations O 0 2.301023960171733e-05
, O 0 9.035624088937766e-07
on O 0 6.339993063875227e-08
the O 0 4.0999457162627095e-09
basis O 0 3.342272236750432e-09
of O 0 1.048698639039003e-08
the O 0 4.901223604747429e-08
constitution O 0 1.4394009539842045e-08
of O 0 2.1143429229653066e-09
a O 0 1.1754350737191999e-07
WT1 O 0 0.00030179345048964024
mutation O 0 2.298173917836266e-08
database O 0 2.0914338705324553e-08
of O 0 1.323286902277232e-08
84 O 0 1.6225818399107084e-05
germ O 0 0.02576284483075142
- O 0 0.002926001325249672
line O 0 2.7090221919934265e-05
mutations O 0 1.2072844413069106e-07
, O 0 1.8718550265361955e-08
to O 0 1.9368731063451605e-09
compare O 0 2.5729983477162932e-08
the O 0 5.740653730157419e-09
distribution O 0 2.0491955865509226e-07
and O 0 2.7529821977623214e-07
type O 0 1.966769787031808e-07
of O 0 2.3625126743809233e-08
mutations O 0 1.1829916957140085e-06
, O 0 2.5142105641862145e-07
according O 0 2.297560364183937e-08
to O 0 4.055690450144311e-09
the O 0 4.8622471382486765e-08
different O 0 4.4052893599655363e-07
symptoms O 0 2.9060647648293525e-05
. O 0 1.0942452718154527e-05

This O 0 1.0490834938536864e-06
demonstrated O 0 1.931759288709145e-05
( O 0 2.900802087424381e-07
1 O 0 2.2713958003350854e-07
) O 0 2.5046691121133335e-07
the O 0 9.353973950965155e-08
association O 0 1.5781198214881442e-07
between O 0 1.883537770197563e-08
mutations O 0 2.4019330524538418e-08
in O 0 7.261227619181909e-09
exons O 0 3.829244121789088e-07
8 O 0 7.78272067236685e-07
and O 0 5.722470177715877e-07
9 O 0 1.0980608749378007e-05
and O 0 1.222833088831976e-05
DMS B-Disease 1 0.555427074432373
; O 0 9.335443564850721e-07
( O 0 2.5144689885792104e-08
2 O 0 4.967982363268675e-07
) O 0 2.1296153818184393e-07
among O 0 7.746763230898068e-08
patients O 0 2.3336600918355543e-07
with O 0 1.3761365380560164e-06
DMS B-Disease 0 0.4180055260658264
, O 0 4.866775071832308e-08
a O 0 1.7557163500825368e-09
higher O 0 1.4346802634790379e-09
frequency O 0 3.513075608196914e-09
of O 0 2.805396581706532e-09
exon O 0 2.7965993467660155e-06
8 O 0 2.101511142882373e-07
mutations O 0 4.614278381609438e-08
among O 0 2.8805333229797725e-08
46 O 0 8.524237273377366e-06
, O 0 5.141661677043885e-05
XY O 1 0.9975735545158386
patients O 0 1.3169488966013887e-06
with O 0 1.436312118130445e-07
female O 0 1.0863199122468359e-06
phenotype O 0 7.23256607670919e-06
than O 0 1.752592027060018e-08
among O 0 9.97799531887722e-08
46 O 0 5.800845246994868e-05
, O 0 0.00028477111482061446
XY O 1 0.9986913800239563
patients O 0 1.4999889117461862e-06
with O 0 3.5501324191500316e-07
sexual O 0 2.2775784600526094e-06
ambiguity O 0 6.119205409049755e-06
or O 0 8.64091759922303e-07
male O 0 1.4098552583163837e-06
phenotype O 0 0.00014962739078328013
; O 0 9.952693744708085e-07
and O 0 5.751846288148954e-07
( O 0 4.3018744122491626e-08
3 O 0 1.8459519424141035e-07
) O 0 2.5146080773197355e-08
statistically O 0 6.610300751219711e-09
significant O 0 3.0716957866161465e-09
evidence O 0 1.2373709523672005e-07
that O 0 5.1388884259040424e-08
mutations O 0 1.8680315960750704e-08
in O 0 4.1725165544903575e-09
exons O 0 2.7476920649860404e-07
8 O 0 5.230697297520237e-07
and O 0 1.8263958168063255e-07
9 O 0 2.4836779743964144e-07
preferentially O 0 5.1019419800013566e-08
affect O 0 1.956156570059875e-09
amino O 0 5.42683120663412e-10
acids O 0 1.7993129208804248e-10
with O 0 3.0712490883821886e-10
different O 0 1.5320018864617424e-10
functions O 0 2.040675406433934e-09
. O 0 1.5870213587731996e-07
. O 0 2.2711624296789523e-06

The O 0 4.16872717323713e-06
185delAG O 0 0.0019319637212902308
BRCA1 O 0 0.00011785197420977056
mutation O 0 2.9998923878338246e-07
originated O 0 3.5446180390863447e-07
before O 0 4.084617799549051e-08
the O 0 1.6357311949377618e-08
dispersion O 0 2.158639972549281e-06
of O 0 6.760118687054728e-09
Jews O 0 8.471591428360625e-08
in O 0 2.3073273069940115e-08
the O 0 8.97564547130969e-08
diaspora O 0 2.952518343590782e-06
and O 0 3.8316952100103663e-07
is O 0 2.7037923899797534e-08
not O 0 2.8994331380260974e-09
limited O 0 1.1058605586811154e-08
to O 0 6.276632547042027e-08
Ashkenazim O 0 7.414040010189638e-05
. O 0 4.272871137800394e-06

The O 0 2.2758349587093107e-06
185delAG O 0 0.0008613436948508024
mutation O 0 4.407833330333233e-06
in O 0 9.458692602493102e-07
BRCA1 O 0 2.798109380819369e-05
is O 0 1.3680822519290814e-07
detected O 0 1.2450477697711904e-06
in O 0 7.625207132377909e-08
Ashkenazi O 0 5.327807230059989e-05
Jews O 0 3.7905596173004596e-07
both O 0 1.482031279920193e-07
in O 0 6.103271061874693e-06
familial B-Disease 1 0.9533705115318298
breast I-Disease 1 0.9999175071716309
and I-Disease 1 0.9999574422836304
ovarian I-Disease 1 0.9999978542327881
cancer I-Disease 1 0.9998795986175537
and O 0 7.837174962332938e-06
in O 0 2.0545377310554613e-07
the O 0 9.97911797639972e-08
general O 0 2.7714247607946163e-07
population O 0 2.491620705313835e-07
. O 0 4.562783942674287e-06

All O 0 4.45685628847059e-07
tested O 0 1.046988290909212e-05
Ashkenazi O 0 0.00011099323455709964
mutation O 0 1.4530326097883517e-06
carriers O 0 2.4273244889627676e-06
share O 0 2.9152730007808714e-07
the O 0 1.2563972973111959e-08
same O 0 1.4678297688419661e-08
allelic O 0 8.723903192731086e-06
pattern O 0 2.1112120521138422e-05
at O 0 3.3913590868905885e-06
the O 0 1.0771283314170432e-06
BRCA1 O 0 0.00016626407159492373
locus O 0 5.6943088566185907e-05
. O 0 1.705516842775978e-05

Our O 0 2.0771992694790242e-06
previous O 0 1.439157404092839e-05
study O 0 7.492911890949472e-07
showed O 0 1.1916530638700351e-05
that O 0 3.1321317095489576e-08
this O 0 6.782902239876876e-09
Ashkenazi O 0 7.829494279576465e-06
mutation O 0 1.3376478591453633e-07
also O 0 2.0501944675288541e-07
occurs O 0 8.924195071813301e-08
in O 0 1.3978428192729098e-08
Iraqi O 0 5.625504968520545e-07
Jews O 0 5.566625205233322e-08
with O 0 2.2172171654233352e-08
a O 0 4.512721929472718e-08
similar O 0 3.808695794305095e-07
allelic O 0 0.00013191827747505158
pattern O 0 0.0006041980814188719
. O 0 2.6664665710995905e-05

We O 0 4.3521936277102213e-07
extended O 0 8.80966624094981e-08
our O 0 1.8652261957186056e-08
analysis O 0 1.1327202287247928e-08
to O 0 1.2257715953367665e-09
other O 0 7.380792643729706e-10
non O 0 3.771309486921837e-09
- O 0 1.5030818758532405e-06
Ashkenazi O 0 4.367927886050893e-07
subsets O 0 1.3622106109778542e-07
354 O 0 5.131767579769075e-07
of O 0 1.3417760236222875e-09
Moroccan O 0 6.164772230476956e-07
origin O 0 1.9331499956365406e-08
, O 0 1.671174310047263e-08
200 O 0 2.6351308690664155e-08
Yemenites O 0 3.961553375120275e-06
and O 0 1.8683666169749813e-08
150 O 0 1.0255041260620601e-08
Iranian O 0 3.2233509728030185e-07
Jews O 0 2.573794404270302e-07
. O 0 1.3315732303453842e-06

Heteroduplex O 0 0.0019729111809283495
analysis O 0 1.038233790495724e-06
complemented O 0 7.289871746252174e-07
by O 0 4.436050193845631e-09
direct O 0 6.682887576658914e-10
DNA O 0 1.3587710157025867e-07
sequencing O 0 1.5774983808114484e-07
of O 0 1.4673315007485144e-08
abnormally O 0 7.846223525120877e-06
migrating O 0 3.5886031923837436e-08
bands O 0 3.7762205806757265e-08
were O 0 8.60427746829373e-08
employed O 0 7.030667461549456e-07
. O 0 3.1615591069567017e-06

Four O 0 2.981061015816522e-07
of O 0 1.6178065109784256e-08
Moroccan O 0 6.0981515161984134e-06
origin O 0 1.1617519390938469e-07
( O 0 6.836753385641714e-09
1 O 0 9.283160018469516e-09
. O 0 1.5535016828494008e-08
1 O 0 3.145476412669268e-08
% O 0 1.5765667882305934e-08
) O 0 2.967496648409451e-08
and O 0 2.3937831272746735e-08
none O 0 1.0602085431798969e-08
of O 0 3.7060324253879173e-10
the O 0 1.8940752966045693e-08
Yemenites O 0 7.370687671937048e-05
or O 0 1.151621091821653e-07
Iranians O 0 9.418582749276538e-07
was O 0 1.6166841305675916e-06
a O 0 4.7657479740337294e-08
carrier O 0 1.2911964404338505e-05
of O 0 1.4537648418411209e-08
the O 0 4.778664219884377e-07
185delAG O 0 0.00015968199295457453
mutation O 0 8.414277203883103e-07
. O 0 4.571329100144794e-06

BRCA1 O 0 0.0003775636141654104
allelic O 0 0.0003616038302425295
patterns O 0 6.750496686436236e-05
were O 0 7.203843210845662e-07
determined O 0 4.292751896173286e-07
for O 0 5.456341156673261e-09
four O 0 5.272958958357776e-08
of O 0 1.1232709873354452e-08
these O 0 1.4335787668073863e-08
individuals O 0 3.140373072696434e-09
and O 0 7.0831789322767236e-09
for O 0 1.403706484381928e-09
12 O 0 3.5040429224864056e-08
additional O 0 1.076277622580335e-09
non O 0 4.3722117482047906e-08
- O 0 3.1870134989731014e-05
Ashkenazi O 0 7.377536530839279e-05
185delAG O 0 6.704479164909571e-05
mutation O 0 1.695075440011351e-07
carriers O 0 4.137651103519602e-06
who O 0 3.756214937311597e-05
had O 0 0.08855252712965012
breast B-Disease 1 0.9991617202758789
/ I-Disease 1 0.9996517896652222
ovarian I-Disease 1 0.9999476671218872
cancer I-Disease 1 0.9995145797729492
. O 0 0.00025639336672611535

Six O 0 5.795554898213595e-06
non O 0 8.14363647805294e-06
- O 0 0.010408671572804451
Ashkenazi O 0 0.002332384930923581
individuals O 0 8.572842347120968e-08
shared O 0 7.848447580727225e-08
the O 0 3.3464711890474064e-08
common O 0 3.7336468494686414e-07
Ashkenazi O 0 0.0011007420253008604
haplotype O 0 0.0073513188399374485
, O 0 8.523470569343772e-07
four O 0 1.6918019696277042e-07
had O 0 6.535361535497941e-06
a O 0 1.8329637896385975e-07
closely O 0 1.6075311577878892e-05
related O 0 9.780776963452809e-06
pattern O 0 0.0002964999002870172
, O 0 1.051983986144478e-06
and O 0 9.790398536324574e-08
the O 0 1.3081220551214301e-08
rest O 0 1.2424710860159394e-07
( O 0 2.0337095563149887e-08
n O 0 1.8522579921409488e-05
= O 0 3.242381353629753e-05
6 O 0 5.130270324116282e-07
) O 0 3.200548448489826e-08
displayed O 0 4.542705767107691e-08
a O 0 7.157124670698067e-09
distinct O 0 5.905332400857333e-08
BRCA1 O 0 2.668751221790444e-05
allelic O 0 0.0001785208296496421
pattern O 0 0.0006084594060666859
. O 0 4.1534942283760756e-05

We O 0 3.0420517305174144e-06
conclude O 0 4.927840109303361e-06
that O 0 2.959283840198168e-08
the O 0 7.525037659661393e-08
185delAG O 0 0.00011300225742161274
BRCA1 O 0 1.005094873107737e-05
mutation O 0 1.5959732024839468e-07
occurs O 0 2.4199959369752833e-08
in O 0 3.0357238944844767e-09
some O 0 7.377105037953413e-10
non O 0 4.2033281744124906e-08
- O 0 8.366986730834469e-05
Ashkenazi O 0 0.00014055836072657257
populations O 0 4.6494307071043295e-07
at O 0 5.8460645959712565e-06
rates O 0 6.948604891476862e-07
comparable O 0 2.4533940745641303e-07
with O 0 3.424974792665125e-08
that O 0 9.353938423828367e-08
of O 0 2.546762516431045e-07
Ashkenazim O 0 0.001252759131602943
. O 0 1.1254089258727618e-05

The O 0 1.1183155947946943e-06
majority O 0 4.425244242156623e-07
of O 0 1.3953919797415892e-08
Jewish O 0 4.889058118351386e-07
185delAG O 0 0.00025090150302276015
mutation O 0 6.296038463915465e-07
carriers O 0 1.3116595027895528e-06
have O 0 5.3537361210942436e-09
a O 0 7.35440508492502e-09
common O 0 7.992885997509802e-08
allelic O 0 3.9965088944882154e-05
pattern O 0 0.00035703854518942535
, O 0 6.294075660662202e-07
supporting O 0 1.8846665739147284e-07
the O 0 1.5078298076787178e-07
founder O 0 2.6166848329012282e-05
effect O 0 1.7540903840540523e-08
notion O 0 6.984681988342345e-08
, O 0 3.6258876434658305e-07
but O 0 7.508994315230666e-08
dating O 0 8.152084092216683e-07
the O 0 1.988289355381312e-08
mutations O 0 3.7840070632455536e-08
origin O 0 3.5810869825070313e-09
to O 0 2.2786883491221488e-09
an O 0 1.173071773052925e-08
earlier O 0 8.402943421970122e-06
date O 0 2.518489452540962e-07
than O 0 2.1469849897925997e-08
currently O 0 2.8033045396114176e-07
estimated O 0 4.276899289834546e-06
. O 0 3.0832895845378516e-06

However O 0 7.000038294791011e-06
, O 0 1.1336231153791232e-07
the O 0 2.612030591819803e-09
different O 0 5.045633910683023e-10
allelic O 0 2.681268597370945e-06
pattern O 0 1.5336254364228807e-05
at O 0 1.7778215806174558e-06
the O 0 1.8919310207365925e-07
BRCA1 O 0 1.5742096366011538e-05
locus O 0 7.0197388595261145e-06
even O 0 1.889915068886694e-07
in O 0 1.3386937780524022e-08
some O 0 5.926031332315063e-10
Jewish O 0 1.8865692652525468e-07
mutation O 0 4.059403977407783e-07
carriers O 0 1.2344588867563289e-05
, O 0 2.4807004592730664e-06
might O 0 1.4000247574585956e-06
suggest O 0 1.1585743209252541e-07
that O 0 1.4203810572155362e-08
the O 0 2.6916282536149083e-08
mutation O 0 1.9995161082420054e-08
arose O 0 5.634854005620582e-08
independently O 0 3.1673604183879434e-08
. O 0 2.439097954720637e-07
. O 0 4.691334652306978e-06

Crystal O 0 0.11307509243488312
structure O 0 1.4760221347387414e-05
of O 0 2.962851226584462e-07
the O 0 2.0229146684869193e-05
hemochromatosis B-Disease 1 0.9997349381446838
protein O 0 9.26836764847394e-06
HFE O 0 0.000572034390643239
and O 0 1.2211305602249922e-06
characterization O 0 3.3576234272914007e-06
of O 0 2.106345098340512e-09
its O 0 1.1116719988990553e-08
interaction O 0 1.8387057210134117e-08
with O 0 2.6225137617075234e-07
transferrin O 0 0.00029481484671123326
receptor O 0 8.406977940467186e-07
. O 0 1.2490449989854824e-06

HFE O 0 0.039201993495225906
is O 0 2.4167686660803156e-06
an O 0 4.806709625881922e-07
MHC O 0 0.004378315061330795
- O 0 0.03248104825615883
related O 0 1.0934857527900022e-05
protein O 0 2.637879674693977e-07
that O 0 2.2814553801708826e-08
is O 0 6.883478231856088e-09
mutated O 0 1.0700070163238706e-07
in O 0 5.393310331669454e-08
the O 0 8.259881724370643e-06
iron B-Disease 1 0.99277663230896
- I-Disease 1 0.9997366070747375
overload I-Disease 1 0.9998970031738281
disease I-Disease 1 0.9929116368293762
hereditary B-Disease 1 0.9998435974121094
hemochromatosis I-Disease 1 0.9999614953994751
. O 0 0.0022355534601956606

HFE O 0 0.0015012250514701009
binds O 0 7.4153522291453555e-06
to O 0 3.956381533498643e-07
transferrin O 0 0.00013747389311902225
receptor O 0 5.840931862621801e-07
( O 0 4.8719112299977496e-08
TfR O 0 5.872288056707475e-06
) O 0 2.6175580813969646e-08
and O 0 1.0608822265112394e-08
reduces O 0 2.245707797499108e-08
its O 0 6.299077370819361e-10
affinity O 0 3.897725520118911e-08
for O 0 2.798370246637205e-08
iron O 0 0.0005493959179148078
- O 0 4.78679321531672e-05
loaded O 0 4.093148891115561e-05
transferrin O 0 0.0007195956422947347
, O 0 3.475932714991359e-07
implicating O 0 0.0003179191844537854
HFE O 0 0.0030416036024689674
in O 0 1.9033409444091376e-06
iron O 0 0.013392534106969833
metabolism O 0 7.039442425593734e-05
. O 0 2.810110800055554e-06

The O 0 5.370001872506691e-06
2 O 0 3.5831522836815566e-05
. O 0 1.4766092135687359e-05

6 O 0 0.00020740556647069752
A O 0 2.934756594186183e-05
crystal O 0 0.07287631183862686
structure O 0 3.8918419704714324e-06
of O 0 1.8493193465474178e-07
HFE O 0 0.005261386279016733
reveals O 0 1.8148362869396806e-05
the O 0 4.343320014754681e-08
locations O 0 4.354552061158756e-07
of O 0 5.737783340009628e-06
hemochromatosis B-Disease 1 0.9999333620071411
mutations O 0 4.944273769069696e-06
and O 0 6.716589950883645e-07
a O 0 5.926285666646436e-07
patch O 0 0.42566022276878357
of O 0 1.3476625326802605e-06
histidines O 0 0.15454785525798798
that O 0 7.030520237094606e-07
could O 0 2.596277397515223e-07
be O 0 4.4524779418964044e-09
involved O 0 3.1303876824040344e-08
in O 0 2.2690552725634916e-07
pH O 0 4.387104854686186e-05
- O 0 0.00025665503926575184
dependent O 0 5.225053882895736e-07
interactions O 0 1.875447139809694e-07
. O 0 1.7528615217088372e-06

We O 0 2.342586412851233e-06
also O 0 5.231216277934436e-07
demonstrate O 0 3.940475892250106e-07
that O 0 1.4005065906985692e-07
soluble O 0 1.7147194739663973e-06
TfR O 0 9.697206223791e-06
and O 0 4.587810735756648e-07
HFE O 0 0.00021735572954639792
bind O 0 1.885886945274251e-06
tightly O 0 6.127860615379177e-06
at O 0 5.211512643654714e-07
the O 0 1.0778271608558043e-08
basic O 0 1.539974903153052e-08
pH O 0 6.24993845121935e-07
of O 0 1.0698938401887403e-09
the O 0 2.478353522405996e-08
cell O 0 0.00017198182467836887
surface O 0 4.423442806000821e-05
, O 0 7.897240834608965e-07
but O 0 8.124270323150995e-08
not O 0 7.14651227085028e-09
at O 0 1.5505389683312387e-07
the O 0 4.954601351414567e-08
acidic O 0 9.361143384012394e-06
pH O 0 8.331401772920799e-07
of O 0 2.363215578782274e-08
intracellular O 0 1.5378727766801603e-05
vesicles O 0 1.772086397977546e-05
. O 0 4.553554845188046e-06

TfR O 0 0.038350943475961685
HFE O 0 0.03535354137420654
stoichiometry O 0 0.00040508597157895565
( O 0 1.980033175641438e-06
2 O 0 8.709968142284197e-07
1 O 0 2.081310981338902e-07
) O 0 4.849271917350961e-08
differs O 0 1.1235307084689339e-07
from O 0 3.844989748813532e-08
TfR O 0 4.8830297600943595e-05
transferrin O 0 9.580905316397548e-05
stoichiometry O 0 4.928145926896832e-07
( O 0 2.463642623240503e-09
2 O 0 4.829122701721644e-08
2 O 0 3.462391475750337e-07
) O 0 4.740797976410249e-08
, O 0 3.121545688600236e-08
implying O 0 6.446149569683257e-08
a O 0 2.399988818790888e-10
different O 0 2.593432066322343e-11
mode O 0 5.729976937374204e-09
of O 0 5.133798386403043e-10
binding O 0 1.771462798672019e-08
for O 0 7.23525062085173e-09
HFE O 0 7.71256527514197e-05
and O 0 6.664549800916575e-07
transferrin O 0 0.00011122123396489769
to O 0 4.666604169756283e-08
TfR O 0 2.5388637368450873e-05
, O 0 5.622883136879864e-08
consistent O 0 5.385495160936671e-09
with O 0 2.752258199123503e-09
our O 0 6.4167315905194755e-09
demonstration O 0 3.246191511152574e-07
that O 0 9.19556200074112e-08
HFE O 0 0.0010428136447444558
, O 0 2.0724507976410678e-06
transferrin O 0 0.0013367539504542947
, O 0 5.042165867052972e-07
and O 0 8.418225547757174e-07
TfR O 0 1.4142643522063736e-05
form O 0 4.403636122418675e-09
a O 0 1.1190053328391514e-07
ternary O 0 1.1190303666808177e-05
complex O 0 7.05281418049708e-05
. O 0 2.3025231712381355e-05

Identification O 0 2.1908067537879106e-06
of O 0 2.8397784035405493e-07
three O 0 9.642985787650105e-07
novel O 0 3.979300799983321e-06
mutations O 0 4.561925379675813e-07
and O 0 6.036661659436504e-08
a O 0 1.187501919019951e-08
high O 0 1.2852433428633958e-07
frequency O 0 2.17083897524617e-08
of O 0 2.1646773262773422e-09
the O 0 1.62096995381944e-07
Arg778Leu O 0 0.0018951368983834982
mutation O 0 1.998572827233147e-07
in O 0 6.354993615786952e-07
Korean O 0 0.004035458900034428
patients O 0 2.3160503133112798e-06
with O 0 3.846608160529286e-05
Wilson B-Disease 0 0.10000669211149216
disease I-Disease 0 0.009509765543043613
. O 0 4.948017522110604e-05

Four O 0 1.2627200476345024e-06
mutations O 0 2.107979526044801e-06
- O 0 0.0001954049221239984
- O 0 0.0003899726434610784
R778L O 0 2.2673521016258746e-05
, O 0 1.4410017001864617e-07
A874V O 0 1.9092894945060834e-06
, O 0 3.8624691001132305e-08
L1083F O 0 9.769931921255193e-07
, O 0 1.3161055356647466e-08
and O 0 2.2538177546493898e-08
2304delC O 0 7.2978405114554334e-06
- O 0 2.3643537133466452e-05
- O 0 1.8802888007485308e-05
in O 0 7.308092797586596e-09
the O 0 1.3680790722503389e-08
copper O 0 8.090210758382455e-05
- O 0 5.641274583467748e-06
transporting O 0 9.093916446545336e-07
enzyme O 0 1.3809480492454895e-07
, O 0 1.5424245702888584e-07
P O 0 0.00035013057640753686
- O 0 0.00018800614634528756
type O 0 1.1981184115938959e-06
ATPase O 0 0.0004906642134301364
( O 0 2.1854546616850712e-08
ATP7B O 0 0.00027237189351581037
) O 0 5.7742926884429835e-08
, O 0 1.9126808581404475e-08
were O 0 3.8772608235149164e-08
identified O 0 4.7523775492663844e-07
in O 0 6.833717520748905e-07
Korean O 0 0.002737600589171052
Patients O 0 2.85192004412238e-06
with O 0 2.764245800790377e-05
Wilson B-Disease 0 0.17221392691135406
disease I-Disease 0 0.005847744643688202
. O 0 2.8910746550536714e-05

Arg778Leu O 0 0.04842032492160797
, O 0 9.805451554711908e-06
the O 0 9.090597075100959e-08
most O 0 3.103871293319571e-08
frequently O 0 8.390254038204148e-07
reported O 0 1.1636913768597879e-05
mutation O 0 8.837903742175968e-09
of O 0 2.0606150119562017e-09
this O 0 5.282045467680518e-09
enzyme O 0 3.786722402310261e-07
, O 0 5.46204432794184e-07
was O 0 1.2962643722858047e-06
found O 0 3.5694901612259855e-07
in O 0 2.1538387073860576e-08
six O 0 6.727347567903053e-08
of O 0 3.343517107623484e-08
eight O 0 5.818864792672684e-06
unrelated O 0 0.004557528533041477
patients O 0 5.339584276953246e-07
studied O 0 1.3585547264938214e-07
, O 0 3.672219506256624e-08
an O 0 3.127939018909842e-09
allele O 0 4.6134861264590654e-08
frequency O 0 1.7168394705890933e-08
of O 0 1.835713092646074e-08
37 O 0 3.2625057428958826e-06
. O 0 5.007303570891963e-06

5 O 0 4.2000567191280425e-05
% O 0 2.645783069965546e-06
, O 0 5.142167651683849e-07
which O 0 1.2867984366948804e-07
is O 0 1.566112928230723e-08
considerably O 0 1.6751563691741467e-07
higher O 0 3.1703219605105915e-08
than O 0 4.509071782621277e-09
those O 0 9.346979190638649e-09
in O 0 3.732695930125374e-08
other O 0 1.3647853336351545e-07
Asian O 0 1.1303027349640615e-05
populations O 0 1.5091533214217634e-06
. O 0 4.168560280959355e-06

The O 0 3.5811441989608284e-07
novel O 0 1.3641346185977454e-07
single O 0 1.3422733147194776e-08
nucleotide O 0 2.3179892139069125e-07
deletion O 0 7.151019417506177e-06
, O 0 8.344498496626329e-07
2304delC O 0 0.0004140158707741648
, O 0 7.896359193182434e-07
was O 0 9.609784683561884e-06
found O 0 1.1749121995308087e-06
in O 0 1.193353540429598e-07
one O 0 2.426726553039771e-07
patient O 0 1.2160346159362234e-05
. O 0 2.0478861188166775e-05

Since O 0 5.502303793036845e-06
a O 0 1.1866113425185176e-07
mutation O 0 2.9493046227457853e-08
at O 0 8.290307818015208e-08
cDNA O 0 5.889752969778783e-07
nucleotide O 0 4.975378828930843e-07
2302 O 0 0.0004017059691250324
( O 0 3.05467189321007e-08
2302insC O 0 2.0294399291742593e-05
) O 0 1.01089661086462e-07
had O 0 4.2176068859589577e-07
been O 0 1.1885332895644751e-07
previously O 0 8.343654940290435e-07
described O 0 2.024865898420103e-05
, O 0 2.1767853297660622e-07
this O 0 5.664830382556829e-09
region O 0 6.596700075078843e-08
of O 0 5.730687480109964e-09
the O 0 6.132111707302101e-07
ATP7B O 0 0.060520198196172714
gene O 0 1.3979741879666108e-06
may O 0 9.731509180710418e-07
be O 0 4.101996964323007e-08
susceptible O 0 3.2374778129451443e-06
to O 0 3.59671652461202e-08
gene O 0 4.147314029978588e-06
rearrangements O 0 0.012462234124541283
causing O 0 0.02957332320511341
Wilson B-Disease 0 0.08870308101177216
disease I-Disease 0 0.007191247772425413
. O 0 4.3877491407329217e-05

Disruption O 0 3.361910057719797e-05
of O 0 4.05534414937847e-08
splicing O 0 8.61756234371569e-07
regulated O 0 1.6831245375215076e-07
by O 0 2.758613781850272e-08
a O 0 1.1024324209074621e-07
CUG O 0 0.0033421888947486877
- O 0 0.00010807262879097834
binding O 0 8.256300247921899e-07
protein O 0 2.966104375445866e-06
in O 0 0.00010042552457889542
myotonic B-Disease 1 0.9998045563697815
dystrophy I-Disease 1 0.9997134804725647
. O 0 0.0002590848889667541

Myotonic B-Disease 1 0.999288022518158
dystrophy I-Disease 1 0.9996821880340576
( O 0 0.17007391154766083
DM B-Disease 1 0.9998801946640015
) O 0 0.0007722103036940098
is O 0 4.707294010586338e-06
caused O 0 5.4391280173149426e-06
by O 0 8.694463815572817e-09
a O 0 2.9657991618137203e-08
CTG O 0 0.000247699354076758
expansion O 0 1.3013834632147336e-07
in O 0 6.229186499950856e-09
the O 0 1.3144096477901712e-08
3 O 0 4.808626385965908e-07
untranslated O 0 7.75652915763203e-06
region O 0 9.189460570269148e-08
of O 0 1.501100044265513e-08
the O 0 9.136936569120735e-06
DM B-Disease 1 0.9993007183074951
gene O 0 8.109536793199368e-06
. O 0 5.936970410402864e-06

One O 0 4.484963085360505e-07
model O 0 4.421828634804115e-06
of O 0 3.162680741297663e-06
DM B-Disease 1 0.9998321533203125
pathogenesis O 0 0.11462967097759247
suggests O 0 7.347548489633482e-06
that O 0 2.086553507751887e-07
RNAs O 0 2.3691971364314668e-05
from O 0 2.8103823712655185e-09
the O 0 9.644157694665978e-10
expanded O 0 6.005983710366536e-09
allele O 0 5.7295537203572167e-08
create O 0 2.8053268597005854e-09
a O 0 1.5409035825086903e-08
gain O 0 1.5921162912491127e-06
- O 0 0.000128602419863455
of O 0 7.909414989626384e-08
- O 0 0.0009910750668495893
function O 0 2.2042174308012363e-08
mutation O 0 5.164551009073648e-09
by O 0 2.9246998156651216e-09
the O 0 8.370304449556443e-09
inappropriate O 0 3.2950137551779335e-07
binding O 0 1.4240078449745397e-08
of O 0 1.1340945960114368e-09
proteins O 0 8.544515317510104e-09
to O 0 7.426945725086398e-09
the O 0 7.143571423284811e-08
CUG O 0 0.0009446473559364676
repeats O 0 9.55585710471496e-06
. O 0 2.2364208689396037e-06

Data O 0 3.9979498978937045e-05
presented O 0 1.667921787884552e-05
here O 0 2.537625277909683e-06
indicate O 0 2.1971369790207973e-07
that O 0 2.9985718352776303e-09
the O 0 1.3803291842862109e-09
conserved O 0 1.4383526369954325e-08
heterogeneous O 0 5.6559001677669585e-06
nuclear O 0 0.0074686878360807896
ribonucleoprotein O 0 0.0016140121733769774
, O 0 4.018053232357488e-07
CUG O 0 0.0003992281563114375
- O 0 1.5409088518936187e-05
binding O 0 5.963305937939367e-08
protein O 0 4.750818405341306e-08
( O 0 8.542885510109954e-09
CUG O 0 0.00012219557538628578
- O 0 0.0007459023618139327
BP O 0 0.0017856521299108863
) O 0 1.1506681829587251e-07
, O 0 2.0330662664491683e-07
may O 0 6.859980317130976e-08
mediate O 0 2.088995415761019e-06
the O 0 5.0516476335360494e-08
trans O 0 7.089194696163759e-06
- O 0 4.676720345742069e-05
dominant O 0 5.566018899116898e-07
effect O 0 1.2813486272023056e-08
of O 0 7.574927907150197e-10
the O 0 2.7685233661145503e-08
RNA O 0 2.5940400973922806e-06
. O 0 2.3718507691228297e-06

CUG O 0 0.28455299139022827
- O 0 0.0498882532119751
BP O 0 0.06349148601293564
was O 0 6.119117460912094e-05
found O 0 1.2180146313767182e-06
to O 0 2.2382241837703987e-08
bind O 0 4.0989942817759584e-07
to O 0 5.916118706039697e-09
the O 0 5.6820933735934886e-08
human O 0 3.600276613724418e-06
cardiac O 0 0.2637929320335388
troponin O 1 0.9630405306816101
T O 1 0.8645799160003662
( O 0 5.831025262637013e-08
cTNT O 0 1.2694147699221503e-05
) O 0 3.182250551958532e-08
pre O 0 6.058925237084622e-07
- O 0 1.72740710695507e-05
messenger O 0 2.329978087800555e-06
RNA O 0 2.495396067558886e-08
and O 0 1.4028687100875459e-09
regulate O 0 1.8574395355130946e-09
its O 0 1.001041138870562e-09
alternative O 0 5.148755199968491e-09
splicing O 0 1.028769929689588e-06
. O 0 2.241365791633143e-06

Splicing O 0 7.392446605081204e-06
of O 0 6.127820597612299e-07
cTNT O 0 0.0015447932528331876
was O 0 9.030213732330594e-06
disrupted O 0 0.00011242808977840468
in O 0 1.1030841051251628e-05
DM B-Disease 1 0.9999080896377563
striated O 1 0.98621666431427
muscle O 0 0.030067650601267815
and O 0 1.112051563723071e-06
in O 0 5.096991273489948e-08
normal O 0 1.4510962387248583e-07
cells O 0 1.3356991530599771e-06
expressing O 0 8.440914456286919e-08
transcripts O 0 3.950217433157377e-07
that O 0 2.0677744316799362e-07
contain O 0 4.6736056447116425e-07
CUG O 0 0.001011715386994183
repeats O 0 1.700482243904844e-05
. O 0 3.622138137870934e-06

Altered O 0 1.8514456314733252e-05
expression O 0 1.4723883623446454e-07
of O 0 2.4458570280216918e-08
genes O 0 1.3171280954793474e-07
regulated O 0 2.7729316798286163e-07
posttranscriptionally O 0 0.00010751531226560473
by O 0 2.5394746216989006e-07
CUG O 0 0.021897362545132637
- O 0 0.02930016815662384
BP O 0 0.005999573040753603
therefore O 0 1.967056846297055e-07
may O 0 8.763194614402892e-08
contribute O 0 1.2476165878183565e-08
to O 0 4.0548420088271087e-07
DM B-Disease 1 0.9996325969696045
pathogenesis O 0 0.0034280363470315933
. O 0 1.726137156765617e-06
. O 0 3.406512632864178e-06

Identification O 0 4.152688688918715e-06
of O 0 1.3908355356306856e-07
a O 0 7.422558496728016e-07
novel O 0 2.8980416573176626e-06
nonsense O 0 1.5500287190661766e-05
mutation O 0 9.190775074330304e-08
and O 0 2.5871612407968314e-08
a O 0 7.076953689733045e-09
missense O 0 2.758897821308892e-08
substitution O 0 1.6952064196829042e-09
in O 0 4.404039355421219e-09
the O 0 7.993310013887367e-09
vasopressin O 0 8.899563113118347e-07
- O 0 0.0011210605734959245
neurophysin O 0 0.0020065391436219215
II O 0 0.0007063870434649289
gene O 0 1.8607275720228245e-08
in O 0 3.2042666298082167e-09
two O 0 7.983739891415098e-09
Spanish O 0 5.623970764645492e-07
kindreds O 0 0.0009991717524826527
with O 0 6.299550295807421e-05
familial B-Disease 1 0.9771094918251038
neurohypophyseal I-Disease 1 0.9997469782829285
diabetes I-Disease 1 0.9993667006492615
insipidus I-Disease 1 0.9325705170631409
. O 0 5.6284978199983016e-05

Familial B-Disease 1 0.9951611161231995
neurohypophyseal I-Disease 1 0.9987614154815674
diabetes I-Disease 1 0.9997434020042419
insipidus I-Disease 1 0.9990992546081543
( O 0 0.014722110703587532
FNDI B-Disease 1 0.9998778104782104
) O 0 0.0005004823324270546
is O 0 5.391723334469134e-06
an O 0 3.548514723661356e-05
autosomal B-Disease 1 0.9898023009300232
dominant I-Disease 1 0.9975976347923279
disease I-Disease 1 0.9982402324676514
caused O 1 0.509653627872467
by O 0 0.16468986868858337
deficiency O 1 0.99112468957901
in O 0 5.037508685745706e-07
the O 0 1.1498623280203901e-06
antidiuretic O 0 0.0003238690260332078
hormone O 0 7.885251989137032e-07
arginine O 0 4.067761892656563e-06
vasopressin O 0 3.2531661418033764e-06
( O 0 3.448599272815045e-08
AVP O 0 2.5376049961778335e-05
) O 0 1.9749952784309244e-09
encoded O 0 3.2377781011838636e-10
by O 0 5.32521748919379e-10
the O 0 1.4050841379287249e-08
AVP O 0 0.008010026067495346
- O 0 0.012245126999914646
neurophysin O 0 0.027857685461640358
II O 0 0.06098143383860588
( O 0 2.0419619772837905e-07
AVP O 0 0.004042112734168768
- O 0 0.006579185836017132
NPII O 0 0.004069337621331215
) O 0 5.070906539117459e-08
gene O 0 2.2076550365568437e-08
on O 0 7.177003453762154e-07
chromosome O 0 0.00031726915040053427
20p13 O 0 0.00021873306832276285
. O 0 7.142697086237604e-06

In O 0 1.923084710142575e-06
this O 0 9.58259391836691e-08
study O 0 8.172511911652691e-08
, O 0 8.074988500084146e-08
we O 0 8.24091195283927e-09
analyzed O 0 7.625672537869832e-08
two O 0 3.139877691182846e-08
families O 0 6.134299042059865e-07
with O 0 7.052525461404002e-07
FNDI B-Disease 1 0.7885470986366272
using O 0 1.5235723793693978e-09
direct O 0 6.749135278427687e-11
automated O 0 2.7843094940749324e-08
fluorescent O 0 8.965225362089768e-08
, O 0 1.4650160196083561e-08
solid O 0 1.7566959797932213e-07
phase O 0 3.374217953933112e-07
, O 0 1.939409699502903e-08
single O 0 5.813043824076658e-09
- O 0 1.4227924111764878e-05
stranded O 0 7.613217434254693e-08
DNA O 0 3.0103151971161424e-08
sequencing O 0 8.20915957433499e-09
of O 0 1.1561825941086568e-09
PCR O 0 2.6922298275167122e-06
- O 0 4.076724871993065e-05
amplified O 0 9.479440450377297e-06
AVP O 0 0.0008810766157694161
- O 0 0.00079476332757622
NPII O 0 0.0018167054513469338
DNA O 0 3.5758333979174495e-05
. O 0 8.541391252947506e-06

In O 0 8.508494602210703e-07
one O 0 4.802081576826822e-08
of O 0 1.7268495966504815e-08
the O 0 5.945532279838517e-07
families O 0 4.9474798288429156e-05
, O 0 1.96569108084077e-05
affected O 0 5.437632353277877e-07
individuals O 0 1.1566727131651078e-08
presented O 0 2.2889703643613757e-07
a O 0 8.00835948666645e-08
novel O 0 5.475912416841311e-07
nonsense O 0 1.0280676860929816e-06
mutation O 0 1.805695504231153e-08
in O 0 1.2446408348409932e-08
exon O 0 2.2357041871146066e-06
3 O 0 1.6802874824861647e-07
of O 0 2.623409711688396e-09
the O 0 3.3322422154924425e-08
gene O 0 5.716825413060178e-08
, O 0 2.287232803155348e-08
consisting O 0 5.121760793258545e-09
in O 0 1.3125607267738815e-08
a O 0 1.6992935059079173e-07
G O 0 0.0027576747816056013
to O 0 1.8824894709723594e-07
T O 0 0.00506571214646101
transition O 0 5.9164936061506523e-08
at O 0 8.116510485933759e-08
nucleotide O 0 9.265333034136347e-08
2101 O 0 9.905576735036448e-05
, O 0 1.0175356379704681e-07
which O 0 9.827664015915616e-09
produces O 0 1.0058916366517678e-08
a O 0 1.5036409894975122e-09
stop O 0 2.720086023089152e-08
signal O 0 4.697861655245106e-08
in O 0 3.8707859140174605e-09
codon O 0 9.603632555865715e-09
82 O 0 3.6481276310951216e-07
( O 0 1.4875248588452905e-08
Glu O 0 4.349015580373816e-05
) O 0 3.663879866167008e-08
of O 0 4.695120736641911e-08
NPII O 0 0.026162808761000633
. O 0 4.648607045965036e-06

The O 0 9.86830400506733e-06
premature O 0 0.00022930985142011195
termination O 0 7.367777925537666e-06
eliminates O 0 2.952146360257757e-06
part O 0 1.0272857231541366e-08
of O 0 4.290424904240808e-09
the O 0 6.752028980372415e-08
C O 0 0.00010072955774376169
- O 0 2.1945659682387486e-05
terminal O 0 3.6586430951501825e-07
domain O 0 6.915363837123323e-09
of O 0 1.3278504518154932e-08
NPII O 0 0.013146721757948399
, O 0 4.609088577467446e-08
including O 0 5.697215477162842e-10
a O 0 1.982524810983932e-09
cysteine O 0 1.218215928133759e-08
residue O 0 5.8791915336087186e-08
in O 0 2.2558037660047603e-09
position O 0 3.0273124451696276e-08
85 O 0 2.7895197263205773e-07
, O 0 1.0661567273473338e-07
which O 0 1.4128889347375662e-07
could O 0 5.712759687526159e-08
be O 0 3.7654013240739914e-09
involved O 0 1.6126861623888544e-08
in O 0 2.916879715542109e-08
the O 0 6.857546708260998e-08
correct O 0 4.871753390034428e-06
folding O 0 4.651248309528455e-05
of O 0 1.7605559676781013e-08
the O 0 1.1614234836088144e-06
prohormone O 0 0.003084866562858224
. O 0 9.591363777872175e-06

In O 0 7.667075578865479e-07
the O 0 1.7894703319143446e-07
second O 0 4.7603789425920695e-06
family O 0 3.2983083656290546e-05
, O 0 4.6241723339335294e-08
a O 0 2.6572968270244246e-09
G279A O 0 1.7403378649305523e-07
substitution O 0 9.735754424866627e-10
at O 0 3.571334872276566e-08
position O 0 2.6492113391896055e-08
- O 0 9.136850167124067e-06
1 O 0 5.449965367887444e-09
of O 0 2.2893428819337203e-10
the O 0 2.325564629757082e-09
signal O 0 1.7852654821126634e-07
peptide O 0 2.501635094631638e-07
was O 0 8.795091162028257e-07
observed O 0 6.131959651156649e-08
in O 0 1.2366049517709143e-08
all O 0 8.739004186963939e-09
affected O 0 4.774327635459485e-07
individuals O 0 6.422170173436825e-08
. O 0 2.735554744504043e-06

This O 0 3.4234537338306836e-07
missense O 0 1.4196453776094131e-05
mutation O 0 1.5965317743393825e-06
, O 0 5.075106628282811e-07
which O 0 2.3482337496716355e-07
replaces O 0 0.000303705659462139
Ala O 0 0.0007830592803657055
with O 0 2.492985458957264e-06
Thr O 0 0.19541995227336884
, O 0 9.641789802117273e-07
is O 0 1.4669732983918493e-08
frequent O 0 1.7059021217846748e-07
among O 0 5.270543624646962e-06
FNDI B-Disease 1 0.9999752044677734
patients O 0 4.860791250393959e-06
and O 0 6.712274398523732e-07
is O 0 8.557730524216822e-08
thought O 0 5.9574521316108076e-08
to O 0 3.251921620872622e-09
reduce O 0 1.3584790181653261e-08
the O 0 1.221321155320254e-09
efficiency O 0 5.803408598126225e-08
of O 0 2.166647528056842e-09
cleavage O 0 2.8641309199883835e-06
by O 0 1.584120568054459e-08
signal O 0 1.601842200216197e-06
peptidases O 0 3.2949385058600456e-05
. O 0 2.4332709358532156e-07
. O 0 2.2101971808297094e-06

Genetic O 0 5.642524774884805e-05
heterogeneity O 0 9.606960520613939e-05
of O 0 6.4084315454238094e-06
Saethre B-Disease 1 0.9937544465065002
- I-Disease 1 0.9998828172683716
Chotzen I-Disease 1 0.9999074935913086
syndrome I-Disease 1 0.9998204112052917
, O 0 2.557123480073642e-06
due O 0 2.2505193442157179e-07
to O 0 1.0840456354799244e-07
TWIST O 0 0.0002488224708940834
and O 0 8.43866200739285e-06
FGFR O 0 0.04321940615773201
mutations O 0 3.924570137314731e-06
. O 0 6.838379704277031e-06

Thirty O 0 2.074595795420464e-05
- O 0 0.007740681990981102
two O 0 1.5097683899512049e-05
unrelated O 0 0.010572873055934906
patients O 0 1.1679011322485167e-06
with O 0 9.176009285738473e-08
features O 0 4.5767893652737257e-07
of O 0 1.587834276506328e-06
Saethre B-Disease 1 0.9684664011001587
- I-Disease 1 0.9998798370361328
Chotzen I-Disease 1 0.9999390840530396
syndrome I-Disease 1 0.9998276233673096
, O 0 6.967955869185971e-06
a O 0 2.365020463912515e-06
common O 0 6.969594687689096e-05
autosomal B-Disease 0 0.12397526204586029
dominant I-Disease 0 0.005264261271804571
condition I-Disease 0 0.0032671308144927025
of O 0 9.963851880456787e-06
craniosynostosis B-Disease 1 0.9994068145751953
and O 0 0.02534879744052887
limb B-Disease 1 0.8668060898780823
anomalies I-Disease 0 0.37085381150245667
, O 0 9.143842589764972e-07
were O 0 9.877617657139126e-08
screened O 0 1.9681921514802525e-07
for O 0 9.196804207078912e-09
mutations O 0 8.0894487552996e-08
in O 0 6.454208545392248e-08
TWIST O 0 0.0002882693079300225
, O 0 8.094346412690356e-06
FGFR2 O 0 0.011351087130606174
, O 0 1.0424444099044194e-06
and O 0 2.4580033368692966e-06
FGFR3 O 0 0.020426377654075623
. O 0 1.1201771485502832e-05

Nine O 0 1.6907348253880627e-05
novel O 0 4.572576017380925e-06
and O 0 7.288996357601718e-07
three O 0 8.186581794689118e-07
recurrent O 0 0.0004039917257614434
TWIST O 0 0.0003324416175018996
mutations O 0 4.837271490032435e-07
were O 0 9.686068125347447e-08
found O 0 5.262951958684425e-07
in O 0 1.1673248678789605e-07
12 O 0 3.854752776533132e-06
families O 0 1.2487122148741037e-05
. O 0 1.565544334880542e-05

Seven O 0 1.2973308002983686e-05
families O 0 2.0777164536411874e-05
were O 0 1.556374627398327e-06
found O 0 4.154921100507636e-07
to O 0 8.004355400714758e-09
have O 0 7.956862724256553e-09
the O 0 5.140809733461538e-08
FGFR3 O 0 0.004361564293503761
P250R O 0 1.7764723452273756e-05
mutation O 0 6.458678569742915e-08
, O 0 1.0312142961765858e-07
and O 0 5.0717286370627335e-08
one O 0 1.0339652689594914e-08
individual O 0 2.6315143841770805e-08
was O 0 1.3453957762976643e-05
found O 0 4.4568139401235385e-07
to O 0 2.0949073586962186e-08
have O 0 9.33133925684615e-09
an O 0 4.3707277797011557e-08
FGFR2 O 0 0.007941829040646553
VV269 O 0 4.0128157706931233e-05
- O 0 0.00010274232045048848
270 O 0 7.2566858762002084e-06
deletion O 0 1.683888149273116e-05
. O 0 2.6880120458372403e-06

To O 0 1.1128386177006178e-06
date O 0 1.4552290394931333e-06
, O 0 8.361994474626044e-08
our O 0 4.4473007498879724e-09
detection O 0 3.0196287070793915e-07
rate O 0 5.929983615260426e-08
for O 0 3.762500977444461e-09
TWIST O 0 3.904707409674302e-05
or O 0 9.188774470203498e-07
FGFR O 0 0.005873512476682663
mutations O 0 1.702956780036402e-07
is O 0 1.4219287969297056e-08
68 O 0 2.2133399397716857e-06
% O 0 4.9190904682916425e-09
in O 0 9.575354731339303e-09
our O 0 4.4216542960384686e-07
Saethre B-Disease 0 0.44730159640312195
- I-Disease 1 0.9997338652610779
Chotzen I-Disease 1 0.9999505281448364
syndrome I-Disease 1 0.9998675584793091
patients O 0 1.2926498129672837e-06
, O 0 1.6673608627115755e-07
including O 0 1.4365430622831354e-08
our O 0 6.942909180907009e-08
five O 0 1.0214553185505792e-06
patients O 0 9.521430115455587e-07
elsewhere O 0 5.827278073411435e-07
reported O 0 6.059449333406519e-06
with O 0 7.037717750790762e-07
TWIST O 0 0.0014337343163788319
mutations O 0 5.9755566326202825e-06
. O 0 3.5562186440074584e-06

More O 0 5.428907101645564e-08
than O 0 2.3043805086331304e-08
35 O 0 4.829749045143217e-08
different O 0 2.1222743562532287e-09
TWIST O 0 9.213180601364002e-05
mutations O 0 3.82885332328442e-07
are O 0 1.0659855220751524e-08
now O 0 8.64474429818074e-08
known O 0 2.476146931940093e-08
in O 0 1.9987304256119387e-08
the O 0 1.5263022135059146e-07
literature O 0 2.1330768618099682e-07
. O 0 4.851750873058336e-06

The O 0 8.14147142591537e-07
most O 0 1.524898962657062e-08
common O 0 6.856043199832129e-08
phenotypic O 0 3.9113245975386235e-08
features O 0 8.72980990607175e-07
, O 0 1.2931602668686537e-06
present O 0 3.5804671227879226e-08
in O 0 6.857544310179264e-09
more O 0 4.723328395073167e-10
than O 0 1.2805367877177787e-09
a O 0 9.337607131953973e-09
third O 0 3.478817802715639e-07
of O 0 3.357993350050492e-08
our O 0 4.5401850456983084e-07
patients O 0 7.877723362526012e-08
with O 0 7.714795913216221e-08
TWIST O 0 0.0002453603665344417
mutations O 0 3.2528544124943437e-07
, O 0 5.173999184648892e-08
are O 0 1.4677113968630806e-09
coronal B-Disease 0 8.238332520704716e-05
synostosis I-Disease 0 0.008509782142937183
, O 0 1.6595320175838424e-06
brachycephaly B-Disease 0 0.0006771979969926178
, O 0 8.867318115335365e-07
low B-Disease 0 8.820891525829211e-05
frontal I-Disease 1 0.7866448163986206
hairline I-Disease 1 0.9996052384376526
, O 0 9.526808571536094e-05
facial B-Disease 0 0.1417410522699356
asymmetry I-Disease 0 0.018505139276385307
, O 0 0.000724346493370831
ptosis B-Disease 1 0.8414183855056763
, O 0 5.454504207591526e-05
hypertelorism B-Disease 0 0.024096833541989326
, O 0 7.99343297330779e-07
broad B-Disease 0 2.315003484909539e-06
great I-Disease 0 1.1523033208504785e-05
toes I-Disease 0 0.03993095085024834
, O 0 1.3687651971849846e-06
and O 0 3.1529480111203156e-06
clinodactyly B-Disease 0 0.003407222218811512
. O 0 5.9431454246805515e-06

Significant O 0 1.6947116137089324e-06
intra O 0 7.029193511698395e-05
- O 0 0.003620046190917492
and O 0 6.6866687120636925e-06
interfamilial O 0 0.0012266937410458922
phenotypic O 0 6.753072057108511e-07
variability O 0 4.632699710782617e-05
is O 0 7.081736441705289e-08
present O 0 1.0138698769424082e-08
for O 0 6.833858812171911e-09
either O 0 7.277563440766244e-08
TWIST O 0 0.00022376469860319048
mutations O 0 1.8515177089284407e-06
or O 0 1.8184858845415874e-06
FGFR O 0 0.07568953931331635
mutations O 0 9.87161820376059e-06
. O 0 5.244596195552731e-06

The O 0 1.2687168009506422e-06
overlap O 0 5.061426236352418e-06
in O 0 4.5476213017536793e-07
clinical O 0 3.4421796613059996e-07
features O 0 1.1822862688859459e-07
and O 0 1.632764394798869e-07
the O 0 5.072880071566033e-08
presence O 0 1.8392709932868456e-07
, O 0 9.107657206186559e-08
in O 0 4.329050895535147e-09
the O 0 4.583364798804723e-09
same O 0 1.561945417449806e-08
genes O 0 5.766632327208754e-08
, O 0 9.59741015549298e-08
of O 0 6.484412118368255e-09
mutations O 0 5.736168873227143e-08
for O 0 1.064351495827509e-09
more O 0 4.692931598881955e-10
than O 0 9.655721555645869e-09
one O 0 1.8407274637866067e-07
craniosynostotic B-Disease 0 0.07252885401248932
condition I-Disease 0 2.522902468626853e-05
- O 0 2.003048030019272e-05
such O 0 1.3386727282238553e-09
as O 0 1.6468632679789152e-08
Saethre B-Disease 0 0.0001070078942575492
- I-Disease 0 0.00022128826822154224
Chotzen I-Disease 0 0.0001759275037329644
, I-Disease 0 3.975693800839508e-07
Crouzon I-Disease 0 0.00023015009355731308
, I-Disease 0 5.26546159562713e-07
and I-Disease 0 1.6527576008229516e-05
Pfeiffer I-Disease 1 0.8409702777862549
syndromes I-Disease 0 0.02672918699681759
- O 0 1.699477252259385e-05
support O 0 1.273362126852362e-08
the O 0 2.4000096132681392e-08
hypothesis O 0 3.527870262587385e-07
that O 0 2.145126742902903e-08
TWIST O 0 1.70762614288833e-05
and O 0 3.9169054844023776e-07
FGFRs O 0 0.00011611781519604847
are O 0 9.58496171321599e-10
components O 0 8.552182606536007e-08
of O 0 4.3034870111924306e-10
the O 0 3.268063375472252e-09
same O 0 4.422414878746395e-09
molecular O 0 7.409283284687262e-07
pathway O 0 4.174262002720752e-08
involved O 0 9.911641285498263e-09
in O 0 7.542205082700093e-09
the O 0 2.702410561994384e-08
modulation O 0 4.7762041504029185e-06
of O 0 2.9109771730873035e-06
craniofacial O 1 0.9995500445365906
and O 0 0.0006938913720659912
limb O 0 0.04432755708694458
development O 0 9.013454018713674e-07
in O 0 2.1412151340882701e-07
humans O 0 2.2406254629459e-07
. O 0 3.080777446484717e-07
. O 0 3.157220817229245e-06

Mutation O 0 1.1020031706721056e-05
analysis O 0 5.6448857321811374e-06
of O 0 1.281422191823367e-05
UBE3A O 1 0.9889634847640991
in O 1 0.988750159740448
Angelman B-Disease 1 0.9999488592147827
syndrome I-Disease 1 0.9999465942382812
patients O 0 0.0028933121357113123
. O 0 0.0005030027241446078

Angelman B-Disease 1 0.9997813105583191
syndrome I-Disease 1 0.9999376535415649
( O 0 0.0006852228543721139
AS B-Disease 0 0.07276947051286697
) O 0 5.118911576573737e-05
is O 0 1.2521338703663787e-06
caused O 0 6.154196398711065e-06
by O 0 2.506226906007214e-07
chromosome O 0 0.00012833267101086676
15q11 O 0 8.769328269409016e-05
- O 0 0.001705727307125926
q13 O 0 2.1831043341080658e-05
deletions O 0 6.593687089662126e-07
of O 0 5.6705303563830967e-08
maternal O 0 4.2089945964107756e-06
origin O 0 1.6238122668710275e-07
, O 0 1.830863851637332e-07
by O 0 3.377939776783023e-07
paternal O 0 0.00019255769439041615
uniparental B-Disease 0 0.13611900806427002
disomy I-Disease 0 0.17562632262706757
( O 0 1.2509975704233511e-06
UPD B-Disease 1 0.9981641173362732
) O 0 2.608547617910517e-07
15 O 0 9.056849137323297e-08
, O 0 1.1721439818757062e-07
by O 0 5.572414352172927e-07
imprinting O 1 0.6148375868797302
defects O 1 0.9501776099205017
, O 0 2.4308178581122775e-06
and O 0 3.2791484727567877e-07
by O 0 7.79636124548233e-08
mutations O 0 6.656534168314465e-08
in O 0 2.2115237641173735e-08
the O 0 4.964373374605202e-07
UBE3A O 0 0.0008599048596806824
gene O 0 2.788705160128302e-06
. O 0 8.793575034360401e-06

UBE3A O 0 0.00032349073444493115
encodes O 0 3.872882189170923e-06
a O 0 3.183944841111952e-07
ubiquitin O 0 0.0002612782409414649
- O 0 0.00037257213261909783
protein O 0 5.577736033046676e-07
ligase O 0 4.022901975986315e-06
and O 0 1.8389411593489058e-07
shows O 0 2.3161164790508337e-06
brain O 0 0.0001397258456563577
- O 0 3.7951413105474785e-05
specific O 0 4.781955453836417e-08
imprinting O 0 0.00023925576533656567
. O 0 1.3443350326269865e-05

Here O 0 3.9680830923316535e-06
we O 0 1.1289698420569039e-07
describe O 0 3.9423329667442886e-07
UBE3A O 0 6.553252751473337e-05
coding O 0 0.00015710591105744243
- O 0 0.006013204343616962
region O 0 2.416800725768553e-06
mutations O 0 2.3384296810036176e-07
detected O 0 7.298010018530476e-07
by O 0 1.0051056875681752e-07
SSCP O 0 0.0009263026877306402
analysis O 0 3.2817013106978266e-07
in O 0 2.035805835021165e-07
13 O 0 7.579748853459023e-06
AS B-Disease 0 0.00015704851830378175
individuals O 0 1.598913428324522e-07
or O 0 1.3998766235090443e-06
families O 0 1.3603321349364705e-05
. O 0 2.056266021099873e-05

Two O 0 5.823289370709972e-07
identical O 0 4.8867268560570665e-06
de O 0 2.5234978693333687e-06
novo O 0 1.6958060768956784e-06
5 O 0 1.6314305639753002e-07
- O 0 2.564475107647013e-05
bp O 0 6.310559001576621e-06
duplications O 0 5.331727379598306e-07
in O 0 1.2912678037935166e-08
exon O 0 1.6114981917780824e-06
16 O 0 2.685362687770976e-07
were O 0 1.3546474519898766e-07
found O 0 2.4385496999457246e-06
. O 0 5.8682180679170415e-06

Among O 0 8.846497507875029e-07
the O 0 5.604990249707953e-08
other O 0 2.032755475056547e-08
11 O 0 5.375737828217098e-07
unique O 0 3.53676981035278e-08
mutations O 0 1.8226930365017324e-07
, O 0 5.000275393740594e-08
8 O 0 5.7664674812940575e-08
were O 0 1.6202335473280982e-08
small O 0 1.9272301088335553e-08
deletions O 0 3.9444464050575334e-07
or O 0 2.1436424901821738e-07
insertions O 0 3.395276144146919e-05
predicted O 0 0.00094081019051373
to O 0 2.6788504214891873e-07
cause O 0 2.2615747639065376e-06
frameshifts O 0 0.0019219302339479327
, O 0 2.913277796778857e-07
1 O 0 1.6535808811113384e-07
was O 0 8.367305213141663e-07
a O 0 1.9519310612281515e-08
mutation O 0 5.681960235648376e-09
to O 0 1.5330637870292207e-09
a O 0 2.4465276471374864e-09
stop O 0 1.7802660678967186e-08
codon O 0 4.834345368465165e-09
, O 0 1.9406975582114683e-08
1 O 0 1.728938947564984e-08
was O 0 2.9127275524842844e-07
a O 0 8.476032320459126e-09
missense O 0 2.5827887384366477e-07
mutation O 0 2.701457013642994e-08
, O 0 8.316693822507659e-08
and O 0 1.9808820184152864e-07
1 O 0 3.3163217949550017e-07
was O 0 0.00017059016681741923
predicted O 0 0.001023917575366795
to O 0 4.916766371820813e-08
cause O 0 5.963715210555165e-08
insertion O 0 5.844108130759196e-08
of O 0 4.162135969210112e-09
an O 0 1.112346907916617e-07
isoleucine O 0 0.0019323121523484588
in O 0 8.720326150069013e-08
the O 0 6.62863541833758e-08
hect O 0 3.715366619871929e-05
domain O 0 3.1660418731149775e-09
of O 0 5.063962027485047e-10
the O 0 3.298304918075701e-08
UBE3A O 0 5.1014558266615495e-05
protein O 0 1.3787753516680823e-07
, O 0 1.2869427301609448e-08
which O 0 8.364395287507875e-10
functions O 0 3.289129524297607e-10
in O 0 9.085671770492354e-09
E2 O 0 2.498671346984338e-05
binding O 0 8.79861730140874e-08
and O 0 1.7389076845120144e-07
ubiquitin O 0 1.6212563423323445e-05
transfer O 0 1.1253194287519364e-07
. O 0 9.850240303421742e-07

Eight O 0 1.5058365079312352e-06
of O 0 1.0139901718275723e-07
the O 0 9.001255989460333e-07
cases O 0 9.874694342215662e-07
were O 0 1.485944721935084e-06
familial O 0 0.0004564076953101903
, O 0 2.082050514218281e-06
and O 0 1.1016210521574976e-07
five O 0 1.1551255596486953e-07
were O 0 2.1623287693728344e-07
sporadic O 0 3.9349588405457325e-06
. O 0 7.287644621101208e-06

In O 0 2.4357466372748604e-06
two O 0 3.532587470544968e-06
familial O 0 0.015108395367860794
cases O 0 9.049422260432038e-06
and O 0 8.363658707821742e-07
one O 0 2.2520389109104144e-08
sporadic O 0 1.002960630103189e-06
case O 0 6.3253692133002914e-06
, O 0 2.1548162294493522e-06
mosaicism O 0 0.0002078406687360257
for O 0 5.490701582289148e-08
UBE3A O 0 0.00030945095932111144
mutations O 0 4.910178290629119e-07
was O 0 1.0257397661916912e-05
detected O 0 9.923824109137058e-07
in O 0 3.2823265883052954e-08
the O 0 1.6595367924310267e-07
mother O 0 1.7280546671827324e-05
of O 0 1.3395673903460192e-08
three O 0 8.487553486702382e-07
AS B-Disease 0 0.011010777205228806
sons O 0 0.07491971552371979
, O 0 5.6845914286896e-07
in O 0 4.666996034075055e-08
the O 0 2.3780062008427194e-07
maternal O 0 6.916355687280884e-06
grandfather O 0 1.7490012396592647e-05
of O 0 3.1287326063278442e-09
two O 0 9.096008568576508e-08
AS B-Disease 0 1.5076807358127553e-05
first O 0 1.7581808720024128e-07
cousins O 0 0.0024034760426729918
, O 0 6.758089625691355e-07
and O 0 2.986735410104302e-07
in O 0 9.623934715818905e-08
the O 0 3.9927618900037487e-07
mother O 0 5.4737687605666e-05
of O 0 3.102421075595885e-08
an O 0 5.469983648254129e-07
AS B-Disease 0 0.005944996606558561
daughter O 0 0.03291279450058937
. O 0 3.1288025638787076e-05

The O 0 7.573273563821203e-08
frequencies O 0 4.6215890847634e-07
with O 0 3.543495665780938e-07
which O 0 3.2226256507783546e-07
we O 0 2.44599220877717e-08
detected O 0 2.4353835215151776e-07
mutations O 0 7.912188237924056e-09
were O 0 1.5751359327964565e-08
5 O 0 7.928295531201002e-08
( O 0 4.5396890691051794e-09
14 O 0 1.7836555343819782e-07
% O 0 1.0084196588877603e-08
) O 0 6.319297973789162e-09
of O 0 2.207594995695672e-09
35 O 0 6.164442112321922e-08
in O 0 2.1173912401195594e-08
sporadic O 0 4.442945567006973e-07
cases O 0 8.33436715197422e-08
and O 0 2.8557909104165446e-07
8 O 0 2.0616223537217593e-06
( O 0 3.171525619904969e-08
80 O 0 6.735731261642286e-08
% O 0 9.992351834853253e-09
) O 0 1.6598907137677088e-08
of O 0 3.3872344928909115e-09
10 O 0 2.4777278895271593e-07
in O 0 1.0459737040946493e-06
familial O 0 0.0007482838700525463
cases O 0 4.877620085608214e-06
. O 0 1.938152763614198e-06
. O 0 1.9602082829806022e-05

The O 0 7.465746602974832e-05
hemochromatosis B-Disease 1 0.9982764720916748
845 O 0 0.03926260024309158
G O 0 0.10864301025867462
- O 0 0.007962899282574654
- O 0 0.0016557610360905528
> O 0 4.1789226656874234e-07
A O 0 5.11114350842945e-09
and O 0 1.4477823384595467e-08
187 O 0 4.887986051471671e-07
C O 0 6.376439159794245e-06
- O 0 0.00013833913544658571
- O 0 0.0008312081336043775
> O 0 1.971155370483757e-06
G O 0 0.0003695386985782534
mutations O 0 1.3676243781901576e-07
: O 0 6.125483054120195e-08
prevalence O 0 1.0418680176371709e-06
in O 0 2.313267266629282e-08
non O 0 3.083643491663679e-07
- O 0 0.002590105403214693
Caucasian O 0 0.00019643963605631143
populations O 0 8.697916200617328e-07
. O 0 2.33858872888959e-06

Hemochromatosis B-Disease 1 0.9919915795326233
, O 0 0.008877130225300789
the O 0 0.3970368802547455
inherited B-Disease 1 0.9999666213989258
disorder I-Disease 1 0.9998766183853149
of I-Disease 0 2.8011798349325545e-05
iron I-Disease 1 0.9709470868110657
metabolism I-Disease 0 0.001515734358690679
, O 0 1.4694043784402311e-05
leads O 0 9.221091022482142e-05
, O 0 8.21408502815757e-06
if O 0 2.9505702059395844e-06
untreated O 0 0.00019374223484192044
, O 0 2.994207477513555e-07
to O 0 1.9605302270520042e-07
progressive O 0 0.0005450082826428115
iron B-Disease 1 0.9655663967132568
overload I-Disease 0 0.40067997574806213
and O 0 3.7673791666748e-05
premature B-Disease 0 0.0012472394155338407
death I-Disease 0 6.28366251476109e-05
. O 0 9.104423952521756e-06

The O 0 0.00019356868870090693
hemochromatosis B-Disease 1 0.9988043308258057
gene O 0 4.923250889987685e-05
, O 0 3.5109165764879435e-05
HFE O 0 0.016566477715969086
, O 0 1.1964675650233403e-05
recently O 0 0.00011277661542408168
has O 0 1.9776366571022663e-06
been O 0 2.4580216972935887e-07
identified O 0 1.4782048083361587e-06
, O 0 3.8115953771011846e-07
and O 0 2.622771262394963e-07
characterization O 0 4.0251547943626065e-06
of O 0 1.2605066324056224e-08
this O 0 1.0782074788551199e-08
gene O 0 1.577882073888759e-07
has O 0 1.006661364044703e-06
shown O 0 2.013846511772499e-07
that O 0 4.507096207362338e-08
it O 0 6.404711427876464e-09
contains O 0 8.979336163505991e-10
two O 0 3.950220417436867e-08
mutations O 0 8.30333206636169e-08
that O 0 1.3234105367132543e-08
result O 0 1.1688348955374295e-08
in O 0 1.0870800926099378e-09
amino O 0 3.753381494497887e-10
acid O 0 2.9119903710572714e-10
substitutions O 0 4.243447537799483e-10
- O 0 6.359637438890786e-08
cDNA O 0 3.087474098606435e-08
nucleotides O 0 4.0981571913789594e-08
845 O 0 6.579713044629898e-06
G O 0 0.0008475333452224731
- O 0 0.00034867439535446465
- O 0 0.000677602831274271
> O 0 2.4261851194751216e-07
A O 0 2.0855303262123925e-08
( O 0 9.014811119811839e-09
C282Y O 0 8.123083148348087e-07
) O 0 1.9290531394489108e-09
and O 0 2.7288407089542943e-09
187 O 0 1.7215884895449562e-07
C O 0 5.212638370721834e-06
- O 0 0.0001306561316596344
- O 0 0.004958909936249256
> O 0 6.4304340412491e-06
G O 0 0.0010298696579411626
( O 0 8.93213041308627e-08
H63D O 0 0.0002454961067996919
) O 0 4.801743216376053e-07
. O 0 8.083385409918264e-07

Although O 0 0.00688038719817996
hemochromatosis B-Disease 1 0.9993466734886169
is O 0 5.558260909310775e-06
common O 0 7.084208277774451e-07
in O 0 9.21932041819673e-07
Caucasians O 0 1.9531733414623886e-05
, O 0 4.5450977381733537e-07
affecting O 0 1.1312287995224324e-07
> O 0 1.0521405329200206e-06
= O 0 1.1405798431951553e-05
1 O 0 6.877194635990236e-08
/ O 0 7.673681352571293e-07
300 O 0 4.828966382319777e-08
individuals O 0 3.6757194510350644e-10
of O 0 3.3066729909769776e-10
northern O 0 1.5509288076032135e-08
European O 0 3.0813856710665277e-07
origin O 0 1.276735872579593e-07
, O 0 2.2432638502323243e-07
it O 0 6.969737142981103e-08
has O 0 1.962969804480963e-07
not O 0 6.89623824712271e-09
been O 0 2.3747647404093186e-08
recognized O 0 5.883046938492953e-09
in O 0 1.9555717045705023e-08
other O 0 9.658930366640561e-08
populations O 0 1.6229790844590752e-06
. O 0 3.133113978037727e-06

The O 0 4.427160718023515e-07
present O 0 4.590471291976428e-08
study O 0 3.0924469651694153e-09
used O 0 2.964372303182472e-09
PCR O 0 1.4249092146201292e-06
and O 0 6.811141162188505e-08
restriction O 0 3.4901553647159744e-08
- O 0 6.792693056922872e-06
enzyme O 0 8.178093935384823e-08
digestion O 0 7.809011748349803e-08
to O 0 2.2386022202613987e-10
analyze O 0 2.19899676245916e-09
the O 0 1.980807740054047e-10
frequency O 0 1.3002656729099726e-09
of O 0 3.8315153827461756e-10
the O 0 8.383629790387204e-09
845 O 0 0.00011007581633748487
G O 0 0.011492726393043995
- O 0 0.0003541446931194514
- O 0 0.00013750062498729676
> O 0 2.6899654059775457e-08
A O 0 1.2535075200048595e-09
and O 0 5.588089546648689e-09
187 O 0 1.54275980435159e-07
C O 0 4.600942702381872e-06
- O 0 4.0978782635647804e-05
- O 0 0.00012044273898936808
> O 0 2.3763104195495544e-07
G O 0 1.8670823919819668e-05
mutations O 0 6.4908838304233996e-09
in O 0 4.4625867445802214e-09
HLA O 0 2.2856468149257125e-06
- O 0 1.677614932305005e-06
typed O 0 4.180764179295693e-08
samples O 0 9.233433573285765e-09
from O 0 1.8402556145602489e-09
non O 0 9.557018287864594e-09
- O 0 6.931893585715443e-05
Caucasian O 0 4.3677686335286126e-05
populations O 0 5.2969397756896797e-08
, O 0 2.2039442271193366e-08
comprising O 0 7.30076443744565e-09
Australian O 0 2.1721692178289231e-07
Aboriginal O 0 2.49315633027436e-07
, O 0 7.978659510854413e-08
Chinese O 0 6.23767526519714e-09
, O 0 6.569278099277653e-08
and O 0 4.1920387161553663e-07
Pacific O 0 4.079988502780907e-05
Islanders O 0 1.5881094441283494e-05
. O 0 5.389728812588146e-06

Results O 0 5.193125980440527e-05
showed O 0 3.4866992791648954e-05
that O 0 5.4856979403439254e-08
the O 0 5.698242588891844e-08
845 O 0 0.0002567088813520968
G O 0 0.005804851185530424
- O 0 0.0031043714843690395
- O 0 0.006258385721594095
> O 0 5.173057502361189e-07
A O 0 2.8164047094492162e-08
mutation O 0 8.287383224114819e-08
was O 0 2.693508577067405e-06
present O 0 2.654218356212823e-08
in O 0 2.6222853222179765e-08
these O 0 9.538770662231855e-09
populations O 0 1.6893521248562138e-08
( O 0 5.384907519889737e-10
allele O 0 1.4186745111999244e-09
frequency O 0 3.083206356890855e-09
0 O 0 4.177700851926147e-09
. O 0 2.0023087632381475e-09
32 O 0 6.024527010595193e-08
% O 0 7.128161616520856e-09
) O 0 1.75487340214886e-08
, O 0 2.558054035262103e-08
and O 0 6.262378349219944e-08
, O 0 1.8199730789092428e-07
furthermore O 0 1.6058818630426686e-07
, O 0 6.306272126721524e-08
it O 0 3.3033668245252557e-08
was O 0 9.70186420090613e-07
always O 0 5.480155351733629e-08
seen O 0 4.798749131396107e-08
in O 0 4.00528366029107e-09
conjunction O 0 3.8208497699088184e-08
with O 0 3.355701494456298e-07
HLA O 0 0.00046333856880664825
haplotypes O 0 1.8256228941027075e-05
common O 0 7.340394603261302e-08
in O 0 8.111464921967126e-08
Caucasians O 0 3.9042620301188435e-06
, O 0 1.5337964498485235e-07
suggesting O 0 3.891568098879361e-07
that O 0 2.7010294445517502e-08
845 O 0 0.00015215788153000176
G O 0 0.041501063853502274
- O 0 0.0019060684135183692
- O 0 0.0011378575582057238
> O 0 4.914975875180971e-07
A O 0 1.355709855488385e-07
may O 0 3.987731247434567e-07
have O 0 6.495689319763187e-09
been O 0 4.260513275511357e-09
introduced O 0 4.564164157727646e-09
into O 0 1.110133096560162e-09
these O 0 3.1420266388693108e-09
populations O 0 6.346526504330541e-08
by O 0 2.0411363266248372e-07
Caucasian O 0 0.00045888908789493144
admixture O 0 0.0012215512106195092
. O 0 2.5952724172384478e-05

187 O 0 6.861156725790352e-05
C O 0 0.0005348414415493608
- O 0 0.004264638293534517
- O 0 0.046226728707551956
> O 0 6.763996498193592e-05
G O 0 0.008046443574130535
was O 0 3.838194061245304e-06
present O 0 1.0694517271758741e-08
at O 0 2.288882505752099e-08
an O 0 7.146440661465192e-10
allele O 0 1.459187526364758e-08
frequency O 0 6.2083107543742244e-09
of O 0 9.467951755937065e-09
2 O 0 2.418324811515049e-06
. O 0 5.805511591461254e-06

68 O 0 0.001280790544115007
% O 0 2.1633654796460178e-06
in O 0 6.029055299450192e-08
the O 0 2.6665592400831883e-08
two O 0 2.9155066272323893e-07
populations O 0 9.528378654977132e-07
analyzed O 0 3.123689339190605e-06
( O 0 8.71636842703083e-08
Australian O 0 8.10673043361021e-07
Aboriginal O 0 7.098998935362033e-07
and O 0 2.6773361128107354e-07
Chinese O 0 5.885788922910251e-08
) O 0 2.740696629643935e-07
. O 0 7.667500199204369e-07

In O 0 4.674853926189826e-07
the O 0 1.0980191689213825e-07
Australian O 0 5.320106311046402e-07
Aboriginal O 0 9.456206129243583e-08
samples O 0 1.6670293589982066e-08
, O 0 7.845345706414264e-09
187 O 0 1.2904435209293297e-07
C O 0 5.776485068054171e-06
- O 0 0.00014693717821501195
- O 0 0.00044102477841079235
> O 0 1.450206923436781e-06
G O 0 0.000811891455668956
was O 0 2.7304097329761134e-06
found O 0 2.4229731820923917e-07
to O 0 8.813477059277375e-09
be O 0 1.6127568613910626e-08
associated O 0 1.1617763107096835e-07
with O 0 3.524877172367269e-07
HLA O 0 0.000911880168132484
haplotypes O 0 1.513302959210705e-05
common O 0 1.345069904346019e-07
in O 0 4.2273035205653287e-07
Caucasians O 0 3.452974124229513e-05
, O 0 1.6253148942269036e-06
suggesting O 0 2.9273912787175504e-06
that O 0 2.465336201851187e-08
it O 0 1.4649153889934041e-08
was O 0 2.5604711595406116e-07
introduced O 0 7.753770603358134e-08
by O 0 2.4671896525774173e-08
recent O 0 1.5832677036087262e-06
admixture O 0 0.00025504824589006603
. O 0 1.6242383935605176e-05

In O 0 6.020006821927382e-07
the O 0 5.515199319461317e-08
Chinese O 0 1.1462451432464604e-08
samples O 0 1.788765224830513e-08
analyzed O 0 5.531148872250924e-08
, O 0 1.790489001507467e-08
187 O 0 1.7159777598863002e-07
C O 0 8.697336852492299e-06
- O 0 0.00015721964882686734
- O 0 0.002443028846755624
> O 0 2.9213169909780845e-06
G O 0 0.0016331931110471487
was O 0 6.456956725742202e-06
present O 0 7.247988520475701e-08
in O 0 1.2375538460673852e-07
association O 0 1.2863347365055233e-07
with O 0 9.111563947783452e-09
a O 0 1.343738453840615e-08
wide O 0 5.986188966744521e-08
variety O 0 9.152844704374274e-09
of O 0 9.400906719747582e-08
HLA O 0 0.0069435881450772285
haplotypes O 0 0.000218048196984455
, O 0 4.907528250441828e-07
showing O 0 8.449981123703765e-07
this O 0 5.941449110480335e-09
mutation O 0 3.856828190151873e-09
to O 0 6.219036396970523e-09
be O 0 6.2076708218228305e-09
widespread O 0 9.603452610917884e-08
and O 0 1.4355454140968504e-06
likely O 0 2.996446823999577e-07
to O 0 1.5118983398565433e-08
predate O 0 2.841638661266188e-06
the O 0 1.8080520414187617e-09
more O 0 6.304630706388537e-10
genetically O 0 1.0938511962876873e-07
restricted O 0 1.6941889668942167e-08
845 O 0 0.00014356960309669375
G O 0 0.01608818769454956
- O 0 0.0022423367481678724
- O 0 0.0007198055973276496
> O 0 6.301198141045461e-07
A O 0 5.8887760445713866e-08
mutation O 0 2.521361466278904e-07
. O 0 3.2199300221691374e-06

Genotype O 0 0.003774391021579504
- O 0 0.04367685317993164
phenotype O 0 0.0009962061885744333
correlations O 0 0.00035003022640012205
in O 0 0.00021160311007406563
attenuated B-Disease 1 0.9918400049209595
adenomatous I-Disease 1 0.9992967844009399
polyposis I-Disease 1 0.9991037249565125
coli I-Disease 1 0.9976314306259155
. O 0 0.0007279421552084386

Germ O 0 0.13828234374523163
- O 0 0.0031050986144691706
line O 0 4.664338121074252e-05
mutations O 0 8.725448310542561e-07
of O 0 5.773246414264577e-08
the O 0 2.8608333195734303e-06
tumor B-Disease 0 0.00962537620216608
suppressor O 0 9.742660768097267e-05
APC O 0 0.00016362470341846347
are O 0 3.987677033023829e-08
implicated O 0 8.372398588107899e-05
in O 0 4.888033799943514e-05
attenuated B-Disease 1 0.9923654198646545
adenomatous I-Disease 1 0.9999178647994995
polyposis I-Disease 1 0.9998619556427002
coli I-Disease 1 0.9998965263366699
( O 0 0.0024667365942150354
AAPC B-Disease 1 0.9998745918273926
) O 0 2.862077735699131e-06
, O 0 2.6866385383073066e-07
a O 0 2.55009695138142e-07
variant O 0 0.00023053355107549578
of O 0 0.00026054662885144353
familial B-Disease 1 0.9999042749404907
adenomatous I-Disease 1 0.9997950196266174
polyposis I-Disease 1 0.9999134540557861
( O 0 7.177582301665097e-05
FAP B-Disease 0 0.0005470075411722064
) O 0 5.86808891966939e-06
. O 0 9.729636076372117e-06

AAPC B-Disease 1 0.9976770281791687
is O 0 8.415437150688376e-06
recognized O 0 1.9708085119418683e-07
by O 0 3.561552475161989e-08
the O 0 1.690802697851268e-08
occurrence O 0 9.571524373086504e-08
of O 0 1.350864486937553e-08
< O 0 4.158839601586806e-06
100 O 0 4.2679820921875944e-07
colonic B-Disease 0 0.0026860390789806843
adenomas I-Disease 0 0.014699640683829784
and O 0 7.328028317488133e-08
a O 0 6.926428142151053e-08
later O 0 5.4079679102869704e-05
onset O 0 0.0712197795510292
of O 0 0.3538930118083954
colorectal B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999749660491943
( O 0 1.8956565099870204e-06
age O 0 1.575462761138624e-06
> O 0 9.209531413034711e-07
40 O 0 1.3938456788764597e-07
years O 0 1.0634042837409652e-06
) O 0 4.571641909478785e-07
. O 0 1.1506664350235951e-06

The O 0 7.477607368855388e-07
aim O 0 2.707224439291167e-06
of O 0 2.959582978689923e-08
this O 0 1.0985111487116228e-08
study O 0 1.528900384073495e-08
was O 0 2.0557803281917586e-07
to O 0 8.373417514917492e-09
assess O 0 5.066595463176782e-07
genotype O 0 4.121307483728742e-06
- O 0 0.00041467210394330323
phenotype O 0 2.103555016219616e-05
correlations O 0 1.7480173482908867e-05
in O 0 2.1138552256161347e-05
AAPC B-Disease 1 0.9994020462036133
families O 0 0.00011241714673815295
. O 0 1.1640175216598436e-05

By O 0 8.765449024394911e-07
protein O 0 1.2506254734034883e-06
- O 0 5.216434146859683e-05
truncation O 0 9.557752491673455e-06
test O 0 8.552432291253353e-07
( O 0 2.2710864300279354e-09
PTT O 0 4.1894654145835375e-07
) O 0 3.160075312536037e-09
assay O 0 6.419255527134737e-08
, O 0 2.904569917916433e-09
the O 0 7.450295380628802e-10
entire O 0 1.6656976242757082e-08
coding O 0 2.723115358094219e-05
region O 0 6.327622514845643e-08
of O 0 9.890541718959867e-10
the O 0 3.1504598041465215e-08
APC B-Disease 0 3.7486792280105874e-05
gene O 0 1.9487286806452175e-07
was O 0 3.3391663691872964e-06
screened O 0 5.917983685321815e-07
in O 0 1.1869090599248011e-07
affected O 0 2.7231544663663954e-07
individuals O 0 6.153867193603446e-09
from O 0 1.111778473728009e-07
11 O 0 0.00023951916955411434
AAPC B-Disease 1 0.9998874664306641
kindreds O 0 0.007355164270848036
, O 0 2.3878462229731667e-07
and O 0 1.3284685351777625e-08
their O 0 3.6378349221877215e-09
phenotypic O 0 2.1289894291953715e-08
differences O 0 2.5818874291871907e-06
were O 0 1.4868858215777436e-06
examined O 0 0.00010751408990472555
. O 0 1.2271836567379069e-05

Five O 0 3.474299546724069e-06
novel O 0 2.095282070513349e-05
germ O 0 0.03334870561957359
- O 0 0.006737339310348034
line O 0 8.62974557094276e-05
APC B-Disease 0 0.00016586486890446395
mutations O 0 2.962184737498319e-07
were O 0 8.910622284474812e-08
identified O 0 2.6011201725850697e-07
in O 0 2.5051923557839473e-07
seven O 0 2.908981969085289e-06
kindreds O 0 0.001324596581980586
. O 0 9.01832027011551e-06

Mutations O 0 1.3944753845862579e-05
were O 0 4.23443736963236e-07
located O 0 7.062730134066442e-08
in O 0 1.0051321552850823e-08
three O 0 3.6481739851268458e-09
different O 0 6.500395222097666e-10
regions O 0 2.8830604570373453e-09
of O 0 3.8008156622026945e-09
the O 0 1.305411956309399e-07
APC B-Disease 0 0.00021071442461106926
gene O 0 1.4447540763740108e-07
( O 0 9.613474460934412e-09
1 O 0 2.271078791693526e-08
) O 0 1.9348615154513027e-08
at O 0 8.487037206350578e-08
the O 0 4.5852361907350314e-09
5 O 0 3.107911439315103e-08
end O 0 6.808880925746053e-08
spanning O 0 4.506777884216717e-08
exons O 0 1.63133876185384e-07
4 O 0 1.4740925280420925e-07
and O 0 1.3272016019527655e-07
5 O 0 3.391552070297621e-07
, O 0 2.44926553705227e-07
( O 0 7.558218939607286e-09
2 O 0 3.889615740604313e-08
) O 0 1.1597538485119685e-09
within O 0 7.705534821322857e-11
exon O 0 5.360759018913086e-07
9 O 0 1.6605467862973455e-06
, O 0 1.851564093158231e-07
and O 0 2.824712055371492e-07
( O 0 1.6527950563727245e-08
3 O 0 7.690833569995448e-08
) O 0 2.0584124627021083e-08
at O 0 5.447453332863006e-08
the O 0 6.077742309429368e-09
3 O 0 5.41299357337266e-07
distal O 0 2.368749846937135e-05
end O 0 4.511904307946679e-07
of O 0 4.8109720651723364e-09
the O 0 1.2087498646451422e-07
gene O 0 1.0514945643080864e-06
. O 0 5.632238298858283e-06

Variability O 0 0.0003541507467161864
in O 0 3.090243865244702e-07
the O 0 5.161678373610812e-08
number O 0 9.209199447468563e-08
of O 0 0.0004117440548725426
colorectal B-Disease 1 0.9999953508377075
adenomas I-Disease 1 0.9999760389328003
was O 0 0.004484087228775024
most O 0 3.2279621109410073e-07
apparent O 0 0.0001564709673402831
in O 0 4.7538460989926534e-07
individuals O 0 1.4273824788801903e-08
with O 0 2.5289907057413075e-07
mutations O 0 7.504597760998877e-07
in O 0 9.362827313452726e-08
region O 0 3.4074153631991067e-07
1 O 0 1.9164500031365606e-07
, O 0 7.251998113133595e-07
and O 0 4.653530595533084e-06
upper O 0 0.0025166841223835945
- O 1 0.9554227590560913
gastrointestinal O 0 0.02443733625113964
manifestations O 0 3.3435894692956936e-06
were O 0 5.215574674366508e-07
more O 0 4.0313025806426594e-07
severe O 0 0.0002598891733214259
in O 0 2.045712079734585e-07
them O 0 2.5205486053891946e-07
. O 0 1.0463324542797636e-05

In O 0 8.026150680962019e-06
individuals O 0 3.2598885013612744e-07
with O 0 2.3951309913172736e-07
mutations O 0 2.943140771094477e-07
in O 0 5.001630043466321e-08
either O 0 2.499740681116691e-08
region O 0 8.493871206383119e-08
2 O 0 1.8573683746581082e-07
or O 0 6.749711189968366e-08
region O 0 2.852932539099129e-07
3 O 0 2.8520432238110516e-07
, O 0 4.7683482051752435e-08
the O 0 5.2771316205735275e-09
average O 0 7.640493038252316e-08
number O 0 3.5625564720476177e-09
of O 0 8.070461632314618e-08
adenomas B-Disease 0 0.008265713229775429
tended O 0 2.264854686018225e-07
to O 0 6.635236360352792e-09
be O 0 1.6432455396397927e-08
lower O 0 9.806356047192821e-07
than O 0 1.6601028107743332e-08
those O 0 6.678204300669677e-08
in O 0 1.1669998656316238e-07
individuals O 0 1.630715829037399e-08
with O 0 1.3799041198581108e-07
mutations O 0 2.2744477234937222e-07
in O 0 3.564386474863568e-08
region O 0 3.13399652895896e-07
1 O 0 2.28438651106444e-07
, O 0 9.810948995436775e-07
although O 0 2.337667268648147e-07
age O 0 2.851642875612015e-06
at O 0 6.355746154440567e-05
diagnosis O 0 0.00010667159949662164
was O 0 1.5436295143445022e-05
similar O 0 8.604902177467011e-06
. O 0 2.2515878299600445e-05

In O 0 6.368951289914548e-06
all O 0 2.5909989744832274e-06
AAPC B-Disease 1 0.996880292892456
kindreds O 0 0.001553337904624641
, O 0 2.7483000053507567e-07
a O 0 2.348817673691883e-08
predominance O 0 6.096819561207667e-06
of O 0 2.0148722512658424e-07
right O 0 0.00012569897808134556
- O 1 0.9994182586669922
sided O 1 0.9999583959579468
colorectal B-Disease 1 0.9999914169311523
adenomas I-Disease 1 0.9999516010284424
and O 0 0.04258774593472481
rectal B-Disease 1 0.9980422258377075
polyp I-Disease 1 0.7944852709770203
sparing O 0 6.202890654094517e-05
was O 0 2.1201196432230063e-05
observed O 0 5.958684141660342e-06
. O 0 1.0031089004769456e-05

No O 0 0.0003903074248228222
desmoid B-Disease 1 0.992367684841156
tumors I-Disease 1 0.9996479749679565
were O 0 3.587711489672074e-06
found O 0 1.8487686475054943e-06
in O 0 1.3545752608479233e-07
these O 0 2.0539165745958599e-07
kindreds O 0 0.0004113383765798062
. O 0 1.0305698197043967e-05

Our O 0 5.049567448622838e-07
data O 0 4.645345597964479e-06
suggest O 0 2.5926256057573482e-06
that O 0 2.0683306445334892e-07
, O 0 2.6200414140475914e-06
in O 0 7.362888936768286e-06
AAPC B-Disease 1 0.9998736381530762
families O 0 9.231672265741508e-06
, O 0 1.090066845677029e-07
the O 0 5.4507243163470775e-09
location O 0 2.7148095327333976e-08
of O 0 5.3882800443716405e-09
the O 0 1.1374939958841424e-06
APC B-Disease 0 0.015548931434750557
mutation O 0 1.0519586794544011e-05
may O 0 1.1665024430840276e-05
partially O 0 2.8325363018666394e-05
predict O 0 7.522274358962022e-07
specific O 0 3.988192442960781e-09
phenotypic O 0 3.602717413286882e-08
expression O 0 1.0587196896949536e-07
. O 0 4.584658199746627e-06

This O 0 7.979631391208386e-07
should O 0 1.4526651170854166e-07
help O 0 9.948824697403325e-08
in O 0 4.7556212301458345e-09
the O 0 4.126131880610728e-09
design O 0 4.761432421673817e-07
of O 0 1.1078386208396296e-08
tailored O 0 1.6160403902176768e-05
clinical O 0 3.6127132716501364e-06
- O 0 0.009349408559501171
management O 0 9.754917300597299e-06
protocols O 0 8.863936500347336e-07
in O 0 1.1582667269749436e-08
this O 0 9.213163010279857e-10
subset O 0 1.9864092593024907e-08
of O 0 6.724717849238004e-08
FAP B-Disease 0 0.0008072181371971965
patients O 0 8.62139302171272e-07
. O 0 4.5386698843685735e-07
. O 0 5.1963979785796255e-06

Wilms B-Disease 1 0.7857102751731873
' I-Disease 0 0.00019320985302329063
tumor I-Disease 0 0.00030075511313043535
1 O 0 1.6837331884289597e-07
and O 0 4.1966148955907556e-07
Dax O 0 0.06758583337068558
- O 0 0.00017033968470059335
1 O 0 3.601714126943989e-08
modulate O 0 2.7799296731245704e-07
the O 0 3.496225176036205e-08
orphan O 0 8.475875802105293e-06
nuclear O 0 1.3180068890505936e-05
receptor O 0 4.6437584444447566e-08
SF O 0 0.0001674044760875404
- O 0 1.5331164831877686e-05
1 O 0 2.236389384790982e-08
in O 0 6.75084166346096e-09
sex O 0 5.975864780793927e-08
- O 0 7.763337634969503e-06
specific O 0 2.1514849901649313e-09
gene O 0 5.5447006985787084e-08
expression O 0 5.8017928239451066e-08
. O 0 2.7126982331537874e-06

Products O 0 7.566662588942563e-06
of O 0 4.3380799752412713e-07
steroidogenic O 0 0.0006459098658524454
factor O 0 1.0547636293267715e-06
1 O 0 1.6128760194078495e-07
( O 0 3.470261589200163e-08
SF O 0 0.002061894629150629
- O 0 0.0002591710945125669
1 O 0 2.2186898718246084e-07
) O 0 9.175221293844515e-08
and O 0 3.3720409646775806e-06
Wilms B-Disease 0 0.47996699810028076
tumor I-Disease 0 0.0008473678608424962
1 O 0 1.7618198455693346e-07
( O 0 5.3074071360015296e-08
WT1 O 0 0.0002359141653869301
) O 0 5.6339192866516896e-08
genes O 0 6.385646234008391e-09
are O 0 1.0108103937200852e-10
essential O 0 3.9681286034820573e-10
for O 0 2.2449355707720997e-09
mammalian O 0 1.2434494465196622e-06
gonadogenesis O 0 0.00019766221521422267
prior O 0 5.107793654701709e-08
to O 0 1.4101557255230546e-08
sexual O 0 2.964731038446189e-07
differentiation O 0 3.93570144296973e-06
. O 0 7.60047214498627e-06

In O 0 1.4930227507647942e-06
males O 0 2.7718156161427032e-06
, O 0 1.485528173361672e-06
SF O 0 0.014994506724178791
- O 0 0.0002699113974813372
1 O 0 6.285845444153892e-08
participates O 0 2.5747658227714965e-08
in O 0 3.313267171733969e-08
sexual O 0 2.2274544164702093e-07
development O 0 6.884964420805773e-08
by O 0 4.817262144740653e-09
regulating O 0 2.061209691817112e-08
expression O 0 7.33201999114641e-10
of O 0 1.0728793409242598e-09
the O 0 6.897688109575029e-08
polypeptide O 0 1.0677296813810244e-05
hormone O 0 2.613647609450709e-07
Mullerian O 0 2.0686018615378998e-05
inhibiting O 0 2.990844905070844e-06
substance O 0 1.838081857385987e-06
( O 0 2.1748306266999862e-07
MIS O 0 0.0002681103942450136
) O 0 8.556373245482973e-07
. O 0 1.6425457260993426e-06

Here O 0 9.956329449778423e-06
, O 0 1.0181621519222972e-06
we O 0 1.8561902237479444e-08
show O 0 5.223040488999686e-08
that O 0 2.988729619346486e-08
WT1 O 0 9.406691970070824e-05
- O 0 0.00020318194583524019
KTS O 0 0.0029415511526167393
isoforms O 0 9.52326395520231e-09
associate O 0 4.308616396997422e-08
and O 0 4.054617264159788e-08
synergize O 0 1.322315165452892e-05
with O 0 4.603737977504352e-07
SF O 0 0.019442815333604813
- O 0 6.409922934835777e-05
1 O 0 3.009413873655831e-08
to O 0 2.4011073129770466e-09
promote O 0 3.0565370678914405e-08
MIS O 0 2.1410452973213978e-05
expression O 0 5.537080838280417e-08
. O 0 1.1170407105964841e-06

In O 0 6.849678356957156e-06
contrast O 0 3.1686362490290776e-05
, O 0 9.907664207275957e-06
WT1 O 0 0.002596262376755476
missense O 0 1.7360393030685373e-05
mutations O 0 2.7691842205967987e-06
, O 0 1.2370752529022866e-06
associated O 0 2.6732462288237e-07
with O 0 4.210164377127512e-07
male B-Disease 0 7.07008657627739e-05
pseudohermaphroditism I-Disease 1 0.9994995594024658
in O 0 4.3472238758113235e-05
Denys B-Disease 1 0.997637152671814
- I-Disease 1 0.9999010562896729
Drash I-Disease 1 0.9999417066574097
syndrome I-Disease 1 0.999901294708252
, O 0 4.960226306138793e-06
fail O 0 1.4531739225276397e-06
to O 0 1.0982325271413629e-08
synergize O 0 3.4873308322858065e-05
with O 0 5.810685479445965e-07
SF O 0 0.15115682780742645
- O 0 0.0004977917997166514
1 O 0 1.1151631724715116e-06
. O 0 1.2601132084455458e-06

Additionally O 0 1.4718910279043484e-05
, O 0 9.630624617784633e-07
the O 0 4.550016114990285e-07
X O 0 0.008530372753739357
- O 0 0.008483105339109898
linked O 0 8.158139098668471e-05
, O 0 1.7730793899772834e-07
candidate O 0 2.7737772967384444e-08
dosage O 0 4.6540711196030315e-07
- O 0 1.702158260741271e-05
sensitive O 0 8.398211548410472e-07
sex O 0 2.2225569296097092e-07
- O 0 9.521032916381955e-05
reversal O 0 6.677517376374453e-06
gene O 0 1.684313666316939e-08
, O 0 1.9077585733384694e-08
Dax O 0 0.003735146950930357
- O 0 0.00010359565931139514
1 O 0 4.132710529347605e-08
, O 0 2.9471564744198986e-08
antagonizes O 0 1.4698925951961428e-06
synergy O 0 3.1028150715428637e-07
between O 0 4.2571361547061315e-08
SF O 0 0.008687163703143597
- O 0 0.0001371295511489734
1 O 0 7.110077149263816e-08
and O 0 2.2545967226506036e-07
WT1 O 0 0.0005696941516362131
, O 0 2.2596034909838636e-07
most O 0 3.984915508681297e-09
likely O 0 2.569829860021855e-08
through O 0 3.87607390628375e-10
a O 0 6.127580665094001e-10
direct O 0 1.457272635896345e-10
interaction O 0 1.705477425950619e-09
with O 0 3.273761706168443e-07
SF O 0 0.2876308560371399
- O 0 0.0013297233963385224
1 O 0 7.458341997335083e-07
. O 0 1.7773385252439766e-06

We O 0 5.745640123677731e-07
propose O 0 5.023040330343065e-07
that O 0 7.222512721227758e-08
WT1 O 0 2.353263698751107e-05
and O 0 2.0670134404099372e-07
Dax O 0 0.03296789899468422
- O 0 0.00018399005057290196
1 O 0 4.7384837387198786e-08
functionally O 0 2.5575255335752445e-07
oppose O 0 7.179274064128549e-09
each O 0 3.435989825995023e-10
other O 0 4.035681566705307e-09
in O 0 2.3690425621225586e-07
testis O 0 0.0009249745635315776
development O 0 2.577959890004422e-08
by O 0 2.136327559298934e-08
modulating O 0 8.38859432406025e-06
SF O 0 0.006459665950387716
- O 0 7.073843880789354e-05
1 O 0 8.243147675557339e-08
- O 0 1.4925592950021382e-05
mediated O 0 2.096499338222202e-05
transactivation O 0 4.553335747914389e-05
. O 0 2.2054838666463183e-07
. O 0 8.724367148715828e-07

A O 0 6.060489795345347e-06
mouse O 0 0.0002602919121272862
model O 0 5.049068931839429e-05
for O 0 3.629276397987269e-05
Prader B-Disease 1 0.9996129870414734
- I-Disease 1 0.9999417066574097
Willi I-Disease 1 0.9999642372131348
syndrome I-Disease 1 0.9994713664054871
imprinting O 0 0.003563589183613658
- O 0 0.06961219012737274
centre O 0 0.00011258546146564186
mutations O 0 8.875128514773678e-06
. O 0 1.0566409400780685e-05

Imprinting O 0 0.0006330165197141469
in O 0 1.5654670733056264e-06
the O 0 3.2619067269479274e-07
15q11 O 0 0.00011340845958329737
- O 0 0.0022504355292767286
q13 O 0 5.3403866331791505e-05
region O 0 8.495102576944191e-08
involves O 0 1.912578717622182e-08
an O 0 1.4366444922586652e-08
imprinting O 0 0.00014949959586374462
centre O 0 1.7295715224463493e-05
( O 0 1.8293140158220922e-07
IC O 0 0.00011303092469461262
) O 0 3.7336501890194995e-08
, O 0 1.0873212552553468e-08
mapping O 0 1.5377626993995364e-07
in O 0 5.172871464509399e-09
part O 0 3.2464742005799962e-09
to O 0 2.8476843105806893e-09
the O 0 1.9294184028240124e-08
promoter O 0 8.20329751149984e-06
and O 0 4.28597779489337e-08
first O 0 1.8722158046102777e-08
exon O 0 5.347999831428751e-06
of O 0 4.236440815930109e-07
SNRPN O 0 0.07004054635763168
. O 0 1.4501167242997326e-05

Deletion O 0 0.00033794910996221006
of O 0 2.0542613299312507e-07
this O 0 5.627239119121441e-08
IC O 0 4.2505842429818586e-05
abolishes O 0 3.1120662242756225e-06
local O 0 7.447798822113327e-09
paternally O 0 1.6680220142006874e-05
derived O 0 8.810065565967307e-09
gene O 0 4.1226155822471355e-09
expression O 0 2.4267801101984787e-09
and O 0 1.9964107877967763e-07
results O 0 1.1766237548727077e-05
in O 0 0.00039280232158489525
Prader B-Disease 1 0.9999444484710693
- I-Disease 1 0.9999887943267822
Willi I-Disease 1 0.9999918937683105
syndrome I-Disease 1 0.9999535083770752
( O 0 0.00022807221102993935
PWS B-Disease 1 0.9996284246444702
) O 0 1.71647534443764e-05
. O 0 8.60826730786357e-06

We O 0 1.918298494274495e-06
have O 0 1.1203593430764158e-07
created O 0 9.415693824621485e-08
two O 0 1.0353353019354472e-07
deletion O 0 1.5258119674399495e-05
mutations O 0 5.711272024200298e-07
in O 0 5.804055831504229e-07
mice O 0 8.689681271789595e-05
to O 0 3.98899402398456e-07
understand O 0 1.3131315427017398e-05
PWS B-Disease 1 0.999570906162262
and O 0 7.79726690325333e-07
the O 0 1.945626948440804e-08
mechanism O 0 6.554859055540874e-08
of O 0 1.1613260575416007e-08
this O 0 1.3072396143343212e-07
IC O 0 0.0008395926561206579
. O 0 6.246051270863973e-06

Mice O 0 0.11559606343507767
harbouring O 0 0.047768719494342804
an O 0 2.676567646631156e-06
intragenic O 0 0.012677393853664398
deletion O 0 5.636898640659638e-05
in O 0 1.2961431821167935e-06
Snrpn O 0 0.0018333145417273045
are O 0 2.207082339111821e-08
phenotypically O 0 4.287370302336058e-06
normal O 0 2.0777669362814777e-07
, O 0 6.309063564913231e-07
suggesting O 0 4.373385763756232e-06
that O 0 6.176658473577845e-08
mutations O 0 9.905068054649746e-08
of O 0 4.284964205680808e-08
SNRPN O 0 0.015407093800604343
are O 0 3.4726499453796578e-09
not O 0 1.8409086477433334e-09
sufficient O 0 4.697429112354712e-09
to O 0 9.347695595351979e-08
induce O 0 1.8253340385854244e-05
PWS B-Disease 1 0.9980934262275696
. O 0 4.100274600205012e-05

Mice O 0 0.0018625912489369512
with O 0 1.0990161172230728e-06
a O 0 2.3067117638220225e-07
larger O 0 8.867343694873853e-07
deletion O 0 4.471600732358638e-06
involving O 0 9.941642247213167e-07
both O 0 1.2292812812120246e-07
Snrpn O 0 0.0004473612643778324
and O 0 2.8487565373325197e-07
the O 0 4.955991244059987e-07
putative O 0 0.00406738230958581
PWS O 1 0.9998929500579834
- O 0 0.1011069044470787
IC O 0 0.0008671403047628701
lack O 0 3.520388602851199e-08
expression O 0 9.92241733221988e-10
of O 0 2.3653607961193757e-09
the O 0 8.020588637691617e-08
imprinted O 0 0.000246304931351915
genes O 0 6.496794071608747e-07
Zfp127 O 0 0.00019639957463368773
( O 0 1.3583364655289643e-08
mouse O 0 3.94362177758012e-06
homologue O 0 1.0429265785205644e-05
of O 0 6.171830335688355e-08
ZNF127 O 0 0.020423009991645813
) O 0 1.543981511531456e-07
, O 0 2.5191164354509965e-07
Ndn O 0 0.0003461330779828131
and O 0 2.03484304961421e-07
Ipw O 0 9.678499191068113e-05
, O 0 3.9884841385173786e-07
and O 0 1.6915195999445132e-07
manifest O 0 4.139709233186295e-07
several O 0 1.503097024624367e-08
phenotypes O 0 8.867581527738366e-06
common O 0 1.4541470818585367e-06
to O 0 3.93035079468973e-05
PWS B-Disease 1 0.9998506307601929
infants O 0 0.0012829252518713474
. O 0 1.1908781743841246e-05

These O 0 2.2229852447708254e-07
data O 0 9.704798458187724e-07
demonstrate O 0 2.088241615183506e-07
that O 0 1.8295610360041792e-08
both O 0 2.9192599448890633e-09
the O 0 4.570427591943371e-09
position O 0 2.0459729910271562e-08
of O 0 1.815467887134048e-09
the O 0 6.386111550682472e-08
IC O 0 8.869085286278278e-05
and O 0 5.484348264417349e-08
its O 0 1.9760399538881757e-08
role O 0 1.562860241222097e-08
in O 0 3.3649671937752146e-09
the O 0 3.0777713710961052e-09
coordinate O 0 3.547566151951287e-08
expression O 0 9.51775769308938e-10
of O 0 2.193078385559488e-09
genes O 0 2.7171354943789083e-08
is O 0 2.9413427249380675e-09
conserved O 0 6.061766200105012e-09
between O 0 1.1797363441701236e-07
mouse O 0 0.0002502058632671833
and O 0 1.048123522195965e-06
human O 0 2.2644313446562592e-07
, O 0 4.6757725158386165e-07
and O 0 3.282052034592198e-07
indicate O 0 1.906969657738955e-07
that O 0 1.4469458520238732e-08
the O 0 3.9196443424316385e-08
mouse O 0 0.0002667562512215227
is O 0 8.500803616584562e-09
a O 0 3.1366078623307203e-09
suitable O 0 5.126337754290944e-08
model O 0 1.6231896324825357e-06
system O 0 1.3272145906739752e-06
in O 0 1.147579951066291e-07
which O 0 6.993280265987778e-08
to O 0 2.204203708444652e-09
investigate O 0 5.117437851254181e-08
the O 0 6.400205254664115e-09
molecular O 0 5.030336751588038e-07
mechanisms O 0 8.892150304973256e-08
of O 0 1.0433755193162142e-08
imprinting O 0 0.00023302763293031603
in O 0 1.6310664818774967e-07
this O 0 1.0900746971742592e-08
region O 0 1.7983333933102585e-08
of O 0 1.8337699136949936e-09
the O 0 1.315493705078552e-07
genome O 0 1.7508735254523344e-05
. O 0 6.616912742174463e-07
. O 0 2.746460495473002e-06

Mutations O 0 8.43830821395386e-06
of O 0 5.068837083399558e-08
the O 0 1.1765094853899427e-07
ATM O 0 0.00012785570288542658
gene O 0 5.394462050389848e-07
detected O 0 6.033178578945808e-06
in O 0 9.643867997510824e-07
Japanese O 0 0.2803114950656891
ataxia B-Disease 1 0.9999825954437256
- I-Disease 1 0.9999778270721436
telangiectasia I-Disease 1 0.9999858140945435
patients O 0 8.372925367439166e-05
: O 0 2.0093419550448743e-07
possible O 0 5.490785426331968e-08
preponderance O 0 5.258012606645934e-06
of O 0 9.13378350730909e-09
the O 0 2.4911541274263982e-08
two O 0 4.325166287344473e-07
founder O 0 0.0002678010205272585
mutations O 0 7.960833841025305e-07
4612del165 O 0 1.2314241757849231e-05
and O 0 1.1128726100650965e-06
7883del5 O 0 0.00012010645878035575
. O 0 6.38013034404139e-06

The O 0 3.556594947440317e-06
ATM O 0 0.00873188953846693
( O 0 8.349024028575514e-06
A O 0 0.013723914511501789
- O 1 0.9991428852081299
T O 1 0.9999557733535767
, O 0 3.361285280334414e-06
mutated O 0 1.855551545304479e-06
) O 0 4.992403646042476e-08
gene O 0 1.4997093344959467e-08
on O 0 5.393443416323862e-07
human O 0 3.5715365811483935e-06
chromosome O 0 0.0006914903642609715
11q22 O 0 0.0003829209308605641
. O 0 1.7643835235503502e-05

3 O 0 0.00017968550673685968
has O 0 2.1872618162888102e-05
recently O 0 3.913169712177478e-05
been O 0 3.2591455578767636e-07
identified O 0 2.3364771095657488e-07
as O 0 2.4569744017099993e-09
the O 0 7.4469039823554795e-09
gene O 0 5.579508410846756e-08
responsible O 0 4.109891094117302e-08
for O 0 2.7880506792143933e-08
the O 0 9.146195225184783e-06
human O 0 0.02132580243051052
recessive B-Disease 1 0.9995918869972229
disease I-Disease 1 0.9998764991760254
ataxia B-Disease 1 0.9999864101409912
- I-Disease 1 0.999970555305481
telangiectasia I-Disease 1 0.9999781847000122
( O 0 3.1486055377172306e-05
A B-Disease 0 0.07802220433950424
- I-Disease 1 0.9994181394577026
T I-Disease 1 0.9998970031738281
) O 0 7.032818757579662e-06
. O 0 3.8020614283595933e-06

In O 0 1.5619625628460199e-06
order O 0 9.624613994674291e-08
to O 0 1.1068881811127085e-08
define O 0 5.877946662735667e-08
the O 0 7.825532577498961e-08
types O 0 2.0840011529799085e-06
of O 0 2.2384338080883026e-05
disease O 0 0.016760673373937607
- O 0 0.013078802265226841
causing O 0 1.626416269573383e-05
ATM O 0 0.00012739421799778938
mutations O 0 9.440545056804694e-08
in O 0 5.550256076958249e-08
Japanese O 0 0.00013265707821119577
A B-Disease 1 0.8581650257110596
- I-Disease 1 0.9999724626541138
T I-Disease 1 0.999993085861206
patients O 0 9.353435643788544e-07
as O 0 4.926545837946605e-09
well O 0 1.3016925315412209e-09
as O 0 1.4485136423658673e-09
to O 0 6.1711808996278705e-09
look O 0 5.557087945362582e-08
for O 0 1.367050694867089e-09
possible O 0 2.5108075618618386e-08
mutational O 0 1.1708447345881723e-05
hotspots O 0 5.064752713224152e-06
, O 0 7.366777055040075e-08
reverse O 0 3.840545105049387e-06
- O 0 7.05404545442434e-06
transcribed O 0 5.8279674419736693e-08
RNA O 0 3.9235633408907233e-08
derived O 0 1.483426936843557e-09
from O 0 1.723344578152819e-09
ten O 0 2.68874469355751e-08
patients O 0 3.4859375830365025e-08
belonging O 0 6.689383980074126e-08
to O 0 9.379947485399498e-09
eight O 0 2.421492695248162e-07
unrelated O 0 2.7012283680960536e-05
Japanese O 0 0.00013949382991995662
A B-Disease 0 0.1395445019006729
- I-Disease 1 0.999906063079834
T I-Disease 1 0.9999879598617554
families O 0 2.3493576009059325e-05
was O 0 1.1461474059615284e-05
analyzed O 0 8.246763059105433e-07
for O 0 1.8410640123533994e-08
mutations O 0 3.1819350709838545e-08
by O 0 1.3936259257718575e-08
the O 0 3.1021372137729486e-08
restriction O 0 2.49612526204146e-07
endonuclease O 0 1.3329541616258211e-05
fingerprinting O 0 7.81802646088181e-06
method O 0 5.235139042270021e-07
. O 0 2.627112280606525e-06

As O 0 2.5739366265042918e-06
has O 0 6.6697020884021185e-06
been O 0 2.311231355633936e-06
reported O 0 3.757526428671554e-05
by O 0 1.4107858703482634e-07
others O 0 3.6145081594440853e-07
, O 0 3.1125983923629974e-07
mutations O 0 4.090160743430715e-08
that O 0 2.956502598294719e-08
lead O 0 1.8639889276528265e-07
to O 0 8.737704781935918e-09
exon O 0 2.054507604043465e-06
skipping O 0 2.4704304451006465e-06
or O 0 2.7343759256837075e-07
premature O 0 2.890782070608111e-06
protein O 0 1.0023867069719472e-08
truncation O 0 4.939471409670659e-07
were O 0 3.427039985126612e-08
also O 0 2.8033653620695986e-08
predominant O 0 2.5206345455330847e-08
in O 0 1.742685284966683e-08
our O 0 2.89810316189687e-07
mutants O 0 9.534269338473678e-05
. O 0 2.175001782234176e-06

Six O 0 1.0462509862918523e-06
different O 0 2.6181972145877808e-08
mutations O 0 3.207350403044984e-07
were O 0 1.1560401702581657e-07
identified O 0 2.4117713337545865e-07
on O 0 1.6274290715045936e-07
12 O 0 1.3737565041083144e-07
of O 0 4.8516377582075165e-09
the O 0 1.1218604356599826e-07
16 O 0 2.776405835902551e-06
alleles O 0 2.2477383936347906e-06
examined O 0 7.125683623598889e-05
. O 0 1.9625087588792667e-05

Four O 0 1.1194638318556827e-06
were O 0 8.110743578981783e-07
deletions O 0 1.629006874281913e-05
involving O 0 2.7000436602975242e-05
a O 0 8.096840247162618e-06
loss O 0 0.0008607218042016029
of O 0 4.806854025929397e-09
a O 0 1.1597567350918325e-08
single O 0 1.1319449377822366e-08
exon O 0 2.4326543552888324e-06
exon O 0 4.300612999941222e-06
7 O 0 3.6710085282720684e-07
, O 0 5.938109737257946e-08
exon O 0 1.110770085688273e-06
16 O 0 1.1407341560243367e-07
, O 0 6.710789790531635e-08
exon O 0 2.07339576263621e-06
33 O 0 3.9594539202880696e-07
or O 0 1.3653320252160484e-07
exon O 0 1.0727390872489195e-05
35 O 0 1.7530386458020075e-06
. O 0 3.547022515704157e-06

The O 0 5.584010978054721e-07
others O 0 3.4797071180037165e-07
were O 0 9.73503500034667e-09
minute O 0 8.082350788640724e-09
deletions O 0 2.7881682740371616e-07
, O 0 6.566772015048628e-08
4649delA O 0 2.265542434543022e-06
in O 0 8.543048934939179e-09
exon O 0 2.5972037747123977e-06
33 O 0 6.433327257582278e-07
and O 0 2.1212601097886363e-07
7883del5 O 0 5.7265656323579606e-06
in O 0 1.1844802116911524e-07
exon O 0 8.495657675666735e-05
55 O 0 1.0209917491010856e-05
. O 0 4.7786552386241965e-06

The O 0 8.013262231543195e-07
mutations O 0 4.1389375837752596e-06
4612del165 O 0 4.692865695687942e-05
and O 0 1.1291696182524902e-06
7883del5 O 0 1.783047446224373e-05
were O 0 1.4927266533959482e-07
found O 0 1.843046106841939e-07
in O 0 3.0388871419262387e-09
more O 0 1.5113288398538316e-10
than O 0 9.575277237772184e-10
two O 0 4.850261703381875e-08
unrelated O 0 0.00019083882216364145
families O 0 3.7843719837837853e-06
; O 0 2.3426126460890373e-07
44 O 0 6.616218115595984e-07
% O 0 3.945694615481443e-08
( O 0 8.008538721071545e-09
7 O 0 4.83378563842507e-08
of O 0 4.967420252910415e-09
16 O 0 3.534531742843683e-07
) O 0 7.82749953742723e-09
of O 0 2.801876231028899e-10
the O 0 1.3896285011583132e-08
mutant O 0 1.5153552340052556e-05
alleles O 0 3.215006643131346e-07
had O 0 4.606671666351758e-07
one O 0 1.1366846353055848e-09
of O 0 1.3858532099675358e-09
the O 0 2.5536861514297016e-08
two O 0 4.5283542249308084e-07
mutations O 0 2.844352820829954e-06
. O 0 4.369008365756599e-06

The O 0 1.4826620144958724e-06
4612del165 O 0 0.0001140840831794776
mutations O 0 9.801138958209776e-07
in O 0 1.658583670405278e-08
three O 0 7.443623495362317e-09
different O 0 3.6523097879381794e-09
families O 0 3.1676779599365545e-07
were O 0 4.131087294467761e-08
all O 0 2.3098887247385846e-09
ascribed O 0 4.936198649829748e-08
to O 0 1.1620190365491112e-09
the O 0 8.20640355669866e-09
same O 0 2.038096198475614e-07
T O 0 0.05999156832695007
- O 0 0.0005487963790073991
- O 0 0.00019945127132814378
> O 0 2.763332140887087e-08
A O 0 7.669863633097407e-10
substitution O 0 5.735167341036629e-10
at O 0 2.2101996677292846e-08
the O 0 2.3136985660698883e-09
splice O 0 6.959548045415431e-06
donor O 0 6.502956466647447e-07
site O 0 2.505445593214972e-07
in O 0 1.080311733403505e-07
intron O 0 0.0010672357166185975
33 O 0 1.227951634064084e-05
. O 0 4.57784699392505e-06

Microsatellite O 0 0.003728449111804366
genotyping O 0 0.00015324454579968005
around O 0 3.2847887609932513e-07
the O 0 1.2250855263573612e-07
ATM O 0 0.0012343521229922771
locus O 0 0.00014470900350715965
also O 0 4.8022106966527645e-06
indicated O 0 1.0810329513333272e-05
that O 0 8.444859389555859e-08
a O 0 1.4633997125201859e-07
common O 0 2.082848823192762e-06
haplotype O 0 0.01864122599363327
was O 0 1.1464415365480818e-05
shared O 0 9.296239511513704e-08
by O 0 3.20902504569176e-09
the O 0 7.715087235737883e-09
mutant O 0 8.68236838869052e-07
alleles O 0 2.8944066698954884e-08
in O 0 2.7888644282825226e-08
both O 0 9.213522389472928e-08
mutations O 0 1.3225749171397183e-06
. O 0 5.404356670624111e-06

This O 0 1.7202555682160892e-06
suggests O 0 3.3824601359810913e-06
that O 0 1.971913476950249e-08
these O 0 1.4476353449310864e-09
two O 0 6.453753087498626e-08
founder O 0 0.0007076550973579288
mutations O 0 2.41291581914993e-06
may O 0 2.3284469818918296e-07
be O 0 9.97903315536064e-10
predominant O 0 1.5694560318024742e-08
among O 0 3.99915389692751e-09
Japanese O 0 6.530220275635656e-07
ATM O 0 0.00021786201978102326
mutant O 0 9.905784281727392e-06
alleles O 0 6.398780101335433e-07
. O 0 2.9029320103290956e-06

W474C O 0 6.005892646498978e-05
amino O 0 2.5994486918534676e-07
acid O 0 1.0115929427456649e-07
substitution O 0 1.2335071630786842e-08
affects O 0 2.4630708139739e-08
early O 0 2.341096649871588e-09
processing O 0 1.0214359136284656e-08
of O 0 1.9221950420256206e-10
the O 0 7.996827644518589e-10
alpha O 0 7.78141373558583e-09
- O 0 8.374268389843564e-08
subunit O 0 4.729124869484735e-10
of O 0 2.910557905799749e-10
beta O 0 4.258825470060401e-08
- O 0 8.665452332934365e-05
hexosaminidase O 0 9.486920316703618e-05
A O 0 6.41311146409862e-08
and O 0 5.390913315750367e-07
is O 0 1.472787118927954e-07
associated O 0 4.995966378373851e-07
with O 0 6.354863671731437e-06
subacute O 0 0.4087492823600769
G B-Disease 1 0.7624146342277527
( I-Disease 0 1.4642989754065638e-06
M2 I-Disease 0 0.020021870732307434
) I-Disease 0 4.19763409809093e-06
gangliosidosis I-Disease 0 0.0009968270314857364
. O 0 3.228160721846507e-06

Mutations O 0 2.0069161109859124e-05
in O 0 2.937154590654245e-07
the O 0 3.0738371492589067e-07
HEXA O 0 0.0005925283185206354
gene O 0 6.929044360504122e-08
, O 0 3.755546540418209e-09
encoding O 0 1.6899959209837334e-09
the O 0 8.945899021561843e-10
alpha O 0 7.595649442748709e-09
- O 0 1.1616677397796593e-07
subunit O 0 8.762701675379958e-10
of O 0 3.225161249176267e-10
beta O 0 2.7707420358069612e-08
- O 0 5.397787390393205e-05
hexosaminidase O 0 6.0525097069330513e-05
A O 0 3.896075639886476e-08
( O 0 6.277443898028423e-09
Hex O 0 2.749332679741201e-06
A O 0 1.3660145725680195e-07
) O 0 8.826923192373215e-08
, O 0 1.883221401044466e-08
that O 0 2.7397981661181348e-09
abolish O 0 4.559537458703744e-08
Hex O 0 5.819613875246432e-07
A O 0 8.150776942272842e-09
enzyme O 0 1.0469522493394834e-07
activity O 0 2.406373141639051e-06
cause O 0 0.00150098348967731
Tay B-Disease 1 0.9999642372131348
- I-Disease 1 0.9999731779098511
Sachs I-Disease 1 0.9999902248382568
disease I-Disease 0 0.2928810715675354
( O 0 1.1021355703633162e-06
TSD B-Disease 0 0.07916724681854248
) O 0 8.783540579315741e-07
, O 0 8.832866456032207e-07
the O 0 3.1692145512352e-06
fatal O 0 0.1473792940378189
infantile B-Disease 0 0.0006986269727349281
form I-Disease 0 6.10143899848481e-08
of I-Disease 0 6.862505301796773e-07
G I-Disease 1 0.6112422347068787
( I-Disease 0 6.242754011509533e-07
M2 I-Disease 0 0.022790299728512764
) I-Disease 0 1.0810377943926142e-06
gangliosidosis I-Disease 0 0.00023941369727253914
, I-Disease 0 1.9160954423114163e-07
Type I-Disease 0 3.8063828355916485e-07
1 I-Disease 0 5.719949740523589e-07
. O 0 1.9364604213478742e-06

Less O 0 0.00017689452215563506
severe O 0 0.26274558901786804
, O 0 0.0008190126391127706
subacute O 1 0.64557284116745
( O 0 2.7669148039421998e-05
juvenile O 1 0.5413922071456909
- O 1 0.9889110326766968
onset O 1 0.562259316444397
) O 0 0.0002748063125181943
and O 0 0.004690317902714014
chronic O 0 0.3830396234989166
( O 0 1.4797181790981995e-07
adult O 0 1.1226946980968933e-06
- O 0 0.4758155643939972
onset O 0 0.00821954570710659
) O 0 5.168535608390812e-07
variants O 0 3.6326022723187634e-07
are O 0 2.0395207300794027e-08
characterized O 0 3.3679273201414617e-06
by O 0 1.900509438712561e-08
a O 0 3.877896759263422e-08
broad O 0 1.6074033055701875e-06
spectrum O 0 3.6751805509993574e-06
of O 0 1.4527759617521951e-07
clinical O 0 5.642861651722342e-06
manifestations O 0 9.969869097403716e-06
and O 0 7.139428362279432e-06
are O 0 4.3251990433645915e-08
associated O 0 1.928959107999617e-07
with O 0 2.9220636577065306e-08
residual O 0 7.274545055224735e-07
levels O 0 3.83909615209177e-09
of O 0 1.851486630677357e-09
Hex O 0 3.873960395139875e-06
A O 0 6.153552334353662e-08
enzyme O 0 1.2366784574169287e-07
activity O 0 5.112852932143142e-07
. O 0 2.3861261979618575e-06

We O 0 6.675631425423489e-07
identified O 0 5.141044994161348e-07
a O 0 4.852399229093862e-07
1422 O 0 0.01320873573422432
G O 0 0.003371116006746888
- O 0 0.0006882183370180428
- O 0 0.0023140711709856987
> O 0 3.1360525554191554e-06
C O 0 6.7042601585853845e-06
( O 0 9.944489676172452e-10
amino O 0 3.87616994057538e-10
acid O 0 5.847807127423721e-09
W474C O 0 6.420798115414073e-08
) O 0 2.4648261209847533e-10
substitution O 0 4.988655322168967e-11
in O 0 3.462806430487575e-10
the O 0 4.639469086686887e-10
first O 0 8.994625599889616e-10
position O 0 1.6583677764359095e-09
of O 0 3.897639988537094e-10
exon O 0 5.992180831526639e-07
13 O 0 8.401065088037285e-08
of O 0 1.0551510776224404e-08
HEXA O 0 0.0009117398294620216
of O 0 1.2416863093278607e-08
a O 0 4.801706410262341e-08
non O 0 2.3339248400588986e-07
- O 0 0.0001902117219287902
Jewish O 0 2.2746633021597518e-06
proband O 0 0.0623382031917572
who O 0 2.665070041985018e-06
manifested O 0 1.2025932392134564e-06
a O 0 1.1266133270737555e-07
subacute O 0 0.000726466765627265
variant O 0 1.0604577255435288e-05
of O 0 1.428020368621219e-06
G B-Disease 0 0.4823440909385681
( I-Disease 0 5.410371386460611e-07
M2 I-Disease 0 0.011613655835390091
) I-Disease 0 1.8014252418652177e-06
gangliosidosis I-Disease 0 0.0005194568657316267
. O 0 5.241211056272732e-06

On O 0 1.185596147479373e-06
the O 0 7.414973879349418e-07
second O 0 1.8463497326592915e-05
maternally O 0 0.07127384096384048
inherited O 0 0.018820224329829216
allele O 0 4.987881766282953e-06
, O 0 6.227567723726679e-07
we O 0 5.691877547064905e-08
identified O 0 3.7225152027531294e-07
the O 0 9.057122838385112e-07
common O 0 0.0003163165529258549
infantile O 1 0.990952730178833
disease O 0 0.14726969599723816
- O 0 0.04999089613556862
causing O 0 4.4951393647352234e-05
4 O 0 7.167933517848724e-07
- O 0 0.0001367888180539012
bp O 0 1.8612567146192305e-05
insertion O 0 4.2698630409176985e-07
, O 0 1.6790860968285415e-07
+ O 0 2.6999121018889127e-06
TATC O 0 0.00011170026118634269
1278 O 0 9.454065730096772e-05
, O 0 5.846538542186863e-08
in O 0 4.01219786283491e-08
exon O 0 1.5133837223402224e-05
11 O 0 9.657889677328058e-06
. O 0 9.511641110293567e-06

Pulse O 0 0.0007072627195157111
- O 0 0.0024909379426389933
chase O 0 0.000266311748418957
analysis O 0 9.055761296394849e-08
using O 0 7.559895465192312e-08
proband O 0 0.00257094856351614
fibroblasts O 0 5.11409089085646e-05
revealed O 0 1.431175314792199e-05
that O 0 7.290049897079598e-09
the O 0 9.014072155366648e-09
W474C O 0 1.5904408883216092e-06
- O 0 9.249702657143644e-07
containing O 0 4.3482746292511365e-09
alpha O 0 6.010005826340148e-09
- O 0 8.20442025428747e-08
subunit O 0 1.954616024590905e-09
precursor O 0 1.3737924575707439e-08
was O 0 3.728569097916079e-08
normally O 0 9.91619342194383e-10
synthesized O 0 1.5331874436697035e-08
, O 0 2.2700049839841085e-08
but O 0 3.620971522622085e-09
not O 0 4.647874585206324e-10
phosphorylated O 0 1.7149707431940442e-08
or O 0 2.2714644387633598e-08
secreted O 0 1.300414425031704e-07
, O 0 3.232376144524096e-08
and O 0 2.144087751787538e-08
the O 0 1.6700591132234877e-08
mature O 0 1.4128053749118408e-07
lysosomal O 0 3.5971911529486533e-06
alpha O 0 3.242929835778341e-08
- O 0 2.4557937194913393e-06
subunit O 0 3.082649158159256e-08
was O 0 3.1427421731677896e-07
not O 0 1.5511950834934396e-08
detected O 0 1.9569115465856157e-06
. O 0 2.529762696212856e-06

When O 0 6.585203777831339e-07
the O 0 4.142401621720637e-08
W474C O 0 3.3285757581325015e-06
- O 0 1.455254050597432e-06
containing O 0 7.3822321589034345e-09
alpha O 0 9.515892074318799e-09
- O 0 3.310984197923972e-07
subunit O 0 9.452541860355268e-09
was O 0 3.4868426723733137e-07
transiently O 0 8.313612852361985e-06
co O 0 3.400091372895986e-05
- O 0 1.2098140359739773e-05
expressed O 0 4.714384438386787e-09
with O 0 6.930941931493351e-10
the O 0 1.205796795744618e-09
beta O 0 4.086088356558548e-09
- O 0 2.2295030532859528e-07
subunit O 0 1.1814533795728721e-09
to O 0 2.6227528482358764e-10
produce O 0 1.182666298227275e-09
Hex O 0 6.294111472016084e-07
A O 0 3.453424213262224e-08
( O 0 2.1114587411830144e-08
alphabeta O 0 4.125309351366013e-05
) O 0 2.1573129060925567e-08
in O 0 3.604270659707254e-08
COS O 0 0.0063509889878332615
- O 0 9.568268433213234e-05
7 O 0 8.876879178387753e-07
cells O 0 2.2865442872443964e-07
, O 0 5.6121653990715e-09
the O 0 1.0580182285835349e-09
mature O 0 5.997912833066721e-09
alpha O 0 5.5121467390506496e-09
- O 0 4.7036539285727486e-07
subunit O 0 1.0772557956784112e-08
was O 0 2.0974665915218793e-07
present O 0 4.838137002138865e-09
, O 0 1.5459020730190787e-08
but O 0 8.43220049340232e-10
its O 0 1.6310044426148806e-09
level O 0 6.793156259732314e-09
was O 0 2.3599167775500973e-07
much O 0 1.664878190865693e-08
lower O 0 4.467060534807388e-07
than O 0 2.6591930879504844e-09
that O 0 1.5862511304476357e-09
from O 0 1.721336406745877e-10
normal O 0 1.6698249727387093e-10
alpha O 0 3.1427880298195987e-09
- O 0 1.0695126775317476e-06
subunit O 0 1.9077440072123864e-08
transfections O 0 2.7314586986904033e-05
, O 0 1.659143755716741e-08
although O 0 2.38593234058726e-09
higher O 0 4.946072440503713e-09
than O 0 9.980289927824515e-10
in O 0 5.820998794092702e-09
those O 0 1.0007743966866656e-08
cells O 0 4.171234593286499e-07
transfected O 0 4.46220383309992e-06
with O 0 3.6642833212141568e-09
an O 0 3.617188992777187e-09
alpha O 0 8.971075260433281e-08
- O 0 5.861193130840547e-06
subunit O 0 1.1286425660728128e-07
associated O 0 2.8410406116563536e-07
with O 0 2.0623638192773797e-06
infantile O 0 0.07024126499891281
TSD B-Disease 0 0.2449670135974884
. O 0 1.997371145989746e-05

Furthermore O 0 1.5931787856970914e-05
, O 0 4.804995796803269e-07
the O 0 1.0442355424800098e-08
precursor O 0 1.764574051321688e-07
level O 0 4.202828751687093e-09
of O 0 2.9747246332867405e-10
the O 0 2.4567214929049896e-09
W474C O 0 3.3897831031026726e-07
alpha O 0 1.3482929439589952e-08
- O 0 6.275722626014613e-07
subunit O 0 1.3255932351796673e-08
was O 0 3.080181159020867e-07
found O 0 2.4336694437465667e-08
to O 0 7.611631325232793e-09
accumulate O 0 2.619756514832261e-06
in O 0 7.110169786272991e-09
comparison O 0 1.5809993314519488e-08
to O 0 4.823787480567887e-10
the O 0 5.13917686184584e-10
normal O 0 2.0513917231568257e-09
alpha O 0 1.016165995793017e-08
- O 0 2.6717628998085274e-07
subunit O 0 1.164153662358558e-08
precursor O 0 1.0091954294466632e-07
levels O 0 2.353068495608568e-08
. O 0 3.2637549907121866e-07

We O 0 7.420109682243492e-07
conclude O 0 1.645524662308162e-06
that O 0 2.078509275804663e-08
the O 0 5.17808693700772e-08
1422 O 0 0.004047370050102472
G O 0 0.0032944774720817804
- O 0 0.0013085096143186092
- O 0 0.002304177964106202
> O 0 1.3330331967154052e-06
C O 0 1.3373535693972372e-05
mutation O 0 3.2442102337881806e-08
is O 0 7.138365454295581e-09
the O 0 2.340838811676349e-08
cause O 0 8.5120674953032e-08
of O 0 7.87334819563057e-09
Hex B-Disease 0 0.006600737106055021
A I-Disease 0 0.002064221305772662
enzyme I-Disease 1 0.9995766282081604
deficiency I-Disease 1 0.9998443126678467
in O 0 2.2612503869368084e-07
the O 0 2.6830357455764897e-06
proband O 0 0.04933420941233635
. O 0 1.9574099496821873e-05

The O 0 1.233594048244413e-06
resulting O 0 1.4680084632345825e-06
W474C O 0 2.156043592549395e-06
substitution O 0 3.52130840042264e-08
clearly O 0 2.0459677330109116e-07
interferes O 0 1.1070765282283901e-07
with O 0 3.811749138549203e-09
alpha O 0 1.1639694541543122e-08
- O 0 2.0750975693317741e-07
subunit O 0 3.267945025697827e-09
processing O 0 5.337415132089518e-08
, O 0 2.2744600869373244e-08
but O 0 6.204001312681839e-09
because O 0 6.953160269773662e-10
the O 0 2.5778687517963306e-10
base O 0 1.316572451059983e-08
substitution O 0 2.6457875890173455e-08
falls O 0 5.011155371903442e-05
at O 0 9.083561280931463e-08
the O 0 3.054187125428598e-09
first O 0 1.2659101544798546e-09
position O 0 4.416160770404076e-09
of O 0 1.2403625904156002e-09
exon O 0 2.153341256416752e-06
13 O 0 2.741112439252902e-07
, O 0 7.767196308350321e-08
aberrant O 0 1.6792251926744939e-06
splicing O 0 2.1814580577483866e-06
may O 0 9.282894666284847e-07
also O 0 1.6946254177696574e-08
contribute O 0 2.2257582443785395e-09
to O 0 1.7401477592215997e-08
Hex B-Disease 0 0.0016840685857459903
A I-Disease 0 0.0008544978336431086
deficiency I-Disease 0 0.21510209143161774
in O 0 5.217604126528386e-08
this O 0 3.832242967405364e-08
proband O 0 0.0010379080194979906
. O 0 5.997315497552336e-07
. O 0 2.5763140456547262e-06

Two O 0 1.5246741895680316e-06
frequent O 0 9.37307868298376e-06
missense O 0 0.00040552797145210207
mutations O 0 0.00041735355625860393
in O 0 0.03268833085894585
Pendred B-Disease 1 0.9997408986091614
syndrome I-Disease 1 0.9998083710670471
. O 0 0.0004244055016897619

Pendred B-Disease 1 0.9992597699165344
syndrome I-Disease 1 0.999832272529602
is O 0 0.1857464462518692
an O 1 0.9788897037506104
autosomal B-Disease 1 0.9999819993972778
recessive I-Disease 1 0.9999901056289673
disorder I-Disease 1 0.9999947547912598
characterized O 1 0.8516372442245483
by O 0 0.0003252019523642957
early O 0 0.024637915194034576
childhood O 1 0.9983540773391724
deafness B-Disease 1 0.9999527931213379
and O 1 0.8650460839271545
goiter B-Disease 1 0.9996740818023682
. O 0 0.001241049962118268

A O 0 4.02829618906253e-06
century O 0 2.3879699710960267e-06
after O 0 1.0699156973714707e-06
its O 0 5.511855150075462e-08
recognition O 0 5.8662312341084544e-08
as O 0 5.445951387628156e-07
a O 0 6.6493266785983e-05
syndrome O 1 0.9029772281646729
by O 0 1.205537387249933e-06
Vaughan O 0 0.0004995767376385629
Pendred O 0 0.060833655297756195
, O 0 9.418237823410891e-06
the O 0 4.467093094717711e-05
disease O 0 0.0023206276819109917
gene O 0 2.0311683783802437e-06
( O 0 5.202529109737952e-07
PDS O 0 0.0007768450304865837
) O 0 4.7144320092229464e-07
was O 0 1.5062717011460336e-06
mapped O 0 2.078899797197664e-06
to O 0 1.2915663205603778e-07
chromosome O 0 0.00012147016968810931
7q22 O 0 0.0001652027276577428
- O 0 0.002483468037098646
q31 O 0 0.00016051932470872998
. O 0 3.381612032171688e-06

1 O 0 1.2705409972113557e-05
and O 0 4.331913260102738e-06
, O 0 2.6517900550970808e-06
recently O 0 1.5485646144952625e-05
, O 0 2.2274076627581962e-07
found O 0 3.173673590595172e-08
to O 0 9.88999548923175e-10
encode O 0 1.28227757301147e-08
a O 0 1.1331355409538446e-07
putative O 0 4.898346378467977e-05
sulfate O 0 0.0005702629568986595
transporter O 0 0.0028744256123900414
. O 0 5.965336185909109e-06

We O 0 1.187287693937833e-06
performed O 0 5.431982685877301e-07
mutation O 0 1.5588389601361996e-07
analysis O 0 3.773729062572784e-08
of O 0 5.077998466163081e-09
the O 0 5.082468419459474e-07
PDS B-Disease 0 0.005591210909187794
gene O 0 1.7040189277395257e-06
in O 0 1.5133632587094326e-06
patients O 0 3.1347317985819245e-07
from O 0 6.419769960075428e-08
14 O 0 4.06840172217926e-06
Pendred B-Disease 0 0.006309370044618845
families O 0 7.429541142300877e-07
originating O 0 5.162741700814877e-08
from O 0 1.1931278187660155e-08
seven O 0 1.4555828897755418e-07
countries O 0 1.6758699317165338e-08
and O 0 4.220962424028585e-08
identified O 0 9.687934721114289e-08
all O 0 9.098018338704605e-09
mutations O 0 1.1790090184149449e-06
. O 0 4.232347691868199e-06

The O 0 1.6744979802751914e-06
mutations O 0 8.075418236330734e-07
include O 0 9.599969708062872e-09
three O 0 4.5043955232415556e-09
single O 0 1.0342532164031581e-08
base O 0 1.5241596429405035e-07
deletions O 0 1.1391657608328387e-06
, O 0 4.5342744670051616e-08
one O 0 1.4416724480881271e-09
splice O 0 3.3948408599826507e-06
site O 0 1.2888683613709873e-06
mutation O 0 5.771243039021101e-08
and O 0 1.6367619082302554e-07
10 O 0 3.3680322530926787e-07
missense O 0 3.7077199976920383e-06
mutations O 0 1.8238212078358629e-06
. O 0 4.29067495133495e-06

One O 0 2.11026440410933e-06
missense O 0 6.0191890952410176e-05
mutation O 0 6.66389087200514e-06
( O 0 3.9022822306833405e-07
L236P O 0 0.00015386198356281966
) O 0 1.1237830221944023e-06
was O 0 4.594448910211213e-06
found O 0 6.599003086193989e-07
in O 0 1.3656570096998166e-08
a O 0 2.2724783832472895e-08
homozygous O 0 2.959126845780702e-07
state O 0 2.25400711428847e-08
in O 0 8.768490822319563e-09
two O 0 2.2256324427871732e-07
consanguineous O 0 0.0015356980729848146
families O 0 3.04079003399238e-06
and O 0 5.136419076734455e-07
in O 0 5.354525001166621e-08
a O 0 3.2414948947234734e-08
heterozygous O 0 1.2859518960794958e-07
state O 0 1.8710554883227815e-08
in O 0 6.370318050841206e-09
five O 0 1.869386068165113e-08
additional O 0 1.2635926083248705e-08
non O 0 3.7069983704896003e-07
- O 0 0.0005350607098080218
consanguineous O 0 0.0002467992599122226
families O 0 7.193955752882175e-06
. O 0 1.0131526323675644e-05

Another O 0 1.0780639058793895e-05
missense O 0 9.255518671125174e-05
mutation O 0 7.083605851221364e-06
( O 0 8.616789841653372e-07
T416P O 0 0.00013373461843002588
) O 0 2.464016233716393e-06
was O 0 2.4208737158915028e-05
found O 0 7.252765499288216e-07
in O 0 3.805982728977142e-08
a O 0 4.988919855009044e-08
homozygous O 0 1.6769513422332238e-07
state O 0 3.604477072371992e-08
in O 0 4.463227654127877e-08
one O 0 1.0768165736863011e-07
family O 0 6.513628613902256e-05
and O 0 5.558773068514711e-07
in O 0 3.740079179692657e-08
a O 0 1.0136633932233963e-07
heterozygous O 0 2.8926882578161894e-07
state O 0 5.3835059077300684e-08
in O 0 2.6135870356824853e-08
four O 0 8.214564672925917e-07
families O 0 2.0925343051203527e-05
. O 0 1.2559210517792962e-05

Pendred B-Disease 1 0.8796064853668213
patients O 0 4.8275247536366805e-05
in O 0 1.851184521228788e-07
three O 0 9.263424516348095e-08
non O 0 8.828133104543667e-07
- O 0 0.0028017929289489985
consanguineous O 0 0.0008750594570301473
families O 0 9.96149651655287e-07
were O 0 6.329976542929217e-08
shown O 0 4.308435563871171e-08
to O 0 3.3438729563073366e-09
be O 0 4.710735357349449e-09
compound O 0 6.183873324516753e-07
heterozygotes O 0 5.62174591323128e-07
for O 0 1.1280889999909505e-08
L236P O 0 1.1327718311804347e-05
and O 0 7.503860501856252e-07
T416P O 0 6.339456012938172e-05
. O 0 2.8808963179471903e-06

In O 0 2.034956878560479e-06
total O 0 5.466635002449038e-07
, O 0 3.802834100952168e-07
one O 0 1.055374454494995e-08
or O 0 2.880247684799997e-08
both O 0 1.8548445002153358e-09
of O 0 2.771047169503049e-09
these O 0 1.3829704492707151e-08
mutations O 0 9.671096989904981e-08
were O 0 2.1859344201402564e-07
found O 0 5.65912500860577e-07
in O 0 1.0106667502896016e-08
nine O 0 2.4545775190176755e-08
of O 0 6.347274261742086e-09
the O 0 1.7970653232168843e-07
14 O 0 3.9853698581282515e-06
families O 0 2.7571888949751155e-06
analyzed O 0 1.0048725016531534e-05
. O 0 4.197866019239882e-06

The O 0 6.264157832447381e-07
identification O 0 3.4240480317748734e-07
of O 0 3.6740757991537976e-08
two O 0 2.0121034083331324e-07
frequent O 0 1.321218405792024e-06
PDS B-Disease 0 0.009269878268241882
mutations O 0 3.2936881666500994e-07
will O 0 3.973022799641512e-09
facilitate O 0 1.9561192665662475e-09
the O 0 9.065733053148506e-08
molecular O 0 0.002262239810079336
diagnosis O 0 0.011101940646767616
of O 0 0.002558937296271324
Pendred B-Disease 1 0.9999501705169678
syndrome I-Disease 1 0.9999121427536011
. O 0 0.00029469936271198094

Insertional O 0 0.002087064553052187
mutation O 0 1.8525455516282818e-06
by O 0 1.759279513180445e-07
transposable O 0 2.2947366232983768e-05
element O 0 2.622498413984431e-07
, O 0 1.499548375250015e-06
L1 O 0 0.02461181953549385
, O 0 3.9185309219647024e-07
in O 0 5.405617642395555e-08
the O 0 1.5218820408335887e-06
DMD B-Disease 1 0.9993213415145874
gene O 0 9.602964610166964e-07
results O 0 1.6306339603033848e-06
in O 0 5.385792974266224e-06
X B-Disease 1 0.9083897471427917
- I-Disease 1 0.9924600720405579
linked I-Disease 1 0.9666551351547241
dilated I-Disease 1 0.9829388856887817
cardiomyopathy I-Disease 1 0.9996654987335205
. O 0 0.0002037134690908715

X B-Disease 1 0.9936127066612244
- I-Disease 1 0.99903404712677
linked I-Disease 1 0.9994316697120667
dilated I-Disease 1 0.9995753169059753
cardiomyopathy I-Disease 1 0.9999314546585083
( O 0 0.00014110653137322515
XLDCM B-Disease 1 0.8054729700088501
) O 0 3.556445790309226e-06
is O 0 2.6636922001443963e-08
a O 0 9.504939413318425e-08
clinical O 0 8.041740784392459e-07
phenotype O 0 5.408512606663862e-06
of O 0 3.308342400032416e-07
dystrophinopathy B-Disease 0 0.42497116327285767
which O 0 5.5717723626003135e-06
is O 0 2.323883734334231e-07
characterized O 0 1.0401899999123998e-05
by O 0 5.87341901336913e-07
preferential O 0 6.269237928790972e-05
myocardial B-Disease 1 0.9924593567848206
involvement I-Disease 0 1.0473708243807778e-05
without O 0 1.6314967155039994e-08
any O 0 3.5260852015994715e-09
overt O 0 4.032475260373758e-07
clinical O 0 8.50992637424497e-06
signs O 0 4.583653571899049e-05
of O 0 0.00011864816769957542
skeletal B-Disease 1 0.9999490976333618
myopathy I-Disease 1 0.9999476671218872
. O 0 0.0015923967584967613

To O 0 3.076171424254426e-07
date O 0 1.242245161847677e-06
, O 0 1.0505608116773146e-07
several O 0 7.080247943491713e-09
mutations O 0 1.78075936219102e-07
in O 0 1.5909006378933555e-07
the O 0 0.00011100117262685671
Duchenne B-Disease 1 0.9999408721923828
muscular I-Disease 1 0.9999040365219116
dystrophy I-Disease 1 0.9990863800048828
gene O 0 0.00024824548745527864
, O 0 0.025268319994211197
DMD O 1 0.9999649524688721
, O 0 1.3746485819865484e-05
have O 0 1.944458887237488e-07
been O 0 6.279098556660756e-07
identified O 0 1.1255528079345822e-05
in O 0 1.5835668136787717e-06
patients O 0 1.2957600574736716e-06
with O 0 5.102680006530136e-06
XLDCM B-Disease 1 0.5817346572875977
, O 0 2.345304665141157e-06
but O 0 3.434184847606048e-08
a O 0 3.573042972604412e-09
pathogenic O 0 7.78739650542093e-09
correlation O 0 2.1004286310244424e-08
of O 0 5.760835808388265e-09
these O 0 2.5595573660552873e-08
cardiospecific O 0 0.00032942177494987845
mutations O 0 2.716789140322362e-07
in O 0 1.2762479855155107e-06
DMD O 1 0.9994544386863708
with O 0 6.293847150118381e-07
the O 0 3.002402081619948e-06
XLDCM B-Disease 1 0.7831463813781738
phenotype O 0 0.00017837109044194221
has O 0 8.294134090647276e-07
remained O 0 5.386822294894955e-07
to O 0 1.5592069857461865e-08
be O 0 5.500429267613072e-08
elucidated O 0 8.222070755437016e-05
. O 0 5.933353349973913e-06

We O 0 3.9052674765116535e-06
report O 0 8.877405889506917e-06
here O 0 3.7561427745913534e-08
the O 0 2.0832671143722337e-09
identification O 0 7.969271464958183e-09
of O 0 1.22316989870086e-09
a O 0 8.395119266424445e-09
unique O 0 7.210452679373702e-09
de O 0 1.363505077733862e-07
novo O 0 2.0600371897216974e-07
L1 O 0 3.1548988772556186e-05
insertion O 0 4.1518781301874697e-08
in O 0 6.018127329809886e-09
the O 0 2.239736218712096e-08
muscle O 0 1.1301109225314576e-05
exon O 0 4.046361937071197e-06
1 O 0 2.3948524585648556e-07
in O 0 1.8094211782226921e-06
DMD O 1 0.9996888637542725
in O 0 5.125223765389819e-07
three O 0 7.396875389531488e-06
XLDCM B-Disease 1 0.9716149568557739
patients O 0 1.0752019079518504e-06
from O 0 1.3582976521320234e-08
two O 0 2.3811971061604709e-07
unrelated O 0 0.00014502587146125734
Japanese O 0 0.00011094582441728562
families O 0 1.971424717339687e-05
. O 0 1.5502415408263914e-05

The O 0 4.789367267221678e-07
insertion O 0 1.2309133126109373e-05
was O 0 2.254520268252236e-06
a O 0 4.4216243111350195e-08
5 O 0 1.7928269357980753e-07
- O 0 2.88061401079176e-05
truncated O 0 4.7272268943743256e-07
form O 0 1.380165981501591e-09
of O 0 1.1892919982159356e-09
human O 0 1.803251947762874e-08
L1 O 0 2.4561672034906223e-05
inversely O 0 2.0246779968147166e-06
integrated O 0 2.2026419799203723e-07
in O 0 1.2409737237817353e-08
the O 0 1.4917553414761642e-08
5 O 0 4.464479843591107e-07
- O 0 0.0009083066252060235
untranslated O 0 3.5065095289610326e-05
region O 0 6.081954495584796e-08
in O 0 5.020379667541874e-09
the O 0 3.7684785070268845e-08
muscle O 0 2.6186668037553318e-05
exon O 0 5.5335617616947275e-06
1 O 0 7.771076298013213e-07
, O 0 5.411012011791172e-07
which O 0 2.3365261370145163e-07
affected O 0 1.7141401187359406e-08
the O 0 3.737460119168645e-09
transcription O 0 8.954646801839772e-08
or O 0 4.930919317303051e-08
the O 0 6.035682531546627e-08
stability O 0 1.4480965546681546e-06
of O 0 1.4726418307020595e-08
the O 0 1.0331943940400379e-06
muscle O 0 0.00012757001968566328
form O 0 3.106967350063883e-09
of O 0 1.0488325763446937e-08
dystrophin O 0 9.626442079024855e-06
transcripts O 0 1.3987462352815783e-06
but O 0 1.6135544456119533e-07
not O 0 1.963355922285359e-09
that O 0 6.471932323393048e-09
of O 0 6.368277460921945e-09
the O 0 1.0786578741317498e-06
brain O 0 0.00045933283399790525
or O 0 7.883996318014397e-07
Purkinje O 0 0.1532367467880249
cell O 0 0.0005631091189570725
form O 0 3.171307980665006e-07
, O 0 5.753597179136705e-06
probably O 0 2.6186826289631426e-06
due O 0 8.245505966897326e-08
to O 0 2.376635110934444e-09
its O 0 8.796398276444961e-09
unique O 0 7.174701721623933e-09
site O 0 1.409395338214381e-07
of O 0 1.7871725432883068e-08
integration O 0 3.909142378688557e-06
. O 0 7.4833665166806895e-06

We O 0 1.379681862090365e-06
speculate O 0 2.2500546492665308e-06
that O 0 5.8066391694922e-09
this O 0 4.387110119630222e-10
insertion O 0 2.8992852563192173e-08
of O 0 7.897634213271942e-10
an O 0 7.484682207348214e-09
L1 O 0 0.0015847560716792941
sequence O 0 4.979907544111484e-07
in O 0 1.7617756384424865e-05
DMD O 1 0.9998563528060913
is O 0 1.2010947614271572e-07
responsible O 0 3.973926965272767e-08
for O 0 1.1062988303223165e-09
some O 0 1.182561965018536e-10
of O 0 2.282141808862548e-09
the O 0 6.533490193305624e-08
population O 0 1.2309477881444764e-08
of O 0 4.9505395338655944e-08
Japanese O 0 0.00033622406772337854
patients O 0 5.739298103435431e-07
with O 0 1.5508362594118807e-06
XLDCM B-Disease 0 0.10109967738389969
. O 0 1.5443512211277266e-06
. O 0 4.265314601070713e-06

Severe O 0 0.04722899571061134
early O 0 0.0007736499537713826
- O 1 0.9991785883903503
onset O 1 0.9996381998062134
obesity B-Disease 1 0.9999502897262573
, O 0 0.38189882040023804
adrenal B-Disease 1 0.9998716115951538
insufficiency I-Disease 1 0.9997947812080383
and O 0 0.0001755740522639826
red O 0 0.0034808525815606117
hair O 1 0.8307323455810547
pigmentation O 0 0.12990926206111908
caused O 0 9.00856830412522e-05
by O 0 1.8870742906074156e-06
POMC O 0 0.051248036324977875
mutations O 0 1.8316076193514164e-06
in O 0 7.719269774497661e-07
humans O 0 3.179525720042875e-06
. O 0 9.068705367099028e-06

Sequential O 0 4.239401278027799e-06
cleavage O 0 0.00018233165610581636
of O 0 2.9140323931642342e-08
the O 0 3.005628101959701e-08
precursor O 0 1.8076551100421057e-07
protein O 0 1.684120931599864e-08
pre O 0 7.118449047993636e-07
- O 0 0.00018732903117779642
pro O 0 5.280699406284839e-05
- O 0 0.01841910183429718
opiomelanocortin O 0 0.018516693264245987
( O 0 6.412035702396679e-08
POMC O 0 1.818890632421244e-05
) O 0 2.866359150033304e-09
generates O 0 1.5811191245163059e-09
the O 0 7.433720305982661e-09
melanocortin O 0 6.641431536991149e-05
peptides O 0 4.2872147787420545e-06
adrenocorticotrophin O 0 0.00047119546798057854
( O 0 2.9110548638300315e-08
ACTH O 0 2.6722570964921033e-06
) O 0 2.026020240464277e-08
, O 0 5.181495055239793e-08
melanocyte O 0 2.4782862965366803e-05
- O 0 0.00018825333972927183
stimulating O 0 1.932742634380702e-06
hormones O 0 6.976972599659348e-08
( O 0 4.676117715263217e-09
MSH O 0 2.6869149678532267e-06
) O 0 1.0200764677392726e-09
alpha O 0 2.953170152864004e-09
, O 0 1.6293066895656239e-09
beta O 0 6.620921588762485e-10
and O 0 9.38105260139821e-10
gamma O 0 1.9209680512943805e-09
as O 0 1.736664423379608e-10
well O 0 3.379798385605426e-10
as O 0 7.891264863779668e-10
the O 0 9.913549980922198e-09
opioid O 0 1.7636366465012543e-06
- O 0 5.200959094509017e-06
receptor O 0 1.8005643198648613e-08
ligand O 0 3.2407161398850803e-08
beta O 0 7.732178630703856e-08
- O 0 9.2196227342356e-05
endorphin O 0 0.0008633186225779355
. O 0 1.6751688463045866e-06

While O 0 7.525979981437558e-06
a O 0 4.112079352580622e-07
few O 0 1.594962810713696e-07
cases O 0 1.8607546792281937e-07
of O 0 6.26103428658098e-07
isolated O 0 0.28180405497550964
ACTH B-Disease 1 0.9880394339561462
deficiency I-Disease 1 0.8908822536468506
have O 0 5.450362436931755e-07
been O 0 2.0748673250636784e-06
reported O 0 0.001418792875483632
( O 0 7.690875918342499e-07
OMIM O 0 0.1867886185646057
201400 O 0 0.002407394116744399
) O 0 9.475078854848107e-07
, O 0 4.6825908839309704e-07
an O 0 3.7321517538657645e-06
inherited O 1 0.9605729579925537
POMC O 1 0.9968354105949402
defect O 0 0.0990697368979454
has O 0 1.5098514722922118e-06
not O 0 1.9987190569281665e-08
been O 0 6.178779443644089e-08
described O 0 7.590374934807187e-06
so O 0 3.2474054023623466e-07
far O 0 6.265795491344761e-07
. O 0 2.3769184736011084e-06

Recent O 0 1.0050449418486096e-05
studies O 0 6.627345214837987e-07
in O 0 1.1820529266515223e-07
animal O 0 4.7580871864738583e-07
models O 0 1.221770162374014e-06
elucidated O 0 3.560076720532379e-06
a O 0 1.0355639012971096e-08
central O 0 3.59653662407311e-09
role O 0 7.995974438124165e-10
of O 0 1.7428474219371992e-09
alpha O 0 1.9494164860134333e-07
- O 0 0.00026906837592832744
MSH O 0 9.711281018098816e-05
in O 0 3.3367499874259465e-09
the O 0 2.3045640951124824e-09
regulation O 0 5.777014067120945e-08
of O 0 1.8087392916754652e-08
food O 0 1.1873505911808024e-07
intake O 0 8.885737479147338e-09
by O 0 6.019823528546908e-10
activation O 0 5.9744382774340465e-09
of O 0 6.589124246225708e-10
the O 0 2.4155413669291192e-08
brain O 0 3.1800944270798936e-05
melanocortin O 0 9.311230314779095e-06
- O 0 2.1913998352829367e-05
4 O 0 2.3457357656297972e-07
- O 0 3.996287705376744e-05
receptor O 0 1.2642850322208687e-07
( O 0 1.4499627276620686e-08
MC4 O 0 0.00029377281316556036
- O 0 0.00046252485481090844
R O 0 0.00022737524705007672
; O 0 4.1438461551024375e-09
refs O 0 4.5049907271277334e-07
3 O 0 7.61095222401309e-08
- O 0 1.526248706795741e-05
5 O 0 1.2878149391326588e-07
) O 0 9.04907615506545e-09
and O 0 6.005330899228056e-09
the O 0 9.613015272691428e-09
linkage O 0 5.487829639605479e-06
of O 0 1.299931966514123e-07
human O 0 2.399168624833692e-05
obesity B-Disease 1 0.8516755104064941
to O 0 1.412402639289212e-07
chromosome O 0 1.1915915820281953e-05
2 O 0 1.537944598339891e-07
in O 0 1.6493466148403968e-08
close O 0 3.281094222984393e-07
proximity O 0 7.200353735470344e-08
to O 0 4.1093168867689656e-09
the O 0 5.196687524744448e-08
POMC O 0 0.004868471063673496
locus O 0 7.61902174417628e-06
, O 0 3.7794455920447945e-07
led O 0 2.816851178977231e-07
to O 0 4.311639489884556e-09
the O 0 3.733692821583645e-08
proposal O 0 9.78095158643555e-07
of O 0 1.7706993205024446e-08
an O 0 3.247232029934821e-07
association O 0 9.820525974646444e-07
of O 0 1.837267120663455e-07
POMC O 1 0.5029590725898743
with O 0 5.0148359150625765e-05
human O 0 0.0011000254889950156
obesity B-Disease 1 0.9912612438201904
. O 0 3.6338889913167804e-05

The O 0 2.0048477722411917e-07
dual O 0 1.583912592195702e-07
role O 0 1.108669422933417e-08
of O 0 7.0249348560480485e-09
alpha O 0 4.772315378431813e-07
- O 0 0.00044002829235978425
MSH O 0 0.00018612899293657392
in O 0 1.2734107990297616e-08
regulating O 0 9.309814430480401e-08
food O 0 5.8647884770834935e-08
intake O 0 1.9996113209685973e-08
and O 0 1.8872704288241948e-08
influencing O 0 6.958320000194362e-07
hair O 0 0.009853443130850792
pigmentation O 0 0.0005108097684569657
predicts O 0 0.0007574296905659139
that O 0 8.30413995345225e-08
the O 0 4.4521073050418636e-07
phenotype O 0 4.5353732275543734e-05
associated O 0 3.9283901287490153e-07
with O 0 3.8780785871495027e-07
a O 0 2.3323134882957675e-05
defect O 0 0.04735887795686722
in O 0 1.5032553619676037e-06
POMC O 0 0.029107550159096718
function O 0 1.6182902129457943e-07
would O 0 3.0050148325244663e-07
include O 0 1.2181042166048428e-06
obesity B-Disease 1 0.9906473755836487
, O 0 1.4077660352995736e-06
alteration O 0 2.244236384285614e-06
in O 0 1.8146694173992728e-06
pigmentation O 0 0.03568992391228676
and O 0 0.01647745445370674
ACTH B-Disease 1 0.8993146419525146
deficiency I-Disease 0 0.37309399247169495
. O 0 5.664871423505247e-06

The O 0 6.939850436538109e-07
observation O 0 3.566196710380609e-06
of O 0 2.4650594809827453e-07
these O 0 6.281973696786736e-07
symptoms O 0 2.304544523212826e-06
in O 0 2.5894124178194033e-08
two O 0 4.356716090114787e-07
probands O 0 0.03185604512691498
prompted O 0 1.679715182945074e-06
us O 0 3.0394687655643793e-07
to O 0 9.48786826882042e-10
search O 0 1.4637702605568848e-08
for O 0 2.807735821619417e-09
mutations O 0 1.7921083284022643e-08
within O 0 8.816314345239107e-10
their O 0 9.496567088262964e-08
POMC O 0 0.0014387285336852074
genes O 0 1.0444535973874736e-06
. O 0 7.060964435368078e-06

Patient O 0 7.923356315586716e-05
1 O 0 1.8448450646246783e-05
was O 0 7.411064871121198e-05
found O 0 1.6423578017565887e-06
to O 0 9.19305076507726e-09
be O 0 2.8380811034622866e-09
a O 0 8.071627810579685e-09
compound O 0 1.0031595820692019e-06
heterozygote O 0 1.3565056633524364e-06
for O 0 4.451779500591613e-10
two O 0 4.9459218942615735e-09
mutations O 0 1.849264030795439e-08
in O 0 1.91777331792764e-08
exon O 0 2.494160071364604e-06
3 O 0 1.2254120065335883e-06
( O 0 5.3499515928479013e-08
G7013T O 0 4.003718277090229e-05
, O 0 2.272193796670763e-06
C7133delta O 0 0.0013654987560585141
) O 0 9.42854327945497e-08
which O 0 1.3121202790955522e-08
interfere O 0 4.9190904682916425e-09
with O 0 4.380404650117242e-10
appropriate O 0 4.1316819410219807e-10
synthesis O 0 5.79665782041161e-09
of O 0 5.43111022821563e-09
ACTH O 0 9.457321539230179e-07
and O 0 2.9483821606390848e-08
alpha O 0 3.8431244320236146e-07
- O 0 0.0004704063176177442
MSH O 0 0.0014147358015179634
. O 0 1.1975837423960911e-06

Patient O 0 7.771613309159875e-05
2 O 0 3.63106228178367e-05
was O 0 2.2085530872573145e-05
homozygous O 0 8.741390047362074e-07
for O 0 1.1809605737767015e-08
a O 0 2.736002890912914e-08
mutation O 0 2.7726663631710835e-08
in O 0 4.7667843006138355e-08
exon O 0 1.2020223948638886e-05
2 O 0 4.233987056068145e-06
( O 0 8.904879678084399e-08
C3804A O 0 9.032229172589723e-06
) O 0 1.1377419895097773e-07
which O 0 1.5940717901230528e-07
abolishes O 0 5.9553109167609364e-05
POMC O 0 0.0015631528804078698
translation O 0 1.648424245104252e-06
. O 0 3.1963566016202094e-06

These O 0 5.455521545627562e-07
findings O 0 1.6833972722452017e-06
represent O 0 1.793640436176247e-08
the O 0 5.555124804601519e-09
first O 0 9.919584265105641e-09
examples O 0 2.4748249671802114e-08
of O 0 7.338770302567355e-08
a O 0 5.073196371085942e-05
genetic B-Disease 1 0.9923861026763916
defect I-Disease 1 0.9633041024208069
within O 0 1.0873212552553468e-08
the O 0 6.524549007735914e-07
POMC O 0 0.06328287720680237
gene O 0 4.658529633161379e-07
and O 0 1.2730056653253996e-07
define O 0 8.008314011931361e-08
a O 0 1.4235601497603056e-07
new O 0 9.245709225069731e-05
monogenic B-Disease 1 0.9951953291893005
endocrine I-Disease 1 0.9984221458435059
disorder I-Disease 0 0.12293186783790588
resulting O 0 4.785578312294092e-06
in O 0 1.6974159962046542e-06
early O 0 0.00020777012105099857
- O 1 0.9996992349624634
onset O 1 0.9989872574806213
obesity B-Disease 1 0.9999593496322632
, O 0 0.3447219431400299
adrenal B-Disease 1 0.9998741149902344
insufficiency I-Disease 1 0.9995478987693787
and O 0 2.5688075766083784e-05
red O 0 0.000707054219674319
hair O 0 0.18789848685264587
pigmentation O 0 0.0012166972737759352
. O 0 2.5644446850492386e-06
. O 0 7.87176668382017e-06

A O 0 1.8936956621473655e-05
European O 0 4.498063572100364e-05
multicenter O 0 0.005175495520234108
study O 0 1.3967626273370115e-06
of O 0 9.080215022549964e-06
phenylalanine B-Disease 1 0.9936878085136414
hydroxylase I-Disease 1 0.9997169375419617
deficiency I-Disease 1 0.999906063079834
: O 0 6.394022307176783e-07
classification O 0 4.208036443742458e-07
of O 0 1.2548214911589639e-08
105 O 0 2.8964252578589367e-06
mutations O 0 1.6357692800283985e-07
and O 0 3.121861169574913e-08
a O 0 5.717084139433837e-09
general O 0 6.33399555027836e-09
system O 0 2.5088718302868074e-07
for O 0 1.8359756381869374e-08
genotype O 0 1.4026859389559831e-05
- O 0 0.0017942000413313508
based O 0 7.925950740172993e-06
prediction O 0 0.00037812552182003856
of O 0 2.9131885526112455e-07
metabolic O 0 0.002846298972144723
phenotype O 0 0.0001363878109259531
. O 0 1.4809090316703077e-05

Phenylketonuria B-Disease 1 0.9426524043083191
( O 0 9.384706208948046e-05
PKU B-Disease 0 0.09152211993932724
) O 0 1.249426986760227e-05
and O 0 5.775983663625084e-05
mild B-Disease 0 0.11708236485719681
hyperphenylalaninemia I-Disease 1 0.9999264478683472
( O 0 8.364162204088643e-05
MHP B-Disease 1 0.999874472618103
) O 0 5.90118224863545e-06
are O 0 8.274224683191278e-07
allelic B-Disease 1 0.8678157329559326
disorders I-Disease 1 0.999529242515564
caused O 0 0.00017672270769253373
by O 0 2.3138767346608802e-07
mutations O 0 1.2093495627141237e-07
in O 0 1.1173541203390869e-08
the O 0 1.683668138241501e-08
gene O 0 6.945942487845969e-08
encoding O 0 2.0356193886073015e-07
phenylalanine O 0 6.965962256799685e-06
hydroxylase O 0 0.0004482867370825261
( O 0 5.567335961131903e-07
PAH O 0 0.0004633198550436646
) O 0 4.516760441219958e-07
. O 0 1.0332860256312415e-06

Previous O 0 3.990202458226122e-05
studies O 0 6.809933438489679e-06
have O 0 5.035871026848326e-07
suggested O 0 1.0709325124480529e-06
that O 0 1.4643288359650342e-08
the O 0 9.632121766856017e-09
highly O 0 1.496401154099658e-07
variable O 0 1.3734199910686584e-06
metabolic O 0 0.007848146371543407
phenotypes O 0 0.0008080978877842426
of O 0 0.00019904585496988147
PAH B-Disease 1 0.9995225667953491
deficiency I-Disease 1 0.6979401707649231
correlate O 0 5.498128757608356e-06
with O 0 5.624612822430208e-05
PAH O 0 0.3819417357444763
genotypes O 0 0.00037230286397971213
. O 0 1.4332242244563531e-05

We O 0 2.5351000658702105e-06
identified O 0 1.0349853027946665e-06
both O 0 5.276852377278374e-08
causative O 0 1.8861782109524938e-06
mutations O 0 2.2601841465075267e-06
in O 0 2.91463288704108e-06
686 O 1 0.601172149181366
patients O 0 5.435710590973031e-06
from O 0 5.318726437053556e-08
seven O 0 4.809296001440089e-07
European O 0 3.662256176539813e-06
centers O 0 4.528450517682359e-06
. O 0 4.764030563819688e-06

On O 0 6.803350061090896e-07
the O 0 2.545865918079926e-08
basis O 0 3.6450442664204274e-09
of O 0 2.5712112439180146e-09
the O 0 2.8293793974398795e-09
phenotypic O 0 3.783550361902144e-09
characteristics O 0 2.6958311138969293e-08
of O 0 2.382482122698093e-08
297 O 0 0.00048686296213418245
functionally O 0 0.0014719952596351504
hemizygous O 0 0.11151327937841415
patients O 0 6.717307883263857e-07
, O 0 3.57918388260714e-08
105 O 0 9.133630385349534e-08
of O 0 1.3643858265410813e-09
the O 0 2.6406551612012663e-08
mutations O 0 3.591287622839445e-08
were O 0 3.630141076627069e-09
assigned O 0 2.7880227015941728e-09
to O 0 1.6617683895603363e-09
one O 0 2.719180713928182e-10
of O 0 3.0667998696110033e-10
four O 0 1.1381734665860677e-08
arbitrary O 0 5.241003009359702e-07
phenotype O 0 2.0100207620998845e-05
categories O 0 2.2459105366579024e-06
. O 0 4.262687980371993e-06

We O 0 1.2260853736734134e-06
proposed O 0 1.0858558425752562e-06
and O 0 4.815142347069923e-07
tested O 0 3.35553522745613e-07
a O 0 5.0411919083614976e-09
simple O 0 2.590746461805793e-08
model O 0 1.7203902302753704e-07
for O 0 2.820919275947631e-09
correlation O 0 6.565795729329693e-08
between O 0 1.1550219625178215e-07
genotype O 0 3.810646603596979e-06
and O 0 3.266034411808505e-07
phenotypic O 0 3.2362905244553986e-07
outcome O 0 1.3961453987576533e-05
. O 0 1.2937872270413209e-05

The O 0 1.0690141607483383e-06
observed O 0 7.157480467867572e-06
phenotype O 0 3.0335719202412292e-05
matched O 0 7.890436245361343e-05
the O 0 4.377011919132201e-06
predicted O 0 0.009518582373857498
phenotype O 0 2.2273947251960635e-05
in O 0 1.059808738546053e-07
79 O 0 9.144137948169373e-06
% O 0 1.0570404995746685e-08
of O 0 4.793276442427441e-09
the O 0 2.0191330918351014e-07
cases O 0 1.6064378769442555e-06
, O 0 1.6924584542721277e-06
and O 0 1.7355147008402128e-07
in O 0 1.0715241138825604e-08
only O 0 6.251608120066976e-10
5 O 0 4.677011844478329e-08
of O 0 4.613996296143341e-08
184 O 0 0.00022674977662973106
patients O 0 3.6818073567701504e-07
was O 0 5.104803904032451e-07
the O 0 4.0854985172700253e-08
observed O 0 3.041898821720679e-07
phenotype O 0 8.337577810380026e-07
more O 0 8.249652072578328e-10
than O 0 4.391457419927747e-09
one O 0 2.116684427733162e-08
category O 0 3.291191887910827e-07
away O 0 2.747602820818429e-07
from O 0 2.9810721002832e-08
that O 0 1.7034115273872885e-07
expected O 0 6.310835942713311e-06
. O 0 4.134645223530242e-06

Among O 0 1.8226354541184264e-06
the O 0 2.948414135062194e-07
seven O 0 5.783639380751993e-07
contributing O 0 1.435612603017944e-06
centers O 0 1.167348244734967e-07
, O 0 2.6281137266437327e-08
the O 0 2.1866178201435105e-08
proportion O 0 9.903084219331504e-08
of O 0 3.974358975256109e-08
patients O 0 2.903832694300945e-07
for O 0 1.9254555283509944e-08
whom O 0 2.6712302769738017e-07
the O 0 3.544536042454638e-08
observed O 0 6.996895081101684e-07
phenotype O 0 3.401847379791434e-06
did O 0 6.872539870528271e-08
not O 0 2.577820845672818e-09
match O 0 1.6257072843472997e-07
the O 0 2.4355415462196106e-07
predicted O 0 0.00020130893972236663
phenotype O 0 1.0642078223099816e-06
was O 0 5.622646312986035e-07
4 O 0 3.605082383728586e-07
% O 0 3.572281670471966e-08
- O 0 0.00026012465241365135
23 O 0 6.062177817511838e-06
% O 0 9.582922899653568e-08
( O 0 7.751330599603534e-08
P O 0 0.001082679140381515
< O 0 4.817889589503466e-07
. O 0 2.433971069137897e-08
0001 O 0 2.809612124110572e-05
) O 0 4.3479783329303245e-08
, O 0 5.947551784402094e-08
suggesting O 0 5.478545404002944e-07
that O 0 3.5008561383165215e-08
differences O 0 1.3920816854806617e-07
in O 0 1.96875937774621e-09
methods O 0 4.101853967597435e-09
used O 0 6.181983813746683e-09
for O 0 2.4843676005303905e-09
mutation O 0 1.4715131335663045e-08
detection O 0 1.7973275134863798e-06
or O 0 8.782853342381713e-07
phenotype O 0 8.57900595292449e-05
classification O 0 0.00027976729325018823
may O 0 2.7510479867487447e-06
account O 0 7.515842526117922e-08
for O 0 1.0887946544357874e-08
a O 0 3.298808337603987e-08
considerable O 0 3.1252870513753805e-08
proportion O 0 2.340910221221293e-08
of O 0 2.6710079481517823e-08
genotype O 0 6.472662789747119e-05
- O 0 0.03032875247299671
phenotype O 0 0.00018693222955334932
inconsistencies O 0 0.0011515729129314423
. O 0 2.5613611796870828e-05

Our O 0 7.485962214559549e-07
data O 0 3.400971763767302e-06
indicate O 0 1.5698249171691714e-06
that O 0 1.093221300152436e-07
the O 0 4.024211648356868e-07
PAH O 0 0.001815246301703155
- O 0 0.0007935806061141193
mutation O 0 2.0188538485399476e-07
genotype O 0 1.4677675608254503e-06
is O 0 3.0300377762415565e-09
the O 0 2.4225070838213014e-09
main O 0 7.641688171133865e-08
determinant O 0 1.625257795012658e-07
of O 0 6.320168211004784e-08
metabolic O 0 0.0023971241898834705
phenotype O 0 3.807608300121501e-05
in O 0 3.59898166379935e-07
most O 0 5.968620371277211e-07
patients O 0 4.663849176722579e-05
with O 0 0.024245765060186386
PAH B-Disease 1 0.9995406866073608
deficiency I-Disease 1 0.9847245812416077
. O 0 1.1136105968034826e-05

In O 0 1.979869011847768e-06
the O 0 2.859661094589683e-07
present O 0 1.5035435296795185e-07
study O 0 5.667502733786023e-08
, O 0 4.837751887976083e-08
the O 0 1.364373503065508e-08
classification O 0 9.065366839422495e-07
of O 0 3.043436080929496e-08
105 O 0 0.00014673697296530008
PAH O 0 0.08062200993299484
mutations O 0 1.0324005188522278e-06
may O 0 5.248946166602764e-08
allow O 0 2.093276663117649e-09
the O 0 2.20517204496673e-08
prediction O 0 7.470560831279727e-06
of O 0 1.856989784165819e-09
the O 0 3.586878705164054e-08
biochemical O 0 6.553599178005243e-06
phenotype O 0 8.574998560106906e-07
in O 0 2.870485715789073e-08
> O 0 1.8043328964267857e-07
10 O 0 2.3108153612838578e-08
, O 0 7.283632186272371e-08
000 O 0 3.2547845307817624e-07
genotypes O 0 5.8262780839868356e-06
, O 0 8.18784712919296e-07
which O 0 6.097967002460791e-07
may O 0 9.233964703980746e-08
be O 0 7.842678728664509e-10
useful O 0 9.627764141484363e-10
for O 0 1.3827852196612866e-09
the O 0 4.732594760525899e-08
management O 0 6.470172593253665e-06
of O 0 1.0830975725184544e-06
hyperphenylalaninemia B-Disease 1 0.9996654987335205
in O 0 1.5724570403108373e-05
newborns O 0 0.00021756807109341025
. O 0 5.0047397053276654e-06

Somatic O 0 5.434007471194491e-05
instability O 0 7.196154911071062e-05
of O 0 3.050753605293721e-08
the O 0 1.3968144685350126e-07
CTG O 0 0.0032983850687742233
repeat O 0 2.0484232663875446e-05
in O 0 9.22016667459502e-08
mice O 0 1.7641445083427243e-05
transgenic O 0 9.477551429881714e-06
for O 0 2.7439082828095707e-07
the O 0 0.0016268208855763078
myotonic B-Disease 1 0.9999923706054688
dystrophy I-Disease 1 0.9999945163726807
region O 0 0.0008768355473875999
is O 0 3.1112233500607545e-06
age O 0 3.903141532646259e-06
dependent O 0 4.4422674250199634e-07
but O 0 1.2330795584603038e-07
not O 0 2.606228122203902e-09
correlated O 0 6.553909059903162e-08
to O 0 3.4077183297398506e-09
the O 0 1.71628613543362e-08
relative O 0 1.2473379911170923e-06
intertissue O 0 2.342842344660312e-05
transcription O 0 1.1078073924863929e-07
levels O 0 5.8315922757401495e-08
and O 0 5.156718998478027e-07
proliferative O 0 0.0026948030572384596
capacities O 0 7.5175080382905435e-06
. O 0 2.70199598162435e-06

A O 0 2.1063391614006832e-05
( O 0 1.9584724668675335e-06
CTG O 0 0.0018124025082215667
) O 0 5.805628120469919e-07
nexpansion O 0 2.8415326596586965e-05
in O 0 7.855213368657132e-09
the O 0 1.947750938313675e-08
3 O 0 8.956839678830875e-07
- O 0 0.00545489089563489
untranslated O 0 0.002086164429783821
region O 0 2.3475447505916236e-06
( O 0 3.817950755546917e-08
UTR O 0 6.930485596967628e-06
) O 0 4.6114601026658875e-09
of O 0 9.229924602394135e-10
the O 0 3.040753142613539e-07
DM O 1 0.9989370703697205
protein O 0 3.7318491763471684e-07
kinase O 0 1.2065092960256152e-06
gene O 0 1.1985727610408503e-07
( O 0 4.9806288870968274e-08
DMPK O 0 0.0011113781947642565
) O 0 1.247733649734073e-07
is O 0 1.0012536577619358e-08
responsible O 0 3.9984928434932954e-07
for O 0 3.5735740766540403e-06
causing O 1 0.9427530169487
myotonic B-Disease 1 0.9999767541885376
dystrophy I-Disease 1 0.9999785423278809
( O 0 0.001612768741324544
DM B-Disease 1 0.9998618364334106
) O 0 2.221675640612375e-05
. O 0 8.334546691912692e-06

Major O 0 7.690591155551374e-05
instability O 0 0.005777071695774794
, O 0 1.446630676582572e-06
with O 0 1.249330381369873e-07
very O 0 2.6100700267761567e-08
large O 0 2.6400408970062017e-08
expansions O 0 6.276123372117581e-07
between O 0 1.5280265586170572e-07
generations O 0 9.738546395965386e-07
and O 0 1.7412840236374905e-07
high O 0 6.726346555296914e-07
levels O 0 3.778336754578504e-09
of O 0 7.658563783152772e-10
somatic O 0 1.0463737680765917e-06
mosaicism O 0 0.002843895461410284
, O 0 1.30079683913209e-06
is O 0 1.7897723125770426e-07
observed O 0 8.603307151133777e-07
in O 0 1.5267897879311931e-06
patients O 0 6.325803497020388e-06
. O 0 1.5308885849663056e-05

There O 0 1.3944122656539548e-06
is O 0 2.219109092038707e-07
a O 0 2.951487942937092e-08
good O 0 7.77999176193589e-08
correlation O 0 8.485596225682457e-08
between O 0 1.4915484314315108e-07
repeat O 0 2.1907062546233647e-05
size O 0 7.09362793713808e-05
( O 0 3.246847413151954e-08
at O 0 1.8267670043314865e-07
least O 0 5.958517235171712e-09
in O 0 3.060195012949407e-07
leucocytes O 0 0.03362768143415451
) O 0 8.505468258590554e-07
, O 0 8.659264381094545e-07
clinical O 0 2.3067455003911164e-06
severity O 0 8.591884397901595e-05
and O 0 2.773320147753111e-06
age O 0 1.3416241699815146e-06
of O 0 4.434149047938263e-07
onset O 0 0.0029090726748108864
. O 0 3.657090928754769e-05

The O 0 1.0969556569762062e-05
trinucleotide O 0 0.09999606758356094
repeat O 0 0.0006143574137240648
instability O 0 3.3504962630104274e-05
mechanisms O 0 2.1521525468415348e-06
involved O 0 2.5738827389432117e-06
in O 0 2.3093291019904427e-05
DM B-Disease 1 0.9999499320983887
and O 0 1.483147843828192e-05
other O 0 1.427852907909255e-06
human O 0 0.001066042808815837
genetic B-Disease 1 0.9998974800109863
diseases I-Disease 1 0.9999123811721802
are O 0 5.372877467380022e-07
unknown O 0 1.6537571355002e-05
. O 0 1.3652055713464506e-05

We O 0 4.986428052689007e-07
studied O 0 4.6287567556646536e-07
somatic O 0 5.83004066356807e-06
instability O 0 0.00010765832848846912
by O 0 1.4191130048857303e-07
measuring O 0 7.819466190994717e-06
the O 0 9.408189782789123e-08
CTG O 0 0.002317143836989999
repeat O 0 6.942762865946861e-06
length O 0 9.425366442883387e-07
at O 0 4.307745484766201e-07
several O 0 1.4002897508191836e-08
ages O 0 2.6609455971993157e-07
in O 0 1.0347504186825063e-08
various O 0 2.294725520712859e-09
tissues O 0 5.457582119561266e-07
of O 0 1.9730759248659524e-08
transgenic O 0 0.0002802061790134758
mice O 0 4.206132507533766e-05
carrying O 0 9.93738581200887e-07
a O 0 1.8305320281797322e-07
( O 0 1.6861065432749456e-07
CTG O 0 0.0003834602830465883
) O 0 1.745327438129607e-07
55expansion O 0 1.620964212634135e-05
surrounded O 0 1.3854386224920745e-06
by O 0 1.8114667099666804e-08
45 O 0 6.675020358670736e-08
kb O 0 0.00028433706029318273
of O 0 6.886117454030227e-09
the O 0 2.4600032588750764e-07
human O 0 1.222990522364853e-05
DM B-Disease 1 0.999826967716217
region O 0 6.086480652811588e-07
, O 0 1.3353837147178638e-08
using O 0 5.760231402973659e-09
small O 0 1.4124496772183193e-07
- O 0 0.0005440252716653049
pool O 0 9.418184163223486e-06
PCR O 0 2.0921792383887805e-05
. O 0 2.934569238277618e-06

These O 0 1.5073841268531396e-06
mice O 0 0.00040650356095284224
have O 0 1.7739758106927184e-07
been O 0 1.1677123268327705e-07
shown O 0 1.2044165487168357e-07
to O 0 1.1557972356968094e-08
reproduce O 0 5.000261467102973e-07
the O 0 7.670188928443622e-09
intergenerational O 0 8.37554853205802e-06
and O 0 1.4683485005662078e-07
somatic O 0 3.8203404528758256e-07
instability O 0 2.039787204921595e-06
of O 0 2.28992491635438e-09
the O 0 4.041584134029108e-08
55 O 0 1.5721681165814516e-06
CTG O 0 0.000645809865090996
repeat O 0 5.94481207372155e-06
suggesting O 0 1.0472703024788643e-06
that O 0 1.1503342278729178e-08
surrounding O 0 1.6009511938364085e-08
sequences O 0 2.9052085182001974e-08
and O 0 1.7658864592817736e-08
the O 0 5.503395961170554e-09
chromatin O 0 2.6415880256536184e-06
environment O 0 7.863939117669361e-07
are O 0 9.155389224524413e-10
involved O 0 7.155954051540903e-08
in O 0 4.815941565539106e-07
instability O 0 4.488747435971163e-05
mechanisms O 0 7.449807981174672e-06
. O 0 1.1382361662981566e-05

As O 0 1.0885257779591484e-06
observed O 0 1.4526777931678225e-06
in O 0 2.9322977823653673e-08
some O 0 2.1734759825253747e-10
of O 0 2.6654898288569484e-09
the O 0 1.5440653555742756e-07
tissues O 0 2.2789758077124134e-05
of O 0 3.227006527595222e-05
DM B-Disease 1 0.9999916553497314
patients O 0 5.5736109061399475e-05
, O 0 2.482906211298541e-06
there O 0 3.100392120813922e-08
is O 0 1.6592640150747684e-08
a O 0 1.789464754153869e-08
tendency O 0 1.2496474255385692e-07
for O 0 6.2776113196605365e-09
repeat O 0 1.7240231500181835e-06
length O 0 1.9070169798851566e-07
and O 0 3.185244423775657e-08
somatic O 0 2.7380292522138916e-07
mosaicism O 0 9.953867265721783e-05
to O 0 2.2052391912552594e-08
increase O 0 1.0961773710960188e-08
with O 0 1.6871204877588752e-08
the O 0 1.503560724813724e-07
age O 0 1.435981999975411e-07
of O 0 4.527349606320286e-09
the O 0 2.6164357791458315e-07
mouse O 0 0.0003232934104744345
. O 0 1.0156418284168467e-05

Furthermore O 0 7.334270776482299e-05
, O 0 4.235868800606113e-06
we O 0 9.064574868489217e-08
observed O 0 7.047093930623305e-08
no O 0 6.147531816935725e-09
correlation O 0 1.932751914068831e-08
between O 0 2.9240134757912983e-09
the O 0 6.819666165114313e-09
somatic O 0 2.1185752530072932e-07
mutation O 0 1.983233488545011e-07
rate O 0 1.086342763301218e-06
and O 0 9.283158760808874e-06
tissue O 0 0.006977106910198927
proliferation O 0 0.0027570021338760853
capacity O 0 8.964333915173484e-07
. O 0 8.869407679412689e-07

The O 0 2.7546423098101513e-07
somatic O 0 5.27995098309475e-06
mutation O 0 5.44602653462789e-06
rates O 0 1.1491345048852963e-06
in O 0 9.385387578220161e-09
different O 0 4.700736244700465e-09
tissues O 0 3.826225110969972e-06
were O 0 2.577336317699519e-07
also O 0 5.980585626730317e-08
not O 0 2.599486181864563e-09
correlated O 0 1.0323912391640988e-07
to O 0 7.812430702358597e-10
the O 0 9.296644343237404e-09
relative O 0 9.383482506564178e-07
inter O 0 8.649477422295604e-06
- O 0 0.051504235714673996
tissue O 0 0.00014102205750532448
difference O 0 5.475892450590436e-08
in O 0 2.5340824993946853e-09
transcriptional O 0 8.389647376816356e-08
levels O 0 9.591697214261785e-09
of O 0 1.9851421895200616e-10
the O 0 3.0113873616954834e-09
three O 0 2.5535205949722695e-08
genes O 0 1.6763324595103768e-07
( O 0 1.2199696186598885e-07
DMAHP O 0 0.004360951017588377
, O 0 8.170094361048541e-07
DMPK O 0 0.0026515910867601633
and O 0 9.868349479802419e-07
59 O 0 3.658856030597235e-06
) O 0 3.222145750214622e-08
surrounding O 0 6.876040714587361e-08
the O 0 1.0355979895848577e-07
repeat O 0 5.857069481862709e-06
. O 0 2.5712353135531885e-07
. O 0 1.4951357343306881e-06

A O 0 1.469693143008044e-05
novel O 0 1.3977267371956259e-05
missense O 0 4.9923808546736836e-05
mutation O 0 1.94346321222838e-05
in O 0 1.1293567695247475e-05
patients O 0 4.61001673102146e-06
from O 0 2.7790630952040374e-07
a O 0 5.252739811112406e-06
retinoblastoma B-Disease 0 0.026312023401260376
pedigree O 0 0.02106974832713604
showing O 0 0.00013525792746804655
only O 0 1.0510818526654475e-07
mild O 0 2.7075780053564813e-06
expression O 0 5.622879939437553e-09
of O 0 5.2032930852874415e-08
the O 0 1.2195118870295119e-05
tumor B-Disease 0 0.24341899156570435
phenotype O 0 0.00019202179100830108
. O 0 1.1807187547674403e-05

We O 0 4.7305638872785494e-07
have O 0 1.1170409486283006e-08
used O 0 2.623024242254246e-09
single O 0 2.9791777933496633e-09
strand O 0 7.080344630594482e-07
conformation O 0 2.627437822866341e-07
polymorphism O 0 5.109460516905528e-07
analysis O 0 2.8167271182155673e-08
to O 0 5.795308677392086e-09
study O 0 1.2216798683795105e-09
the O 0 2.951114908000818e-09
27 O 0 2.2465223992185201e-07
exons O 0 1.127799080791192e-07
of O 0 3.795816994056622e-09
the O 0 3.169360809351929e-07
RB1 O 0 0.21888919174671173
gene O 0 5.395460220825044e-07
in O 0 1.7824108056174737e-07
individuals O 0 6.403455898862376e-08
from O 0 7.271819413290359e-08
a O 0 1.3767009932053043e-06
family O 0 0.01521365437656641
showing O 0 0.003171181306242943
mild O 0 1.2769547538482584e-05
expression O 0 1.0811852746428485e-08
of O 0 1.5139384856865945e-08
the O 0 3.353210786372074e-06
retinoblastoma B-Disease 0 0.015067149884998798
phenotype O 0 0.00012279713700991124
. O 0 1.0324230061087292e-05

In O 0 1.1146826182084624e-05
this O 0 2.198303263867274e-06
family O 0 0.0006547930533997715
affected O 0 2.579630518084741e-06
individuals O 0 2.360578434945637e-07
developed O 0 3.396526517462917e-05
unilateral B-Disease 0 0.020342890173196793
tumors I-Disease 1 0.9999730587005615
and O 0 3.181468491675332e-05
, O 0 2.3284142116608564e-06
as O 0 1.5839210831813944e-08
a O 0 6.047990552815463e-08
result O 0 8.939765905324748e-08
of O 0 8.30358182213331e-09
linkage O 0 2.4641580239403993e-05
analysis O 0 1.0308048103979672e-06
, O 0 1.1806406519099255e-06
unaffected O 0 5.076014531368855e-06
mutation O 0 1.5409365516916296e-07
carriers O 0 1.3182708471504156e-06
were O 0 8.128564132903193e-08
also O 0 1.0484149726153191e-07
identified O 0 1.0431132579924451e-07
within O 0 5.34586908074175e-09
the O 0 9.430391969544871e-07
pedigree O 0 0.005623755510896444
. O 0 1.876401984191034e-05

A O 0 2.304910822203965e-07
single O 0 3.115431113087652e-08
band O 0 1.4841727136172267e-07
shift O 0 7.577824590043747e-08
using O 0 5.0671648210709463e-08
SSCP O 0 0.0036233600694686174
was O 0 4.250919118931051e-06
identified O 0 1.0228868774220246e-07
in O 0 2.736550896997869e-08
exon O 0 1.8448678019922227e-05
21 O 0 3.0721771508979145e-06
which O 0 2.614011407331418e-07
resulted O 0 4.242197917392332e-07
in O 0 1.1696043245024157e-08
a O 0 3.725980946001073e-08
missense O 0 3.265971884047758e-07
mutation O 0 3.0768263492575443e-09
converting O 0 4.5839771978251065e-09
a O 0 4.683904109015202e-08
cys O 0 0.00018470898794475943
- O 0 7.661429845029488e-05
- O 0 9.164872608380392e-05
> O 0 1.1383248477159214e-07
arg O 0 1.8880990637626383e-07
at O 0 6.918490669249877e-09
nucleotide O 0 2.0776838027813938e-09
position O 0 9.68619406904736e-09
28 O 0 3.8656086331911865e-08
in O 0 4.15621803639965e-09
the O 0 1.7970755550322792e-07
exon O 0 0.00013135981862433255
. O 0 6.072355972719379e-06

The O 0 1.4286620171333198e-06
mutation O 0 8.736341442272533e-06
destroyed O 0 0.00033307771082036197
an O 0 6.020655973770772e-07
NdeI O 0 0.0008234888664446771
restriction O 0 6.69069208925066e-07
enzyme O 0 3.423695318360842e-07
site O 0 1.7743120679369895e-06
. O 0 2.621985913719982e-06

Analysis O 0 4.315782007324742e-06
of O 0 8.365248760355826e-08
all O 0 5.177148310053781e-08
family O 0 6.725090770487441e-06
members O 0 1.721075548744011e-08
demonstrated O 0 7.121857947822718e-07
that O 0 1.5213082349418983e-08
the O 0 1.1160293134082622e-08
missense O 0 9.50632284002495e-07
mutation O 0 2.1503090863461694e-07
co O 0 0.00014367014227900654
- O 0 0.00020630971994251013
segregated O 0 6.582995411008596e-06
with O 0 8.602375601185486e-06
patients O 0 5.442874680738896e-06
with O 0 0.002594982273876667
tumors B-Disease 1 0.9999836683273315
or O 0 5.9051733842352405e-05
who O 0 4.199315662845038e-05
, O 0 1.2118911172365188e-06
as O 0 1.5966971744774128e-08
a O 0 1.2633256574190455e-07
result O 0 1.7757820103270205e-07
of O 0 1.2648682101712438e-08
linkage O 0 1.7384068996761926e-05
analysis O 0 3.957517265007482e-07
had O 0 8.996879842015915e-06
been O 0 1.4670119981019525e-06
predicted O 0 3.42564053426031e-05
to O 0 4.293200017713161e-09
carry O 0 4.898625505234122e-08
the O 0 1.3687112243587762e-07
predisposing O 0 2.40539538935991e-05
mutation O 0 9.770342330739368e-07
. O 0 4.8731844799476676e-06

These O 0 1.7514834382836852e-07
observations O 0 4.941172164762975e-07
point O 0 3.971586011175532e-07
to O 0 1.3607870386067589e-08
another O 0 2.439074009430442e-08
region O 0 4.384354213016195e-08
of O 0 1.3226527650900266e-09
the O 0 1.00912423306454e-07
RB1 O 0 0.00778372073546052
gene O 0 6.817223408006612e-08
where O 0 4.398106767666832e-08
mutations O 0 1.3605846227449092e-08
only O 0 3.17112891501381e-10
modify O 0 2.669184873127506e-08
the O 0 4.062681746574981e-09
function O 0 3.2215909939736775e-09
of O 0 2.5344497611712313e-09
the O 0 8.217497082796399e-08
gene O 0 3.0306060239126964e-07
and O 0 2.857877916540019e-07
raise O 0 4.0481726415464436e-08
important O 0 1.7541063046522254e-09
questions O 0 4.192830616034371e-08
for O 0 2.8945223107257334e-08
genetic O 0 6.286256393650547e-06
counseling O 0 4.9477635002403986e-06
in O 0 1.0073490557260811e-06
families O 0 4.4584291458704683e-07
with O 0 4.2068649008797365e-08
these O 0 1.518397674260541e-08
distinctive O 0 1.2945496337124496e-06
phenotypes O 0 1.775964119588025e-05
. O 0 7.362604037552956e-07
. O 0 3.250768713769503e-06

Maternal B-Disease 0 0.010242567397654057
disomy I-Disease 1 0.6160722970962524
and O 0 0.1367451548576355
Prader B-Disease 1 0.999671459197998
- I-Disease 1 0.999930739402771
Willi I-Disease 1 0.999981164932251
syndrome I-Disease 1 0.9998346567153931
consistent O 0 1.064890057023149e-06
with O 0 9.399398095411016e-07
gamete O 0 0.00098386500030756
complementation O 0 0.4623255729675293
in O 0 3.273280810844881e-07
a O 0 9.498142361508144e-08
case O 0 8.270406510746398e-07
of O 0 8.661083228389543e-08
familial O 0 0.0017637282144278288
translocation O 0 0.0047035724855959415
( O 0 2.46030595008051e-07
3 O 0 5.465718118102814e-07
; O 0 3.230718448321568e-07
15 O 0 3.9926402450873866e-07
) O 0 9.773345510666331e-08
( O 0 4.332413094942922e-09
p25 O 0 2.067959258056362e-06
; O 0 5.991694962403926e-08
q11 O 0 1.5566328102067928e-06
. O 0 2.8364915749534703e-08
2 O 0 3.658978187104367e-07
) O 0 2.2343775185618142e-07
. O 0 7.942194315546658e-07

Maternal B-Disease 0 0.0196050014346838
uniparental I-Disease 1 0.9469033479690552
disomy I-Disease 1 0.9240119457244873
( I-Disease 0 8.12998550827615e-05
UPD I-Disease 1 0.999015212059021
) I-Disease 0 2.6185825845459476e-06
for I-Disease 0 7.832640847027506e-08
chromosome I-Disease 0 0.00014019910304341465
15 I-Disease 0 1.086033989849966e-06
is O 0 4.417603349793353e-08
responsible O 0 5.2585463095056184e-08
for O 0 3.717489427401688e-09
an O 0 4.235705119981503e-08
estimated O 0 7.139688591450977e-07
30 O 0 4.52677362261511e-08
% O 0 2.1665567118134277e-09
of O 0 7.571724580657246e-09
cases O 0 5.229939006312634e-07
of O 0 0.00011252268450334668
Prader B-Disease 1 0.999964714050293
- I-Disease 1 0.9999873638153076
Willi I-Disease 1 0.9999932050704956
syndrome I-Disease 1 0.9999532699584961
( O 0 0.0002452228218317032
PWS B-Disease 1 0.9996293783187866
) O 0 1.0634829777700361e-05
. O 0 4.110427198611433e-06

We O 0 4.057320438732859e-06
report O 0 2.281434944961802e-06
on O 0 9.887192931046229e-08
an O 0 1.9032265541341076e-08
unusual O 0 6.016729798830056e-07
case O 0 5.758234351560532e-07
of O 0 3.338483267611991e-08
maternal B-Disease 0 2.6006438929471187e-05
disomy I-Disease 0 0.007571918424218893
15 I-Disease 0 2.401412075414555e-06
in O 0 1.5053260540298652e-05
PWS B-Disease 1 0.9999618530273438
that O 0 2.0107424916204764e-06
is O 0 2.4868624493024072e-08
most O 0 6.262611540464036e-10
consistent O 0 1.5725303725844242e-08
with O 0 3.9965250664408813e-08
adjacent O 0 6.02629654622433e-07
- O 0 0.0006721449317410588
1 O 0 1.8259639489315305e-07
segregation O 0 8.42963345348835e-07
of O 0 3.927597358455159e-09
a O 0 3.841676914362324e-07
paternal O 0 0.00011955478839809075
t O 0 0.1570836454629898
( O 0 1.3156738809527724e-08
3 O 0 1.8897745235335606e-07
; O 0 1.3062090431503748e-07
15 O 0 2.0094647368296137e-07
) O 0 9.850337079342353e-08
( O 0 6.125119078603802e-09
p25 O 0 1.1846648249047576e-06
; O 0 5.2805170014380565e-08
q11 O 0 1.4866648143652128e-06
. O 0 1.0572986930412753e-08
2 O 0 7.415950165068352e-08
) O 0 2.9896742859136793e-09
with O 0 1.2168428487058236e-09
simultaneous O 0 6.92870116836275e-08
maternal O 0 8.989881280285772e-06
meiotic O 0 0.0033729413989931345
nondisjunction O 0 0.0005671397084370255
for O 0 5.234180022739565e-08
chromosome O 0 5.125711322762072e-05
15 O 0 1.841016910475446e-06
. O 0 6.033046702214051e-06

The O 0 1.2604180483322125e-05
patient O 0 3.778979953494854e-05
( O 0 1.0837081845238572e-06
J O 0 0.003410554490983486
. O 0 6.630898496950977e-07
B O 0 1.2572045307024382e-05
. O 0 5.4110746106061924e-08
) O 0 1.1286227064033483e-08
, O 0 4.230543471095416e-09
a O 0 5.6030957651387325e-09
17 O 0 5.658558279719728e-07
- O 0 0.0009673932800069451
year O 0 2.470027538947761e-06
- O 0 0.0008869707817211747
old O 0 0.0008206370985135436
white O 0 0.0006351395277306437
male O 0 6.748578584847564e-07
with O 0 1.8226968677481636e-05
PWS B-Disease 1 0.9999606609344482
, O 0 8.081511623458937e-06
was O 0 1.1040859135391656e-05
found O 0 1.8283162717125379e-07
to O 0 7.825230241564896e-09
have O 0 1.0121715021682576e-08
47 O 0 4.0431342540614423e-07
chromosomes O 0 9.765591357790981e-07
with O 0 5.811283898538022e-08
a O 0 4.518156231370085e-07
supernumerary O 0 0.00034964203950949013
, O 0 7.276144970091991e-06
paternal O 0 0.00018351174367126077
der O 0 0.012727056629955769
( O 0 2.7779067934829982e-08
15 O 0 2.9050090333271328e-08
) O 0 6.671454055862114e-09
consisting O 0 1.1467540250720276e-09
of O 0 3.069692500190513e-09
the O 0 1.3421124833712383e-07
short O 0 4.18622512370348e-05
arm O 0 0.04895004257559776
and O 0 3.3311943070657435e-07
the O 0 3.2240643577097217e-07
proximal O 0 0.003128885757178068
long O 0 0.0006514979177154601
arm O 0 0.02121875062584877
of O 0 1.0419977058973018e-07
chromosome O 0 0.0001124630362028256
15 O 0 1.6789305163911195e-06
, O 0 1.2213519084980362e-06
and O 0 6.6856355260824785e-06
distal O 0 0.023812396451830864
chromosome O 0 0.025308657437562943
arm O 1 0.5057260990142822
3p O 1 0.6850425601005554
. O 0 1.7303338609053753e-05

The O 0 2.2632300897384994e-05
t O 0 0.13144294917583466
( O 0 6.043620714990539e-07
3 O 0 6.600777737730823e-07
; O 0 4.1736970501915494e-07
15 O 0 5.277003651826817e-07
) O 0 1.9754979518893379e-07
was O 0 6.430002486013109e-07
present O 0 4.035473732955097e-09
in O 0 6.8664443020338695e-09
the O 0 2.199396398339104e-08
balanced O 0 7.717090966252727e-07
state O 0 4.7857877660817394e-08
in O 0 7.647228983387322e-08
the O 0 2.1955083866487257e-06
patients O 0 2.221862814622e-06
father O 0 7.6533515311894e-06
and O 0 5.465457206810242e-07
a O 0 2.1135936094651697e-06
sister O 0 0.0044895741157233715
. O 0 1.7426909835194238e-05

Fluorescent O 0 1.003495435725199e-05
in O 0 2.2803487809142098e-07
situ O 0 4.921716367789486e-07
hybridization O 0 4.885170596935495e-07
analysis O 0 1.4290419869666948e-07
demonstrated O 0 2.098219965773751e-06
that O 0 3.2655796644576185e-07
the O 0 7.678676411160268e-06
PWS B-Disease 1 0.9998701810836792
critical O 0 1.9998569769086316e-06
region O 0 4.79108564377384e-07
resided O 0 3.205650216386857e-07
on O 0 8.120041172787751e-08
the O 0 5.2912145775962927e-08
derivative O 0 2.200426024501212e-06
chromosome O 0 4.600666943588294e-05
3 O 0 5.837512730977323e-07
and O 0 2.3704052409811993e-07
that O 0 1.2862635401234002e-07
there O 0 1.2640433588728683e-08
was O 0 1.6454447404612438e-06
no O 0 2.248335029264581e-08
deletion O 0 3.261856988956424e-07
of O 0 1.0434232144973521e-08
the O 0 8.469824024359696e-06
PWS B-Disease 1 0.9999518394470215
region O 0 4.308254801799194e-07
on O 0 4.6207777160134356e-08
the O 0 1.59733364313297e-08
normal O 0 1.9143014284850324e-08
pair O 0 9.484200518272701e-07
of O 0 2.938865506507682e-08
15s O 0 5.736163984693121e-06
present O 0 7.047349015465443e-08
in O 0 6.502807536890032e-07
J O 0 0.01230649370700121
. O 0 6.672667041129898e-06

B O 0 0.008477550931274891
. O 0 0.00019385202904231846

Methylation O 0 1.1556963727343827e-05
analysis O 0 1.353600623588136e-06
at O 0 7.502665653191798e-07
exon O 0 1.5275966234185034e-06
alpha O 0 6.783318440284347e-08
of O 0 1.8428407688730886e-09
the O 0 4.0066456818976803e-08
small O 0 9.24441167171608e-07
nuclear O 0 0.0018563378835096955
ribonucleoprotein O 0 0.0010543178068473935
- O 0 0.0003872804227285087
associated O 0 7.695153385611775e-07
polypeptide O 0 6.054886398487724e-06
N O 0 5.132642399985343e-05
( O 0 5.639498823484246e-08
SNRPN O 0 0.0007311830995604396
) O 0 7.967010873244362e-08
gene O 0 3.429341433047739e-08
showed O 0 2.9974924018461024e-06
a O 0 4.5865505171605037e-08
pattern O 0 2.643668449309189e-05
characteristic O 0 2.3568557594444428e-07
of O 0 4.530295694138431e-09
only O 0 1.4585023189184199e-09
the O 0 3.556237615498503e-08
maternal O 0 4.383904069982236e-06
chromosome O 0 5.841535676154308e-05
15 O 0 7.252800173773721e-07
in O 0 2.179894181608688e-06
J O 0 0.042016562074422836
. O 0 9.862057595455553e-06

B O 0 0.004920931998640299
. O 0 0.00015853156219236553

Maternal B-Disease 0 0.015176741406321526
disomy I-Disease 0 0.4119318425655365
was O 0 0.00010542595555307344
confirmed O 0 3.302647428427008e-06
by O 0 7.519442135617282e-08
polymerase O 0 5.5056869314284995e-05
chain O 0 7.244233711389825e-05
reaction O 0 7.481745001314266e-08
analysis O 0 1.1968406710138879e-08
of O 0 6.4554250833737115e-09
microsatellite O 0 8.327393879881129e-05
repeats O 0 7.448916221619584e-07
at O 0 7.93416461419838e-08
the O 0 5.7508673378947606e-09
gamma O 0 1.4791847036121908e-07
- O 0 2.4544742700527422e-05
aminobutyric O 0 3.343500065966509e-05
acid O 0 6.788001272184374e-09
receptor O 0 6.070397517987658e-09
beta3 O 0 2.636489170981804e-06
subunit O 0 6.3673809336251e-08
( O 0 3.609058651932173e-08
GABRB3 O 0 6.301532994257286e-05
) O 0 1.0754085622011189e-07
locus O 0 3.203185769962147e-06
. O 0 1.3985302302899072e-06

A O 0 7.949223800096661e-05
niece O 0 0.09307640045881271
( O 0 1.8163834738516016e-06
B O 0 2.0246226995368488e-05
. O 0 1.3997936321175075e-07
B O 0 2.00668910110835e-06
. O 0 1.0413335971293236e-08
) O 0 3.894558009420734e-09
with O 0 7.79918440940719e-09
45 O 0 3.805431347814192e-08
chromosomes O 0 8.282885914923099e-07
and O 0 1.2051744491259342e-08
the O 0 1.7482308933836066e-09
derivative O 0 9.272510936852996e-08
3 O 0 1.1071357164382789e-07
but O 0 5.429528471267986e-08
without O 0 8.282717622876135e-09
the O 0 1.0289567597965288e-07
der O 0 0.0014622261514887214
( O 0 2.1462071231326263e-08
15 O 0 9.75561533778091e-08
) O 0 1.7323786849487988e-08
demonstrated O 0 1.5604170755523228e-07
a O 0 9.156812552646443e-08
phenotype O 0 6.226650839380454e-06
consistent O 0 1.1616677397796593e-07
with O 0 5.192611070015118e-07
that O 0 5.630974442283332e-07
reported O 0 1.1534534678503405e-05
for O 0 2.245399421951788e-08
haploinsufficiency O 0 0.0001108540382119827
of O 0 3.810064796994084e-08
distal O 0 0.0004150198947172612
3 O 0 3.570010812836699e-05
p O 0 0.009326810017228127
. O 0 7.924551937321667e-06

Uniparental B-Disease 1 0.995229959487915
disomy I-Disease 1 0.9973708391189575
associated O 0 0.0003339260001666844
with O 0 4.0150334825739264e-06
unbalanced O 0 0.0020057775545865297
segregation O 0 3.312312765046954e-05
of O 0 5.6173302453998986e-08
non O 0 5.675658485415624e-07
- O 0 0.008708699606359005
Robertsonian O 0 0.015060307458043098
translocations O 0 0.0004257536493241787
has O 0 2.940087597380625e-06
been O 0 9.826165978665813e-07
reported O 0 0.00013136908819433302
previously O 0 1.0102939995704219e-06
but O 0 2.635302394082828e-07
has O 0 1.791346875279487e-07
not O 0 2.1387574378195495e-08
, O 0 2.5836799366629748e-08
to O 0 1.813038719156168e-09
our O 0 3.2877700562039536e-09
knowledge O 0 1.0883918655224534e-08
, O 0 1.3191367997933412e-07
been O 0 6.651127648638067e-08
observed O 0 5.0846981736185626e-08
in O 0 1.2298094986817887e-08
a O 0 8.777430338113845e-08
case O 0 1.4984909284976311e-05
of O 0 2.0030631276313215e-05
PWS B-Disease 1 0.9997182488441467
. O 0 7.909646956250072e-05

Furthermore O 0 9.393363143317401e-05
, O 0 2.5143356197077082e-06
our O 0 2.3821463912554464e-07
findings O 0 6.37388211544021e-07
are O 0 1.0045719811557774e-09
best O 0 5.3017887857720325e-09
interpreted O 0 1.1507599317894801e-08
as O 0 2.480447180985834e-09
true O 0 1.9415793417465466e-07
gamete O 0 8.003533002920449e-05
complementation O 0 0.1415882706642151
resulting O 0 6.8338358687469736e-06
in O 0 2.9219438602012815e-06
maternal B-Disease 0 0.001841544988565147
UPD I-Disease 1 0.999110996723175
15 I-Disease 0 5.0991016905754805e-05
and O 0 0.00027716284967027605
PWS B-Disease 1 0.9978038668632507

Schwartz B-Disease 1 0.6188668012619019
- I-Disease 1 0.9975491166114807
Jampel I-Disease 1 0.9988937973976135
syndrome I-Disease 1 0.9985007047653198
type I-Disease 0 4.8292422434315085e-06
2 I-Disease 0 6.617451163037913e-06
and O 0 3.471079980954528e-05
Stuve B-Disease 1 0.887130618095398
- I-Disease 1 0.9999011754989624
Wiedemann I-Disease 1 0.9999748468399048
syndrome I-Disease 1 0.9997740387916565
: O 0 3.8200272456379025e-07
a O 0 5.919575229995644e-08
case O 0 5.725587470806204e-07
for O 0 6.242022010383153e-08
" O 0 8.454688895653817e-07
lumping O 0 0.00016241008415818214
" O 0 1.2890944844912156e-06
. O 0 1.78277923623682e-06

Recent O 0 2.5024821297847666e-05
studies O 0 1.2004480822724872e-06
demonstrated O 0 3.5292200664116535e-06
the O 0 7.620815978270912e-08
existence O 0 1.4051221342015197e-07
of O 0 6.2288538771326785e-09
a O 0 1.433486289670327e-07
genetically O 0 4.480970801523654e-06
distinct O 0 1.2332888843502587e-07
, O 0 8.754320788284531e-07
usually O 0 1.6964753157822088e-08
lethal O 0 5.082274157075517e-08
form O 0 2.9519426902879786e-09
of O 0 2.3600984278004944e-08
the O 0 4.2429360291862395e-06
Schwartz B-Disease 1 0.6127472519874573
- I-Disease 1 0.9990426898002625
Jampel I-Disease 1 0.9998483657836914
syndrome I-Disease 1 0.9997860789299011
( O 0 2.8353233574307524e-06
SJS B-Disease 0 0.49071556329727173
) O 0 9.640267251143086e-08
of O 0 1.6380751333144872e-07
myotonia B-Disease 1 0.5992145538330078
and O 0 0.00011305958469165489
skeletal B-Disease 1 0.99812251329422
dysplasia I-Disease 1 0.9985311031341553
, O 0 5.671033704857109e-06
which O 0 2.7513735290085606e-07
we O 0 5.0654641370329045e-08
called O 0 2.769141701719491e-06
SJS B-Disease 0 0.05143963545560837
type I-Disease 0 1.0482085599505808e-06
2 I-Disease 0 1.4344506098495913e-06
. O 0 1.3999513157614274e-06

This O 0 0.00020840184879489243
disorder O 0 0.3590596914291382
is O 0 9.616289844416315e-07
reminiscent O 0 0.0004249258781783283
of O 0 3.7130627106307657e-07
another O 0 9.511098141956609e-06
rare O 0 4.318539868108928e-05
condition O 0 7.984032708918676e-05
, O 0 1.5464764828720945e-06
the O 0 4.5705269258178305e-06
Stuve B-Disease 1 0.9776849150657654
- I-Disease 1 0.9999350309371948
Wiedemann I-Disease 1 0.9999747276306152
syndrome I-Disease 1 0.9996466636657715
( O 0 6.610718514821201e-07
SWS B-Disease 0 0.05272660404443741
) O 0 9.511501843917358e-07
, O 0 1.453976210541441e-07
which O 0 4.8450743861394585e-08
comprises O 0 1.4276199067353446e-07
campomelia B-Disease 0 0.003957455512136221
at O 0 1.2763667655235622e-05
birth O 0 3.0167295790306525e-06
with O 0 3.235342228435911e-05
skeletal B-Disease 1 0.9997538924217224
dysplasia I-Disease 1 0.9998277425765991
, O 0 0.0006607537507079542
contractures B-Disease 0 0.4435054063796997
, O 0 2.028133167186752e-06
and O 0 7.525165983679472e-07
early B-Disease 0 2.5517153972032247e-06
death I-Disease 0 4.750052175950259e-05
. O 0 9.995278560381848e-06

To O 0 6.254976483432984e-07
test O 0 8.832099069877586e-07
for O 0 2.3148826855390325e-08
possible O 0 5.356455972105323e-07
nosologic O 0 0.0031928850803524256
identity O 0 5.362888259696774e-06
between O 0 4.991417426936096e-06
these O 0 1.3906917047279421e-05
disorders O 1 0.6260966062545776
, O 0 2.5522215310047613e-06
we O 0 1.9263591610751973e-08
reviewed O 0 2.5117943280861255e-08
the O 0 5.030808658545993e-09
literature O 0 5.372086775423668e-09
and O 0 4.414747678538333e-08
obtained O 0 2.3257431536194417e-08
a O 0 4.461285119106151e-09
follow O 0 1.0585980980692966e-08
- O 0 8.985219210444484e-06
up O 0 4.944075726598385e-08
of O 0 1.3175163182665983e-09
the O 0 8.156749053966905e-09
only O 0 1.752811895627815e-09
two O 0 4.664873358706245e-07
surviving O 0 0.004294135142117739
patients O 0 8.548934715690848e-07
, O 0 6.476911806885255e-08
one O 0 9.04407215784886e-09
with O 0 7.218284849841439e-07
SJS B-Disease 0 0.17258349061012268
type I-Disease 0 1.9114816041110316e-07
2 I-Disease 0 3.7074087799737754e-07
at O 0 1.379087279929081e-06
age O 0 1.7374043181916932e-07
10 O 0 5.7588174229294964e-08
years O 0 2.1883874978811946e-07
and O 0 6.262497720399551e-08
another O 0 1.2892177991830067e-08
with O 0 8.654665748508705e-07
SWS B-Disease 1 0.6673255562782288
at O 0 3.8332349504344165e-05
age O 0 1.1918414202227723e-06
7 O 0 3.304411620774772e-06
years O 0 6.1161713347246405e-06
. O 0 6.699038294755155e-06

Patients O 0 0.0009872528025880456
reported O 0 0.0003400870773475617
as O 0 3.0742063472644077e-07
having O 0 1.3881444829166867e-06
either O 0 1.9827164123853436e-06
neonatal O 1 0.6589057445526123
SJS B-Disease 1 0.9902170896530151
or O 0 1.2601223716046661e-05
SWS B-Disease 0 0.04995972663164139
presented O 0 1.1288982477708487e-06
a O 0 6.26393088509758e-08
combination O 0 1.1900865501957014e-06
of O 0 1.5281125342880841e-07
a O 0 2.5359817300341092e-05
severe O 0 0.006709967739880085
, O 0 5.775323370471597e-05
prenatal O 0 0.007434446830302477
- O 1 0.9998476505279541
onset O 1 0.9994319081306458
neuromuscular B-Disease 1 0.999982476234436
disorder I-Disease 1 0.9983997941017151
( O 0 4.594594793161377e-05
with O 0 0.08897311985492706
congenital B-Disease 1 0.9999765157699585
joint I-Disease 1 0.9813848733901978
contractures I-Disease 1 0.9999508857727051
, O 0 0.4614480137825012
respiratory O 1 0.6784440875053406
and O 0 5.635044362861663e-05
feeding O 0 0.0006152580608613789
difficulties O 0 0.003083776915445924
, O 0 1.4773986549698748e-06
tendency O 0 2.018188979491242e-06
to O 0 2.099088533213944e-06
hyperthermia B-Disease 1 0.9812378287315369
, O 0 1.766823402249429e-06
and O 0 3.0476306278615084e-07
frequent O 0 1.2752123268455762e-07
death O 0 1.0066603863378987e-05
in O 0 3.6171261399431387e-06
infancy O 0 0.004613192286342382
) O 0 9.035281323122035e-08
with O 0 1.5299709943406015e-08
a O 0 6.201992874821372e-08
distinct O 0 6.024245635671832e-07
campomelic B-Disease 0 0.25783011317253113
- I-Disease 1 0.7009361982345581
metaphyseal I-Disease 1 0.9308432936668396
skeletal I-Disease 1 0.9973638653755188
dysplasia I-Disease 1 0.9980716109275818
. O 0 0.00016385983326472342

The O 0 6.111544053055695e-07
similarity O 0 1.7482556131653837e-06
of O 0 4.008113307918393e-08
the O 0 4.827851398658822e-07
clinical O 0 1.9378328488528496e-06
and O 0 7.04796639183769e-06
radiographic O 0 0.02412625215947628
findings O 0 5.469677944347495e-06
is O 0 2.197287329863684e-08
so O 0 4.962148025811075e-08
extensive O 0 6.982137534805588e-08
that O 0 5.438921107270289e-06
these O 0 2.039824721578043e-05
disorders O 1 0.8577606081962585
appear O 0 1.2787162404492847e-06
to O 0 4.1484899071519976e-08
be O 0 9.013762181098173e-09
a O 0 8.766768644363765e-09
single O 0 6.31927576932867e-08
entity O 0 1.0290769751009066e-05
. O 0 1.623581920284778e-05

The O 0 2.826662921506795e-07
follow O 0 2.6747812853500363e-07
- O 0 2.885249341488816e-05
up O 0 3.024496493253537e-07
observation O 0 1.99425301161682e-07
of O 0 3.403807680157911e-09
an O 0 1.6486076503952063e-08
identical O 0 6.806011697335634e-06
and O 0 1.983562611940215e-07
unique O 0 5.6178127039174797e-08
pattern O 0 5.482911365106702e-05
of O 0 1.9000691509063472e-06
progressive O 0 0.3563668429851532
bone B-Disease 1 0.9998970031738281
dysplasia I-Disease 1 0.996282160282135
in O 0 1.4150965625958634e-06
the O 0 1.2149392887295107e-06
two O 0 4.6867033233866096e-05
patients O 0 4.284100577933714e-05
( O 0 8.908396154083675e-08
one O 0 2.6230205563138043e-08
with O 0 2.642938625285751e-06
SJS B-Disease 1 0.6492470502853394
type I-Disease 0 1.030002863444679e-06
2 I-Disease 0 4.823562562705774e-07
, O 0 7.63484138133208e-08
one O 0 7.470334573156379e-09
with O 0 8.897254133444221e-07
SWS B-Disease 0 0.11744272708892822
) O 0 5.231764816926443e-07
surviving O 0 2.630893050081795e-06
beyond O 0 1.0931248652923387e-06
infancy O 0 7.996665954124182e-05
adds O 0 1.1919721600861521e-06
to O 0 2.886174632621419e-09
the O 0 9.599109063174183e-09
evidence O 0 2.5081064336518466e-07
in O 0 2.077582017534496e-08
favor O 0 1.4761718603040208e-07
of O 0 4.6574719192449265e-08
identity O 0 8.617163075541612e-06
. O 0 1.1858102880069055e-05

The O 0 2.0094678347959416e-06
hypothesis O 0 1.7251762983505614e-05
that O 0 1.7976634580918471e-06
SWS B-Disease 0 0.0791921392083168
and O 0 3.0930594220990315e-05
SJS B-Disease 0 0.23167452216148376
type I-Disease 0 8.399765647482127e-07
2 I-Disease 0 3.040973695078719e-07
are O 0 2.3405921645291983e-09
the O 0 1.0582553500171343e-07
same O 0 1.2058652828272898e-05
disorder O 0 0.05040034279227257
should O 0 4.017259769284465e-08
be O 0 3.2533422622549324e-09
testable O 0 2.47774369910303e-08
by O 0 4.846310464046155e-09
molecular O 0 7.111351578714675e-07
methods O 0 1.3998882764099108e-07
. O 0 3.802156243182253e-07
. O 0 4.391678885440342e-06

A O 0 9.22510662348941e-06
mouse O 0 0.0004172397602815181
model O 0 8.670676470501348e-05
of O 0 0.0005028308951295912
severe O 1 0.9995936751365662
von B-Disease 1 0.9999908208847046
Willebrand I-Disease 1 0.9999790191650391
disease I-Disease 1 0.99997878074646
: O 0 0.0369146429002285
defects O 1 0.9988658428192139
in O 0 0.0001396234438288957
hemostasis O 1 0.9684703946113586
and O 0 0.011437543667852879
thrombosis B-Disease 1 0.9098180532455444
. O 0 0.00016237013915088028

von B-Disease 1 0.9942837357521057
Willebrand I-Disease 1 0.9961806535720825
factor I-Disease 0 0.0030291967559605837
( I-Disease 0 4.2636362195480615e-05
vWf I-Disease 0 0.4029298722743988
) I-Disease 0 0.35400131344795227
deficiency I-Disease 1 0.9997046589851379
causes O 0 0.18824701011180878
severe O 1 0.9995245933532715
von B-Disease 1 0.9999877214431763
Willebrand I-Disease 1 0.9999657869338989
disease I-Disease 1 0.999876856803894
in O 0 5.388226782088168e-05
humans O 0 2.3067712390911765e-05
. O 0 2.602281529107131e-05

We O 0 3.7023806953584426e-07
generated O 0 8.427289088785983e-08
a O 0 2.530306986159303e-08
mouse O 0 3.814076990238391e-05
model O 0 1.1932655070268083e-05
for O 0 3.3841629942799045e-07
this O 0 2.73131604444643e-06
disease O 0 2.8941009077243507e-05
by O 0 6.7168182127375076e-09
using O 0 2.985658298371163e-08
gene O 0 1.9815018958979635e-07
targeting O 0 5.494805463968078e-06
. O 0 6.17939713265514e-06

vWf B-Disease 0 0.11766307055950165
- I-Disease 1 0.904030442237854
deficient I-Disease 1 0.8924310207366943
mice O 0 0.00567634915933013
appeared O 0 4.086218723386992e-06
normal O 0 3.2799147220430314e-07
at O 0 8.019760571187362e-06
birth O 0 2.1428709260362666e-06
; O 0 1.5674463327286503e-07
they O 0 1.574775509993742e-08
were O 0 4.2672979816416046e-08
viable O 0 5.884407983103301e-07
and O 0 1.0003030865846085e-06
fertile O 0 9.853793926595245e-06
. O 0 1.101045108953258e-05

Neither O 0 0.00030966909253038466
vWf O 0 0.003006288781762123
nor O 0 0.00015170763072092086
vWf O 0 0.0017852764576673508
propolypeptide O 0 0.044919081032276154
( O 0 1.9442195480223745e-05
von B-Disease 1 0.9293468594551086
Willebrand I-Disease 1 0.9079758524894714
antigen O 0 0.01125083863735199
II O 0 0.14965803921222687
) O 0 1.3552781297221372e-07
were O 0 2.3887842814929172e-08
detectable O 0 3.97261601392529e-08
in O 0 7.0386687589518715e-09
plasma O 0 2.0958816094207577e-05
, O 0 9.398608540323039e-07
platelets O 0 8.878054359229282e-05
, O 0 3.7619724935211707e-07
or O 0 2.977606357035256e-07
endothelial O 0 0.00043049632222391665
cells O 0 5.911282485726588e-08
of O 0 1.4656049707184593e-09
the O 0 8.084081315473668e-08
homozygous O 0 2.7703147225111024e-06
mutant O 0 0.0001521583180874586
mice O 0 0.0006118561141192913
. O 0 7.90774811321171e-06

The O 0 4.847948730457574e-06
mutant O 0 0.008981853723526001
mice O 1 0.7335401177406311
exhibited O 0 0.07654212415218353
defects O 1 0.9944003224372864
in O 0 2.4023416699492373e-05
hemostasis O 0 0.24120156466960907
with O 0 7.337062584156229e-07
a O 0 1.2516431979747722e-06
highly O 0 8.354878445970826e-06
prolonged O 0 0.006010805256664753
bleeding O 0 0.04853682965040207
time O 0 1.1037743661290733e-06
and O 0 8.723069413463236e-07
spontaneous O 0 7.121341809579462e-07
bleeding O 0 0.007611468434333801
events O 0 3.091865039550612e-07
in O 0 5.8896741705893874e-08
approximately O 0 2.453501046772999e-08
10 O 0 2.307013176050532e-07
% O 0 6.07517165462923e-08
of O 0 4.4447466507335776e-07
neonates O 0 0.004314277786761522
. O 0 1.0979729268001392e-05

As O 0 1.0410308277641889e-06
in O 0 1.5877525356700062e-06
the O 0 4.017645551357418e-06
human O 0 0.0006832150975242257
disease O 0 0.011759885586798191
, O 0 4.98177939789457e-07
the O 0 8.659250028131282e-08
factor O 0 5.73349950627744e-07
VIII O 0 0.000623521045781672
level O 0 2.5119188507005674e-08
in O 0 1.6252478474143572e-08
these O 0 1.4787863378273869e-08
mice O 0 3.3347558201057836e-05
was O 0 1.290686213906156e-06
reduced O 0 1.031058900480275e-07
strongly O 0 2.0437425973796053e-07
as O 0 6.450403322588727e-09
a O 0 6.320613721300106e-08
result O 0 5.924081847297202e-08
of O 0 5.333677499663736e-09
the O 0 1.3118604158535163e-07
lack O 0 1.1715270886725193e-07
of O 0 2.949900768101088e-08
protection O 0 3.727353430349467e-07
provided O 0 1.33099263166514e-07
by O 0 1.909417051138007e-06
vWf O 0 0.00013084251258987933
. O 0 2.505355041648727e-06

Defective O 1 0.7295215129852295
thrombosis B-Disease 1 0.914663553237915
in O 0 1.0189033673668746e-05
mutant O 0 0.001971642253920436
mice O 0 0.016557035967707634
was O 0 1.7163838492706418e-05
also O 0 3.9223442627189797e-07
evident O 0 1.545467966934666e-06
in O 0 2.599324133711889e-08
an O 0 1.4950311211237022e-08
in O 0 1.0678906647854092e-07
vivo O 0 0.00013864260108675808
model O 0 2.3872731617302634e-05
of O 0 9.187195246340707e-06
vascular B-Disease 1 0.9989287257194519
injury I-Disease 0 0.011212647892534733
. O 0 3.4298893297091126e-05

In O 0 9.246122090189601e-07
this O 0 2.333149851097005e-08
model O 0 8.112020282169397e-07
, O 0 7.523014033949948e-08
the O 0 1.0166917263632058e-07
exteriorized O 0 0.0016828806838020682
mesentery O 0 0.00017039621889125556
was O 0 1.2936762686877046e-05
superfused O 0 0.00026734540006145835
with O 0 1.1771496701840078e-06
ferric O 0 0.014530859887599945
chloride O 0 1.0248206763208145e-06
and O 0 4.5134708415162095e-08
the O 0 1.4213675569862971e-08
accumulation O 0 1.7957733007278875e-06
of O 0 3.254299940635974e-08
fluorescently O 0 0.006533186882734299
labeled O 0 0.0002514652442187071
platelets O 0 0.00025854274281300604
was O 0 8.544989782421908e-07
observed O 0 4.508815720782877e-08
by O 0 3.750966826032709e-08
intravital O 0 0.00011625408660620451
microscopy O 0 1.9741730284295045e-05
. O 0 2.8309543722571107e-06

We O 0 3.118843096672208e-06
conclude O 0 6.775677320547402e-06
that O 0 5.951898174316739e-08
these O 0 1.6029739313694336e-08
mice O 0 8.625162990938406e-06
very O 0 2.624256723038343e-08
closely O 0 2.5010220269905403e-05
mimic O 0 0.16857393085956573
severe O 0 0.19982793927192688
human O 0 0.1904468685388565
von B-Disease 1 0.9999961853027344
Willebrand I-Disease 1 0.9999932050704956
disease I-Disease 1 0.9999598264694214
and O 0 6.0186612245161086e-05
will O 0 6.019978400217951e-07
be O 0 8.142323260074136e-09
very O 0 5.432726712939484e-09
useful O 0 2.9775473198156988e-09
for O 0 2.2614685679656077e-09
investigating O 0 2.232771407761902e-07
the O 0 9.837153314151692e-09
role O 0 1.7639340654795888e-08
of O 0 1.0316486331873875e-08
vWf O 0 9.219336789101362e-06
in O 0 3.4300477125270845e-08
normal O 0 1.0694275687228583e-07
physiology O 0 2.8638947696890682e-05
and O 0 3.5150426356267417e-06
in O 0 8.687302761245519e-05
disease O 0 0.0008525966550223529
models O 0 2.9884099603805225e-06
. O 0 5.976766033199965e-07
. O 0 5.2503255574265495e-06

Oral O 0 0.00018000790441874415
contraceptives O 0 0.0025957622565329075
and O 0 9.647230399423279e-06
the O 0 3.981916051998269e-06
risk O 0 0.00014188179920893162
of O 0 8.671603427501395e-05
hereditary B-Disease 1 0.9998507499694824
ovarian I-Disease 1 0.9999672174453735
cancer I-Disease 1 0.9996919631958008
. O 0 0.0015187495155259967

Hereditary B-Disease 1 0.9969913959503174
Ovarian I-Disease 1 0.9992539286613464
Cancer I-Disease 1 0.9763756990432739
Clinical O 0 0.00024594919523224235
Study O 0 1.0714488780649845e-05
Group O 0 0.00016616801440250129
. O 0 4.658461330109276e-05

BACKGROUND O 0 5.428414078778587e-05
Women O 0 3.3690357668092474e-06
with O 0 2.4122613240251667e-07
mutations O 0 3.2560512863710755e-07
in O 0 2.969342460801272e-08
either O 0 1.7374116367818715e-08
the O 0 3.7705137856391957e-07
BRCA1 O 0 6.899078289279714e-05
or O 0 5.052042979514226e-07
the O 0 2.2913837938176584e-07
BRCA2 O 0 8.735258234082721e-06
gene O 0 5.5612659366488515e-08
have O 0 2.7566990468130825e-08
a O 0 3.0674999607072095e-07
high O 0 0.0005351012223400176
lifetime O 0 0.0012044527102261782
risk O 0 0.001057840185239911
of O 0 0.00234992615878582
ovarian B-Disease 1 0.9999805688858032
cancer I-Disease 1 0.9995408058166504
. O 0 0.00013296380348037928

Oral O 0 0.00039753265446051955
contraceptives O 0 0.14560334384441376
protect O 0 0.37959226965904236
against O 1 0.9993440508842468
ovarian B-Disease 1 0.999987006187439
cancer I-Disease 1 0.999526858329773
in O 0 2.2111689759185538e-06
general O 0 4.2939106492667634e-07
, O 0 1.935967247845838e-06
but O 0 2.165860166769562e-07
it O 0 6.050262868484424e-08
is O 0 9.085532326480461e-09
not O 0 3.2168998576054264e-09
known O 0 9.898283970244393e-09
whether O 0 1.8278903723967233e-08
they O 0 2.4759296834986344e-08
also O 0 1.4627103439579514e-07
protect O 0 1.0838219850484165e-06
against O 0 2.095509807986673e-05
hereditary B-Disease 0 0.006406919099390507
forms I-Disease 0 4.32094657298876e-06
of I-Disease 0 0.04364920035004616
ovarian I-Disease 1 0.9999885559082031
cancer I-Disease 1 0.9997445940971375
. O 0 0.00030401040567085147

METHODS O 0 2.421075350866886e-06
We O 0 2.360423252412147e-07
enrolled O 0 5.410511221271008e-07
207 O 0 0.0003173532022628933
women O 0 1.2004105883534066e-05
with O 0 0.01128427404910326
hereditary B-Disease 1 0.9999746084213257
ovarian I-Disease 1 0.999997615814209
cancer I-Disease 1 0.9999023675918579
and O 0 4.76881268696161e-06
161 O 0 1.94894960259262e-06
of O 0 1.0862350130480536e-08
their O 0 2.3183740438526002e-07
sisters O 0 1.0809896593855228e-05
as O 0 1.4746627918782451e-08
controls O 0 5.336758590601676e-07
in O 0 2.6193060165269344e-08
a O 0 1.2286892570045893e-07
case O 0 7.680757335037924e-06
- O 0 0.0018288418650627136
control O 0 7.594676389999222e-06
study O 0 3.295224360044813e-07
. O 0 1.96011478692526e-06

All O 0 4.824910320166964e-07
the O 0 1.9441563381406013e-06
patients O 0 1.6297477714033448e-06
carried O 0 7.681508122914238e-07
a O 0 4.8916881212335284e-08
pathogenic O 0 2.7340891506355547e-07
mutation O 0 6.33346672884727e-08
in O 0 3.2678283190534785e-08
either O 0 1.86681049285653e-07
BRCA1 O 0 4.018222898594104e-05
( O 0 1.2544606420306081e-07
179 O 0 1.185407836601371e-05
women O 0 1.2065311238984577e-06
) O 0 2.923246711361571e-07
or O 0 1.0665385161701124e-06
BRCA2 O 0 2.568253876233939e-05
( O 0 1.8202420903890015e-07
28 O 0 3.902061962435255e-06
women O 0 1.3821736501995474e-06
) O 0 6.084060828470683e-07
. O 0 3.3027986319211777e-06

The O 0 1.2135010365454946e-06
control O 0 7.474366157111945e-06
women O 0 4.991494506612071e-07
were O 0 4.602534886544163e-08
enrolled O 0 2.4800794307111573e-08
regardless O 0 1.6561653382041186e-08
of O 0 4.7580437367855666e-09
whether O 0 1.4178209539750242e-07
or O 0 1.8825360825758253e-07
not O 0 2.6498531369156808e-08
they O 0 2.381060149048153e-08
had O 0 7.013102276687277e-07
either O 0 5.38268452032753e-08
mutation O 0 5.358652970244293e-07
. O 0 5.14215162183973e-06

Lifetime O 0 8.501817501382902e-05
histories O 0 1.1436415661592036e-05
of O 0 1.638961037997433e-07
oral O 0 5.1400629672571085e-06
- O 0 0.00395726365968585
contraceptive O 0 5.875962597201578e-05
use O 0 2.6878781866912504e-08
were O 0 1.3684579869277513e-07
obtained O 0 8.290070496741464e-08
by O 0 1.0603343270076948e-07
interview O 0 1.8010361600317992e-05
or O 0 1.1150616785471357e-07
by O 0 2.0445764192800198e-08
written O 0 1.717773123743882e-08
questionnaire O 0 6.066684363759123e-07
and O 0 9.493214179201459e-07
were O 0 9.416067427991948e-07
compared O 0 4.508206984610297e-05
between O 0 3.231376695111976e-06
patients O 0 1.2406231917339028e-06
and O 0 4.965287416780484e-07
control O 0 1.9747153601201717e-06
women O 0 1.1691647614497924e-06
, O 0 5.104014917378663e-07
after O 0 3.3571175208635395e-06
adjustment O 0 5.419036597231752e-07
for O 0 9.591331284752869e-09
year O 0 1.0928125959708268e-07
of O 0 7.357829012732964e-09
birth O 0 2.587162043710123e-06
and O 0 2.0747841062984662e-06
parity O 0 2.9041975722066127e-05
. O 0 6.4694322645664215e-06

RESULTS O 0 4.634560173144564e-05
The O 0 6.3425267171624e-07
adjusted O 0 0.00020965626754332334
odds O 0 0.03051735647022724
ratio O 0 0.0032468766439706087
for O 0 0.3742106258869171
ovarian B-Disease 1 0.9999970197677612
cancer I-Disease 1 0.9999847412109375
associated O 0 3.336307781864889e-05
with O 0 1.2537309146409825e-07
any O 0 7.153467151965742e-09
past O 0 1.9082353475141645e-08
use O 0 3.404885706714822e-09
of O 0 1.9233523218531445e-08
oral O 0 2.922557087003952e-06
contraceptives O 0 0.00015771875041536987
was O 0 2.5470384571235627e-05
0 O 0 2.1670762180292513e-06
. O 0 2.9507109502446838e-06

5 O 0 2.0544001017697155e-05
( O 0 3.06351807921601e-07
95 O 0 1.3462984043144388e-06
percent O 0 5.628243798128096e-06
confidence O 0 3.301279321021866e-07
interval O 0 1.1507373898211881e-07
, O 0 2.026576773062061e-08
0 O 0 5.342953635079084e-09
. O 0 8.130246476056868e-10
3 O 0 4.869019409881048e-09
to O 0 1.8570179838306444e-09
0 O 0 1.7652196149242627e-08
. O 0 1.0157919838604812e-08
8 O 0 3.7534076113843184e-07
) O 0 3.0264874339991366e-07
. O 0 1.1052848094550427e-06

The O 0 4.47682905360125e-05
risk O 0 0.0005329958512447774
decreased O 0 6.742107416357612e-06
with O 0 2.7997263174484033e-08
increasing O 0 3.196070608169066e-08
duration O 0 3.043459528839776e-08
of O 0 1.6483174825054903e-09
use O 0 1.9019564589939364e-08
( O 0 3.087815869662336e-08
P O 0 7.879534678068012e-05
for O 0 1.4468816145196683e-09
trend O 0 3.1726875704407576e-07
, O 0 2.278619959383832e-08
< O 0 3.571402729107831e-08
0 O 0 3.0542917084375176e-09
. O 0 4.135326747700674e-09
001 O 0 1.940103629749501e-06
) O 0 8.401702444871262e-09
; O 0 6.625179294061923e-10
use O 0 1.465383370202744e-10
for O 0 4.0290495939565574e-10
six O 0 4.90459015622946e-08
or O 0 4.042369994294859e-08
more O 0 4.260529262722912e-09
years O 0 1.262992213924008e-06
was O 0 9.049732398125343e-06
associated O 0 5.3228060181709225e-08
with O 0 1.0504422220947163e-08
a O 0 6.798499185833862e-08
60 O 0 3.6424303289095405e-06
percent O 0 0.0002921188424807042
reduction O 0 4.799289854418021e-06
in O 0 7.600057188028586e-07
risk O 0 7.84653821028769e-06
. O 0 7.636859663762152e-06

Oral O 0 6.104924250394106e-05
- O 0 0.002117954660207033
contraceptive O 0 0.0004377193981781602
use O 0 1.302985765505582e-06
protected O 0 0.017008492723107338
against O 1 0.9997952580451965
ovarian B-Disease 1 0.9999960660934448
cancer I-Disease 1 0.9993938207626343
both O 0 1.5209811010663543e-07
for O 0 9.513935594895884e-08
carriers O 0 1.001521127363958e-06
of O 0 5.781817247196841e-09
the O 0 3.6208183473718236e-07
BRCA1 O 0 0.00017753966676536947
mutation O 0 4.1197927203029394e-07
( O 0 1.3399716181083932e-07
odds O 0 1.2646901268453803e-05
ratio O 0 8.737541890013745e-08
, O 0 2.312111568869568e-08
0 O 0 6.440789235284683e-09
. O 0 1.3330087034191251e-09
5 O 0 1.2223309475700717e-08
; O 0 1.5403394115764968e-08
95 O 0 9.265509959277551e-08
percent O 0 1.7503858771306113e-06
confidence O 0 1.288289155354505e-07
interval O 0 1.7516430972364105e-08
, O 0 4.811119058700797e-09
0 O 0 1.1863512394683084e-09
. O 0 2.415842803582535e-10
3 O 0 1.6219148246676696e-09
to O 0 8.274392837570588e-10
0 O 0 9.155708191599388e-09
. O 0 6.228283666587231e-09
9 O 0 5.217206080487813e-07
) O 0 1.818386863305932e-08
and O 0 1.3204252802268002e-08
for O 0 2.3709436636210057e-09
carriers O 0 8.041574517392291e-08
of O 0 4.247433960102853e-09
the O 0 4.963199558005726e-07
BRCA2 O 0 2.3255153791978955e-05
mutation O 0 1.276920897907985e-07
( O 0 2.392564368847161e-08
odds O 0 6.2724229792365804e-06
ratio O 0 3.396429093527331e-08
, O 0 1.1491872342617171e-08
0 O 0 6.110684402926836e-09
. O 0 1.5006528242267336e-09
4 O 0 5.0404544538196205e-08
; O 0 2.797911236029904e-08
95 O 0 1.0424747642900911e-07
percent O 0 8.892826599549153e-07
confidence O 0 5.7617729254388905e-08
interval O 0 1.8168025306408708e-08
, O 0 1.1057529114566478e-08
0 O 0 1.8415512448299864e-09
. O 0 5.843545092254487e-10
2 O 0 2.8424205211763365e-09
to O 0 9.131950196028527e-10
1 O 0 8.958076946896654e-09
. O 0 1.2728473386403039e-08
1 O 0 4.695989375136378e-08
) O 0 1.5368155459327681e-07
. O 0 5.615455052065954e-07

CONCLUSIONS O 0 4.014453952549957e-05
Oral O 0 1.1147166333103087e-05
- O 0 0.0036532136145979166
contraceptive O 0 0.000759436865337193
use O 0 1.6935341307089402e-07
may O 0 7.330600055865943e-07
reduce O 0 2.073702773941477e-07
the O 0 1.4038860172149725e-06
risk O 0 0.00032264593755826354
of O 0 0.016908418387174606
ovarian B-Disease 1 0.9999972581863403
cancer I-Disease 1 0.999862790107727
in O 0 2.367773731748457e-06
women O 0 6.763009992027946e-07
with O 0 2.918767165738245e-07
pathogenic O 0 1.4116109241513186e-06
mutations O 0 1.345500919569531e-07
in O 0 3.828611738754262e-08
the O 0 3.052156500871206e-07
BRCA1 O 0 0.0002790597500279546
or O 0 9.410544407728594e-06
BRCA2 O 0 0.00034298989339731634
gene O 0 6.46920598228462e-05

A O 0 2.1699177523260005e-05
Japanese O 0 0.0005805013352073729
family O 0 0.003291494445875287
with O 0 0.00014471700706053525
adrenoleukodystrophy B-Disease 1 0.9997596144676208
with O 0 1.8979126537033153e-07
a O 0 3.694905714723973e-08
codon O 0 5.327965979518012e-08
291 O 0 6.9080624598427676e-06
deletion O 0 6.081738320062868e-06
: O 0 5.1949434975995246e-08
a O 0 8.320089506241857e-08
clinical O 0 2.505163820387679e-06
, O 0 8.290896403195802e-06
biochemical O 0 0.0010567482095211744
, O 0 1.4502065823762678e-05
pathological O 0 0.00046473060501739383
, O 0 4.210950010019587e-06
and O 0 6.6721131588565186e-06
genetic O 0 9.156810119748116e-05
report O 0 0.00010043031215900555
. O 0 8.250386599684134e-06

We O 0 3.6175538298266474e-06
report O 0 2.001099119297578e-06
a O 0 8.857364974801385e-08
Japanese O 0 7.473354344256222e-05
family O 0 0.0030404936987906694
with O 0 0.010693605989217758
adrenoleukodystrophy B-Disease 1 0.9999803304672241
( O 0 0.003805636428296566
ALD B-Disease 1 0.9999852180480957
) O 0 8.60010800352029e-07
with O 0 8.872527601511138e-09
a O 0 5.889806420356081e-09
three O 0 2.111116437220062e-08
base O 0 1.075122895599634e-06
pair O 0 4.8761987272882834e-05
deletion O 0 1.2060976587235928e-05
( O 0 4.564984834587449e-08
delGAG O 0 3.4255815990036353e-05
291 O 0 9.28925146581605e-06
) O 0 1.4019605032444815e-07
in O 0 9.422682012427686e-08
the O 0 7.590303084725747e-06
ALD B-Disease 1 0.9997765421867371
gene O 0 1.350227466900833e-05
. O 0 5.248173238214804e-06

A O 0 1.88987485216785e-06
variety O 0 2.2732334059583081e-07
of O 0 2.476175779975165e-07
phenotypes O 0 3.20784529321827e-05
were O 0 1.3392586595273315e-07
observed O 0 1.5852378965064418e-07
within O 0 3.908563250831776e-09
this O 0 3.143533078286964e-08
family O 0 7.492070290027186e-05
. O 0 2.2177468053996563e-05

While O 0 1.3751377082371619e-05
the O 0 9.633715308154933e-06
proband O 0 0.12086073309183121
( O 0 5.157033911018516e-07
patient O 0 5.996662935103814e-07
1 O 0 4.307285337290523e-07
) O 0 2.9804101586705656e-07
was O 0 3.889655999955721e-06
classified O 0 1.6357489585061558e-06
as O 0 2.07963175569148e-08
having O 0 1.719771915986712e-07
a O 0 1.0121024729414785e-07
rare O 0 6.515638801829482e-07
intermediate O 0 9.131572369369678e-07
type O 0 1.8285813041529764e-07
of O 0 1.768704471771798e-08
adult O 0 6.446226507250685e-06
cerebral O 0 0.14640960097312927
and O 0 0.00011692960833897814
cerebello O 1 0.8854538202285767
- O 1 0.8607274293899536
brain O 0 0.04737786948680878
stem O 0 3.1671377655584365e-05
forms O 0 2.6885292214728906e-08
, O 0 6.852872047602432e-07
his O 0 1.9278813851997256e-05
younger O 0 0.000771102961152792
brother O 0 0.008725153282284737
( O 0 1.664627973241295e-07
patient O 0 1.5351734816704266e-07
2 O 0 1.2903983588330448e-06
) O 0 5.91633579460904e-07
and O 0 9.540294740872923e-06
nephew O 0 0.03235001862049103
( O 0 1.7909624716594408e-07
patient O 0 1.8528022849295667e-07
3 O 0 4.7631947381887585e-06
) O 0 1.3488158856489463e-06
had O 0 2.4914594177971594e-05
a O 0 1.9371054804651067e-05
childhood O 0 0.3723805248737335
ALD B-Disease 1 0.9999040365219116
type O 0 0.00020435759506653994
. O 0 4.71575403935276e-05

Another O 0 0.00011677159636747092
nephew O 0 0.13977618515491486
( O 0 5.570805569732329e-06
patient O 0 4.788874775840668e-06
4 O 0 8.904987225832883e-06
) O 0 3.321753183627152e-07
of O 0 3.412969107330355e-08
patient O 0 2.444999836370698e-06
1 O 0 7.308555041163345e-07
was O 0 3.272997128078714e-05
classified O 0 4.4435064410208724e-06
as O 0 7.829653014823634e-08
having O 0 4.406075504448381e-07
an O 0 1.9756053859509848e-07
adolescent O 0 0.0003627006954047829
form O 0 8.287144055429962e-07
. O 0 1.2024385796394199e-05

The O 0 9.963777074517566e-07
tau O 0 7.238839316414669e-06
level O 0 2.2828706391919695e-07
in O 0 5.046427986599156e-08
the O 0 3.227546585549135e-07
cerebrospinal O 0 0.00473004998639226
fluid O 0 0.0010470080887898803
( O 0 2.152407205358031e-06
CSF O 1 0.835848331451416
) O 0 8.228717547353881e-07
in O 0 8.515819160948013e-08
patient O 0 3.643871764325013e-07
1 O 0 3.338757323945174e-07
was O 0 1.942573589985841e-06
as O 0 2.5840099837637354e-08
high O 0 3.234101768612163e-06
as O 0 1.6999409879758787e-08
that O 0 1.2988640207822755e-07
of O 0 6.23384835307661e-07
patients O 0 2.2635020286543295e-05
with O 0 0.025673378258943558
Alzheimers B-Disease 1 0.9999363422393799
disease I-Disease 0 0.1873980015516281
( O 0 5.48919331322395e-07
AD B-Disease 0 7.206655573099852e-05
) O 0 1.6026016282921773e-06
. O 0 2.7485225473355968e-06

His O 0 5.389758007368073e-05
brain O 0 0.0011363411322236061
magnetic O 0 1.9447925296844915e-05
resonance O 0 5.609047002508305e-05
image O 0 0.000305718305753544
( O 0 1.099472228816012e-06
MRI O 0 0.0038793988060206175
) O 0 4.419800461619161e-06
showed O 0 0.0030946191400289536
abnormalities B-Disease 0 0.025925608351826668
in I-Disease 0 1.0805095485011407e-07
the I-Disease 0 1.8858550276945607e-07
bilateral I-Disease 0 0.00018463081505615264
cerebellar I-Disease 1 0.7306422591209412
hemispheres I-Disease 0 0.0038828274700790644
and O 0 0.000296568323392421
brain O 0 0.12780581414699554
stem O 0 0.0024286010302603245
, O 0 5.60063654120313e-06
but O 0 2.2450831238529645e-07
not O 0 1.0437835484822244e-08
in O 0 6.885739622930487e-08
the O 0 5.740470896853367e-06
cerebral O 0 0.46227777004241943
white O 0 0.008695445954799652
matter O 0 6.484674486273434e-07
, O 0 1.6994556517602177e-07
where O 0 1.2336299448634236e-07
marked O 0 2.4495461730111856e-06
reductions O 0 8.034527354539023e-07
of O 0 1.8151952829725815e-08
the O 0 6.058109192963457e-06
cerebral O 0 0.23994915187358856
blood O 0 2.2933278160053305e-05
flow O 0 5.46747969565331e-07
and O 0 2.4007061938391416e-07
oxygen O 0 1.2497741863626288e-06
metabolism O 0 1.0580449725239305e-06
were O 0 6.760379278603068e-08
clearly O 0 3.864562643229874e-07
demonstrated O 0 3.08553808281431e-07
by O 0 1.773183377906662e-08
positron O 0 1.38396017064224e-05
emission O 0 6.512743766506901e-07
tomography O 0 2.400711309746839e-05
( O 0 1.301706191725316e-07
PET O 0 2.31620178965386e-05
) O 0 1.073365979209484e-06
. O 0 2.4252790353784803e-06

In O 0 1.6618614608887583e-05
patients O 0 8.897865882318001e-06
2 O 0 1.849130171649449e-06
and O 0 9.648579180066008e-07
3 O 0 1.5257127188306185e-06
, O 0 2.612331684304081e-07
the O 0 5.670551104230981e-07
autopsy O 0 0.003080683993175626
findings O 0 1.0996473974955734e-05
showed O 0 0.005628698505461216
massive O 0 0.05935709923505783
demyelination B-Disease 1 0.9994568228721619
of I-Disease 0 6.735089073117706e-07
the I-Disease 0 0.00010080190986627713
cerebral I-Disease 1 0.8348637819290161
white I-Disease 0 0.0011480270186439157
matter I-Disease 0 1.8204242735464504e-07
with O 0 3.353275701556413e-08
sparing O 0 1.969561083114968e-07
of O 0 6.467847590840847e-09
the O 0 3.536922292823874e-07
U O 0 0.0015366890002042055
- O 0 0.025220118463039398
fibers O 0 0.0035259155556559563
, O 0 6.8395209495975e-08
compatible O 0 8.767354415795126e-07
with O 0 1.4333592446291732e-07
the O 0 3.822592873348185e-07
findings O 0 6.180540367495269e-06
of O 0 7.965261829667725e-06
childhood O 0 0.32640713453292847
ALD B-Disease 1 0.9996976852416992
. O 0 0.00020739962928928435

Oleic O 0 0.0010422157356515527
and O 0 1.6897225577849895e-05
erucic O 0 0.00202210433781147
acids O 0 3.7444337408487627e-07
( O 0 1.0622149204664311e-07
Lorenzos O 0 7.71283739595674e-05
Oil O 0 3.6260510114516364e-06
) O 0 1.867226728791138e-08
were O 0 4.7847450446170114e-09
administered O 0 4.753308857630145e-09
to O 0 1.413430172902963e-08
patients O 0 3.632012735010903e-08
1 O 0 1.9833390041412713e-08
and O 0 8.646921401123109e-08
4 O 0 4.893218488177808e-07
, O 0 9.715617466099502e-08
but O 0 3.9305145804746644e-08
sufficient O 0 1.0359353375122282e-08
effectiveness O 0 1.881355160548992e-07
was O 0 1.6466613033117028e-06
not O 0 3.3514854891336654e-08
obtained O 0 4.16659503343908e-07
. O 0 2.2562494450539816e-06

The O 0 4.098852059541969e-06
findings O 0 2.0115396182518452e-05
in O 0 5.229559860708832e-07
this O 0 1.873103769867157e-07
family O 0 0.0001062940718838945
suggest O 0 2.0940976810379652e-06
that O 0 1.7581993461135426e-07
delGAG291 O 0 5.4045402066549286e-05
is O 0 1.4125353331451151e-08
part O 0 7.807340551835296e-09
of O 0 2.2388817910723446e-08
the O 0 9.029524790094001e-07
cause O 0 1.3669088048118283e-06
of O 0 3.6061896935279947e-07
Japanese O 0 0.008691846393048763
ALD B-Disease 1 0.9997590184211731
with O 0 1.151840137936233e-06
phenotypic O 0 6.594711976504186e-07
variations O 0 6.041930646460969e-06
. O 0 1.2269028047739994e-05

Moreover O 0 0.00012312390026636422
, O 0 1.897045535770303e-06
although O 0 4.046829005233121e-08
the O 0 1.1193805882214747e-08
scale O 0 7.85979409556603e-06
of O 0 8.306718868311691e-09
the O 0 1.750922393739529e-07
study O 0 4.893265170835548e-08
is O 0 1.8378186084078152e-08
limited O 0 5.8808737435356306e-08
, O 0 1.842069110580269e-07
there O 0 4.6404888820461565e-09
is O 0 7.956165504197088e-09
a O 0 1.9424122754685413e-08
possibility O 0 3.8682276226609247e-07
that O 0 6.675338113382168e-07
PET O 0 0.00010960447980323806
can O 0 4.770531703002234e-08
detect O 0 8.610238182882313e-06
an O 0 4.7608739350835094e-07
insidious B-Disease 0 0.1436598300933838
lesion I-Disease 1 0.7486563920974731
which O 0 2.3363152195088333e-06
is O 0 8.189832811922315e-08
undetectable O 0 1.8641078440850833e-06
by O 0 1.2547927141781656e-08
computed O 0 8.699724389771291e-07
tomogram O 0 0.004029985051602125
( O 0 7.565505910633874e-08
CT O 0 0.002346721012145281
) O 0 1.0311159570619566e-07
or O 0 6.497475624200888e-08
MRI O 0 2.305113412148785e-05
analysis O 0 2.24430394268893e-07
, O 0 8.935146666999572e-08
and O 0 3.507279089376425e-08
that O 0 5.682675219276234e-09
the O 0 3.694170969126276e-09
higher O 0 3.55570186627574e-08
level O 0 4.005428877462691e-09
of O 0 2.7175073302743158e-09
tau O 0 6.763551851918237e-08
reflects O 0 5.324377383431056e-09
the O 0 1.2220084943947995e-09
process O 0 8.937836248890108e-09
of O 0 3.6443509543460095e-08
neuronal B-Disease 0 0.013444803655147552
degeneration I-Disease 1 0.8134154677391052
in O 0 0.00016490748384967446
ALD B-Disease 1 0.9997442364692688
. O 0 0.0003326334117446095

Lorenzos O 0 0.031935907900333405
Oil O 0 3.4837881685234606e-05
should O 0 3.5261209063719434e-08
be O 0 1.673202132401741e-09
given O 0 2.789755371157554e-10
in O 0 1.7009651465116349e-09
the O 0 6.41855502081512e-09
early O 0 1.189091207720594e-07
stage O 0 2.286065182488528e-06
. O 0 4.922086986880458e-07
. O 0 2.4099190341075882e-06

Nonsense O 0 0.00011757203901652247
mutation O 0 3.195865929228603e-06
in O 0 3.0067863576732634e-07
exon O 0 2.445378777338192e-05
4 O 0 2.057250412690337e-06
of O 0 1.5052602719833885e-08
human O 0 5.996725604973108e-08
complement O 0 1.4861953445688414e-07
C9 O 0 0.001136268489062786
gene O 0 4.0133349443749466e-07
is O 0 2.13885122946067e-08
the O 0 3.963684491736785e-08
major O 0 2.332318302933345e-07
cause O 0 1.4987891461260006e-07
of O 0 2.7131013879966304e-08
Japanese O 0 5.192764365347102e-05
complement B-Disease 0 6.67273998260498e-05
C9 I-Disease 1 0.9852502942085266
deficiency I-Disease 1 0.7413814663887024
. O 0 1.7613338059163652e-05

Deficiency B-Disease 1 0.979548454284668
of I-Disease 0 9.164727288180075e-08
the I-Disease 0 8.287762653935715e-08
ninth I-Disease 0 5.342082204151666e-06
component I-Disease 0 4.5376313551059866e-07
of I-Disease 0 1.111281910937123e-08
human I-Disease 0 9.964321634470252e-08
complement I-Disease 0 2.0775311782017525e-07
( O 0 5.733784291805932e-08
C9 O 0 0.001538435579277575
) O 0 1.109786893493947e-07
is O 0 3.2380018666344768e-09
the O 0 4.652062735033269e-09
most O 0 6.798992302492479e-08
common O 0 2.3505184799432755e-05
complement B-Disease 1 0.9837427735328674
deficiency I-Disease 1 0.9999181032180786
in O 0 4.685467729359516e-07
Japan O 0 8.776071626925841e-05
but O 0 9.10754238248046e-07
is O 0 1.0380442461155326e-07
rare O 0 2.895699537930341e-07
in O 0 3.533870085448143e-08
other O 0 3.4679853655461557e-08
countries O 0 1.5588670976285357e-07
. O 0 4.69146925752284e-06

We O 0 2.5986605578509625e-07
studied O 0 7.159516712818004e-08
the O 0 3.990558994360072e-09
molecular O 0 4.6605913439634605e-07
basis O 0 3.005931858979238e-08
of O 0 7.759896107017994e-06
C9 B-Disease 1 0.9994426369667053
deficiency I-Disease 1 0.5122982263565063
in O 0 3.5112819318783295e-08
four O 0 2.329570918391255e-07
Japanese O 0 0.00020278364536352456
C9 B-Disease 1 0.8098819851875305
- I-Disease 1 0.9936269521713257
deficient I-Disease 1 0.976148247718811
patients O 0 3.2495532650500536e-05
who O 0 0.00018403076683171093
had O 0 0.09674502164125443
suffered O 1 0.9893892407417297
from O 0 0.0007799559971317649
meningococcal B-Disease 1 0.9993972778320312
meningitis I-Disease 1 0.9983054399490356
. O 0 8.952989446697757e-05

Direct O 0 8.221447700407225e-08
sequencing O 0 3.4547920790828357e-07
of O 0 1.2513271308023377e-08
amplified O 0 3.3092144349211594e-06
C9 O 0 6.180511991260573e-05
cDNA O 0 2.071948756565689e-06
and O 0 6.172944040372386e-07
DNA O 0 1.8146718502976e-05
revealed O 0 7.250570433825487e-06
a O 0 1.0358800039966809e-08
nonsense O 0 3.467506530796527e-07
substitution O 0 4.047020496500409e-09
( O 0 2.2988830838954755e-09
CGA O 0 4.5042788769933395e-06
- O 0 0.00032683060271665454
- O 0 0.003454396268352866
> O 0 2.8932199711562134e-06
TGA O 0 0.0004291055665817112
) O 0 3.1546913970004198e-09
at O 0 9.330177741517787e-10
codon O 0 1.6076937003894898e-10
95 O 0 1.4161819494873384e-09
in O 0 1.3846906954384508e-09
exon O 0 3.8956079606577987e-07
4 O 0 4.5271708160044e-08
in O 0 3.739677900682636e-09
the O 0 2.1537688965622692e-08
four O 0 3.5283453598822234e-06
C9 B-Disease 0 0.3827260434627533
- I-Disease 0 0.38635969161987305
deficient I-Disease 0 0.06426308304071426
individuals O 0 4.772743409375835e-07
. O 0 3.339268232593895e-06

An O 0 3.332315827719867e-07
allele O 0 3.005048938575783e-06
- O 0 1.5527512005064636e-05
specific O 0 5.991052987042167e-09
polymerase O 0 4.8241559852613136e-05
chain O 0 2.326060894120019e-05
reaction O 0 2.8245226602052753e-08
system O 0 7.586285022398442e-08
designed O 0 1.4238361245588749e-06
to O 0 9.997784822246558e-09
detect O 0 5.91657283166569e-07
exclusively O 0 2.545563537736939e-09
only O 0 2.866024084724472e-10
one O 0 6.862146406660941e-10
of O 0 4.1319578314436e-10
the O 0 3.653800595415646e-09
normal O 0 1.4835523032274978e-08
and O 0 1.0472557931962001e-07
mutant O 0 6.696177024423378e-06
alleles O 0 2.6892428195424145e-07
indicated O 0 7.635873657818593e-07
that O 0 3.979302221068792e-09
all O 0 4.490393890055344e-10
the O 0 1.6429227756020737e-08
four O 0 4.831508704228327e-07
patients O 0 8.92079157210901e-08
were O 0 2.6286150145438114e-08
homozygous O 0 2.4863409109343593e-08
for O 0 9.77958380943278e-10
the O 0 7.530677414990805e-09
mutation O 0 1.3897663464490506e-08
in O 0 1.876509436726792e-08
exon O 0 6.391025181073928e-06
4 O 0 1.9192682430002606e-06
and O 0 4.629926309007715e-07
that O 0 4.248675367080068e-08
the O 0 6.474317615356995e-08
parents O 0 4.015413068714224e-08
of O 0 1.094767032583377e-08
patient O 0 5.436802439362509e-07
2 O 0 5.09269568738091e-07
were O 0 3.028063702004147e-07
heterozygous O 0 2.8784904770873254e-06
. O 0 4.020754204248078e-06

The O 0 5.436574497252877e-07
common O 0 1.7212306602232275e-07
mutation O 0 6.111338990422155e-08
at O 0 4.353861982053786e-08
codon O 0 3.702353534862368e-09
95 O 0 1.6575304684351977e-08
in O 0 9.449621529711294e-09
exon O 0 5.28217742612469e-06
4 O 0 1.8674209059099667e-06
might O 0 1.824719362275573e-07
be O 0 2.0114494514444914e-09
responsible O 0 2.0495114938512415e-08
for O 0 2.285260647383325e-09
most O 0 5.4894240264502514e-08
Japanese O 0 0.004993036389350891
C9 B-Disease 1 0.9986016154289246
deficiency I-Disease 1 0.8444547057151794
. O 0 6.117917337178369e-07
. O 0 3.437689429119928e-06

BRCA1 O 0 0.00016011316620279104
required O 0 1.6079906117738574e-07
for O 0 3.086014288555816e-08
transcription O 0 4.5168999349698424e-06
- O 0 0.054916396737098694
coupled O 0 0.002087048487737775
repair O 0 0.003488466376438737
of O 0 9.566559810991748e-08
oxidative O 0 0.00014403610839508474
DNA O 0 0.006424501072615385
damage O 0 0.012577957473695278
. O 0 2.7266491088084877e-05

The O 0 0.0012701541418209672
breast B-Disease 1 0.9987702965736389
and I-Disease 1 0.9984121322631836
ovarian I-Disease 1 0.9999758005142212
cancer I-Disease 1 0.9998489618301392
susceptibility O 0 0.00127115985378623
gene O 0 5.3929270507069305e-06
BRCA1 O 0 2.3105889340513386e-05
encodes O 0 1.6231587096626754e-06
a O 0 2.0190668692521285e-06
zinc O 0 0.007547466084361076
finger O 0 0.00014878655201755464
protein O 0 3.6948705428585527e-08
of O 0 5.61181190406046e-09
unknown O 0 3.9789938455214724e-07
function O 0 6.459146817405781e-08
. O 0 2.5502192784188082e-06

Association O 0 1.3318779565452132e-05
of O 0 4.333721292937298e-08
the O 0 1.6682707837389898e-07
BRCA1 O 0 1.458322731195949e-05
protein O 0 6.486504844360752e-08
with O 0 2.500312845654662e-08
the O 0 1.7702747356906912e-07
DNA O 0 0.00024358769587706774
repair O 0 0.014282308518886566
protein O 0 4.7377790224345517e-07
Rad51 O 0 8.408034773310646e-05
and O 0 2.4975866708132344e-08
changes O 0 2.07727968160043e-09
in O 0 2.3450159591931197e-09
the O 0 1.0195493338471806e-09
phosphorylation O 0 5.889716270246481e-09
and O 0 3.8130600898966804e-08
cellular O 0 3.6177473248244496e-06
localization O 0 1.4866107278521667e-07
of O 0 4.3715572828340044e-10
the O 0 2.8758382342175537e-09
protein O 0 4.5211304922077034e-08
after O 0 8.495440511069319e-07
exposure O 0 9.556566027413282e-08
to O 0 1.1211434447488955e-08
DNA O 0 1.83538122655591e-05
- O 0 0.027972685173153877
damaging O 0 0.000762291019782424
agents O 0 7.951736620270822e-07
are O 0 3.0203382017646163e-09
consistent O 0 1.0594606969505094e-08
with O 0 1.3147757549347716e-08
a O 0 9.72410418853542e-09
role O 0 3.635506118371268e-08
for O 0 5.6495867539752e-08
BRCA1 O 0 2.3403770683216862e-05
in O 0 1.40953659411025e-06
DNA O 0 0.0033579629380255938
repair O 0 0.3006823658943176
. O 0 3.75361560145393e-05

Here O 0 2.2336700567393564e-05
, O 0 1.6702858829376055e-06
it O 0 6.369093341618282e-08
is O 0 1.56611594803735e-08
shown O 0 3.1526898425227046e-08
that O 0 1.66152194225333e-08
mouse O 0 2.2280237317318097e-05
embryonic O 0 1.58263610501308e-05
stem O 0 0.0003602902579586953
cells O 0 7.967589772306383e-05
deficient B-Disease 0 0.020123355090618134
in I-Disease 0 1.0031279771283153e-06
BRCA1 I-Disease 0 7.943146920297295e-05
are O 0 2.2874685257079364e-08
defective O 0 0.00012611485726665705
in O 0 9.668238476479019e-08
the O 0 3.146232074868749e-08
ability O 0 6.034635902096852e-08
to O 0 1.6605231634159168e-09
carry O 0 4.9710884297837765e-09
out O 0 1.2131610382937197e-08
transcription O 0 2.049093978939709e-07
- O 0 0.0019442146876826882
coupled O 0 0.000271880766376853
repair O 0 0.0023437633644789457
of O 0 4.26928465913079e-08
oxidative O 0 0.0001114356709877029
DNA O 0 0.04647766426205635
damage O 0 0.0987769216299057
, O 0 5.855187055203714e-07
and O 0 1.2391174664116988e-07
are O 0 7.491709475004882e-09
hypersensitive O 0 2.828485048667062e-05
to O 0 3.455848940348005e-08
ionizing O 0 3.5930966646446905e-07
radiation O 0 4.7004922976157104e-07
and O 0 1.7595622736621408e-08
hydrogen O 0 5.166573942005925e-07
peroxide O 0 8.449926826870069e-05
. O 0 5.615135250991443e-06

These O 0 4.213007969156024e-07
results O 0 6.799005404900527e-06
suggest O 0 1.954050731001189e-06
that O 0 2.817157565004891e-07
BRCA1 O 0 7.122454007912893e-06
participates O 0 1.5825779087208502e-07
, O 0 1.1424847201624289e-07
directly O 0 1.9183440613801395e-08
or O 0 1.3193783843234996e-07
indirectly O 0 1.1562578947632574e-06
, O 0 1.1606091021576503e-07
in O 0 1.1083756135121803e-08
transcription O 0 4.2366102093183144e-07
- O 0 0.005479414947330952
coupled O 0 0.000511064485181123
repair O 0 0.0023462465032935143
of O 0 1.0028097818803872e-07
oxidative O 0 0.0002037290105363354
DNA O 0 0.0019325717585161328
damage O 0 0.004132246598601341
. O 0 1.7082934391510207e-06
. O 0 6.25120037511806e-06

Truncation O 0 0.00025267989258281887
mutations O 0 1.5751227692817338e-05
in O 0 2.9581337912532035e-07
the O 0 1.0782017767496654e-07
transactivation O 0 0.00010067808034364134
region O 0 7.582277135043114e-07
of O 0 6.258365914391106e-08
PAX6 O 0 0.0002714518050197512
result O 0 3.279630220731633e-07
in O 0 5.256530499764267e-08
dominant O 0 1.845909650910471e-06
- O 0 0.0007077198242768645
negative O 0 1.3209614735387731e-06
mutants O 0 5.7349519920535386e-05
. O 0 4.155755050305743e-06

PAX6 O 0 0.031264618039131165
is O 0 1.1942499895667424e-06
a O 0 5.368504574221333e-08
transcription O 0 3.5064704206888564e-07
factor O 0 6.891757209359639e-08
with O 0 5.253210311195744e-09
two O 0 2.7410225200696914e-08
DNA O 0 2.9522610930143856e-05
- O 0 9.563508501742035e-05
binding O 0 2.225513640041754e-07
domains O 0 1.8796048095737206e-07
( O 0 1.8983248750714665e-08
paired O 0 2.820070903908345e-06
box O 0 0.00023002151283435524
and O 0 5.042039902036777e-06
homeobox O 0 3.8606758607784286e-05
) O 0 1.0409543449441117e-08
and O 0 3.4068212695359534e-09
a O 0 5.3907061037250514e-09
proline O 0 4.6632143835267925e-07
- O 0 3.898420345649356e-06
serine O 0 2.39013388636522e-07
- O 0 8.597290616307873e-06
threonine O 0 2.271088987981784e-06
( O 0 2.7594294849109247e-08
PST O 0 0.00018522520258557051
) O 0 2.757882455739491e-08
- O 0 7.28066379451775e-06
rich O 0 2.74795155519314e-07
transactivation O 0 4.600271495291963e-06
domain O 0 2.3649613467568997e-07
. O 0 9.66743300523376e-07

PAX6 O 0 0.024725347757339478
regulates O 0 0.000209579142392613
eye O 0 0.0007453496218658984
development O 0 2.4930614017648622e-06
in O 0 2.443048288114369e-07
animals O 0 3.4261515224898176e-07
ranging O 0 7.250877729347849e-07
from O 0 7.309741079097876e-08
jellyfish O 0 1.0395098115623114e-06
to O 0 3.4833038675685657e-09
Drosophila O 0 4.367394268456337e-08
to O 0 2.3662735770813015e-08
humans O 0 2.9901153197897656e-07
. O 0 1.6606876442892826e-06

Heterozygous O 0 4.0517148590879515e-05
mutations O 0 9.971704457711894e-06
in O 0 6.457606787080294e-07
the O 0 3.577559652967466e-07
human O 0 2.080435024254257e-06
PAX6 O 0 0.0006893319077789783
gene O 0 8.217338631766324e-07
result O 0 1.0038163367198649e-07
in O 0 7.1906760545914494e-09
various O 0 6.141976705009711e-09
phenotypes O 0 8.519296898157336e-06
, O 0 1.0265060836900375e-06
including O 0 1.8661548892850988e-05
aniridia B-Disease 1 0.9999508857727051
, O 0 0.1817195564508438
Peters B-Disease 1 0.9999043941497803
anomaly I-Disease 1 0.9998430013656616
, O 0 0.00023861198860686272
autosomal B-Disease 0 0.006997960619628429
dominant I-Disease 0 0.005388197954744101
keratitis I-Disease 1 0.8877289295196533
, O 0 3.405133611522615e-05
and O 0 0.00014145894965622574
familial B-Disease 1 0.8477015495300293
foveal I-Disease 1 0.9990430474281311
dysplasia I-Disease 1 0.9989521503448486
. O 0 0.00018604134675115347

It O 0 9.384561963088345e-06
is O 0 1.123845208894636e-06
believed O 0 7.483228046112345e-07
that O 0 1.8967967196914515e-09
the O 0 2.230726492413737e-09
mutated O 0 1.8778239052608114e-07
allele O 0 1.1782375253233113e-07
of O 0 1.4343308762931883e-08
PAX6 O 0 0.00012823652650695294
produces O 0 8.310128407629236e-08
an O 0 2.955356404044096e-09
inactive O 0 6.707220023827176e-08
protein O 0 1.274329690659215e-07
and O 0 1.558768781251274e-05
aniridia B-Disease 1 0.9997861981391907
is O 0 4.053599695907906e-06
caused O 0 3.690788435051218e-05
due O 0 4.875169565821125e-07
to O 0 2.3014030148260645e-07
genetic O 0 7.713448576396331e-05
haploinsufficiency O 0 0.020151184871792793
. O 0 2.1770749299321324e-05

However O 0 6.1595806073455606e-06
, O 0 1.7818329922647536e-07
several O 0 1.124402793095669e-08
truncation O 0 2.85904789052438e-05
mutations O 0 7.842295417503919e-07
have O 0 5.177671980050036e-08
been O 0 1.2822560790937132e-07
found O 0 2.8910224614264735e-07
to O 0 9.211866824898607e-09
occur O 0 4.33289226720035e-09
in O 0 3.020724115287976e-09
the O 0 6.162208165960692e-08
C O 0 0.00029976549558341503
- O 0 0.00011710378748830408
terminal O 0 3.3381188586645294e-06
half O 0 1.6150503157064122e-08
of O 0 1.1817583356332761e-08
PAX6 O 0 0.0003087916993536055
in O 0 9.826577525018365e-07
patients O 0 4.290500896786398e-07
with O 0 3.362593361089239e-06
Aniridia B-Disease 1 0.9980296492576599
resulting O 0 2.497039986337768e-06
in O 0 4.766884487139578e-08
mutant O 0 2.305538146174513e-06
proteins O 0 1.133169735823003e-08
that O 0 5.9297087240395285e-09
retain O 0 1.1196902072185821e-08
the O 0 8.557416109056248e-09
DNA O 0 6.903208941366756e-06
- O 0 0.00011330631241435185
binding O 0 8.733343292988138e-08
domains O 0 6.072692571024163e-08
but O 0 5.868022157073938e-08
have O 0 2.9500245801727942e-08
lost O 0 2.3832196802686667e-06
most O 0 4.4958872735811894e-10
of O 0 1.700452667563468e-09
the O 0 8.188926869934221e-08
transactivation O 0 4.512301165959798e-05
domain O 0 1.1513458275658195e-06
. O 0 5.975049589324044e-06

It O 0 5.071601663075853e-06
is O 0 2.0332291228442045e-07
not O 0 9.455209948328047e-09
clear O 0 3.046293528541355e-08
whether O 0 1.174677155546533e-08
such O 0 2.836652468474199e-09
mutants O 0 1.2584410796989687e-05
really O 0 5.487047474161955e-07
behave O 0 2.2745584260519536e-07
as O 0 4.127897312855566e-08
loss O 0 8.323314250446856e-05
- O 0 3.1500167096965015e-05
of O 0 1.623999068556259e-08
- O 0 3.55664269591216e-05
function O 0 1.6992602880350205e-08
mutants O 0 2.2677213564747944e-06
as O 0 4.1579564680205294e-08
predicted O 0 8.932434866437688e-06
by O 0 2.3609838706306618e-07
haploinsufficiency O 0 0.0020315872970968485
. O 0 3.938697773264721e-06

Contrary O 0 1.1031913345505018e-05
to O 0 1.730412861888908e-07
this O 0 1.7575196409325144e-08
theory O 0 8.876357071585517e-08
, O 0 3.2324255272442315e-08
our O 0 8.80398420832762e-09
data O 0 4.1996977984126715e-07
showed O 0 1.6835867882036837e-06
that O 0 7.22781612338963e-09
these O 0 2.214638028519289e-09
mutants O 0 1.8571165583125548e-06
are O 0 1.0535979866332923e-09
dominant O 0 1.3201814397234557e-07
- O 0 5.288344618747942e-05
negative O 0 1.3341209026407341e-08
in O 0 4.363861272338454e-09
transient O 0 1.227955976901285e-07
transfection O 0 3.216428740415722e-05
assays O 0 6.32478645457013e-07
when O 0 7.045844085951103e-08
they O 0 5.264203739585582e-09
are O 0 1.3017545930082974e-09
coexpressed O 0 1.929047539306339e-05
with O 0 1.8613670249578718e-07
wild O 0 8.051294571487233e-06
- O 0 0.005087132100015879
type O 0 2.5876362997223623e-05
PAX6 O 0 0.0006389243062585592
. O 0 7.867533895478118e-06

We O 0 1.9012129541806644e-06
found O 0 1.1863652389365598e-06
that O 0 6.512836847605286e-08
the O 0 6.108822248052093e-08
dominant O 0 3.6539152006298536e-06
- O 0 0.0046935114078223705
negative O 0 6.235988507796719e-07
effects O 0 5.836989203089615e-07
result O 0 4.626607363888979e-08
from O 0 1.1127151422485326e-09
the O 0 2.6461495217233733e-09
enhanced O 0 2.583488480922824e-07
DNA O 0 4.261159574525664e-06
binding O 0 4.302530953737005e-08
ability O 0 6.749039105358179e-09
of O 0 9.142459012068116e-10
these O 0 1.1699345492388602e-08
mutants O 0 3.244361141696572e-05
. O 0 2.786764525808394e-06

Kinetic O 0 2.4358128939638846e-05
studies O 0 1.3887032537240884e-06
of O 0 2.28667023094431e-08
binding O 0 5.350630658540467e-07
and O 0 1.971319079530076e-06
dissociation O 0 1.6446116205770522e-05
revealed O 0 3.4296404010092374e-06
that O 0 1.2967339424463376e-09
various O 0 9.655877486469677e-11
truncation O 0 4.477142567793635e-07
mutants O 0 1.2300087064431864e-06
have O 0 3.413859417378262e-09
3 O 0 2.6275873921122184e-08
- O 0 9.556485565553885e-06
5 O 0 9.231217745764297e-08
- O 0 2.7943975510424934e-05
fold O 0 4.834707283407624e-07
higher O 0 1.1371487085298781e-09
affinity O 0 2.7970934457499652e-09
to O 0 1.5500990768746448e-10
various O 0 1.264454513316693e-10
DNA O 0 1.7436849475416238e-06
- O 0 1.4939820175641216e-05
binding O 0 1.8651904909461337e-08
sites O 0 1.2129714122011137e-08
when O 0 1.2191321729915217e-07
compared O 0 1.640653124468372e-07
with O 0 1.639832802879937e-08
the O 0 7.199187024298226e-08
wild O 0 4.585528131428873e-06
- O 0 0.006955967750400305
type O 0 3.174437370034866e-05
PAX6 O 0 0.0010705807944759727
. O 0 6.85104987496743e-06

These O 0 7.388552489828726e-07
results O 0 1.6807118754513795e-06
provide O 0 8.551689134606022e-09
a O 0 8.666697581816152e-09
new O 0 3.281563110135721e-08
insight O 0 1.9010865059954085e-07
into O 0 1.845204322670213e-09
the O 0 1.7254658812859702e-09
role O 0 3.515113089491706e-09
of O 0 1.0514423998131406e-08
mutant O 0 2.125445826095529e-05
PAX6 O 0 0.00029598252149298787
in O 0 2.829148797900416e-06
causing O 0 0.00034894791315309703
aniridia B-Disease 1 0.9736214876174927
. O 0 3.965370979130967e-06
. O 0 1.1635182090685703e-05

Reversal O 0 0.354815810918808
of O 0 0.020156636834144592
severe O 1 0.9995334148406982
hypertrophic B-Disease 1 0.9998444318771362
cardiomyopathy I-Disease 1 0.9999439716339111
and O 0 0.00010287662735208869
excellent O 0 1.1243554581596982e-05
neuropsychologic O 0 0.021006617695093155
outcome O 0 4.999950306228129e-06
in O 0 1.5334980218995042e-07
very B-Disease 0 3.306077758225001e-07
- I-Disease 0 0.01817399263381958
long I-Disease 0 3.7753346987301484e-05
- I-Disease 0 0.004642877262085676
chain I-Disease 0 0.0005270311376079917
acyl I-Disease 0 1.7576875279701198e-06
- I-Disease 0 0.0002892992924898863
coenzyme I-Disease 0 9.202260116580874e-06
A I-Disease 0 2.3457396309822798e-05
dehydrogenase I-Disease 0 0.39389753341674805
deficiency I-Disease 0 0.1328011453151703
. O 0 3.464036808509263e-06

Very B-Disease 0 1.1223907677049283e-05
- I-Disease 0 0.004211784806102514
long I-Disease 0 0.00010940587526420131
- I-Disease 0 0.007561923936009407
chain I-Disease 0 0.00032270682277157903
acyl I-Disease 0 2.344844006074709e-06
- I-Disease 0 5.541780046769418e-05
coenzyme I-Disease 0 1.2305343943808111e-06
A I-Disease 0 1.2294716498217895e-06
dehydrogenase I-Disease 0 0.0017056113574653864
( I-Disease 0 2.4245111944765085e-06
VLCAD I-Disease 1 0.9356029033660889
) I-Disease 0 0.011929345317184925
deficiency I-Disease 1 0.8320789337158203
is O 0 4.1933662942028604e-07
a O 0 9.20534148463048e-06
disorder O 0 0.00817027036100626
of O 0 1.2314741582031274e-07
fatty O 0 1.9444269128143787e-06
acid O 0 7.5296753720977e-08
beta O 0 2.0130931588369094e-08
oxidation O 0 2.66817696825683e-08
that O 0 6.677031905155673e-08
reportedly O 0 6.661131919827312e-05
has O 0 4.794412689079763e-07
high O 0 2.9127822926966473e-06
rates O 0 6.907574743308942e-07
of O 0 1.7269556451537937e-07
morbidity O 0 0.0067639220505952835
and O 0 1.564153535582591e-05
mortality O 0 7.47607700759545e-05
. O 0 3.4218385280837538e-06

We O 0 1.047359091899125e-06
describe O 0 4.2282547951799643e-07
the O 0 3.140692328429395e-08
outcome O 0 1.216753418020744e-07
of O 0 1.0885864432097492e-09
a O 0 3.336191412017797e-08
5 O 0 4.3278691919113044e-07
- O 0 0.000350253249052912
year O 0 1.0653288882167544e-06
- O 0 0.0007046564132906497
old O 0 0.00044688477646559477
girl O 0 0.06740762293338776
with O 0 0.07298589497804642
VLCAD B-Disease 1 0.9999949932098389
deficiency I-Disease 1 0.9999769926071167
who O 0 4.5560918806586415e-06
was O 0 1.1890814448634046e-06
first O 0 3.22215782944113e-08
seen O 0 7.511357011935615e-07
at O 0 8.06683544851694e-07
5 O 0 5.70432064250781e-07
months O 0 1.4773422662983648e-06
of O 0 2.0313821380568697e-07
age O 0 0.000393172464100644
with O 0 0.10068105906248093
severe O 1 0.9996961355209351
hypertrophic B-Disease 1 0.9999542236328125
cardiomyopathy I-Disease 1 0.99998939037323
, O 1 0.9336630702018738
hepatomegaly B-Disease 1 0.999968409538269
, O 0 0.39665696024894714
encephalopathy B-Disease 1 0.9826204180717468
, O 0 4.0763789002085105e-05
and O 0 9.400666021974757e-05
hypotonia B-Disease 1 0.689233660697937
. O 0 3.711202589329332e-05

Biochemical O 0 0.011417633853852749
studies O 0 0.008532519452273846
indicated O 1 0.9985063672065735
VLCAD B-Disease 1 0.9999651908874512
deficiency I-Disease 1 0.9999699592590332
caused O 0 0.003282658290117979
by O 0 2.66276316551739e-07
a O 0 4.2984137849089166e-07
stable O 0 1.7881628082250245e-05
yet O 0 5.223663492870401e-07
inactive O 0 1.4176901004248066e-06
enzyme O 0 2.0007557850476587e-06
. O 0 3.241302465539775e-06

Molecular O 0 0.0005863114492967725
genetic O 0 7.094433385645971e-05
analysis O 0 3.109757926722523e-06
of O 0 2.4904281303861353e-07
her O 0 9.410872007720172e-05
VLCAD O 0 0.2912848889827728
gene O 0 4.875462309428258e-06
revealed O 0 3.459668732830323e-05
a O 0 2.2899398288700468e-07
T1372C O 0 0.00034091438283212483
( O 0 1.9097033998605184e-07
F458L O 0 1.2514386980910785e-05
) O 0 1.1032022939616581e-07
missense O 0 3.777993242692901e-07
mutation O 0 5.462487706608954e-08
and O 0 1.8571329007954773e-07
a O 0 1.5304518683478818e-06
1668 O 0 0.09619743376970291
ACAG O 0 0.1426774561405182
1669 O 0 0.0004858717729803175
splice O 0 2.8552009098348208e-05
site O 0 7.424685463774949e-06
mutation O 0 1.0226415270153666e-06
. O 0 5.680067260982469e-06

After O 0 0.00011208426440134645
initial O 0 1.591230829944834e-05
treatment O 0 2.461606754877721e-06
with O 0 2.0555333435368084e-07
intravenous O 0 1.5487597693208954e-06
glucose O 0 4.975415322405752e-06
and O 0 1.2352186331554549e-06
carnitine O 0 0.00031474087154492736
, O 0 5.592634124695905e-07
the O 0 1.7364286009069474e-07
patient O 0 6.93864535605826e-07
has O 0 2.840574495621695e-07
thrived O 0 3.016847358594532e-06
on O 0 6.982963185464541e-08
a O 0 7.597073192755488e-08
low O 0 4.5718566070718225e-06
- O 0 0.0008361699292436242
fat O 0 4.2526974652901117e-07
diet O 0 1.3084389571815791e-08
supplemented O 0 3.7043244027756828e-09
with O 0 8.307383225769627e-09
medium O 0 6.54028553981334e-07
- O 0 4.5383276301436126e-05
chain O 0 1.1102141797891818e-05
triglyceride O 0 2.8801056828342553e-07
oil O 0 1.873087711601329e-07
and O 0 3.924147407019518e-08
carnitine O 0 7.513443961215671e-06
and O 0 5.776440659133186e-08
avoidance O 0 1.0895964805968106e-06
of O 0 2.289764644558545e-08
fasting O 0 4.1352209336764645e-06
. O 0 3.4634686016943306e-06

Her O 0 0.0030598740559071302
ventricular O 1 0.750671923160553
hypertrophy O 0 0.19565293192863464
resolved O 0 4.258333865436725e-05
significantly O 0 2.579357442300534e-06
over O 0 2.1466557598159852e-07
1 O 0 2.585531717613776e-07
year O 0 4.5525507630372886e-07
, O 0 4.635511174910789e-07
and O 0 2.443368430249393e-06
cognitively O 0 0.09672341495752335
, O 0 6.54310724712559e-06
she O 0 3.1387037324748235e-06
is O 0 1.0865996991071825e-08
in O 0 5.966239058352585e-09
the O 0 2.7180375283819558e-08
superior O 0 9.822409992921166e-06
range O 0 8.780140205999487e-07
for O 0 8.46500114448645e-08
age O 0 5.606836111837765e-06
. O 0 8.475359209114686e-06

Clinical O 0 6.082661639084108e-05
recognition O 0 2.0074847270734608e-05
of O 0 0.007302235346287489
VLCAD B-Disease 1 0.9999805688858032
deficiency I-Disease 1 0.9999758005142212
is O 0 9.66923039413814e-07
important O 0 5.3453717896445596e-08
because O 0 4.042937860049278e-07
it O 0 4.3473978195152085e-08
is O 0 6.350556081002878e-09
one O 0 1.148658612670772e-09
of O 0 2.829605882936903e-09
the O 0 2.5097571665355645e-07
few O 0 1.4905117495800368e-06
directly O 0 4.514961256063543e-05
treatable O 1 0.6860325336456299
causes O 0 0.00022557436022907495
of O 0 0.0010166270658373833
cardiomyopathy B-Disease 1 0.9999678134918213
in O 0 1.443500877940096e-05
children O 0 1.2484407307056244e-05
. O 0 5.173099907551659e-06
. O 0 1.0720518730522599e-05

Cloning O 0 0.00011440196249168366
of O 0 4.743366730508569e-07
a O 0 4.1736373646017455e-07
novel O 0 4.295225437545014e-07
member O 0 1.0994941845865469e-08
of O 0 1.8494077380637464e-09
the O 0 4.100057182654382e-08
low O 0 3.3272235668846406e-06
- O 0 0.0004794345295522362
density O 0 1.2200853234389797e-06
lipoprotein O 0 9.460693399887532e-05
receptor O 0 4.548215599697869e-07
family O 0 2.822645728883799e-05
. O 0 4.392952632770175e-06

A O 0 1.2036097132295254e-06
gene O 0 2.2864985282922135e-07
encoding O 0 1.2529839921171515e-07
a O 0 1.4223090261111793e-07
novel O 0 2.2844176328362664e-06
transmembrane O 0 3.236931434003054e-06
protein O 0 1.0020793439480258e-07
was O 0 3.06294225538295e-07
identified O 0 2.1018232487790556e-08
by O 0 2.445006863638355e-09
DNA O 0 2.817560584844614e-07
sequence O 0 8.656835248643802e-09
analysis O 0 6.490710635631558e-09
within O 0 3.8210209996059064e-10
the O 0 1.9076300361575704e-07
insulin B-Disease 0 0.0018174025462940335
- I-Disease 1 0.998305082321167
dependent I-Disease 1 0.8791434168815613
diabetes I-Disease 1 0.9999867677688599
mellitus I-Disease 1 0.9999512434005737
( O 0 1.0527294762141537e-05
IDDM B-Disease 0 0.018537739291787148
) O 0 5.988667908241041e-07
locus O 0 5.783258984592976e-06
IDDM4 O 0 0.0012647839030250907
on O 0 9.800038242246956e-06
chromosome O 0 0.0013639265671372414
11q13 O 0 0.0006280973320826888
. O 0 1.4110743904893752e-05

Based O 0 1.796426090550085e-06
on O 0 4.326812472754682e-07
its O 0 6.112622372711485e-07
chromosomal O 0 0.0001586133730597794
position O 0 6.061248427613464e-07
, O 0 1.8337330232043314e-07
this O 0 2.7237394562007466e-09
gene O 0 3.8489961440291154e-08
is O 0 7.606088203715444e-09
a O 0 1.0803463013075998e-08
candidate O 0 4.467494818527484e-08
for O 0 2.5624295574289135e-08
conferring O 0 0.0001427548995707184
susceptibility O 0 0.001460165367461741
to O 0 3.694475526572205e-05
diabetes B-Disease 1 0.5664814710617065
. O 0 3.6563724279403687e-05

The O 0 1.6330679954990046e-06
gene O 0 5.215139481151709e-06
, O 0 2.055021013802616e-06
termed O 0 2.665058127604425e-05
low O 0 4.904991783405421e-06
- O 0 0.0007954740431159735
density O 0 8.113706826406997e-07
lipoprotein O 0 1.624167271074839e-05
receptor O 0 4.6582805168782215e-08
related O 0 1.7477725577919045e-07
protein O 0 6.077767977785697e-08
5 O 0 1.206962281230517e-07
( O 0 4.874132386589736e-08
LRP5 O 0 0.0012026436161249876
) O 0 3.885315180696125e-08
, O 0 4.564843170129507e-09
encodes O 0 4.127052921631957e-09
a O 0 2.997485371025732e-09
protein O 0 1.046592412734526e-08
of O 0 1.117600789690698e-09
1615 O 0 1.3596161807072349e-05
amino O 0 2.3808455207330326e-09
acids O 0 3.627688982543731e-10
that O 0 2.9293040215705446e-10
contains O 0 5.525277804729889e-11
conserved O 0 1.3041850932538068e-09
modules O 0 2.3757215217301564e-07
which O 0 2.0570112724271894e-08
are O 0 2.1587183429705448e-10
characteristic O 0 4.004886200448254e-09
of O 0 7.083013620068357e-10
the O 0 7.154861947356039e-08
low O 0 1.7965279766940512e-05
- O 0 0.02569088339805603
density O 0 1.624322248972021e-05
lipoprotein O 0 0.005708862561732531
( O 0 2.1366948033119115e-07
LDL O 0 1.9280691049061716e-05
) O 0 1.1826132606529427e-07
receptor O 0 1.8758764497306402e-07
family O 0 1.2184829756733961e-05
. O 0 3.2602818009763723e-06

These O 0 1.5791826513122942e-07
modules O 0 2.5073820779653033e-06
include O 0 9.02277541570129e-09
a O 0 7.663257584056282e-09
putative O 0 2.451981231388345e-07
signal O 0 8.371010551400104e-08
peptide O 0 2.8415762187705695e-08
for O 0 6.628048110357554e-10
protein O 0 5.640560907238523e-09
export O 0 4.444665790970248e-08
, O 0 5.651408230278321e-08
four O 0 3.767444241020712e-07
epidermal O 0 0.01318665873259306
growth O 0 2.417196265014354e-05
factor O 0 1.1175138752150815e-06
( O 0 8.56766035894907e-08
EGF O 0 5.264920764602721e-05
) O 0 2.9902576414997384e-08
repeats O 0 2.524961075778265e-07
with O 0 7.205341034932644e-08
associated O 0 7.469339493582083e-07
spacer O 0 5.397756103775464e-05
domains O 0 2.4802173470561684e-07
, O 0 9.166161163420838e-08
three O 0 7.638832499878845e-08
LDL O 0 8.752444409765303e-05
- O 0 0.0001501931546954438
receptor O 0 2.4003375642678293e-07
( O 0 4.11901801555814e-08
LDLR O 0 0.0006718458025716245
) O 0 8.139564044995495e-08
repeats O 0 7.364612315541308e-07
, O 0 1.2534244753226176e-08
a O 0 4.073622328348847e-09
single O 0 3.346866961351225e-08
transmembrane O 0 1.205040803142765e-06
spanning O 0 3.158880872433656e-07
domain O 0 6.374015271148892e-08
, O 0 1.1249417042336063e-07
and O 0 4.7126157198817964e-08
a O 0 7.754613307042746e-08
cytoplasmic O 0 4.409649591252673e-06
domain O 0 4.684797545451147e-07
. O 0 2.2203037133294856e-06

The O 0 1.0697437602402715e-07
encoded O 0 2.315280624998195e-07
protein O 0 3.939709358746768e-07
has O 0 4.3787046877241664e-08
a O 0 4.703372802339345e-09
unique O 0 7.666473678114016e-09
organization O 0 1.8971810789025767e-08
of O 0 4.850344836881959e-08
EGF O 0 0.0007733440725132823
and O 0 1.2596722172020236e-06
LDLR O 0 0.0025085192173719406
repeats O 0 4.008131782029523e-06
; O 0 1.3781746588392707e-07
therefore O 0 3.093510514418085e-08
, O 0 6.669191634500748e-07
LRP5 O 0 0.02198517508804798
likely O 0 6.602969051527907e-07
represents O 0 1.8922481359595622e-08
a O 0 1.965918761115404e-09
new O 0 3.6925879243199233e-08
category O 0 9.190389249624786e-08
of O 0 1.5894775273750383e-08
the O 0 4.532529146672459e-06
LDLR O 1 0.6789281964302063
family O 0 0.0004999449593015015
. O 0 1.2504520782385953e-05

Both O 0 9.817978252613102e-07
human O 0 1.2012726529064821e-06
and O 0 1.7972108707908774e-06
mouse O 0 0.0014451739843934774
LRP5 O 0 0.05844917520880699
cDNAs O 0 0.0016094805905595422
have O 0 1.7971888155443594e-07
been O 0 2.338777704835593e-07
isolated O 0 1.2033939356115297e-06
and O 0 2.0685270385456533e-08
the O 0 2.2364949892050845e-09
encoded O 0 8.541516827165196e-09
mature O 0 4.271891285156926e-08
proteins O 0 3.5551914745468594e-09
are O 0 2.2473851946092083e-10
95 O 0 6.808101460364924e-08
% O 0 1.426364626411214e-08
identical O 0 1.6679583495715633e-05
, O 0 2.4622734144941205e-06
indicating O 0 4.619985702447593e-06
a O 0 6.01951839485082e-08
high O 0 1.0059781061499962e-06
degree O 0 2.69768278826632e-08
of O 0 3.567288908712385e-09
evolutionary O 0 1.0216580221822369e-06
conservation O 0 6.091294153520721e-07
. O 0 2.066426105784558e-07
. O 0 1.6632633332847035e-06

The O 0 1.2508854752013576e-06
APC B-Disease 0 0.00010490677232155576
variants O 0 2.295676040375838e-06
I1307K O 0 3.52702772943303e-05
and O 0 4.6943995357651147e-07
E1317Q O 0 3.694877159432508e-05
are O 0 3.860590780391249e-08
associated O 0 2.437825060042087e-05
with O 0 0.36048200726509094
colorectal B-Disease 1 0.9999988079071045
tumors I-Disease 1 0.9999986886978149
, O 0 0.000607496069278568
but O 0 1.3587506373369251e-06
not O 0 5.7270842290790824e-08
always O 0 1.0391198657089262e-07
with O 0 1.8482103314454434e-07
a O 0 1.2541775049612625e-06
family O 0 0.0011579296551644802
history O 0 9.755280188983306e-06
. O 0 1.416345730831381e-05

Classical O 0 0.021323882043361664
familial B-Disease 1 0.9983426332473755
adenomatous I-Disease 1 0.9986391663551331
polyposis I-Disease 1 0.999669075012207
( O 0 0.0006933949189260602
FAP B-Disease 0 0.013837472535669804
) O 0 7.177056431828532e-06
is O 0 1.1243088948731383e-07
a O 0 6.918717190274037e-07
high O 0 0.005513398442417383
- O 1 0.9962877035140991
penetrance O 1 0.9843770265579224
autosomal B-Disease 1 0.9017220735549927
dominant I-Disease 1 0.7174371480941772
disease I-Disease 0 0.2527371048927307
that O 0 1.040340976032894e-06
predisposes O 0 4.3338332034181803e-05
to O 0 1.010144501378818e-08
hundreds O 0 1.5245244355810428e-07
or O 0 1.9978963905487035e-07
thousands O 0 9.191735443891957e-06
of O 0 0.0032496682833880186
colorectal B-Disease 1 0.999998927116394
adenomas I-Disease 1 0.9999926090240479
and I-Disease 1 0.8658366203308105
carcinoma I-Disease 1 0.9999936819076538
and O 0 9.453128586756065e-05
that O 0 5.066565904598974e-07
results O 0 1.1101888048870023e-06
from O 0 3.448684893214704e-08
truncating O 0 1.9930388589273207e-05
mutations O 0 6.681172237676947e-08
in O 0 1.978313868278292e-08
the O 0 1.764952770599848e-07
APC B-Disease 0 0.0003513893752824515
gene O 0 9.01494968275074e-06
. O 0 7.427284799632616e-06

A O 0 1.2098104889446404e-05
variant O 0 0.00011270587128819898
of O 0 2.2151875782583375e-06
FAP B-Disease 0 0.01132285688072443
is O 0 4.738139978144318e-05
attenuated B-Disease 1 0.7647433280944824
adenomatous I-Disease 1 0.9998629093170166
polyposis I-Disease 1 0.9998447895050049
coli I-Disease 1 0.9992098808288574
, O 0 3.413463491597213e-05
which O 0 1.166217202808184e-06
results O 0 9.019283879752038e-07
from O 0 4.407343823231713e-08
germ O 0 0.01074658241122961
- O 0 0.0009449952631257474
line O 0 4.550399353320245e-06
mutations O 0 3.152407046513872e-08
in O 0 3.647513180382589e-09
the O 0 5.702131655738185e-09
5 O 0 4.516596519010818e-08
and O 0 3.787646463138117e-08
3 O 0 1.3448723734654777e-07
regions O 0 2.7215014686277073e-09
of O 0 3.2450937492711773e-09
the O 0 1.514612080200095e-07
APC B-Disease 0 9.085159399546683e-05
gene O 0 9.89709519672033e-07
. O 0 1.8897216023106012e-06

Attenuated B-Disease 1 0.9888817667961121
adenomatous I-Disease 1 0.9987128973007202
polyposis I-Disease 1 0.9990897178649902
coli I-Disease 1 0.9993768334388733
patients O 0 0.0010649687610566616
have O 0 3.4334170777583495e-06
" O 0 2.6323662041249918e-06
multiple O 0 6.553764978889376e-05
" O 1 0.7934352159500122
colorectal B-Disease 1 0.999996542930603
adenomas I-Disease 1 0.9999772310256958
( O 0 1.1651798104139743e-06
typically O 0 8.511889149076524e-08
fewer O 0 1.2067822297012754e-08
than O 0 3.918879443176593e-09
100 O 0 6.358836657227585e-08
) O 0 3.775716450604705e-08
without O 0 1.6850263406809063e-09
the O 0 3.565583384101956e-08
florid O 0 0.00022529902344103903
phenotype O 0 6.202611984917894e-06
of O 0 4.480473947410246e-08
classical O 0 4.491277195484145e-06
FAP B-Disease 0 0.00011166767217218876
. O 0 6.975534688535845e-06

Another O 0 3.922280029655667e-06
group O 0 3.241120066377334e-05
of O 0 6.435818136196758e-07
patients O 0 1.0335826345908572e-06
with O 0 9.533169418318721e-07
multiple O 0 0.00046472373651340604
adenomas B-Disease 1 0.941881000995636
has O 0 6.3344969021272846e-06
no O 0 2.075990295224983e-07
mutations O 0 8.208568402778837e-08
in O 0 2.160475354173741e-08
the O 0 1.2737123711303866e-07
APC B-Disease 0 0.0005475854850374162
gene O 0 2.5343845777570095e-07
, O 0 1.466775358949235e-07
and O 0 3.0627813174533e-08
their O 0 8.448226651580626e-08
phenotype O 0 6.0880702221766114e-05
probably O 0 1.818531018216163e-06
results O 0 2.425849743303843e-07
from O 0 5.3424340507035595e-09
variation O 0 1.3618127070458286e-08
at O 0 8.487650120514445e-07
a O 0 1.0548475870564289e-07
locus O 0 4.215035460219951e-06
, O 0 2.939634384802048e-07
or O 0 3.805518389299323e-08
loci O 0 1.3375189666930964e-07
, O 0 4.5461857212103496e-07
elsewhere O 0 3.398062276005476e-08
in O 0 9.095017183824439e-09
the O 0 1.3022598466250201e-07
genome O 0 5.298031464917585e-05
. O 0 1.1359936252119951e-05

Recently O 0 0.0006048364448361099
, O 0 1.10393430077238e-05
however O 0 2.812717241340579e-07
, O 0 5.721374307654514e-08
a O 0 8.676291685105753e-09
missense O 0 4.744479724649864e-07
variant O 0 1.205220087285852e-06
of O 0 4.929894359406717e-08
APC B-Disease 0 0.001998526742681861
( O 0 2.335058155722436e-07
I1307K O 0 4.640035695047118e-05
) O 0 8.158943956004805e-07
was O 0 1.0985081644321326e-05
described O 0 1.4511640074488241e-05
that O 0 9.189267302645021e-08
confers O 0 5.499725261870481e-07
an O 0 6.19714484173528e-08
increased O 0 4.176104539510561e-06
risk O 0 8.738392352825031e-05
of O 0 0.033792220056056976
colorectal B-Disease 1 0.9999988079071045
tumors I-Disease 1 0.999997615814209
, O 0 4.3587471736827865e-05
including O 0 4.96642826419702e-07
multiple O 0 0.0001803853956516832
adenomas B-Disease 1 0.8978643417358398
, O 0 7.748027201159857e-06
in O 0 2.3406346372212283e-06
Ashkenazim O 0 0.0009478506399318576
. O 0 1.6663574569975026e-05

We O 0 1.92004267773882e-06
have O 0 4.241291762241417e-08
studied O 0 1.6796940727203946e-08
a O 0 4.512529905298379e-09
set O 0 6.252364670444877e-08
of O 0 6.620915371513547e-08
164 O 0 0.0004599357198458165
patients O 0 1.933258772623958e-06
with O 0 2.0704295820905827e-05
multiple O 1 0.8559175133705139
colorectal B-Disease 1 0.9999978542327881
adenomas I-Disease 1 0.9999817609786987
and I-Disease 0 0.004860416986048222
/ I-Disease 0 0.020544594153761864
or I-Disease 0 0.0008987511973828077
carcinoma I-Disease 1 0.9999332427978516
and O 0 7.639734462827619e-07
analyzed O 0 3.843527451863338e-07
codons O 0 2.452247827022802e-07
1263 O 0 6.617306644329801e-05
- O 0 0.000772247847635299
1377 O 0 0.00185556395445019
( O 0 1.2906694379921646e-08
exon O 0 7.322648230001505e-07
15G O 0 2.0181619220238645e-06
) O 0 3.453501484784738e-09
of O 0 3.3562544410337125e-10
the O 0 1.5417914056570226e-08
APC B-Disease 0 1.056073779182043e-05
gene O 0 2.6000776642831624e-08
for O 0 1.5256670593544186e-08
germ O 0 0.0011303664650768042
- O 0 9.939924348145723e-05
line O 0 4.210600309306756e-06
variants O 0 1.4629380302721984e-06
. O 0 2.0500217488006456e-06

Three O 0 2.7753898393712007e-05
patients O 0 5.764944489783375e-06
with O 0 9.491604657796415e-08
the O 0 1.9820934937797574e-07
I1307K O 0 5.030066677136347e-05
allele O 0 2.039989340119064e-06
were O 0 1.760345185175538e-07
detected O 0 7.099723688952508e-07
, O 0 1.0839666941819814e-08
each O 0 3.6799424618649823e-10
of O 0 2.7046485939763443e-08
Ashkenazi O 0 0.0009906995110213757
descent O 0 0.0009106836514547467
. O 0 3.52589413523674e-05

Four O 0 0.00016332058294210583
patients O 0 8.921337575884536e-05
had O 0 4.504777280089911e-06
a O 0 6.775824772375927e-07
germ O 0 0.05531027913093567
- O 0 0.003264943603426218
line O 0 1.5519606677116826e-05
E1317Q O 0 5.110218353365781e-06
missense O 0 3.208445775726432e-07
variant O 0 5.766433446297015e-07
of O 0 4.335705483526908e-08
APC O 0 0.00041348495869897306
that O 0 6.035510864421667e-07
was O 0 1.0210929758613929e-05
not O 0 2.1956031659442488e-08
present O 0 5.903944444440867e-09
in O 0 2.686540412355498e-08
controls O 0 3.056227569686598e-06
; O 0 8.444924048944813e-08
one O 0 1.8462639195249153e-09
of O 0 5.188791174504104e-09
these O 0 3.5429206235448873e-08
individuals O 0 2.774660678994678e-08
had O 0 3.5799112652057374e-07
an O 0 1.6743522124329502e-08
unusually O 0 9.300014767177345e-07
large O 0 1.1072281758117697e-08
number O 0 2.0592438865207896e-09
of O 0 1.8460119122210017e-07
metaplastic B-Disease 0 0.4108019769191742
polyps I-Disease 0 0.0005131918005645275
of I-Disease 0 3.124762315565022e-08
the I-Disease 0 1.4226444591258769e-06
colorectum I-Disease 0 0.010524943470954895
. O 0 1.0183148333453573e-05

There O 0 1.6325681144735427e-06
is O 0 3.5221452776568185e-07
increasing O 0 1.6048470286023075e-07
evidence O 0 7.655378340132302e-07
that O 0 5.545451742250407e-08
there O 0 4.581913959356143e-09
exist O 0 1.3202085646923933e-08
germ O 0 0.00040101498598232865
- O 0 9.268961002817377e-05
line O 0 6.160869929772161e-07
variants O 0 2.5699280925550738e-08
of O 0 1.917216385649567e-09
the O 0 9.743230577896611e-08
APC B-Disease 0 6.298373045865446e-05
gene O 0 1.668722546810386e-07
that O 0 9.762651131950406e-08
predispose O 0 9.69732241173915e-07
to O 0 2.7035638172634435e-09
the O 0 6.073964442521174e-09
development O 0 7.566978155182369e-08
of O 0 2.3543621807675663e-07
multiple O 0 0.44149017333984375
colorectal B-Disease 1 0.999997615814209
adenomas I-Disease 1 0.9999884366989136
and I-Disease 1 0.9292628169059753
carcinoma I-Disease 1 0.999995231628418
, O 0 4.8114568926393986e-05
but O 0 1.115091450287764e-07
without O 0 5.284161996854664e-09
the O 0 2.0639713937953275e-08
florid O 0 0.00039614125853404403
phenotype O 0 3.4989986943401163e-06
of O 0 3.634214706949024e-09
classical O 0 3.8083834397184546e-07
FAP B-Disease 0 4.565549170365557e-05
, O 0 9.378140930493828e-07
and O 0 1.808986525020373e-07
possibly O 0 1.5585564483444614e-07
with O 0 5.0898989911729586e-08
importance O 0 6.655799097643467e-06
for O 0 0.40675586462020874
colorectal B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.999991774559021
risk O 0 0.00016350459191016853
in O 0 5.2808395878400916e-08
the O 0 3.330558229208691e-08
general O 0 3.8896899923202e-08
population O 0 5.935460123396297e-08
. O 0 4.6819747012705193e-07
. O 0 4.277094831195427e-06

Genomic O 0 0.00013487052638083696
structure O 0 2.1806550648761913e-05
of O 0 2.212309937021928e-06
the O 0 0.00015722714306320995
human O 0 0.21573784947395325
congenital B-Disease 1 0.9999439716339111
chloride I-Disease 1 0.9985249638557434
diarrhea I-Disease 1 0.999937891960144
( O 0 8.167439955286682e-05
CLD B-Disease 1 0.6383182406425476
) O 0 3.2924772312981077e-06
gene O 0 2.2954197902436135e-06
. O 0 9.289145964430645e-06

Congenital B-Disease 1 0.9993601441383362
chloride I-Disease 1 0.9982489347457886
diarrhea I-Disease 1 0.9998301267623901
( O 0 0.0027613043785095215
CLD B-Disease 1 0.9977502226829529
) O 0 0.00033872085623443127
is O 0 3.243949549869285e-06
caused O 0 1.6333624444087036e-05
by O 0 1.5830912047931633e-07
mutations O 0 3.136735529096768e-07
in O 0 2.1366821201240782e-08
a O 0 9.470303297121063e-08
gene O 0 1.260497413113626e-07
which O 0 8.318010458197023e-08
encodes O 0 1.1946874565182952e-06
an O 0 1.8142972066925722e-06
intestinal O 0 0.14416633546352386
anion O 0 0.0003804243460763246
transporter O 0 0.05856124684214592
. O 0 1.4012380233907606e-05

We O 0 1.2183098988316488e-05
report O 0 4.57843179901829e-06
here O 0 2.5709869788670403e-08
the O 0 3.854107255563122e-09
complete O 0 4.9014854397455565e-08
genomic O 0 1.467283368583594e-06
organization O 0 2.6318959456261837e-08
of O 0 8.053681277431224e-09
the O 0 2.966306169582822e-07
human O 0 2.496585011613206e-06
CLD B-Disease 0 0.0034403803292661905
gene O 0 9.759262553643566e-08
which O 0 6.306921562782009e-08
spans O 0 1.1451980981291854e-06
approximately O 0 1.6045346740156674e-07
39kb O 0 0.0027456548996269703
, O 0 1.9861141709043295e-07
and O 0 8.085407188218596e-08
comprises O 0 6.517757356050424e-08
21 O 0 7.164912290136272e-07
exons O 0 8.787278602540027e-06
. O 0 9.7834918051376e-06

All O 0 2.683980255824281e-07
exon O 0 8.899551176000386e-05
/ O 0 3.05681605823338e-05
intron O 0 4.742823148262687e-05
boundaries O 0 5.497439659052361e-08
conform O 0 1.3624106998122443e-07
to O 0 2.4257620356848975e-09
the O 0 8.851807820065005e-08
GT O 0 0.014064855873584747
/ O 0 0.00010086855763802305
AG O 1 0.6935239434242249
rule O 0 5.694793344446225e-06
. O 0 3.88014950658544e-06

An O 0 4.21192339672416e-07
analysis O 0 2.524648152757436e-07
of O 0 7.712394278769352e-09
the O 0 1.162281648703356e-07
putative O 0 1.4053665836399887e-05
promoter O 0 1.2740062629745807e-05
region O 0 3.896179734397265e-08
sequence O 0 3.0439339937515797e-09
shows O 0 1.6258212554021156e-08
a O 0 4.012771981365404e-08
putative O 0 7.708698103670031e-05
TATA O 1 0.8963198065757751
box O 0 0.0016772655071690679
and O 0 5.7766446843743324e-06
predicts O 0 0.00017350011330563575
multiple O 0 6.1671002526964e-08
transcription O 0 1.6677743985837878e-07
factor O 0 4.694046040754074e-08
binding O 0 2.383809416528493e-08
sites O 0 4.095103065537842e-07
. O 0 2.8952904358447995e-06

The O 0 1.2044307595715509e-06
genomic O 0 3.732619370566681e-05
structure O 0 9.484395377512556e-06
was O 0 3.1703573313279776e-06
determined O 0 5.1053390848210256e-08
using O 0 6.731888824162979e-09
DNA O 0 1.2247156519151758e-05
from O 0 2.773935925404203e-08
several O 0 1.54888224468408e-09
sources O 0 8.227311276698401e-09
including O 0 2.2935136012591784e-09
multiple O 0 4.3170892638499936e-08
large O 0 1.6715098638542258e-07
- O 0 0.00030374908237718046
insert O 0 9.278741345042363e-06
libaries O 0 0.00017494104395154864
and O 0 9.321860972022478e-08
genomic O 0 5.576039256993681e-07
DNA O 0 1.1080182957812212e-05
from O 0 5.708407684323902e-07
Finnish O 0 0.003993401303887367
CLD B-Disease 1 0.8553166389465332
patients O 0 3.1189622404781403e-06
and O 0 9.785728707356611e-07
controls O 0 2.416394454485271e-05
. O 0 1.0639283573254943e-05

Exon O 0 0.0001686596660874784
- O 0 0.00010155474592465907
specific O 0 6.40323563061429e-08
primers O 0 5.4865093261469156e-05
developed O 0 4.047426955366973e-06
in O 0 6.940989294434985e-08
this O 0 7.840962545913044e-09
study O 0 1.1068840066741359e-08
will O 0 2.4025090805679383e-09
facilitate O 0 2.9394526812609456e-09
mutation O 0 1.773058322385168e-08
screening O 0 4.610152259942879e-08
studies O 0 6.407683628140148e-08
of O 0 1.690629432005153e-07
patients O 0 1.437105652257742e-06
with O 0 3.0166863780323183e-06
the O 0 0.00023719477758277208
disease O 0 0.018076801672577858
. O 0 3.059055234189145e-05

Genomic O 0 9.432691513211466e-06
sequencing O 0 3.1842591852182522e-06
of O 0 6.199248758775866e-08
a O 0 3.2871830057956686e-07
BAC O 0 0.00010627056326484308
clone O 1 0.5001673102378845
H O 1 0.9996035695075989
_ O 0 3.0733128369320184e-05
RG364P16 O 0 2.9371140044531785e-05
revealed O 0 5.983084065519506e-06
the O 0 1.0582347442777973e-08
presence O 0 9.064760497778934e-09
of O 0 1.596050847041397e-09
another O 0 3.115591695745934e-08
, O 0 1.6680280268133174e-08
highly O 0 2.320553305068529e-09
homologous O 0 8.334733081483137e-08
gene O 0 3.750208321662285e-08
3 O 0 4.4922316533302364e-08
of O 0 4.698369693301174e-09
the O 0 5.947483714408008e-07
CLD B-Disease 0 0.03435378149151802
gene O 0 3.423238013056107e-07
, O 0 1.0877676714926565e-07
with O 0 1.1835989077724207e-08
a O 0 2.4741169113440264e-08
similar O 0 5.620352538926454e-08
genomic O 0 2.0471145489864284e-06
structure O 0 4.326930138631724e-06
, O 0 1.192851073028578e-06
recently O 0 5.579695880442159e-06
identified O 0 5.629718202726508e-07
as O 0 4.674969886764302e-07
the O 0 0.004253774881362915
Pendred B-Disease 1 0.999991774559021
syndrome I-Disease 1 0.9999921321868896
gene O 0 4.004879156127572e-05
( O 0 1.3081204315312789e-06
PDS B-Disease 0 0.0011807892005890608
) O 0 1.0097575113832136e-06
. O 0 3.087439495175204e-07
. O 0 1.8142453654945712e-06

The O 0 2.5092119813052705e-06
APCI1307K O 0 0.07869802415370941
allele O 0 0.0012474817922338843
and O 0 0.0076896632090210915
cancer B-Disease 1 0.8650557994842529
risk O 0 7.808831287547946e-05
in O 0 1.1683027167919136e-07
a O 0 1.3486032912624069e-07
community O 0 1.2314201569552097e-07
- O 0 0.00036790597368963063
based O 0 6.379756314345286e-07
study O 0 1.3570649493033216e-08
of O 0 2.0283751567262698e-08
Ashkenazi O 0 6.673580355709419e-05
Jews O 0 3.178664428560296e-06
. O 0 5.910487288929289e-06

Mutations O 0 5.632352622342296e-05
in O 0 7.76403430791106e-06
APC O 0 0.0022354470565915108
are O 0 1.0940239008050412e-06
classically O 0 0.04142593592405319
associated O 0 0.000263315683696419
with O 0 0.004933549091219902
familial B-Disease 1 0.9999477863311768
adenomatous I-Disease 1 0.9999043941497803
polyposis I-Disease 1 0.999956488609314
( O 0 6.36794648016803e-05
FAP B-Disease 0 0.0030792932957410812
) O 0 1.5527260757153272e-06
, O 0 3.419104359636549e-07
a O 0 4.733890364150284e-07
highly O 0 8.766051178099588e-05
penetrant O 1 0.9838269352912903
autosomal B-Disease 1 0.99997878074646
dominant I-Disease 1 0.9998329877853394
disorder I-Disease 1 0.9999886751174927
characterized O 0 0.039994288235902786
by O 0 5.1466548029566184e-05
multiple O 0 0.04836266115307808
intestinal O 1 0.9998455047607422
polyps B-Disease 1 0.7654277086257935
and O 0 4.8715879529481754e-05
, O 0 3.834030849247938e-06
without O 0 9.982049675727467e-08
surgical O 0 6.562170892721042e-05
intervention O 0 3.891533651767531e-06
, O 0 1.7191668177929387e-07
the O 0 7.184057437825686e-08
development O 0 1.1507813724165317e-05
of O 0 0.040178317576646805
colorectal B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999723434448242
( O 0 5.181155211175792e-05
CRC B-Disease 0 0.01839599385857582
) O 0 3.3319167869194644e-06
. O 0 3.4576933103380725e-06

APC B-Disease 0 0.006080195773392916
is O 0 8.081588021013886e-06
a O 0 1.4273179658630397e-05
tumour O 1 0.9994041919708252
- O 0 0.020399225875735283
suppressor O 0 0.00010876014130190015
gene O 0 3.1579682513438456e-07
, O 0 1.58866896526888e-07
and O 0 2.0864500527295604e-07
somatic O 0 1.030695693771122e-05
loss O 0 0.016734344884753227
occurs O 0 3.403800974410842e-06
in O 0 3.558654134394601e-05
tumours B-Disease 1 0.9997276663780212
. O 0 0.00011282631021458656

The O 0 2.722185854509007e-06
germline O 0 0.000872002390678972
T O 0 0.2284463495016098
- O 0 0.0002498415997251868
to O 0 2.452168246236397e-07
- O 0 0.00017286832735408098
A O 0 1.0541029951127712e-06
transversion O 0 0.0003580623015295714
responsible O 0 2.6626253202266525e-08
for O 0 9.263292910510756e-10
the O 0 8.910754800695031e-09
APC O 0 3.344951210237923e-06
I1307K O 0 3.0357492164512223e-07
allele O 0 5.926588109161912e-09
converts O 0 2.358274908687008e-09
the O 0 8.756757985395325e-09
wild O 0 2.9266243473102804e-07
- O 0 4.5611541281687096e-05
type O 0 6.533166185818118e-08
sequence O 0 1.0224749047438308e-08
to O 0 3.576133167371154e-08
a O 0 6.2090275605442e-06
homopolymer O 1 0.9862310290336609
tract O 0 0.16628912091255188
( O 0 2.431492703180993e-06
A8 O 1 0.9330782890319824
) O 0 1.7721847598295426e-06
that O 0 1.198863088802682e-07
is O 0 3.6760005173164245e-07
genetically O 0 0.00021463094162754714
unstable O 1 0.6075663566589355
and O 0 3.1210896850097924e-05
prone O 0 0.0006355253863148391
to O 0 8.655237593302445e-08
somatic O 0 4.5099263843439985e-06
mutation O 0 1.2446762411855161e-06
. O 0 6.329243205982493e-06

The O 0 1.31408967263269e-06
I1307K O 0 9.458970453124493e-05
allele O 0 3.459738218225539e-05
was O 0 3.2249918149318546e-05
found O 0 2.2490012270282023e-06
in O 0 3.7969198274367955e-07
6 O 0 2.3802576833986677e-05
. O 0 1.413342215528246e-05

1 O 0 1.8647922388481675e-06
% O 0 3.5033142609108836e-08
of O 0 2.725911940615333e-09
unselected O 0 9.856810720521025e-06
Ashkenazi O 0 3.0030065317987464e-05
Jews O 0 2.128039824356165e-07
and O 0 2.9952585123282915e-07
higher O 0 4.140759699566843e-07
proportions O 0 3.472491243883269e-06
of O 0 3.3782868058551685e-08
Ashkenazim O 0 0.0031287099700421095
with O 0 2.142736775567755e-05
family O 0 0.002823759103193879
or O 0 3.4241236335219583e-06
personal O 0 1.857102324720472e-05
histories O 0 5.926019184698816e-06
of O 0 1.271252926926536e-06
CRC B-Disease 0 0.09507662057876587
( O 0 3.7834232102795795e-07
ref O 0 0.0003562305646482855
. O 0 1.1296870638943801e-07
2 O 0 1.2339517070358852e-06
) O 0 6.256975666474318e-07
. O 0 1.24100904486113e-06

To O 0 2.4473180815220985e-07
evaluate O 0 1.3403831644609454e-07
the O 0 1.0196179012211815e-08
role O 0 1.1775237673816719e-08
of O 0 3.587672736671266e-08
I1307K O 0 0.0006298534572124481
in O 0 8.111734132398851e-06
cancer B-Disease 0 0.0016102163353934884
, O 0 1.6602460561898624e-07
we O 0 2.3817868566311517e-08
genotyped O 0 4.402906051836908e-05
5 O 0 9.058128114247666e-08
, O 0 1.351062053345231e-07
081 O 0 5.6232616771012545e-05
Ashkenazi O 0 7.299288427020656e-06
volunteers O 0 6.197546298380985e-08
in O 0 4.434495792793314e-08
a O 0 2.3004288607353374e-07
community O 0 8.790126457824954e-07
survey O 0 2.0402292648213916e-05
. O 0 8.1025254985434e-06

Risk O 0 0.0001375972933601588
of O 0 3.4207487260573544e-06
developing O 0 0.023168860003352165
colorectal B-Disease 1 0.999909520149231
, I-Disease 0 0.0024699100758880377
breast I-Disease 0 0.01938726380467415
and I-Disease 0 8.050833457673434e-06
other I-Disease 0 2.33655987358361e-06
cancers I-Disease 0 0.0070741442032158375
were O 0 7.32639932721213e-07
compared O 0 1.3411056897894014e-05
between O 0 7.933512051749858e-07
genotyped O 0 0.022317105904221535
I1307K O 0 0.00010013999417424202
carriers O 0 1.3735117363466998e-06
and O 0 1.6262578128589666e-07
non O 0 7.844062821504849e-08
- O 0 8.662675827508792e-05
carriers O 0 2.1558244611696864e-07
and O 0 5.493737020856315e-09
their O 0 1.8080726915670198e-09
first O 0 3.0489907487663004e-08
- O 0 0.00036069334601052105
degree O 0 1.300096073464374e-06
relatives O 0 1.4148013178783003e-05
. O 0 7.09904497853131e-06

Sperm O 0 7.70004335208796e-05
DNA O 0 0.00012548784434329718
analysis O 0 2.1631612980854698e-06
in O 0 5.238899234427663e-07
a O 0 7.117537734302459e-06
Friedreich B-Disease 1 0.9631215929985046
ataxia I-Disease 1 0.9782363772392273
premutation O 1 0.6530513763427734
carrier O 0 0.002174150664359331
suggests O 0 9.6330313681392e-07
both O 0 1.4501424949742159e-08
meiotic O 0 0.00011452836042735726
and O 0 4.1189952071363223e-07
mitotic O 0 0.00023663749743718654
expansion O 0 5.011723942516255e-07
in O 0 4.613758974869597e-08
the O 0 2.9602728091049357e-07
FRDA B-Disease 0 0.004636405035853386
gene O 0 2.815494553942699e-06
. O 0 9.454920473217499e-06

Friedreich B-Disease 1 0.9948983788490295
ataxia I-Disease 1 0.9981476068496704
is O 0 0.0005633678520098329
usually O 0 5.0654572987696156e-05
caused O 0 5.508029062184505e-05
by O 0 6.536157570735668e-08
an O 0 1.036729901926492e-08
expansion O 0 1.481033820027733e-07
of O 0 8.827491626561823e-09
a O 0 3.7937891761430365e-07
GAA O 0 0.0014686343492940068
trinucleotide O 0 0.001008424675092101
repeat O 0 3.102219579886878e-06
in O 0 4.2322003679373665e-08
intron O 0 0.0001391230762237683
1 O 0 4.2349782347628206e-08
of O 0 7.79091813285504e-09
the O 0 6.388316933225724e-07
FRDA B-Disease 0 0.005591852590441704
gene O 0 3.0993480777397053e-06
. O 0 4.304190952097997e-06

Occasionally O 0 1.8531201931182295e-05
, O 0 1.032246927934466e-06
a O 0 1.524765202987055e-08
fully O 0 4.3072684974276854e-08
expanded O 0 1.7447606026621543e-08
allele O 0 6.288999543357932e-07
has O 0 4.150216170728527e-07
been O 0 1.5056083668696374e-07
found O 0 2.935387612978957e-07
to O 0 6.74726550187188e-08
arise O 0 2.2351534312292642e-07
from O 0 5.79473402595454e-09
a O 0 6.193505441842717e-08
premutation O 0 0.0001416668383171782
of O 0 4.065440872835779e-09
100 O 0 3.1114524290387635e-08
or O 0 8.499916503978966e-08
less O 0 1.010709596016568e-07
triplet O 0 0.0005973379011265934
repeats O 0 0.00018379578250460327
. O 0 1.424598212906858e-05

We O 0 1.6080656450867536e-06
have O 0 1.3899258988203655e-07
examined O 0 8.599722036706225e-07
the O 0 2.8796380391327148e-08
sperm O 0 3.396547754164203e-06
DNA O 0 3.6313247164798668e-06
of O 0 2.9074922025529304e-08
a O 0 2.884321474994067e-06
premutation O 0 0.015896214172244072
carrier O 0 0.0014141417341306806
. O 0 1.2496712770371232e-05

This O 0 2.890027417379315e-07
mans O 0 3.485396518954076e-05
leucocyte O 0 0.0025758175179362297
DNA O 0 0.00010911103163380176
showed O 0 8.270333637483418e-06
one O 0 3.5084619653957816e-09
normal O 0 1.5118231999622367e-08
allele O 0 1.2154150397236663e-07
and O 0 1.1995648030449502e-08
one O 0 1.0832055252762984e-09
allele O 0 1.4875900511412965e-08
of O 0 1.007936512031904e-09
approximately O 0 1.0826897600679786e-08
100 O 0 6.694004639484774e-08
repeats O 0 8.1949146988336e-06
. O 0 2.8565855245688e-06

His O 0 1.5403578800032847e-05
sperm O 0 0.00014991842908784747
showed O 0 2.4018241674639285e-05
an O 0 1.2827179318719573e-08
expanded O 0 7.694634263089029e-08
allele O 0 4.995194444745721e-07
in O 0 2.5176795759307424e-08
a O 0 2.366535412079429e-08
tight O 0 9.89336876955349e-06
range O 0 1.3962898037789273e-07
centering O 0 5.153159321480416e-08
on O 0 5.0241851567989215e-08
a O 0 2.8948978325615826e-08
size O 0 9.770044471224537e-07
of O 0 7.062888940367884e-09
approximately O 0 7.649445876722893e-08
320 O 0 1.0277313776896335e-05
trinucleotide O 0 0.0003380438720341772
repeats O 0 1.6971644072327763e-05
. O 0 4.389853529573884e-06

His O 0 0.00013614482304546982
affected O 0 0.00013557869533542544
son O 0 0.002094171242788434
has O 0 2.7372616386855952e-06
repeat O 0 5.039055395172909e-06
sizes O 0 6.847358235972933e-07
of O 0 1.5784834772603062e-08
1040 O 0 6.0284259234322235e-05
and O 0 2.2825668111181585e-06
540 O 0 0.00010779546573758125
. O 0 6.174425379867898e-06

These O 0 4.1657446558929223e-07
data O 0 4.7588491725036874e-06
suggest O 0 1.326771553067374e-06
that O 0 6.757517212463426e-08
expansion O 0 3.303146911548538e-07
occurs O 0 3.6977823469896975e-08
in O 0 6.827813425758222e-09
two O 0 2.015775102393036e-08
stages O 0 1.658791347836086e-06
, O 0 3.8832851601000584e-08
the O 0 1.6376034972509501e-09
first O 0 7.891690856354217e-09
during O 0 6.744074454445581e-08
meiosis O 0 2.5356268906762125e-07
followed O 0 1.4832501449291158e-07
by O 0 6.760995763244182e-09
a O 0 8.497059056367107e-09
second O 0 5.807893330711522e-07
mitotic O 0 0.0008625201298855245
expansion O 0 1.5078404430823866e-05
. O 0 3.4942167985718697e-06

We O 0 2.3999377845029812e-06
also O 0 3.614425452269643e-07
show O 0 2.930900677711179e-07
that O 0 5.32288479959675e-09
in O 0 1.4894943056731336e-09
all O 0 2.8002469787402617e-10
informative O 0 1.1707821556683484e-07
carrier O 0 0.0003087263321503997
father O 0 8.812917258183006e-06
to O 0 8.741876200701881e-08
affected O 0 6.574868649522614e-08
child O 0 3.476788208445214e-07
transmissions O 0 1.871853237389587e-05
, O 0 1.6474233177632414e-07
with O 0 1.7719900213819528e-08
the O 0 5.980700024110774e-08
notable O 0 2.2063456839305218e-08
exception O 0 1.861990561735638e-09
of O 0 1.3166622236937542e-09
the O 0 1.0951830375915961e-07
premutation O 0 0.011645296588540077
carrier O 0 7.670903869438916e-05
, O 0 3.1434190361778747e-08
the O 0 8.569225329324581e-09
expansion O 0 6.308990805337089e-07
size O 0 1.9889108443749137e-05
decreases O 0 1.4751318531125435e-06
. O 0 2.616842209590686e-07
. O 0 1.9854412585118553e-06

The O 0 2.274713096994674e-06
R496H O 0 0.00021444012236315757
mutation O 0 9.730015335662756e-07
of O 0 3.062086761929095e-07
arylsulfatase O 0 0.009800816886126995
A O 0 3.0536577924067387e-06
does O 0 1.198786890199699e-06
not O 0 1.1663918257909245e-06
cause O 0 0.00014536715752910823
metachromatic B-Disease 1 0.9983762502670288
leukodystrophy I-Disease 1 0.9989390969276428
. O 0 0.00010110217408509925

Deficiency B-Disease 1 0.9919426441192627
of I-Disease 0 2.348883754166309e-06
arylsulfatase I-Disease 0 0.12463072687387466
A I-Disease 0 2.5052855562535115e-05
( O 0 2.1329415176296607e-06
ARSA O 0 0.11235762387514114
) O 0 3.658845457721327e-07
enzyme O 0 7.27580072634737e-07
activity O 0 4.175272351858439e-06
causes O 0 0.00032516225473955274
metachromatic B-Disease 1 0.9998021721839905
leukodystrophy I-Disease 1 0.9998457431793213
( O 0 6.143662903923541e-05
MLD B-Disease 1 0.9955262541770935
) O 0 6.880815362819703e-06
. O 0 3.6755170640390133e-06

A O 0 1.4892174249325763e-06
number O 0 7.261064638441894e-08
of O 0 1.674589213962463e-07
ARSA O 0 0.18736661970615387
gene O 0 1.1730178357538534e-06
mutations O 0 6.084890173951862e-07
responsible O 0 8.089138532341167e-07
for O 0 1.8903903082900797e-06
MLD B-Disease 1 0.9993576407432556
have O 0 7.993737085598696e-07
been O 0 3.74944363557006e-07
identified O 0 2.4662310806888854e-06
. O 0 4.716599960374879e-06

Recently O 0 0.00017450588347855955
, O 0 8.044755190894648e-07
the O 0 6.765384341633762e-08
R496H O 0 1.7985887097893283e-05
mutation O 0 1.1249652942524335e-07
of O 0 4.3210516764702334e-07
ARSA O 1 0.8807252049446106
was O 0 2.506423152226489e-05
proposed O 0 1.9408055607073038e-07
to O 0 2.303312740536967e-08
be O 0 1.031715601840233e-08
a O 0 9.208479667677238e-08
cause O 0 2.177093620048254e-06
of O 0 2.256968400615733e-06
MLD B-Disease 1 0.9997268319129944
( O 0 2.811269439462194e-07
Draghia O 0 0.00020452271564863622
et O 0 1.4793521586398128e-05
al O 0 1.3816247701470274e-05
. O 0 1.8332976026158576e-07
, O 0 5.257784323475789e-07
1997 O 0 7.856691809138283e-06
) O 0 3.3889557471411536e-07
. O 0 5.591108447333681e-07

We O 0 9.719079798742314e-07
have O 0 6.712530620234247e-08
investigated O 0 7.659489824618504e-07
the O 0 5.33003934322096e-08
R496H O 0 1.4139784980216064e-05
mutation O 0 1.772112483422461e-07
and O 0 7.819562028998917e-07
found O 0 5.368933670979459e-07
this O 0 5.5764837192384675e-09
mutation O 0 2.510750185535926e-08
at O 0 1.5400800634779443e-07
a O 0 1.0074200140763878e-08
relatively O 0 3.6914471479576605e-08
high O 0 2.4031115231082367e-07
frequency O 0 4.911649043037869e-08
in O 0 1.0043560649819483e-08
an O 0 7.452658934425926e-09
African O 0 3.64148178277901e-07
American O 0 3.151791361233336e-07
population O 0 1.121109161061895e-08
( O 0 6.822306275466872e-09
f O 0 6.006621333654039e-06
= O 0 1.420380385752651e-06
0 O 0 4.267002751134896e-09
. O 0 2.201212323527102e-09
09 O 0 1.4939429604510224e-07
, O 0 4.719776214301419e-08
n O 0 2.576289261924103e-06
= O 0 5.117182809044607e-06
61 O 0 2.1479542056113132e-07
subjects O 0 5.908216493821783e-08
) O 0 2.120265065741478e-07
. O 0 8.672950571053661e-07

The O 0 5.468457402457716e-06
ARSA O 0 0.055917371064424515
enzyme O 0 7.177268798841396e-06
activity O 0 5.005676371183654e-07
in O 0 7.159476211882065e-08
subjects O 0 4.913129103556457e-08
with O 0 1.031652985261644e-07
and O 0 3.3528863241372164e-07
without O 0 8.982954824432454e-09
the O 0 1.719034870006908e-08
R496H O 0 1.102437363442732e-05
mutation O 0 5.2815448015053335e-08
was O 0 1.6792188262115815e-06
determined O 0 5.207712092669681e-07
and O 0 2.0879031126241898e-07
found O 0 1.8294046810751752e-07
to O 0 8.798125783471278e-09
be O 0 1.995332787885218e-08
normal O 0 2.583651053100766e-07
. O 0 1.6173920585060841e-06

It O 0 5.655684162775287e-06
is O 0 9.300005672230327e-07
therefore O 0 2.0396109334797075e-07
concluded O 0 1.0626055200191331e-06
that O 0 8.822542696407254e-09
the O 0 1.1074985373227264e-08
R496H O 0 7.982759598235134e-06
mutation O 0 4.4634575147028954e-08
of O 0 1.0742071765434957e-07
ARSA O 1 0.5174908638000488
does O 0 1.3078306437819265e-07
not O 0 2.1019304075053924e-09
negatively O 0 6.3340195310956915e-09
influence O 0 1.778493574633444e-09
the O 0 1.529739779293493e-09
activity O 0 1.7477717051406216e-08
of O 0 6.061028301473925e-08
ARSA O 1 0.6534253358840942
and O 0 1.08230142359389e-06
is O 0 5.039896677772049e-08
not O 0 1.2391430104230494e-08
a O 0 5.479622018356167e-07
cause O 0 1.7035856217262335e-05
of O 0 1.2414692719175946e-05
MLD B-Disease 1 0.9975658655166626

Down O 0 0.0003661972878035158
- O 0 0.0003447231720201671
regulation O 0 2.2016938601154834e-06
of O 0 3.947667082115913e-08
transmembrane O 0 5.235396201896947e-06
carbonic O 0 9.620751370675862e-06
anhydrases O 0 0.004393750801682472
in O 0 2.7242316718911752e-05
renal B-Disease 1 0.9981675148010254
cell I-Disease 1 0.9568366408348083
carcinoma I-Disease 1 0.9999538660049438
cell O 0 0.003573894966393709
lines O 0 4.26347651227843e-06
by O 0 2.0324343097399833e-07
wild O 0 8.567783879698254e-06
- O 0 0.142897367477417
type O 0 0.00017914356430992484
von B-Disease 1 0.85460364818573
Hippel I-Disease 1 0.8439446091651917
- I-Disease 0 0.4344285726547241
Lindau I-Disease 0 0.15349449217319489
transgenes O 0 0.0007989373989403248
. O 0 6.243466486921534e-06

To O 0 6.803986138947948e-07
discover O 0 1.8152102711610496e-05
genes O 0 2.3363166690160142e-07
involved O 0 5.211964548834658e-07
in O 0 3.735000746019068e-06
von B-Disease 1 0.975229024887085
Hippel I-Disease 1 0.9872704744338989
- I-Disease 1 0.995236337184906
Lindau I-Disease 1 0.9368381500244141
( O 0 1.4484143093795865e-06
VHL B-Disease 0 0.0014391621807590127
) O 0 3.0824793384454097e-07
- O 0 8.411522139795125e-05
mediated O 0 0.0003910124069079757
carcinogenesis O 0 0.17420662939548492
, O 0 1.502391114627244e-06
we O 0 7.343054875263988e-08
used O 0 6.672819836239796e-06
renal B-Disease 1 0.982239842414856
cell I-Disease 1 0.9207819700241089
carcinoma I-Disease 1 0.9999517202377319
cell O 0 0.0012187666725367308
lines O 0 5.630847681459272e-06
stably O 0 8.182306191883981e-05
transfected O 0 0.00010519677744014189
with O 0 5.701883765141247e-07
wild O 0 1.021719344862504e-05
- O 0 0.07235141098499298
type O 0 0.00014942933921702206
VHL O 0 0.03069894388318062
- O 0 0.002632585121318698
expressing O 0 9.999816938943695e-06
transgenes O 0 0.0001979300141101703
. O 0 6.902530458319234e-06

Large O 0 5.920664079894777e-06
- O 0 8.938665996538475e-05
scale O 0 1.500335565651767e-05
RNA O 0 2.973673360884277e-07
differential O 0 2.0797871513877908e-07
display O 0 2.5290339067396417e-07
technology O 0 4.297956365917344e-06
applied O 0 3.930370251481463e-09
to O 0 4.946117959647722e-10
these O 0 7.701381199431978e-10
cell O 0 9.848185072769411e-06
lines O 0 1.3493176993506495e-06
identified O 0 7.097639098674335e-08
several O 0 4.09976586013272e-09
differentially O 0 1.7350575944874436e-06
expressed O 0 6.74574707204556e-08
genes O 0 6.711634625844454e-08
, O 0 5.0643244264847453e-08
including O 0 2.9941311652237346e-09
an O 0 2.156764544736234e-09
alpha O 0 1.433781591231309e-07
carbonic O 0 8.620472158327175e-07
anhydrase O 0 2.9389073006313993e-06
gene O 0 9.435289172188277e-08
, O 0 6.334649924610858e-07
termed O 0 8.789178536972031e-05
CA12 O 0 0.007564741186797619
. O 0 1.0700396160245873e-05

The O 0 2.866120780709025e-07
deduced O 0 7.689644121455785e-07
protein O 0 7.826666603705235e-08
sequence O 0 5.8354423515538656e-08
was O 0 1.0082572998726391e-06
classified O 0 2.6828647037291375e-07
as O 0 6.266462015958041e-09
a O 0 3.5346655380408265e-08
one O 0 1.339274149358971e-07
- O 0 0.030248047783970833
pass O 0 5.753992354584625e-06
transmembrane O 0 2.2404692572308704e-05
CA O 0 4.463348886929452e-06
possessing O 0 3.922217217677826e-07
an O 0 1.713780584111646e-08
apparently O 0 7.205243491625879e-06
intact O 0 1.5257010090863332e-06
catalytic O 0 5.487236265366846e-08
domain O 0 9.877443751804549e-09
in O 0 2.658888886841737e-09
the O 0 4.873974290831029e-08
extracellular O 0 6.600755114050116e-06
CA O 0 4.3866737541975453e-05
module O 0 0.00045122264418751
. O 0 5.294361926644342e-06

Reintroduced O 0 8.421001984970644e-05
wild O 0 4.4962111132917926e-05
- O 0 0.02875257097184658
type O 0 0.00015311746392399073
VHL B-Disease 0 0.0055647664703428745
strongly O 0 2.157306198569131e-06
inhibited O 0 5.195686867409677e-07
the O 0 1.1968567470432845e-08
overexpression O 0 6.381642947417276e-07
of O 0 7.18424653101124e-09
the O 0 2.3149736705363466e-07
CA12 O 0 0.005871191155165434
gene O 0 9.069191975186186e-08
in O 0 4.4530409581966524e-08
the O 0 4.063676044552267e-07
parental O 0 0.00018072266539093107
renal B-Disease 1 0.9991152882575989
cell I-Disease 1 0.9665456414222717
carcinoma I-Disease 1 0.9999221563339233
cell O 0 0.01454403717070818
lines O 0 0.00014266972721088678
. O 0 3.0342718673637137e-05

Similar O 0 6.279234185058158e-06
results O 0 7.994722182047553e-06
were O 0 5.027808924751298e-07
obtained O 0 1.9917021631954412e-07
with O 0 4.1446156728852657e-07
CA9 O 0 0.06082995980978012
, O 0 1.0690217067121921e-07
encoding O 0 6.439759658860567e-08
another O 0 5.123180812915962e-07
transmembrane O 0 2.4878409021766856e-05
CA O 0 3.370562126292498e-06
with O 0 2.593811743167862e-08
an O 0 5.619527243538869e-08
intact O 0 1.2048100870742928e-05
catalytic O 0 5.728361429646611e-07
domain O 0 2.566069099430024e-07
. O 0 1.4181904361976194e-06

Although O 0 2.1747528080595657e-06
both O 0 4.506305373297437e-08
domains O 0 2.7095390464637603e-07
of O 0 9.570352510479552e-09
the O 0 1.790694454939512e-07
VHL B-Disease 0 0.0012918327702209353
protein O 0 8.413267948981229e-08
contribute O 0 2.000548615654907e-09
to O 0 2.063080817293894e-09
regulation O 0 2.4247272634170258e-08
of O 0 1.0767832847591308e-08
CA12 O 0 0.00048125500325113535
expression O 0 9.453227534095276e-09
, O 0 2.736243054357601e-08
the O 0 3.7528987917312406e-08
elongin O 0 5.2277780923759565e-05
binding O 0 9.036022419195433e-08
domain O 0 1.8737577534011507e-07
alone O 0 3.138401325486484e-06
could O 0 1.1585500203636911e-07
effectively O 0 1.0116621069755638e-06
regulate O 0 3.180763087584637e-06
CA9 O 0 0.0017805597744882107
expression O 0 1.7300909860296088e-07
. O 0 1.456181507819565e-06

We O 0 4.347508365754038e-06
mapped O 0 0.00013644815771840513
CA12 O 0 0.007844450883567333
and O 0 5.41009148946614e-06
CA9 O 0 0.001571468310430646
loci O 0 2.3600316012561962e-07
to O 0 3.0536700279526485e-08
chromosome O 0 4.147756953898352e-06
bands O 0 3.8117954659355746e-07
15q22 O 0 3.424007081775926e-05
and O 0 1.405891794092895e-06
17q21 O 0 0.0001104235925595276
. O 0 5.441344001155812e-06

2 O 0 1.8166025256505236e-05
respectively O 0 4.153038753429428e-05
, O 0 6.223147920536576e-06
regions O 0 5.414000270320685e-07
prone O 0 7.1227754233405e-05
to O 0 3.513016721967688e-08
amplification O 0 1.8644755982677452e-05
in O 0 7.265483503715586e-08
some O 0 2.132260767950811e-08
human O 0 4.3390729842940345e-05
cancers B-Disease 0 0.021273227408528328
. O 0 2.2329033527057618e-05

Additional O 0 4.898130328001571e-07
experiments O 0 7.233607902890071e-06
are O 0 1.2484616007668592e-08
needed O 0 3.352661792632716e-08
to O 0 1.8029622239623677e-09
define O 0 1.2329426368751228e-08
the O 0 3.381096069787759e-09
role O 0 2.5279240034592476e-08
of O 0 1.3038082613547886e-07
CA O 0 0.0001680501300143078
IX O 0 0.0009230751311406493
and O 0 1.0342776477045845e-05
CA O 0 2.393646900600288e-05
XII O 0 0.0003186191897839308
enzymes O 0 1.1711941994008157e-07
in O 0 6.426199128384269e-09
the O 0 4.695484889793988e-09
regulation O 0 1.1521286324978064e-07
of O 0 1.70630478635303e-08
pH O 0 2.156627488147933e-06
in O 0 3.2259688254043795e-09
the O 0 2.3666379966869044e-09
extracellular O 0 2.5103844336626935e-07
microenvironment O 0 4.543452178040752e-06
and O 0 5.673397041050521e-08
its O 0 3.837414297436226e-08
potential O 0 4.1934944761123916e-07
impact O 0 8.014591799110349e-07
on O 0 1.6904139556572773e-05
cancer B-Disease 0 0.00802946463227272
cell O 0 0.005744055844843388
growth O 0 6.920710438862443e-05
. O 0 6.780538114981027e-06

A O 0 9.644365945860045e-07
gene O 0 2.964391967452684e-07
encoding O 0 1.947758789810905e-07
a O 0 2.4634377382426464e-07
transmembrane O 0 2.7858875455422094e-06
protein O 0 5.98605183199652e-08
is O 0 1.79717432047255e-08
mutated O 0 3.5639186535263434e-06
in O 0 7.992411156010348e-06
patients O 0 0.0005977411055937409
with O 1 0.9594672918319702
diabetes B-Disease 1 0.9999927282333374
mellitus I-Disease 1 0.999982476234436
and O 1 0.87458735704422
optic B-Disease 1 0.9999706745147705
atrophy I-Disease 1 0.9998388290405273
( O 0 0.13640138506889343
Wolfram B-Disease 1 0.9999469518661499
syndrome I-Disease 1 0.9999681711196899
) O 0 5.796593177365139e-05
. O 0 3.0192164558684453e-05

Wolfram B-Disease 1 0.9984355568885803
syndrome I-Disease 1 0.999727189540863
( O 0 0.0010548945283517241
WFS B-Disease 1 0.995419979095459
; O 0 0.0013068794505670667
OMIM O 1 0.9632941484451294
222300 O 0 0.4277704954147339
) O 0 7.558802462881431e-05
is O 0 8.56628867040854e-06
an O 0 0.0005368412821553648
autosomal B-Disease 1 0.9998530149459839
recessive I-Disease 1 0.9999401569366455
neurodegenerative I-Disease 1 0.9999879598617554
disorder I-Disease 1 0.9833689332008362
defined O 0 2.7162318474438507e-06
by O 0 3.0115900244709337e-06
young O 0 3.6463577998802066e-05
- O 0 0.4143766164779663
onset O 0 0.0043593114241957664
non O 0 3.7425024856929667e-06
- O 0 0.036845285445451736
immune O 0 0.0054949624463915825
insulin B-Disease 0 0.0008137891418300569
- I-Disease 1 0.9788763523101807
dependent I-Disease 1 0.7080462574958801
diabetes I-Disease 1 0.9999778270721436
mellitus I-Disease 1 0.9999061822891235
and O 0 0.0007078270427882671
progressive O 0 0.04241625964641571
optic B-Disease 1 0.9998306035995483
atrophy I-Disease 1 0.8323179483413696
. O 0 0.000103738610050641

Linkage O 0 0.00017732885316945612
to O 0 9.068272106560471e-07
markers O 0 2.857881372619886e-05
on O 0 1.2917741514684167e-05
chromosome O 0 0.08110709488391876
4p O 1 0.996636152267456
was O 0 0.00012204603262944147
confirmed O 0 8.056716978899203e-06
in O 0 1.6959486970336002e-07
five O 0 7.131835673135356e-07
families O 0 1.2890409379906487e-05
. O 0 8.723113751329947e-06

On O 0 5.884688221158285e-07
the O 0 1.5907026806871727e-08
basis O 0 5.765100841159665e-09
of O 0 7.86944838182535e-08
meiotic O 1 0.6310540437698364
recombinants O 1 0.9821542501449585
and O 0 0.009382813237607479
disease O 0 0.020335828885436058
- O 0 0.02360086515545845
associated O 0 1.0353276593377814e-05
haplotypes O 0 7.301667210413143e-05
, O 0 2.818555060457584e-07
the O 0 4.439413032741868e-07
WFS B-Disease 0 0.09207458794116974
gene O 0 3.0706902975907724e-07
was O 0 1.3094746691422188e-06
localized O 0 8.398581741175803e-08
to O 0 5.022007698585185e-09
a O 0 4.8378442585317316e-08
BAC O 0 6.257606401049998e-06
/ O 0 4.186472324363422e-06
P1 O 0 0.0034582235384732485
contig O 0 8.819298273010645e-06
of O 0 5.343979703198443e-10
less O 0 1.9599695200156475e-09
than O 0 3.825427530301795e-09
250 O 0 4.3588644871306315e-07
kb O 0 0.0017516069347038865
. O 0 7.092197392921662e-06

Mutations O 0 3.1168903660727665e-05
in O 0 1.5007357205831795e-06
a O 0 7.919859399407869e-07
novel O 0 3.0950739073887235e-06
gene O 0 1.1999146636298974e-06
( O 0 1.222336010187064e-07
WFS1 O 0 0.0007519025821238756
) O 0 5.884775333697689e-09
encoding O 0 2.5469575337666583e-09
a O 0 9.224877750568794e-09
putative O 0 3.0254420835262863e-06
transmembrane O 0 9.717485909277457e-07
protein O 0 3.00137159570113e-08
were O 0 2.7199822838497312e-08
found O 0 1.426967912721011e-07
in O 0 1.0493628188612547e-08
all O 0 4.649862717087672e-09
affected O 0 4.242043871727219e-08
individuals O 0 1.7245972427915035e-09
in O 0 7.501964915945791e-08
six O 0 3.423654561629519e-05
WFS B-Disease 1 0.9674042463302612
families O 0 6.50792117085075e-06
, O 0 4.380484313060151e-07
and O 0 1.329044465592233e-07
these O 0 9.296431180416675e-09
mutations O 0 2.0689421376118844e-07
were O 0 2.838895625245641e-07
associated O 0 1.0328072903575958e-06
with O 0 6.098280778132903e-07
the O 0 7.409163663396612e-05
disease O 0 0.03727683424949646
phenotype O 0 0.00025396235287189484
. O 0 2.916106313932687e-05

WFS1 O 0 0.40446776151657104
appears O 0 5.499159306054935e-05
to O 0 8.704041931650863e-08
function O 0 5.246934264846459e-08
in O 0 2.0260713995412516e-07
survival O 0 6.503610347863287e-05
of O 0 1.747524969175629e-08
islet O 0 0.0006334211793728173
beta O 0 4.641341320166248e-07
- O 0 0.0001167604568763636
cells O 0 7.57554062147392e-07
and O 0 1.8179433425302705e-07
neurons O 0 1.2036326779707451e-06
. O 0 1.8638289134287334e-07
. O 0 2.91453557110799e-06

Stable O 0 3.142407877021469e-05
interaction O 0 3.978257723247225e-07
between O 0 3.624919600042631e-07
the O 0 1.370636653064139e-07
products O 0 4.834089395444607e-07
of O 0 2.0147901125255885e-09
the O 0 1.0249413406882013e-07
BRCA1 O 0 8.332034485647455e-05
and O 0 1.2699303624685854e-05
BRCA2 O 0 0.0006003595190122724
tumor B-Disease 0 0.0006465334445238113
suppressor O 0 3.6540648125082953e-06
genes O 0 1.3392964959280107e-08
in O 0 2.232340712282621e-08
mitotic O 0 0.00013175446656532586
and O 0 4.361128048913088e-06
meiotic O 0 0.0046264538541436195
cells O 0 3.998857209808193e-05
. O 0 1.0298742381564807e-05

BRCA1 O 0 0.008465521037578583
and O 0 3.295774513389915e-05
BRCA2 O 0 0.0006332421908155084
account O 0 6.796359457439394e-07
for O 0 2.4425142797213084e-08
most O 0 1.8434146653589778e-08
cases O 0 1.1241073849532768e-07
of O 0 6.5608006138973e-08
familial O 0 0.0014618661953136325
, O 0 3.8898859202163294e-05
early O 0 0.00016782658349256963
onset O 0 0.17017701268196106
breast B-Disease 0 0.04973282665014267
and I-Disease 0 0.0020533078350126743
/ I-Disease 1 0.8823109865188599
or I-Disease 1 0.9148499965667725
ovarian I-Disease 1 0.9999966621398926
cancer I-Disease 1 0.9994219541549683
and O 0 1.9159015209879726e-06
encode O 0 4.508424638061115e-07
products O 0 1.2464355449992581e-06
that O 0 9.854580262924628e-09
each O 0 8.823615726960554e-10
interact O 0 8.828451747433519e-09
with O 0 6.183012715155201e-07
hRAD51 O 0 0.0009074471308849752
. O 0 5.60281660000328e-06

Results O 0 5.4391402954934165e-05
presented O 0 7.642745913472027e-06
here O 0 2.526531659441389e-07
show O 0 3.1285435397876427e-07
that O 0 1.3397787768099079e-07
BRCA1 O 0 8.439707926299889e-06
and O 0 1.6955798400886124e-06
BRCA2 O 0 2.152604611183051e-05
coexist O 0 7.520297458540881e-06
in O 0 1.2635781310166294e-08
a O 0 6.26792271418708e-08
biochemical O 0 4.593928679241799e-05
complex O 0 9.351016160508152e-06
and O 0 1.7329491583950585e-06
colocalize O 0 0.0006519255694001913
in O 0 2.1950341988485889e-07
subnuclear O 0 0.0032415417954325676
foci O 0 1.392427566315746e-05
in O 0 5.063442554131825e-09
somatic O 0 6.036005117948662e-08
cells O 0 1.2570089324981382e-07
and O 0 1.3428263834214249e-08
on O 0 1.0968612684791879e-08
the O 0 2.1042529940729082e-09
axial O 0 9.894701236135006e-08
elements O 0 6.67955157851452e-09
of O 0 1.63987667889387e-08
developing O 0 4.50440757049364e-06
synaptonemal O 0 0.0014514701906591654
complexes O 0 2.7861275157192722e-05
. O 0 2.7750054414354963e-06

Like O 0 1.1418084795877803e-05
BRCA1 O 0 0.0001279733987757936
and O 0 4.861111392528983e-06
RAD51 O 0 0.03452626243233681
, O 0 1.661530404817313e-06
BRCA2 O 0 3.109778617726988e-06
relocates O 0 9.076605238078628e-06
to O 0 1.131019544686751e-07
PCNA O 0 0.0017269866075366735
+ O 0 1.7087236301449593e-06
replication O 0 1.2431145535174437e-07
sites O 0 1.4815445759097656e-08
following O 0 2.152922640163979e-08
exposure O 0 6.745914049588464e-08
of O 0 2.2573574121054207e-09
S O 0 0.0003157895407639444
phase O 0 4.481833286718029e-07
cells O 0 2.7492410481499974e-07
to O 0 1.4387861568820881e-08
hydroxyurea O 0 8.902312401914969e-06
or O 0 1.6899588217711425e-07
UV O 0 1.2642728506762069e-05
irradiation O 0 3.0047908694541547e-06
. O 0 2.2195245037437417e-06

Thus O 0 1.5052613889565691e-05
, O 0 6.471455890277866e-06
BRCA1 O 0 3.471914533292875e-05
and O 0 1.3649926131620305e-06
BRCA2 O 0 5.224273536441615e-06
participate O 0 1.6282449166737933e-08
, O 0 3.0717652066414303e-07
together O 0 1.1408357067921315e-06
, O 0 1.5315454504616355e-07
in O 0 9.403270162522404e-09
a O 0 5.977928196898574e-08
pathway O 0 1.1272823030594736e-06
( O 0 1.8777343768761057e-07
s O 0 0.00730007141828537
) O 0 2.5067600972761284e-07
associated O 0 3.955996064064493e-08
with O 0 2.496494566628371e-09
the O 0 2.8807791707663455e-09
activation O 0 2.8866162793406147e-08
of O 0 6.671161401072823e-09
double O 0 2.2977765183895826e-06
- O 0 0.002130183158442378
strand O 0 0.00018425444432068616
break O 0 2.9101836844347417e-05
repair O 0 0.020715482532978058
and O 0 1.0171160056415829e-06
/ O 0 1.0482995094207581e-06
or O 0 2.048296110501724e-08
homologous O 0 2.122303385476698e-06
recombination O 0 6.79016302456148e-05
. O 0 1.1809642273874488e-05

Dysfunction O 0 0.3619900345802307
of O 0 6.417890290322248e-07
this O 0 3.0578581800000393e-07
pathway O 0 2.9649561383848777e-06
may O 0 6.714969913446112e-07
be O 0 1.5170189548996404e-09
a O 0 3.5298939327077505e-09
general O 0 1.3996195313836779e-08
phenomenon O 0 1.7986855027629645e-06
in O 0 3.704990092501248e-08
the O 0 1.59688667622504e-07
majority O 0 1.925544239611554e-07
of O 0 3.675884130416307e-08
cases O 0 3.1151731150202977e-07
of O 0 1.4255779205996078e-06
hereditary B-Disease 1 0.8933985829353333
breast I-Disease 0 0.4528103768825531
and I-Disease 0 0.0051979124546051025
/ I-Disease 1 0.6295168995857239
or I-Disease 1 0.7355838418006897
ovarian I-Disease 1 0.999981164932251
cancer I-Disease 1 0.99941086769104
. O 0 3.142563582514413e-05
. O 0 4.682432336267084e-05

A O 0 9.353335371997673e-06
novel O 0 1.3486457646649797e-05
Arg362Ser O 0 0.0003819090488832444
mutation O 0 3.312610772354674e-07
in O 0 3.0204084566776146e-08
the O 0 3.096072376251868e-08
sterol O 0 2.5169047148665413e-05
27 O 0 1.1154035746585578e-05
- O 0 0.0013339719735085964
hydroxylase O 0 0.00014928080781828612
gene O 0 2.620121222207672e-07
( O 0 1.0800830807511375e-07
CYP27 O 0 0.002882582601159811
) O 0 1.0304848530040545e-07
: O 0 6.126649410020946e-09
its O 0 7.731880025119153e-09
effects O 0 3.9861792089368464e-08
on O 0 9.598505101848787e-09
pre O 0 2.6483834858481714e-07
- O 0 3.639780459252506e-07
mRNA O 0 7.779984434463927e-10
splicing O 0 1.70647069808183e-08
and O 0 1.4782449042627377e-08
enzyme O 0 4.9255710621309845e-08
activity O 0 1.5563018962438946e-07
. O 0 7.579363341392309e-07

A O 0 3.7734453144366853e-06
novel O 0 9.614752343622968e-06
C O 0 6.306004797806963e-05
to O 0 1.8181786742843542e-08
A O 0 6.633820959223158e-08
mutation O 0 1.3615554905754834e-08
in O 0 4.197965530750025e-09
the O 0 4.01594171250963e-08
sterol O 0 2.9827622711309232e-05
27 O 0 6.605742782994639e-06
- O 0 0.0014246675418689847
hydroxylase O 0 9.319710079580545e-05
gene O 0 1.6769321575793583e-07
( O 0 3.9365918524936205e-08
CYP27 O 0 0.0020484300330281258
) O 0 1.2675276650497835e-07
was O 0 4.049478548040497e-07
identified O 0 1.387398551599972e-08
by O 0 1.4916095025796494e-09
sequencing O 0 2.6849275513995963e-07
amplified O 0 1.0512225344427861e-05
CYP27 O 0 0.002002982422709465
gene O 0 2.6113278295269993e-07
products O 0 6.983695470808016e-07
from O 0 1.9407272233706863e-08
a O 0 2.1385866944001464e-07
patient O 0 8.01963142293971e-06
with O 0 0.000583379587624222
cerebrotendinous B-Disease 1 0.9999037981033325
xanthomatosis I-Disease 1 0.9996166229248047
( O 0 5.840442099724896e-06
CTX B-Disease 1 0.6591905355453491
) O 0 1.750295723468298e-06
. O 0 1.9598194285208592e-06

The O 0 8.680910923430929e-07
mutation O 0 6.474472229456296e-07
changed O 0 4.822716164198937e-07
the O 0 3.696788297702369e-08
adrenodoxin O 0 5.490031617227942e-05
cofactor O 0 1.439522208102062e-07
binding O 0 3.393230585402307e-08
residue O 0 4.929937063025136e-07
362Arg O 0 1.7526709825688158e-06
to O 0 1.3374253704512284e-08
362Ser O 0 1.5741885363240726e-05
( O 0 2.827740530619849e-08
CGT O 0 1.1807896953541785e-05
362Arg O 0 3.271956302342005e-06
to O 0 2.718436675763769e-08
AGT O 0 0.0002081274287775159
362Ser O 0 0.0001860718912212178
) O 0 2.3209533139834093e-07
, O 0 8.507733895157799e-08
and O 0 1.1437297331440277e-07
was O 0 3.52595043295878e-06
responsible O 0 4.239675945427734e-06
for O 0 1.2041875379509293e-05
deficiency O 0 0.035416699945926666
in O 0 3.1579001635861914e-09
the O 0 1.3441332491481717e-08
sterol O 0 6.3677612160972785e-06
27 O 0 1.4021948118170258e-06
- O 0 0.0003610685234889388
hydroxylase O 0 4.122410973650403e-05
activity O 0 4.149582366608229e-08
, O 0 1.9737873557801322e-08
as O 0 3.8010261604881634e-09
confirmed O 0 5.274739223182223e-08
by O 0 3.7480735182171543e-10
expression O 0 2.525645317885683e-11
of O 0 1.0454023063877216e-10
mutant O 0 5.0179504995639945e-08
cDNA O 0 5.976252737127652e-08
into O 0 4.303007017369964e-08
COS O 0 0.0035290394444018602
- O 0 6.11396026215516e-05
1 O 0 2.504752671939059e-07
cells O 0 1.2342742365945014e-06
. O 0 1.2735379186779028e-06

Quantitative O 0 9.276750461140182e-06
analysis O 0 8.116346180031542e-06
showed O 0 0.00011561818973859772
that O 0 3.8765435306231666e-08
the O 0 3.678709337151531e-09
expression O 0 2.1560777607732007e-09
of O 0 8.674570395328374e-09
CYP27 O 0 8.338646875927225e-05
gene O 0 7.914648492146625e-09
mRNA O 0 3.6859433283353837e-09
in O 0 1.16764287128035e-08
the O 0 5.208794107147696e-08
patient O 0 4.7015279847073543e-07
represented O 0 4.4822994027526875e-07
52 O 0 2.4864484657882713e-05
. O 0 9.615202543500345e-06

5 O 0 3.809405825450085e-05
% O 0 3.491427946755721e-07
of O 0 9.035829862114042e-09
the O 0 7.452349137793135e-08
normal O 0 3.253313707318739e-07
level O 0 7.80608388595283e-07
. O 0 5.423817128757946e-06

As O 0 5.836583341078949e-07
the O 0 1.6158951154920942e-07
mutation O 0 1.2297373075398355e-07
occurred O 0 2.8579214017554477e-07
at O 0 1.0532453131872899e-07
the O 0 1.5695870159149194e-09
penultimate O 0 1.993249014731191e-07
nucleotide O 0 4.904185058052235e-09
of O 0 1.9856165600629083e-09
exon O 0 5.1444567361613736e-06
6 O 0 6.070909535083047e-07
( O 0 1.0845126574565711e-08
- O 0 1.8253247162647313e-06
2 O 0 2.032111900973632e-08
position O 0 2.2249346809388726e-09
of O 0 9.87922965656196e-10
exon O 0 2.8911101708217757e-06
6 O 0 5.834763214807026e-07
- O 0 5.051216794527136e-05
intron O 0 9.396202949574217e-05
6 O 0 4.12420718021167e-07
splice O 0 5.5211844482983e-06
site O 0 2.6297743715986144e-06
) O 0 1.1142299527477917e-08
of O 0 4.690237642712702e-10
the O 0 1.7490455306301556e-08
gene O 0 1.3537021459342213e-07
, O 0 5.466000274623184e-08
we O 0 1.3571581192195481e-08
hypothesized O 0 1.0178112574976694e-07
that O 0 1.3961161116071708e-08
the O 0 1.276039540698548e-07
mutation O 0 1.2583623174577951e-06
may O 0 2.1055363959021633e-06
partially O 0 4.217408331896877e-06
affect O 0 2.6565976085635157e-09
the O 0 4.306204559600957e-10
normal O 0 3.818237948038927e-10
splicing O 0 2.2698836588119775e-08
efficiency O 0 1.1394261179020759e-07
in O 0 9.438759107638361e-09
exon O 0 3.33231719196192e-06
6 O 0 1.1318044244035264e-06
and O 0 8.794305017545412e-08
cause O 0 7.079761665806927e-09
alternative O 0 2.6781984963086813e-10
splicing O 0 1.9224431468956027e-07
elsewhere O 0 2.724817136368074e-07
, O 0 9.131679234997137e-08
which O 0 6.738493851798921e-08
resulted O 0 5.678766115124745e-07
in O 0 1.7947942865248478e-07
decreased O 0 3.1076144750841195e-06
transcript O 0 1.1193954378541093e-05
in O 0 1.7515986883154255e-07
the O 0 1.050439095706679e-06
patient O 0 9.5050399977481e-06
. O 0 1.214942767546745e-05

Transfection O 0 0.0025140319485217333
of O 0 4.073946001881268e-06
constructed O 0 0.0006819430855102837
minigenes O 0 0.07242784649133682
, O 0 8.981259611573478e-07
with O 0 7.16125185817873e-08
or O 0 6.957571230259418e-08
without O 0 1.5804135777841566e-09
the O 0 2.6046627077391804e-09
mutation O 0 8.674271967379354e-09
, O 0 8.75138095324246e-09
into O 0 4.385675467233341e-08
COS O 0 0.017944633960723877
- O 0 6.71528687234968e-05
1 O 0 6.958340037499511e-08
cells O 0 1.054065279504357e-07
confirmed O 0 3.657867964079742e-08
that O 0 2.8851561140186277e-09
the O 0 2.5175403095545335e-08
mutant O 0 5.2330455218907446e-05
minigene O 0 0.006266783457249403
was O 0 1.4090850299908197e-06
responsible O 0 1.7181532641075137e-08
for O 0 9.139198287044792e-10
a O 0 3.18996673520644e-09
mRNA O 0 1.3325696990307279e-08
species O 0 2.695793810403302e-09
alternatively O 0 3.0626178926240755e-08
spliced O 0 8.664205779496115e-06
at O 0 7.758865194773534e-07
an O 0 8.769293735610972e-09
activated O 0 4.700721092376625e-07
cryptic O 0 1.2179717714388971e-06
5 O 0 1.4093248346114251e-08
splice O 0 1.1896553360202233e-06
site O 0 3.9392133999172074e-07
88 O 0 2.5731219466251787e-07
bp O 0 1.6016084600778413e-06
upstream O 0 2.2181140479915484e-08
from O 0 3.954038207965027e-10
the O 0 1.9528907380106375e-09
3 O 0 4.710054568590749e-08
end O 0 4.869096059678668e-08
of O 0 1.4966316186360018e-08
exon O 0 5.154695827513933e-05
6 O 0 1.3316087461134885e-05
. O 0 5.0069024837284815e-06

Our O 0 1.3344437093110173e-06
data O 0 3.083519004576374e-06
suggest O 0 3.4974965501533006e-07
that O 0 1.4132036874059395e-08
the O 0 4.381896445693201e-08
C O 0 2.5815013941610232e-05
to O 0 1.7718910783059982e-09
A O 0 1.4670292536322904e-08
mutation O 0 7.031717874639298e-09
at O 0 2.835831658387633e-08
the O 0 1.3539720455923998e-09
penultimate O 0 1.1807492938942232e-07
nucleotide O 0 1.9622476976621783e-09
of O 0 1.0019198803945528e-09
exon O 0 1.0520201385588734e-06
6 O 0 2.0886359664018528e-07
of O 0 6.043433753433192e-09
the O 0 2.5405842052350636e-07
CYP27 O 0 0.011505361646413803
gene O 0 1.4976917839248927e-07
not O 0 2.184946090721951e-08
only O 0 9.035812986724068e-09
causes O 0 3.247527729399735e-06
the O 0 3.7292713386705145e-05
deficiency B-Disease 0 0.16089868545532227
in I-Disease 0 2.4092191353020098e-08
the I-Disease 0 3.8439633698317266e-08
sterol I-Disease 0 1.6075786334113218e-05
27 I-Disease 0 1.570488279867277e-06
- I-Disease 0 8.431527385255322e-05
hydroxylase I-Disease 0 1.1239395462325774e-05
activity I-Disease 0 2.786386588127243e-08
, O 0 4.843328227366328e-08
but O 0 4.456363100757699e-08
also O 0 6.062138169227183e-08
partially O 0 1.0119304079125868e-06
leads O 0 7.300211279925861e-08
to O 0 7.489833753204778e-10
alternative O 0 8.207260426829066e-10
pre O 0 2.0451425086775998e-07
- O 0 2.804617622587102e-07
mRNA O 0 5.916826473217895e-10
splicing O 0 5.111182588279917e-09
of O 0 1.6812381486985828e-09
the O 0 3.097596135148706e-08
gene O 0 6.676776820313535e-07
. O 0 4.7750745579833165e-06

To O 0 2.155006200155185e-07
our O 0 6.212174241682078e-08
knowledge O 0 9.660993782745209e-08
, O 0 1.9863965405875206e-07
this O 0 8.68702088041573e-09
is O 0 2.2459648363337692e-08
the O 0 3.933521952603769e-08
first O 0 2.456484367030498e-07
report O 0 4.766793608723674e-07
regarding O 0 1.8790522915423935e-08
effects O 0 8.543378271497204e-08
on O 0 3.8571023708300345e-08
pre O 0 7.984389185367036e-07
- O 0 5.505964963958832e-07
mRNA O 0 7.236502508334297e-10
splicing O 0 9.055809435665196e-09
of O 0 5.615932163749449e-10
a O 0 5.9917386607821754e-09
mutation O 0 1.1869108362816405e-08
at O 0 1.4267828873926192e-07
the O 0 2.848082303330557e-08
- O 0 0.00013990075967740268
2 O 0 1.677587988524465e-07
position O 0 9.894281838285224e-09
of O 0 1.0454068721799104e-09
a O 0 2.1101380198729203e-08
5 O 0 9.991574501100331e-08
splice O 0 2.7753923859563656e-05
site O 0 9.660892828833312e-06
. O 0 6.806362307543168e-06

ATM O 0 0.001839211443439126
germline O 0 0.0007961314986459911
mutations O 0 3.584826845326461e-05
in O 0 8.35472656035563e-06
classical O 0 0.002085508778691292
ataxia B-Disease 1 0.9999457597732544
- I-Disease 1 0.9999457597732544
telangiectasia I-Disease 1 0.9999688863754272
patients O 0 0.00014956347877159715
in O 0 3.003267181611591e-07
the O 0 3.5504947959452693e-07
Dutch O 0 3.462352469796315e-05
population O 0 4.733335003948014e-07
. O 0 3.7624781725753564e-06

Germline O 0 0.0021639978513121605
mutations O 0 1.82074054464465e-05
in O 0 2.3209400978885242e-07
the O 0 2.065716699917175e-07
ATM O 0 0.0013753748498857021
gene O 0 7.983551313373027e-07
are O 0 1.6468506558453555e-08
responsible O 0 4.93922186706186e-07
for O 0 2.751011152213323e-06
the O 1 0.5435714721679688
autosomal B-Disease 1 0.9999914169311523
recessive I-Disease 1 0.9999942779541016
disorder I-Disease 1 0.9999986886978149
ataxia B-Disease 1 0.9999910593032837
- I-Disease 1 0.9999827146530151
telangiectasia I-Disease 1 0.9999809265136719
( O 0 0.0002746554382611066
A B-Disease 0 0.2925463020801544
- I-Disease 1 0.9997164607048035
T I-Disease 1 0.9999215602874756
) O 0 1.1660808922897559e-05
. O 0 4.073965556017356e-06

In O 0 1.093578475774848e-06
our O 0 1.4818249383097282e-07
study O 0 2.0062132932707755e-07
, O 0 2.779158307930629e-07
we O 0 1.4494733413528138e-08
have O 0 1.3720190539245891e-09
determined O 0 5.986369622235088e-09
the O 0 4.41227054892579e-09
ATM O 0 1.7577061953488737e-05
mutation O 0 6.196433144367575e-09
spectrum O 0 3.481233079583035e-08
in O 0 3.730098185883435e-08
19 O 0 3.452377654866723e-07
classical O 0 5.691116484740633e-07
A B-Disease 0 0.08095763623714447
- I-Disease 1 0.999961256980896
T I-Disease 1 0.9999954700469971
patients O 0 1.052954303304432e-05
, O 0 1.3403167997694254e-07
including O 0 4.131148312325195e-09
some O 0 8.915305715895272e-10
immigrant O 0 1.5655357401556103e-06
populations O 0 1.7352002146253653e-07
, O 0 1.0504105318887014e-07
as O 0 5.131030711424955e-09
well O 0 4.969732625426104e-09
as O 0 3.987021379714406e-09
12 O 0 3.3191305703894614e-08
of O 0 7.137317403760335e-09
Dutch O 0 2.3355441953754053e-06
ethnic O 0 1.9382456173389073e-07
origin O 0 7.88022987308068e-07
. O 0 1.0954084245895501e-05

Both O 0 1.7109626071487583e-07
the O 0 3.609471832533018e-08
protein O 0 1.3470184967445675e-07
truncation O 0 4.077926405443577e-06
test O 0 9.980695949707297e-07
( O 0 7.934464640868555e-09
PTT O 0 1.552840103613562e-06
) O 0 9.767452624487305e-09
and O 0 2.64430810581473e-09
the O 0 2.5023727534545515e-09
restriction O 0 3.556963434903082e-08
endonuclease O 0 1.2135995348216966e-05
fingerprinting O 0 8.258523303084075e-05
( O 0 2.262190257340535e-08
REF O 0 5.903877899982035e-05
) O 0 1.1605748584386788e-09
method O 0 3.9167627474689937e-10
were O 0 2.995279357875802e-09
used O 0 5.8942792868776905e-09
and O 0 5.7392334440464765e-08
compared O 0 2.663433633642853e-07
for O 0 2.568132095870368e-10
their O 0 1.0213575540873876e-09
detection O 0 2.2693559742492653e-07
efficiency O 0 1.0208481882045817e-07
, O 0 2.2089269080538543e-08
identifying O 0 1.559338471679439e-07
76 O 0 1.5575326415273594e-06
% O 0 3.883831478646016e-09
and O 0 2.0497303410138557e-08
60 O 0 8.387088001882148e-08
% O 0 2.0700732239475883e-09
of O 0 1.3821286337645233e-09
the O 0 1.1554693202242561e-07
mutations O 0 5.459742169477977e-07
, O 0 4.2636332864276483e-07
respectively O 0 2.380552814429393e-06
. O 0 2.3663833417231217e-06

Most O 0 6.5579374677327e-06
patients O 0 2.9864622774766758e-05
were O 0 1.1631503866738058e-06
found O 0 3.63968695182848e-07
to O 0 2.384336639238427e-08
be O 0 5.591931184767418e-08
compound O 0 1.7853273675427772e-05
heterozygote O 0 0.000192414183402434
. O 0 4.934936896461295e-06

Seventeen O 0 1.3716366993321571e-05
mutations O 0 5.6501962717447896e-06
were O 0 2.1330097865757125e-07
distinct O 0 5.0651649985411495e-08
, O 0 1.769980997323728e-07
of O 0 1.2170779051245972e-08
which O 0 1.290401741016467e-07
10 O 0 5.525328106159577e-08
were O 0 1.1023314527847106e-07
not O 0 1.5920541329705884e-07
reported O 0 4.901421198155731e-05
previously O 0 4.6341110646608286e-06
. O 0 5.758845418313285e-06

Mutations O 0 3.558620301191695e-05
are O 0 2.2197141902324802e-07
small O 0 3.6168910355627304e-07
deletions O 0 4.390188678371487e-06
or O 0 9.662400088927825e-07
point O 0 2.9065720354992663e-06
mutations O 0 2.9785010724481253e-07
frequently O 0 1.4541495829689666e-07
affecting O 0 5.845802419912616e-08
splice O 0 1.1716108929249458e-05
sites O 0 3.3333342344121775e-06
. O 0 1.0424691936350428e-05

Moreover O 0 8.139767305692658e-05
, O 0 2.058693098661024e-06
a O 0 6.47760316496715e-07
16 O 0 1.136002265411662e-05
. O 0 8.769999112701043e-06

7 O 0 7.442403875757009e-05
- O 0 0.005997455213218927
kb O 0 0.038132790476083755
genomic O 0 5.092771971249022e-06
deletion O 0 1.173243845187244e-06
of O 0 2.4158073319568985e-09
the O 0 8.648468607930226e-09
3 O 0 1.4077322418870608e-07
end O 0 9.743602191747414e-08
of O 0 3.1022655555545953e-09
the O 0 4.83262425632347e-08
gene O 0 2.785170636343537e-07
, O 0 2.451981231388345e-07
most O 0 7.834833226638693e-09
likely O 0 2.319448810794711e-07
a O 0 1.5090719784893736e-08
result O 0 2.4018504518608097e-08
of O 0 2.247686481382516e-09
recombination O 0 1.1675825817292207e-06
between O 0 3.221015276722028e-08
two O 0 2.8125503703790855e-08
LINE O 0 3.7447230170073453e-06
elements O 0 2.4819280497467844e-07
, O 0 7.04710714671819e-07
was O 0 3.760641448025126e-06
identified O 0 2.9865184387745103e-06
. O 0 7.4780873546842486e-06

The O 0 5.221168066782411e-07
most O 0 7.810263014107477e-08
frequently O 0 8.02052511517104e-07
found O 0 4.7077193698896735e-07
mutation O 0 2.406648036412662e-07
, O 0 3.601645914841356e-07
identified O 0 3.2793550985843467e-07
in O 0 2.4269851905955875e-08
three O 0 8.525928052449672e-08
unrelated O 0 5.112715734867379e-05
Turkish O 0 1.0176508112635929e-05
A B-Disease 0 0.21071621775627136
- I-Disease 1 0.9998345375061035
T I-Disease 1 0.9999855756759644
individuals O 0 2.788357278404874e-07
, O 0 1.6520691588084446e-06
was O 0 3.5956461942987517e-05
previously O 0 3.8088408018666087e-06
described O 0 5.599782070930814e-06
to O 0 1.3772267770661983e-08
be O 0 2.8822300102149256e-09
a O 0 3.3015904676858554e-08
Turkish O 0 5.848830824106699e-06
A B-Disease 0 0.010838746093213558
- I-Disease 1 0.9968710541725159
T I-Disease 1 0.9998959302902222
founder O 0 0.0003979599568992853
mutation O 0 8.709071721568762e-07
. O 0 1.8336471612201422e-06

The O 0 7.142303957152762e-07
presence O 0 2.2953709333251027e-07
of O 0 4.670531339456829e-08
a O 0 2.0606049133675697e-07
founder O 0 2.083359140669927e-05
mutation O 0 3.8159122084380215e-08
among O 0 8.874795121016632e-09
relatively O 0 2.9481910246431653e-08
small O 0 1.642412073010746e-08
ethnic O 0 2.6429328059407453e-08
population O 0 3.900713529958466e-09
groups O 0 2.1773109981637617e-09
in O 0 1.84735338137898e-08
Western O 0 4.167195015725156e-07
Europe O 0 8.395157237828244e-06
could O 0 5.28883333572594e-07
indicate O 0 5.154821280939359e-08
a O 0 2.166227375255403e-08
high O 0 2.813285618685768e-06
carrier O 0 3.0649634936708026e-06
frequency O 0 3.7482490000684265e-08
in O 0 1.1388466170103584e-08
such O 0 3.862305142376954e-09
communities O 0 9.710837645116044e-08
. O 0 3.3043925213860348e-06

In O 0 2.0569485059240833e-05
patients O 0 2.5867032036330784e-06
of O 0 1.7962491938305902e-08
Dutch O 0 1.4370248209161218e-06
ethnic O 0 1.2902908963496884e-07
origin O 0 3.84921321483489e-07
, O 0 3.177609642079915e-06
however O 0 1.711511004032218e-07
, O 0 1.1227445639860889e-07
no O 0 2.1694027907415148e-08
significant O 0 2.9709909199482354e-08
founder O 0 5.9308393247192726e-05
effect O 0 1.5730410041214782e-07
could O 0 5.79586476590066e-08
be O 0 1.2345381605882721e-08
identified O 0 1.0610591516524437e-06
. O 0 4.911264568363549e-06

The O 0 2.582522711236379e-06
observed O 0 4.200589501124341e-06
genetic O 0 6.950049737497466e-06
heterogeneity O 0 2.7421019694884308e-05
including O 0 1.7323728229712287e-07
the O 0 7.921735090121729e-08
relative O 0 1.4701744248668547e-06
high O 0 2.4601235963928048e-06
percentage O 0 1.8277827962265292e-07
of O 0 3.646935642365179e-09
splice O 0 0.00022002679179422557
- O 0 0.012044004164636135
site O 0 1.7637896235100925e-05
mutations O 0 4.5862270781071857e-07
had O 0 4.944443503518414e-07
no O 0 9.455751737164064e-09
reflection O 0 2.6952863052542853e-08
on O 0 1.0463572408525579e-07
the O 0 7.34304080651782e-07
phenotype O 0 0.00010836715955520049
. O 0 9.298310033045709e-06

All O 0 2.503850055290968e-06
patients O 0 6.9477437136811204e-06
manifested O 0 2.660087830008706e-06
classical O 0 1.1736132137230015e-06
A B-Disease 0 0.025302059948444366
- I-Disease 1 0.9978995323181152
T I-Disease 1 0.9998795986175537
and O 0 3.3918786357389763e-07
increased O 0 1.495473895829491e-07
cellular O 0 3.983389615314081e-05
radioresistant O 0 5.854462870047428e-05
DNA O 0 2.9317495773284463e-06
synthesis O 0 1.511591904090892e-06
. O 0 5.105337550048716e-06

Determination O 0 8.360386345884763e-06
of O 0 3.8704776272879826e-08
the O 0 5.270907621479637e-08
genomic O 0 1.7256220417039003e-06
structure O 0 2.564023873219412e-07
of O 0 9.347015605953857e-09
the O 0 3.4041022445308045e-07
COL4A4 O 0 0.019105851650238037
gene O 0 1.389965689213568e-07
and O 0 1.7198210855440266e-07
of O 0 1.616968035023092e-07
novel O 0 0.00011317736789351329
mutations O 0 0.0008186423801817
causing O 0 0.49510297179222107
autosomal B-Disease 1 0.9991111159324646
recessive I-Disease 1 0.999800980091095
Alport I-Disease 1 0.9999125003814697
syndrome I-Disease 1 0.9997569918632507
. O 0 0.0012384302681311965

Autosomal B-Disease 1 0.997990608215332
recessive I-Disease 1 0.9994187355041504
Alport I-Disease 1 0.9998683929443359
syndrome I-Disease 1 0.9998661279678345
is O 0 6.145495717646554e-05
a O 0 8.714460273040459e-05
progressive O 1 0.5199763774871826
hematuric B-Disease 1 0.9997244477272034
glomerulonephritis I-Disease 1 0.9998927116394043
characterized O 0 0.013216128572821617
by O 0 6.233838939806446e-05
glomerular B-Disease 1 0.997512698173523
basement I-Disease 1 0.9564753174781799
membrane I-Disease 0 0.17872081696987152
abnormalities I-Disease 1 0.9615300297737122
and O 0 6.816132372478023e-05
associated O 0 6.546053555211984e-06
with O 0 3.7153685639168543e-07
mutations O 0 1.6342724507012463e-07
in O 0 2.3122261438857095e-08
either O 0 1.4525564751011188e-08
the O 0 2.5106118073381367e-07
COL4A3 O 0 0.020304320380091667
or O 0 1.8060819684251328e-07
the O 0 1.8817175373442296e-07
COL4A4 O 0 0.06126849353313446
gene O 0 1.878646145314633e-07
, O 0 2.983978930615194e-08
which O 0 1.4553205307521466e-09
encode O 0 5.485778942215802e-09
the O 0 8.158853148643175e-08
alpha3 O 0 0.0015394246438518167
and O 0 1.2168919738542172e-06
alpha4 O 0 0.0038137040100991726
type O 0 5.89135333939339e-06
IV O 0 0.11217960715293884
collagen O 0 0.0016430551186203957
chains O 0 0.0001324672339251265
, O 0 6.309821856120834e-07
respectively O 0 1.130690066020179e-06
. O 0 1.458778001506289e-06

To O 0 2.5631391054048436e-07
date O 0 1.3048423852524138e-06
, O 0 1.2612670730050013e-07
mutation O 0 9.2958822861533e-09
screening O 0 1.5847701817506277e-08
in O 0 8.01951394180378e-09
the O 0 6.707255195692596e-09
two O 0 6.756563664112036e-08
genes O 0 3.787459093018697e-07
has O 0 2.522237082303036e-06
been O 0 2.0599106846930226e-06
hampered O 0 0.0033781661186367273
by O 0 5.7955109156182516e-08
the O 0 4.0921975141827716e-08
lack O 0 4.076578008493925e-08
of O 0 1.2276159644386553e-08
genomic O 0 6.316519829852041e-06
structure O 0 1.6353434375560028e-06
information O 0 7.131175721042382e-07
. O 0 3.863250185531797e-06

We O 0 7.245275810419116e-06
report O 0 3.7388672353699803e-06
here O 0 3.626516331678431e-08
the O 0 6.664840679349027e-09
complete O 0 1.4096265488205972e-07
characterization O 0 5.744045665778685e-07
of O 0 2.197152015881443e-09
the O 0 8.376789040198673e-09
48 O 0 4.479550952396494e-08
exons O 0 5.863558172336525e-08
of O 0 4.420854793352191e-09
the O 0 5.010266477256664e-07
COL4A4 O 0 0.026362741366028786
gene O 0 4.649355389574339e-07
, O 0 1.0311572395949042e-07
a O 0 6.4496403773262045e-09
comprehensive O 0 1.4221620325827189e-08
gene O 0 9.312993398680192e-08
screen O 0 9.938326002156828e-06
, O 0 2.361661728400577e-07
and O 0 1.5578068612853713e-08
the O 0 1.589118947542545e-09
subsequent O 0 8.362979642129176e-09
detection O 0 2.065348496671504e-07
of O 0 3.118407754243435e-09
10 O 0 5.7509033979386004e-08
novel O 0 2.4378840635108645e-07
mutations O 0 2.0396653610532667e-07
in O 0 9.883739267024794e-07
eight O 0 0.006060206331312656
patients O 0 0.06299334019422531
diagnosed O 1 0.9830752015113831
with O 0 0.27270880341529846
autosomal B-Disease 1 0.9998319149017334
recessive I-Disease 1 0.9998887777328491
Alport I-Disease 1 0.9999234676361084
syndrome I-Disease 1 0.9997968077659607
. O 0 0.0008380156941711903

Furthermore O 0 5.0566199206514284e-05
, O 0 1.6968787122095819e-06
we O 0 2.4747777160882833e-08
identified O 0 1.5336436121060615e-08
a O 0 1.1167122782040906e-09
glycine O 0 7.537175861216383e-08
to O 0 5.55868295837314e-10
alanine O 0 1.4116035451650077e-08
substitution O 0 6.700986432406353e-10
in O 0 2.6036792721839674e-09
the O 0 1.1387163212361884e-08
collagenous O 0 0.000501100264955312
domain O 0 7.693401471442485e-08
that O 0 9.743602191747414e-08
is O 0 6.483734438234023e-08
apparently O 0 4.646550223696977e-06
silent O 0 4.906101480628422e-07
in O 0 5.478156595017936e-09
the O 0 1.6603339147991392e-08
heterozygous O 0 2.433479835417529e-07
carriers O 0 1.025328060677566e-06
, O 0 1.385102734730026e-07
in O 0 1.308391972543177e-07
11 O 0 1.4125177585810889e-05
. O 0 7.079223451000871e-06

5 O 0 1.1939895557588898e-05
% O 0 2.3692909678629803e-07
of O 0 4.904774808522916e-09
all O 0 6.661790230566567e-09
control O 0 1.693700255600561e-06
individuals O 0 2.6599858315989877e-08
, O 0 1.594521705783336e-07
and O 0 4.088582272743224e-07
in O 0 4.92745044766707e-08
one O 0 1.864937893003571e-08
control O 0 3.99852353893948e-07
individual O 0 9.03491681469859e-09
homozygous O 0 3.255516745070963e-08
for O 0 1.0665544003529703e-09
this O 0 1.1538253685827726e-09
glycine O 0 1.6960748894234712e-07
substitution O 0 6.418324716150892e-08
. O 0 1.2418755659382441e-06

There O 0 2.732107986957999e-06
has O 0 3.420497705519665e-06
been O 0 2.995238332914596e-07
no O 0 3.1764290753244495e-08
previous O 0 2.1781019654554257e-07
finding O 0 2.2290942425229332e-08
of O 0 3.3233590879255814e-10
a O 0 3.005660831334467e-09
glycine O 0 7.52930162661869e-08
substitution O 0 6.537601571210416e-09
that O 0 8.052932543023417e-08
is O 0 3.255075853303424e-08
not O 0 2.808219079497576e-08
associated O 0 9.891267183093078e-08
with O 0 2.0853473614579343e-08
any O 0 2.8134680363223197e-08
obvious O 0 4.23720621256507e-06
phenotype O 0 1.0152292816201225e-05
in O 0 2.6254838303430006e-07
homozygous O 0 3.7744493965874426e-06
individuals O 0 4.129433932575921e-07
. O 0 6.451140507124364e-06

Founder O 0 0.0026787372771650553
BRCA1 O 0 0.0009253962780348957
and O 0 1.4529143300023861e-05
BRCA2 O 0 0.0001416297018295154
mutations O 0 8.091714676083939e-07
in O 0 1.6455798856895854e-07
French O 0 4.14610949519556e-05
Canadian O 0 0.005810949951410294
breast B-Disease 1 0.9995092153549194
and I-Disease 1 0.9993890523910522
ovarian I-Disease 1 0.9999861717224121
cancer I-Disease 1 0.9998171925544739
families O 0 0.000350597983924672
. O 0 5.91090829402674e-05

We O 0 1.8307536038264516e-06
have O 0 8.924739347548893e-08
identified O 0 1.9451303501227812e-07
four O 0 4.177280743533629e-08
mutations O 0 2.0652629828532554e-08
in O 0 3.944669479949425e-09
each O 0 1.2497761714413969e-09
of O 0 1.1412781475428346e-07
the O 0 0.001395119004882872
breast B-Disease 1 0.9895716905593872
cancer I-Disease 0 0.19005665183067322
- O 0 0.06701268255710602
susceptibility O 0 1.57156064233277e-05
genes O 0 5.586430162907163e-08
, O 0 3.726742079379619e-07
BRCA1 O 0 1.266213075723499e-05
and O 0 2.451004320391803e-06
BRCA2 O 0 1.7186588593176566e-05
, O 0 2.9659298661499633e-07
in O 0 1.1812741007588556e-07
French O 0 9.658510680310428e-05
Canadian O 0 0.01188906840980053
breast B-Disease 1 0.9988196492195129
cancer I-Disease 1 0.9779341816902161
and O 1 0.5083514451980591
breast B-Disease 1 0.9998512268066406
/ I-Disease 1 0.9999024868011475
ovarian I-Disease 1 0.9999868869781494
cancer I-Disease 1 0.9999079704284668
families O 0 0.00015901892038527876
from O 0 3.326655814817059e-06
Quebec O 0 3.077612927882001e-05
. O 0 2.275290353281889e-05

To O 0 1.6129649793583667e-06
identify O 0 2.5841834940365516e-05
founder O 0 0.0043161301873624325
effects O 0 2.1844893126399256e-05
, O 0 3.2696181051505846e-07
we O 0 1.900280999223014e-08
examined O 0 1.5773403561070154e-07
independently O 0 1.828169260420509e-08
ascertained O 0 4.635953132492432e-07
French O 0 3.3612470815569395e-06
Canadian O 0 0.0005143703892827034
cancer B-Disease 0 0.10736511647701263
families O 0 4.359164051948028e-07
for O 0 4.4456212044963195e-09
the O 0 1.4717264740227165e-08
distribution O 0 4.8128470098163234e-08
of O 0 2.5550928040019016e-09
these O 0 8.240974125328648e-09
eight O 0 6.574178428309096e-07
mutations O 0 1.3747973071076558e-06
. O 0 4.630236617231276e-06

Mutations O 0 2.404587939963676e-05
were O 0 2.1762361939181574e-06
found O 0 1.6721888869142276e-06
in O 0 1.2548002814583015e-07
41 O 0 5.920687158322835e-07
of O 0 3.883114629843476e-08
97 O 0 1.5129537132452242e-05
families O 0 8.941827218222897e-06
. O 0 6.440634479076834e-06

Six O 0 2.346494966332102e-06
of O 0 6.952463849074775e-08
eight O 0 1.0318315162294311e-06
mutations O 0 2.29349140568047e-07
were O 0 5.8063871932745315e-08
observed O 0 1.2981369934550457e-07
at O 0 5.483448148879688e-07
least O 0 4.028108691045418e-08
twice O 0 3.579594476832426e-06
. O 0 3.629074399214005e-06

The O 0 2.505338215996744e-06
BRCA1 O 0 0.0002965836029034108
C4446T O 0 0.0004677257966250181
mutation O 0 1.6407765315307188e-06
was O 0 3.851409019262064e-06
the O 0 6.251291750913879e-08
most O 0 1.4390880487269442e-08
common O 0 2.2134528876449622e-07
mutation O 0 2.3003147475719743e-07
found O 0 2.865234591808985e-06
, O 0 1.25196265798877e-07
followed O 0 4.6317460089539964e-08
by O 0 3.6413769777254856e-08
the O 0 2.4406708121205156e-07
BRCA2 O 0 5.654612323269248e-05
8765delAG O 0 0.00022545007232110947
mutation O 0 1.4922155742169707e-06
. O 0 3.942771854781313e-06

Together O 0 9.319066521129571e-06
, O 0 7.130637982299959e-07
these O 0 6.311263067715345e-09
mutations O 0 6.49856630730028e-08
were O 0 5.375133227403239e-08
found O 0 2.0020620183913707e-07
in O 0 4.002307463224497e-08
28 O 0 7.480360295630817e-07
of O 0 4.619896643021093e-08
41 O 0 1.5823870853637345e-05
families O 0 1.287038116970507e-06
identified O 0 2.702756773942383e-07
to O 0 1.5896958416306006e-08
have O 0 2.3562213513628194e-08
a O 0 1.773234998836415e-07
mutation O 0 5.544123382605903e-07
. O 0 8.395285476581194e-06

The O 0 3.1706231311545707e-06
odds O 0 0.00017616248806007206
of O 0 3.2331715971167796e-08
detection O 0 2.1144023776287213e-06
of O 0 8.351486613378256e-09
any O 0 1.2781989910948255e-09
of O 0 1.244210623418951e-09
the O 0 1.7016571263184233e-08
four O 0 5.32924673279922e-07
BRCA1 O 0 6.114397547207773e-05
mutations O 0 5.751549565502501e-07
was O 0 5.444572252599755e-06
18 O 0 5.578822765528457e-06
. O 0 7.180432021414163e-06

7x O 0 0.17493653297424316
greater O 0 1.4340020015879418e-06
if O 0 1.0830474650447286e-07
one O 0 1.027207296999677e-08
or O 0 2.992888070707522e-08
more O 0 1.4114149848865054e-08
cases O 0 1.82923049578676e-05
of O 0 0.10196493566036224
ovarian B-Disease 1 0.9999980926513672
cancer I-Disease 1 0.9999490976333618
were O 0 1.9908502508769743e-05
also O 0 9.750366416483303e-07
present O 0 3.090007538730788e-08
in O 0 1.04729771521761e-07
the O 0 1.663377474869776e-06
family O 0 0.0017744115320965648
. O 0 2.892627162509598e-05

The O 0 3.965715222875588e-06
odds O 0 0.0001398567546857521
of O 0 4.4829874923379975e-08
detection O 0 2.73725640909106e-06
of O 0 5.249694456921361e-09
any O 0 1.1147970324643097e-09
of O 0 2.5258695135477183e-09
the O 0 2.7100808708269142e-08
four O 0 6.27873362191167e-07
BRCA2 O 0 4.229986006976105e-05
mutations O 0 4.806384481526038e-07
was O 0 9.822560059546959e-06
5 O 0 3.182273758284282e-06
. O 0 4.642811745725339e-06

3x O 0 0.0031227979343384504
greater O 0 8.601567742516636e-07
if O 0 2.5553651994414395e-07
there O 0 1.08177324875669e-08
were O 0 3.6032943739883194e-08
at O 0 2.7540460223463015e-07
least O 0 2.247763530860425e-09
five O 0 8.4884781870187e-08
cases O 0 1.2843627246184042e-06
of O 0 8.056383376242593e-05
breast B-Disease 1 0.9972743391990662
cancer I-Disease 0 0.23727622628211975
in O 0 1.6283806871797424e-06
the O 0 2.920013685070444e-06
family O 0 0.0012313042534515262
. O 0 3.672955062938854e-05

Interestingly O 0 0.00014818509225733578
, O 0 2.614884124341188e-06
the O 0 5.467147090598701e-08
presence O 0 5.2751616408386326e-08
of O 0 1.561091380608559e-07
a O 0 0.00027205239166505635
breast B-Disease 1 0.9842550754547119
cancer I-Disease 0 0.06733338534832001
case O 0 3.062741961912252e-05
< O 0 4.772625288751442e-06
36 O 0 3.7641075323335826e-07
years O 0 3.5221151506448223e-07
of O 0 5.766841582044435e-08
age O 0 7.864824169701023e-07
was O 0 1.5772216102050152e-06
strongly O 0 1.843812640345277e-07
predictive O 0 2.5558065885888936e-07
of O 0 3.2979259323440147e-09
the O 0 1.3590257808004935e-08
presence O 0 4.149809829101514e-09
of O 0 6.553778630902229e-10
any O 0 6.359219262286331e-10
of O 0 1.5307818346244062e-09
the O 0 2.505096041716115e-08
eight O 0 3.9994080225369544e-07
mutations O 0 3.934505343750061e-07
screened O 0 2.842313733708579e-06
. O 0 2.5882477530103642e-06

Carriers O 0 1.1947002349188551e-05
of O 0 4.862052449539078e-08
the O 0 2.850723568315061e-08
same O 0 5.767149247049019e-08
mutation O 0 1.0540511397039154e-07
, O 0 4.600937586474174e-08
from O 0 4.2022354485027336e-09
different O 0 4.7019645954549105e-09
families O 0 2.8391980322339805e-06
, O 0 4.1979200204878e-07
shared O 0 2.5564355610185885e-07
similar O 0 8.868468626133108e-07
haplotypes O 0 0.0002510936465114355
, O 0 1.134932404056599e-06
indicating O 0 4.2133373767683224e-07
that O 0 3.7069110003784544e-09
the O 0 5.05347585999516e-09
mutant O 0 1.991445060411934e-06
alleles O 0 1.1087205820103918e-07
were O 0 1.6464683483263798e-07
likely O 0 4.797120709554292e-07
to O 0 1.186053211199578e-08
be O 0 7.011695668523998e-09
identical O 0 5.963624971627723e-07
by O 0 5.006592829204237e-08
descent O 0 2.421631961624371e-06
for O 0 1.0426493446402674e-08
a O 0 1.0990731169613355e-07
mutation O 0 6.82956127207035e-08
in O 0 5.053912488506285e-08
the O 0 2.7814598979603034e-07
founder O 0 0.00014050021127332002
population O 0 1.620101528487794e-07
. O 0 2.969143906739191e-06

The O 0 4.957768169333576e-07
identification O 0 3.7447907175192086e-07
of O 0 8.115473804082285e-08
common O 0 1.1711299521266483e-06
BRCA1 O 0 0.00012872535444330424
and O 0 7.967472811287735e-06
BRCA2 O 0 2.5494151486782357e-05
mutations O 0 7.259499312795015e-08
will O 0 2.7493149978852216e-09
facilitate O 0 6.008263664369906e-09
carrier O 0 3.3303983855148545e-06
detection O 0 4.6660881025673007e-07
in O 0 5.1760920882770733e-08
French O 0 1.4409962204808835e-05
Canadian O 0 0.004697986412793398
breast B-Disease 1 0.9949740171432495
cancer I-Disease 1 0.9379732608795166
and O 0 0.13235732913017273
breast B-Disease 1 0.9997730851173401
/ I-Disease 1 0.9998176693916321
ovarian I-Disease 1 0.9999810457229614
cancer I-Disease 1 0.9998354911804199
families O 0 0.0006021985318511724
. O 0 0.00010891207057284191

Are O 0 1.1849947441078257e-06
Dp71 O 0 0.0005325477104634047
and O 0 4.848938260693103e-06
Dp140 O 0 0.00039418047526851296
brain O 0 0.0003231886657886207
dystrophin O 0 1.8631748389452696e-05
isoforms O 0 2.475439089266729e-07
related O 0 5.720823082810966e-06
to O 0 6.007877004776674e-07
cognitive B-Disease 0 0.0016017694724723697
impairment I-Disease 1 0.8063819408416748
in O 0 0.006309600081294775
Duchenne B-Disease 1 0.9996998310089111
muscular I-Disease 1 0.9996508359909058
dystrophy I-Disease 1 0.9995373487472534
? O 0 0.013299087062478065

Molecular O 0 0.00023673500982113183
study O 0 3.3724911645549582e-06
and O 0 2.515381538614747e-06
neuropsychological O 0 7.723222370259464e-05
analysis O 0 1.1959009782458452e-07
were O 0 1.552408512850434e-08
performed O 0 6.0332752127578715e-09
concurrently O 0 1.0316132836862835e-08
on O 0 2.225234311481472e-06
49 O 0 0.0005035827634856105
patients O 0 1.584578239999246e-05
with O 0 0.013356028124690056
Duchenne B-Disease 1 0.9999721050262451
muscular I-Disease 1 0.9999806880950928
dystrophy I-Disease 1 0.9999707937240601
( O 0 0.000851081742439419
DMD B-Disease 1 0.9999747276306152
) O 0 1.954704885065439e-06
in O 0 3.194138997741902e-08
order O 0 2.177636204692135e-08
to O 0 1.0446578713185772e-08
find O 0 2.2120891784993546e-08
a O 0 8.810048690577332e-09
molecular O 0 1.078976765711559e-06
explanation O 0 5.992141183241984e-08
for O 0 1.7601260893229664e-08
the O 0 6.758663744221849e-07
cognitive B-Disease 0 0.0013772196834906936
impairment I-Disease 0 0.008545567281544209
observed O 0 1.1477402495074784e-06
in O 0 2.326208232261706e-06
most O 0 1.4941701920179185e-05
DMD B-Disease 1 0.9998842477798462
patients O 0 0.00016264719306491315
. O 0 1.9586495909607038e-05

Complete O 0 2.851120598279522e-06
analysis O 0 4.5963724915054627e-07
of O 0 1.2846423480539215e-08
the O 0 1.194735972376293e-07
dystrophin O 0 6.927288632141426e-05
gene O 0 6.387804774021788e-07
was O 0 2.8300985377427423e-06
performed O 0 2.326435222244072e-08
to O 0 3.5381848562110463e-09
define O 0 9.379303556045215e-09
the O 0 4.564895572656269e-09
localization O 0 1.361729999871386e-07
of O 0 2.1210966316687063e-09
deletions O 0 6.854774028397514e-07
and O 0 1.7230931348422018e-07
duplications O 0 3.33159914589487e-06
in O 0 4.60002489433009e-08
relation O 0 1.0756854607052446e-07
to O 0 6.291444254458156e-09
the O 0 7.849300942552873e-08
different O 0 6.79005552228773e-07
DMD B-Disease 1 0.9994519352912903
promoters O 0 0.0003719186643138528
. O 0 8.402294042753056e-06

Qualitative O 0 9.378991308039986e-07
analysis O 0 2.617433949581027e-07
of O 0 1.2616707678603234e-08
the O 0 1.6275161840439978e-07
Dp71 O 0 0.00018031487707048655
transcript O 0 1.7218055290868506e-05
and O 0 2.458068593114149e-07
testing O 0 4.023002730946246e-08
for O 0 3.8428965565273643e-10
the O 0 6.548005471174179e-10
specific O 0 1.8148368918780022e-10
first O 0 5.097639643736329e-09
exon O 0 8.30377416605188e-07
of O 0 1.64263767032935e-08
Dp140 O 0 1.9579738363972865e-05
were O 0 5.805656044799434e-08
also O 0 4.4935084986263973e-08
carried O 0 2.659436120211467e-07
out O 0 6.802208076805982e-07
. O 0 2.753735770966159e-06

Neuropsychological O 0 0.0021212699357420206
analysis O 0 1.1919872122234665e-05
assessed O 0 1.5377641830127686e-05
verbal O 0 2.121261331922142e-06
and O 0 3.1195152132568182e-06
visuospatial O 0 0.0001911021099658683
intelligence O 0 2.3289820092031732e-05
, O 0 6.940882713024621e-07
verbal O 0 2.9438469937304035e-06
memory O 0 0.00039137748535722494
, O 0 9.235636184712348e-07
and O 0 3.071416472266719e-07
reading O 0 6.337374998111045e-07
skills O 0 2.547047415646375e-06
. O 0 2.92261006507033e-06

Comparison O 0 6.397702236426994e-06
of O 0 2.828750211847364e-07
molecular O 0 3.46059568983037e-05
and O 0 4.2148508327954914e-06
psychometric O 0 5.088706166134216e-05
findings O 0 1.6289552604575874e-06
demonstrated O 0 1.3372184639592888e-06
that O 0 4.0854985172700253e-08
deletions O 0 7.281686862370407e-07
and O 0 3.880598171690508e-07
duplications O 0 3.566866553228465e-06
that O 0 6.590386902871614e-08
were O 0 3.075595600421366e-08
localized O 0 1.7217067238561867e-07
in O 0 2.734406656657029e-08
the O 0 1.0073473077909512e-07
distal O 0 8.77605561981909e-05
part O 0 3.3797562082327204e-08
of O 0 8.470360413070921e-09
the O 0 9.222594599123113e-08
gene O 0 1.741295676538357e-07
seemed O 0 1.0471674158907263e-06
to O 0 5.130551095078317e-09
be O 0 7.446321781401366e-09
preferentially O 0 9.711038728710264e-07
associated O 0 1.2288503512536408e-06
with O 0 3.6900009945384227e-06
cognitive B-Disease 0 0.0008850147132761776
impairment I-Disease 0 0.0386352576315403
. O 0 3.197717524017207e-05

Two O 0 1.1249733233853476e-06
altered O 0 5.506317029357888e-05
Dp71 O 0 0.0004133294860366732
transcripts O 0 2.73230853053974e-06
and O 0 5.3511865161226524e-08
two O 0 6.299249122321271e-09
deleted O 0 7.672709756434415e-08
Dp140 O 0 2.623208956720191e-07
DNA O 0 3.5210405258112587e-07
sequences O 0 6.583828593420549e-08
were O 0 1.6394956503518188e-07
found O 0 5.32477088199812e-07
in O 0 1.886299259012958e-07
four O 0 1.1071774679294322e-05
patients O 0 5.05830321344547e-05
with O 0 0.0030463384464383125
severe O 1 0.9596014022827148
cerebral B-Disease 1 0.9992559552192688
dysfunction I-Disease 1 0.9837892055511475
. O 0 0.000331824499880895

These O 0 2.457288474033703e-06
findings O 0 1.0279156413162127e-05
suggest O 0 7.515534434787696e-07
that O 0 3.3055711501361884e-09
some O 0 7.77499592485853e-11
sequences O 0 5.514523060412557e-09
located O 0 9.102461895338365e-09
in O 0 1.1799811794332982e-08
the O 0 8.872057577491432e-08
distal O 0 4.1142735426547006e-05
part O 0 1.8977926785623822e-08
of O 0 5.406460168444482e-09
the O 0 5.635950017790492e-08
gene O 0 2.66692865125151e-07
and O 0 4.785770215676166e-07
, O 0 1.787371104455815e-07
in O 0 2.0235333408891165e-08
particular O 0 1.049012698928209e-08
, O 0 9.01483190318686e-08
some O 0 9.235089137860086e-09
DMD B-Disease 1 0.7685937881469727
isoforms O 0 2.2438666036350696e-08
expressed O 0 7.764425902223593e-08
in O 0 8.768143544557461e-08
the O 0 6.1647638176509645e-06
brain O 0 0.3511004149913788
may O 0 4.8069482545543e-06
be O 0 3.344288757034519e-08
related O 0 6.012680273670412e-07
to O 0 3.776451151793481e-08
the O 0 1.1115234883618541e-06
cognitive B-Disease 0 0.003980483394116163
impairment I-Disease 0 0.1735990345478058
associated O 0 1.2021461770928e-05
with O 0 0.00027734131435863674
DMD B-Disease 1 0.9998762607574463
. O 0 6.3490483626083005e-06
. O 0 1.0059463420475367e-05

I1307K O 0 0.0010762494057416916
APC O 0 0.0006915899575687945
and O 0 1.6733147276681848e-05
hMLH1 O 0 0.0008735423907637596
mutations O 0 2.4004139049793594e-06
in O 0 1.0842131814570166e-07
a O 0 1.6913132583340484e-07
non O 0 9.255526833840122e-07
- O 0 0.0011522157583385706
Jewish O 0 3.0600920126744313e-06
family O 0 6.66730193188414e-05
with O 0 2.871624928957317e-06
hereditary B-Disease 0 0.19025321304798126
non I-Disease 0 0.007710678968578577
- I-Disease 1 0.9998759031295776
polyposis I-Disease 1 0.9998052716255188
colorectal I-Disease 1 0.9999812841415405
cancer I-Disease 1 0.9996620416641235
. O 0 0.0006195710739120841

We O 0 1.408109710610006e-06
describe O 0 7.900351306489029e-07
a O 0 1.0741785416712446e-07
French O 0 3.1641168334317626e-06
Canadian O 0 1.5673114830860868e-05
hereditary B-Disease 0 0.17575177550315857
non I-Disease 0 0.02651997283101082
- I-Disease 1 0.9999309778213501
polyposis I-Disease 1 0.9999539852142334
colorectal I-Disease 1 0.9999974966049194
cancer I-Disease 1 0.999981164932251
( O 0 0.0007581879617646337
HNPCC B-Disease 1 0.9690759181976318
) O 0 1.2654416423174553e-05
kindred O 0 0.00010388233204139397
which O 0 2.0367417619127082e-07
carries O 0 5.138873575560865e-07
a O 0 6.874007851820352e-08
novel O 0 4.949284289068601e-07
truncating O 0 2.315826350240968e-05
mutation O 0 4.033202571918082e-07
in O 0 7.652218414477829e-07
hMLH1 O 0 0.0006986038060858846
. O 0 1.7426078557036817e-05

Interestingly O 0 5.6096356274792925e-05
, O 0 4.81070856039878e-07
the O 0 1.2869175236573938e-07
I1307K O 0 7.989395089680329e-05
APC O 0 0.000602578860707581
polymorphism O 0 7.24181008990854e-05
, O 0 1.6689308495188016e-06
associated O 0 1.6347587461496005e-07
with O 0 2.6555401433370207e-08
an O 0 2.3787707448263973e-07
increased O 0 2.6618758056429215e-05
risk O 0 0.0003256797499489039
of O 0 0.02940130978822708
colorectal B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999827146530151
, O 0 0.000330898241372779
is O 0 7.695205113122938e-07
also O 0 3.9420018538294244e-07
present O 0 4.4193647852353024e-08
in O 0 1.2344467847924534e-07
this O 0 1.6130806557157484e-07
family O 0 0.0001753137621562928
. O 0 6.221343937795609e-06

The O 0 1.3803083902530489e-06
I1307K O 0 0.00014486654254142195
polymorphism O 0 2.8208345611346886e-05
has O 0 8.277950200863415e-07
previously O 0 4.6657055463583674e-07
only O 0 3.898943390368004e-09
been O 0 1.931598916371513e-07
identified O 0 3.661679954802821e-07
in O 0 7.425475700983952e-08
individuals O 0 1.6372950994991697e-08
of O 0 1.7739242963443758e-08
self O 0 6.020614364388166e-06
- O 0 0.05817900225520134
reported O 0 0.00032398238545283675
Ashkenazi O 0 4.433561844052747e-05
Jewish O 0 2.908538135670824e-06
origins O 0 4.24074569309596e-05
. O 0 1.8316044588573277e-05

In O 0 1.5270519497789792e-06
addition O 0 3.9290196696128987e-07
, O 0 4.4908566110279935e-07
in O 0 1.1066290284134084e-07
this O 0 5.213684417526565e-08
family O 0 0.00011439487570896745
, O 0 1.320152932748897e-06
there O 0 4.7130921387861235e-08
appears O 0 3.0273527045210358e-06
to O 0 2.5401957870485603e-08
be O 0 1.1596792859336347e-08
no O 0 9.932741740215079e-09
relationship O 0 2.1304094843799248e-07
between O 0 2.8576916832889765e-08
the O 0 3.161571981991074e-08
I1307K O 0 1.2797637282346841e-05
polymorphism O 0 4.834389528696192e-07
and O 0 8.35646147834268e-08
the O 0 2.8635080084882247e-08
presence O 0 1.1954676892855787e-07
or O 0 3.502580341319117e-07
absence O 0 4.548020058336988e-07
of O 0 2.085333107970655e-06
cancer B-Disease 0 0.017820637673139572
. O 0 2.993921270899591e-06
. O 0 9.354040230391547e-06

Identification O 0 1.940022457347368e-06
of O 0 1.0659289984005227e-07
a O 0 2.1529911009565694e-07
novel O 0 3.287277081653883e-07
mutation O 0 2.1704789077148234e-08
of O 0 6.344696323878907e-09
the O 0 7.271056290392153e-08
CPO O 0 0.00016663418500684202
gene O 0 3.887561206283863e-08
in O 0 1.592266052341529e-08
a O 0 3.1511393672190025e-07
Japanese O 0 0.00020714032871183008
hereditary B-Disease 0 0.10487101972103119
coproporphyria I-Disease 0 0.4202333688735962
family O 0 0.0005616997950710356
. O 0 2.2540327336173505e-05

Hereditary B-Disease 1 0.9261922240257263
coproporphyria I-Disease 1 0.9940783977508545
( O 0 0.0012553940759971738
HCP B-Disease 1 0.9977045655250549
) O 0 6.538577872561291e-05
is O 0 2.688063204914215e-06
an O 0 2.3206788682728074e-05
autosomal B-Disease 1 0.9732317924499512
dominant I-Disease 1 0.9967358708381653
disease I-Disease 1 0.985072672367096
characterized O 0 0.008558246307075024
by O 0 4.302541128708981e-05
a O 0 0.010633320547640324
deficiency B-Disease 1 0.8623780012130737
of I-Disease 0 1.696045757171305e-07
coproporphyrinogen I-Disease 0 0.045492224395275116
oxidase I-Disease 0 1.7004011169774458e-05
( O 0 1.5622768501089013e-07
CPO O 0 0.0073510329239070415
) O 0 2.0693639726232504e-06
caused O 0 6.059653401280229e-07
by O 0 2.9874285267794676e-09
a O 0 1.491243395435049e-08
mutation O 0 6.691030307592882e-08
in O 0 2.2892622908443627e-08
the O 0 2.3114066038942838e-07
CPO O 0 0.0008753862930461764
gene O 0 1.938842160598142e-06
. O 0 4.543890099739656e-06

Only O 0 3.2197564792113553e-07
11 O 0 5.940006303717382e-06
mutations O 0 3.7110274320184544e-07
of O 0 7.868889539963675e-09
the O 0 9.094100761330992e-08
gene O 0 5.914913572269143e-07
have O 0 3.38839356572862e-07
been O 0 2.210753564213519e-06
reported O 0 0.0006975260912440717
in O 0 3.087849108851515e-05
HCP B-Disease 1 0.9885700345039368
patients O 0 1.7797856344259344e-05
. O 0 1.2100607818865683e-05

We O 0 6.20085529590142e-06
report O 0 5.29284761796589e-06
another O 0 8.266702167247786e-08
mutation O 0 7.785855871134117e-08
in O 0 4.8532875496221095e-08
a O 0 3.8631989696114033e-07
Japanese O 0 0.0002235446299891919
family O 0 0.0007900733617134392
. O 0 2.2753012672183104e-05

Polymerase O 0 0.0018522912869229913
chain O 0 0.0016687766183167696
reaction O 0 5.061440788267646e-06
- O 0 4.4251224608160555e-05
single O 0 9.00036596362952e-08
strand O 0 8.575557330914307e-06
conformational O 0 1.150979898056903e-07
polymorphism O 0 1.1486574180707976e-07
and O 0 3.866712727784716e-09
direct O 0 2.5647836632280985e-10
sequence O 0 2.8433422283313803e-09
analyses O 0 8.434830789383341e-08
demonstrated O 0 1.124718522760304e-07
a O 0 1.3939820853181573e-08
C O 0 3.2438877042295644e-06
to O 0 1.1089105633743657e-08
T O 0 4.928437192575075e-05
substitution O 0 8.765075332206607e-10
in O 0 1.8360238884795876e-09
exon O 0 1.4825543814822595e-07
1 O 0 2.6952435838722977e-09
of O 0 6.344705316685406e-10
the O 0 1.570288432617417e-08
CPO O 0 2.675912583072204e-05
gene O 0 5.841430450459484e-09
at O 0 1.2525831927234776e-08
nucleotide O 0 4.8164809918205265e-09
position O 0 7.357692055620646e-08
85 O 0 2.3278428784578864e-07
, O 0 7.410364588622542e-08
which O 0 7.028260995411983e-08
lies O 0 7.031304107840697e-07
in O 0 7.695188486422921e-09
the O 0 1.524887238701922e-08
putative O 0 7.291440397239057e-06
presequence O 0 5.967454126221128e-05
for O 0 1.1728921167630801e-09
targeting O 0 1.3260249431823468e-07
to O 0 5.072260833571818e-08
mitochondria O 0 5.047533704782836e-06
. O 0 2.851917315638275e-06

This O 0 2.896978514854709e-07
mutation O 0 2.476570273302059e-07
changes O 0 5.1739470485756556e-09
the O 0 1.1112559761272678e-09
codon O 0 3.001822124204523e-09
for O 0 5.69733482613799e-10
glutamine O 0 2.163081092021457e-08
to O 0 1.1102347929892176e-09
a O 0 2.8723023959287275e-09
termination O 0 1.8960835745929217e-07
codon O 0 4.839345368878867e-09
at O 0 3.654862013036109e-08
amino O 0 2.407610333321486e-09
acid O 0 1.048858599972391e-08
position O 0 2.2344920580508187e-08
29 O 0 1.3536392771129613e-06
. O 0 2.3373156636807835e-06

MaeI O 0 0.002566630020737648
restriction O 0 4.134164100833004e-06
analysis O 0 1.9518436147336615e-06
showed O 0 5.828211669722805e-06
two O 0 2.9706905380066928e-08
other O 0 3.255795988366117e-08
carriers O 0 5.366451318877807e-07
in O 0 3.997485720219629e-08
the O 0 3.060314668346109e-07
family O 0 0.0012242747470736504
. O 0 3.445878974162042e-05

The O 0 6.495272828033194e-06
C O 0 0.009827191941440105
- O 1 0.7325403094291687
T O 1 0.9409164786338806
mutation O 0 5.1634316378113e-07
is O 0 1.9418491703504515e-08
located O 0 1.15995364424748e-08
within O 0 5.693500115810934e-10
a O 0 3.150772442950256e-08
recently O 0 2.741781372606056e-06
proposed O 0 2.905352403104189e-08
putative O 0 8.706930998414464e-08
alternative O 0 4.2153747159545674e-10
translation O 0 7.427621850908395e-10
initiation O 0 3.1735327699067284e-09
codon O 0 1.5139269393671384e-08
( O 0 2.1160547092335946e-08
TIC O 0 0.0009236882324330509
- O 0 0.00010682918218662962
1 O 0 8.893489678030164e-08
) O 0 1.9418898489220737e-08
, O 0 1.2217505229727976e-08
supporting O 0 3.179969354505374e-08
that O 0 1.0477832290689548e-07
TIC O 0 0.002970266854390502
- O 0 0.00026034945040009916
1 O 0 1.2649699954181415e-07
is O 0 7.727575912497286e-09
the O 0 3.082978494717281e-08
real O 0 2.9581465241790283e-06
TIC O 0 0.0013775915140286088
rather O 0 1.0289779694971912e-08
than O 0 4.895150951256255e-08
TIC O 0 0.015549879521131516
- O 0 0.0003002428566105664
2 O 0 1.1071500694015413e-06
. O 0 2.157852492246093e-07
. O 0 1.8368887140240986e-06

Human B-Disease 0 1.0017093700298574e-05
complement I-Disease 0 0.00010035162995336577
factor I-Disease 0 0.16780900955200195
H I-Disease 1 0.9999589920043945
deficiency I-Disease 1 0.9995728135108948
associated O 0 0.003463213099166751
with O 1 0.8744276165962219
hemolytic B-Disease 1 0.9999536275863647
uremic I-Disease 1 0.9999300241470337
syndrome I-Disease 1 0.9997019171714783
. O 0 0.0004158388765063137

This O 0 2.562918837156758e-07
study O 0 1.057480503163788e-07
reports O 0 1.859654759073237e-07
on O 0 2.516564165944146e-07
six O 0 3.831735284620663e-06
cases O 0 5.910452728130622e-06
of O 0 0.00015383938443847
deficiency B-Disease 1 0.9803354740142822
in I-Disease 0 9.577696857832052e-08
the I-Disease 0 3.0429834652068166e-08
human I-Disease 0 1.4868497544284764e-08
complement I-Disease 0 1.170258112637157e-08
regulatory I-Disease 0 7.466668421329814e-07
protein I-Disease 0 4.332357548264554e-07
Factor I-Disease 0 2.0128916276007658e-06
H I-Disease 1 0.9820325970649719
( O 0 1.4473232567979721e-07
FH O 0 0.0014990316703915596
) O 0 3.705131490505664e-08
in O 0 1.502542978926158e-09
the O 0 2.2305008950951333e-09
context O 0 2.6540666553387382e-08
of O 0 8.81791834217438e-07
an O 0 0.051098473370075226
acute B-Disease 1 0.999788224697113
renal I-Disease 1 0.9999792575836182
disease I-Disease 1 0.9997268319129944
. O 0 0.00048305990640074015

Five O 0 9.067771316040307e-07
of O 0 5.0012101127094866e-08
the O 0 4.965414746038732e-07
cases O 0 5.58932867988915e-07
were O 0 2.6926559826279117e-07
observed O 0 7.640011290277471e-07
in O 0 3.880998065142194e-07
children O 0 4.012851150037022e-06
presenting O 0 0.00024606622173450887
with O 1 0.9760308265686035
idiopathic O 1 0.9999744892120361
hemolytic B-Disease 1 0.999984860420227
uremic I-Disease 1 0.9999831914901733
syndrome I-Disease 1 0.9999322891235352
( O 0 0.0008810984436422586
HUS B-Disease 1 0.999031662940979
) O 0 4.5519027480622754e-05
. O 0 1.6072213838924654e-05

Two O 0 6.905032137183298e-07
of O 0 1.864090251046946e-07
the O 0 1.262871705876023e-06
children O 0 4.153172085352708e-06
exhibited O 0 1.0161649697693065e-05
a O 0 2.5663197448011488e-05
homozygous O 1 0.5333738923072815
deficiency O 1 0.9897375702857971
characterized O 0 2.6582254577078857e-05
by O 0 1.1520648968144087e-07
the O 0 8.303933896058879e-08
absence O 0 8.00373243237118e-08
of O 0 1.1020530044092425e-09
the O 0 6.195771451444898e-09
150 O 0 6.035671162862855e-08
- O 0 1.9111013898509555e-05
kD O 0 1.2465312465792522e-05
form O 0 3.92147980754487e-10
of O 0 2.7286481962818243e-09
Factor O 0 5.578783657256281e-07
H O 0 0.4729105532169342
and O 0 5.8177722195296155e-08
the O 0 5.273207648315292e-09
presence O 0 1.1611246186760127e-08
, O 0 2.2520172393569737e-08
upon O 0 1.0921599624680312e-08
immunoblotting O 0 0.000151556683704257
, O 0 1.4882910903679658e-08
of O 0 8.32092283964414e-10
the O 0 1.1797493648657564e-08
42 O 0 3.2668876315256057e-07
- O 0 3.618048503994942e-05
kD O 0 7.391732651740313e-05
Factor O 0 2.9829152481397614e-07
H O 0 0.05093560740351677
- O 0 1.8380925439487328e-06
like O 0 5.942242253809127e-09
protein O 0 9.88999904194543e-09
1 O 0 4.287954435966412e-09
( O 0 2.7741884345289236e-09
FHL O 0 8.589782737544738e-06
- O 0 2.56456078204792e-05
1 O 0 4.426011912528338e-08
) O 0 9.918883492332498e-09
and O 0 1.542806238319372e-08
other O 0 2.6294122434933342e-08
FH O 0 0.0019379680743440986
- O 0 0.0002126321487594396
related O 0 1.787714950296504e-06
protein O 0 2.2561970070000825e-07
( O 0 3.364654332926875e-08
FHR O 0 8.098763646557927e-05
) O 0 3.855741326219686e-08
bands O 0 4.2952333956236544e-07
. O 0 3.384354386071209e-06

Southern O 0 6.89546459398116e-06
blot O 0 0.0001533256727270782
and O 0 3.674069546377723e-07
PCR O 0 4.338752205512719e-06
analysis O 0 8.055820899244281e-08
of O 0 8.342571078401306e-09
DNA O 0 7.795440069457982e-06
of O 0 7.0507915950202e-08
one O 0 5.232093940321647e-07
patient O 0 3.796445525949821e-06
with O 0 8.318728214362636e-05
homozygous O 0 0.09681904315948486
deficiency O 1 0.9071118235588074
ruled O 0 3.6649114463216392e-06
out O 0 2.6207153780433146e-08
the O 0 2.314238223277698e-08
presence O 0 1.1879413897020186e-08
of O 0 3.4666940429417537e-09
a O 0 3.6851648843594376e-08
large O 0 1.4038926110515604e-07
deletion O 0 1.0834178283403162e-06
of O 0 6.414589748260369e-09
the O 0 2.1216405343693623e-07
FH O 0 0.005856950301676989
gene O 0 3.5026125999593205e-08
as O 0 1.3561439082820925e-08
the O 0 7.581612067042443e-07
underlying O 0 0.007767067290842533
defect O 0 0.00645533436909318
for O 0 8.928508918870648e-07
the O 0 0.0005628968356177211
deficiency O 1 0.9526557326316833
. O 0 1.6557534763705917e-05

The O 0 4.5206562049315835e-07
other O 0 7.934134771403478e-08
four O 0 1.7336152495772694e-06
children O 0 2.235111423942726e-06
presented O 0 3.4150966712331865e-06
with O 0 2.4357779693673365e-05
heterozygous O 0 0.0256723053753376
deficiency O 1 0.9162009954452515
and O 0 1.6964531823759899e-06
exhibited O 0 1.902283088384138e-06
a O 0 7.352584674436002e-08
normal O 0 4.3909489022553316e-07
immunoblotting O 0 0.0012494218535721302
pattern O 0 2.8872718758066185e-06
of O 0 8.409252849617133e-09
proteins O 0 1.9794047290133676e-08
of O 0 8.878977553195e-09
the O 0 2.9955606350995367e-06
FH O 0 0.1744890809059143
family O 0 0.00011959196854149923
. O 0 7.4533104452711996e-06

Factor B-Disease 1 0.8058885335922241
H I-Disease 1 0.9997586607933044
deficiency I-Disease 1 0.9978618025779724
is O 0 4.473233161661483e-07
the O 0 3.1916789566821535e-07
only O 0 2.1419884888018714e-06
complement B-Disease 1 0.9807989597320557
deficiency I-Disease 1 0.9999063014984131
associated O 0 1.8263195670442656e-05
with O 0 4.998407166567631e-05
HUS B-Disease 1 0.9981051683425903
. O 0 7.966328848851845e-05

These O 0 4.88617729388352e-07
observations O 0 1.443139012735628e-06
suggest O 0 3.349201733726659e-07
a O 0 1.1837659741331663e-08
role O 0 8.78067893950174e-08
for O 0 2.4147402655216865e-07
FH O 0 0.0068613337352871895
and O 0 8.42174358695047e-07
/ O 0 3.7873469409532845e-06
or O 0 2.672945242920832e-07
FH O 0 0.00030294916359707713
receptors O 0 1.7006098573801864e-07
in O 0 2.123271514165026e-08
the O 0 4.90091565552575e-07
pathogenesis O 0 0.02140967920422554
of O 0 2.0488238078542054e-05
idiopathic O 1 0.9986600875854492
HUS B-Disease 1 0.9982043504714966
. O 0 1.0067535185953602e-05
. O 0 9.88369356491603e-06

Further O 0 1.4504877299259533e-06
evidence O 0 7.965717259139637e-07
for O 0 2.129204546008623e-08
a O 0 4.577531242944133e-08
major O 0 3.593103485854954e-07
ancient O 0 1.6678564861649647e-05
mutation O 0 0.0004189304308965802
underlying O 1 0.9881656169891357
myotonic B-Disease 1 0.9999853372573853
dystrophy I-Disease 1 0.9999703168869019
from O 0 1.0452693459228612e-05
linkage O 0 0.0014867314603179693
disequilibrium O 0 0.02577143907546997
studies O 0 6.978542614888283e-07
in O 0 4.514598472837861e-08
the O 0 1.237089009009651e-07
Japanese O 0 1.843925019784365e-05
population O 0 1.9070841972279595e-07
. O 0 3.748463996089413e-06

The O 0 0.366142213344574
myotonic B-Disease 1 0.9997586607933044
dystrophy I-Disease 1 0.9999208450317383
( O 0 0.022432101890444756
DM B-Disease 1 0.9998890161514282
) O 0 4.318090941524133e-05
mutation O 0 2.1630457922583446e-06
is O 0 2.6269066211170866e-07
an O 0 6.049813805475424e-07
unstable O 0 0.1272915154695511
( O 0 3.973692344061419e-07
CTG O 0 0.0009507803479209542
) O 0 2.878194607092155e-07
n O 0 6.835145541117527e-06
repeat O 0 2.3072627755027497e-06
, O 0 1.2299203433485673e-07
present O 0 9.668971401310955e-09
at O 0 7.534099921713278e-08
a O 0 2.2999313564753265e-09
copy O 0 3.238362111801507e-08
number O 0 8.128907963422805e-11
of O 0 7.926306833105912e-10
5 O 0 2.5010194804053754e-07
- O 0 4.163635094300844e-05
37 O 0 1.330403733845742e-07
repeats O 0 9.453429328232232e-08
on O 0 1.917776870641319e-08
normal O 0 2.105177365763211e-08
chromosomes O 0 5.713276891583519e-07
but O 0 4.265163777716907e-09
amplified O 0 2.4038671497805808e-08
to O 0 5.670264813240067e-10
50 O 0 2.518009800667187e-09
- O 0 3.7672893995477352e-06
3000 O 0 9.481306619818497e-07
copies O 0 1.5336266301346768e-07
on O 0 1.138127572630765e-05
DM B-Disease 1 0.9994803071022034
chromosomes O 0 0.0002981394645757973
. O 0 1.1230245945625938e-05

Previous O 0 1.5605923181283288e-05
findings O 0 7.650475708942395e-06
in O 0 8.721721656002046e-07
Caucasian O 0 0.00012093090481357649
populations O 0 3.3165872537210817e-07
of O 0 7.318627837094027e-08
a O 0 5.96018617216032e-05
DM B-Disease 1 0.9999756813049316
founder O 0 0.13693810999393463
chromosome O 0 0.00022372865350916982
raise O 0 2.7710493100130407e-07
a O 0 3.430191952702444e-08
question O 0 2.4662204722858405e-08
about O 0 8.36216518251831e-09
the O 0 2.0530718458644515e-08
molecular O 0 2.157232302124612e-06
events O 0 1.4909880974300904e-07
involved O 0 7.096312515386671e-08
in O 0 1.9906458703644603e-08
the O 0 3.7071956171530474e-08
expansion O 0 2.7482160476210993e-06
mutation O 0 7.149077418944216e-07
. O 0 4.320105745136971e-06

To O 0 7.12674989244988e-07
investigate O 0 5.75840658711968e-06
whether O 0 3.983405747476354e-07
a O 0 2.4676162979631044e-07
founder O 0 0.00015323080879170448
chromosome O 0 1.941081245604437e-05
for O 0 3.9403627027922994e-08
the O 0 4.148865173192462e-06
DM B-Disease 1 0.9998472929000854
mutation O 0 5.152609219294391e-07
exists O 0 3.240536727844301e-08
in O 0 4.607732417838406e-09
the O 0 2.8378119409921965e-08
Japanese O 0 5.827750555909006e-06
population O 0 1.9322467181837055e-08
, O 0 1.658024473272235e-07
we O 0 7.523961187416717e-08
genotyped O 0 7.698252011323348e-05
families O 0 2.2156616097390724e-08
using O 0 4.228938532691018e-09
polymorphic O 0 8.664964070703718e-07
markers O 0 1.250428340426879e-05
near O 0 1.4609095160267316e-06
the O 0 1.705924717043672e-07
( O 0 5.846483119853474e-08
CTG O 0 0.0001264475577045232
) O 0 8.261721262670108e-08
n O 0 3.205074108336703e-06
repeat O 0 2.46144463744713e-06
region O 0 1.3780314134237415e-07
and O 0 2.9493784836631676e-07
constructed O 0 2.1438056137412786e-05
haplotypes O 0 0.0002422901161480695
. O 0 7.1404633672500495e-06

Six O 0 6.652522870354005e-07
different O 0 6.010260733546602e-08
haplotypes O 0 0.00013549545838031918
were O 0 1.2313138313402305e-06
found O 0 2.8308788841968635e-06
and O 0 8.347766197402962e-06
DM B-Disease 1 0.9984503984451294
alleles O 0 7.048437282719533e-07
were O 0 3.861784421133052e-07
always O 0 9.357637509310734e-07
haplotype O 0 5.2520132157951593e-05
A O 0 2.617171958263498e-06
. O 0 1.2742347280436661e-05

To O 0 7.060075972731283e-07
find O 0 6.330633937068342e-07
an O 0 1.283248973749096e-08
origin O 0 2.0136077694132837e-08
of O 0 5.1262176725686e-09
the O 0 2.3043196506478125e-07
( O 0 1.1228623009174044e-07
CTG O 0 9.269791189581156e-05
) O 0 5.447775208722305e-08
n O 0 1.532566784590017e-06
repeat O 0 1.7195341683873266e-07
mutation O 0 5.407017056313634e-09
and O 0 1.34207098767547e-08
to O 0 2.110479124795006e-09
investigate O 0 6.990839551690442e-08
the O 0 3.1986304716014047e-09
mechanism O 0 2.2013143308186045e-08
of O 0 1.0629312985344086e-09
the O 0 6.57037801943261e-09
expansion O 0 1.1739295047163978e-07
mutation O 0 7.969895854387232e-09
in O 0 3.2026474805491034e-09
the O 0 1.0869064759333469e-08
Japanese O 0 1.1701218909365707e-06
population O 0 6.037315980478297e-09
we O 0 3.415565830167111e-09
have O 0 4.906802741899696e-10
studied O 0 1.928276871510093e-09
90 O 0 1.3770534934565148e-08
Japanese O 0 1.1360065400367603e-05
DM B-Disease 1 0.9993757605552673
families O 0 3.7443979294948804e-07
comprising O 0 2.1544467543321844e-08
190 O 0 9.98505583993392e-07
affected O 0 5.43031539734784e-08
and O 0 3.13530534867823e-08
130 O 0 8.401944455727062e-07
unaffected O 0 7.763323083054274e-06
members O 0 5.6537256654110024e-08
. O 0 2.2501083094539354e-06

The O 0 7.666544661333319e-06
results O 0 1.4762811588298064e-05
suggest O 0 1.4323891264211852e-06
that O 0 6.629305460137402e-08
a O 0 4.084640892187963e-08
few O 0 6.650975592492614e-08
common O 0 1.0428585994759487e-07
ancestral O 0 1.868726576503832e-05
mutations O 0 6.3499889790819e-08
in O 0 1.1413126443926558e-08
both O 0 2.611792915274691e-08
Caucasian O 0 4.047200127388351e-05
and O 0 5.259424256109924e-07
Japanese O 0 6.094651780585991e-06
populations O 0 3.2372383884649025e-07
have O 0 3.9759811443218496e-08
originated O 0 1.0563979202515839e-07
by O 0 5.221433951874133e-09
expansion O 0 4.641367823410292e-08
of O 0 1.073278577123915e-09
an O 0 9.215557206232461e-09
ancestral O 0 3.359845868544653e-05
n O 0 1.5959663869580254e-05
= O 0 3.1559382023260696e-06
5 O 0 8.618283864336718e-09
repeat O 0 5.6236981293977806e-08
to O 0 3.1452644932983276e-09
n O 0 1.479355546507577e-06
= O 0 1.2065173677910934e-06
19 O 0 6.582635592167208e-08
- O 0 2.1872034267289564e-05
37 O 0 3.582462682061305e-07
copies O 0 2.9938561851849954e-07
. O 0 2.4907469651225256e-06

These O 0 9.420219981848277e-08
data O 0 1.3865921744127263e-07
support O 0 1.9036475507050454e-08
multistep O 0 8.533083928341512e-07
models O 0 6.336873639156693e-07
of O 0 2.3554216355137214e-08
triplet O 0 0.000520905654411763
repeat O 0 1.015760972222779e-05
expansion O 0 7.917352036201919e-07
that O 0 5.236407218944805e-08
have O 0 3.328423092696653e-09
been O 0 5.775490308224107e-09
proposed O 0 1.768316693073757e-08
for O 0 4.770938755171983e-09
both O 0 8.520106007381401e-07
DM B-Disease 1 0.9998799562454224
and O 0 6.16995312157087e-05
Friedreichs B-Disease 0 0.06235869601368904
ataxia I-Disease 0 0.052844107151031494
. O 0 4.045721198053798e-06
. O 0 8.866617463354487e-06

The O 0 4.001579156920343e-07
molecular O 0 4.0856148189050145e-06
basis O 0 4.4426488443605194e-07
of O 0 0.0004687226319219917
C6 B-Disease 1 0.9999837875366211
deficiency I-Disease 1 0.9999333620071411
in O 0 1.454325797567435e-07
the O 0 8.095375392258575e-08
western O 0 7.863797691243235e-06
Cape O 0 0.00015586652443744242
, O 0 1.1565776958377683e-06
South O 0 9.879962817649357e-06
Africa O 0 4.136700226808898e-06
. O 0 1.0580207572274958e-06

Deficiency B-Disease 1 0.976885199546814
of I-Disease 0 1.0427213226193999e-07
the I-Disease 0 9.343951745677259e-08
sixth I-Disease 0 1.7219906567333965e-06
component I-Disease 0 1.5808598163857823e-07
of I-Disease 0 6.863550172653277e-09
human I-Disease 0 2.3621160138986852e-08
complement I-Disease 0 7.302035243128557e-08
( O 0 7.661157042093691e-08
C6 O 0 0.08860571682453156
) O 0 5.810563834529603e-07
has O 0 4.22610639816412e-07
been O 0 5.786287715636718e-07
reported O 0 3.1385210604639724e-05
in O 0 1.5369408856713562e-08
a O 0 5.8869309427223016e-09
number O 0 6.670228813732137e-10
of O 0 1.1415237644030185e-08
families O 0 2.0618394103166793e-07
from O 0 5.056049801055451e-09
the O 0 1.2592690445956123e-08
western O 0 2.1065666260255966e-06
Cape O 0 3.0699266062583774e-05
, O 0 3.6952340565221675e-07
South O 0 2.718649739108514e-06
Africa O 0 4.205070581519976e-06
. O 0 2.1049540919193532e-06

Meningococcal B-Disease 1 0.9960283041000366
disease I-Disease 1 0.9909838438034058
is O 0 8.876158972270787e-05
endemic O 0 0.004542729817330837
in O 0 4.93064192141901e-07
the O 0 8.833472975311452e-07
Cape O 0 9.781878907233477e-05
and O 0 1.0907552194794334e-07
almost O 0 3.413442639654818e-09
all O 0 5.934344682323456e-10
pedigrees O 0 3.080902843066724e-06
of O 0 5.029348812968237e-07
total O 0 0.03777448087930679
C6 B-Disease 1 0.9999929666519165
deficiency I-Disease 1 0.9999823570251465
( O 0 8.165575877683295e-07
C6Q0 O 0 0.048816487193107605
) O 0 3.057365347558516e-07
have O 0 3.0426935637706265e-08
been O 0 1.0017755158742148e-07
ascertained O 0 1.970219727809308e-06
because O 0 1.3090485140310193e-07
of O 0 9.140267707152816e-07
recurrent O 1 0.6379808783531189
disease O 0 0.2182416170835495
. O 0 5.9436009905766696e-05

We O 0 8.795744861345156e-07
have O 0 2.6589560775391874e-08
sequenced O 0 1.415192230069806e-07
the O 0 1.0669130467988452e-08
expressed O 0 7.334527207802921e-09
exons O 0 2.745428062667088e-08
of O 0 4.2166954372646615e-09
the O 0 1.5081577942055446e-07
C6 O 0 0.047800660133361816
gene O 0 1.247851457719662e-07
from O 0 7.136351065639701e-09
selected O 0 1.3691074940425096e-08
cases O 0 8.087381075938538e-08
and O 0 5.837389949192584e-07
have O 0 8.471219814509823e-08
found O 0 4.262791719611414e-07
three O 0 9.379017456012662e-07
molecular O 0 0.1967678964138031
defects O 1 0.9006003737449646
leading O 0 1.159110433945898e-05
to O 0 1.918433781611384e-06
total O 0 0.0009405566961504519
deficiency O 1 0.695250928401947
879delG O 0 0.0010593457845970988
, O 0 1.2310414376770495e-06
which O 0 4.4475154936662875e-07
is O 0 3.293464345688335e-08
the O 0 1.1803125232745515e-07
common O 0 3.944802756450372e-06
defect O 0 0.0003631080617196858
in O 0 4.3590887344180373e-08
the O 0 3.4466143006284256e-07
Cape O 0 4.019165498903021e-05
and O 0 4.606583843269618e-07
hitherto O 0 1.9179487935616635e-06
unreported O 0 1.4824712479821756e-06
, O 0 6.653157669234133e-08
and O 0 1.256994721643423e-07
1195delC O 0 8.995232747111004e-06
and O 0 2.912399850174552e-07
1936delG O 0 3.0677176255267113e-05
, O 0 2.2789770071085513e-07
which O 0 4.908024209271389e-08
have O 0 1.978049724016273e-08
been O 0 1.1372224406613896e-07
previously O 0 1.4861176396152587e-06
reported O 0 2.1253526938380674e-05
in O 0 6.180901124253069e-08
African O 0 2.914974629675271e-06
- O 0 0.001251258421689272
Americans O 0 3.5246862353233155e-06
. O 0 2.9901632387918653e-06

We O 0 3.2600019039819017e-06
also O 0 1.85728694646059e-07
show O 0 9.281995261289921e-08
that O 0 8.561873876544723e-09
the O 0 2.575090007894687e-08
879delG O 0 0.0006207769038155675
and O 0 1.1833339158329181e-05
1195delC O 1 0.5412237644195557
defects O 1 0.6499364972114563
are O 0 1.0618478540891374e-08
associated O 0 8.265472928314921e-08
with O 0 8.318058064560319e-08
characteristic O 0 9.756982763065025e-06
C6 O 1 0.6420325040817261
/ O 0 0.00019689624605234712
C7 O 0 0.05590515211224556
region O 0 1.6415373238487518e-06
DNA O 0 2.73299592663534e-05
marker O 0 2.359614154556766e-05
haplotypes O 0 0.00013297698751557618
, O 0 5.097020334687841e-07
although O 0 2.9075698293468122e-08
small O 0 2.127767473325548e-08
variations O 0 7.253395750694835e-08
were O 0 1.9597543143845542e-07
observed O 0 3.060912149521755e-06
. O 0 6.9060602072568145e-06

The O 0 7.797961188771296e-06
1936delG O 0 0.05140746757388115
defect O 0 0.0338396355509758
was O 0 1.672909638728015e-05
observed O 0 2.950312705252145e-07
only O 0 3.296479533787533e-09
once O 0 9.775843778925264e-08
in O 0 1.5567495736945602e-08
the O 0 2.8043419320056273e-07
Cape O 0 0.00034170428989455104
, O 0 3.2109375069921953e-07
but O 0 6.575972122391249e-08
its O 0 1.448327111575054e-07
associated O 0 2.9381508284131996e-06
haplotype O 0 0.00014773615112062544
could O 0 2.0168543812815187e-07
be O 0 2.241205976361016e-08
deduced O 0 2.0949428289895877e-06
. O 0 1.462368913962564e-06

The O 0 5.472060138345114e-07
data O 0 4.128557520743925e-06
from O 0 9.822008451010333e-08
the O 0 1.9829573716378945e-07
haplotypes O 0 9.549164678901434e-05
indicate O 0 2.3443985242010967e-07
that O 0 1.1481290584924864e-08
these O 0 2.8184452549595562e-09
three O 0 9.76736032498593e-07
molecular O 0 0.11966176331043243
defects O 1 0.6846230030059814
account O 0 4.2049558146572963e-07
for O 0 1.0307541487009075e-07
the O 0 1.983522088266909e-05
defects O 1 0.8402535915374756
in O 0 3.4298910378538494e-08
all O 0 8.123147154925903e-10
the O 0 7.03794640344313e-08
38 O 0 6.0036777540517505e-06
unrelated O 0 0.0008460733806714416
C6Q0 O 0 0.3874985873699188
individuals O 0 3.1338466044417146e-08
we O 0 6.468082069943648e-09
have O 0 2.9827369463220066e-09
studied O 0 1.1821189360716744e-08
from O 0 1.6041973083247285e-08
the O 0 7.099141043909185e-07
Cape O 0 0.0001290658110519871
. O 0 5.917570433666697e-06

We O 0 2.5338770228700014e-06
have O 0 1.284522852529335e-07
also O 0 2.2704206514845282e-08
observed O 0 2.8535959373243713e-08
the O 0 1.1894835694192807e-07
879delG O 0 0.002730721142143011
defect O 0 5.549834168050438e-05
in O 0 8.183473454437262e-09
two O 0 1.9548041052530607e-07
Dutch O 0 0.010196409188210964
C6 B-Disease 1 0.9999589920043945
- I-Disease 1 0.9981258511543274
deficient I-Disease 1 0.999518632888794
kindreds O 0 0.00031427733483724296
, O 0 1.1068654259815958e-07
but O 0 1.5398457620108275e-08
the O 0 6.332548707632668e-08
879delG O 0 0.003129703691229224
defect O 0 0.0001375025894958526
in O 0 1.2831877782559786e-08
the O 0 2.9548911584242887e-07
Cape O 0 0.0003263912512920797
probably O 0 3.6518979413813213e-06
did O 0 4.915828810680978e-08
not O 0 1.5704824107842796e-09
come O 0 3.354176270065068e-09
from O 0 1.058428011901924e-09
The O 0 2.8570159571472686e-08
Netherlands O 0 1.1037553122150712e-05
. O 0 3.5293544442538405e-07
. O 0 1.6179149042727659e-06

Complement B-Disease 0 0.23015041649341583
C7 I-Disease 1 0.9997732043266296
deficiency I-Disease 1 0.9998225569725037
: O 0 3.4933373171952553e-06
seven O 0 6.235328555703745e-07
further O 0 1.2335423207332497e-06
molecular O 0 0.07504899054765701
defects O 1 0.8798997402191162
and O 0 8.32665989491943e-07
their O 0 4.759902196838084e-07
associated O 0 1.2022895134577993e-05
marker O 0 4.375439675641246e-05
haplotypes O 0 0.0003822848084382713
. O 0 1.8354898202233016e-05

Seven O 0 4.062978860019939e-07
further O 0 3.546889715266843e-08
molecular O 0 4.526839802565519e-06
bases O 0 1.535823685117066e-05
of O 0 0.003264087252318859
C7 B-Disease 1 0.9999730587005615
deficiency I-Disease 1 0.9999258518218994
are O 0 5.713505402127339e-07
described O 0 0.000127732491819188
. O 0 1.1113561413367279e-05

All O 0 8.166325926595164e-08
these O 0 3.0164247988295756e-08
new O 0 8.275171694549499e-07
molecular O 0 0.0020641859155148268
defects O 0 0.03217159956693649
involve O 0 4.5234937573468414e-08
single O 0 4.554722110583498e-08
- O 0 5.8470192016102374e-05
nucleotide O 0 5.7088598737209395e-08
events O 0 4.137853082397669e-08
, O 0 3.98538091417322e-08
deletions O 0 2.0955151569523878e-07
and O 0 4.244455809043757e-08
substitutions O 0 3.719611996189087e-08
, O 0 6.905481342300845e-08
some O 0 1.2117676306822034e-10
of O 0 1.2231745616375633e-09
which O 0 3.095021483545679e-08
alter O 0 8.470144052807882e-07
splice O 0 8.452644578937907e-06
sites O 0 3.3670110610728443e-07
, O 0 3.281986096226319e-07
and O 0 1.731378489466806e-07
others O 0 2.7469320684758713e-07
codons O 0 1.0680246305128094e-06
. O 0 1.157919768957072e-06

They O 0 2.9816638402735407e-07
are O 0 4.2084198348391055e-09
distributed O 0 9.561594183082889e-09
along O 0 8.881009705419274e-09
the O 0 6.877142766370525e-08
C7 O 0 0.02142350934445858
gene O 0 2.6069412228935107e-07
, O 0 6.903479032871473e-08
but O 0 5.205791797635584e-09
predominantly O 0 6.519616513323001e-10
towards O 0 4.9394826007187476e-09
the O 0 3.2326475718491565e-08
3 O 0 5.994570528855547e-07
end O 0 8.300263289129362e-06
. O 0 3.4838685678550974e-06

All O 0 1.1884358741554024e-07
were O 0 1.2495644341470324e-06
found O 0 2.504385065549286e-06
in O 0 1.6579944883687858e-07
compound O 0 2.0016786947962828e-05
heterozygous O 0 2.758714344963664e-06
individuals O 0 2.2995382664703357e-07
. O 0 3.847594598482829e-06

The O 0 2.1765123165096156e-05
C6 O 1 0.6840097904205322
/ O 0 0.00558392284438014
C7 O 1 0.6912517547607422
marker O 0 0.0008158187265507877
haplotypes O 0 0.0008207138162106276
associated O 0 3.038013346667867e-06
with O 0 6.792911904085486e-07
most O 0 7.771175660309382e-06
C7 B-Disease 1 0.9996089339256287
defects I-Disease 1 0.9764257073402405
are O 0 1.513994050128531e-07
tabulated O 0 0.0014349586563184857
. O 0 1.7343792251267587e-06
. O 0 8.138605153362732e-06

A O 0 1.068188066710718e-05
genome O 0 6.212681910255924e-05
- O 0 7.735899998806417e-05
wide O 0 1.754218317273626e-07
search O 0 1.3747380478434934e-07
for O 0 2.799309939405248e-08
chromosomal O 0 0.00025242316769436
loci O 0 5.647750185744371e-06
linked O 0 0.0022679597605019808
to O 0 7.463440852006897e-05
mental O 0 0.16703912615776062
health O 0 2.1115803974680603e-05
wellness O 0 0.00035683231544680893
in O 0 1.808782940315723e-06
relatives O 0 4.467357211979106e-05
at O 0 0.0004439537588041276
high O 0 0.03425958752632141
risk O 0 0.0016726545291021466
for O 0 0.00032124383142217994
bipolar B-Disease 1 0.9999821186065674
affective I-Disease 1 0.9998359680175781
disorder I-Disease 1 0.9541052579879761
among O 0 1.3580987001660105e-07
the O 0 1.9071589463237615e-07
Old O 0 3.292029578005895e-05
Order O 0 1.5362014664788148e-06
Amish O 0 0.004437230993062258
. O 0 2.0084613424842246e-05

Bipolar B-Disease 1 0.9988271594047546
affective I-Disease 1 0.9990691542625427
disorder I-Disease 1 0.9992687106132507
( O 0 0.007046817801892757
BPAD B-Disease 1 0.9998728036880493
; O 0 0.17306344211101532
manic B-Disease 1 0.9998390674591064
- I-Disease 1 0.999962329864502
depressive I-Disease 1 0.9999605417251587
illness I-Disease 1 0.9782946705818176
) O 0 1.5122670447453856e-05
is O 0 4.1558087104931474e-07
characterized O 0 5.451617653307039e-06
by O 0 4.133483244572744e-08
episodes O 0 1.3388144282089343e-07
of O 0 4.205782033750438e-07
mania B-Disease 1 0.9246088266372681
and O 0 2.5793926397454925e-05
/ O 0 0.0002148551429854706
or O 0 4.684994564740919e-06
hypomania B-Disease 0 0.0191968884319067
interspersed O 0 2.372298695263453e-06
with O 0 4.2920643750221643e-07
periods O 0 6.285239919634478e-07
of O 0 1.462371756133507e-06
depression B-Disease 0 0.010519343428313732
. O 0 4.212812928017229e-05

Compelling O 0 1.1343339792801999e-05
evidence O 0 6.119357294664951e-06
supports O 0 2.815344259943231e-06
a O 0 1.313564297333869e-07
significant O 0 4.4486093031537166e-08
genetic O 0 1.2861031564170844e-06
component O 0 5.784152108390117e-07
in O 0 6.673861463468711e-08
the O 0 1.6211029674195743e-07
susceptibility O 0 1.1916177754756063e-05
to O 0 5.691376827599015e-07
develop O 0 4.68601101601962e-05
BPAD B-Disease 1 0.998505711555481
. O 0 3.597244358388707e-05

To O 0 1.7665116729403962e-06
date O 0 6.324862624751404e-06
, O 0 1.0899727840296691e-06
however O 0 1.270216500870447e-07
, O 0 4.5984720031810866e-08
linkage O 0 1.5843098708501202e-06
studies O 0 4.651479557082894e-08
have O 0 2.4263369979848903e-08
attempted O 0 2.0572072116920026e-06
only O 0 7.490648656904852e-10
to O 0 7.2240258219835596e-09
identify O 0 4.199985994546296e-07
chromosomal O 0 0.0003126217925455421
loci O 0 1.8458903241480584e-06
that O 0 1.6544656773476163e-06
cause O 0 2.2878537038195645e-06
or O 0 2.3861707632022444e-07
increase O 0 4.2732928307032125e-08
the O 0 4.0478141727362527e-07
risk O 0 3.3286487450823188e-06
of O 0 1.593883212080982e-07
developing O 0 0.0003727762377820909
BPAD B-Disease 1 0.9990851879119873
. O 0 3.53922150679864e-05

To O 0 6.393180456143455e-07
determine O 0 1.1845744438687689e-06
whether O 0 3.4504421364545124e-07
there O 0 4.318142998727126e-08
could O 0 8.995903755248946e-08
be O 0 8.644625459908184e-09
protective O 0 1.931110318764695e-06
alleles O 0 3.132165034003265e-07
that O 0 2.49542068786468e-07
prevent O 0 2.6676332254282897e-06
or O 0 3.7769123650832626e-07
reduce O 0 8.564030622437713e-07
the O 0 8.997928802045863e-08
risk O 0 5.670746077157673e-07
of O 0 3.612488441717687e-08
developing O 0 4.363597327028401e-05
BPAD B-Disease 1 0.9988414645195007
, O 0 6.256474307519966e-07
similar O 0 8.046699662145329e-08
to O 0 2.7313049599797523e-08
what O 0 4.5842856621902683e-08
is O 0 5.0298805120974066e-08
observed O 0 1.8333972207074112e-07
in O 0 1.3646450724991155e-06
other O 0 0.00019082934886682779
genetic B-Disease 1 0.9999412298202515
disorders I-Disease 1 0.9999884366989136
, O 0 0.00027004731236957014
we O 0 1.1443528819654603e-05
used O 0 0.0003518749144859612
mental O 0 0.4941006600856781
health O 0 0.00040081256884150207
wellness O 0 0.007524562533944845
( O 0 3.398944272703375e-07
absence O 0 3.7925991591691854e-07
of O 0 2.5051420493582555e-07
any O 0 1.4856448615319096e-05
psychiatric B-Disease 1 0.9618712663650513
disorder I-Disease 1 0.780007541179657
) O 0 8.055665148276603e-07
as O 0 9.937366485246457e-09
the O 0 5.5854073366390367e-08
phenotype O 0 2.8851854949607514e-06
in O 0 4.187132063293575e-08
our O 0 8.159273079400009e-08
genome O 0 4.807704954146175e-06
- O 0 4.5035576476948336e-05
wide O 0 2.587635776762909e-07
linkage O 0 4.555739906209055e-06
scan O 0 1.8616240140545415e-06
of O 0 1.1098303387413466e-09
several O 0 3.525204350651734e-09
large O 0 3.525744602939085e-07
multigeneration O 0 0.0002890701871365309
Old O 0 1.4290626495494507e-06
Order O 0 3.971570095018251e-08
Amish O 0 7.514042954426259e-05
pedigrees O 0 1.2397300451993942e-05
exhibiting O 0 3.1299762781600293e-07
an O 0 6.492236082067393e-08
extremely O 0 1.274076657864498e-05
high O 0 0.00020872919412795454
incidence O 0 0.0003704925475176424
of O 0 3.6282647215557517e-06
BPAD B-Disease 1 0.9995180368423462
. O 0 3.0493270969600417e-05

We O 0 2.385966809015372e-06
have O 0 3.912925592430838e-07
found O 0 5.619381795440859e-07
strong O 0 4.184745350244157e-08
evidence O 0 2.2152649137296976e-07
for O 0 1.861394038904507e-09
a O 0 1.0771099567818965e-08
locus O 0 9.363940876028209e-07
on O 0 9.484323527431116e-06
chromosome O 0 0.05665798485279083
4p O 1 0.9344685077667236
at O 0 5.2394270824152045e-06
D4S2949 O 0 6.837955879746005e-06
( O 0 3.6196525776688304e-09
maximum O 0 1.0415759810200598e-08
GENEHUNTER O 0 0.0003418334817979485
- O 0 2.76710470643593e-05
PLUS O 0 1.1120923204543942e-07
nonparametric O 0 3.067014233693044e-07
linkage O 0 1.911075315774724e-07
score O 0 1.4765626055179837e-08
= O 0 4.281925214399962e-07
4 O 0 1.6191956220268366e-08
. O 0 3.8531662305274494e-09
05 O 0 9.215804084306001e-07
, O 0 8.60240731981321e-08
P O 0 3.437175473663956e-05
= O 0 3.8340130004144157e-07
5 O 0 5.156184812449283e-09
. O 0 2.5992532570739968e-09
22 O 0 6.161796761716687e-08
x O 0 1.7201396985910833e-05
10 O 0 8.556686026395255e-08
( O 0 9.042415705096118e-09
- O 0 2.315702658961527e-05
4 O 0 4.998349254492496e-07
) O 0 7.858108830305355e-08
; O 0 6.901346694121457e-08
SIBPAL O 0 5.200411396799609e-05
Pempirical O 0 5.501601208379725e-06
value O 0 3.92472143673217e-09
< O 0 7.467916418590903e-08
3 O 0 3.137806103836738e-08
x O 0 5.781406343885465e-06
10 O 0 4.2043943437874987e-08
( O 0 5.082096965480787e-09
- O 0 1.8005777747021057e-05
5 O 0 3.0317968935378303e-07
) O 0 7.527750511826525e-08
) O 0 2.3895770695503415e-08
and O 0 5.797810231911171e-08
suggestive O 0 6.324219725684088e-07
evidence O 0 4.043897305905375e-08
for O 0 8.442000987152198e-10
a O 0 1.4400874270847908e-08
locus O 0 1.0480725904926658e-06
on O 0 5.640107701765373e-06
chromosome O 0 0.013409612700343132
4q O 1 0.667675793170929
at O 0 1.337174944637809e-05
D4S397 O 0 2.286856761202216e-05
( O 0 7.396678380899857e-09
maximum O 0 1.3504909190942271e-08
GENEHUNTER O 0 0.00016478582983836532
- O 0 2.1252290025586262e-05
PLUS O 0 1.1448646830558573e-07
nonparametric O 0 2.523227919937199e-07
linkage O 0 3.108308987975761e-07
score O 0 1.2806594895664603e-08
= O 0 4.1598414668442274e-07
3 O 0 1.1420725698485512e-08
. O 0 5.5708495594331e-09
29 O 0 6.196246431500185e-07
, O 0 2.11121346183063e-07
P O 0 0.0002469777246005833
= O 0 8.937718121160287e-07
2 O 0 2.0917211074333864e-08
. O 0 1.0662559724039511e-08
57 O 0 2.1381278259013925e-07
x O 0 1.2057204003212973e-05
10 O 0 6.487544368383169e-08
( O 0 1.3485398575596719e-08
- O 0 1.8606087905936874e-05
3 O 0 2.547459985180467e-07
) O 0 5.315034812269914e-08
; O 0 3.581211771574999e-08
SIBPAL O 0 3.969154568039812e-05
Pempirical O 0 4.590940534399124e-06
value O 0 2.7721571704830694e-09
< O 0 4.587784374621151e-08
1 O 0 5.3423927504070434e-09
x O 0 1.0465570085216314e-05
10 O 0 4.4112464792078754e-08
( O 0 9.461740724248102e-09
- O 0 2.739420233410783e-05
3 O 0 5.197956625124789e-07
) O 0 5.581041051527791e-08
) O 0 1.926623660608584e-08
that O 0 2.1463135269073064e-08
are O 0 8.1458653156119e-09
linked O 0 6.630332063650712e-05
to O 0 1.53230666910531e-05
mental O 0 0.053310003131628036
health O 0 4.490357605391182e-05
wellness O 0 0.0009965483332052827
. O 0 1.5395457012346014e-05

These O 0 2.1836601717950543e-06
findings O 0 4.603159140970092e-06
are O 0 1.7831784049349153e-08
consistent O 0 5.567474659073923e-08
with O 0 7.662559653454082e-08
the O 0 1.748344260477097e-07
hypothesis O 0 9.987664952859632e-07
that O 0 1.8279775915175378e-08
certain O 0 1.834256302402082e-09
alleles O 0 7.927659595452496e-08
could O 0 5.242793008619628e-07
prevent O 0 1.387818883813452e-06
or O 0 7.222912756787991e-08
modify O 0 2.5175890527862066e-07
the O 0 9.898703723365543e-08
clinical O 0 3.830489845313423e-07
manifestations O 0 8.670634770169272e-07
of O 0 1.667718606768176e-06
BPAD B-Disease 1 0.9999221563339233
and O 0 4.05336068070028e-05
perhaps O 0 9.605172408555518e-07
other O 0 9.921420769387623e-07
related O 0 0.00898787472397089
affective B-Disease 1 0.9363458156585693
disorders I-Disease 1 0.9911786913871765
. O 0 0.00043240346712991595

Segregation O 0 0.020829498767852783
distortion O 1 0.5892395973205566
in O 0 0.07250161468982697
myotonic B-Disease 1 0.9990890026092529
dystrophy I-Disease 1 0.9994738698005676
. O 0 0.004432039335370064

Myotonic B-Disease 1 0.9988798499107361
dystrophy I-Disease 1 0.9996954202651978
( O 0 0.23206022381782532
DM B-Disease 1 0.9998552799224854
) O 0 0.00108935940079391
is O 0 7.667495083296672e-06
an O 0 2.614355253172107e-05
autosomal B-Disease 1 0.913224995136261
dominant I-Disease 1 0.849404513835907
disease I-Disease 1 0.540367841720581
which O 0 6.149672572064446e-06
, O 0 1.6099651247714064e-06
in O 0 5.2298990027566106e-08
the O 0 2.1833635344137292e-07
typical O 0 9.878201126412023e-06
pedigree O 0 0.0024939693976193666
, O 0 4.7651303702878067e-07
shows O 0 4.040065348931421e-08
a O 0 9.129881739511347e-09
three O 0 3.555586403081179e-08
generation O 0 4.022192115371581e-06
anticipation O 0 1.60188865265809e-05
cascade O 0 0.001134697929956019
. O 0 3.829572506219847e-06

This O 0 4.873453690379392e-06
results O 0 0.00021294581529218704
in O 0 0.0031121268402785063
infertility B-Disease 1 0.9997029900550842
and O 1 0.9992848038673401
congenital B-Disease 1 0.9999840259552002
myotonic I-Disease 1 0.9999891519546509
dystrophy I-Disease 1 0.9999876022338867
( O 0 0.00038396893069148064
CDM B-Disease 0 0.05279797315597534
) O 0 3.5533366826712154e-07
with O 0 2.3581634422953357e-08
the O 0 9.052325111724713e-08
disappearance O 0 0.0004856147861573845
of O 0 3.1466458949580556e-06
DM B-Disease 1 0.99986732006073
in O 0 1.0398687209089985e-06
that O 0 3.1262611628335435e-06
pedigree O 0 0.004014219157397747
. O 0 2.0240628145984374e-05

The O 0 1.400511990823361e-07
concept O 0 1.746442848116203e-07
of O 0 1.3656016051299957e-07
segregation O 0 0.00011090669431723654
distortion O 0 0.0008412007591687143
, O 0 6.925952220626641e-07
where O 0 8.001870099860753e-08
there O 0 4.257182606437482e-09
is O 0 2.4758055605644813e-09
preferential O 0 3.3870537485825025e-09
transmission O 0 3.837304802800645e-07
of O 0 5.23779020156212e-10
the O 0 3.3264302423674508e-09
larger O 0 2.630636330991365e-08
allele O 0 1.3258389230941248e-07
at O 0 4.549764298644732e-07
the O 0 1.2820057690987596e-06
DM B-Disease 1 0.999876856803894
locus O 0 3.943528645322658e-05
, O 0 5.323730078998778e-07
has O 0 2.051506697853256e-07
been O 0 2.292137324388932e-08
put O 0 3.326837827444251e-08
forward O 0 6.457863133135788e-09
to O 0 1.1094034135794573e-08
explain O 0 7.212861987682118e-07
partially O 0 1.514207610853191e-06
the O 0 2.433920087696606e-08
maintenance O 0 3.991211542597739e-06
of O 0 3.713314526976319e-07
DM B-Disease 1 0.9998868703842163
in O 0 1.7465396240368136e-07
the O 0 1.7880546465676161e-07
population O 0 3.341203580475849e-07
. O 0 3.445192078288528e-06

In O 0 1.8548631715020747e-06
a O 0 4.2236285935359774e-07
survey O 0 4.1786265683185775e-06
of O 0 5.661678414980997e-07
DM B-Disease 1 0.9997105002403259
in O 0 4.0650678556630737e-07
Northern O 0 2.2074618755141273e-07
Ireland O 0 5.872382757843297e-07
, O 0 6.134042109806614e-07
59 O 0 3.4272079574293457e-06
pedigrees O 0 1.1872608411067631e-05
were O 0 4.869672238783096e-07
ascertained O 0 1.3903933904657606e-05
. O 0 3.056390596611891e-06

Sibships O 0 0.006819451693445444
where O 0 1.5283762877515983e-06
the O 0 8.64527223143341e-08
status O 0 8.018810504495377e-09
of O 0 2.1422266183179772e-09
all O 0 5.320405227493552e-10
the O 0 8.050011324201023e-09
members O 0 1.5950838871958695e-08
had O 0 1.457056669096346e-06
been O 0 2.0801917344215326e-07
identified O 0 2.413069069007179e-07
were O 0 7.145615654735593e-08
examined O 0 5.06842184222478e-07
to O 0 5.9708158417492996e-09
determine O 0 2.142321697817806e-08
the O 0 4.438199585621305e-09
transmission O 0 1.921240482261055e-06
of O 0 2.1252123616477547e-08
the O 0 5.849633907928364e-06
DM B-Disease 1 0.9999217987060547
expansion O 0 1.9169165170751512e-05
from O 0 2.437242301311926e-07
affected O 0 6.539961106000192e-08
parents O 0 4.868685454795241e-09
to O 0 2.2585331382884988e-09
their O 0 5.02384018830071e-08
offspring O 0 5.41659619557322e-06
. O 0 3.3451617582613835e-06

Where O 0 1.9387664451642195e-06
the O 0 2.608214515475993e-07
transmitting O 0 0.00014321001071948558
parent O 0 4.6175584429875016e-05
was O 0 1.00316246971488e-05
male O 0 1.4816456541666412e-06
, O 0 2.1359828679123893e-06
58 O 0 1.4632011698267888e-05
. O 0 3.42295493283018e-06

3 O 0 2.601626329123974e-05
% O 0 1.8595501671825332e-07
of O 0 5.358926191689761e-09
the O 0 4.517251639413189e-08
offspring O 0 2.1392547751020174e-06
were O 0 4.7144274617494375e-07
affected O 0 2.674730410490156e-07
, O 0 2.3413039684783143e-07
and O 0 2.750948624452576e-07
in O 0 7.055849948756077e-08
the O 0 8.047251753851015e-08
case O 0 3.8866056684128125e-07
of O 0 8.570043341649125e-09
a O 0 9.734259265314904e-08
female O 0 9.692902267488535e-07
transmitting O 0 0.00023858195345383137
parent O 0 1.655698179092724e-05
, O 0 2.145627377103665e-06
68 O 0 2.3819791749701835e-05
. O 0 4.118694505450549e-06

7 O 0 0.00014474874478764832
% O 0 3.905684479832416e-06
were O 0 2.2478818664239952e-06
affected O 0 3.3089841053879354e-06
. O 0 3.890495008818107e-06

Studies O 0 6.063804107725446e-07
on O 0 5.490643388839089e-07
meiotic O 0 0.0016284347511827946
drive O 0 0.00025900511536747217
in O 0 1.1619592442002613e-05
DM B-Disease 1 0.9998165965080261
have O 0 2.3943727001096704e-07
shown O 0 9.196491390639494e-08
increased O 0 1.8694288783649426e-08
transmission O 0 3.997044473180722e-07
of O 0 6.27195961833138e-10
the O 0 3.589970765105477e-09
larger O 0 4.604220649184754e-08
allele O 0 2.98770402196169e-07
at O 0 4.355665055300051e-07
the O 0 5.468877475323097e-07
DM B-Disease 1 0.9994615912437439
locus O 0 1.0692134310374968e-05
in O 0 3.177829626110906e-07
non O 0 2.0643199150072178e-06
- O 0 0.10998715460300446
DM O 1 0.9996269941329956
heterozygotes O 0 2.7730802685255185e-05
for O 0 1.8592416495266662e-07
CTGn O 0 0.0005934226792305708
. O 0 3.03692991110438e-06

This O 0 3.506627876959101e-07
study O 0 6.093286941677434e-08
provides O 0 8.90987017498901e-09
further O 0 1.351299960816732e-08
evidence O 0 1.0535748629081354e-07
that O 0 9.488744723284981e-08
the O 0 1.1241024822084e-06
DM B-Disease 1 0.9997653365135193
expansion O 0 8.425475243711844e-06
tends O 0 2.793712781112845e-07
to O 0 1.5820181831216473e-09
be O 0 4.156186061976541e-09
transmitted O 0 1.7007332075991144e-07
preferentially O 0 9.059593253368803e-07
. O 0 2.472575488354778e-06

Diagnosis O 0 0.12192199379205704
of O 0 0.0007144809351302683
hemochromatosis B-Disease 1 0.9970242381095886
. O 0 0.0009429205092601478

If O 0 0.009444517083466053
untreated O 1 0.9479082822799683
, O 0 0.391696572303772
hemochromatosis B-Disease 1 0.9999536275863647
can O 0 0.0012237909249961376
cause O 0 0.006435187067836523
serious O 0 0.022178560495376587
illness O 0 0.07939668744802475
and O 0 3.9964288589544594e-06
early B-Disease 0 6.452303296100581e-06
death I-Disease 0 0.00047403370263054967
, O 0 9.475022125116084e-06
but O 0 9.520944331598002e-06
the O 0 5.521650018636137e-05
disease O 0 0.007706403266638517
is O 0 3.444366711846669e-07
still O 0 3.005071675943327e-06
substantially O 0 2.209673766628839e-05
under O 0 1.1603623534028884e-05
- O 1 0.9687770009040833
diagnosed O 1 0.5108765363693237
. O 0 4.938924394082278e-05

The O 0 1.3339805491341394e-06
cornerstone O 0 6.270499579841271e-05
of O 0 6.4432732926889e-08
screening O 0 4.2829296376112325e-07
and O 0 6.132684688964218e-07
case O 0 1.214343797073525e-06
detection O 0 4.26085489380057e-06
is O 0 5.036098649213727e-09
the O 0 3.983076091174098e-09
measurement O 0 6.121115916357667e-07
of O 0 3.340706200560817e-08
serum O 0 1.9451059415587224e-05
transferrin O 0 5.549372872337699e-06
saturation O 0 1.4166397477310966e-07
and O 0 1.929396375999204e-08
the O 0 6.605412750104733e-08
serum O 0 1.667411379457917e-05
ferritin O 0 1.971768870134838e-05
level O 0 1.3728893577535928e-07
. O 0 1.184386974273366e-06

Once O 0 0.00013047049287706614
the O 0 9.544481144985184e-06
diagnosis O 0 0.0011636395938694477
is O 0 1.234330738952849e-06
suspected O 0 0.001393266604281962
, O 0 4.12623103329679e-06
physicians O 0 7.866776741138892e-08
must O 0 1.5131929043121772e-09
use O 0 2.721579184239431e-09
serum O 0 7.824523891031276e-06
ferritin O 0 2.574362042651046e-05
levels O 0 5.783187617680596e-08
and O 0 1.2823995803046273e-06
hepatic O 0 0.007405193522572517
iron O 0 0.01953417807817459
stores O 0 1.1689724487951025e-05
on O 0 5.6668392062420025e-05
liver O 0 0.02309812791645527
biopsy O 0 0.010257252492010593
specimens O 0 8.19718206912512e-06
to O 0 2.784899777452665e-07
assess O 0 2.019531893893145e-05
patients O 0 1.7148374809039524e-07
for O 0 3.1618840878877563e-09
the O 0 5.8111847778263837e-08
presence O 0 9.249176713410634e-08
of O 0 5.686646318281419e-07
iron B-Disease 0 0.4627990126609802
overload I-Disease 0 0.04668522998690605
. O 0 5.541990503843408e-06

Liver O 1 0.9636083841323853
biopsy O 0 0.12322714179754257
is O 0 2.4091241357382387e-06
also O 0 1.8729519979387987e-07
used O 0 1.568342966606906e-08
to O 0 5.19280041189063e-09
establish O 0 1.2905562840614948e-08
the O 0 1.8082356945114952e-08
presence O 0 4.7919719747824274e-08
or O 0 1.5322262925110408e-07
absence O 0 4.0381789290222514e-07
of O 0 5.792703632323537e-06
cirrhosis B-Disease 1 0.7053840756416321
, O 0 4.741675184050109e-06
which O 0 1.3611137319458066e-06
can O 0 1.0665615235438963e-07
affect O 0 2.5910683234542375e-06
prognosis O 0 0.0006879071588627994
and O 0 6.117209977674065e-06
management O 0 0.00010835889406735078
. O 0 1.1347938198014162e-05

A O 0 4.888125204161042e-06
DNA O 0 8.323616202687845e-05
- O 0 0.000361686252290383
based O 0 7.607207521687087e-07
test O 0 1.5833568056677905e-07
for O 0 1.2654007841561565e-09
the O 0 1.2461159215604312e-08
HFE O 0 3.613514491007663e-05
gene O 0 8.648632920937871e-09
is O 0 1.0661883598217514e-09
commercially O 0 6.776707639488677e-09
available O 0 3.6466576425198127e-09
, O 0 2.0370443110095948e-08
but O 0 5.4441580132902345e-09
its O 0 6.612091318913826e-09
place O 0 3.24312772193025e-08
in O 0 2.548013178227393e-08
the O 0 3.2095110213958833e-07
diagnosis O 0 0.0004090512520633638
of O 0 7.643154276593123e-06
hemochromatosis B-Disease 1 0.9999724626541138
is O 0 1.7344635807603481e-06
still O 0 1.6718332744858344e-06
being O 0 5.769909989794542e-07
evaluated O 0 2.878210580092855e-06
. O 0 2.3291761408472667e-06

Currently O 0 4.1763237277336884e-06
, O 0 4.50228043291645e-07
the O 0 1.4521160274227896e-08
most O 0 1.4620702426526577e-09
useful O 0 2.066105286857578e-09
role O 0 1.0711215914227523e-08
for O 0 5.280947679153769e-09
this O 0 5.042567252644403e-09
test O 0 1.1358036289266238e-07
is O 0 2.4188642200329014e-09
in O 0 1.7680762409710837e-09
the O 0 1.4926463620668073e-08
detection O 0 4.247292508807732e-06
of O 0 1.1376523616490886e-06
hemochromatosis B-Disease 1 0.9999474287033081
in O 0 6.383390314113058e-07
the O 0 5.675344709743513e-07
family O 0 4.815441570826806e-05
members O 0 3.9136825336072434e-08
of O 0 3.304051006125519e-07
patients O 0 8.909056532502291e-07
with O 0 1.862565568444552e-07
a O 0 1.2843676131524262e-06
proven O 0 0.000761637813411653
case O 0 3.4931408663396724e-06
of O 0 1.8058753425975738e-07
the O 0 5.2873310778522864e-05
disease O 0 0.016019674018025398
. O 0 3.739110616152175e-05

It O 0 3.0252806482167216e-06
is O 0 4.905666060039948e-07
crucial O 0 1.4869001461192966e-06
to O 0 1.3583538930106442e-05
diagnose O 1 0.9924277663230896
hemochromatosis B-Disease 1 0.9999513626098633
before O 1 0.6105973720550537
hepatic B-Disease 1 0.999221682548523
cirrhosis I-Disease 1 0.9586822986602783
develops O 0 0.004580242559313774
because O 0 3.596462556743063e-05
phlebotomy O 0 0.40524595975875854
therapy O 0 0.0011943236459046602
can O 0 1.646490090934094e-05
avert O 1 0.9601618647575378
serious O 1 0.9985040426254272
chronic O 1 0.999969482421875
disease O 1 0.6483147144317627
and O 0 7.194123463705182e-05
can O 0 2.479171996583318e-07
even O 0 1.7248981976081268e-07
lead O 0 4.775702677761728e-07
to O 0 3.585209995549121e-08
normal O 0 1.3227574413576804e-07
life O 0 1.5913270772216492e-06
expectancy O 0 4.387066383060301e-06
. O 0 4.3812903527395974e-07
. O 0 4.706669642473571e-06

Prevalence O 0 0.00045196741120889783
of O 0 6.856578949054892e-08
the O 0 5.525243409465475e-07
I1307K O 0 0.00011872682080138475
APC B-Disease 0 9.425421740161255e-05
gene O 0 2.835291752489866e-07
variant O 0 3.3771902963053435e-06
in O 0 4.769804107240816e-08
Israeli O 0 6.592832164642459e-07
Jews O 0 3.3899183904395613e-08
of O 0 1.4213070720359156e-09
differing O 0 2.2468130467245828e-08
ethnic O 0 7.439084726001965e-08
origin O 0 4.993175366507785e-07
and O 0 4.685881140176207e-05
risk O 0 0.0009777148952707648
for O 0 0.001774265430867672
colorectal B-Disease 1 0.9999908208847046
cancer I-Disease 1 0.9997684359550476
. O 0 0.0002339144703000784

BACKGROUND O 0 3.106112853856757e-05
& O 0 0.0003964767383877188
AIMS O 0 9.604506885807496e-06
Israeli O 0 1.0346122962801019e-06
Jews O 0 1.6165995475603268e-07
of O 0 4.398115294179661e-08
European O 0 5.853662969457218e-06
birth O 0 5.368414804252097e-06
, O 0 5.871324333384109e-07
i O 0 3.2008267680794233e-07
. O 0 2.5540417780689495e-08
e O 0 3.648162589797721e-07
. O 0 2.8385048977952465e-08
, O 0 1.0555238105780518e-07
Ashkenazim O 0 1.1918154996237718e-05
, O 0 1.9456813049600896e-07
have O 0 2.124231457401038e-08
the O 0 2.4039940399234183e-05
highest O 1 0.9943617582321167
colorectal B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999877214431763
incidence O 0 0.0024061298463493586
of O 0 1.494321288930678e-08
any O 0 5.997867535967316e-09
Israeli O 0 1.402951852469414e-06
ethnic O 0 1.2638572570722317e-06
group O 0 6.57076234347187e-05
. O 0 4.575106231641257e-06

The O 0 2.862825567717664e-06
I1307K O 0 0.00030926603358238935
APC B-Disease 0 0.00021614796423818916
gene O 0 1.7335474922219873e-06
variant O 0 2.9554837965406477e-05
was O 0 4.3552656279644e-05
found O 0 2.4258295070467284e-06
in O 0 1.1695373132170062e-06
6 O 0 3.929271406377666e-05
. O 0 1.723686364130117e-05

1 O 0 5.138524102221709e-06
% O 0 2.278981412473513e-07
of O 0 1.1181643166935373e-08
American O 0 6.206578291312326e-07
Jews O 0 6.121488809185394e-07
, O 0 4.838914264837513e-07
28 O 0 6.595793706765107e-07
% O 0 5.961313664926138e-09
of O 0 1.718117204063674e-08
their O 0 0.0011153807863593102
familial O 1 0.9999743700027466
colorectal B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999864101409912
cases O 0 4.3018026190111414e-05
, O 0 1.4954075595596805e-05
but O 0 9.703576324682217e-07
not O 0 2.5717326934682205e-08
in O 0 3.073713372714337e-08
non O 0 2.4974156076496e-07
- O 0 0.0004815955471713096
Jews O 0 2.4506864519935334e-06
. O 0 5.8839027587964665e-06

We O 0 2.896472096836078e-06
assessed O 0 2.097039669024525e-06
the O 0 8.727049305434775e-08
I1307K O 0 0.00011518617247929797
prevalence O 0 3.2014460884965956e-05
in O 0 2.3140394489473692e-08
Israeli O 0 3.719612493569002e-07
Jews O 0 2.081421257571492e-08
of O 0 1.4729697461746127e-09
differing O 0 1.3032209977836828e-08
ethnic O 0 7.065249718607447e-08
origin O 0 3.3479338412689685e-07
and O 0 0.00012511707609519362
risk O 0 0.003062985837459564
for O 0 0.0020540289115160704
colorectal B-Disease 1 0.9999876022338867
cancer I-Disease 1 0.9997584223747253
. O 0 0.0004203165299259126

METHODS O 0 4.202136096864706e-06
DNA O 0 1.612884079804644e-05
samples O 0 4.542341969226982e-07
from O 0 4.8216492132269195e-08
500 O 0 1.0273737416355289e-06
unrelated O 0 5.0346311581961345e-06
Jews O 0 3.651399183013382e-08
of O 0 3.3713913882849056e-09
European O 0 4.910075404040981e-07
or O 0 1.413587114029724e-07
non O 0 6.762236637314345e-08
- O 0 5.965099626337178e-05
European O 0 4.858983970734698e-07
origin O 0 7.349724739924568e-08
, O 0 1.22517789691301e-07
with O 0 9.797142297429673e-08
or O 0 1.3203703019826207e-07
without O 0 8.081795677128412e-09
a O 0 3.068377196768779e-08
personal O 0 3.168859984725714e-05
and O 0 1.9419034288148396e-05
/ O 0 0.00015131036343518645
or O 0 1.7115891068897326e-06
family O 0 1.810321191442199e-05
history O 0 2.903043423430063e-07
of O 0 2.751588681348949e-07
neoplasia B-Disease 1 0.7276100516319275
, O 0 1.6896249235287542e-06
were O 0 1.5738453384983586e-07
examined O 0 4.988377781955933e-07
for O 0 2.533029119788921e-09
the O 0 2.8863301082537873e-08
I1307K O 0 4.248167442710837e-06
variant O 0 2.983285014579451e-07
by O 0 8.822172326006239e-09
the O 0 6.231206661766464e-09
allele O 0 2.0082710250335367e-07
- O 0 2.9943837489554426e-06
specific O 0 3.803027670556958e-09
oligonucleotide O 0 0.0008975279051810503
( O 0 5.241533358457673e-07
ASO O 0 0.014882861636579037
) O 0 5.075173703517066e-08
method O 0 4.7855504448079955e-08
. O 0 1.5446281622644165e-06

RESULTS O 0 8.64341709529981e-05
In O 0 8.036956842261134e-07
persons O 0 2.208460045949323e-07
at O 0 3.047681639145594e-05
average O 0 0.0008306882809847593
risk O 0 0.004610351286828518
for O 0 0.03382187336683273
colorectal B-Disease 1 0.9999971389770508
cancer I-Disease 1 0.9999402761459351
, O 0 4.2551913793431595e-05
I1307K O 0 0.0006076871650293469
was O 0 6.839234265498817e-05
found O 0 1.680115815361205e-06
in O 0 4.7605925601601484e-07
5 O 0 2.8323531751084374e-06
. O 0 6.048260729585309e-06

0 O 0 1.2380382031551562e-05
% O 0 5.903181232724819e-08
of O 0 1.9044492649555878e-09
120 O 0 3.335994236408624e-08
European O 0 1.3607498772216786e-07
and O 0 2.2409119537769584e-07
1 O 0 5.052852429798804e-07
. O 0 1.735916612233268e-06

6 O 0 5.3415988077176735e-05
% O 0 1.931845758917916e-07
of O 0 1.0162861663332023e-08
188 O 0 1.9166488982591545e-06
non O 0 1.709908872271626e-07
- O 0 5.962994691799395e-05
European O 0 6.462930173256609e-07
Jews O 0 5.596133973995165e-07
( O 0 1.0740822631305491e-07
P O 0 0.0007332279346883297
= O 0 7.248081601574086e-06
0 O 0 3.0199998946045525e-08
. O 0 1.321856490932305e-08
08 O 0 1.6288142035136843e-07
) O 0 7.178879712910202e-08
. O 0 3.350619977027236e-07

It O 0 2.3643260647077113e-06
occurred O 0 8.192078894353472e-06
in O 0 3.063687188387121e-07
15 O 0 1.6051162674557418e-06
. O 0 5.159467036719434e-06

4 O 0 1.9634017007774673e-05
% O 0 1.9426609298989206e-07
of O 0 1.219685241693469e-08
52 O 0 2.477735279171611e-06
Ashkenazi O 0 0.00020825448154937476
Israelis O 0 9.193846926791593e-05
with O 0 8.829440776025876e-05
familial O 1 0.9448384046554565
cancer B-Disease 1 0.5637774467468262
( O 0 7.27538406408712e-07
P O 0 0.010576315224170685
= O 0 2.1444109734147787e-05
0 O 0 9.216228846753438e-08
. O 0 2.9002144685819076e-08
02 O 0 5.600594249699498e-06
) O 0 1.690622219996385e-08
and O 0 4.539985809515201e-08
was O 0 8.050181463659101e-07
not O 0 6.107410133182611e-09
detected O 0 1.4126679559467448e-07
in O 0 1.530102444746717e-08
51 O 0 5.189655212234356e-07
non O 0 3.9508531557430615e-08
- O 0 4.82274845126085e-05
European O 0 3.354447244419134e-07
Jews O 0 2.701504229207785e-07
at O 0 5.330342901288532e-05
increased O 0 4.44087345385924e-05
cancer B-Disease 0 0.01023847796022892
risk O 0 2.984691491292324e-05
. O 0 7.209216164483223e-06

Colorectal B-Disease 1 0.9939965009689331
neoplasia I-Disease 1 0.9952329993247986
occurred O 0 0.002321456791833043
personally O 0 0.0005670937825925648
or O 0 4.332702701503877e-06
in O 0 2.138425543307676e-07
the O 0 1.586591622526612e-07
families O 0 4.202329932923021e-07
of O 0 6.03351679728803e-09
13 O 0 1.1251198372974613e-07
of O 0 3.0721525323684773e-09
20 O 0 7.612709396198625e-08
Ashkenazi O 0 7.002542133704992e-06
I1307K O 0 2.2707969037583098e-05
carriers O 0 6.087618658057181e-07
, O 0 4.416061472056754e-08
8 O 0 1.2154544037912274e-07
of O 0 1.2607904054107166e-08
whom O 0 1.1402787549741333e-06
also O 0 5.419599915512663e-07
had O 0 1.5196442291198764e-06
a O 0 9.59517620913175e-08
personal O 0 4.31592961831484e-05
or O 0 5.9778994909720495e-06
family O 0 0.00011040779645554721
history O 0 2.6648870061762864e-06
of O 0 4.714000624517212e-06
noncolonic O 1 0.571952223777771
neoplasia B-Disease 1 0.663927435874939
. O 0 2.4238539481302723e-05

CONCLUSIONS O 0 1.6949452401604503e-05
The O 0 8.278684049400908e-07
I1307K O 0 0.0001917934132507071
APC O 0 0.0021261568181216717
variant O 0 0.00031217560172080994
may O 0 3.6140640986559447e-06
represent O 0 2.572486668128704e-09
a O 0 3.361100908705339e-08
susceptibility O 0 8.57817485666601e-06
gene O 0 3.3489556017229916e-07
for O 0 3.976364496338647e-06
colorectal B-Disease 1 0.9999358654022217
, I-Disease 0 2.3466593120247126e-05
or I-Disease 0 1.2364797612463008e-06
other I-Disease 0 5.388934596339823e-07
, I-Disease 0 3.0633469577878714e-05
cancers I-Disease 0 0.001491081202402711
in O 0 1.713349888632365e-07
Ashkenazi O 0 0.0003143498324789107
Jews O 0 1.7499736486570328e-06
, O 0 6.454675940403831e-07
and O 0 1.6774804407759802e-06
partially O 0 7.324080797843635e-05
explains O 0 1.4773535212952993e-06
the O 0 3.70106327807207e-08
higher O 0 3.303711991975433e-06
incidence O 0 0.01027610246092081
of O 0 0.010335427708923817
colorectal B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.99988853931427
in O 0 2.277276507811621e-06
European O 0 6.5101185100502335e-06
Israelis O 0 0.00010942413791781291
. O 0 2.5425877538509667e-05

Systematic O 0 3.836978976323735e-06
analysis O 0 1.4803745216340758e-06
of O 0 4.054958253618679e-07
coproporphyrinogen O 0 0.02378755621612072
oxidase O 0 0.00013832884724251926
gene O 0 0.00010247646423522383
defects O 1 0.6670778393745422
in O 0 1.2148916539445054e-06
hereditary B-Disease 0 0.00868351012468338
coproporphyria I-Disease 0 0.04818803071975708
and O 0 2.918866584877833e-06
mutation O 0 1.0800700920299278e-06
update O 0 5.621202944894321e-05
. O 0 9.014021088660229e-06

Hereditary B-Disease 1 0.8878185749053955
coproporphyria I-Disease 1 0.9644837379455566
( O 0 0.0001480187347624451
HC B-Disease 1 0.9949042797088623
) O 0 0.00011233903205720708
is O 0 8.80674269865267e-06
an O 0 0.0004221366543788463
acute O 1 0.99299156665802
hepatic B-Disease 1 0.9995470643043518
porphyria I-Disease 1 0.9974743723869324
with O 0 0.0014576258836314082
autosomal O 1 0.8916956186294556
dominant O 0 0.1575479358434677
inheritance O 1 0.6742678284645081
caused O 0 0.002277660882100463
by O 0 1.18353491416201e-05
deficient B-Disease 0 0.006165625061839819
activity I-Disease 0 7.711942373589409e-08
of I-Disease 0 1.2715690900222398e-07
coproporphyrinogen I-Disease 0 0.12261875718832016
III I-Disease 1 0.5556565523147583
oxidase I-Disease 0 1.9005450667464174e-05
( O 0 1.1537878208400798e-07
CPO O 0 0.0001245338498847559
) O 0 4.724090274521586e-07
. O 0 4.992632511857664e-07

Clinical O 0 0.000527174852322787
manifestations O 0 0.00023280023015104234
of O 0 4.323848315834766e-06
the O 0 0.002935832366347313
disease O 1 0.5881404876708984
are O 0 8.592515996497241e-07
characterized O 0 0.0011071290355175734
by O 0 8.466744475299492e-05
acute O 0 0.02188081666827202
attacks O 0 0.023863311856985092
of O 0 0.006980721838772297
neurological B-Disease 1 0.9999151229858398
dysfunction I-Disease 1 0.9722451567649841
often O 0 1.1381969670765102e-05
precipitated O 0 0.001805983716621995
by O 0 1.9130277451040456e-06
drugs O 0 3.2394452773587545e-06
, O 0 3.97042697386496e-07
fasting O 0 1.8436946902511409e-06
, O 0 3.1526892598776612e-06
cyclical O 0 0.000769588106777519
hormonal O 0 3.927758734789677e-05
changes O 0 3.790414950799459e-07
, O 0 1.1305529369565193e-05
or O 0 0.00010643383575370535
infectious B-Disease 0 0.20075131952762604
diseases I-Disease 0 0.020477551966905594
. O 0 1.8941922462545335e-05

Skin O 1 0.992879331111908
photosensitivity O 1 0.9930397272109985
may O 0 0.00015589730173815042
also O 0 8.468504120173748e-07
be O 0 5.4571039243000996e-08
present O 0 4.2028631241919356e-07
. O 0 4.983260168955894e-06

The O 0 1.9409054630159517e-07
seven O 0 3.2295787377734086e-07
exons O 0 3.2908258162933635e-06
, O 0 1.9629902681117528e-07
the O 0 2.6079051806959797e-08
exon O 0 1.0755603398138192e-05
/ O 0 3.1403380944539094e-06
intron O 0 1.6465468434034847e-05
boundaries O 0 9.274045531526554e-09
and O 0 2.1691876739282634e-08
part O 0 9.33144117531981e-10
of O 0 6.960457765714523e-10
3 O 0 5.443828499096526e-08
noncoding O 0 3.557697141332028e-07
sequence O 0 1.366018520521095e-09
of O 0 6.201620883494741e-10
the O 0 2.2278999978198044e-08
CPO O 0 5.061858973931521e-05
gene O 0 1.760236933989745e-08
were O 0 2.009172916928037e-08
systematically O 0 3.5061668768321397e-06
analyzed O 0 8.119157968167201e-08
by O 0 2.0115262788777954e-09
an O 0 5.2686228713128e-09
exon O 0 2.1182247564865975e-06
- O 0 8.643160981591791e-06
by O 0 5.191258622971873e-08
- O 0 1.1515059668454342e-05
exon O 0 3.133493464702042e-06
denaturing O 0 1.743901339068543e-05
gradient O 0 6.9862330747128e-06
gel O 0 0.0004664966545533389
electrophoresis O 0 0.007607846055179834
( O 0 3.4999391118617496e-07
DGGE O 0 0.0008046700386330485
) O 0 4.136401443588511e-08
strategy O 0 4.884900590695906e-07
followed O 0 1.7120228790190595e-08
by O 0 2.352289751872405e-10
direct O 0 1.5320895940806878e-10
sequencing O 0 9.636148945446621e-08
in O 0 1.338540567275004e-08
seven O 0 2.1121901738752058e-07
unrelated O 0 0.00019681217963807285
heterozygous O 0 3.573324647732079e-05
HC B-Disease 1 0.9892106056213379
patients O 0 5.857136329723289e-06
from O 0 1.5580273782234144e-07
France O 0 9.97024017124204e-06
, O 0 2.7932139801123412e-06
Holland O 0 0.0003165247035212815
, O 0 2.3568107110349956e-07
and O 0 4.312472583478666e-07
Czech O 0 1.2935109225509223e-05
Republic O 0 6.581332399946405e-06
. O 0 5.62631157663418e-06

Seven O 0 6.845589723525336e-06
novel O 0 5.8874556998489425e-06
mutations O 0 1.2237570672368747e-06
and O 0 2.0085546736936521e-07
two O 0 5.404751490800663e-08
new O 0 7.442915830324637e-07
polymorphisms O 0 2.1547240976360627e-05
were O 0 2.726095772231929e-06
detected O 0 3.2325911888619885e-05
. O 0 5.774254077550722e-06

Among O 0 1.3826165741193108e-06
these O 0 3.647800284056757e-08
mutations O 0 1.703018455145866e-07
two O 0 6.659505658035414e-08
are O 0 1.3283139921327347e-08
missense O 0 2.5877245661831694e-06
( O 0 3.602504605737522e-08
G197W O 0 5.491316187544726e-06
, O 0 3.5715362400878803e-07
W427R O 0 1.6786660125944763e-05
) O 0 5.7721894819451336e-08
, O 0 1.2109278912930677e-08
two O 0 7.529642687131854e-09
are O 0 6.212337755329145e-09
nonsense O 0 2.687299456738401e-06
( O 0 1.5816750575936567e-08
Q306X O 0 2.2655012799077667e-06
, O 0 1.79221146368036e-07
Q385X O 0 1.2739551493723411e-05
) O 0 5.507651934522073e-08
, O 0 7.772750443280074e-09
two O 0 1.963666784732254e-09
are O 0 6.992900147828607e-10
small O 0 3.7937343932981094e-08
deletions O 0 1.896112053145771e-06
( O 0 3.7208963021839736e-08
662de14bp O 0 6.843683877377771e-06
; O 0 1.5118153839921433e-07
1168del3bp O 0 7.638112037966494e-06
removing O 0 7.344007713072642e-08
a O 0 3.1996800764488853e-09
glycine O 0 1.8786407451898413e-07
at O 0 9.15361724196373e-08
position O 0 1.911601366089144e-08
390 O 0 3.896346697729314e-06
) O 0 9.512102394637623e-08
, O 0 4.2333791583359925e-08
and O 0 2.72205298301742e-08
one O 0 7.106061516992668e-09
is O 0 1.5357533023063752e-09
a O 0 1.281526329499627e-09
splicing O 0 2.980987119372003e-07
mutation O 0 5.6054503261293576e-08
( O 0 1.7255459283660457e-08
IVS1 O 0 6.394294177880511e-05
- O 0 6.287091673584655e-05
15c O 0 2.258193262605346e-06
- O 0 0.00010562196985119954
- O 0 0.0007255811360664666
> O 0 2.604292376418016e-06
g O 0 0.00019414130656514317
) O 0 4.156323285542385e-08
which O 0 4.6882719928476035e-09
creates O 0 7.882394292835215e-09
a O 0 9.354358398994123e-10
new O 0 6.535943342100836e-09
acceptor O 0 1.3001802301459975e-07
splice O 0 7.392742645606631e-06
site O 0 6.904282145114848e-06
. O 0 5.653095740854042e-06

The O 0 1.3229282558313571e-05
pathological O 0 0.0003554825088940561
significance O 0 3.9494148040830623e-07
of O 0 8.433089782045045e-09
the O 0 6.881262493152462e-08
point O 0 4.505119477471453e-07
mutations O 0 6.315600842299318e-08
G197W O 0 7.086694040481234e-06
, O 0 1.979703796450849e-07
W427R O 0 6.28103089184151e-06
, O 0 4.349653792701247e-08
and O 0 1.3607299287343722e-08
the O 0 8.967222520084306e-09
in O 0 4.649865203987247e-08
- O 0 0.0005187770002521574
frame O 0 0.0027606463991105556
deletion O 0 3.98521024180809e-06
390delGly O 0 2.7361409593140706e-05
were O 0 5.4351545486497344e-08
assessed O 0 4.656166652239335e-08
by O 0 9.256351241049288e-10
their O 0 7.520768452451421e-10
respective O 0 2.3250235070548797e-09
expression O 0 1.9024415376378556e-09
in O 0 8.467161194403161e-09
a O 0 1.3389849229383799e-08
prokaryotic O 0 2.8243616156942153e-07
system O 0 2.964272880490171e-07
using O 0 3.8305401517391147e-08
site O 0 1.1081567663495662e-06
- O 0 4.688003900810145e-05
directed O 0 9.864811545412522e-07
mutagenesis O 0 1.750746559991967e-05
. O 0 2.3020318167255027e-06

These O 0 5.158194653631654e-07
mutations O 0 4.021148924948648e-06
resulted O 0 3.896822363458341e-06
in O 0 3.560510890565638e-07
the O 0 2.8236561888661527e-07
absence O 0 6.75753597079165e-07
or O 0 1.5829854760340822e-07
a O 0 5.76471919089272e-08
dramatic O 0 3.0642590900242794e-06
decrease O 0 3.0995056476967875e-07
of O 0 1.1976604596952711e-08
CPO O 0 0.0003255409828852862
activity O 0 1.0949381703539984e-06
. O 0 1.9991534827568103e-06

The O 0 2.335844300205281e-07
two O 0 1.078485567518328e-07
polymorphisms O 0 8.336661267094314e-06
were O 0 1.4687238092392363e-07
localized O 0 9.001719263324048e-07
in O 0 3.3180995728798734e-07
noncoding O 0 7.022178760962561e-05
part O 0 2.70209614683381e-08
of O 0 3.6932974456505008e-09
the O 0 1.9085046432110175e-08
gene O 0 4.7665299263144334e-08
1 O 0 3.382677959962166e-08
) O 0 8.663194606128855e-09
a O 0 1.0432083641376266e-08
C O 0 5.6911980209406465e-05
/ O 0 3.6144779187452514e-06
G O 0 3.7496298318728805e-05
polymorphism O 0 8.821940866710065e-08
in O 0 6.4088294671194035e-09
the O 0 1.035151164785475e-08
promotor O 0 0.00012257789785508066
region O 0 1.4821218030647287e-07
, O 0 1.7058329859764854e-08
142 O 0 2.3014425210021727e-07
bp O 0 6.296960691543063e-06
upstream O 0 1.657982728886509e-08
from O 0 2.191082870695027e-10
the O 0 1.7925338990920636e-10
transcriptional O 0 5.458204554997792e-09
initiation O 0 5.088268295594389e-08
site O 0 1.2046180017932784e-06
( O 0 1.463055721018236e-08
- O 0 3.112191552645527e-05
142C O 0 2.0556446543196216e-05
/ O 0 3.2034363357524853e-06
G O 0 0.0001469109847676009
) O 0 1.4175905782565223e-08
, O 0 7.493682119275036e-09
and O 0 1.7098656712732918e-08
2 O 0 8.84492266095549e-08
) O 0 5.608056241612758e-09
a O 0 4.9507349331179284e-09
6 O 0 5.889426688554522e-07
bp O 0 1.884640550997574e-05
deletion O 0 2.1826515705924976e-07
polymorphism O 0 6.75045797038365e-08
in O 0 1.6970602700894233e-09
the O 0 6.767188587275541e-09
3 O 0 2.303181503293672e-07
noncoding O 0 6.468630090239458e-06
part O 0 2.1428723240290992e-09
of O 0 6.1366922654571e-10
the O 0 2.003470989109246e-08
CPO O 0 6.583262438653037e-05
gene O 0 4.514168239211358e-08
, O 0 4.121170960047493e-08
574 O 0 2.918404561569332e-06
bp O 0 7.476390692318091e-06
downstream O 0 5.873565100955602e-08
of O 0 3.767691159062281e-10
the O 0 1.2251692105280654e-08
last O 0 6.522483317894512e-07
base O 0 1.1243727726650832e-08
of O 0 6.714445666133884e-10
the O 0 5.179130901922235e-09
normal O 0 1.632200152812402e-08
termination O 0 1.9575242049540975e-07
codon O 0 2.7632268029265106e-08
( O 0 1.7099701210554485e-08
+ O 0 2.0339266484370455e-06
574 O 0 1.1267490663158242e-05
delATTCTT O 0 0.00011600991274463013
) O 0 6.20205184986844e-07
. O 0 7.844614060559252e-07

Five O 0 2.4835057047312148e-05
intragenic O 0 0.06654687970876694
dimorphisms O 0 0.04243495687842369
are O 0 2.497048967597948e-07
now O 0 2.9299533821358636e-07
well O 0 1.26667458744123e-07
characterized O 0 1.3312303963175509e-05
and O 0 1.4994425612258055e-07
the O 0 3.8439193161821095e-08
high O 0 1.23865834211756e-06
degree O 0 1.7896352844104513e-08
of O 0 3.1556481872030417e-09
allelic O 0 2.171561573049985e-05
heterogeneity O 0 7.118715438991785e-05
in O 0 4.727254236058798e-06
HC B-Disease 1 0.975307822227478
is O 0 5.332841510607977e-07
demonstrated O 0 1.1930285381822614e-06
with O 0 8.085159919346552e-08
seven O 0 7.3468939376653e-08
new O 0 3.1653129894948506e-08
different O 0 1.0504657144139173e-09
mutations O 0 1.9403273654461373e-08
making O 0 4.819807664091513e-09
a O 0 4.0787067057124204e-09
total O 0 7.0470242974352004e-09
of O 0 3.87810228374974e-09
nineteen O 0 1.3050788538748748e-06
CPO O 0 0.07272469997406006
gene B-Disease 0 0.000392060523154214
defects I-Disease 1 0.9116322994232178
reported O 0 6.10416173003614e-05
so O 0 9.861804528554785e-08
far O 0 2.879440899050678e-07
. O 0 5.285011752675928e-07
. O 0 3.630673745647073e-06

Coincidence O 0 1.4510726941807661e-05
of O 0 8.044121102557256e-08
two O 0 2.973707182718499e-07
novel O 0 3.873354671668494e-06
arylsulfatase O 0 0.00023357884492725134
A O 0 1.396151247945454e-07
alleles O 0 1.10120303986605e-07
and O 0 6.24277163296938e-08
mutation O 0 1.7049741174446353e-08
459 O 0 4.819571131520206e-06
+ O 0 6.937799298611935e-06
1G O 0 3.874174217344262e-05
> O 0 3.5560384503696696e-07
A O 0 1.372935898302785e-08
within O 0 2.0724753024836673e-09
a O 0 3.146520839436562e-07
family O 0 0.002764647826552391
with O 0 0.0015402451390400529
metachromatic B-Disease 1 0.9999556541442871
leukodystrophy I-Disease 1 0.9998654127120972
: O 0 1.7085885417600366e-07
molecular O 0 2.889280494855484e-07
basis O 0 1.2773679891608936e-09
of O 0 1.1152335055442109e-08
phenotypic O 0 4.12964254792314e-07
heterogeneity O 0 0.00010022863716585562
. O 0 2.9878354325774126e-05

In O 0 3.1702634260000195e-06
a O 0 9.753509857546305e-07
family O 0 3.518310040817596e-05
with O 0 4.592660900470946e-07
three O 0 2.9027853543084348e-06
siblings O 0 0.0004335012927185744
, O 0 2.443227913317969e-07
one O 0 1.522280612675786e-08
developed O 0 4.6068740289229027e-07
classical O 0 8.906592938728863e-07
late O 0 0.005698197055608034
infantile O 1 0.9954512715339661
metachromatic B-Disease 1 0.999931812286377
leukodystrophy I-Disease 1 0.9999247789382935
( O 0 2.8980666684219614e-05
MLD B-Disease 1 0.9996156692504883
) O 0 7.769945113977883e-06
, O 0 5.733516900363611e-06
fatal O 0 0.0037231692112982273
at O 0 1.1283942512818612e-05
age O 0 1.2961048696524813e-06
5 O 0 1.7466140889155213e-06
years O 0 5.879857781110331e-06
, O 0 8.651620646560332e-07
with O 0 6.483489869424375e-06
deficient O 1 0.5080676078796387
arylsulfatase O 0 0.011967220343649387
A O 0 3.7988866097293794e-06
( O 0 1.1343134929120424e-06
ARSA O 0 0.13219410181045532
) O 0 2.6091742100220472e-08
activity O 0 1.503908642064289e-08
and O 0 3.288254646349742e-08
increased O 0 2.4436332068944466e-07
galactosylsulfatide O 0 0.0014582566218450665
( O 0 6.206311695677869e-07
GS O 1 0.9983057975769043
) O 0 9.433099421585212e-07
excretion O 0 2.0383695300552063e-06
. O 0 1.937404249474639e-06

The O 0 2.3742060761833272e-07
two O 0 2.203656919164132e-07
other O 0 2.0183880167223833e-07
siblings O 0 7.638720126124099e-05
, O 0 1.2307878023420926e-06
apparently O 0 8.55998405313585e-06
healthy O 0 2.3140400173815578e-07
at O 0 1.960066128958715e-06
12 O 0 4.182957695775258e-07
( O 0 6.865095159014345e-09
1 O 0 9.413732904306471e-09
/ O 0 2.0932462518885586e-07
2 O 0 5.3332527727434353e-08
) O 0 4.090517702337593e-09
and O 0 1.0739732658748835e-08
15 O 0 4.003109310701802e-08
years O 0 2.505067868696642e-07
, O 0 2.13811148341847e-07
respectively O 0 4.0706112258703797e-07
, O 0 5.97236677890578e-08
and O 0 1.9989670363429468e-08
their O 0 5.547482828660577e-08
father O 0 0.0001378845190629363
, O 0 1.8278487914358266e-06
apparently O 0 3.31081282638479e-05
healthy O 0 9.928464805852855e-08
as O 0 5.362085442328635e-09
well O 0 1.5122443741688585e-08
, O 0 1.6247788892087556e-07
presented O 0 1.5406706097564893e-06
ARSA O 0 0.194351464509964
and O 0 5.651349511026638e-06
GS O 1 0.9899104237556458
values O 0 4.76111416958247e-08
within O 0 5.058208296659927e-10
the O 0 1.1520688403265922e-08
range O 0 1.2259894219823764e-06
of O 0 5.149473508936353e-06
MLD B-Disease 1 0.9992995262145996
patients O 0 2.916771154559683e-05
. O 0 1.2380593943817075e-05

Mutation O 0 2.673700009836466e-06
screening O 0 4.839841949433321e-07
and O 0 9.763843422661012e-08
sequence O 0 6.904914329197709e-08
analysis O 0 4.146450010011904e-07
disclosed O 0 4.852790880249813e-05
the O 0 4.014356491666149e-08
involvement O 0 5.403286991167988e-07
of O 0 2.626844519681981e-09
three O 0 1.2304947283325873e-08
different O 0 2.4415641064479132e-08
ARSA O 0 0.03852662444114685
mutations O 0 4.9220020059692615e-08
being O 0 5.709924533192634e-09
the O 0 6.152622855637446e-09
molecular O 0 5.870041945854609e-07
basis O 0 9.976145243228984e-09
of O 0 1.0970332198212418e-07
intrafamilial O 0 0.0013446066295728087
phenotypic O 0 6.421153670999047e-07
heterogeneity O 0 5.588161729974672e-05
. O 0 1.4663863112218678e-05

The O 0 1.7321746781817637e-05
late O 0 0.008494056761264801
infantile O 1 0.9736690521240234
patient O 0 0.11237737536430359
inherited O 1 0.8361313343048096
from O 0 2.8875692805740982e-06
his O 0 5.575003888225183e-05
mother O 0 9.504052286501974e-05
the O 0 4.273472242743992e-08
frequent O 0 1.0043678599913619e-07
0 O 0 1.6609016029178747e-07
- O 0 1.3914519513491541e-05
type O 0 9.246972609844306e-08
mutation O 0 7.693515158280206e-09
459 O 0 1.5411202411996783e-06
+ O 0 2.496311481081648e-06
1G O 0 2.405931991233956e-05
> O 0 2.683473780962231e-07
A O 0 4.2077154205344414e-08
, O 0 2.548210602526524e-07
and O 0 1.9889726843302924e-07
from O 0 4.173155687681174e-08
his O 0 1.2680950476351427e-06
father O 0 5.5189943850564305e-06
a O 0 4.393177022166128e-08
novel O 0 2.871543358651252e-07
, O 0 8.205093138258235e-08
single O 0 3.817418914309201e-08
basepair O 0 0.0004586800641845912
microdeletion O 0 8.290675395983271e-06
of O 0 7.991964312559219e-10
guanine O 0 1.0940744488152632e-07
at O 0 2.033317691996217e-08
nucleotide O 0 7.71402763888318e-09
7 O 0 8.390624373078026e-08
in O 0 1.5147760379363717e-08
exon O 0 5.188192972127581e-06
1 O 0 4.817889589503466e-07
( O 0 1.1602605098914864e-07
7delG O 0 8.41265355120413e-05
) O 0 6.922214765836543e-07
. O 0 1.2393589940984384e-06

The O 0 6.856225240881031e-07
two O 0 3.542583726812154e-06
clinically O 0 0.0006900571752339602
unaffected O 0 0.0005808850401081145
siblings O 0 6.786991434637457e-05
carried O 0 1.1402048585296143e-06
the O 0 9.107500886784692e-08
maternal O 0 1.7953607311937958e-06
mutation O 0 2.3219403288976537e-08
459 O 0 5.341348696674686e-06
+ O 0 4.090109541721176e-06
1G O 0 2.1898120394325815e-05
> O 0 5.146274588696542e-07
A O 0 5.993729956799143e-08
and O 0 3.1187877880256565e-07
, O 0 4.008694176604877e-08
on O 0 4.9069853957917076e-08
their O 0 1.6899837973483045e-08
paternal O 0 9.691387958810083e-07
allele O 0 3.595084763219347e-07
, O 0 2.5512081336387382e-08
a O 0 2.235531093575105e-09
novel O 0 1.1741551730892752e-08
cytosine O 0 7.685247283006902e-08
to O 0 1.36057609623208e-09
thymidine O 0 2.1386436799275543e-07
transition O 0 1.8781779687060407e-08
at O 0 1.8132885415411693e-08
nucleotide O 0 9.68216706809244e-09
2435 O 0 6.463573754444951e-06
in O 0 6.859139922710256e-09
exon O 0 8.183998261301895e-07
8 O 0 4.5290536831998907e-07
, O 0 1.0566337493855826e-07
resulting O 0 2.2207004235497152e-08
in O 0 6.226356097371877e-10
substitution O 0 4.967238287356679e-10
of O 0 3.85541598646455e-09
alanine O 0 2.7829162263515173e-06
464 O 0 7.0112560024426784e-06
by O 0 2.3779382729571807e-07
valine O 0 4.317485945648514e-05
( O 0 1.7742229374562157e-07
A464V O 0 1.536412673885934e-05
) O 0 2.8240572191862157e-07
. O 0 8.332347078976454e-07

The O 0 3.2141836072696606e-06
fathers O 0 1.9179589799023233e-05
genotype O 0 2.9980674298712984e-05
thus O 0 8.804599360701104e-07
was O 0 1.3238051906228065e-05
7delG O 0 0.0003918596776202321
/ O 0 7.901475328253582e-05
A464V O 0 0.0001801119651645422
. O 0 6.1992172959435266e-06

Mutation O 0 2.725396007008385e-05
A464V O 0 0.0007985066040419042
was O 0 4.6522462071152404e-05
not O 0 2.341308373843276e-07
found O 0 1.4097585108174826e-06
in O 0 4.964344952895772e-07
18 O 0 6.440412107622251e-05
unrelated O 0 0.27936652302742004
MLD B-Disease 1 0.9999043941497803
patients O 0 6.634658348048106e-06
and O 0 2.7094691290585615e-07
50 O 0 1.9001366524662444e-07
controls O 0 1.0823017873917706e-05
. O 0 7.634455869265366e-06

A464V O 0 0.0012772096088156104
, O 0 9.214484634867404e-06
although O 0 5.290810918268107e-07
clearly O 0 6.201602218425251e-07
modifying O 0 5.98421956965467e-06
ARSA O 0 0.061194196343421936
and O 0 9.448772289033514e-06
GS O 1 0.9993638396263123
levels O 0 2.214023879787419e-06
, O 0 5.056429586147715e-07
apparently O 0 1.3797917745250743e-05
bears O 0 2.8120732622483047e-06
little O 0 6.230448690303092e-08
significance O 0 2.4032756229530605e-08
for O 0 1.8411061120104932e-08
clinical O 0 4.649749882901233e-07
manifestation O 0 3.226409489798243e-06
of O 0 1.1010009757228545e-06
MLD B-Disease 1 0.9994555115699768
, O 0 4.801679096999578e-06
mimicking O 0 2.7740692530642264e-05
the O 0 2.454922309880203e-07
frequent O 0 3.69908457287238e-06
ARSA O 0 0.27059805393218994
pseudodeficiency O 0 0.0017330643022432923
allele O 0 6.338255388982361e-06
. O 0 3.3685057587717893e-06

Our O 0 1.6951964880718151e-06
results O 0 6.378481430147076e-06
demonstrate O 0 1.8710163658397505e-06
that O 0 1.1607330918650405e-07
in O 0 3.3862605164358683e-08
certain O 0 1.6344618103403263e-08
genetic O 0 2.2564545361092314e-05
conditions O 0 0.0005110790953040123
MLD B-Disease 1 0.9990307092666626
- O 0 0.030419135466217995
like O 0 3.9442834349756595e-06
ARSA O 0 0.09159517288208008
and O 0 3.979232587880688e-06
GS O 1 0.9918714761734009
values O 0 3.246495055009291e-07
need O 0 4.9882702413128754e-09
not O 0 2.250594821617824e-09
be O 0 6.25204066295737e-09
paralleled O 0 1.2026610420434736e-05
by O 0 4.249441553838551e-05
clinical O 0 0.025589779019355774
disease O 0 0.009329441003501415
, O 0 9.685095392342191e-07
a O 0 1.532021656203142e-07
finding O 0 3.822398866759613e-06
with O 0 1.2752825568895787e-05
serious O 0 0.00020453089382499456
diagnostic O 0 0.00011595338582992554
and O 0 4.391751281218603e-05
prognostic O 0 0.002591639757156372
implications O 0 0.00010851524712052196
. O 0 1.564672675158363e-05

Moreover O 0 6.527606456074864e-05
, O 0 1.7171921626868425e-06
further O 0 2.0366758235468296e-07
ARSA O 0 0.007775038480758667
alleles O 0 3.688653578137746e-07
functionally O 0 3.747766868400504e-06
similar O 0 7.201988694305328e-08
to O 0 9.225268371437778e-08
A464V O 0 4.811145117855631e-05
might O 0 3.559285346454999e-07
exist O 0 5.5935704956766585e-09
which O 0 2.8416467401370937e-08
, O 0 2.8190488166046634e-08
together O 0 2.4995118863557764e-08
with O 0 1.0548134099508388e-07
0 O 0 1.732572400214849e-06
- O 0 0.0026601499412208796
type O 0 6.033725185261574e-06
mutations O 0 2.633870508361724e-06
, O 0 3.756135811272543e-06
may O 0 4.1513821997796185e-06
cause O 0 2.0764387045346666e-06
pathological O 0 0.00016888028767425567
ARSA O 1 0.6101745963096619
and O 0 3.941446266253479e-05
GS O 1 0.9998941421508789
levels O 0 2.1922655832895543e-06
, O 0 3.6354302324070886e-07
but O 0 2.2312558201065258e-07
not O 0 9.007715817688222e-08
clinical O 0 8.456107707388583e-07
outbreak O 0 1.5612685047017294e-06
of O 0 7.642869093160698e-08
the O 0 0.00012616968888323754
disease O 0 0.004802708048373461
. O 0 1.687766484792519e-06
. O 0 1.8502454622648656e-05

Human O 0 0.04538849741220474
MLH1 O 1 0.9970918893814087
deficiency O 1 0.9980048537254333
predisposes O 0 0.020810600370168686
to O 0 8.478888048557565e-05
hematological B-Disease 1 0.9648557305335999
malignancy I-Disease 1 0.996736466884613
and O 0 0.006581567227840424
neurofibromatosis B-Disease 1 0.9917038679122925
type I-Disease 0 3.5736044083023444e-05
1 I-Disease 0 5.370898634282639e-06
. O 0 9.859452802629676e-06

Heterozygous O 0 0.00011759848712245002
germ O 0 0.12809482216835022
- O 0 0.012935076840221882
line O 0 4.501646617427468e-05
mutations O 0 5.163840341992909e-07
in O 0 2.9366185927415245e-08
the O 0 1.2042305286286137e-07
DNA O 0 0.006633312441408634
mismatch O 1 0.8038992285728455
repair O 0 0.20214258134365082
genes O 0 9.020952234095603e-07
lead O 0 6.892492820043117e-06
to O 0 1.0068428309750743e-05
hereditary B-Disease 1 0.9950305223464966
nonpolyposis I-Disease 1 0.9998784065246582
colorectal I-Disease 1 0.9999866485595703
cancer I-Disease 1 0.9998396635055542
. O 0 0.0008785433019511402

The O 0 0.003330024890601635
disease O 1 0.8806719183921814
susceptibility O 0 0.00048012170009315014
of O 0 1.2520907830548822e-06
individuals O 0 1.5519133285124553e-06
who O 0 1.0181944162468426e-05
constitutionally O 0 3.71318674297072e-06
lack O 0 1.2060945664416067e-07
both O 0 3.907253187662718e-08
wild O 0 4.0638260543346405e-06
- O 0 0.03199063241481781
type O 0 3.387305696378462e-06
alleles O 0 2.4456150526930287e-07
is O 0 1.2868034104940307e-07
unknown O 0 2.077550107060233e-06
. O 0 8.034573511395138e-06

We O 0 1.4580435845346074e-06
have O 0 1.3122871678206138e-07
identified O 0 1.337772914666857e-07
three O 0 5.203809294584971e-08
offspring O 0 1.5482280559808714e-06
in O 0 5.525606638911995e-07
a O 0 3.20825565722771e-05
hereditary B-Disease 1 0.999610960483551
nonpolyposis I-Disease 1 0.9999803304672241
colorectal I-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999873638153076
family O 1 0.5283011794090271
who O 0 0.001017606700770557
developed O 0 0.0070939394645392895
hematological B-Disease 1 0.9700819253921509
malignancy I-Disease 1 0.622801661491394
at O 0 1.0839028618647717e-05
a O 0 1.0095786251440586e-07
very O 0 6.94591548722201e-08
early O 0 5.181762503525533e-07
age O 0 2.261104555145721e-06
, O 0 1.801038962412349e-07
and O 0 2.6411547082716424e-07
at O 0 8.048860991038964e-07
least O 0 1.148713346665886e-09
two O 0 2.6558983901026068e-09
of O 0 6.758004378326632e-09
them O 0 2.2875862981663886e-08
displayed O 0 9.928283361659851e-06
signs O 0 4.391260063130176e-06
of O 0 1.174838189399452e-06
neurofibromatosis B-Disease 1 0.9061042666435242
type I-Disease 0 4.736198206956033e-06
1 I-Disease 0 1.2041678019159008e-06
( O 0 5.836371315126598e-07
NF1 B-Disease 0 0.0011440208181738853
) O 0 7.138197588574258e-07
. O 0 1.5023754258436384e-06

DNA O 0 5.345348654373083e-06
sequence O 0 2.0316551285759488e-07
analysis O 0 2.1181148213145207e-07
and O 0 6.973353805506122e-08
allele O 0 2.09335794920662e-07
- O 0 2.6964332846546313e-06
specific O 0 1.8291659298341756e-09
amplification O 0 4.628934220818337e-06
in O 0 3.861113739844768e-08
two O 0 6.887104291308788e-07
siblings O 0 0.00015679237549193203
revealed O 0 1.5033348063298035e-05
a O 0 1.402048752652263e-07
homozygous O 0 2.8540341645566514e-06
MLH1 O 0 0.0013897642493247986
mutation O 0 1.7289661968789005e-07
( O 0 4.763894168036131e-08
C676T O 0 1.5024418644316029e-05
- O 0 0.0018117014551535249
- O 0 0.011909151449799538
> O 0 8.50475043989718e-06
Arg226Stop O 0 0.00018651827122084796
) O 0 6.310013986876584e-07
. O 0 6.184675953591068e-07

Thus O 0 8.354265446541831e-06
, O 0 3.361858205153112e-07
a O 0 4.8085343706816275e-08
homozygous O 0 2.2893250388733577e-06
germ O 0 0.03788437694311142
- O 0 0.003449773881584406
line O 0 2.4067443519015796e-05
MLH1 O 0 0.0038237404078245163
mutation O 0 2.706310908706655e-07
and O 0 6.631235919485334e-06
consequent O 0 0.0637102723121643
mismatch O 1 0.9998179078102112
repair O 1 0.9999785423278809
deficiency O 1 0.9969515800476074
results O 0 7.198073490144452e-06
in O 0 1.4810734683123883e-07
a O 0 1.2103872677471372e-06
mutator O 1 0.6279297471046448
phenotype O 0 0.004949699621647596
characterized O 0 0.003473979188129306
by O 0 0.0008725828374736011
leukemia B-Disease 1 0.9993263483047485
and O 0 0.0013107836712151766
/ O 0 0.44840019941329956
or O 0 0.3357590436935425
lymphoma B-Disease 1 0.999995231628418
associated O 0 0.0010394486598670483
with O 0 0.00015396661183331162
neurofibromatosis B-Disease 1 0.9859470129013062
type I-Disease 0 9.079885785467923e-06
1 I-Disease 0 7.662397933927423e-07
. O 0 1.3068921589365345e-06
. O 0 2.995869181177113e-06

Missense O 0 0.0002547221374697983
mutations O 0 3.214472235413268e-05
in O 0 5.117780119689996e-07
the O 0 3.695716443985475e-08
most O 0 3.211223287280518e-09
ancient O 0 4.8221824755501075e-08
residues O 0 3.155703964807799e-08
of O 0 1.1355967277637546e-09
the O 0 6.583288580941371e-08
PAX6 O 0 3.970699253841303e-05
paired O 0 5.4681026995240245e-06
domain O 0 1.2068792898389802e-07
underlie O 0 2.4927619506343035e-06
a O 0 6.253807782741205e-08
spectrum O 0 4.9534191930433735e-06
of O 0 9.907465027936269e-06
human O 0 0.2914876937866211
congenital B-Disease 1 0.9999282360076904
eye I-Disease 1 0.9820128083229065
malformations I-Disease 1 0.9991874098777771
. O 0 0.0012012411607429385

Mutations O 0 1.813888047763612e-05
of O 0 2.0740507977734524e-07
the O 0 7.102540280357061e-07
human O 0 8.560791684431024e-06
PAX6 O 0 0.021698005497455597
gene O 0 0.00045151656377129257
underlie O 1 0.8709627389907837
aniridia B-Disease 1 0.9999746084213257
( O 0 0.028582891449332237
congenital B-Disease 1 0.9998313188552856
absence I-Disease 0 4.924152108287672e-06
of I-Disease 0 1.503332782704092e-07
the I-Disease 0 1.1067973900935613e-05
iris I-Disease 1 0.8250669836997986
) O 0 5.255225005385e-06
, O 0 9.680192079031258e-07
a O 0 7.535852546425303e-07
rare O 0 0.00012075230915797874
dominant O 0 0.005464988760650158
malformation B-Disease 1 0.9935550093650818
of I-Disease 0 7.000800223977421e-07
the I-Disease 0 1.6657710148137994e-05
eye I-Disease 0 0.0018053484382107854
. O 0 3.127996751572937e-05

The O 0 4.5214238753032987e-07
spectrum O 0 2.1011433091189247e-06
of O 0 3.286048411155207e-07
PAX6 O 0 0.002301086438819766
mutations O 0 1.0243692486255895e-05
in O 0 6.0487192968139425e-05
aniridia B-Disease 1 0.9999239444732666
patients O 0 1.3052384019829333e-05
is O 0 2.369977458727135e-08
highly O 0 4.6926853514150935e-08
biased O 0 7.142043159547029e-06
, O 0 2.1632860125464504e-07
with O 0 2.5830991035036277e-07
92 O 0 2.460340147081297e-05
% O 0 6.921974993190361e-09
of O 0 4.633935013487189e-09
all O 0 3.84032112776822e-08
reported O 0 0.00025386965717189014
mutations O 0 1.3677782817467232e-07
leading O 0 2.3981661456673464e-07
to O 0 4.243290163685742e-08
premature O 0 3.4974038953805575e-06
truncation O 0 5.236112201600918e-07
of O 0 5.168413697020924e-09
the O 0 7.366748633330644e-08
protein O 0 2.0120957344715862e-07
( O 0 4.056456059942093e-09
nonsense O 0 2.2523229858961713e-07
, O 0 4.46108083806962e-09
splicing O 0 2.7532099267091326e-08
, O 0 1.6507314626323932e-08
insertions O 0 1.2816863659281807e-07
and O 0 7.387799882963009e-08
deletions O 0 7.941172270875541e-07
) O 0 3.1059911975717114e-08
and O 0 2.3048068342745864e-08
just O 0 2.7360970378254024e-08
2 O 0 1.929654587229379e-07
% O 0 6.4294969348566156e-09
leading O 0 2.7125063084554313e-08
to O 0 3.5050956581628157e-10
substitution O 0 1.7302238808358794e-10
of O 0 1.9532772621566608e-10
one O 0 2.0888655249962085e-09
amino O 0 2.971794144102091e-09
acid O 0 9.812436196909857e-09
by O 0 4.933353281444397e-09
another O 0 9.475362361399675e-08
( O 0 1.1618948292380082e-07
missense O 0 2.264376007587998e-06
) O 0 4.0393342715105973e-07
. O 0 7.284589855771628e-07

The O 0 1.2394831401252304e-06
extraordinary O 0 2.6307172902306775e-06
conservation O 0 1.7170728483506537e-07
of O 0 4.0782945909256796e-09
the O 0 3.314025676104393e-08
PAX6 O 0 2.4608492822153494e-05
protein O 0 3.4821962202613577e-08
at O 0 2.188787640022838e-08
the O 0 1.0173465403440218e-09
amino O 0 2.833980827787741e-09
acid O 0 1.0446617793036239e-08
level O 0 3.5104164020083317e-09
amongst O 0 1.614532862959095e-08
vertebrates O 0 6.194508387125097e-06
predicts O 0 0.0030330875888466835
that O 0 4.641270550109766e-07
pathological O 0 4.307303606765345e-05
missense O 0 7.080026080075186e-06
mutations O 0 4.900634849036578e-07
should O 0 2.3249226543953228e-08
in O 0 7.728375095439333e-08
fact O 0 2.3592484410528414e-07
be O 0 2.6614676684744154e-08
common O 0 7.193998641241706e-08
even O 0 2.4576652890573314e-07
though O 0 1.863277958591425e-07
they O 0 1.8641165056010323e-08
are O 0 2.659081621558812e-09
hardly O 0 3.2456620147058857e-07
ever O 0 7.09104881480016e-07
seen O 0 2.7165970095666125e-06
in O 0 6.755017693649279e-06
aniridia B-Disease 1 0.999743640422821
patients O 0 3.8202506402740255e-05
. O 0 1.230230373039376e-05

This O 0 4.282711415726226e-06
indicates O 0 2.3695249183219858e-05
that O 0 2.78984941814997e-07
there O 0 9.569384396002079e-09
is O 0 4.4752277439386035e-09
a O 0 1.5925241569902937e-08
heavy O 0 0.00022661536058876663
ascertainment O 0 0.0026154809165745974
bias O 0 6.368186404870357e-06
in O 0 1.6125845547776407e-08
the O 0 3.8904377497317455e-09
selection O 0 5.180770479285002e-09
of O 0 5.370348077349263e-08
patients O 0 2.556298852596228e-07
for O 0 2.143343635907513e-08
PAX6 O 0 0.0001617631351109594
mutation O 0 6.216725978447357e-08
analysis O 0 1.9453084121323627e-07
and O 0 1.2094557177988463e-07
that O 0 3.901303102793463e-08
the O 0 2.8043177735526115e-07
missing O 0 7.17781440471299e-05
PAX6 O 0 0.0012885633623227477
missense O 0 1.853901267168112e-05
mutations O 0 2.2641729628958274e-06
frequently O 0 2.8608058073587017e-06
may O 0 6.567914169863798e-06
underlie O 0 3.67322500096634e-05
phenotypes O 0 6.875240160297835e-06
distinct O 0 2.646754921897809e-07
from O 0 2.18891864278703e-06
textbook O 0 0.002029533963650465
aniridia B-Disease 1 0.9984387755393982
. O 0 0.00010039469634648412

Here O 0 6.3164293351292145e-06
we O 0 9.773066267371178e-08
present O 0 1.3624050332339266e-08
four O 0 5.060471863771454e-08
novel O 0 1.3612252587336116e-06
PAX6 O 0 0.00012186277308501303
missense O 0 4.560034540190827e-06
mutations O 0 3.452963710515178e-07
, O 0 2.288119134163935e-07
two O 0 2.60766228166176e-07
in O 0 1.376057866764313e-06
association O 0 9.132286891144759e-07
with O 0 1.3573014712164877e-06
atypical O 0 0.0008583078160881996
phenotypes O 0 0.0022138298954814672
ectopia B-Disease 1 0.6956211924552917
pupillae I-Disease 0 0.2429555207490921
( O 0 2.0556234403557028e-07
displaced B-Disease 0 4.989091166862636e-07
pupils I-Disease 0 1.3384951103034837e-07
) O 0 9.623926416679751e-06
and O 0 0.008402768522500992
congenital B-Disease 1 0.9998044371604919
nystagmus I-Disease 0 0.0007792342221364379
( O 0 3.567073036947477e-08
searching B-Disease 0 7.235873908939539e-07
gaze I-Disease 0 2.2651647668681107e-05
) O 0 2.308045310428497e-07
, O 0 4.8081489012474776e-08
and O 0 4.051354807188545e-08
two O 0 1.1227660223767089e-07
in O 0 4.7253246293621487e-07
association O 0 1.3832374179401086e-07
with O 0 2.5335426201422706e-08
more O 0 3.5896164263249375e-08
recognizable O 0 5.111243444844149e-05
aniridia B-Disease 1 0.9960619807243347
phenotypes O 0 0.0003865268372464925
. O 0 1.479170168749988e-05

Strikingly O 0 0.00036625369102694094
, O 0 1.6622975635982584e-06
all O 0 8.900341796902467e-09
four O 0 1.9596423328493984e-07
mutations O 0 1.7355843340283172e-07
are O 0 9.539875556185962e-10
located O 0 3.0612730128609655e-09
within O 0 4.6059989156077563e-10
the O 0 3.379266644287782e-08
PAX6 O 0 4.578638618113473e-05
paired O 0 1.6538788258912973e-06
domain O 0 3.997348585471627e-08
and O 0 1.947163852378253e-08
affect O 0 1.336879051905271e-09
amino O 0 4.645800411040568e-10
acids O 0 4.869007974583894e-10
which O 0 3.696080996817841e-09
are O 0 1.2516243597104904e-10
highly O 0 1.8850820904248167e-09
conserved O 0 2.4469335446752893e-09
in O 0 2.224429751507273e-09
all O 0 3.9112979521860325e-10
known O 0 1.0244093573419377e-08
paired O 0 7.602869800393819e-07
domain O 0 6.426103738021993e-08
proteins O 0 9.366971198687679e-08
. O 0 6.896286777191563e-07

Our O 0 1.2743214483634802e-06
results O 0 1.4336027334138635e-06
support O 0 5.892067633794795e-08
the O 0 9.527990840751954e-08
hypothesis O 0 4.013139971448254e-07
that O 0 7.548278446734003e-09
the O 0 5.822775595021312e-09
under O 0 2.338108018307139e-08
- O 0 4.117347543797223e-06
representation O 0 3.3417177913719343e-09
of O 0 1.741841337832284e-08
missense O 0 9.486503586231265e-06
mutations O 0 1.998148945858702e-06
is O 0 2.669333127869322e-07
caused O 0 2.4881210265448317e-06
by O 0 9.745163254137879e-08
ascertainment O 0 0.0011263367487117648
bias O 0 0.00018815012299455702
and O 0 3.3105939110100735e-06
suggest O 0 4.1082068946707295e-07
that O 0 3.4116219183033536e-08
a O 0 7.24135560403738e-08
substantial O 0 1.3087951344914472e-07
burden O 0 1.878181501524523e-05
of O 0 3.0892067570675863e-07
PAX6 B-Disease 1 0.533028781414032
- I-Disease 1 0.9956405162811279
related I-Disease 0 0.35124778747558594
disease I-Disease 0 0.01709921658039093
remains O 0 6.751089586032322e-06
to O 0 5.59556916357451e-08
be O 0 8.318422572983764e-08
uncovered O 0 0.0005936928791925311
. O 0 1.8022363974523614e-06
. O 0 6.9262828219507355e-06

The O 0 4.932090632792097e-06
chromosomal O 0 0.0015033392701297998
order O 0 1.7499206705906545e-07
of O 0 1.6595771867855547e-08
genes O 0 2.3093795675777073e-07
controlling O 0 1.5923593537081615e-06
the O 0 2.8397396434343136e-08
major O 0 2.3742921939629014e-07
histocompatibility O 0 0.0031014522537589073
complex O 0 6.418162229238078e-06
, O 0 1.3783220538243768e-06
properdin O 0 0.0016164312837645411
factor O 0 9.499227076048555e-07
B O 0 1.4443216059589759e-05
, O 0 3.5572463730204618e-06
and O 0 0.0012895192485302687
deficiency B-Disease 0 0.01152076106518507
of I-Disease 0 1.6474341890670985e-09
the I-Disease 0 1.228238932782233e-08
second I-Disease 0 1.3629019690597488e-07
component I-Disease 0 8.14467284726561e-08
of I-Disease 0 8.469116075104921e-09
complement I-Disease 0 5.605342039416428e-07
. O 0 3.942320290661883e-06

The O 0 1.8490949287297553e-06
relationship O 0 4.020757842226885e-06
of O 0 7.671798307740119e-09
the O 0 1.708499830499477e-08
genes O 0 6.504916427729768e-08
coding O 0 1.03941547422437e-05
for O 0 2.1967174745896045e-08
HLA O 0 9.597876669431571e-06
to O 0 2.639384932834332e-09
those O 0 1.9802497419618703e-09
coding O 0 2.231859070889186e-06
for O 0 1.657521053743949e-08
properdin O 0 0.0001356019638478756
Factor O 0 2.587107985618786e-07
B O 0 6.775237579859095e-06
allotypes O 0 0.0004633606586139649
and O 0 1.8036599840343115e-06
for O 0 1.7813414388001547e-06
deficiency B-Disease 0 0.004228157456964254
of I-Disease 0 9.412129964303517e-10
the I-Disease 0 6.41665787171064e-09
second I-Disease 0 6.233289440160661e-08
component I-Disease 0 3.3334945470642197e-08
of I-Disease 0 1.1913217079495553e-09
complement I-Disease 0 1.1806253752411067e-07
( O 0 5.3622720486146136e-08
C2 O 0 0.0019617960788309574
) O 0 1.207111779422121e-07
was O 0 8.002662070794031e-07
studied O 0 6.416232167794078e-08
in O 0 5.6429740880048485e-08
families O 0 8.166456382241449e-07
of O 0 8.598164527029439e-07
patients O 0 2.0041752577526495e-05
with O 0 0.00032223641755990684
connective O 1 0.9979037046432495
tissue O 1 0.9991649389266968
disorders O 1 0.9977664947509766
. O 0 0.00024710444267839193

Patients O 0 6.82643658365123e-05
were O 0 6.456793926190585e-07
selected O 0 5.3455352144737844e-08
because O 0 3.651001989624092e-08
they O 0 4.041874834825876e-09
were O 0 8.866590128775442e-09
heterozygous O 0 5.820591297833744e-08
or O 0 2.3252226810654975e-07
homozygous O 0 1.7587639376870357e-05
for O 0 0.0003479619335848838
C2 B-Disease 1 0.9998866319656372
deficiency I-Disease 1 0.9997045397758484
. O 0 7.915827154647559e-05

12 O 0 5.075625449535437e-05
families O 0 2.7912462883250555e-06
with O 0 1.385997308034348e-07
15 O 0 3.145320590647316e-07
matings O 0 2.8755806852132082e-05
informative O 0 9.453783604840282e-06
for O 0 0.0005719634937122464
C2 B-Disease 1 0.9999703168869019
deficiency I-Disease 1 0.9998748302459717
were O 0 1.7679240045254119e-06
found O 0 1.0112798918271437e-05
. O 0 1.045592398440931e-05

Of O 0 4.2040016978717176e-07
57 O 0 3.9494138945883606e-06
informative O 0 9.24645746636088e-07
meioses O 0 0.0004124562838114798
, O 0 5.5770613016647985e-08
two O 0 4.182173718447757e-09
crossovers O 0 5.400896725404891e-07
were O 0 1.1707464153687397e-07
noted O 0 3.4893176348305133e-07
between O 0 1.0080198080686387e-06
the O 0 0.003035404486581683
C2 B-Disease 1 0.9999946355819702
deficiency I-Disease 1 0.9997569918632507
gene O 0 4.867257885621257e-08
and O 0 3.5506598550227864e-08
the O 0 1.216681511095885e-07
HLA O 0 0.0005988231278024614
- O 0 0.0018780750688165426
B O 0 4.624437679012772e-06
gene O 0 2.100264495652482e-08
, O 0 9.260118005727236e-09
with O 0 3.4947966742748804e-09
a O 0 6.301965171928714e-09
recombinant O 0 1.250460428536826e-07
fraction O 0 1.0096205649290368e-08
of O 0 1.9271015005983827e-08
0 O 0 7.871652769608772e-07
. O 0 1.3051659379925695e-06

035 O 0 0.11122439056634903
. O 0 0.0006244669784791768

A O 0 7.119180736481212e-06
lod O 0 0.00024229752307292074
score O 0 1.1101277408442911e-07
of O 0 1.8379518351707702e-08
13 O 0 7.202139045148215e-07
was O 0 3.8716748917977384e-07
calculated O 0 1.0341392453483422e-07
for O 0 7.278213143280254e-09
linkage O 0 0.00019091198919340968
between O 0 0.015371836721897125
C2 B-Disease 1 0.9999887943267822
deficiency I-Disease 1 0.9999059438705444
and O 0 2.8156316602689913e-06
HLA O 0 0.002123831072822213
- O 0 0.005857405252754688
B O 0 8.804340723145287e-06
at O 0 1.0076605860831478e-07
a O 0 4.532040964733142e-09
maximum O 0 6.599932156348132e-09
likelihood O 0 2.8900375426132996e-08
value O 0 5.030997840549389e-10
of O 0 2.1315144094202765e-10
the O 0 1.6707591976583558e-09
recombinant O 0 1.203135298055713e-07
fraction O 0 1.5456485868980963e-08
of O 0 1.989677933522671e-08
0 O 0 9.808356935536722e-07
. O 0 1.5173691281233914e-06

04 O 0 0.007087022997438908
. O 0 0.0003502640756778419

18 O 0 6.376586679834872e-05
families O 0 3.1147533263720106e-06
with O 0 3.900210288065864e-07
21 O 0 2.993145358232141e-07
informative O 0 6.532243901347101e-08
matings O 0 3.0489668461086694e-06
for O 0 2.6950279785609155e-09
both O 0 1.4605630482833476e-08
properdin O 0 0.00014497197116725147
Factor O 0 1.7425732323772536e-07
B O 0 1.1169938716193428e-06
allotype O 0 1.0802187716763001e-05
and O 0 1.2044900188357133e-07
HLA O 0 4.939734571962617e-05
- O 0 0.0004254874656908214
B O 0 4.774751232616836e-06
were O 0 5.4267331961455056e-08
found O 0 9.114137355936691e-07
. O 0 1.8070397800329374e-06

Of O 0 3.594015254293481e-07
72 O 0 6.372292773448862e-06
informative O 0 1.4665265553048812e-06
meioses O 0 0.0004941790830343962
, O 0 1.441756296571839e-07
three O 0 1.175278185883144e-07
recombinants O 0 0.0015514917904511094
were O 0 2.0962288260761852e-07
found O 0 8.385870842175791e-07
, O 0 2.9504860776796704e-08
giving O 0 7.318090577967951e-10
a O 0 1.746757849474534e-09
recombinant O 0 2.0806440659271175e-07
fraction O 0 3.5830499456324105e-08
of O 0 1.7031085874918972e-08
0 O 0 1.608846332601388e-06
. O 0 1.2664006590057397e-06

042 O 0 0.030759945511817932
. O 0 0.0003776483645197004

A O 0 5.247361968940822e-06
lod O 0 8.463345147902146e-05
score O 0 2.7152394110885325e-08
of O 0 2.225588380255772e-09
16 O 0 2.9396334255693546e-08
between O 0 9.488057628459501e-08
HLA O 0 0.00014758184261154383
- O 0 0.001001988654024899
B O 0 3.871508397423895e-06
and O 0 7.704591098445235e-08
Factor O 0 1.1969359547947533e-07
B O 0 5.372465693653794e-06
allotypes O 0 0.00010002823546528816
was O 0 7.007373028500297e-07
calculated O 0 7.268089774470354e-08
at O 0 2.1946235051473195e-08
a O 0 1.7173986677221365e-09
maximum O 0 6.770868310468359e-09
likelihood O 0 3.2339919187052146e-08
value O 0 1.27453514409126e-09
of O 0 2.6120741680735193e-10
the O 0 3.127599068619702e-09
recombinant O 0 1.2287924278098217e-07
fraction O 0 1.5084848925539518e-08
of O 0 3.2689005280417405e-08
0 O 0 1.1459213737907703e-06
. O 0 1.0422535297038849e-06

04 O 0 0.008074913173913956
. O 0 0.00035900669172406197

A O 0 1.2207183317514136e-06
crossover O 0 2.006435715884436e-05
was O 0 2.4415547159151174e-05
shown O 0 5.890825605092687e-07
to O 0 1.6651195977601674e-08
have O 0 9.473370532475656e-09
occurred O 0 9.794021593734215e-08
between O 0 5.874705166775129e-09
genes O 0 3.424554861908291e-09
for O 0 8.907385384837596e-10
Factor O 0 2.5290283645063028e-08
B O 0 2.7246559852756036e-07
and O 0 1.0604496480937087e-07
HLA O 0 0.000105392282421235
- O 0 0.028101708739995956
D O 0 0.02193809300661087
, O 0 3.41199957176741e-08
in O 0 6.929478324479987e-09
which O 0 9.747598284093328e-08
HLA O 0 8.071162301348522e-05
- O 0 0.013717861846089363
D O 0 0.008418142795562744
segregared O 0 1.612113555893302e-05
with O 0 3.54697071713872e-08
HLA O 0 2.3369915652438067e-05
- O 0 3.358737376402132e-05
A O 0 2.3510951052685414e-07
and O 0 1.6734539940443938e-06
B O 0 2.2954240193939768e-05
. O 0 8.911657118915173e-07

These O 0 6.410409696400166e-07
studies O 0 1.4362054798766621e-06
suggest O 0 6.841150934633333e-07
that O 0 6.02092864454562e-09
the O 0 2.2545734168488707e-09
genes O 0 7.268099899704339e-09
for O 0 5.925819390739662e-09
Factor O 0 8.816992931315326e-07
B O 0 0.0009171142592094839
and O 0 0.02901841327548027
C2 B-Disease 1 0.9999927282333374
deficiency I-Disease 1 0.9998675584793091
are O 0 1.513054348478704e-09
located O 0 7.515152056214447e-09
outside O 0 1.0608578904225396e-08
those O 0 1.0648231629772908e-08
for O 0 4.126472674670367e-08
HLA O 0 0.00140002288389951
, O 0 2.2524818632518873e-07
that O 0 4.0871328543801155e-09
the O 0 1.1763267027120605e-09
order O 0 3.895352929106366e-09
of O 0 8.105105919753441e-09
genese O 0 0.000873651122674346
is O 0 3.4206138366243977e-08
HLA O 0 4.951964001520537e-06
- O 0 3.798582156377961e-06
A O 0 5.4582383057777406e-08
, O 0 1.804339717637049e-07
- O 0 0.00016842807235661894
B O 0 5.974753548798617e-06
, O 0 1.0995366039878718e-07
- O 0 0.0005111601785756648
D O 0 0.005290312226861715
, O 0 8.114297145311866e-08
Factor O 0 1.2873410071279068e-07
B O 0 8.454418093606364e-06
allotype O 0 0.02777552604675293
, O 0 0.017362309619784355
C2 B-Disease 1 0.9999920129776001
deficiency I-Disease 1 0.9999104738235474
, O 0 1.576232193656324e-07
that O 0 2.8402256102566525e-09
the O 0 3.0720004318141036e-09
genes O 0 3.415489402414096e-08
coding O 0 0.00044451485155150294
for O 0 0.0004054454620927572
C2 B-Disease 1 0.9999945163726807
deficiency I-Disease 1 0.99996018409729
and O 0 1.420908802174381e-06
Factor O 0 3.4213127264592913e-07
B O 0 1.1594070201681461e-06
allotypes O 0 3.774316155613633e-06
are O 0 1.3546481991699721e-10
approximately O 0 3.9994646483521024e-10
3 O 0 1.5473299086465886e-08
- O 0 8.234391316364054e-06
- O 0 4.1561088437447324e-05
5 O 0 1.1090970986060711e-07
centimorgans O 0 1.8136666767532006e-05
from O 0 1.780051439581598e-09
the O 0 5.308649519975006e-09
HLA O 0 5.193841388972942e-06
- O 0 3.6406800063559785e-06
A O 0 5.0434930898290986e-08
and O 0 2.3377296543003467e-07
HLA O 0 2.4847942768246867e-05
- O 0 0.00010143464896827936
B O 0 8.233230914811429e-07
loci O 0 1.1027937674157329e-08
, O 0 3.55331550849769e-08
and O 0 4.343668180695204e-08
that O 0 2.1617202250467926e-08
the O 0 2.7579403649724554e-08
apparent O 0 7.880705197749194e-06
lack O 0 4.2924000354105374e-08
of O 0 3.260773695501484e-08
recombinants O 0 0.0007138507789932191
between O 0 2.7865514340419395e-08
the O 0 2.856787162386354e-08
Factor O 0 4.5173982243795763e-07
B O 0 1.2365195289021358e-05
gene O 0 3.372414084878983e-06
and O 0 0.10136592388153076
C2 B-Disease 1 0.9999916553497314
deficiency I-Disease 1 0.9999523162841797
gene O 0 7.930319156912446e-07
suggests O 0 9.609368589735823e-07
that O 0 1.876645328025006e-08
these O 0 1.1142846645384452e-09
two O 0 2.708318902477913e-08
genes O 0 3.0913992077330477e-07
lie O 0 3.5907373785448726e-06
in O 0 1.4229488698447312e-08
close O 0 7.333844678214518e-07
proximity O 0 1.0063448740993408e-07
to O 0 8.785851157711022e-09
one O 0 1.490532497427921e-08
another O 0 1.9998427092104976e-07
. O 0 2.4977209704957204e-06

Distribution O 0 2.1099867808516137e-06
of O 0 5.320279115039739e-07
emerin O 0 0.009994321502745152
and O 0 2.1882506189285778e-05
lamins O 0 0.006024534814059734
in O 0 5.950654440312064e-07
the O 0 3.4792799397109775e-06
heart O 0 0.0004958498757332563
and O 0 2.4727521577005973e-06
implications O 0 4.433812591742026e-06
for O 0 3.1405070899381826e-07
Emery B-Disease 0 0.1438315361738205
- I-Disease 1 0.9905934929847717
Dreifuss I-Disease 1 0.9985148310661316
muscular I-Disease 1 0.9995458722114563
dystrophy I-Disease 1 0.9985042810440063
. O 0 0.00021629621915053576

Emerin O 0 0.007897807285189629
is O 0 7.949901714709995e-07
a O 0 9.779163434586735e-08
nuclear O 0 6.922117609065026e-05
membrane O 0 2.4611699700471945e-06
protein O 0 1.1992405291039177e-07
which O 0 3.6642013867549394e-08
is O 0 1.0653309345798334e-08
missing O 0 1.320032083640399e-06
or O 0 4.1654905658106145e-07
defective O 0 0.0003542020858731121
in O 0 6.8676449700433295e-06
Emery B-Disease 1 0.7782608270645142
- I-Disease 1 0.9977748990058899
Dreifuss I-Disease 1 0.9996668100357056
muscular I-Disease 1 0.9998918771743774
dystrophy I-Disease 1 0.999788224697113
( O 0 0.00031842305907048285
EDMD B-Disease 1 0.9995371103286743
) O 0 4.821842230740003e-05
. O 0 8.563853953091893e-06

It O 0 1.830987457651645e-06
is O 0 5.6886538146727617e-08
one O 0 4.276095477706576e-09
member O 0 6.064333479827155e-09
of O 0 5.289354731985441e-09
a O 0 9.337858841718116e-08
family O 0 1.2032071936118882e-05
of O 0 2.2349018991008052e-07
lamina O 0 0.06762701272964478
- O 0 0.003395306644961238
associated O 0 8.217338631766324e-07
proteins O 0 8.167708287487585e-09
which O 0 1.9213759472336278e-08
includes O 0 6.881104752665124e-08
LAP1 O 0 0.0019186183344572783
, O 0 6.004142392157519e-07
LAP2 O 0 0.00019347606576047838
and O 0 7.405447490782535e-07
lamin O 0 0.0004973251488991082
B O 0 3.866545739583671e-05
receptor O 0 1.2774668221027241e-06
( O 0 5.274337127048057e-07
LBR O 0 0.0008540115086361766
) O 0 4.893956315754622e-07
. O 0 1.117684405471664e-06

A O 0 5.5754294407961424e-06
panel O 0 1.2872253137174994e-05
of O 0 6.575520927754042e-08
16 O 0 1.9060257727687713e-06
monoclonal O 0 1.0079803359985817e-05
antibodies O 0 1.7064893427232164e-06
( O 0 6.733380786272392e-08
mAbs O 0 2.655235402926337e-05
) O 0 1.0146091966589665e-07
has O 0 1.7907963112406833e-08
been O 0 7.574382898667409e-09
mapped O 0 1.5182752122200327e-07
to O 0 1.4173708873244095e-09
six O 0 2.4943431764512525e-09
specific O 0 7.281732855579648e-11
sites O 0 1.3603996817934672e-09
throughout O 0 2.509823460172811e-10
the O 0 2.9292051006990505e-09
emerin O 0 4.580501808959525e-06
molecule O 0 7.013956526691345e-09
using O 0 2.2739037319752242e-09
phage O 0 2.53543589678884e-07
- O 0 2.95474887934688e-06
displayed O 0 9.326075911531007e-08
peptide O 0 2.3746515864786488e-08
libraries O 0 4.645386297852383e-09
and O 0 6.188025736264535e-08
has O 0 3.661351044570438e-08
been O 0 7.177986649509194e-09
used O 0 7.332666918102859e-09
to O 0 7.242857869016461e-09
localize O 0 8.666453140904196e-06
emerin O 0 0.0004608015588019043
in O 0 8.389088179683313e-08
human O 0 7.745595667074667e-07
and O 0 6.598339678021148e-05
rabbit O 0 0.36587634682655334
heart O 0 0.0018157802987843752
. O 0 1.8850270862458274e-05

Several O 0 1.1687211554090027e-06
mAbs O 0 0.00011714599531842396
against O 0 1.3052556369075319e-06
different O 0 2.0141531109629796e-08
emerin O 0 0.0007769760559312999
epitopes O 0 7.666421151952818e-05
did O 0 1.3737643200784078e-07
not O 0 2.6256672391866687e-09
recognize O 0 2.4384647190345277e-08
intercalated O 0 4.517994057096075e-06
discs O 0 0.00028985645622015
in O 0 3.202979428351682e-07
the O 0 4.432366495166207e-06
heart O 0 0.0013426494551822543
, O 0 8.926712098400458e-07
though O 0 1.1542379496631838e-07
they O 0 4.047753687785871e-09
recognized O 0 7.859934036957839e-09
cardiomyocyte O 0 3.5221710277255625e-05
nuclei O 0 1.3515752925741253e-06
strongly O 0 5.028182954447402e-07
, O 0 7.759599185419574e-08
both O 0 5.600285568618801e-09
at O 0 1.1837557849503355e-06
the O 0 4.711438634785736e-07
rim O 0 0.005746177397668362
and O 0 5.83329949677136e-07
in O 0 1.0010611362076816e-07
intranuclear O 0 0.00010218247189186513
spots O 0 4.2874250993918395e-07
or O 0 6.183224598999004e-08
channels O 0 1.1228146377106896e-06
. O 0 2.5494457531749504e-06

A O 0 1.1556335266504902e-05
polyclonal O 0 0.0005341824726201594
rabbit O 0 0.0064498926512897015
antiserum O 0 0.0005601897137239575
against O 0 0.0001207840905408375
emerin O 0 0.030808979645371437
did O 0 6.761294457646727e-07
recognize O 0 1.649847014562056e-08
both O 0 3.534980974606583e-09
nuclear O 0 3.479870656519779e-06
membrane O 0 5.6330165421059064e-08
and O 0 4.643209550181382e-08
intercalated O 0 1.7934526113094762e-06
discs O 0 2.6824171072803438e-05
but O 0 2.1275441852708354e-08
, O 0 6.147273801104802e-09
after O 0 3.089064648520434e-08
affinity O 0 3.6685019466631275e-08
purification O 0 6.390224029928504e-07
against O 0 1.2676727578764257e-07
a O 0 8.080069946458934e-09
pure O 0 1.8929200962247705e-07
- O 0 0.00016075445455498993
emerin O 0 4.431169145391323e-05
band O 0 4.030937006405111e-08
on O 0 1.83075492543594e-08
a O 0 1.2625807954691481e-08
western O 0 3.1791449828233453e-07
blot O 0 0.00016116669576149434
, O 0 4.1581952814340184e-07
it O 0 6.155865150958562e-08
stained O 0 0.00015719953808002174
only O 0 1.6053320894826584e-09
the O 0 5.848423256793467e-08
nuclear O 0 0.00012823689030483365
membrane O 0 5.366065124690067e-06
. O 0 2.152439947167295e-06

These O 0 8.692940127730253e-07
results O 0 6.6315396907157265e-06
would O 0 1.2990274456115003e-07
not O 0 6.3517067161456e-09
be O 0 4.160516819950999e-09
expected O 0 1.2077566680090968e-07
if O 0 4.505385930997363e-08
immunostaining O 0 6.438630953198299e-05
at O 0 8.126933721541718e-07
intercalated O 0 1.1706772056641057e-05
discs O 0 0.00010450509580550715
were O 0 9.650312193798527e-08
due O 0 3.1657720001021517e-08
to O 0 2.718756775266229e-09
a O 0 9.86855575035861e-09
product O 0 8.169456577888923e-08
of O 0 3.194521092098057e-09
the O 0 1.4388992042313475e-07
emerin O 0 0.0016146855195984244
gene O 0 1.118587107384883e-07
and O 0 4.259573245235515e-07
, O 0 4.549334562398144e-07
therefore O 0 3.427196659799847e-08
, O 0 8.240820648097724e-08
cast O 0 1.6621209297795758e-08
some O 0 6.098664351306127e-10
doubt O 0 7.11893832772148e-08
upon O 0 1.0909024794614197e-08
the O 0 1.5712808476564533e-07
hypothesis O 0 2.1165296857361682e-05
that O 0 4.3051310058217496e-05
cardiac B-Disease 1 0.9805918335914612
defects I-Disease 1 0.9851998090744019
in O 0 0.0002786014520097524
EDMD B-Disease 1 0.9999829530715942
are O 0 1.1287023653494543e-06
caused O 0 6.738379397575045e-06
by O 0 4.875982639873655e-08
absence O 0 8.47896160394157e-07
of O 0 1.3841216173204884e-07
emerin O 0 0.00886967871338129
from O 0 3.1072241313268023e-07
intercalated O 0 0.00012864830205217004
discs O 0 0.0013295833487063646
. O 0 5.811012215417577e-06

Although O 0 1.4502245903713629e-05
emerin O 0 0.0023527941666543484
was O 0 4.4114585762145e-06
abundant O 0 5.622604248856078e-08
in O 0 1.6937303115582836e-08
the O 0 6.7572827333606256e-09
membranes O 0 5.339482527233486e-07
of O 0 1.4536040815471551e-08
cardiomyocyte O 0 0.0005807337583974004
nuclei O 0 4.410659130371641e-06
, O 0 2.9802706080772623e-07
it O 0 5.765499722087952e-08
was O 0 2.5948691018129466e-06
absent O 0 1.8313421890070458e-07
from O 0 3.594362807390894e-09
many O 0 3.617490473839524e-10
non O 0 5.51932473058514e-08
- O 0 0.0011772526195272803
myocyte O 0 0.022498292848467827
cells O 0 1.574399334458576e-06
in O 0 7.752528574656026e-08
the O 0 1.8486489352653734e-06
heart O 0 0.0026703313924372196
. O 0 1.4291131265053991e-05

This O 0 1.414242376540642e-07
distribution O 0 3.782564590437687e-07
of O 0 1.5175008627466013e-07
emerin O 0 0.00532947713509202
was O 0 3.462715767454938e-06
similar O 0 4.8694118959247135e-08
to O 0 4.111457396760443e-09
that O 0 1.1629464502505016e-08
of O 0 1.2852673592078645e-08
lamin O 0 0.00017928403394762427
A O 0 5.020459070692596e-07
, O 0 3.1713292969470785e-07
a O 0 7.042592642392265e-08
candidate O 0 1.00009543757551e-07
gene O 0 8.85042439335848e-08
for O 0 4.390973984413904e-08
an O 0 6.987785923229239e-07
autosomal O 0 0.000200115711777471
form O 0 2.9078705665597226e-07
of O 0 9.490791853750125e-06
EDMD B-Disease 1 0.9995607733726501
. O 0 9.571152622811496e-05

In O 0 5.477670129039325e-06
contrast O 0 1.8409136828267947e-05
, O 0 1.8230410205433145e-05
lamin O 0 0.12211070209741592
B1 O 1 0.8368319869041443
was O 0 1.1701727089530323e-05
absent O 0 4.848208163821255e-07
from O 0 4.209505632957189e-08
cardiomyocyte O 0 7.048222323646769e-05
nuclei O 0 1.6084736671473365e-06
, O 0 2.0094627473099536e-07
showing O 0 4.081825409230078e-06
that O 0 2.9495236049115192e-06
lamin O 0 0.13762018084526062
B1 O 0 0.20128047466278076
is O 0 1.0841569419994812e-08
not O 0 7.293383674777942e-10
essential O 0 3.8724087825237063e-10
for O 0 4.501610195717376e-10
localization O 0 2.041076214709392e-07
of O 0 4.471908621184184e-09
emerin O 0 8.682947373017669e-05
to O 0 8.262095896327537e-09
the O 0 1.7718083711315558e-07
nuclear O 0 0.0016417836304754019
lamina O 0 0.003467448055744171
. O 0 5.108420737087727e-06

Lamin O 1 0.9307467341423035
B1 O 1 0.9819338917732239
is O 0 3.6374108276504558e-06
also O 0 2.854660863249592e-07
almost O 0 6.174114730583824e-08
completely O 0 2.2012907265889226e-06
absent O 0 2.9050422654108843e-06
from O 0 9.372776617055933e-07
skeletal O 0 0.18830659985542297
muscle O 0 0.0018584057688713074
nuclei O 0 7.805198401911184e-05
. O 0 2.289936128363479e-05

In O 0 0.0001371290418319404
EDMD B-Disease 1 0.9967942833900452
, O 0 1.2660456150115351e-06
the O 0 1.6206572084342952e-08
additional O 0 3.854621954957338e-09
absence O 0 5.967903149439735e-08
of O 0 2.4797063247206097e-07
lamin O 0 0.2597481608390808
B1 O 1 0.8844764232635498
from O 0 7.722038048996183e-07
heart O 0 0.00014556260430254042
and O 0 7.7293252616073e-06
skeletal O 0 0.20870067179203033
muscle O 0 0.0009666773257777095
nuclei O 0 2.5452151021454483e-05
which O 0 1.048487433763512e-06
already O 0 6.536814453284023e-06
lack O 0 1.0835769899131265e-06
emerin O 0 0.027822257950901985
may O 0 3.891939002187428e-07
offer O 0 4.745807746786568e-09
an O 0 1.123154791393688e-09
alternative O 0 3.3075577832164527e-09
explanation O 0 3.500048251225962e-08
of O 0 1.7716317302074458e-08
why O 0 3.929053491447121e-07
these O 0 1.2016097450384677e-08
tissues O 0 2.0999214029870927e-06
are O 0 5.964691851545467e-09
particularly O 0 1.54145396891181e-07
affected O 0 1.2735496568438975e-07
. O 0 2.521121018617123e-07
. O 0 3.669618990898016e-06

Genetic O 0 4.777955109602772e-05
mapping O 0 9.384786608279683e-06
of O 0 1.3140579824266752e-07
the O 0 2.50889615927008e-06
copper B-Disease 0 0.03578685596585274
toxicosis I-Disease 0 0.002972286893054843
locus O 0 1.5712328149675159e-06
in O 0 9.557513891422786e-08
Bedlington O 0 0.0005238433368504047
terriers O 0 0.0002443749108351767
to O 0 1.0051516596831789e-07
dog O 0 0.00010957209451589733
chromosome O 0 0.00028602551901713014
10 O 0 3.8994141959847184e-07
, O 0 1.945015242199588e-07
in O 0 2.0151061264073178e-08
a O 0 1.2613260480520694e-07
region O 0 4.2944120650645345e-06
syntenic O 0 0.0015729774022474885
to O 0 2.8558607922946067e-08
human O 0 5.013578743273683e-07
chromosome O 0 5.510593473445624e-05
region O 0 2.863054987756186e-06
2p13 O 0 9.99716721707955e-05
- O 0 0.00176466372795403
p16 O 0 0.00011598633864196017
. O 0 2.6441741738381097e-06

Abnormal O 1 0.9423204064369202
hepatic B-Disease 1 0.9975997805595398
copper I-Disease 1 0.9660080075263977
accumulation I-Disease 0 0.010303772054612637
is O 0 7.196379101515049e-07
recognized O 0 2.735440034484782e-07
as O 0 1.7153915905510075e-06
an O 0 0.018004292622208595
inherited B-Disease 1 0.9999949932098389
disorder I-Disease 1 0.9999101161956787
in O 0 1.5954929040162824e-05
man O 0 0.0011489437893033028
, O 0 8.110882845357992e-06
mouse O 0 0.0009398001711815596
, O 0 1.2294468433537986e-05
rat O 0 0.00400250731036067
and O 0 8.00190719019156e-06
dog O 0 0.00030541239539161325
. O 0 1.1195683327969164e-05

The O 0 1.124743721447885e-05
major O 0 1.2334950952208601e-05
cause O 0 2.535894418542739e-05
of O 0 5.253180916042766e-06
hepatic B-Disease 1 0.9869455695152283
copper I-Disease 1 0.7768797278404236
accumulation I-Disease 0 0.0007353810942731798
in O 0 1.4062055697650067e-06
man O 0 4.213624561089091e-05
is O 0 1.1132128463486879e-07
a O 0 6.933935310371453e-07
dysfunctional O 0 0.09823194891214371
ATP7B O 0 0.33836475014686584
gene O 0 1.632096609682776e-05
, O 0 0.00021199991169851273
causing O 0 0.051314353942871094
Wilson B-Disease 1 0.5061265826225281
disease I-Disease 0 0.39978739619255066
( O 0 1.3669747204403393e-05
WD B-Disease 1 0.9134464263916016
) O 0 5.445174338092329e-06
. O 0 4.336923666414805e-06

Mutations O 0 9.953559128916822e-06
in O 0 3.419831671180873e-07
the O 0 4.4095307316638355e-07
ATP7B O 0 0.014290099032223225
genes O 0 5.469430561788613e-07
have O 0 8.075235058413455e-08
also O 0 6.717756662055763e-08
been O 0 4.5168032869469243e-08
demonstrated O 0 5.921968977418146e-07
in O 0 1.1071420402686272e-07
mouse O 0 0.0001442276843590662
and O 0 1.1271230505371932e-05
rat O 0 0.006240253336727619
. O 0 7.184548849181738e-06

The O 0 3.7942882045172155e-06
ATP7B O 0 0.0075081707909703255
gene O 0 3.40769861395529e-06
has O 0 2.039468199654948e-06
been O 0 3.234609096125496e-07
excluded O 0 3.4133344684050826e-07
in O 0 1.9801600359414806e-08
the O 0 3.86633871585218e-08
much O 0 2.54901266316665e-07
rarer O 0 0.00016106391558423638
human O 0 0.00010912663128692657
copper B-Disease 1 0.9933793544769287
overload I-Disease 1 0.9807290434837341
disease O 0 0.0008143872837536037
non B-Disease 0 1.8356522559770383e-06
- I-Disease 0 0.3512240946292877
Indian I-Disease 0 0.0011167337652295828
childhood I-Disease 0 0.13133487105369568
cirrhosis I-Disease 0 0.21900562942028046
, O 0 2.6758887088362826e-06
indicating O 0 1.3924115592089947e-05
genetic O 0 1.2873578270955477e-05
heterogeneity O 0 0.0001848120300564915
. O 0 2.989664972119499e-05

By O 0 4.731557055492885e-06
investigating O 0 0.00014514375652652234
the O 0 2.210350430686958e-05
common O 0 0.00044722697930410504
autosomal O 1 0.9703190326690674
recessive O 1 0.9584199786186218
copper B-Disease 1 0.9989297986030579
toxicosis I-Disease 1 0.9728526473045349
( O 0 1.2579447457028436e-06
CT B-Disease 0 0.007952765561640263
) O 0 1.0062259292453746e-07
in O 0 3.5814235133102557e-08
Bedlington O 0 0.0010042364010587335
terriers O 0 0.01543840579688549
, O 0 8.913884244066139e-07
we O 0 2.238617113903274e-08
have O 0 2.8183646527679684e-09
identified O 0 7.370554833130427e-09
a O 0 2.013076816353987e-09
new O 0 5.911857314799818e-08
locus O 0 7.589274900965393e-06
involved O 0 3.943320734833833e-06
in O 0 9.520977619104087e-05
progressive O 1 0.9962806105613708
liver B-Disease 1 0.9999357461929321
disease I-Disease 1 0.9991316199302673
. O 0 0.000378571858163923

We O 0 1.83846941581578e-06
examined O 0 1.3573114301834721e-05
whether O 0 2.887465200274164e-07
the O 0 9.574825980962487e-07
WD B-Disease 0 0.3009442389011383
gene O 0 4.547084699879633e-06
ATP7B O 0 0.03611969202756882
was O 0 2.0297226001275703e-05
also O 0 1.3260527964575886e-07
causative O 0 1.8402676005280227e-07
for O 0 2.3229768331134437e-08
CT B-Disease 0 0.0016189233865588903
by O 0 3.3914577812765856e-08
investigating O 0 1.001960526991752e-06
the O 0 3.971525188717351e-07
chromosomal O 0 0.02079770714044571
co O 0 0.0006806798046454787
- O 0 4.624600478564389e-05
localization O 0 5.730066163778247e-07
of O 0 1.5756707938408e-08
ATP7B O 0 0.0005668408120982349
and O 0 9.956190183402214e-08
C04107 O 0 1.1165423074999126e-06
, O 0 8.432297082805462e-10
using O 0 2.2389266829403454e-10
fluorescence O 0 2.8734492119042443e-08
in O 0 5.792303081619821e-09
situ O 0 6.677350938844029e-08
hybridization O 0 3.19038576890307e-07
( O 0 3.483444999119456e-08
FISH O 0 5.35091146502964e-07
) O 0 1.6112940670609532e-07
. O 0 6.703165240651288e-07

C04107 O 0 0.0064107212238013744
is O 0 3.742138460438582e-06
an O 0 2.1407414863006125e-07
anonymous O 0 3.474988943708013e-06
microsatellite O 0 0.008684520609676838
marker O 0 4.848960452363826e-05
closely O 0 1.067697121470701e-05
linked O 0 5.8265031839255244e-05
to O 0 8.423606345786538e-07
CT B-Disease 0 0.019919482991099358
. O 0 8.517323294654489e-06

However O 0 7.349678980972385e-06
, O 0 2.534109171392629e-06
BAC O 0 2.22933722398011e-05
clones O 0 5.140416033100337e-05
containing O 0 8.018529342734837e-07
ATP7B O 0 0.0007331898668780923
and O 0 4.0215226704276574e-07
C04107 O 0 4.390406047605211e-06
mapped O 0 6.109160040068673e-07
to O 0 1.6674387426363069e-09
the O 0 1.9545312923696656e-08
canine O 0 7.112810999387875e-05
chromosome O 0 0.00015984165656846017
regions O 0 1.0458864352358432e-07
CFA22q11 O 0 0.00011125103628728539
and O 0 5.430175065157528e-07
CFA10q26 O 0 0.000561023480258882
, O 0 6.636972216256254e-07
respectively O 0 6.267360959100188e-07
, O 0 5.064083197225955e-08
demonstrating O 0 2.2071756689001631e-07
that O 0 3.3097686014116334e-07
WD B-Disease 0 0.11044945567846298
cannot O 0 6.6323792680123e-08
be O 0 5.185583074052147e-10
homologous O 0 2.2027469981367176e-07
to O 0 2.7272295710645267e-07
CT B-Disease 0 0.0036985184997320175
. O 0 3.07007417177374e-06

The O 0 2.8476042643887922e-06
copper O 0 0.0004419160832185298
transport O 0 4.117229764233343e-06
genes O 0 5.984545623505255e-07
CTR1 O 0 0.002215969143435359
and O 0 7.496931630157633e-06
CTR2 O 0 0.010971429757773876
were O 0 2.034870192346716e-07
also O 0 4.0336516349270823e-08
excluded O 0 3.141746773849263e-08
as O 0 9.245429422044538e-10
candidate O 0 3.2716434006374584e-09
genes O 0 3.983357643733143e-09
for O 0 3.51116113961325e-08
CT B-Disease 0 0.019284691661596298
since O 0 6.383493769135384e-07
they O 0 3.436692930236518e-09
both O 0 3.0388407346038093e-09
mapped O 0 1.2956587625012617e-06
to O 0 7.298874749039896e-08
canine O 0 0.00012820094707421958
chromosome O 0 0.0019232705235481262
region O 0 2.3561018679174595e-05
CFA11q22 O 0 0.006310909986495972
. O 0 1.0186780855292454e-05

2 O 0 6.530284008476883e-05
- O 0 0.0015345972497016191
22 O 0 3.625650788308121e-05
. O 0 1.046954366756836e-05

5 O 0 0.0004036675381939858
. O 0 9.597685857443139e-05

A O 0 1.2626935586013133e-06
transcribed O 0 2.8400429528119275e-06
sequence O 0 3.138061117624602e-07
identified O 0 4.666969743993832e-07
from O 0 6.148341391565282e-09
the O 0 1.9566277487115258e-08
C04107 O 0 1.0314171959180385e-05
- O 0 5.7864366681315005e-05
containing O 0 8.298770808323752e-07
BAC O 0 3.887149432557635e-06
was O 0 1.3128934597261832e-06
found O 0 4.5885890642693994e-08
to O 0 2.6444242351431058e-09
be O 0 2.4067883241940535e-09
homologous O 0 1.2573735830301302e-07
to O 0 7.589176398425934e-09
a O 0 2.4029596090713312e-08
gene O 0 8.859273492589637e-08
expressed O 0 1.6546472636491671e-07
from O 0 1.504201208035738e-08
human O 0 8.386480487843073e-08
chromosome O 0 1.7023319742293097e-05
2p13 O 0 7.209658360807225e-05
- O 0 0.003397264750674367
p16 O 0 3.33980678988155e-05
, O 0 1.2070036348177382e-07
a O 0 2.7078590036921923e-08
region O 0 7.909505228553826e-08
devoid O 0 1.123395776403413e-07
of O 0 1.1013239209489711e-09
any O 0 1.434308227743486e-09
positional O 0 6.176500733090506e-07
candidate O 0 4.6894194838387193e-07
genes O 0 6.394973297574325e-07
. O 0 7.941845979075879e-06

Molecular O 0 7.0149966632016e-05
analysis O 0 1.0260597491651424e-06
of O 0 6.597782942208141e-08
the O 0 2.642074150571716e-07
APC B-Disease 0 9.547061199555174e-05
gene O 0 2.1504382630155305e-07
in O 0 5.997011953695619e-08
205 O 0 6.224815933819627e-06
families O 0 7.439580826940073e-07
: O 0 2.7758837006786052e-08
extended O 0 4.2409112666064175e-08
genotype O 0 6.157712505228119e-06
- O 0 0.0005233358242549002
phenotype O 0 4.763853212352842e-06
correlations O 0 1.8697196537686978e-06
in O 0 2.367095817135123e-07
FAP B-Disease 0 3.4508018870837986e-05
and O 0 4.957616965839406e-07
evidence O 0 9.753271257295637e-08
for O 0 1.498104640340614e-09
the O 0 2.846961999480868e-09
role O 0 2.678608446160524e-09
of O 0 2.198069948278203e-09
APC B-Disease 0 6.212047992448788e-06
amino O 0 9.935735789667888e-09
acid O 0 5.5491018002840065e-08
changes O 0 2.2963912726936542e-07
in O 0 0.005719094071537256
colorectal B-Disease 1 0.9999908208847046
cancer I-Disease 1 0.9998723268508911
predisposition O 0 0.15240833163261414
. O 0 0.00011598501441767439

BACKGROUND O 0 2.552646037656814e-05
/ O 0 3.288694279035553e-05
AIMS O 0 2.559221684350632e-06
The O 0 5.6270241799438736e-08
development O 0 7.809778253431432e-06
of O 0 0.005101957358419895
colorectal B-Disease 1 0.9999982118606567
cancer I-Disease 1 0.999950647354126
and O 0 3.2729174108681036e-06
a O 0 8.89535556325427e-08
variable O 0 2.4159564304682135e-07
range O 0 5.800824283141992e-07
of O 0 1.440640176042507e-07
extracolonic O 0 0.11028420925140381
manifestations O 0 0.00015989104576874524
in O 0 0.0004918925114907324
familial B-Disease 1 0.9999126195907593
adenomatous I-Disease 1 0.9998617172241211
polyposis I-Disease 1 0.9999523162841797
( O 0 5.232147668721154e-05
FAP B-Disease 0 0.0012870492646470666
) O 0 1.1826307400042424e-06
is O 0 3.428523953630247e-08
the O 0 4.010736631698819e-08
result O 0 3.4825614392275384e-08
of O 0 3.983220864256509e-09
the O 0 2.007644894774785e-07
dominant O 0 7.827051740605384e-05
inheritance O 0 0.007297045551240444
of O 0 0.0060614594258368015
adenomatous B-Disease 1 0.9999579191207886
polyposis I-Disease 1 0.9999181032180786
coli I-Disease 1 0.9998030066490173
( O 0 1.0298664165020455e-05
APC B-Disease 0 0.0009806373855099082
) O 0 3.3638113450251694e-07
gene O 0 6.553084404004039e-07
mutations O 0 2.2372355488187168e-06
. O 0 2.8402189400367206e-06

In O 0 4.7156913751678076e-06
this O 0 1.0794774851774491e-07
study O 0 5.899005728338125e-08
, O 0 2.4947775401074068e-08
direct O 0 7.894607745306814e-10
mutation O 0 4.558735167137229e-09
analysis O 0 1.029576779387753e-08
of O 0 2.868918658194275e-09
the O 0 6.046041534091273e-08
APC B-Disease 0 0.00018734206969384104
gene O 0 2.6709628286880616e-07
was O 0 1.7898968280860572e-06
performed O 0 2.0351917484617843e-08
to O 0 9.116291721511516e-09
determine O 0 3.607871690292086e-07
genotype O 0 6.211070740391733e-06
- O 0 0.00030086288461461663
phenotype O 0 1.9203300780645804e-06
correlations O 0 4.344343835782638e-07
for O 0 5.895886889817348e-09
nine O 0 1.7830240039984346e-06
extracolonic O 0 0.025120221078395844
manifestations O 0 1.4147930187391466e-06
and O 0 6.363884352822424e-08
to O 0 5.93633986412101e-09
investigate O 0 5.252401820143859e-07
the O 0 2.9084361585773877e-07
incidence O 0 3.7143854569876567e-05
of O 0 3.845297769089484e-08
APC B-Disease 0 9.36982614803128e-05
mutations O 0 1.7662206630575383e-07
in O 0 1.7384367367867526e-07
non O 0 1.7523803762742318e-05
- O 1 0.9970581531524658
FAP O 1 0.9984227418899536
colorectal B-Disease 1 0.9999794960021973
cancer I-Disease 1 0.999634861946106
. O 0 0.0001236122043337673

METHODS O 0 2.9489667667803587e-06
The O 0 6.341522862385318e-07
APC B-Disease 0 7.03734258422628e-05
gene O 0 4.5532192416430917e-07
was O 0 1.4172967439662898e-06
analysed O 0 3.2248698289549793e-07
in O 0 3.227841816055843e-08
190 O 0 1.1121386478407658e-06
unrelated O 0 9.439837413083296e-06
FAP B-Disease 0 1.4199377801560331e-05
and O 0 4.123884878026729e-07
15 O 0 5.439706569632108e-07
non O 0 7.781171916576568e-06
- O 1 0.9915880560874939
FAP O 1 0.9993343949317932
colorectal B-Disease 1 0.9999958276748657
cancer I-Disease 1 0.9998462200164795
patients O 0 2.5503331357867864e-07
using O 0 2.603248638877176e-08
denaturing O 0 0.00012941606109961867
gradient O 0 5.206633431953378e-05
gel O 0 0.0004708411870524287
electrophoresis O 0 0.002510278718546033
, O 0 3.964471062545272e-08
the O 0 1.4219416755167913e-09
protein O 0 6.8677801223770985e-09
truncation O 0 1.1105000794486841e-06
test O 0 1.853215820801779e-07
, O 0 1.3884734251234931e-08
and O 0 6.9663852464429965e-09
direct O 0 2.599223503096937e-09
sequencing O 0 2.9390109830274014e-06
. O 0 2.6905049708148e-06

RESULTS O 0 8.479438110953197e-05
Chain O 0 7.891302084317431e-05
terminating O 0 3.910969553544419e-06
signals O 0 1.8816866713677882e-06
were O 0 9.500190145672605e-08
only O 0 7.480686292637984e-09
identified O 0 1.1168681339768227e-06
in O 0 5.345158342606737e-07
patients O 0 3.5253816577096586e-07
belonging O 0 7.053171202642261e-07
to O 0 1.4335077125338103e-08
the O 0 2.620218424453924e-07
FAP B-Disease 0 8.162417361745611e-05
group O 0 1.7046029824996367e-05
( O 0 1.2255739534339227e-07
105 O 0 7.942300726426765e-06
patients O 0 1.253919208465959e-06
) O 0 7.568925752821087e-07
. O 0 3.6941632970410865e-06

Amino O 0 7.885981858635205e-07
acid O 0 1.1792767509177793e-06
changes O 0 3.9779003202511376e-08
were O 0 5.940511371704815e-08
identified O 0 1.0461537414130362e-07
in O 0 5.4214257971807456e-08
four O 0 1.7744913520800765e-06
patients O 0 9.974463637263398e-07
, O 0 4.829140820561406e-08
three O 0 2.263899467891406e-08
of O 0 7.203445306913636e-08
whom O 0 3.1571032650390407e-06
belonged O 0 4.0027339309745e-06
to O 0 4.331132341661714e-09
the O 0 8.678128438077692e-09
non O 0 1.1171777458685028e-07
- O 0 0.0006851953803561628
FAP O 0 6.831972859799862e-05
group O 0 0.0004442336212377995
of O 0 0.023689592257142067
colorectal B-Disease 1 0.9999951124191284
cancer I-Disease 1 0.999929666519165
patients O 0 0.0003951310063712299
. O 0 8.738743053982034e-05

Genotype O 0 0.004904437810182571
- O 0 0.3559752404689789
phenotype O 0 0.0027657956816256046
correlations O 0 0.000314761302433908
identified O 0 9.369091458211187e-06
significant O 0 1.4709833351389534e-07
differences O 0 3.879831183439819e-06
in O 0 1.7197309887251322e-07
the O 0 7.783005173678248e-08
nature O 0 2.2216923412088363e-07
of O 0 9.302586256865197e-09
certain O 0 4.2997744031936236e-08
extracolonic O 0 0.005586941726505756
manifestations O 0 3.6703750083688647e-06
in O 0 1.2620062079804484e-06
FAP B-Disease 0 0.00022337035625241697
patients O 0 2.9613570973197056e-07
belonging O 0 4.3899942170355644e-07
to O 0 8.539025486697938e-09
three O 0 1.0388285431872646e-07
mutation O 0 6.282513140831725e-07
subgroups O 0 1.0183381164097227e-05
. O 0 8.413398973061703e-06

CONCLUSIONS O 0 1.1846302186313551e-05
Extended O 0 2.5091160296142334e-06
genotype O 0 0.0002357252815272659
- O 0 0.02074100263416767
phenotype O 0 5.416639396571554e-05
correlations O 0 1.493056242907187e-05
made O 0 1.0018593457061797e-06
in O 0 1.5512593165567523e-07
this O 0 3.406725568311231e-08
study O 0 2.8786942607439414e-07
may O 0 1.086537508854235e-06
have O 0 1.8310412741584514e-08
the O 0 2.0508332809754393e-08
potential O 0 1.0118495907818215e-07
to O 0 9.163238168241605e-09
determine O 0 2.8050340716845312e-08
the O 0 3.0904716563640022e-09
most O 0 3.1627869767625327e-10
appropriate O 0 3.9779496363578914e-10
surveillance O 0 1.297298240388045e-06
and O 0 8.65601975874597e-07
prophylactic O 0 7.909475243650377e-06
treatment O 0 2.014881147260894e-06
regimens O 0 8.136990800267085e-06
for O 0 8.449145383337964e-08
those O 0 8.688961656844185e-07
patients O 0 4.1364100411556137e-07
with O 0 8.748028221816639e-07
mutations O 0 4.834379979001824e-06
associated O 0 2.490518909326056e-06
with O 0 3.667114015115658e-06
life O 0 0.0004591170290950686
threatening O 0 0.04722880944609642
conditions O 0 0.0003142009081784636
. O 0 2.7429075998952612e-05

This O 0 9.323778726866294e-07
study O 0 3.675716868656309e-07
also O 0 2.7379823563933314e-07
provided O 0 4.120668251061943e-08
evidence O 0 1.6784426293270371e-07
for O 0 1.2878611066469148e-08
the O 0 2.1777529468636203e-07
pathological O 0 1.5786084986757487e-05
nature O 0 2.744255311881716e-08
of O 0 2.368493845494868e-09
amino O 0 7.904796817115312e-09
acid O 0 1.6294286808715697e-08
changes O 0 3.40132211285038e-09
in O 0 7.271431456956634e-08
APC O 0 0.00020484627748373896
associated O 0 1.4534715830905043e-07
with O 0 1.4235705059206794e-08
both O 0 3.810907855950063e-08
FAP B-Disease 0 7.914763955341186e-06
and O 0 5.178516744308581e-07
non O 0 9.238461643690243e-06
- O 1 0.9945393204689026
FAP O 1 0.9996459484100342
colorectal B-Disease 1 0.9999958276748657
cancer I-Disease 1 0.9999642372131348
patients O 0 7.485057722078636e-05
. O 0 4.519209142017644e-06
. O 0 8.241406248998828e-06

Inherited B-Disease 1 0.9989136457443237
colorectal I-Disease 1 0.9997795224189758
polyposis I-Disease 1 0.9995242357254028
and O 1 0.9622513651847839
cancer B-Disease 1 0.9935169219970703
risk O 0 5.474128920468502e-05
of O 0 5.862025886926858e-08
the O 0 1.5733546661067521e-06
APC O 0 0.002226609271019697
I1307K O 0 0.0002512318314984441
polymorphism O 0 1.8764483684208244e-05
. O 0 5.089577371109044e-06

Germ O 0 0.017781639471650124
- O 0 0.00244481791742146
line O 0 2.1106119675096124e-05
and O 0 1.4563006800472067e-07
somatic O 0 2.407249439784209e-07
truncating O 0 7.110183560143923e-06
mutations O 0 6.676802399852022e-08
of O 0 8.298420617336433e-09
the O 0 2.974078938677849e-07
APC B-Disease 0 0.0002289633557666093
gene O 0 4.364080297136752e-08
are O 0 5.130940117226146e-10
thought O 0 1.625207524114103e-08
to O 0 3.246995916583728e-08
initiate O 0 4.948583955410868e-05
colorectal B-Disease 1 0.9999334812164307
tumor I-Disease 1 0.6586938500404358
formation O 0 0.0002756970061454922
in O 0 0.02526838704943657
familial B-Disease 1 0.9999527931213379
adenomatous I-Disease 1 0.9999371767044067
polyposis I-Disease 1 0.9999799728393555
syndrome I-Disease 1 0.999930739402771
and O 0 0.0006708413129672408
sporadic O 0 0.040796902030706406
colorectal O 1 0.9998980760574341
carcinogenesis O 1 0.9869264960289001
, O 0 6.982494960539043e-05
respectively O 0 3.3154894481413066e-05
. O 0 1.9782288291025907e-05

Recently O 0 0.00016236951341852546
, O 0 7.932588914627559e-07
an O 0 9.396998734700901e-08
isoleucine O 0 0.0006511617684736848
- O 0 0.0030845424626022577
- O 0 0.006069827824831009
> O 0 1.945541725945077e-06
lysine O 0 8.723601467863773e-07
polymorphism O 0 6.46135234205758e-08
at O 0 2.473994165086424e-08
codon O 0 1.0891020529868456e-08
1307 O 0 5.14448583999183e-05
( O 0 1.4406204229544528e-08
I1307K O 0 2.372314611420734e-06
) O 0 6.950750197631805e-09
of O 0 4.78116657376404e-10
the O 0 4.6334690750882146e-08
APC B-Disease 0 3.142569403280504e-05
gene O 0 4.131150532771244e-08
has O 0 3.677518378708555e-08
been O 0 2.4240289775434576e-08
identified O 0 5.555826732006608e-08
in O 0 1.3373105289815612e-08
6 O 0 7.417569349854602e-07
% O 0 4.118609453485078e-08
- O 0 0.0001432957942597568
7 O 0 2.315741085112677e-06
% O 0 3.982590257578522e-09
of O 0 1.1202130334453386e-09
the O 0 1.0046897358506612e-07
Ashkenazi O 0 6.045755435479805e-05
Jewish O 0 2.1333523818611866e-06
population O 0 5.195072390051791e-07
. O 0 4.243478088028496e-06

To O 0 1.4596017763324198e-06
assess O 0 2.2871052351547405e-05
the O 0 2.3437619347532745e-06
risk O 0 3.3979208637902047e-06
of O 0 5.640291789177354e-09
this O 0 6.236961613836911e-09
common O 0 5.471361674835862e-08
APC B-Disease 0 1.3860536455467809e-05
allelic O 0 2.8876387659693137e-05
variant O 0 0.0003913211403414607
in O 0 0.00040946208173409104
colorectal O 1 0.9999644756317139
carcinogenesis O 1 0.9793856143951416
, O 0 1.2322007023612969e-05
we O 0 1.079578382245927e-07
have O 0 7.9730728685945e-09
analyzed O 0 3.198668707682373e-08
a O 0 6.916629935460605e-09
large O 0 3.358601574632303e-08
cohort O 0 3.1525641475127486e-07
of O 0 5.862571317294396e-09
unselected O 0 1.7449794540880248e-05
Ashkenazi O 0 1.008736126095755e-05
Jewish O 0 2.418003361981391e-07
subjects O 0 1.7128728302395757e-07
with O 0 3.878721145156305e-06
adenomatous B-Disease 1 0.7575755715370178
polyps I-Disease 0 0.11306755244731903
and O 0 4.108333814656362e-05
. O 0 0.00016290608618874103
or O 1 0.848191499710083
colorectal B-Disease 1 0.9999985694885254
cancer I-Disease 1 0.9999432563781738
, I-Disease 0 2.3271779809874715e-06
for O 0 3.0997771460761214e-08
the O 0 5.056101599620888e-07
APC O 0 0.001117533422075212
I1307K O 0 0.00017861073138192296
polymorphism O 0 1.4252762412070297e-05
. O 0 3.905587618646678e-06

The O 0 1.1222730336157838e-06
APC O 0 0.00021317819482646883
I1307K O 0 7.234666554722935e-05
allele O 0 5.239017355052056e-06
was O 0 6.71217321723816e-06
identified O 0 2.867170678655384e-07
in O 0 2.7863174878461905e-08
48 O 0 4.751017854687234e-07
( O 0 7.177343164244121e-09
10 O 0 8.759696967786113e-09
. O 0 1.0466682631715685e-08
1 O 0 8.164332143678621e-08
% O 0 1.643226710257295e-08
) O 0 3.667599557388712e-08
of O 0 4.99612831106333e-08
476 O 0 0.0018119161250069737
patients O 0 7.618091785843717e-06
. O 0 8.38225332699949e-06

Compared O 0 4.283218368072994e-05
with O 0 8.306737697694189e-08
the O 0 6.894659954070903e-09
frequency O 0 8.042556487453112e-08
in O 0 9.359967023669924e-09
two O 0 6.784765194112197e-09
separate O 0 1.4441920370700245e-07
population O 0 1.7047726785790474e-08
control O 0 1.2907142377116543e-07
groups O 0 2.513163677164698e-09
, O 0 1.0163093477899565e-08
the O 0 7.850225358652096e-09
APC O 0 3.7571538996417075e-05
I1307K O 0 2.9669432478840463e-05
allele O 0 2.9975412871863227e-06
is O 0 1.540536800348491e-07
associated O 0 1.7210926728239428e-07
with O 0 5.011265002963228e-08
an O 0 3.0914907256374136e-07
estimated O 0 2.0643572497647256e-05
relative O 0 6.628308256040327e-06
risk O 0 6.22899278823752e-07
of O 0 1.7619029790694185e-08
1 O 0 1.5552468539681286e-06
. O 0 7.384273430943722e-06

5 O 0 3.2876094337552786e-05
- O 0 0.0006821780116297305
1 O 0 6.311629931587959e-06
. O 0 5.5410919230780564e-06

7 O 0 0.0003637370828073472
for O 0 0.00014797612675465643
colorectal B-Disease 1 0.9997997879981995
neoplasia I-Disease 1 0.9925044775009155
( O 0 2.198156607846613e-06
both O 0 3.882345538386289e-07
P O 0 0.06715554744005203
= O 0 0.00013635620416607708
. O 0 3.101992547271948e-07
01 O 0 3.325587385916151e-05
) O 0 5.113394081490696e-07
. O 0 1.357023279524583e-06

Furthermore O 0 5.697742017218843e-05
, O 0 3.007047098435578e-06
compared O 0 2.4343671611859463e-06
with O 0 4.90150398491096e-07
noncarriers O 0 0.00707951420918107
, O 0 1.0688296470107161e-06
APC O 0 4.237593020661734e-05
I1307K O 0 3.342039781273343e-05
carriers O 0 8.613257591605361e-07
had O 0 5.946122314526292e-07
increased O 0 1.4470783682440924e-08
numbers O 0 6.270707064714998e-09
of O 0 1.4047469676370383e-07
adenomas B-Disease 1 0.8903957605361938
and O 0 0.07791931182146072
colorectal B-Disease 1 0.9999895095825195
cancers I-Disease 1 0.8157692551612854
per O 0 1.5511454876104835e-06
patient O 0 4.585694114211947e-06
( O 0 1.819846175976636e-07
P O 0 0.04921470582485199
= O 0 6.00432904320769e-05
. O 0 6.65140689193322e-08
03 O 0 6.116410986578558e-06
) O 0 4.419322507942525e-08
, O 0 6.686434961267196e-09
as O 0 6.43759212604067e-10
well O 0 2.3109818503286306e-09
as O 0 1.690576234558705e-09
a O 0 4.498576444689206e-08
younger O 0 1.1514883226482198e-05
age O 0 3.290518407084164e-06
at O 0 8.822287782095373e-05
diagnosis O 0 0.0004537857312243432
. O 0 1.0026154086517636e-05

We O 0 1.7902998479257803e-06
conclude O 0 5.23459220858058e-06
that O 0 2.5590301433453533e-08
the O 0 3.608494125728612e-08
APC O 0 1.5569294191664085e-05
I1307K O 0 8.50275500852149e-06
variant O 0 3.6075798561796546e-06
leads O 0 1.8619542743181228e-06
to O 0 3.3875113558679004e-07
increased O 0 1.3819647392665502e-05
adenoma B-Disease 1 0.9993113279342651
formation O 0 3.1225692964653717e-06
and O 0 1.2363389600977825e-07
directly O 0 5.473989261872703e-09
contributes O 0 1.4970201078767786e-08
to O 0 1.418571704547844e-09
3 O 0 5.9314086087169926e-08
% O 0 1.2551566008767168e-08
- O 0 3.4865464840549976e-05
4 O 0 6.110162757977378e-07
% O 0 3.187770936108336e-09
of O 0 2.112158448142054e-09
all O 0 4.053248403579346e-08
Ashkenazi O 0 0.014634361490607262
Jewish O 0 0.4249180555343628
colorectal B-Disease 1 0.9999833106994629
cancer I-Disease 1 0.9996757507324219
. O 0 0.000489105936139822

The O 0 1.0275235581502784e-05
estimated O 0 5.72396966163069e-05
relative O 0 3.818502591457218e-05
risk O 0 1.2032301128783729e-05
for O 0 1.9436561160546262e-07
carriers O 0 1.962224268936552e-05
may O 0 1.064662569660868e-06
justify O 0 3.470427714091784e-07
specific O 0 6.92199797480697e-10
clinical O 0 1.6232650779102187e-08
screening O 0 1.2900861712239475e-08
for O 0 7.031982773852974e-10
the O 0 2.591590053668824e-09
360 O 0 6.748166470060823e-07
, O 0 1.5103744033240218e-07
000 O 0 1.5722011426078097e-07
Americans O 0 7.276120328469915e-08
expected O 0 1.4648644253156817e-07
to O 0 1.815801198290501e-08
harbor O 0 2.507025419618003e-05
this O 0 3.782071544833343e-09
allele O 0 5.18609283517435e-07
, O 0 1.0769131364440909e-07
and O 0 9.399114020425259e-08
genetic O 0 1.902925816921197e-07
testing O 0 9.354616281598283e-08
in O 0 8.152860608845458e-09
the O 0 8.361081604846277e-09
setting O 0 1.4811412540893798e-07
of O 0 1.7144900610333025e-08
long O 0 2.333241172891576e-05
- O 0 0.0012215065071359277
term O 0 5.681485504283046e-07
- O 0 0.004467224236577749
outcome O 0 5.886590770387556e-06
studies O 0 2.6977889433510427e-07
may O 0 3.3065194315895496e-07
impact O 0 1.0621071169225615e-06
significantly O 0 3.963473500334658e-05
on O 1 0.8283901810646057
colorectal B-Disease 1 0.9999985694885254
cancer I-Disease 1 0.999975323677063
prevention O 0 0.0007258484838530421
in O 0 4.020095900614251e-07
this O 0 1.012909649489302e-07
population O 0 4.5366880385699915e-07
. O 0 4.94658434035955e-06

Localization O 0 5.033003617427312e-05
of O 0 4.513057660915365e-07
human O 0 3.77155993191991e-06
BRCA1 O 0 0.00011127808102173731
and O 0 1.2400909099596902e-06
its O 0 3.0542753393092426e-06
loss O 0 0.0021290488075464964
in O 0 1.6330011476384243e-07
high O 0 1.5696612535975873e-05
- O 0 0.005640883464366198
grade O 0 1.2047273230564315e-05
, O 0 1.0366171636633226e-06
non B-Disease 0 4.223336873110384e-06
- I-Disease 1 0.9459123611450195
inherited I-Disease 1 0.9852675199508667
breast I-Disease 1 0.9478204250335693
carcinomas I-Disease 1 0.9995762705802917
. O 0 0.00015999504830688238

Although O 0 4.318215360399336e-06
the O 0 1.6279243197914184e-07
link O 0 2.5702718176034978e-06
between O 0 5.283852146931167e-07
the O 0 4.520605671132216e-06
BRCA1 O 0 0.3161484897136688
tumour B-Disease 1 0.9998939037322998
- O 0 0.010934125632047653
suppressor O 0 5.284407961880788e-05
gene O 0 8.420056474278681e-07
and O 0 1.8862068827729672e-05
hereditary B-Disease 1 0.9148274064064026
breast I-Disease 1 0.9997324347496033
and I-Disease 1 0.9999160766601562
ovarian I-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999364614486694
is O 0 8.907425126380986e-07
established O 0 4.0525461031393206e-07
, O 0 4.928728571940155e-07
the O 0 5.260753255242889e-08
role O 0 1.634259945149097e-07
, O 0 1.9219335456455156e-07
if O 0 4.258319474814698e-09
any O 0 8.564351450246477e-10
, O 0 1.6081340703522073e-08
of O 0 1.1870037397443411e-08
BRCA1 O 0 2.6177756808465347e-05
in O 0 3.28403388039078e-07
non B-Disease 0 8.784078090684488e-06
- I-Disease 1 0.9054840803146362
familial I-Disease 1 0.8009430170059204
cancers I-Disease 1 0.6429746747016907
is O 0 8.572660021854972e-07
unclear O 0 5.10559084432316e-06
. O 0 4.249767698638607e-06

BRCA1 O 0 0.02976140007376671
mutations O 0 8.288479875773191e-05
are O 0 3.0227781167013745e-07
rare O 0 2.0601660253305454e-06
in O 0 5.638573270516645e-07
sporadic B-Disease 0 0.0002579333959147334
cancers I-Disease 1 0.6320073008537292
, O 0 4.6650591684738174e-05
but O 0 8.376858204428572e-06
loss O 0 0.0006876136176288128
of O 0 1.5253169749485096e-07
BRCA1 O 0 0.0005474453209899366
resulting O 0 4.913569227937842e-06
from O 0 2.927156650400775e-08
reduced O 0 4.324753888340638e-08
expression O 0 5.674519965026548e-09
or O 0 3.6857837670822846e-08
incorrect O 0 4.3699904495042574e-07
subcellular O 0 9.602332511349232e-07
localization O 0 2.2082417672208976e-06
is O 0 3.409260784792423e-08
postulated O 0 8.022148989539346e-08
to O 0 5.120999180263652e-09
be O 0 3.1721043569632457e-09
important O 0 1.0566307828696608e-09
in O 0 4.231360861695066e-08
non B-Disease 0 8.501454544784792e-07
- I-Disease 0 0.3945055603981018
familial I-Disease 1 0.9233338236808777
breast I-Disease 1 0.9966377019882202
and I-Disease 1 0.9731835722923279
ovarian I-Disease 1 0.999983549118042
cancers I-Disease 1 0.9998242259025574
. O 0 0.0002135843096766621

Epigenetic O 0 0.060830388218164444
loss O 1 0.7193540334701538
, O 0 4.0558279579272494e-05
however O 0 3.378762357897358e-06
, O 0 1.0801278449434903e-06
has O 0 1.2218465883506724e-07
not O 0 5.6982831786456245e-09
received O 0 4.369541617421646e-09
general O 0 8.105569548888525e-09
acceptance O 0 7.19876766197558e-07
due O 0 2.91746459879505e-07
to O 0 1.4857072017093742e-08
controversy O 0 7.279701463858146e-08
regarding O 0 2.3083603917228857e-09
the O 0 1.3432355228104598e-09
subcellular O 0 1.7273610808388185e-07
localization O 0 1.8922413858035725e-07
of O 0 4.715715373748708e-09
BRCA1 O 0 5.099975169287063e-06
proteins O 0 6.691310971973508e-08
, O 0 3.231537704095899e-08
reports O 0 3.2471074717932424e-08
of O 0 6.618702919070074e-09
which O 0 2.681327373466047e-07
have O 0 2.3444984620368814e-08
ranged O 0 1.6414277297371882e-06
from O 0 5.484921405951582e-09
exclusively O 0 2.481120198183362e-08
nuclear O 0 7.057665061438456e-05
, O 0 7.3892900687155816e-09
to O 0 1.0426149943398855e-09
conditionally O 0 2.0765198769368e-06
nuclear O 0 7.144462870201096e-05
, O 0 1.1120154574939534e-08
to O 0 6.273993546912493e-10
the O 0 1.4784846236182148e-08
ER O 0 2.546100949984975e-05
/ O 0 2.431703478578129e-06
golgi O 0 0.0003473085816949606
, O 0 1.4946119009096037e-08
to O 0 2.481866934189725e-09
cytoplasmic O 0 5.259128670331847e-07
invaginations O 0 2.47726279667404e-06
into O 0 1.8855854655441817e-09
the O 0 1.701017815491923e-08
nucleus O 0 7.498859417864878e-07
. O 0 2.142490984624601e-06

In O 0 1.1569527487154119e-06
an O 0 1.1895947693574271e-07
attempt O 0 6.831020982644986e-06
to O 0 1.007802836738847e-07
resolve O 0 4.034855010104366e-06
this O 0 1.2575601004982673e-08
issue O 0 2.6454475232640107e-07
, O 0 1.462876468849572e-07
we O 0 2.058451542552575e-08
have O 0 3.709777374183432e-08
comprehensively O 0 7.873569848015904e-05
characterized O 0 3.4283323202544125e-06
19 O 0 9.958827149603167e-07
anti O 0 1.6621246686554514e-05
- O 0 0.060053590685129166
BRCA1 O 0 0.00027676994795911014
antibodies O 0 4.3137738430232275e-06
. O 0 2.4812516130623408e-06

These O 0 1.1770639218866563e-07
reagents O 0 1.185518158308696e-06
detect O 0 1.3120422863721615e-06
a O 0 1.1718149117712073e-08
220 O 0 2.9455671324285504e-07
- O 0 2.50301218329696e-05
kD O 0 1.1819286555692088e-05
protein O 0 2.915209407206021e-09
localized O 0 2.5063708886108316e-09
in O 0 5.656071722093259e-10
discrete O 0 6.491467985370036e-08
nuclear O 0 3.91622306779027e-05
foci O 0 2.6766033442982007e-06
in O 0 6.351585479791311e-09
all O 0 2.2302157898224095e-09
epithelial O 0 1.9850320313707925e-05
cell O 0 0.00010841822222573683
lines O 0 4.981692200090038e-06
, O 0 4.708150527221733e-07
including O 0 3.729849495925919e-08
those O 0 7.140656066439988e-08
derived O 0 1.6166812599749392e-07
from O 0 4.941708994010696e-06
breast B-Disease 0 0.0704401358962059
malignancies I-Disease 0 0.08607827872037888
. O 0 5.6113691243808717e-05

Immunohistochemical O 0 0.0018319651717320085
staining O 0 0.0002756554458756
of O 0 3.7373663417383796e-06
human O 0 0.00015323299157898873
breast O 0 0.09759127348661423
specimens O 0 0.00011249725503148511
also O 0 5.501758550963132e-06
revealed O 0 0.0006969423266127706
BRCA1 O 0 0.00020675042469520122
nuclear O 0 0.002811189042404294
foci O 0 0.0008189629879780114
in O 0 2.3327294911723584e-05
benign O 1 0.5636566877365112
breast O 0 0.2584576904773712
, O 0 0.0002109226625179872
invasive B-Disease 0 0.05521825700998306
lobular I-Disease 1 0.9993215799331665
cancers I-Disease 0 0.18883034586906433
and O 0 1.0910128366958816e-05
low B-Disease 0 0.00016563870303798467
- I-Disease 0 0.3826870620250702
grade I-Disease 0 0.0015644454397261143
ductal I-Disease 1 0.8130192160606384
carcinomas I-Disease 1 0.9992766976356506
. O 0 0.00012075898848706856

Conversely O 0 0.00015223886293824762
, O 0 5.001724275643937e-06
BRCA1 O 0 2.1776086214231327e-05
expression O 0 1.3606734228233108e-07
was O 0 5.0992848628084175e-06
reduced O 0 8.381616680708248e-07
or O 0 5.297819143379456e-07
undetectable O 0 9.208501978719141e-06
in O 0 2.3080799493868653e-08
the O 0 1.3729044567867277e-08
majority O 0 2.2917133080113672e-08
of O 0 7.779246580241761e-09
high O 0 1.0284098607371561e-05
- O 0 0.007601292338222265
grade O 0 2.422726174700074e-05
, O 0 3.777322854148224e-05
ductal B-Disease 1 0.6344901919364929
carcinomas I-Disease 1 0.9999326467514038
, O 0 2.398930701019708e-05
suggesting O 0 1.443283417756902e-05
that O 0 1.6231543042977137e-07
absence O 0 3.2864556942513445e-07
of O 0 2.582173124210385e-07
BRCA1 O 0 0.0011769940610975027
may O 0 8.26328744096827e-07
contribute O 0 6.273912944720905e-09
to O 0 2.188627723498371e-09
the O 0 9.56862251655366e-08
pathogenesis O 0 7.466829265467823e-05
of O 0 7.039984595280657e-09
a O 0 1.225673287308382e-07
significant O 0 2.918265096241157e-08
percentage O 0 3.354907960329001e-07
of O 0 5.33792423595969e-08
sporadic B-Disease 0 0.0005443951231427491
breast I-Disease 1 0.9482334852218628
cancers I-Disease 0 0.251983642578125
. O 0 6.390915586962365e-06
. O 0 1.4807762454438489e-05

